10/ 540,359

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1202txn

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	JAN 02	STN pricing information for 2008 now available
NEWS	3	JAN 16	CAS patent coverage enhanced to include exemplified prophetic substances
NEWS	4	JAN 28	USPATFULL, USPAT2, and USPATOLD enhanced with new custom IPC display formats
NEWS	5	JAN 28	MARPAT searching enhanced
NEWS	6	JAN 28	USGENE now provides USPTO sequence data within 3 days of publication
NEWS	7	JAN 28	TOXCENTER enhanced with reloaded MEDLINE segment
NEWS	8	JAN 28	MEDLINE and LMEDLINE reloaded with enhancements
NEWS	9	FEB 08	STN Express, Version 8.3, now available
NEWS	10	FEB 20	PCI now available as a replacement to DPCI
NEWS	11	FEB 25	IFIREF reloaded with enhancements
NEWS	12	FEB 25	IMSPRODUCT reloaded with enhancements
NEWS	13	FEB 29	WPINDEX/WPIDS/WPIX enhanced with ECLA and current U.S. National Patent Classification
NEWS	14	MAR 31	IFICDB, IFIPAT, and IFIUDB enhanced with new custom IPC display formats
NEWS	15	MAR 31	CAS REGISTRY enhanced with additional experimental spectra
NEWS	16	MAR 31	CA/CAplus and CASREACT patent number format for U.S. applications updated
NEWS	17	MAR 31	LPCI now available as a replacement to LDPCI
NEWS	18	MAR 31	EMBASE, EMBAL, and LEMBASE reloaded with enhancements
NEWS	19	APR 04	STN AnaVist, Version 1, to be discontinued
NEWS	20	APR 15	WPIDS, WPINDEX, and WPIX enhanced with new predefined hit display formats
NEWS	21	APR 28	EMBASE Controlled Term thesaurus enhanced
NEWS	22	APR 28	IMSRESEARCH reloaded with enhancements

NEWS EXPRESS FEBRUARY 08 CURRENT WINDOWS VERSION IS V8.3,
AND CURRENT DISCOVER FILE IS DATED 20 FEBRUARY 2008

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation

of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 16:56:23 ON 29 MAY 2008

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 16:56:51 ON 29 MAY 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 28 MAY 2008 HIGHEST RN 1023436-44-3
DICTIONARY FILE UPDATES: 28 MAY 2008 HIGHEST RN 1023436-44-3

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\10540359.str

10/ 540,359





chain nodes :
11
ring nodes :
1 2 3 4 5 6 7 8 9 10 13 14 15 16 17 18
ring/chain nodes :
19
chain bonds :
7-19 8-11 10-13
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-10 7-8 8-9 9-10 13-14 13-18 14-15 15-16
16-17 17-18
exact/norm bonds :
5-7 6-10 7-8 7-19 8-9 8-11 9-10
exact bonds :
10-13
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 13-14 13-18 14-15 15-16 16-17 17-18
isolated ring systems :
containing 1 : 13 :

G1:O,S

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:Atom 9:Atom 10:Atom
11:CLASS 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:CLASS

10/ 540,359

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



G1 O,S

Structure attributes must be viewed using STN Express query preparation.

=> s l1
SAMPLE SEARCH INITIATED 16:57:11 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 3555 TO ITERATE

56.3% PROCESSED 2000 ITERATIONS 36 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 67524 TO 74676
PROJECTED ANSWERS: 800 TO 1758

L2 36 SEA SSS SAM L1

=> s l1 ful
FULL SEARCH INITIATED 16:57:16 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 72035 TO ITERATE

100.0% PROCESSED 72035 ITERATIONS 1304 ANSWERS
SEARCH TIME: 00.00.01

L3 1304 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 178.36 178.57

FILE 'CAPLUS' ENTERED AT 16:57:23 ON 29 MAY 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

10/ 540,359

FILE COVERS 1907 - 29 May 2008 VOL 148 ISS 22
FILE LAST UPDATED: 28 May 2008 (20080528/ED)


```
=> s l3
L4          370 L3

=> s l4 not (isopropyl or cyclopentyl)
          81625 ISOPROPYL
          10634 CYCLOPENTYL
L5          327 L4 NOT (ISOPROPYL OR CYCLOPENTYL)

=> d l5 1- ibib abs hitstr
YOU HAVE REQUESTED DATA FROM 327 ANSWERS - CONTINUE? Y/(N):y
```

L5 ANSWER 1 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2008:219154 CAPLUS
DOCUMENT NUMBER: 148:262628
TITLE: Preparation of quinazolinone pyrrolo[2,1-c][1,4]benzodiazepine hybrids as anticancer drugs.
INVENTOR(S): Kamal, Ahmed; Ramana, Adhi Venkata; Babu, Ankati Hari
PATENT ASSIGNEE(S): Council of Scientific & Industrial Research, India
SOURCE: PCT Int. Appl., 28pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008020456	A2	20080221	WO 2007-IN337	20070810
WO 2008020456	A3	20080424		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA			
IN 2006DE01822	A	20080404	IN 2006-DE1822	20060814
US 20080064685	A1	20080313	US 2007-893380	20070814
PRIORITY APPLN. INFO.:			IN 2006-DE1822 A	20060814

OTHER SOURCE(S): CASREACT 148:262628; MARPAT 148:262628
GI



I

AB Title compds. (I; R = H, Cl, F, Me; n = 1-3), were prepared Thus, 7-methoxy-8-[3-(6-chloro-2-oxo-4-phenyl-1,2-dihydro-1-quinazolinyl)propoxy]-(11aS)-1,2,3,11a-tetrahydro-5H-pyrrolo[2,1-c][1,4]benzodiazepine-5-one [preparation from (2S)-N-(4-hydroxy-3-methoxy-2-



RN 1007383-19-8 CAPLUS
CN 5H-Pyrrolo[2,1-c][1,4]benzodiazepin-5-one, 1,2,3,11a-tetrahydro-7-methoxy-8-[[5-(2-oxo-4-phenyl-1(2H)-quinazolinyl)pentyl]oxy]-, (11aS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1007383-20-1 CAPLUS
CN 5H-Pyrrolo[2,1-c][1,4]benzodiazepin-5-one, 8-[3-(6-chloro-2-oxo-4-phenyl-1(2H)-quinazolinyl)propoxy]-1,2,3,11a-tetrahydro-7-methoxy-, (11aS)- (CA INDEX NAME)

Absolute stereochemistry.



nitrobenzoyl)pyrrolidine-2-carboxaldehyde di-Et thioacetal and 1-(3-bromopropyl)-6-chloro-4-phenyl-1,2-dihydro-2-quinazolinone given] showed an IC50 of 8 μg/mL against Colo205 cancer cells, vs. 5 μg/mL for adriamycin.
IT 1007383-17-6P 1007383-18-7P 1007383-19-8P
1007383-20-1P 1007383-21-2P 1007383-22-3P
1007383-23-4P 1007383-24-5P 1007383-25-6P
1007383-26-7P 1007383-27-8P 1007383-28-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(claimed compound; preparation of quinazolinone pyrrolobenzodiazepine hybrids
as anticancer drugs)
RN 1007383-17-6 CAPLUS
CN 5H-Pyrrolo[2,1-c][1,4]benzodiazepin-5-one, 1,2,3,11a-tetrahydro-7-methoxy-8-[3-(2-oxo-4-phenyl-1(2H)-quinazolinyl)propoxy]-, (11aS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1007383-18-7 CAPLUS
CN 5H-Pyrrolo[2,1-c][1,4]benzodiazepin-5-one, 1,2,3,11a-tetrahydro-7-methoxy-8-[4-(2-oxo-4-phenyl-1(2H)-quinazolinyl)butoxy]-, (11aS)- (CA INDEX NAME)

Absolute stereochemistry.

RN 1007383-21-2 CAPLUS
CN 5H-Pyrrolo[2,1-c][1,4]benzodiazepin-5-one, 8-[4-(6-chloro-2-oxo-4-phenyl-1(2H)-quinazolinyl)butoxy]-1,2,3,11a-tetrahydro-7-methoxy-, (11aS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1007383-22-3 CAPLUS
CN 5H-Pyrrolo[2,1-c][1,4]benzodiazepin-5-one, 8-[[5-(6-chloro-2-oxo-4-phenyl-1(2H)-quinazolinyl)pentyl]oxy]-1,2,3,11a-tetrahydro-7-methoxy-, (11aS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1007383-23-4 CAPLUS
CN 5H-Pyrrolo[2,1-c][1,4]benzodiazepin-5-one, 8-[3-(6-fluoro-2-oxo-4-phenyl-1(2H)-quinazolinyl)propoxy]-1,2,3,11a-tetrahydro-7-methoxy-, (11aS)- (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 1 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 1007383-24-5 CAPLUS
CN 5H-Pyrrolo[2,1-c][1,4]benzodiazepin-5-one, 8-[4-(6-fluoro-2-oxo-4-phenyl-1(2H)-quinazolinyl)butoxy]-1,2,3,11a-tetrahydro-7-methoxy-, (11aS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1007383-25-6 CAPLUS
CN 5H-Pyrrolo[2,1-c][1,4]benzodiazepin-5-one, 8-[[5-(6-fluoro-2-oxo-4-phenyl-1(2H)-quinazolinyl)pentyl]oxy]-1,2,3,11a-tetrahydro-7-methoxy-, (11aS)- (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 1 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 1007383-28-9 CAPLUS
CN 5H-Pyrrolo[2,1-c][1,4]benzodiazepin-5-one, 1,2,3,11a-tetrahydro-7-methoxy-8-[[5-(6-methyl-2-oxo-4-phenyl-1(2H)-quinazolinyl)pentyl]oxy]-, (11aS)- (CA INDEX NAME)

Absolute stereochemistry.



IT 1007383-35-8 1007383-36-9 1007383-37-0
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of quinazolinone pyrrolobenzodiazepine hybrids as anticancer drugs)
RN 1007383-35-8 CAPLUS
CN 2(1H)-Quinazolinone, 1-(3-bromopropyl)-6-chloro-4-phenyl- (CA INDEX NAME)

L5 ANSWER 1 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

RN 1007383-26-7 CAPLUS
CN 5H-Pyrrolo[2,1-c][1,4]benzodiazepin-5-one, 1,2,3,11a-tetrahydro-7-methoxy-8-[3-(6-methyl-2-oxo-4-phenyl-1(2H)-quinazolinyl)propoxy]-, (11aS)- (CA INDEX NAME)

Absolute stereochemistry.

RN 1007383-27-8 CAPLUS
CN 5H-Pyrrolo[2,1-c][1,4]benzodiazepin-5-one, 1,2,3,11a-tetrahydro-7-methoxy-8-[4-(6-methyl-2-oxo-4-phenyl-1(2H)-quinazolinyl)butoxy]-, (11aS)- (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 1 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 1007383-36-9 CAPLUS
CN 2(1H)-Quinazolinone, 1-(4-bromobutyl)-6-chloro-4-phenyl- (CA INDEX NAME)



RN 1007383-37-0 CAPLUS
CN 2(1H)-Quinazolinone, 1-(5-bromopentyl)-6-chloro-4-phenyl- (CA INDEX NAME)



IT 1007383-29-0P 1007383-30-3P 1007383-31-4P
1007383-32-5P 1007383-33-6P 1007383-34-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of quinazolinone pyrrolobenzodiazepine hybrids as anticancer drugs)
RN 1007383-29-0 CAPLUS
CN 2(1H)-Quinazolinone, 1-[3-[4-[[(2S)-2-[bis(ethylthio)methyl]-1-pyrrolidinyl]carbonyl]-2-methoxy-5-nitrophenoxy]propyl]-6-chloro-4-phenyl- (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 1 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A

RN 1007383-30-3 CAPLUS
CN 2(1H)-Quinazolinone, 1-[3-[5-amino-4-[[(2S)-2-[bis(ethylthio)methyl]-1-pyrrolidinyl]carbonyl]-2-methoxyphenoxy]propyl]-6-chloro-4-phenyl- (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 1 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A

RN 1007383-31-4 CAPLUS
CN 2(1H)-Quinazolinone, 1-[4-[4-[[(2S)-2-[bis(ethylthio)methyl]-1-pyrrolidinyl]carbonyl]-2-methoxy-5-nitrophenoxy]butyl]-6-chloro-4-phenyl- (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 1 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A

RN 1007383-32-5 CAPLUS
CN 2(1H)-Quinazolinone, 1-[4-[5-amino-4-[[(2S)-2-[bis(ethylthio)methyl]-1-pyrrolidinyl]carbonyl]-2-methoxyphenoxy]butyl]-6-chloro-4-phenyl- (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 1 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A

RN 1007383-33-6 CAPLUS
CN 2(1H)-Quinazolinone, 1-[5-[4-[[(2S)-2-[bis(ethylthio)methyl]-1-pyrrolidinyl]carbonyl]-2-methoxy-5-nitrophenoxy]pentyl]-6-chloro-4-phenyl- (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 1 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A

RN 1007383-34-7 CAPLUS
CN 2(1H)-Quinazolinone, 1-[5-[5-amino-4-[[(2S)-2-[bis(ethylthio)methyl]-1-pyrrolidinyl]carbonyl]-2-methoxyphenoxy]pentyl]-6-chloro-4-phenyl- (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 1 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A

L5 ANSWER 2 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2007:1314645 CAPLUS
DOCUMENT NUMBER: 148:127847
TITLE: Quantitative structure-property relationship study of n-octanol-water partition coefficients of some of diverse drugs using multiple linear regression
AUTHOR(S): Ghasemi, Jahanbakhsh; Saaidpour, Saadi
CORPORATE SOURCE: Chemistry Department, Faculty of Sciences, Razi University, Kermanshah, Iran
SOURCE: Analytica Chimica Acta (2007), 604(2), 99-106
CODEN: ACACAM; ISSN: 0003-2670
PUBLISHER: Elsevier B.V.
DOCUMENT TYPE: Journal
LANGUAGE: English

AB A quant. structure-property relationship (QSPR) study was performed to develop models those relate the structures of 150 drug organic compds. to their n-octanol-water partition coeffs. (log Po/w). Mol. descriptors derived solely from 3D structures of the mol. drugs. A genetic algorithm was also applied as a variable selection tool in QSPR anal. The models were constructed using 110 mols. as training set, and predictive ability tested using 40 compds. Modeling of log Po/w of these compds. as a function of the theor. derived descriptors was established by multiple linear regression (MLR). Four descriptors for these compds. mol. volume (MV) (geometrical), hydrophilic-lipophilic balance (HLB) (constitutional), hydrogen bond forming ability (HB) (electronic) and polar surface area (PSA) (electrostatic) are taken as inputs for the model. The use of descriptors calculated only from mol. structure eliminates the need for exptl. determination of properties for use in the correlation and allows for the estimation of log Po/w for mols. not yet synthesized. Application of the developed model to a testing set of 40 drug organic compds. demonstrates that the model is reliable with good predictive accuracy and simple formulation. The prediction results are in good agreement with the exptl. value. The root mean square error of prediction (RMSEP) and square correlation coefficient (R2) for MLR model were 0.22 and 0.99 for the prediction set log Po/w.

IT 22760-18-5, Proquazone
RL: ANT (Analyte); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(quant. structure-property relationship study of n-octanol-water partition coeffs. of some of diverse drugs using multiple linear regression)

RN 22760-18-5 CAPLUS
CN 2(1H)-Quinazolinone, 7-methyl-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)



L5 ANSWER 2 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

REFERENCE COUNT: 48 THERE ARE 48 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 3 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2007:1090523 CAPLUS
DOCUMENT NUMBER: 147:398668
TITLE: Use of gelsolin to diagnose and treat inflammatory diseases
INVENTOR(S): Stossel, Thomas P.; Magnusson Osborn, Anna Charlotta Teresia; Tarkowski, Andrej
PATENT ASSIGNEE(S): The Brigham Women's Hospital, Inc., USA
SOURCE: PCT Int. Appl., 53pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007109056	A2	20070927	WO 2007-US6451	20070315
WO 2007109056	A3	20071206		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

PRIORITY APPLN. INFO.: US 2006-782508P P 20060315

AB The invention relates to the use of gelsolin to treat inflammatory diseases (e.g., rheumatoid arthritis) and to the use of gelsolin to diagnose, monitor, and evaluate therapies of inflammatory diseases (e.g., rheumatoid arthritis).

IT 22760-18-5, Proquazone 37554-40-8, Fluquazone
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(use of gelsolin to diagnose and treat inflammatory diseases)
RN 22760-18-5 CAPLUS
CN 2(1H)-Quinazolinone, 7-methyl-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)



L5 ANSWER 3 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
RN 37554-40-8 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-4-phenyl-1-(2,2,2-trifluoroethyl)- (CA INDEX NAME)



L5 ANSWER 4 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2007:942275 CAPLUS
DOCUMENT NUMBER: 147:285204
TITLE: Compositions and methods for effecting controlled posterior vitreous detachment
INVENTOR(S): Bartels, Stephen P.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 15pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20070196350	A1	20070823	US 2007-671672	20070206
WO 2007101005	A2	20070907	WO 2007-US62402	20070220

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: US 2006-775738P P 20060222

AB A composition comprises plasmin or an enzymically equivalent derivative thereof and at
least an anti-inflammatory medicament. The composition can be used to effect
or induce a controlled posterior vitreous detachment ("PVD") to prevent, treat, or ameliorate a potential complication of a pathol. ocular condition. Such a composition can be administered intravitreally.

IT 22760-18-5, Proquazone
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(plasmin compns. and methods for effecting controlled posterior vitreous detachment)
RN 22760-18-5 CAPLUS
CN 2(1H)-Quinazolinone, 7-methyl-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)



L5 ANSWER 4 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

L5 ANSWER 5 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2007:869688 CAPLUS
DOCUMENT NUMBER: 147:202957
TITLE: High-performance liquid chromatographic determination of proquazone and its m-hydroxy metabolite in spiked human plasma and urine
AUTHOR(S): Hassan, Ekram M.; Gazy, Azza A.; Abdel-Hay, Mohamed H.; Belal, Tarek S.
CORPORATE SOURCE: Faculty of Pharmacy, Pharmaceutical Analytical Chemistry Department, University of Alexandria, Alexandria, 21521, Egypt
SOURCE: Journal of AOAC International (2007), 90(4), 971-976
CODEN: JAINEE; ISSN: 1060-3271
PUBLISHER: AOAC International
DOCUMENT TYPE: Journal
LANGUAGE: English

AB A simple and rapid high-performance liquid chromatog. method for the determination of proquazone (PQZ) and its major metabolite, m-hydroxyproquazone, in spiked human plasma and urine was developed. Plasma samples were purified using acetonitrile as a protein precipitant, while urine samples were diluted only with the mobile phase and filtered prior to injection. Samples containing the parent compds. and glafenine (internal standard) were eluted from a reversed-phase C8 column using acetonitrile-0.025 M sodium acetate (60+40) adjusted to pH 5 as the mobile phase and detected at 234 nm. Peak area ratios of the analytes vs. internal standard were used for calibration. The mean recoveries from plasma and urine samples spiked with PQZ and its m-hydroxy metabolite ranged from 97.87 to 103.88%. The relative standard deviation for the within- and between-day analyses were <4%. The proposed method was applied for the assay of PQZ in laboratory-made tablets.

IT 22760-18-5, Proquazone
RL: PKT (Pharmacokinetics); BIOL (Biological study)
(high-performance liquid chromatog. determination of proquazone and its m-hydroxy metabolite in spiked human plasma and urine)
RN 22760-18-5 CAPLUS
CN 2(1H)-Quinazolinone, 7-methyl-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)



L5 ANSWER 5 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 6 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2007:378611 CAPLUS
DOCUMENT NUMBER: 146:408390
TITLE: Transdermal delivery of non-steroidal anti-inflammatory drugs
INVENTOR(S): Klose, Kathryn Traci-Jane; Bakalova, Margarita Vladislavova; Morgan, Timothy Matthias; Finnin, Berrie Charles; Reed, Barry Leonard
PATENT ASSIGNEE(S): Acrux DDS Pty Ltd., Australia
SOURCE: U.S. Pat. Appl. Publ., 11pp., Cont.-in-part of U.S. Ser. No. 759,303.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 7
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20070077288	A1	20070405	US 2006-517575	20060908
WO 9729735	A1	19970821	WO 1997-AU91	19970219
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
EP 1769785	A1	20070404	EP 2006-25287	19970219
R: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
US 6299900	B1	20011009	US 1998-125436	19981218
AU 9952589	A	19991202	AU 1999-52589	19991001
US 20020028235	A1	20020307	US 2001-910780	20010724
US 6818226	B2	20041116		
US 20040146469	A1	20040729	US 2004-759303	20040120
EP 1674068	A1	20060628	EP 2005-22951	20051020
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2007326867	A	20071220	JP 2007-185782	20070717

PRIORITY APPLN. INFO.:
AU 1996-8144 A 19960219
WO 1997-AU91 W 19970219
US 1998-125436 A3 19981218
US 2001-910780 A2 20010724
US 2004-759303 A2 20040120
AU 1997-17134 A3 19970219
EP 1997-904304 A3 19970219
JP 1997-528834 A3 19970219
EP 2005-22951 A3 20051020

L5 ANSWER 6 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
OTHER SOURCE(S): MARPAT 146:408390

AB The present invention provides a transdermal drug delivery system which comprises: a therapeutically effective amount of a non-steroidal anti-inflammatory drug; at least one dermal penetration enhancer, which is a safe skin-tolerant ester sunscreen ester; and at least one volatile liquid Enhanced skin penetration of ibuprofen using Padimate O in a transdermal gel composition shows the cumulative amount of ibuprofen penetration into a microdialysis probe, adjusted for individual probe recovery over 24 h.

IT 22760-18-5, Proquazone
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(transdermal delivery of NSAIDs)
RN 22760-18-5 CAPLUS
CN 2(1H)-Quinazolinone, 7-methyl-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)



L5 ANSWER 7 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2007:133786 CAPLUS
DOCUMENT NUMBER: 146:309356
TITLE: Methods using farnesyl transferase inhibitors for the treatment of synucleinopathies
INVENTOR(S): Lansbury, Peter T.; Liu, Zhihua
PATENT ASSIGNEE(S): The Brigham and Women's Hospital, Inc., USA
SOURCE: Aust. Pat. Appl., 520pp.
CODEN: AUXXCM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
AU 2006230674	A1	20061116	AU 2006-230674	20061018

PRIORITY APPLN. INFO.: AU 2006-230674 20061018

OTHER SOURCE(S): MARPAT 146:309356
AB The invention provides methods for treating synucleinopathies, e.g. Parkinson's disease, diffuse Lewy body disease, and multiple system atrophy, comprising administering a synucleinopathic subject a farnesyl transferase inhibitor.
IT 215034-66-5 215034-66-5D, stereoisomers and salts
215034-78-9 215034-78-9D, stereoisomers and salts
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(farnesyl transferase inhibitors for treatment of synucleinopathies)
RN 215034-66-5 CAPLUS
CN 2(1H)-Quinazolinone, 6-[amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methyl- (CA INDEX NAME)



RN 215034-66-5 CAPLUS
CN 2(1H)-Quinazolinone, 6-[amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methyl- (CA INDEX NAME)

L5 ANSWER 7 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 215034-78-9 CAPLUS
CN 2(1H)-Quinazolinone, 6-[amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-3,4-dihydro-1,3-dimethyl- (CA INDEX NAME)



RN 215034-78-9 CAPLUS
CN 2(1H)-Quinazolinone, 6-[amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-3,4-dihydro-1,3-dimethyl- (CA INDEX NAME)



L5 ANSWER 7 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

L5 ANSWER 8 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2005:1143958 CAPLUS
DOCUMENT NUMBER: 144:141980
TITLE: Evaluating molecular similarity using reduced representations of the electron density
AUTHOR(S): Meurice, Nathalie; Maggiora, Gerald M.; Vercauteren, Daniel P.
CORPORATE SOURCE: Department of Pharmacology and Toxicology, College of Pharmacy, University of Arizona, Tucson, AZ, 85721, USA
SOURCE: Journal of Molecular Modeling (2005), 11(3), 237-247
CODEN: JMMOFK; ISSN: 0948-5023
URL: http://www.springerlink.com/media/49TLWVTRTK6N1DK T9T0M/Contributions/Q/0/0/2/Q002M7X954165113.pdf
PUBLISHER: Springer GmbH
DOCUMENT TYPE: Journal; (online computer file)
LANGUAGE: English
AB A model system of four benzodiazepine-like ligands for the central benzodiazepine receptors (CBRs) and peripheral benzodiazepine receptors (PBRs)is examined using a genetic algorithm procedure (GAGS) designed for evaluating mol. similarity. The method is based on the alignment of reduced representations generated from the critical points of the electron d.
computed at medium crystallog. resolution The results are further characterized by a comparison with alignments produced by MIMIC, a field-based superimposition method that matches both steric and electrostatic mol. fields. The alignments produced by the two methods are
generally seen to be consistent. The relationships of the compds.' binding affinities for both CBRs and PBRs to the alignments determined by GAGS
yield a set of structural features required for significant binding to benzodiazepine receptors. Benefits of using reduced representations for evaluating mol. similarities and for constructing pharmacophore models are
discussed.
IT 20927-53-1
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(stereoelectronic mol. of benzodiazepine-type ligand quinazolinone were
analyzed for binding affinity to central and peripheral benzodiazepine receptor by GAGS and MIMIC alignment method)
RN 20927-53-1 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-1-methyl-4-phenyl- (CA INDEX NAME)



REFERENCE COUNT: 61 THERE ARE 61 CITED REFERENCES AVAILABLE FOR THIS

L5 ANSWER 8 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L5 ANSWER 9 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 215034-78-9 CAPLUS
CN 2(1H)-Quinazolinone, 6-[amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-3,4-dihydro-1,3-dimethyl- (CA INDEX NAME)



L5 ANSWER 9 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2005:1049845 CAPLUS
DOCUMENT NUMBER: 143:319179
TITLE: Methods using farnesyl transferase inhibitors for the treatment of synucleinopathies
INVENTOR(S): Lansbury, Peter T.; Liu, Zhihua
PATENT ASSIGNEE(S): The Brigham and Women's Hospital, Inc., USA
SOURCE: PCT Int. Appl., 118 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 5
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005089504	A2	20050929	WO 2005-US9235	20050318
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2559221	A1	20050929	CA 2005-2559221	20050318
EP 1809265	A2	20070725	EP 2005-732712	20050318
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR				
JP 2007538004	T	20071227	JP 2007-504171	20050318
PRIORITY APPLN. INFO.:			US 2004-555092P	P 20040318
			WO 2005-US9235	W 20050318

OTHER SOURCE(S): MARPAT 143:319179
AB Methods are provided for treating synuceinopathies, e.g. Parkinson's disease, diffuse Lewy body disease and multiple system atrophy, comprising
administering to a synucleinopathic subject a farnesyl transferase inhibitor compound
IT 215034-66-5 215034-78-9
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(farnesyl transferase inhibitors for treatment of synucleinopathies)
RN 215034-66-5 CAPLUS
CN 2(1H)-Quinazolinone, 6-[amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methyl- (CA INDEX NAME)

L5 ANSWER 10 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2005:902714 CAPLUS
DOCUMENT NUMBER: 143:235463
TITLE: Combination of proton pump inhibitor, buffering agent,
and nonsteroidal anti-inflammatory agent
INVENTOR(S): Proehl, Gerald T.; Olmstead, Kay; Hall, Warren
PATENT ASSIGNEE(S): Santarus, Inc., USA
SOURCE: PCT Int. Appl., 99 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005076987	A2	20050825	WO 2005-US3791	20050204
WO 2005076987	A3	20060608		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, SM				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2005213472	A1	20050825	AU 2005-213472	20050204
CA 2554271	A1	20050825	CA 2005-2554271	20050204
US 20050249806	A1	20051110	US 2005-51260	20050204
EP 1718303	A2	20061108	EP 2005-722791	20050204
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, BA, HR, IS, YU				
JP 2007522217	T	20070809	JP 2006-553174	20050204
MX 2006PA09036	A	20061019	MX 2006-PA9036	20060809
PRIORITY APPLN. INFO.:			US 2004-543636P	P 20040210
			WO 2005-US3791	W 20050204

AB Pharmaceutical compns. comprising a proton pump inhibitor, one or more buffering agent and a nonsteroidal anti-inflammatory drug are described. Methods are described for treating gastric acid-related disorders and treating inflammatory disorders, using pharmaceutical compns. comprising a
proton pump inhibitor, a buffering agent, and a nonsteroidal anti-inflammatory drug. For example, a powder for suspension formulation contained omeprazole 20 mg, ibuprofen 400 mg, sodium bicarbonate 1895 mg, Xylitol 300 (sweetener) 2000 mg, sucrose (sweetener) 1750 mg, sucralose (sweetener) 125 mg, xanthan gum 17 mg, peach flavor 47 mg, and peppermint 26 mg.
IT 22760-18-5, Proquazone
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(combination of proton pump inhibitor, buffering agent, and NSAID agent
for treatment of gastric acid-related disorders and inflammation)

L5 ANSWER 10 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
RN 22760-18-5 CAPLUS
CN 2(1H)-Quinazolinone, 7-methyl-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)



L5 ANSWER 11 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2005:823571 CAPLUS
DOCUMENT NUMBER: 143:199941
TITLE: Pharmaceutical combinations of (S)-pantoprazole with NSAID or corticosteroids
INVENTOR(S): Huber, Reinhard; Kohl, Bernhard; Kromer, Wolfgang; Simon, Wolfgang-Alexander
PATENT ASSIGNEE(S): Altana Pharma A.-G., Germany
SOURCE: PCT Int. Appl., 44 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005074930	A1	20050818	WO 2005-EP50335	20050127
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRIORITY APPLN. INFO.:			EP 2004-1755	A 20040128

AB The present invention relates to new combinations and new use of (S)-pantoprazole and/or its salts in the prevention or treatment of medicament caused gastrointestinal diseases. The compns. comprise a first active ingredient, which is (S)-pantoprazole and/or its salt; and a second active ingredient, which is selected from a group consisting of NSAIDs, COX-2 inhibitors, NO-NSAIDs, bisphosphonates and corticosteroids.
IT 22760-18-5, PROQUAZONE
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmaceutical combinations of (S)-pantoprazole with NSAID or corticosteroids)
RN 22760-18-5 CAPLUS
CN 2(1H)-Quinazolinone, 7-methyl-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)

L5 ANSWER 11 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 12 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2005:490281 CAPLUS
DOCUMENT NUMBER: 143:48056
TITLE: Novel nanoparticulate nimesulide compositions
INVENTOR(S): Bosch, H. William; Wertz, Christian F.
PATENT ASSIGNEE(S): Elan Pharma International Ltd., Ire.
SOURCE: PCT Int. Appl., 87 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005051356	A1	20050609	WO 2003-US32731	20031031
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2544404	A1	20050609	CA 2003-2544404	20031031
AU 2003303744	A1	20050617	AU 2003-303744	20031031
EP 1684725	A1	20060802	EP 2003-815810	20031031
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, SK				
JP 2007522079	T	20070809	JP 2005-510942	20031031
PRIORITY APPLN. INFO.:			WO 2003-US32731	W 20031031

AB The present invention provides nanoparticulate nimesulide compns. The compns. preferably comprise nimesulide and at least one surface stabilizer adsorbed on or associated with the surface of the nimesulide particles. The nanoparticulate nimesulide particles preferably have an effective average particle size of less than about 2000 nm. The invention also provides methods of making and using nanoparticulate nimesulide compns. An aqueous solution of 1% (weight/weight) Plasdone S-630 was combined with 4.25 g of nimesulide (5% weight/weight) and stirred for 1 h at 4200 rpm with chilled water (10°) recirculated through the milling chamber. The process yielded a colloidal dispersion of nimesulide with a mean particle size of 150 nm, a D50 of 124 nm, a D90 of 256 nm, and a D95 of 293 nm.
IT 22760-18-5, Proquazone 40507-23-1, Fluproquazone
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(novel nanoparticulate nimesulide compns.)
RN 22760-18-5 CAPLUS
CN 2(1H)-Quinazolinone, 7-methyl-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)

L5 ANSWER 12 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 40507-23-1 CAPLUS
CN 2(1H)-Quinazolinone, 4-(4-fluorophenyl)-7-methyl-1-(1-methylethyl)- (CA INDEX NAME)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 13 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



L5 ANSWER 13 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2005:472002 CAPLUS
DOCUMENT NUMBER: 143:13359
TITLE: Nanoparticle compositions comprising antibodies for targeted delivery
INVENTOR(S): Liversidge, Elaine; Cunningham, James
PATENT ASSIGNEE(S): Elan Pharma International Ltd., Ire.
SOURCE: PCT Int. Appl., 95 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005049091	A2	20050602	WO 2004-US37246	20041109
WO 2005049091	A3	20061109		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 20050147664	A1	20050707	US 2004-979792	20041103
CA 2545856	A1	20050602	CA 2004-2545856	20041109
EP 1689442	A2	20060816	EP 2004-810555	20041109
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR, IS, YU				
JP 2007511513	T	20070510	JP 2006-539722	20041109

PRIORITY APPLN. INFO.: US 2003-519251P P 20031113
WO 2004-US37246 W 20041109

AB The present invention is directed to compns. of one or more nanoparticulate active agents, at least one PEG-derivatized surface stabilizer, and at least one antibody or fragment thereof, and methods of using such compns. for targeting delivery of the one or more active agents to a desired site. The one or more active agents preferably have a particle size of ≤2 μ. The targeted delivery can be used, e.g., for disease diagnosis, imaging, or drug delivery. Thud, WIN-68209 particles wee stabilized by PEG-DSPE stabilizer.

IT 22760-18-5, Proquazone
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(nanoparticle compns. comprising antibodies for targeted delivery)

RN 22760-18-5 CAPLUS
CN 2(1H)-Quinazolinone, 7-methyl-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)

L5 ANSWER 14 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2005:386659 CAPLUS
DOCUMENT NUMBER: 143:52926
TITLE: A novel class of sodium/calcium exchanger inhibitor: design, synthesis, and structure-activity relationships of 3,4-dihydro-2(1H)-quinazolinone derivatives
AUTHOR(S): Hasegawa, Hirohiko; Muraoka, Masami; Ohmori, Mikiko; Matsui, Kazuki; Kojima, Atsuyuki
CORPORATE SOURCE: Research Division, Ltd, Sumitomo Pharmaceuticals Co., Osaka, 554-0022, Japan
SOURCE: Bioorganic & Medicinal Chemistry (2005), 13(11), 3721-3735
CODEN: BMECEP; ISSN: 0968-0896
PUBLISHER: Elsevier Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 143:52926
GI



I

AB Design, synthesis, and structure-activity relationships of 3,4-dihydro-2(1H)-quinazolinone derivs. as inhibitors of the sodium/calcium (Na+/Ca2+) exchanger are discussed. These studies, based on a lead compound (I), which was identified in our library, involved systematic modification of three regions and revealed that (1) the 3,4-dihydro-2(1H)-quinazolinone having a tertiary amino alkyl side chain at the 3-position is essential for activity, (2) a nonsubstituted Ph ring is most suitable for high activity, and (3) introduction of a 4-substituted piperidine moiety enhanced the activity, in particular 4-benzylpiperidin-1-yl showed strong inhibitory activity. Based on these SAR studies, a structurally novel and highly potent inhibitor against the Na+/Ca2+ exchanger (II, SM-15811), was discovered. In particular, SM-15811 directly inhibited the Na+-dependent Ca2+ influx via the Na+/Ca2+ exchanger in cardiomyocytes with a high potency. The activity was almost two orders more potent than the lead compound I and SM-15811 exerted a protective effect against myocardial ischemic reperfusion injury. These Na+/Ca2+ inhibitors could have a therapeutic potential for the treatment of ischemic reperfusion injury.

IT 625835-76-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(design, synthesis, and structure-activity relationships of 3,4-dihydro-2(1H)-quinazolinone derivs., novel class of sodium-calcium

L5 ANSWER 14 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
exchanger inhibitor)
RN 625835-76-9 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-3-[3-(dimethylamino)propyl]-3,4-dihydro-1-methyl-4-phenyl- (CA INDEX NAME)



REFERENCE COUNT: 29 THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 15 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
nonabsorbable primary amine polymeric co-agents, so as to produce an additive or synergistic physiol. effect of an anti-inflammatory nature.
IT 22760-18-5, Proquazone
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(compns. treatment of chronic inflammatory diseases)
RN 22760-18-5 CAPLUS
CN 2(1H)-Quinazolinone, 7-methyl-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)



L5 ANSWER 15 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2005:369133 CAPLUS
DOCUMENT NUMBER: 142:435774
TITLE: Compositions treatment of chronic inflammatory diseases
INVENTOR(S): Shapiro, Howard K.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 44 pp., Cont.-in-part of U.S. Ser. No. 610,073, abandoned.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20050090553	A1	20050428	US 2004-924945	20040824
PRIORITY APPLN. INFO.:			US 1992-906909	B2 19920630
			US 1994-241603	B2 19940511
			US 1997-814291	B2 19970310
			US 2000-610073	B2 20000705

OTHER SOURCE(S): MARPAT 142:435774
AB This invention defines novel compns. that can be used for clin. treatment of a class of chronic inflammatory diseases. Increased generation of carbonyl substances, aldehydes and ketones, occurs at sites of chronic inflammation and is common to the etiologies of all of the clin. disorders addressed herein. Such carbonyl substances are cytotoxic and addnl. serve to perpetuate and disseminate the inflammatory process. This invention defines use of compns., the orally administered required primary agents of which are primary amine derivs. of benzoic acid capable of reacting with the carbonyl substances. P-Aminobenzoic acid (or PABA) is an example of the required primary agent of the present invention. PABA has a small mol. weight, is water soluble, has a primary amine group which reacts with carbonyl-containing substances and is tolerated by the body in relatively high dosages for extended periods. The method of the present invention includes administration of a composition comprising: (1) an orally consumed primary agent; (2) a previously known medicament co-agent recognized as effective to treat a chronic inflammatory disease addressed herein administered to the mammalian subject via the oral route, other systemic routes of administration or via the topical route; and (3) optionally 1 or more addnl. orally consumed co-agent selected from the group consisting of antioxidants, vitamins, metabolites at risk of depletion, sulfhydryl co-agents, co-agents which may facilitate glutathione activity and

L5 ANSWER 16 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2005:284340 CAPLUS
DOCUMENT NUMBER: 142:475259
TITLE: Inductive QSAR descriptors. Distinguishing compounds with antibacterial activity by artificial neural networks
AUTHOR(S): Cherkasov, Artem
CORPORATE SOURCE: Division of Infectious Diseases, Faculty of Medicine, University of British Columbia, Vancouver, BC, V5Z 3J5, Can.
SOURCE: International Journal of Molecular Sciences (2005), 6(1-2), 63-86
CODEN: IJMCFK; ISSN: 1422-0067
URL: http://www.mdpi.org/ijms/papers/i6010063.pdf
PUBLISHER: Molecular Diversity Preservation International
DOCUMENT TYPE: Journal; (online computer file)
LANGUAGE: English
AB On the basis of the previous models of inductive and steric effects, 'inductive' electronegativity and mol. capacitance, a range of new 'inductive' QSAR descriptors has been derived. These mol. parameters are easily accessible from electronegativities and covalent radii of the constituent atoms and interat. distances and can reflect a variety of aspects of intra- and intermol. interactions. Using 34 'inductive' QSAR descriptors alone we have been able to achieve 93% correct separation of compds. with- and without antibacterial activity (in the set of 657). The elaborated QSAR model based on the Artificial Neural Networks approach has been extensively validated and has confidently assigned antibacterial character to a number of trial antibiotics from the literature.
IT 40507-23-1, Fluproquazone
RL: PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(quant. structure activity relationship model based on artificial neural network approach showed antibacterial activity and inductive QSAR descriptor achieved correct separation of compds. with and without antibacterial activity)
RN 40507-23-1 CAPLUS
CN 2(1H)-Quinazolinone, 4-(4-fluorophenyl)-7-methyl-1-(1-methylethyl)- (CA INDEX NAME)



REFERENCE COUNT: 47 THERE ARE 47 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 16 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

L5 ANSWER 17 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2005:158522 CAPLUS
DOCUMENT NUMBER: 142:246155
TITLE: Novel nanoparticulate metaxalone compositions comprising surface stabilizers and use for treating musculoskeletal disorders
INVENTOR(S): Pruitt, John D.; Ryde, Tuula A.; Bosch, William H.
PATENT ASSIGNEE(S): Elan Pharma International, Ltd., Ire.
SOURCE: PCT Int. Appl., 70 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005016310	A1	20050224	WO 2004-US19108	20040726
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2534924	A1	20050224	CA 2004-2534924	20040726
EP 1651189	A1	20060503	EP 2004-776615	20040726
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
JP 2007501839	T	20070201	JP 2006-523181	20040726
US 20050063913	A1	20050324	US 2004-912552	20040806
PRIORITY APPLN. INFO.:			US 2003-493446P	P 20030808
			WO 2004-US19108	W 20040726

AB The present invention relates to novel compns. of metaxalone, comprising metaxalone particles having an effective average particle size of less than about 2000 nm and at least one surface stabilizer that is preferably adsorbed to or associated with the surface of the drug particles. The invention further discloses a method of making a nanoparticulate metaxalone composition comprising contacting metaxalone and at least one surface stabilizer for a time and under conditions sufficient to provide a nanoparticulate metaxalone composition The one or more surface stabilizers can be contacted with metaxalone either before, preferably during, or after size reduction of the metaxalone. The present invention is also directed to methods of treatment using the nanoparticulate metaxalone compns. of the invention for treatment of musculoskeletal disorders.
IT 22760-18-5, Proquazone

L5 ANSWER 17 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(novel nanoparticulate metaxalone compns. comprising surface stabilizers and use for treating musculoskeletal disorders)
RN 22760-18-5 CAPLUS
CN 2(1H)-Quinazolinone, 7-methyl-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 18 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2005:60159 CAPLUS
DOCUMENT NUMBER: 142:423075
TITLE: The pH Dependency of the Binding of Drugs to Plasma Proteins in Man
AUTHOR(S): Hinderling, Peter H.; Hartmann, Dieter
CORPORATE SOURCE: Food and Drug Administration, Office of Clinical Pharmacology and Biopharmaceutics, Center for Drug Evaluation and Research, Rockville, MD, 20852, USA
SOURCE: Therapeutic Drug Monitoring (2005), 27(1), 71-85
CODEN: TDMODV; ISSN: 0163-4356
PUBLISHER: Lippincott Williams & Wilkins
DOCUMENT TYPE: Journal
LANGUAGE: English
AB An anal. of pH-induced changes of drug binding may contribute to the understanding of the mechanisms involved and the clin. relevance. A literature search was performed, and acceptance criteria set up, to select reported data for quant. evaluation. The relationship between percentage of unbound drug, fu, and pH was analyzed, and the relevance of physicochem. characteristics of the ligand drugs and the importance of hydrogen ion-induced changes in plasma proteins for the pH sensitivity of the binding were evaluated. With all basic and the majority of acidic drugs, fu depended linearly on pH. Basic drugs showed a consistent behavior with fu decreasing with increasing pH. Acidic compds. behaved differently: With some, fu increased, and with others fu decreased, with pH, and with a third group of acids fu was pH independent. Large differences in the pH sensitivity of the plasma protein binding among individual compds. were found. The fu in plasma for some bases and acids increased up to 136% and 95%, resp., at pH values seen in severe acidemia or alkemia. These changes in fu could be clin. relevant with narrow-therapeutic-range drugs. Physicochem. properties and other characteristics of the ligands affect the pH sensitivity of the interaction with plasma proteins, but there was clear evidence indicating that pH-induced changes in the plasma proteins are also involved in the observed pH-dependent interaction with ligands. It is generally accepted that the unbound, free fraction in whole blood or plasma is an important determinant of the pharmacokinetics and pharmacodynamics of drugs. PH-dependent protein binding and consequent changes in the free fraction have been reported for many drugs. From a basic science point of view, the systematic study of pH-induced perturbations of the drug-protein interaction may provide insight into the mechanism and forces involved in the binding of drugs to plasma proteins. From a clin. viewpoint it may be of interest to know the extent of pH-induced changes in the unbound fraction of drugs under extreme acidemic or alkalemic conditions. Arterial blood pH values compatible with life reportedly range between 6.7 and 8.0. PH values as low as 6.3 have been measured in survivors of drowning accidents. To the best knowledge of the authors, a review and interpretation of pH-associated changes in the protein binding of drugs has not been attempted to date. The goals of this investigation were to (1) review published results of studies that determined the impact of pH changes on the protein binding of drugs in man, (2) select representative data using predetd. criteria, (3) determine relevant factors impacting the pH sensitivity of the drug-protein interaction, and (4) attempt to interpret the results and their clin. relevance.

L5 ANSWER 18 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
IT 22760-18-5, Proquazone
RL: PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(binding of drugs to plasma proteins is pH dependent and hydrogen ion catalyzed change of protein are responsible for pH sensitivity of drug interaction in human)
RN 22760-18-5 CAPLUS
CN 2(1H)-Quinazolinone, 7-methyl-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)



REFERENCE COUNT: 132 THERE ARE 132 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 19 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2005:17015 CAPLUS
DOCUMENT NUMBER: 142:120515
TITLE: Dispersible formulations containing anti-inflammatory agents and other active ingredients for infusion
INVENTOR(S): Britten, Nancy Jean; Waldron, Niki Ann; Watts, Jeffrey
L.; Hallberg, John Walter; Burns, John W.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 22 pp., Cont.-in-part of U.S. Ser. No. 803,146.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20050004098	A1	20050106	US 2004-909050	20040730
US 20040235803	A1	20041125	US 2004-803146	20040317
AU 2004258745	A1	20050203	AU 2004-258745	20040719
CA 2533101	A1	20050203	CA 2004-2533101	20040719
WO 2005009436	A1	20050203	WO 2004-IB2461	20040719
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1651210	A1	20060503	EP 2004-744112	20040719
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
CN 1829510	A	20060906	CN 2004-80022099	20040719
BR 2004012581	A	20060919	BR 2004-12581	20040719
JP 2007500691	T	20070118	JP 2006-521702	20040719
RU 2319508	C2	20080320	RU 2006-101628	20040719
IN 2005DN06136	A	20070824	IN 2005-DN6136	20051229
KR 780983	B1	20071130	KR 2006-702034	20060127
MX 2006PA01288	A	20060411	MX 2006-PA1288	20060131
NO 2006000982	A	20060502	NO 2006-982	20060228

PRIORITY APPLN. INFO.:
US 2003-456325P P 20030320
US 2003-492121P P 20030731
US 2004-803146 A2 20040317
WO 2004-IB2461 W 20040719

OTHER SOURCE(S): MARPAT 142:120515
AB A method is provided for treatment and/or prevention of an inflammatory

L5 ANSWER 19 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
condition in a fluid-contg. organ having a natural exterior orifice, such as the udder of a milk-producing animal or an ear of a subject. The invention also relates to a dispersible pharmaceutical compn. suitable for
infusion into the organ according to the method of the invention, and a process for prepg. such a compn. For example, a suspension to be administered by intrammary infusion was prepd. contg. parecoxib 100 mg/mL,
Labrafil M-1944CS 50 mg/mL, microcryst. wax 70 mg/mL,, and cottonseed oil q.s.
IT 22760-18-5, Proquazone 40507-23-1, Fluproquazone
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(dispersible formulation containing anti-inflammatory agents and other active ingredients for infusion)
RN 22760-18-5 CAPLUS
CN 2(1H)-Quinazolinone, 7-methyl-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)



RN 40507-23-1 CAPLUS
CN 2(1H)-Quinazolinone, 4-(4-fluorophenyl)-7-methyl-1-(1-methylethyl)- (CA INDEX NAME)



L5 ANSWER 20 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:967970 CAPLUS
DOCUMENT NUMBER: 142:303397
TITLE: Search for technological reasons to develop a capsule or a tablet formulation with respect to wettability and dissolution
AUTHOR(S): von Orelli, Johannes; Leuenberger, Hans
CORPORATE SOURCE: Institute of Pharmaceutical Technology, Pharmacenter, University of Basel, Basel, CH-4056, Switz.
SOURCE: International Journal of Pharmaceutics (2004), 287(1-2), 135-145
CODEN: IJPHDE; ISSN: 0378-5173
PUBLISHER: Elsevier B.V.
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Proquazone, a poorly wettable compound, was used as a model drug in the search for reasons to develop a capsule or tablet formulation. The capsules were filled with proquazone as active ingredient, with lactose monohydrate (200 mesh) as filler and with magnesium stearate as lubricant.
The tablet was made out of a granulate as internal phase which consisted of proquazone as active ingredient, lactose as filler, corn starch as disintegrant and PVP as a binding agent. The external phase consisted of magnesium stearate and corn starch. The concentration of proquazone in the
capsule and in the tablet formulation was varied. The capsule formulations showed a significantly slower dissoln. of the drug substance than the tablet formulations especially for a high-drug load. Independently of
the drug load, only the tablet formulation showed a high-dissoln. rate. Thus, concerning drug load, only the tablet formulations showed to be robust. It became clear that proquazone needs to be formulated as a granulate or a tablet to achieve a fast dissoln. rate. Thus, a poorly wettable drug, especially when it is found in high concns., can have direct
impact on the decision to develop a tablet or a capsule formulation.
IT 22760-18-5, Proquazone
RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES
(Uses)
(technol. reasons to develop capsule or tablet formulation with respect
to wettability and dissoln.)
RN 22760-18-5 CAPLUS
CN 2(1H)-Quinazolinone, 7-methyl-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)



REFERENCE COUNT: 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS

L5 ANSWER 20 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L5 ANSWER 21 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:802738 CAPLUS
DOCUMENT NUMBER: 141:301477
TITLE: Dispersible pharmaceutical composition for treatment of mastitis and otic disorders
INVENTOR(S): Britten, Nancy J.; Burns, John W.; Hallberg, John W.; Waldron, Niki A.; Watts, Jeffrey L.
PATENT ASSIGNEE(S): Pharmacia Corporation, USA
SOURCE: PCT Int. Appl., 58 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004082719	A1	20040930	WO 2004-IB802	20040310
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004222518	A1	20040930	AU 2004-222518	20040310
CA 2519589	A1	20040930	CA 2004-2519589	20040310
EP 1608406	A1	20051228	EP 2004-719029	20040310
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK				
BR 2004008559	A	20060321	BR 2004-8559	20040310
CN 1761486	A	20060419	CN 2004-80007551	20040310
JP 2006520778	T	20060914	JP 2006-506360	20040310
RU 2321423	C2	20080410	RU 2005-126363	20040310
TW 265809	B	20061111	TW 2004-93107484	20040319
IN 2005DN03645	A	20070817	IN 2005-DN3645	20050818
KR 765614	B1	20071009	KR 2005-717520	20050916
NO 2005004777	A	20051017	NO 2005-4777	20051017
PRIORITY APPLN. INFO.:			US 2003-456201P	P 20030320
			WO 2004-IB802	A 20040310

AB A method is provided for treatment of an infective condition in a fluid-containing organ having a natural exterior orifice, such as the udder of a milk producing animal or an ear. The method comprises administering an antibacterial agent to the organ via the exterior orifice and administering in combination therapy with the antibacterial agent a second agent that is an anti-inflammatory agent, an analgesic and/or an antipyretic. The antibacterial agent and, optionally, the second agent, are administered as a pharmaceutical composition further comprising a vehicle

L5 ANSWER 21 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
that comprises an amphipathic oil that is water dispersible and ethanol insol., microcryst. wax and a pharmaceutically acceptable non-aq. carrier.
Also provided is such a compn. comprising the antibacterial agent and the second agent. The compn. is readily dispersible in the fluid of the fluid-contg. organ. A suspension to be administered by intramammary infusion was contained ceftiofur hydrochloride (micronized) 12.5 mg/mL, Labrafil M-1944CS 50 mg/mL, microcryst. wax 100 mg/mL, cottonseed oil q.s.
IT 40507-23-1, Fluproquazone
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(dispersible pharmaceutical composition for treatment of mastitis and otic disorders)
RN 40507-23-1 CAPLUS
CN 2(1H)-Quinazolinone, 4-(4-fluorophenyl)-7-methyl-1-(1-methylethyl)- (CA INDEX NAME)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L5 ANSWER 22 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:802681 CAPLUS
DOCUMENT NUMBER: 141:301462
TITLE: Dispersible formulations of an anti-inflammatory agent
INVENTOR(S): Britten, Nancy J.; Burns, John W.; Hallberg, John W.; Waldron, Niki A.; Watts, Jeffrey L.
PATENT ASSIGNEE(S): Pharmacia Corporation, USA
SOURCE: PCT Int. Appl., 45 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004082588	A2	20040930	WO 2004-IB826	20040310
WO 2004082588	A3	20041223		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004222523	A1	20040930	AU 2004-222523	20040310
CA 2519125	A1	20040930	CA 2004-2519125	20040310
EP 1608407	A2	20051228	EP 2004-719030	20040310
EP 1608407	B1	20060830		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK				
BR 2004008556	A	20060321	BR 2004-8556	20040310
CN 1761487	A	20060419	CN 2004-80007593	20040310
JP 2006520779	T	20060914	JP 2006-506364	20040310
AT 337793	T	20060915	AT 2004-719030	20040310
ES 2270361	T3	20070401	ES 2004-719030	20040310
RU 2325189	C2	20080527	RU 2005-129266	20040310
TW 262084	B	20060921	TW 2004-93107507	20040319
IN 2005DN03644	A	20070824	IN 2005-DN3644	20050818
NO 2005004260	A	20051212	NO 2005-4260	20050915
PRIORITY APPLN. INFO.:			US 2003-456325P	P 20030320
			WO 2004-IB826	A 20040310

AB A method is provided for treatment of an inflammatory condition in a fluid-containing organ having a natural exterior orifice, such as the udder of a milk producing animal or an ear. The method comprises administering, to the organ via the exterior orifice, a pharmaceutical composition comprising an anti-inflammatory agent and a vehicle that comprises an amphipathic oil that is water dispersible and ethanol insol., microcryst. wax and a pharmaceutically acceptable non-aqueous carrier. Also provided is such a composition comprising the anti-inflammatory agent. The composition is readily

L5 ANSWER 22 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
dispersible in the fluid of the fluid-contg. organ. Thus, a suspension to
be administered by intramammary infusion comprised parecoxib 100, Labrafil
M-1944CS 50, and microcryst. wax 70 mg/mL, and cottonseed oil qs.
IT 22760-18-5, Proquazone 40507-23-1, Fluproquazone
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(dispersible formulations of anti-inflammatory agent)
RN 22760-18-5 CAPLUS
CN 2(1H)-Quinazolinone, 7-methyl-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)



RN 40507-23-1 CAPLUS
CN 2(1H)-Quinazolinone, 4-(4-fluorophenyl)-7-methyl-1-(1-methylethyl)- (CA INDEX NAME)



L5 ANSWER 23 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:718340 CAPLUS
DOCUMENT NUMBER: 141:230701
TITLE: Menthol solutions of drugs
INVENTOR(S): Flashner-Barak, Moshe; Lerner, Itzhak E.; Rosenberger, Vered; Moldavski, Naomi
PATENT ASSIGNEE(S): Teva Pharmaceutical Industries Ltd., Israel; Teva Pharmaceuticals USA, Inc.
SOURCE: PCT Int. Appl., 18 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004073686	A2	20040902	WO 2004-US4684	20040217
WO 2004073686	A3	20041104		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004212989	A1	20040902	AU 2004-212989	20040217
CA 2516798	A1	20040902	CA 2004-2516798	20040217
US 20040198646	A1	20041007	US 2004-781543	20040217
EP 1596832	A2	20051123	EP 2004-711866	20040217
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2006524190	T	20061026	JP 2006-501172	20040217
CN 1882313	A	20061220	CN 2004-80010174	20040217
MX 2005PA08902	A	20051005	MX 2005-PA8902	20050819
AU 2008200464	A1	20080221	AU 2008-200464	20080131

PRIORITY APPLN. INFO.: US 2003-449246P P 20030220
AU 2004-212989 A3 20040217
WO 2004-US4684 A 20040217

AB The present invention relates to compns. comprising solns. of drugs in menthol, especially drugs that are poorly soluble in water, and to methods for making such compns. Simvastatin was solubilized in menthol and the drug bioavailability was improved compared to tablets.
IT 22760-18-5, Proquazone
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(menthol solns. of drugs)
RN 22760-18-5 CAPLUS
CN 2(1H)-Quinazolinone, 7-methyl-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)

L5 ANSWER 23 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



L5 ANSWER 24 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:698112 CAPLUS
DOCUMENT NUMBER: 141:200194
TITLE: New combinations and new use of selected pharmaceutically active tricyclic imidazo[1,2-a]pyridine compounds for preventing or treating medicament-caused gastrointestinal diseases
INVENTOR(S): Zimmermann, Peter Jan; Palmer, Andreas; Brehm, Christof; Klein, Thomas; Senn-Bilfinger, Joerg; Simon, Wolfgang-Alexander; Postius, Stefan; Chiesa, M. Vittoria; Buhr, Wilm; Kromer, Wolfgang
PATENT ASSIGNEE(S): Altana Pharma Ag, Germany
SOURCE: PCT Int. Appl., 97 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004071391	A2	20040826	WO 2004-EP50138	20040216
WO 2004071391	A3	20050512		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004212337	A1	20040826	AU 2004-212337	20040216
CA 2515676	A1	20040826	CA 2004-2515676	20040216
EP 1599175	A2	20051130	EP 2004-711371	20040216
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2004007541	A	20060214	BR 2004-7541	20040216
CN 1747731	A	20060315	CN 2004-80003825	20040216
JP 2006517952	T	20060803	JP 2006-502030	20040216
ZA 2005005451	A	20060830	ZA 2005-5451	20050706
MX 2005PA08490	A	20051018	MX 2005-PA8490	20050810
NO 2005004160	A	20051114	NO 2005-4160	20050907
IN 2005MN00980	A	20060120	IN 2005-MN980	20050908
US 20060154954	A1	20060713	US 2005-545031	20051110

PRIORITY APPLN. INFO.: EP 2003-3530 A 20030217
WO 2004-EP50138 W 20040216

AB The present invention relates to new combinations and new use of certain selected tricyclic imidazo[1,2-a]pyridine compds. in the prevention or treatment of medicament-caused gastrointestinal diseases. At 3.0 μmol/kg, (7R,8R,9R)-8-hydroxy-7-(2-methoxyethoxy)-2,3-dimethyl-9-phenyl-7,8,9,10-tetrahydroimidazo[1,2-h][1,7]naphthyridine reduced gastric lesions induced by 100 mg/kg acetylsalicylic acid in rats.
IT 22760-18-5, PROQUAZone
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(as second active agent; new combinations and new use of selected pharmaceutically active tricyclic imidazo[1,2-a]pyridine compds. for

L5 ANSWER 24 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
preventing or treating medicament-caused gastrointestinal diseases)
RN 22760-18-5 CAPLUS
CN 2(1H)-Quinazolinone, 7-methyl-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)



L5 ANSWER 25 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:539686 CAPLUS
DOCUMENT NUMBER: 142:126433
TITLE: ADME evaluation in drug discovery. 2. Prediction of partition coefficient by atom-additive approach based on atom-weighted solvent accessible surface areas. [Erratum to document cited in CA139:017053]
AUTHOR(S): Hou, T. J.; Xu, X. J.
CORPORATE SOURCE: College of Chemistry and Molecular Engineering, Peking University, Beijing, 100871, Peop. Rep. China
SOURCE: Journal of Chemical Information and Computer Sciences (2004), 44(4), 1516
CODEN: JCISD8; ISSN: 0095-2338
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
AB An important paper reported by Wang et al. was not cited; the reference should read: "40. Wang, R. X.; Lai, L. H. Calculating partition coefficient by atom-additive method. Perspect. Drug Discov. 2000, 19, 47-66". Moreover, the data used in the training set were obtained from Lai's group (http://mdl.ipc.pku.edu.cn/).
IT 23441-63-6
RL: PKT (Pharmacokinetics); BIOL (Biological study)
(ADME evaluation in drug discovery and prediction of partition coefficient by atom-additive approach based on atom-weighted solvent accessible surface areas (Erratum))
RN 23441-63-6 CAPLUS
CN 2(1H)-Quinazolinone, 7-chloro-1-methyl-4-phenyl- (CA INDEX NAME)



L5 ANSWER 26 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:202749 CAPLUS
DOCUMENT NUMBER: 142:176722
TITLE: Product class 2: six-membered hetarenes with three heteroatoms. Product subclass 1: 1,2,3-triazines and phosphorus analogues
AUTHOR(S): Doepp, H.; Doepp, D.
CORPORATE SOURCE: Moers, 47447, Germany
SOURCE: Science of Synthesis (2004), 17, 223-355
CODEN: SSCYJ9
PUBLISHER: Georg Thieme Verlag
DOCUMENT TYPE: Journal; General Review
LANGUAGE: English
AB A review. Methods for preparing triazines and their phosphorus analogs are reviewed including cyclization, ring transformation, aromatization, and substituent modification.
IT 55271-19-7
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of triazines and their phosphorus analogs via cyclization, ring transformation, aromatization, and substituent modification)
RN 55271-19-7 CAPLUS
CN 2(1H)-Quinazolinone, 1-amino-4-phenyl- (CA INDEX NAME)



REFERENCE COUNT: 568 THERE ARE 568 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 27 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:60267 CAPLUS
DOCUMENT NUMBER: 140:117461
TITLE: Therapeutic devices for patterned cell growth
INVENTOR(S): Uhrich, Kathryn E.; Schmalenberg, Kristine
PATENT ASSIGNEE(S): Rutgers State University, USA
SOURCE: PCT Int. Appl., 72 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004006863	A2	20040122	WO 2003-US22361	20030717
WO 2004006863	A3	20040826		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003251992	A1	20040202	AU 2003-251992	20030717
US 20040096476	A1	20040520	US 2003-622072	20030717
PRIORITY APPLN. INFO.:			US 2002-396628P	P 20020717
			WO 2003-US22361	W 20030717

OTHER SOURCE(S): MARPAT 140:117461
AB The invention provides therapeutic devices comprising a polymeric anti-inflammatory agent that biodegrades to release anti-inflammatory agents. The therapeutic devices are useful for repair and regeneration of a variety of injured tissues.
IT 22760-18-5, Proquazone
RL: PEP (Physical, engineering or chemical process); PYP (Physical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(therapeutic devices for patterned cell growth)
RN 22760-18-5 CAPLUS
CN 2(1H)-Quinazolinone, 7-methyl-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)



L5 ANSWER 27 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

L5 ANSWER 28 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2003:1001966 CAPLUS
DOCUMENT NUMBER: 140:321317
TITLE: A novel Pd-catalyzed cyclization reaction of ureas for the synthesis of dihydroquinazolinone p38 kinase inhibitors
AUTHOR(S): Schlapbach, Achim; Heng, Richard; Di Padova, Franco
CORPORATE SOURCE: Novartis Institute for Biomedical Research, Arthritis and Bone Metabolism, Basel, CH-4002, Switz.
SOURCE: Bioorganic & Medicinal Chemistry Letters (2004), 14(2), 357-360
CODEN: BMCLE8; ISSN: 0960-894X
PUBLISHER: Elsevier Science B.V.
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 140:321317
GI



I



II III

AB A series of potent p38 inhibitors based on the dihydroquinazoline scaffold was synthesized using a novel Pd-catalyzed cyclization reaction of aryl benzyl ureas. For example, cyclization of a urea derivative (I) gave 1-(4-hydroxy-2,6-dimethylphenyl)-3,4-dihydro-6-nitro-2(1H)-quinazolinone (II). Sequential treatment of II with 4-(3-chloropropyl)morpholine and then with 3-chloro-4-fluorobenzenesulfonyl chloride a 2(1H)-quinazolinone

L5 ANSWER 28 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

deriv. (III). Optimization of this compd. class led to III, which inhibits p38α in vitro with IC50 = 14 nM and is active in the mouse TNFα-release model.

IT 678173-03-0, 1-(1-Methylethyl)-6-methoxy-7-(4-morpholinyl)-4-phenyl-2(1H)-quinazolinone
RL: PAC (Pharmacological activity); BIOL (Biological study)
(preparation of dihydro-2(1H)-quinazolinone derivs. by palladium-catalyzed cyclization of urea derivs. and their study as p38 kinase inhibitors and TNFα release inhibitors)

RN 678173-03-0 CAPLUS

CN 2(1H)-Quinazolinone, 6-methoxy-1-(1-methylethyl)-7-(4-morpholinyl)-4-phenyl- (CA INDEX NAME)



REFERENCE COUNT: 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 29 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2003:931166 CAPLUS
DOCUMENT NUMBER: 140:751
TITLE: Annelated pyrrole compounds as proton pump inhibitors for treating ulcers and other gastric acid-related conditions
INVENTOR(S): Smolka, Adams J.; Hammond, Charles E.; Gupta, Sandeep
PATENT ASSIGNEE(S): Merckle GMBH, Germany
SOURCE: PCT Int. Appl., 58 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003097041	A1	20031127	WO 2003-EP5171	20030516
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2484238	A1	20031127	CA 2003-2484238	20030516
AU 2003232788	A1	20031202	AU 2003-232788	20030516
EP 1505964	A1	20050216	EP 2003-752754	20030516
EP 1505964	B1	20071121		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003010068	A	20050308	BR 2003-10068	20030516
CN 1652771	A	20050810	CN 2003-811246	20030516
JP 2006509720	T	20060323	JP 2004-505040	20030516
NZ 536444	A	20061222	NZ 2003-536444	20030516
ES 2297204	T3	20080501	ES 2003-752754	20030516
MX 2004PA11097	A	20050214	MX 2004-PA11097	20041109
ZA 2004010123	A	20060726	ZA 2004-10123	20041215
US 20060040945	A1	20060223	US 2005-513327	20050713

PRIORITY APPLN. INFO.: EP 2002-11081 A 20020517
US 2002-380928P P 20020517
WO 2003-EP5171 W 20030516

OTHER SOURCE(S): MARPAT 140:751
GI

L5 ANSWER 29 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



I

AB Inhibiting gastric proton pumps in a mammal is accomplished by the use of an annelated pyrrole compound A preferred compound is I (ML 3000). The treatment ameliorates, diminishes, actively treats, reverses, or prevents any injury, damage or lesions of gastric mucosa, e.g. gastric mucosal lesions and ulceration.

IT 22760-18-5, Proquazone
RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(annelated pyrrole compds. as proton pump inhibitors for treating ulcers and other gastric acid-related conditions, and use with other agents)

RN 22760-18-5 CAPLUS

CN 2(1H)-Quinazolinone, 7-methyl-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 30 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2003:855743 CAPLUS
DOCUMENT NUMBER: 139:335104
TITLE: Gelsolin as a prognostic marker of atherosclerotic diseases
INVENTOR(S): Stossel, Thomas P.
PATENT ASSIGNEE(S): The Brigham and Women's Hospital, Inc., USA
SOURCE: PCT Int. Appl., 46 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003088811	A2	20031030	WO 2003-US11722	20030416
WO 2003088811	A3	20040226		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003226401	A1	20031103	AU 2003-226401	20030416
PRIORITY APPLN. INFO.:			US 2002-373043P	P 20020416
			WO 2003-US11722	W 20030416

AB This invention involves the using blood gelsolin levels as a diagnostic test to determine the risk of atherosclerotic diseases such as myocardial infarction, stroke, and peripheral ischemic cardiovascular disease, particularly among subjects with no signs or symptoms of current disease and among nonsmokers. Further, this invention involves the new use of a diagnostic test to assist physicians in determining which subjects at risk will preferentially benefit from certain treatments designed either to prevent first or recurrent myocardial infarctions and strokes, or to treat acute and chronic cardiovascular disorders.

IT 22760-18-5, Proquazone 37554-40-8, Fluquazone
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(gelsolin as prognostic marker of atherosclerotic diseases)

RN 22760-18-5 CAPLUS

CN 2(1H)-Quinazolinone, 7-methyl-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)

L5 ANSWER 30 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 37554-40-8 CAPLUS

CN 2(1H)-Quinazolinone, 6-chloro-4-phenyl-1-(2,2,2-trifluoroethyl)- (CA INDEX NAME)



L5 ANSWER 31 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2003:832983 CAPLUS
DOCUMENT NUMBER: 140:41652
TITLE: Structural Identification of Local Maxima in Low-Resolution Promolecular Electron Density Distributions
AUTHOR(S): Leherte, Laurence; Dury, Laurent; Vercauteren, Daniel P.
CORPORATE SOURCE: Laboratoire de Physico-Chimie Informatique, Facultes Universitaires Notre-Dame de la Paix, Namur, B-5000, Belg.
SOURCE: Journal of Physical Chemistry A (2003), 107(46), 9875-9886
CODEN: JPCAFH; ISSN: 1089-5639
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English

AB In this paper, we present a theor. method to describe mol. structures in terms of hierarchically related substructures. The approach is based on the location of local maxima (peaks) in promol. electron d. distributions (EDD) established at continuously varying resolution levels. For each of the so-calculated EDD, the local maxima are determined by using a hierarchical clustering algorithm wherein peaks obtained at a given resolution are used as starting points for discovering peaks at the next lower resolution level through gradient trajectories of the EDD. The use of such an approach allows assignment of mol. fragments or chemical groups to peaks, at any resolution level. Results, obtained for a set of four benzodiazepine-related mols. and three thrombin inhibitors, are presented in terms of dendrograms wherein each node corresponds to a well-defined mol. substructure.

IT 20927-53-1, 6-Chloro-4-phenyl-1-methyl-2(1H)-quinazolinone
RL: PRP (Properties)
(structural identification of local maxima in low-resolution promol. electron d. distributions)

RN 20927-53-1 CAPLUS

CN 2(1H)-Quinazolinone, 6-chloro-1-methyl-4-phenyl- (CA INDEX NAME)



REFERENCE COUNT: 53 THERE ARE 53 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 32 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2003:796454 CAPLUS
DOCUMENT NUMBER: 139:297013
TITLE: Drug microparticles deposited on sugar, starch, lactose, or cellulose carrier particles from solid solutions
INVENTOR(S): Lerner, Itzhak E.; Rosenberger, Vered; Flashner-Barak, Moshe; Drabkin, Anna; Moldavski, Naomi
PATENT ASSIGNEE(S): Teva Pharmaceutical Industries Ltd., Israel; Teva Pharmaceuticals USA, Inc.
SOURCE: PCT Int. Appl., 20 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003082247	A2	20031009	WO 2003-US9327	20030325
WO 2003082247	A3	20040205		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2480377	A1	20031009	CA 2003-2480377	20030325
AU 2003226021	A1	20031013	AU 2003-226021	20030325
US 20030224059	A1	20031204	US 2003-400100	20030325
EP 1487416	A2	20041222	EP 2003-745623	20030325
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2005531521	T	20051020	JP 2003-579785	20030325
NZ 535854	A	20060831	NZ 2003-535854	20030325
NZ 546777	A	20060929	NZ 2003-546777	20030325
MX 2004PA09385	A	20050125	MX 2004-PA9385	20040924
US 20060141050	A1	20060629	US 2006-356682	20060217
US 20060141051	A1	20060629	US 2006-357248	20060217
US 20060141052	A1	20060629	US 2006-357757	20060217

PRIORITY APPLN. INFO.:	US 2002-367957P	P 20020326
	NZ 2003-535854	A1 20030325
	US 2003-400100	A1 20030325
	WO 2003-US9327	W 20030325

AB A drug delivery vehicle is provided including a pharmaceutical carrier particle, especially sugar, starch, lactose, or microcryst. cellulose particles,

L5 ANSWER 32 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
bearing microparticles of a drug, esp. a drug with poor water soly. The microparticles of the drug are deposited on the pharmaceutical carrier particles from a solid soln. of the drug in a sublimable carrier such as menthol, thymol, camphor, tert-butanol, trichloro-tert-butanol, imidazole, coumarin, glacial acetic acid, dimethylsulfone, urea, vanillin, camphene, salicylamide, and 2-aminopyridine. A method of making a drug delivery vehicle comprises the steps of (a) forming a solid soln. of the drug and a sublimable carrier on the surface of a pharmaceutical carrier particle, and (b) subliming the sublimable carrier from the solid soln. to deposit microparticles of the drug on the surface of the pharmaceutical carrier particle to obtain the drug delivery vehicle. The sublimable carrier is sublimed from the solid soln. by treating the pharmaceutical carrier particles in a fluidized bed drier at a temp. below the m.p. of the solid soln. For example, fenofibrate was dissolved in melted menthol, microcryst. cellulose was added to the melt, and the mass obtained was allowed to cool to room temp. and milled. The powder was transferred to a fluid bed dryer where the menthol was removed and micronized fenofibrate deposited on microcryst. cellulose was obtained. Fenofibrate micronized by the methanol method gave 100% dissoln. in 2 h. The equivalent simple combination with microcryst. cellulose (control, not deposited from menthol) gave 40.2% dissoln. in 3 h, while a mech. micronized fenofibrate mixed with microcryst. cellulose gave 72.1% dissoln. in 3 h.
IT 22760-18-5, Proquazone
RL: PEP (Physical, engineering or chemical process); PRP (Properties); PYP (Physical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(drug microparticles deposited on carrier particles from solid solution in sublimable carrier)
RN 22760-18-5 CAPLUS
CN 2(1H)-Quinazolinone, 7-methyl-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)



L5 ANSWER 33 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2003:747138 CAPLUS
DOCUMENT NUMBER: 139:392238
TITLE: Toxicological Screening with Formula-Based Metabolite Identification by Liquid Chromatography/Time-of-Flight Mass Spectrometry
AUTHOR(S): Pelander, Anna; Ojanperae, Ilkka; Laks, Suvi; Rasanen, Ilpo; Vuori, Erkki
CORPORATE SOURCE: Department of Forensic Medicine, University of Helsinki, FIN-00014, Finland
SOURCE: Analytical Chemistry (2003), 75(21), 5710-5718
CODEN: ANCHAM; ISSN: 0003-2700
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
AB An anal. procedure was evaluated for the comprehensive toxicol. screening of drugs, metabolites, and pesticides in 1-mL urine samples by TurboIon spray liquid chromatog./time-of-flight mass spectrometry (LC/TOFMS) in the pos. ionization mode and continuous mass measurement. The substance database consisted of exact monoisotopic masses for 637 compds., of which an LC retention time was available for 392. A macroprogram was refined for extracting the data into a legible report, utilizing metabolic patterns and preset identification criteria. These criteria included ±30 ppm mass tolerance, a ±0.2-min window for absolute retention time, if available, and a min. area count of 500. The limit of detection, determined for 90 compds., was <0.1 mg/L for 73% of the compds. studied and >1.0 mg/L for 6% of the compds. For method comparisons, 50 successive autopsy urine samples were analyzed by this method, and the results confirmed by gas chromatog./mass spectrometry (GC/MS). Findings for parent drugs were consistent with both methods; in addition, LC/TOFMS regularly revealed apparently correct findings for metabolites not shown by GC/MS. Mean and median mass accuracy by LC/TOFMS was 7.6 and 5.4 ppm, resp. The procedure proved well-suited for tentative identification without reference substances. The few false positives emphasized the fact that all three parameters, exact mass, retention time, and metabolite pattern, are required for unequivocal identification.
IT 22760-18-5, Proquazone
RL: ANT (Analyte); PRP (Properties); ANST (Analytical study)
(toxicol. screening of drugs and metabolites in urine samples with formula-based metabolite identification by liquid chromatog./time-of-flight mass spectrometry)
RN 22760-18-5 CAPLUS
CN 2(1H)-Quinazolinone, 7-methyl-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)

L5 ANSWER 33 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



REFERENCE COUNT: 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 34 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2003:746332 CAPLUS
DOCUMENT NUMBER: 139:395885
TITLE: Discovery of a novel potent Na+/Ca2+ exchanger inhibitor: design, synthesis and structure-activity relationships of 3,4-dihydro-2(1H)-quinazolinone derivatives
AUTHOR(S): Hasegawa, Hirohiko; Muraoka, Masami; Matsui, Kazuki; Kojima, Atsuyuki
CORPORATE SOURCE: Research Center, Sumitomo Pharmaceuticals Co., Ltd., Konohana-ku, Osaka, 554-0022, Japan
SOURCE: Bioorganic & Medicinal Chemistry Letters (2003), 13(20), 3471-3475
CODEN: BMCLE8; ISSN: 0960-894X
PUBLISHER: Elsevier Science B.V.
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 139:395885
AB Design, synthesis and structure-activity relationships for 3,4-dihydro-2(1H)-quinazolinone derivs. with inhibitory activities of the Na+/Ca2+ exchanger are discussed. These studies based on the lead compound 6-chloro-3-[3-(dimethylamino)propyl]-3,4-dihydro-4-phenyl-2(1H)-quinazolinone lead to the discovery of a structurally novel and highly potent inhibitor against the Na+/Ca2+ exchanger SM-15811 [3,4-dihydro-4-phenyl-3-[1-(phenylmethyl)-4-piperidinyl]-2(1H)-quinazolinone 2-hydroxy-1,2,3-propanetricarboxylate] which directly inhibited the Na+-dependent Ca2+ influx via the Na+/Ca2+ exchanger in cardiomyocytes with a high potency.
IT 625835-76-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(design, preparation and structure-activity relationship of dihydro-2(1H)-quinazolinone derivs. (potent sodium/calcium exchanger inhibitors))
RN 625835-76-9 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-3-[3-(dimethylamino)propyl]-3,4-dihydro-1-methyl-4-phenyl- (CA INDEX NAME)



REFERENCE COUNT: 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 35 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2003:599169 CAPLUS
DOCUMENT NUMBER: 140:22831
TITLE: Effects of inflammation and antiinflammatory treatment on serum trace elements concentrations
AUTHOR(S): Akcil, Ethem; Yavuz, Guelnur; Kocak, Mehtap
CORPORATE SOURCE: Department of Pathophysiology, Faculty of Medicine, Ankara University, Ankara, Turk.
SOURCE: Biological Trace Element Research (2003), 93(1-3), 95-103
CODEN: BTERDG; ISSN: 0163-4984
PUBLISHER: Humana Press Inc.
DOCUMENT TYPE: Journal
LANGUAGE: English
AB We investigated the serum concns. of zinc and copper during the inflammatory process together with the effect of treatment with a non-steroid anti-inflammatory agent on these trace elements concns. In the present study, we used 92 guinea pigs, 12 of which constituted the control group; the remaining 80 were the exptl. group. To start with, proquazone (as anti-inflammatory agent) was administered orally to 40 guinea pigs of the exptl. group at 20-mg/kg doses 2 h before the surgery. Throughout the exptl. period, the above dose was administered to the animals twice a day. We produced inflammation in all animals of the exptl. group by using carrageenan (inflammatory agent) dropped into mandibular surgical defects. Serum concns. of zinc and copper were determined by atomic absorption spectrophotometry in both groups at the 6th, 48th, 120th, 168th, and 240th h. The serum zinc concns. of the carrageenan-administered group decreased significantly ($p < 0.01$). When comparing the serum zinc concns. of the carrageenan plus proquazone-administered group with those of control group, the decrease ($p < 0.05$) at the 6th, 48th, and 120th h were statistically significant. When the copper serum concns. of the carrageenan-administered group were compared with those of the control group, at the 48th, 120th, and 168th h, a statistically significant increase ($p < 0.01$) was observed However, there was no significant change in the carrageenan plus proquazone-administered group at the 168th and 240th h. As a result during the acute phase of inflammation, serum zinc concns. decreased, whereas serum copper concns. increased. The alterations in zinc concns. were more rapid than those in copper concns., but the administration of proquazone slowed the rate of decrease in serum zinc concns.
IT 22760-18-5, Proquazone
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(effects of inflammation and antiinflammatory treatment on serum trace elements concns.)
RN 22760-18-5 CAPLUS
CN 2(1H)-Quinazolinone, 7-methyl-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)

L5 ANSWER 35 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



REFERENCE COUNT: 35 THERE ARE 35 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 36 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2003:407345 CAPLUS
DOCUMENT NUMBER: 140:35516
TITLE: Effects of cyclooxygenase inhibitors on nitric oxide production and survival in a mice model of sepsis
AUTHOR(S): Tunctan, Bahar; Altug, Sedat; Uludag, Orhan; Demirkay, Beray; Abacioglu, Nurettin
CORPORATE SOURCE: Department of Pharmacology, Gazi University, Ankara, 06330, Turk.
SOURCE: Pharmacological Research (2003), 48(1), 37-48
CODEN: PHMREP; ISSN: 1043-6618
PUBLISHER: Elsevier Science Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English
AB The effects of selective ((5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulfonyl-2(5H)-furanone); DFU) and (N-(2-cyclohexyloxy-4-nitrophenyl)-methanesulfonamide; NS 398)) or non-selective (diclofenac and proquazone) inducible cyclooxygenase (COX-2) inhibitors on the survival, nitrite (stable product of nitric oxide (NO) as an index for inducible NO synthase (iNOS) activity) and 6-keto-prostaglandin F1α (6-keto-PGF1α, stable product of prostacyclin as an index for COX-2 activity) production in serum, lungs, brain and/or kidney were investigated in endotoxin-induced sepsis model in mice. Endotoxin (10 mg kg-1, i.p.)-induced mortality was prevented by DFU, NS 398 and proquazone (0.1, 10 and 1 mg kg-1, resp.) and enhanced 2.6-fold with 0.1 mg kg-1 diclofenac. Endotoxin-induced increase in the serum levels of nitrite was only inhibited by 10 mg kg-1 diclofenac. Endotoxin caused a significant decrease only in the brain levels of nitrite without affecting 6-keto-PGF1α levels in all tissues. The decreased levels of nitrite induced by endotoxin is further reduced by 0.1 mg kg-1 DFU and 1 and 10 mg kg-1 diclofenac while 10 mg kg-1 DFU and 1 mg kg-1 proquazone increased it. On the other hand, 1 mg kg-1 diclofenac and proquazone, and 10 mg kg-1 NS 398 increased the endotoxin-induced lung levels of 6-keto-PGF1α. The results suggest that the COX inhibitors may have different effects on the survival and NO production depending on tissue and dose.
IT 22760-18-5, Proquazone
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(effects of cyclooxygenase inhibitors on nitric oxide production and survival in a mouse model of sepsis)
RN 22760-18-5 CAPLUS
CN 2(1H)-Quinazolinone, 7-methyl-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)

L5 ANSWER 36 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



REFERENCE COUNT: 71 THERE ARE 71 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L5 ANSWER 37 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2003:377132 CAPLUS
DOCUMENT NUMBER: 138:367144
TITLE: Soluble CD40L (CD154) as a prognostic marker of atherosclerotic diseases
INVENTOR(S): Schoenbeck, Uwe; Ridker, Paul M.; Libby, Peter
PATENT ASSIGNEE(S): The Brigham and Women's Hospital, Inc., USA
SOURCE: PCT Int. Appl., 66 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003040691	A2	20030515	WO 2002-US35505	20021105
WO 2003040691	A3	20031113		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2464531	A1	20030515	CA 2002-2464531	20021105
AU 2002343620	A1	20030519	AU 2002-343620	20021105
US 20030152566	A1	20030814	US 2002-288253	20021105
US 7189518	B2	20070313		
EP 1451577	A2	20040901	EP 2002-780578	20021105
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
CN 1613012	A	20050504	CN 2002-826711	20021105
JP 2005515407	T	20050526	JP 2003-542897	20021105
US 20080058360	A1	20080306	US 2007-716996	20070312

PRIORITY APPLN. INFO.: US 2001-338841P P 20011105
US 2002-288253 A1 20021105
WO 2002-US35505 W 20021105

AB The invention involves the new use of a diagnostic test to determine the risk of atherosclerotic diseases, e.g. myocardial infarction and stroke, particularly among individuals with no signs or symptoms of current disease and among nonsmokers. Further, the invention involves the new use of a diagnostic test to assist physicians in determining which individuals at risk will preferentially benefit from certain treatments designed either to prevent first or recurrent myocardial infarctions and strokes, or to treat acute and chronic cardiovascular disorders. Methods for treatment are also described.

L5 ANSWER 37 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
IT 22760-18-5, Proquazone 37554-40-8, Fluquazone
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(soluble CD40L as prognostic marker of atherosclerotic diseases, and use
in therapeutic agent assessment)
RN 22760-18-5 CAPLUS
CN 2(1H)-Quinazolinone, 7-methyl-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)



RN 37554-40-8 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-4-phenyl-1-(2,2,2-trifluoroethyl)- (CA INDEX NAME)



L5 ANSWER 38 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2003:293606 CAPLUS
DOCUMENT NUMBER: 139:197461
TITLE: 5-Imidazolylquinolinones, -quinazolinones, and -benzoazepinones as farnesyltransferase inhibitors
AUTHOR(S): Angibaud, Patrick; Bourdrez, Xavier; Devine, Ann; End, David W.; Freyne, Eddy; Ligny, Yannick; Muller, Philippe; Mannens, Geert; Pilatte, Isabelle; Poncelet, Virginie; Skrzat, Stacy; Smets, Gerda; Van Dun, Jacky; Van Remoortere, Pieter; Venet, Marc; Wouters, Walter
CORPORATE SOURCE: Medicinal Chemistry Department, Johnson & Johnson Pharmaceutical Research & Development, Val de Reuil, 27106, Fr.
SOURCE: Bioorganic & Medicinal Chemistry Letters (2003), 13(9), 1543-1547
CODEN: BMCLE8; ISSN: 0960-894X
PUBLISHER: Elsevier Science B.V.
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 139:197461
GI



I

AB The evaluation of structure-activity relationships associated with the modification of the R115777 quinolinone ring moiety displaying potent in vitro inhibiting activity is described. E.g., pyrrol[3,2,1-ij]quinolin-4-one I, an analog of R115777, was prepared from 2,3-dihydroindole and its farnesyltransferase-inhibiting activity was determined

IT 215034-66-5P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation of imidazolylquinolinones, -quinazolinones, and -benzoazepinones as farnesyltransferase inhibitors)
RN 215034-66-5 CAPLUS
CN 2(1H)-Quinazolinone, 6-[amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methyl- (CA INDEX NAME)

L5 ANSWER 38 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



IT 215034-62-1P 215034-86-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of imidazolylquinolinones, -quinazolinones, and -benzoazepinones as farnesyltransferase inhibitors)
RN 215034-62-1 CAPLUS
CN 2(1H)-Quinazolinone, 4-(3-chlorophenyl)-6-[(4-chlorophenyl)hydroxy(1-methyl-1H-imidazol-5-yl)methyl]-1-methyl- (CA INDEX NAME)



RN 215034-86-9 CAPLUS
CN 2(1H)-Quinazolinone, 6-(4-chlorobenzoyl)-4-(3-chlorophenyl)-1-methyl- (CA
INDEX NAME)

L5 ANSWER 38 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



REFERENCE COUNT: 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L5 ANSWER 39 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2003:282929 CAPLUS
DOCUMENT NUMBER: 139:17053
TITLE: ADME Evaluation in Drug Discovery. 2. Prediction of Partition Coefficient by Atom-Additive Approach Based on Atom-Weighted Solvent Accessible Surface Areas
AUTHOR(S): Hou, T. J.; Xu, X. J.
CORPORATE SOURCE: College of Chemistry and Molecular Engineering, Peking
University, Beijing, 100871, Peop. Rep. China
SOURCE: Journal of Chemical Information and Computer Sciences (2003), 43(3), 1058-1067
CODEN: JCISD8; ISSN: 0095-2338
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English

AB A novel method for the calcns. of 1-octanol/water partition coefficient (log P)
of organic mols. has been presented here. The method, SLOGP v1.0, ests. the
log P values by summing the contribution of atom-weighted solvent accessible surface areas (SASA) and correction factors. Altogether 100 atom/group types were used to classify atoms with different chemical environments, and two correlation factors were used to consider the intermol. hydrophobic interactions and intramol. hydrogen bonds. Coefficient
values for 100 atom/group and two correction factors have been derived from a training set of 1850 compds. The parametrization procedure for different kinds of atoms was performed as follows: first, the atoms in a mol. were defined to different atom/group types based on SMARTS language, and the correction factors were determined by substructure searching; then,
SASA for each atom/group type was calculated and added; finally, multivariate
linear regression anal. was applied to optimize the hydrophobic parameters
for different atom/group types and correction factors in order to reproduce the exptl. log P. The correlation based on the training set gives a model with the correlation coefficient (r) of 0.988, the standard deviation
(SD) of 0.368 log units, and the absolute unsigned mean error of 0.261. Comparison of various procedures of log P calcns. for the external test set of 138 organic compds. demonstrates that our method bears very good accuracy and is comparable or even better than the fragment-based approaches. Moreover, the atom-additive approach based on SASA was compared with the simple atom-additive approach based on the number of atoms.
The calculated results show that the atom-additive approach based on SASA gives better predictions than the simple atom-additive one. Due to the connection between the mol. conformation and the mol. surface areas, the atom-additive model based on SASA may be a more universal model for log P estimation especially for large mols.

IT 23441-63-6
RL: PKT (Pharmacokinetics); BIOL (Biological study)
(ADME evaluation in drug discovery and prediction of partition coefficient
by atom-additive approach based on atom-weighted solvent accessible surface areas)
RN 23441-63-6 CAPLUS
CN 2(1H)-Quinazolinone, 7-chloro-1-methyl-4-phenyl- (CA INDEX NAME)

L5 ANSWER 39 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



REFERENCE COUNT: 42 THERE ARE 42 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L5 ANSWER 40 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2003:242192 CAPLUS
DOCUMENT NUMBER: 138:248511
TITLE: Combination of phosphodiesterase 4 inhibitor and nonsteroidal antiinflammatory drug in treatment of inflammation
INVENTOR(S): Hatzelmann, Armin; Eltze, Manfrid; Klein, Thomas; Kley, Hans-Peter
PATENT ASSIGNEE(S): Altana Pharma A.-G., Germany
SOURCE: PCT Int. Appl., 42 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003024489	A2	20030327	WO 2002-EP10424	20020917
WO 2003024489	A3	20030918		
W: AE, AL, AU, BA, BR, CA, CN, CO, CU, DZ, EC, GE, HR, HU, ID, IL, IN, IS, JP, KR, LT, LV, MA, MK, MX, NO, NZ, PH, PL, RO, SG, SI, TN, UA, US, VN, YU, ZA, ZW				
RW: AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR				
CA 2459757	A1	20030327	CA 2002-2459757	20020917
AU 2002337105	A1	20030401	AU 2002-337105	20020917
AU 2002337105	B2	20080320		
EP 1429807	A2	20040623	EP 2002-772313	20020917
EP 1429807	B1	20070228		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
BR 2002012606	A	20040817	BR 2002-12606	20020917
HU 2004001582	A2	20041129	HU 2004-1582	20020917
HU 2004001582	A3	20080428		
JP 2005504077	T	20050210	JP 2003-528583	20020917
CN 1625411	A	20050608	CN 2002-818241	20020917
NZ 532278	A	20060224	NZ 2002-532278	20020917
AT 355080	T	20060315	AT 2002-772313	20020917
ES 2282469	T3	20071016	ES 2002-772313	20020917
IN 2004MN00112	A	20050218	IN 2004-MN112	20040213
MX 2004PA02562	A	20040531	MX 2004-PA2562	20040318
US 20040242597	A1	20041202	US 2004-489920	20040318
ZA 2004002654	A	20050214	ZA 2004-2654	20040405
NO 2004001596	A	20040618	NO 2004-1596	20040419
HK 1066730	A1	20070824	HK 2004-109770	20041209

PRIORITY APPLN. INFO.: EP 2001-473 A 20010919
WO 2002-EP10424 W 20020917

AB The invention relates to the combined administration of PDE4-inhibitors and NSAIDs for the treatment of an inflammatory disease and/or an inflammation associated disorder while minimizing gastrointestinal side effects, such as gastric erosions and ulcer, which are frequently associated with the use of NSAIDs. PDE4 inhibitors Rolipram, Roflumilast, and

L5 ANSWER 40 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
RP73401 inhibited or prevented diclofenac induced gastrointestinal bleeding in mice.
IT 22760-18-5, PROQUAZONE
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(NSAID; combination of phosphodiesterase 4 inhibitor and nonsteroidal antiinflammatory drug in treatment of inflammation)
RN 22760-18-5 CAPLUS
CN 2(1H)-Quinazolinone, 7-methyl-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)



L5 ANSWER 41 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2003:84725 CAPLUS
DOCUMENT NUMBER: 139:254942
TITLE: Risk of stroke associated with NSAID drugs. A nested case-control study
AUTHOR(S): Bak, Soren; Andersen, Morten; Tsiropoulos, Ioannis; Garcia Rodriguez, Luis Alberto; Hallas, Jesper; Christensen, Kaare; Gaist, David; Qureshi, Adnan I.
CORPORATE SOURCE: Institute of PUblic Health, Departments of Epidemiology and Clinical Pharmacology, University of Southern Denmark, Odense, 5000, Den.
SOURCE: Stroke (2003), 34(2), 379-386
CODEN: SJCCA7; ISSN: 0039-2499
PUBLISHER: Lippincott Williams & Wilkins
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Nonsteroidal anti-inflammatory drugs (NSAIDs) have been associated with bleeding complications and may affect the risk of hemorrhagic stroke through inhibition of platelet cyclooxygenase-1. We performed a population-based case-control study to estimate the risk of intracerebral hemorrhage, subarachnoid hemorrhage, and ischemic stroke in users of NSAIDs. We used a population-based patient registry to identify all patients with a first-ever stroke discharge diagnosis in the period of 1994 to 1999. All diagnoses were validated according to predefined criteria. We selected 40000 random controls from the background population. Information on drug use for cases and controls was retrieved from a prescription registry. Odds ratios were adjusted for age, sex, calendar year, and use of other medication. To evaluate the effect of various potential confounders not recorded in the register, we performed sep. analyses on data from 2 large population-based surveys with more detailed information on risk factors. The cases were classified as intracerebral hemorrhage (n = 649), subarachnoid hemorrhage (n = 208), and ischemic stroke (n = 2717). The adjusted odds ratio of stroke in current NSAID users compared with never users was 1.2 (95% CI, 0.9 to 1.6) for intracerebral hemorrhage, 1.2 (95% CI, 0.7 to 2.1) for subarachnoid hemorrhage and 1.2 (95% CI, 0.7 to 2.1) for subarachnoid hemorrhage and 1.2 (95% confidence interval, 1.0 to 1.4) for ischemic stroke. The survey data indicated that addnl. confounder control would not have led to an increase in relative risk ests. Current exposure to NSAIDS is not a risk factor for intracerebral hemorrhage or subarachnoid hemorrhage. Furthermore, NSAIDS probably offer no protection against first-ever ischemic stroke.
IT 22760-18-5, Proquazone
RL: ADV (Adverse effect, including toxicity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(risk of stroke associated with NSAID drugs)
RN 22760-18-5 CAPLUS
CN 2(1H)-Quinazolinone, 7-methyl-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)

L5 ANSWER 41 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 42 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2003:72023 CAPLUS
DOCUMENT NUMBER: 138:247937
TITLE: Pharmacophore Modeling as an Efficient Tool in the Discovery of Novel Noncompetitive AMPA Receptor Antagonists
AUTHOR(S): Barreca, Maria Letizia; Gitto, Rosaria; Quartarone, Silvana; De Luca, Laura; De Sarro, Giovambattista; Chimirri, Alba
CORPORATE SOURCE: Dipartimento Farmaco-Chimico, Universita di Messina, Messina, 98168, Italy
SOURCE: Journal of Chemical Information and Computer Sciences (2003), 43(2), 651-655
CODEN: JCISD8; ISSN: 0095-2338
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
AB A three-dimensional pharmacophore model for the binding of noncompetitive AMPA receptor antagonists was developed to map common structural features of highly active compds. This hypothesis, which consists of two hydrophobic regions, one hydrogen bond acceptor and one aromatic region, was successfully used as framework for the design of a new class of allosteric modulators containing a tetrahydroisoquinoline skeleton and for in silico screening. The promising biol. results suggested that the identified mols. might be useful "lead compds." for future drug development.
IT 23441-88-5, RH 01490
RL: PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmacophore modeling and discovery of novel noncompetitive AMPA receptor antagonists)
RN 23441-88-5 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-4-(2-chlorophenyl)-1-methyl- (CA INDEX NAME)



REFERENCE COUNT: 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 43 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2003:49279 CAPLUS
DOCUMENT NUMBER: 139:159420
TITLE: Discrimination and selection of new potential antibacterial compounds using simple topological descriptors
AUTHOR(S): Murcia-Soler, Miguel; Perez-Gimenez, Facundo; Garcia-March, Francisco J.; Salabert-Salvador, M. Teresa; Diaz-Villanueva, Wladimiro; Medina-Casamayor, Piedad
CORPORATE SOURCE: Faculty of Pharmacy, Department of Physical Chemistry, Universitat de Valencia, Valencia, Spain
SOURCE: Journal of Molecular Graphics & Modelling (2003), 21(5), 375-390
CODEN: JMGMFI; ISSN: 1093-3263
PUBLISHER: Elsevier Science Inc.
DOCUMENT TYPE: Journal
LANGUAGE: English
AB The aim of the work was to discriminate between antibacterial and non-antibacterial drugs by topol. methods and to select new potential antibacterial agents from among new structures. The method used for antibacterial activity selection was a linear discriminant anal. (LDA). It is possible to obtain a QSAR interpretation of the information contained in the discriminant function. We make use of the pharmacol. distribution diagrams (PDDs) as a visualizing technique for the identification and selection of new antibacterial agents.
IT 40507-23-1, Fluproquazone
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(discrimination and selection of new potential antibacterial compds. using simple topol. descriptors)
RN 40507-23-1 CAPLUS
CN 2(1H)-Quinazolinone, 4-(4-fluorophenyl)-7-methyl-1-(1-methylethyl)- (CA INDEX NAME)



REFERENCE COUNT: 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 43 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

L5 ANSWER 44 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2002:946092 CAPLUS
DOCUMENT NUMBER: 138:11401
TITLE: Steroid hormone and nonsteroidal anti-inflammatory drug (NSAID) combinations for inducing tumor cell apoptosis
INVENTOR(S): Andrews, Peter; Djakiew, Daniel
PATENT ASSIGNEE(S): Georgetown University, USA
SOURCE: PCT Int. Appl., 49 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002098403	A1	20021212	WO 2002-US17193	20020603
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002312204	A1	20021216	AU 2002-312204	20020603
PRIORITY APPLN. INFO.:			US 2001-294583	A 20010601
			WO 2002-US17193	W 20020603

AB A pharmaceutical composition is described, having at least one nonsteroidal anti-inflammatory drug (NSAID), at least one steroid hormone, a pharmaceutically acceptable carrier, and optionally, one or more excipients, wherein the at least one NSAID and the at least one steroid hormone are present in amts. sufficient to induce tumor cell apoptosis. Also described is a method of inducing apoptosis of cancer cells in which therapeutically effective amts. of at least one NSAID and at least one steroid hormone are administered to a subject. The NSAID and steroid hormone may administered prophylactically to a subject having nonmeasurable tumor burden, or may be administered to a subject having a detectable tumor.
IT 22760-18-5, Proquazone
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(steroid hormone and nonsteroidal anti-inflammatory drug combination for inducing tumor cell apoptosis)
RN 22760-18-5 CAPLUS
CN 2(1H)-Quinazolinone, 7-methyl-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)

L5 ANSWER 44 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 45 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2002:595343 CAPLUS
DOCUMENT NUMBER: 137:150228
TITLE: Antiinflammatory compositions and methods for therapy through enhanced tissue regeneration
INVENTOR(S): Uhrich, Kathryn E.; Macedo, Braz
PATENT ASSIGNEE(S): Rutgers, The State University of New Jersey, USA
SOURCE: U.S. Pat. Appl. Publ., 17 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
US 20020106345	A1	20020808	US 2000-732516		20001207
US 6685928	B2	20040203			
AU 2006201924	A1	20060601	AU 2006-201924		20060509
US 20070014832	A1	20070118	US 2006-524664		20060921
PRIORITY APPLN. INFO.:			US 1999-304190P	P	19991207
			US 1999-455861	A	19991207
			AU 2001-19565	A3	20001207
			US 2000-732516	A1	20001207
			WO 2000-US33378	A1	20001207
			US 2003-368288	B1	20030218

AB The invention provides methods of promoting healing through enhanced regeneration of tissue (e.g. hard tissue or soft tissue) by contacting the tissue or the surrounding tissue with an antiinflammatory agent, preferably in a controlled-release form, e.g. by dispersing the agent through a polymer matrix, appending the agent to a polymer backbone, or incorporating the agent directly into a biodegradable polymer backbone. These methods are useful in a variety of dental and orthopedic applications. Expts. are presented which demonstrate that implantation of a film comprising an aromatic polyanhydride that hydrolyzes to form a therapeutically useful salicylate resulted in less swelling in tissues adjacent to the film and a decrease in the d. of inflammatory cells as compared to other polyanhydride films. Preparation of e.g. poly[1,6-bis(o-carboxyphenoxy) hexane] is described.
IT 22760-18-5, Proquazone
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(antiinflammatory compns. and methods for therapy through enhanced tissue regeneration)
RN 22760-18-5 CAPLUS
CN 2(1H)-Quinazolinone, 7-methyl-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)

L5 ANSWER 45 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



L5 ANSWER 46 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2002:426876 CAPLUS
DOCUMENT NUMBER: 137:149790
TITLE: Structure-Based Classification of Antibacterial Activity
AUTHOR(S): Cronin, Mark T. D.; Aptula, Aynur O.; Dearden, John C.; Duffy, Judith C.; Netzeva, Tatiana I.; Patel, Hiren; Rowe, Philip H.; Schultz, T. Wayne; Worth, Andrew P.; Voutzoulidis, Konstantinos; Schueuermann, Gerrit
CORPORATE SOURCE: School of Pharmacy and Chemistry, Liverpool John Moores University, Liverpool, L3 3AF, UK
SOURCE: Journal of Chemical Information and Computer Sciences (2002), 42(4), 869-878
CODEN: JCISD8; ISSN: 0095-2338
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
AB The aim of this study was to develop a simple quant. structure-activity relation (QSAR) for the classification and prediction of antibacterial activity, to enable in silico screening. To this end a database of 661 compds., classified according to whether they had antibacterial activity, and for which a total of 167 physicochem. and structural descriptors were calculated, was analyzed. To identify descriptors that allowed separation of the two classes (i.e. those compds. with and without antibacterial activity), anal. of variance was utilized and models were developed using linear discriminant and binary logistic regression analyses. Model predictivity was assessed and validated by the random removal of 30% of the compds. to form a test set, for which predictions were made from the model. The results of the analyses indicated that six descriptors, accounting for hydrophobicity and inter- and intramol. hydrogen bonding, provided excellent separation of the data. Logistic regression anal. was shown to model the data slightly more accurately than discriminant anal.
IT 40507-23-1, Fluproquazone
RL: PAC (Pharmacological activity); BIOL (Biological study)
(structure-based classification of antibacterial activity)
RN 40507-23-1 CAPLUS
CN 2(1H)-Quinazolinone, 4-(4-fluorophenyl)-7-methyl-1-(1-methylethyl)- (CA INDEX NAME)



REFERENCE COUNT: 29 THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 46 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

L5 ANSWER 47 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2002:240763 CAPLUS
DOCUMENT NUMBER: 136:279471
TITLE: Preparation of 6-heterocyclylmethyl quinoline and quinazoline derivatives as farnesyl transferase inhibitors for treatment of tumors and proliferative diseases
INVENTOR(S): Angibaud, Patrick Rene; Venet, Marc Gaston; Mevellec, Laurence Anne
PATENT ASSIGNEE(S): Janssen Pharmaceutica N.V., Belg.
SOURCE: PCT Int. Appl., 63 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002024686	A2	20020328	WO 2001-EP10894	20010918
WO 2002024686	A3	20020613		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002020559	A	20020402	AU 2002-20559	20010918
EP 1322650	A2	20030702	EP 2001-985254	20010918
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004509887	T	20040402	JP 2002-529096	20010918
US 20030207887	A1	20031106	US 2003-381361	20030324
US 7196094	B2	20070327		

PRIORITY APPLN. INFO.:	EP 2000-203368	A	20000925
	EP 2001-202190	A	20010607
	WO 2001-EP10894	W	20010918

OTHER SOURCE(S): MARPAT 136:279471
GI

L5 ANSWER 47 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



I



II

AB Title compds. I [wherein m = independently 0-5; q = 0-3; Y1Y2 = C:N, C:CR9, CHNR9, or CHCHR9; C9 = H, halo, CN, (cyclo)alkyl, hydroxyalkyl, alkoxy(alkyl), aminoalkyl, (amino)alkenyl, (amino)alkynyl, halocarbonyl, hydroxycarbonyl, alkoxycarbonyl, aryl, (un)substituted amino or carbamoyl, etc.; R1 = azido, OH, halo, CN, NO2, trihalomethyl, alkoxy, aryloxy, heterocycyloxy, alkylthio, or (un)substituted (cyclo)alkyl, alkenyl, alkynyl, carbamoyl, amino, sulfamoyl, etc.; or 2 adjacent R1 = OCH2O, OCH2CH2O, OCH:CH, OCH2CH2, OCH2CH2CH2, CH:CHCH:CH; R2 = (un)substituted mono- or bicyclic heterocyclic ring; R3 = H, halo, CN, alkenyl, alkynyl, hydroxycarbonyl, alkoxycarbonyl, aryl, heterocyclyl, alkoxy, alkylthio, (un)substituted (cyclo)alkyl or amino, etc.; R4 = (un)substituted imidazolyl, triazolyl, or pyridyl; R5 = CN, OH, halo, alkenyl, alkynyl, hydroxycarbonyl, alkoxycarbonyl, or (un)substituted (cyclo)alkyl, alkoxy, amino, or carbamoyl, etc.; R6 = halo or (un)substituted (cyclo)alkyl, alkenyl, alkynyl, alkylthio, carboxy, carbamoyl, acyl(amino), etc.; R7 = O or S; or R6R7 = (un)substituted CH:CHN:, CH:NN:, CONHN:, N;NN:, N:CHN:, CH:CHCH:, CH:NCH:, CONHCH:, N:NCH:, or CH2(CH2)0-1CH2N: ; or pharmaceutically acceptable salts, N-oxides, or stereochem. isomeric forms thereof] were prepared For example, 2,2,2-trichloro-N-[2-(3-chlorobenzoyl)-4-[(5-chloro-2-thienyl)carbonyl]phenyl]acetamide (5-step preparation given) was cyclized with ammonium acetate in DMSO to give 4-(3-chlorophenyl)-6-[(5-chloro-2-thienyl)carbonyl]-2(1H)-quinazolinone (83.8%). Chlorination (88.4%), followed by addition of 1-methyl-1H-imidazole in the presence of BuLi and SiEt3Cl in THF, afforded the α-(1-methyl-1H-imidazol-5-yl)-6-quinazolinemethanol. Cycloaddn. with NaN3 in DMF gave the tetrazolo[1,5-a]quinazoline-7-methanol II (66%). I have potent farnesyl transferase inhibitory effect and are useful for inhibiting proliferative diseases and growth of tumors expressing an activated ras oncogene (no data).

IT 406197-10-2P, 4-(3-Chlorophenyl)-6-[hydroxy(1-methyl-1H-imidazol-5-yl)-6-quinolinylmethyl]-1-methyl-2(1H)-quinazolinone 406197-23-7P, 4-(3-Chlorophenyl)-6-[(5-chloro-2-thienyl)hydroxy(1-methyl-1H-imidazol-5-yl)methyl]-1-methyl-2(1H)-quinazolinone
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(farnesyl transferase inhibitor; preparation of quinoline and quinazoline

L5 ANSWER 47 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
derivs. as farnesyl transferase inhibitors for treatment of tumors and proliferative diseases)

RN 406197-10-2 CAPLUS
CN 2(1H)-Quinazolinone, 4-(3-chlorophenyl)-6-[hydroxy(1-methyl-1H-imidazol-5-yl)-6-quinolinylmethyl]-1-methyl- (CA INDEX NAME)



RN 406197-23-7 CAPLUS
CN 2(1H)-Quinazolinone, 4-(3-chlorophenyl)-6-[(5-chloro-2-thienyl)hydroxy(1-methyl-1H-imidazol-5-yl)methyl]-1-methyl- (CA INDEX NAME)



L5 ANSWER 48 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2002:240760 CAPLUS
DOCUMENT NUMBER: 136:279470
TITLE: Preparation of 6-[(substituted phenyl)methyl]quinoline and quinazoline derivatives as farnesyl transferase inhibitors for treatment of tumors and proliferative diseases
INVENTOR(S): Angibaud, Patrick Rene; Venet, Marc Gaston; Saha, Ashis Kumar; Mevellec, Laurence Anne
PATENT ASSIGNEE(S): Janssen Pharmaceutica N.V., Belg.
SOURCE: PCT Int. Appl., 97 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002024683	A1	20020328	WO 2001-EP10895	20010918
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2001093829	A	20020402	AU 2001-93829	20010918
EP 1322636	A1	20030702	EP 2001-974276	20010918
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004509884	T	20040402	JP 2002-529093	20010918
US 20040048882	A1	20040311	US 2003-381556	20030324
US 7173040	B2	20070206		
PRIORITY APPLN. INFO.:			EP 2000-203366 A	20000925
			WO 2001-EP10895 W	20010918

OTHER SOURCE(S): MARPAT 136:279470
GI

L5 ANSWER 48 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



I



II

AB Title compds. I [wherein m and n = independently 0-5; q = 0-3; Y1Y2 = C:N, C:CR9, CHNR9, or CHCHR9; C9 = H, halo, CN, (cyclo)alkyl, hydroxyalkyl, alkoxy(alkyl), aminoalkyl, (amino)alkenyl, (amino)alkynyl, halocarbonyl, hydroxycarbonyl, alkoxycarbonyl, aryl, (un)substituted amino or carbamoyl, etc.; R1 and R2 = independently azido, OH, halo, CN, NO2, trihalomethyl, alkoxy, aryloxy, heterocyclyloxy, alkylthio, or (un)substituted (cyclo)alkyl, alkenyl, alkynyl, carbamoyl, amino, sulfamoyl, etc.; or 2 adjacent R1 = OCH2O, OCH2CH2O, OCH:CH, OCH2CH2, OCH2CH2CH2, CH:CHCH:CH; R3 = H, halo, CN, alkenyl, alkynyl, hydroxycarbonyl, alkoxycarbonyl, aryl, heterocyclyl, alkoxy, alkylthio, (un)substituted (cyclo)alkyl or amino, etc.; R4 = (un)substituted imidazolyl, triazolyl, or pyridyl; R5 = CN, OH, halo, alkenyl, alkynyl, hydroxycarbonyl, alkoxycarbonyl, or (un)substituted (cyclo)alkyl, alkoxy, amino, or carbamoyl, etc.; R6 = halo or (un)substituted (cyclo)alkyl, alkenyl, alkynyl, alkylthio, carboxy, carbamoyl, acyl(amino), etc.; R7 = O or S; or R6R7 = (un)substituted CH:CHN:, CH:NN:, CONHN:, N;NN:, N:CHN:, CH:CHCH:, CH:NCH:, CONHCH:, N:NCH:, or CH2(CH2)0-1CH2N: ; or pharmaceutically acceptable salts, N-oxides, or stereochem. isomeric forms thereof] were prepared For example, 6-bromo-2-chloro-4-(3-chlorophenyl)quinoline (6-step preparation given) was coupled with 4-(diethoxymethyl)benzaldehyde in the presence of BuLi in THF to give the 6-quinolinemethanol (64%), which was treated with MnO2 in 1,4-dioxane to afford the methanone. Methoxylation using MeONa in MeOH (74%), followed by addition of 1-methyl-1H-imidazole in the presence of BULi and ClSiEt3 in THF, gave 4-(3-chlorophenyl)-α-[4-(diethoxymethyl)phenyl]-2-methoxy-α-(1-methyl-1H-imidazol-5-yl)-6-quinolinemethanol (56%). The latter was refluxed in HCl for 24 h, cooled, poured out into H2O, and stirred at room temperature for 1 h to afford the quinolinone II•HCl (98%). I have potent farnesyl transferase

L5 ANSWER 48 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
inhibitory effect and are useful for inhibiting proliferative diseases and growth of tumors expressing an activated ras oncogene (no data).
IT 406163-49-3P 406163-51-7P 406164-24-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(farnesyl transferase inhibitor; preparation of quinoline and quinazoline derivs. as farnesyl transferase inhibitors for treatment of tumors and proliferative diseases)
RN 406163-49-3 CAPLUS
CN 2(1H)-Quinazolinone, 4-(3-chlorophenyl)-6-[(4-chlorophenyl)hydroxy(4-methyl-4H-1,2,4-triazol-3-yl)methyl]-1-methyl- (CA INDEX NAME)



RN 406163-51-7 CAPLUS
CN 2(1H)-Quinazolinone, 4-(3-chlorophenyl)-6-[(2,3-dihydro-1,4-benzodioxin-6-yl)hydroxy(1-methyl-1H-imidazol-5-yl)methyl]-1-methyl- (CA INDEX NAME)



RN 406164-24-7 CAPLUS
CN 2(1H)-Quinazolinone, 6-[amino(4-chlorophenyl)(4-methyl-4H-1,2,4-triazol-3-yl)methyl]-4-(3-chlorophenyl)-1-methyl- (CA INDEX NAME)

L5 ANSWER 48 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 49 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2001:434854 CAPLUS
DOCUMENT NUMBER: 135:51045
TITLE: Therapeutic compositions containing anti-inflammatory agents and biodegradable polyanhydrides
INVENTOR(S): Uhrich, Kathryn; Macedo, Braz
PATENT ASSIGNEE(S): Rutgers, the State University of New Jersey, USA; University of Medicine and Dentistry
SOURCE: PCT Int. Appl., 40 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001041753	A2	20010614	WO 2000-US33378	20001207
WO 2001041753	A3	20020912		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2393676	A1	20010614	CA 2000-2393676	20001207
EP 1261347	A1	20021204	EP 2000-982544	20001207
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2003528044	T	20030924	JP 2001-543098	20001207
US 20040038948	A1	20040226	US 2003-368288	20030218
AU 2006201924	A1	20060601	AU 2006-201924	20060509
US 20070014832	A1	20070118	US 2006-524664	20060921

PRIORITY APPLN. INFO.:
US 1999-455861 A 19991207
US 1999-304190P P 19991207
AU 2001-19565 A3 20001207
US 2000-732516 A1 20001207
WO 2000-US33378 W 20001207
US 2002-165220 B1 20020607
US 2003-368288 B1 20030218

AB Methods of promoting healing through enhanced regeneration of tissue (e.g. hard tissue or soft tissue) by contacting the tissue or the surrounding tissue with an antiinflammatory agent are useful in a variety of dental and orthopedic applications. Thus, poly[1,6-bis(o-carboxyphenoxy)hexane] was prepared in a series of steps by the treatment of salicylic acid with

L5 ANSWER 49 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
1,6-dibromohexane, and polymn. of the resulting 1,6-bis(o-carboxyphenoxy)hexane. The polymer was characterized by glass transition temp. measurements and then subjected to compression molding.
IT 22760-18-5, Proquazone
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(therapeutic compns. containing antiinflammatory agents and biodegradable polyanhydrides)
RN 22760-18-5 CAPLUS
CN 2(1H)-Quinazolinone, 7-methyl-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)



L5 ANSWER 50 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2001:167849 CAPLUS
DOCUMENT NUMBER: 134:217194
TITLE: Systemic inflammatory markers as diagnostic tools in the prevention of atherosclerotic diseases
INVENTOR(S): Ridker, Paul; Hennekens, Charles H.
PATENT ASSIGNEE(S): The Brigham and Women's Hospital, Inc., USA
SOURCE: PCT Int. Appl., 53 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001015744	A1	20010308	WO 2000-US24251	20000831
WO 2001015744	A9	20020926		
W: AU, CA, JP				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
US 7030152	B1	20060418	US 1999-387028	19990831
CA 2381926	A1	20010308	CA 2000-2381926	20000831
AU 2000071103	A	20010326	AU 2000-71103	20000831
AU 782386	B2	20050721		
EP 1212101	A1	20020612	EP 2000-959851	20000831
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY				
JP 2003508453	T	20030304	JP 2001-520155	20000831
AU 2005225101	A1	20051117	AU 2005-225101	20051021

PRIORITY APPLN. INFO.:
US 1999-387028 A 19990831
US 1997-41950P P 19970402
US 1997-43039P P 19970402
US 1998-70894P P 19980109
US 1998-54212 A2 19980402
WO 2000-US24251 W 20000831

AB The invention involves methods for characterizing an individual's risk profile of developing a future cardiovascular disorder such as atherosclerosis, stroke, and myocardial infarction by assessing the level of systemic inflammation marker (such as sICAM or C-reactive protein) in an individual. The invention also involves methods for evaluating the likelihood that an individual will benefit from treatment with an agent for reducing the risk of future cardiovascular disorders; and of drug combinations (anti-inflammatory agents, lipid-reducing agents, angiotensisin system inhibitors, calcium channel blockers, β-adrenergic receptor blockers) suitable for prevention future cardiovascular disease.
IT 22760-18-5, Proquazone 37554-40-8, Fluquazone
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(use of agents and systemic inflammatory markers to predict and inhibit

L5 ANSWER 50 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
cardiovascular diorders in humans)
RN 22760-18-5 CAPLUS
CN 2(1H)-Quinazolinone, 7-methyl-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)



RN 37554-40-8 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-4-phenyl-1-(2,2,2-trifluoroethyl)- (CA INDEX NAME)



REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 51 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2001:115086 CAPLUS
DOCUMENT NUMBER: 134:178573
TITLE: Process for the metalloporphyrin catalyzed oxidation of organic compounds
INVENTOR(S): Bernardelli, Patrick
PATENT ASSIGNEE(S): Warner Lambert Company, USA
SOURCE: PCT Int. Appl., 20 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001010797	A1	20010215	WO 2000-EP7726	20000809
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2380851	A1	20010215	CA 2000-2380851	20000809
BR 2000013018	A	20020416	BR 2000-13018	20000809
EP 1208069	A1	20020529	EP 2000-960420	20000809
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
HU 2002002521	A2	20021028	HU 2002-2521	20000809
JP 2003506419	T	20030218	JP 2001-515270	20000809
TR 200200330	T2	20030221	TR 2002-330	20000809
AU 776140	B2	20040826	AU 2000-72738	20000809
IN 2002MN00003	A	20070309	IN 2002-MN3	20020102
ZA 2002000130	A	20030407	ZA 2002-130	20020107
MX 2002PA01388	A	20040716	MX 2002-PA1388	20020208
US 6815543	B1	20041109	US 2002-49208	20020208
PRIORITY APPLN. INFO.:			US 1999-148079P P	19990810
			US 1999-150101P P	19990820
			WO 2000-EP7726 W	20000809

OTHER SOURCE(S): CASREACT 134:178573
AB An organic compound (e.g., Diazepam) is oxidized using a catalytic amount of metalloporphyrin (tetrakis(pentafluorophenylporphyrin)manganese (III) chloride) and an oxidizing agent (iodosyl benzene, hydrogen peroxide) in an inert, aprotic, polyhalogenated solvent (benzotrifluoride). Oxidation of diazepam is conducted to mimic oxidation (metabolism) in biol. systems. The products of the oxidation of diazepam are separated and quantitated. A polar,

L5 ANSWER 51 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
non-nucleophilic co-solvent may be used (hexafluoroisopropanol, trifluoroethanol) in the range of 1-30%. The reaction may be biphasic and use a phase-transfer catalyst (dodecyl trimethylammonium bromide). Use of an inert aprotic solvent shows improved oxidn. yields when compared to prior art (e.g., CH3CN-CH2Cl2-water mixts.).
IT 20927-53-1P, 6-Chloro-4-phenyl-1-methyl-2-(1H)-quinazolinone
RL: BPN (Biosynthetic preparation); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(process for metalloporphyrin-catalyzed oxidation of organic compds.)
RN 20927-53-1 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-1-methyl-4-phenyl- (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 52 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2000:778465 CAPLUS
DOCUMENT NUMBER: 133:335243
TITLE: Preparation of quinazolinones, cholesterol acyltransferase inhibitors, and pharmaceuticals for treatment of hyperlipemia and arteriosclerosis
INVENTOR(S): Muraoka, Masazane; Onuma, Satoshi; Ohashi, Naohito
PATENT ASSIGNEE(S): Sumitomo Pharmaceuticals Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 19 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2000309576	A	20001107	JP 1999-121118	19990428
PRIORITY APPLN. INFO.:			JP 1999-121118	19990428

OTHER SOURCE(S): MARPAT 133:335243
GI



I

AB Title compds. I (ring A = (un)substituted benzene ring, pyridine ring; L = (un)substituted alkyl, alkenyl, cycloalkyl, aryl; R = H, (un)substituted alkyl, alkenyl, alkynyl, cycloalkyl; Y = (un)substituted alkyl, cycloalkyl, aryl), their prodrugs, and pharmaceutically acceptable salts are prepared Imidazole (0.57 g) was reacted with 0.5 g N-[2-tert-butyl-5-(bromomethyl)phenyl]-[1-butyl-6-chloro-4-phenyl-3,4-dihydro-2(1H)-quinazolinon-3-yl]acetamide in DMF in the presence of K2CO3 and KI at room temperature for 2 h and treated with HCl/ether to give 0.35 g N-[2-tert-butyl-5-(1-imidazolylmethyl)phenyl]-[1-butyl-6-chloro-4-phenyl-3,4-dihydro-2(1H)-quinazolinon-3-yl]acetamide hydrochloride showing good activity for inhibiting cholesterol acyltransferase.
IT 303738-10-5P 303738-12-7P 303738-14-9P 303738-15-0P 303738-19-4P 303738-21-8P 303738-22-9P 303738-23-0P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of quinazolinones as cholesterol acyltransferase inhibitors for treatment of hyperlipemia and arteriosclerosis)

L5 ANSWER 52 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
RN 303738-10-5 CAPLUS
CN 3(2H)-Quinazolineacetamide, N-[2,6-bis(1-methylethyl)phenyl]-1-butyl-6-chloro-1,4-dihydro-2-oxo-4-phenyl- (CA INDEX NAME)



RN 303738-12-7 CAPLUS
CN 3(2H)-Quinazolineacetamide, 1-butyl-6-chloro-N-[2-(1,1-dimethylethyl)-5-(hydroxymethyl)phenyl]-1,4-dihydro-2-oxo-4-phenyl- (CA INDEX NAME)



RN 303738-14-9 CAPLUS
CN 3(2H)-Quinazolineacetamide, N-[5-(bromomethyl)-2-(1,1-dimethylethyl)phenyl]-1-butyl-6-chloro-1,4-dihydro-2-oxo-4-phenyl- (CA INDEX NAME)



RN 303738-15-0 CAPLUS
CN 3(2H)-Quinazolineacetamide, 1-butyl-6-chloro-N-[2-(1,1-dimethylethyl)-5-(1H-imidazol-1-ylmethyl)phenyl]-1,4-dihydro-2-oxo-4-phenyl- (CA INDEX NAME)



RN 303738-19-4 CAPLUS
CN 3(2H)-Quinazolineacetamide, N-[2,6-bis(1-methylethyl)phenyl]-1-butyl-1,4-dihydro-4-(3-methoxyphenyl)-2-oxo- (CA INDEX NAME)



RN 303738-21-8 CAPLUS
CN 3(2H)-Quinazolineacetamide, N-[2,6-bis(1-methylethyl)phenyl]-1-butyl-1,4-dihydro-4-(3-hydroxyphenyl)-2-oxo- (CA INDEX NAME)



RN 303738-22-9 CAPLUS
CN 3(2H)-Quinazolineacetamide, N-[2,6-bis(1-methylethyl)phenyl]-1-butyl-1,4-dihydro-2-oxo-4-[3-(3-pyridinylmethoxy)phenyl]- (CA INDEX NAME)



RN 303738-17-2 CAPLUS
CN 3(2H)-Quinazolineacetamide, N-[2,6-bis(1-methylethyl)phenyl]-1-butyl-1,4-dihydro-2-oxo-4-phenyl- (CA INDEX NAME)



RN 303738-18-3 CAPLUS
CN 3(2H)-Quinazolineacetamide, 1-butyl-6-chloro-N-[5-[(diethylamino)methyl]-2-(1,1-dimethylethyl)phenyl]-1,4-dihydro-2-oxo-4-phenyl-, monohydrochloride (9CI) (CA INDEX NAME)



RN 303738-24-1 CAPLUS
CN 3(2H)-Quinazolineacetamide, N-[2,6-bis(1-methylethyl)phenyl]-1-butyl-1,4-dihydro-4-[3-(3-hydroxypropoxy)phenyl]-2-oxo- (CA INDEX NAME)



RN 303738-23-0 CAPLUS
CN 3(2H)-Quinazolineacetamide, N-[2,6-bis(1-methylethyl)phenyl]-1-butyl-1,4-dihydro-2-oxo-4-[3-[3-(phenylmethoxy)propoxy]phenyl]- (CA INDEX NAME)



IT 303738-16-1P 303738-17-2P 303738-18-3P
303738-24-1P 303738-25-2P 303738-32-1P
303738-33-2P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of quinazolinones as cholesterol acyltransferase inhibitors for
treatment of hyperlipemia and arteriosclerosis)
RN 303738-16-1 CAPLUS
CN 3(2H)-Quinazolineacetamide, 1-butyl-6-chloro-N-[2-(1,1-dimethylethyl)-5-(1H-pyrazol-1-ylmethyl)phenyl]-1,4-dihydro-2-oxo-4-phenyl- (CA INDEX NAME)



RN 303738-25-2 CAPLUS
CN 3(2H)-Quinazolineacetamide, N-[2,6-bis(1-methylethyl)phenyl]-1-butyl-1,4-dihydro-2-oxo-4-[3-[3-(1-piperidinyl)propoxy]phenyl]- (CA INDEX NAME)



RN 303738-32-1 CAPLUS
CN 3(2H)-Quinazolineacetamide, 1-butyl-6-chloro-N-[2-(1,1-dimethylethyl)-5-(1H-imidazol-1-ylmethyl)phenyl]-1,4-dihydro-2-oxo-4-phenyl-, monohydrochloride (9CI) (CA INDEX NAME)



RN 303738-33-2 CAPLUS
CN 3(2H)-Quinazolineacetamide, N-[2,6-bis(1-methylethyl)phenyl]-1-butyl-1,4-dihydro-2-oxo-4-[3-(3-pyridinylmethoxy)phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)

L5 ANSWER 52 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



● HCl

IT 303738-30-9
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of quinazolinones as cholesterol acyltransferase inhibitors for
treatment of hyperlipemia and arteriosclerosis)
RN 303738-30-9 CAPLUS
CN 2(1H)-Quinazolinone, 1-butyl-4-(3-methoxyphenyl)- (CA INDEX NAME)



IT 303738-11-6P 303738-13-8P 303738-20-7P
303738-28-5P 303738-29-6P 303738-31-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of quinazolinones as cholesterol acyltransferase inhibitors for
treatment of hyperlipemia and arteriosclerosis)
RN 303738-11-6 CAPLUS
CN 3(2H)-Quinazolineacetic acid, 1-butyl-6-chloro-1,4-dihydro-2-oxo-4-phenyl- (CA INDEX NAME)

L5 ANSWER 52 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 303738-13-8 CAPLUS
CN 3(2H)-Quinazolineacetamide, 1-butyl-6-chloro-N-[2-(1,1-dimethylethyl)-5-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]methyl]phenyl]-1,4-dihydro-2-oxo-4-phenyl- (CA INDEX NAME)



RN 303738-20-7 CAPLUS
CN 3(2H)-Quinazolineacetic acid, 1-butyl-1,4-dihydro-4-(3-methoxyphenyl)-2-oxo- (CA INDEX NAME)



RN 303738-28-5 CAPLUS
CN 3(2H)-Quinazolineacetic acid, 1-butyl-6-chloro-1,4-dihydro-2-oxo-4-phenyl-, ethyl ester (CA INDEX NAME)

L5 ANSWER 52 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 303738-29-6 CAPLUS
CN 2(1H)-Quinazolinone, 1-butyl-3,4-dihydro-4-(3-methoxyphenyl)- (CA INDEX NAME)



RN 303738-31-0 CAPLUS
CN 3(2H)-Quinazolineacetic acid, 1-butyl-1,4-dihydro-4-(3-methoxyphenyl)-2-oxo-, ethyl ester (CA INDEX NAME)



L5 ANSWER 53 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2000:513681 CAPLUS
DOCUMENT NUMBER: 133:120346
TITLE: Preparation of polyazanaphthalenone derivatives useful
as alpha 1a adrenoceptor antagonists
INVENTOR(S): Bock, Mark G.; Patane, Michael A.; Steele, Thomas G.
PATENT ASSIGNEE(S): Merck and Co., Inc., USA
SOURCE: PCT Int. Appl., 105 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000043374	A1	20000727	WO 2000-US1775	20000124
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6358959	B1	20020319	US 2000-481991	20000111
PRIORITY APPLN. INFO.:			US 1999-117255P	P 19990126

OTHER SOURCE(S): MARPAT 133:120346
GI

L5 ANSWER 53 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



I



II

AB Dihydroquinazolin-2-one and dihydropteridin-2-one derivs. (I) [wherein Q = (un)substituted piperidinylaminoalkylamino, cycloalkylaminoalkylamino, piperidinylaminoalkypiperidinyl, cycloalkylaminoalkylpiperidinyl, etc.; A1-A4 = independently (un)substituted C or N; X1 = H, halo, CN, NO2, (fluorinated) (cyclo)alkyl, or (un)substituted alkoxy(alkyl); R1 = H, (fluorinated) (cyclo)alkyl, or (un)substituted Ph; R2 = H or (fluorinated) alkyl; q = 0-5] and pharmaceutically acceptable salts were prepared as alpha 1a adrenergic receptor antagonists for use in the treatment of benign prostatic hyperplasia. For example, II was formed in a multistep sequence. Anthranilonitrile was treated with 3,4-difluorophenyl magnesium bromide, followed by (EtO)2CO, to give the 2(1H)-quinazolinone. The quinazolinone was then N-alkylated with 4-MeOC6H4CH2Cl and hydrogenated with NaBH4. Finally, addition of 4-NO2C6H4OC(O)Cl, followed by amidation with N-(3-aminopropyl)-4-(2-cyanophenyl)-4-cycanopiperidine•HCl, and deprotection using TFA gave II. I are selective in their ability to relax smooth muscle tissue enriched in the alpha 1a receptor subtype, e.g. the tissue found surrounding the urethral lining, without at the same time inducing hypotension (no data). Therefore, I give acute relief to males suffering from benign prostatic hyperplasia by permitting less hindered urine flow. Combination of I with a human 5-alpha reductase inhibitory compound provides both acute and chronic relief from the effects of benign prostatic hyperplasia.

IT 285569-93-9P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn of dihydroquinazolin-2-one and dihydropteridin-2-one derivative 1a adrenoceptor antagonists by treatment of o-amino(hetero)arylnitriles with arylmagnesium bromides, followed by cycloaddn. with (EtO)2CO, and further ring substitution)

RN 285569-93-9 CAPLUS
CN 3(2H)-Quinazolinecarboxamide, 4-(3,4-difluorophenyl)-N-[3-[4-(4-fluorophenyl)-1-piperidinyl]propyl]-1,4-dihydro-1-[(4-methoxyphenyl)methyl]-2-oxo- (CA INDEX NAME)



IT 285569-99-5P, 4-(3,4-Difluorophenyl)-1-(4-methoxybenzyl)quinazolin-2-one 285570-00-5P, 4-(3,4-Difluorophenyl)-1-(4-methoxybenzyl)-3,4-dihydroquinazolin-2-one 285570-01-6P, 4-(3,4-Difluorophenyl)-1-(4-methoxybenzyl)-3-(4-nitrophenoxycarbonyl)-3,4-dihydroquinazolin-2-one 285570-02-7P, 4-(3,4-Difluorophenyl)-1-(4-methoxybenzyl)-3-((3-(4-cyano-4-(2-cyanophenyl)piperidin-1-yl)propyl)carbamoyl)-3,4-dihydroquinazolin-2-one
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn of dihydroquinazolin-2-one and dihydropteridin-2-one derivative 1a adrenoceptor antagonists by treatment of o-amino(hetero)arylnitriles with arylmagnesium bromides, followed by cycloaddn. with (EtO)2CO, and further ring substitution)

RN 285569-99-5 CAPLUS
CN 2(1H)-Quinazolinone, 4-(3,4-difluorophenyl)-1-[(4-methoxyphenyl)methyl]-

L5 ANSWER 53 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
(CA INDEX NAME)



RN 285570-00-5 CAPLUS
CN 2(1H)-Quinazolinone, 4-(3,4-difluorophenyl)-3,4-dihydro-1-[(4-methoxyphenyl)methyl]- (CA INDEX NAME)



RN 285570-01-6 CAPLUS
CN 3(2H)-Quinazolinecarboxylic acid, 4-(3,4-difluorophenyl)-1,4-dihydro-1-[(4-methoxyphenyl)methyl]-2-oxo-, 4-nitrophenyl ester (CA INDEX NAME)

L5 ANSWER 53 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 285570-02-7 CAPLUS
CN 3(2H)-Quinazolinecarboxamide, N-[3-[4-cyano-4-(2-cyanophenyl)-1-piperidinyl]propyl]-4-(3,4-difluorophenyl)-1,4-dihydro-1-[(4-methoxyphenyl)methyl]-2-oxo- (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 54 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2000:303160 CAPLUS
DOCUMENT NUMBER: 133:89506
TITLE: Ring expansion of 2-alkylidenedihydroquinazolines to iminodihydro-1,4-benzodiazepines by methanesulfonyl and trifluoromethanesulfonyl azide
AUTHOR(S): Quast, Helmut; Ivanova, Svetlana; Peters, Eva-Maria; Peters, Karl
CORPORATE SOURCE: Institut fur Organische Chemie der Universitat Wurzburg, Am Hubland, Wurzburg, D-97074, Germany
SOURCE: European Journal of Organic Chemistry (2000), (8), 1577-1587
CODEN: EJOCFK; ISSN: 1434-193X
PUBLISHER: Wiley-VCH Verlag GmbH
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 133:89506
GI





AB 2-Alkyl-1-methylquinazolinium hexafluorophosphates I (R1 = H, Me; R2 = H, Me, Ph) are deprotonated by sodium or potassium hydride to afford solns. of 2-alkylidenedihydroquinazolines II, which were investigated by NMR spectroscopy. Trapping with methanesulfonyl azide of II in situ or subsequent treatment with trifluoromethanesulfonyl azide gave mixts. of colorless N-sulfonylimino-1,4-benzodiazepines III (R3 = Me, CF3) and intensely yellow benzodiazepines IV along with products due to cleavage of the exocyclic double bond of II. The ethylidene compound II (R1 = H, R2 = Me) yielded bicyclic products, apparently by complex sequences of reactions that are triggered by removal of the acidic proton at C-2 of IV

L5 ANSWER 54 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
(R1 = H, R2 = R3 = Me; R1 = H, R2 = Me, R3 = CF3). The structure of the products are based on spectroscopic evidence and X-ray diffraction analyses of representative compds.
IT 17629-04-8P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn of iminodihydro-1,4-benzodiazepines via ring expansion of 2-alkylidenedihydroquinazolines by methanesulfonyl and trifluoromethanesulfonyl azide)
RN 17629-04-8 CAPLUS
CN 2(1H)-Quinazolinone, 1-methyl-4-phenyl- (CA INDEX NAME)



REFERENCE COUNT: 52 THERE ARE 52 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 55 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2000:277974 CAPLUS
DOCUMENT NUMBER: 132:308350
TITLE: Preparation of quinazolinone derivatives having anticholinergic activity
INVENTOR(S): Muraoka, Masami; Matsui, Kazuki; Morishita, Koji; Ohashi, Naohito
PATENT ASSIGNEE(S): Sumitomo Pharmaceuticals Co., Ltd., Japan
SOURCE: PCT Int. Appl., 54 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000023436	A1	20000427	WO 1999-JP5560	19991007
W: CA, JP, KR, US				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
CA 2347506	A1	20000427	CA 1999-2347506	19991007
EP 1122253	A1	20010808	EP 1999-970659	19991007
EP 1122253	B1	20050817		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
AT 302199	T	20050915	AT 1999-970659	19991007
PT 1122253	T	20051130	PT 1999-970659	19991007
ES 2244243	T3	20051201	ES 1999-970659	19991007
US 6645971	B1	20031111	US 2001-807173	20010410
PRIORITY APPLN. INFO.:			JP 1998-295050 A	19981016
			WO 1999-JP5560 W	19991007

OTHER SOURCE(S): MARPAT 132:308350
GI



AB Compds. represented by general formula [I; T = O, S; Y = alkyl, cycloalkyl, cycloalkylalkyl, (un)substituted Ph, (un)substituted aralkyl, (un)substituted heteroaryl; ring W = benzene ring, 5- to 6-membered heteroarom. ring, or 5- to 10-membered cycloalkene or cycloalkane ring; R1, R2 = H, lower alkyl, halo, cyano, CF3, NO2, (un)substituted NH2, OH, lower alkoxy, lower alkylthio, lower alkylsulfinyl, lower alkylsulfonyl; R3 = H, (un)substituted alkyl, (un)substituted alkenyl, (un)substituted alkynyl, (un)substituted cycloalkyl, cycloalkylalkyl, (un)substituted aralkyl; Z = -G-NA1A2; A1, A2 = H, (un)substituted alkyl, cycloalkyl, saturated heterocyclyl, cycloalkylalkyl, cycloalkenylalkyl, (un)substituted

L5 ANSWER 55 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
aralkyl, (un)substituted heteroarylalkyl, CH2 R4 ; wherein R4 = alkenyl, alkynyl; or A1 and A2 are linked to each other to form a heterocyclic ring; G = C1-6 linear alkylene, C1-8 branched alkylene, (CH2)p-cycloalkylene-(CH2)m, etc.; wherein p, m = 0, 1,2], prodrugs thereof, or pharmacol. acceptable salts of these are prepd. They are muscarinic receptor antagonists usable as anticholinergics and are useful as, for example, a remedy for urinary incontinence or frequent urination. Thus, a soln. of 3-(piperidin-4-yl)-4-phenyl-3,4-dihydro-2(1H)-quinazoline in DMF was stirred with K2CO3 and bromomethylcyclopropane at .apprx.50° for 5 h to give 3-[1-(cyclopropylmethyl)piperidin-4-yl]-4-phenyl-3,4-dihydro-2(1H)-quinazoline which was converted into the HCl salt. I in vitro exhibited the antagonism against muscarine-like receptor prepn. from rabbit's seminal duct and guinea pig's heart atrium and bladder.
IT 265328-74-3P 265328-75-4P 265328-76-5P
265328-77-6P 265328-78-7P 265328-79-8P
265328-80-1P 265328-81-2P 265328-82-3P
265328-86-7P 265328-87-8P 265328-88-9P
265328-89-0P 265328-92-5P 265328-93-6P
265328-94-7P 265328-95-8P 265328-96-9P
265328-97-0P 265328-99-2P 265329-00-8P
265329-02-0P 265329-03-1P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of quinazolinone derivs. having anticholinergic activity as muscarine receptor antagonists for treatment of urinary incontinence)
RN 265328-74-3 CAPLUS
CN 2(1H)-Quinazolinone, 1-butyl-3-[1-(cyclohexylmethyl)-4-piperidinyl]-3,4-dihydro-4-phenyl- (CA INDEX NAME)



RN 265328-75-4 CAPLUS
CN 2(1H)-Quinazolinone, 1-butyl-3-[1-(cyclohexylmethyl)-4-piperidinyl]-3,4-dihydro-4-phenyl-, monohydrochloride (9CI) (CA INDEX NAME)

L5 ANSWER 55 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



● HCl

RN 265328-76-5 CAPLUS
CN 2(1H)-Quinazolinone, 3-[1-(cyclohexylmethyl)-4-piperidinyl]-3,4-dihydro-4-phenyl-1-propyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 265328-77-6 CAPLUS
CN 2(1H)-Quinazolinone, 3-[1-(cyclohexylmethyl)-4-piperidinyl]-1-ethyl-3,4-dihydro-4-phenyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 265328-78-7 CAPLUS

L5 ANSWER 55 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

CN 2(1H)-Quinazolinone, 3-[1-(cyclohexylmethyl)-4-piperidinyl]-3,4-dihydro-1-methyl-4-phenyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 265328-79-8 CAPLUS
CN 2(1H)-Quinazolinone, 3-[1-(cyclohexylmethyl)-4-piperidinyl]-1-hexyl-3,4-dihydro-4-phenyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 265328-80-1 CAPLUS
CN 2(1H)-Quinazolinone, 3-[1-(cyclohexylmethyl)-4-piperidinyl]-3,4-dihydro-1-(2-methoxyethyl)-4-phenyl-, monohydrochloride (9CI) (CA INDEX NAME)

L5 ANSWER 55 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



● HCl

RN 265328-81-2 CAPLUS
CN 2(1H)-Quinazolinone, 3-[1-(cyclohexylmethyl)-4-piperidinyl]-3,4-dihydro-4-phenyl-1-(phenylmethyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 265328-82-3 CAPLUS
CN 2(1H)-Quinazolinone, 1-(cyclohexylmethyl)-3-[1-(cyclohexylmethyl)-4-piperidinyl]-3,4-dihydro-4-phenyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

L5 ANSWER 55 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

RN 265328-86-7 CAPLUS
CN 2(1H)-Quinazolinone, 3,4-dihydro-3-[1-[[3-(hydroxymethyl)phenyl]methyl]-4-piperidinyl]-4-phenyl-1-propyl- (CA INDEX NAME)



RN 265328-87-8 CAPLUS
CN 2(1H)-Quinazolinone, 3,4-dihydro-3-[1-[[3-(hydroxymethyl)phenyl]methyl]-4-piperidinyl]-4-phenyl-1-propyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 265328-88-9 CAPLUS
CN 2(1H)-Quinazolinone, 3,4-dihydro-1-(2-hydroxyethyl)-3-[1-[[3-(hydroxymethyl)phenyl]methyl]-4-piperidinyl]-4-phenyl- (CA INDEX NAME)



RN 265328-89-0 CAPLUS
CN 2(1H)-Quinazolinone, 3,4-dihydro-1-(2-hydroxyethyl)-3-[1-[[3-(hydroxymethyl)phenyl]methyl]-4-piperidinyl]-4-phenyl-, ethanedioate (salt) (9CI) (CA INDEX NAME)

CM 1

L5 ANSWER 55 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

CRN 265328-88-9
CMF C29 H33 N3 O3



CM 2

CRN 144-62-7
CMF C2 H2 O4

RN 265328-92-5 CAPLUS
CN 1(2H)-Quinazolinebutanenitrile, 3-[1-(cyclohexylmethyl)-4-piperidinyl]-3,4-dihydro-2-oxo-4-phenyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 265328-93-6 CAPLUS
CN 2(1H)-Quinazolinone, 3,4-dihydro-1-(2-methoxyethyl)-4-phenyl-3-[1-(phenylmethyl)-4-piperidinyl]- (CA INDEX NAME)

L5 ANSWER 55 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 265328-94-7 CAPLUS
CN 1(2H)-Quinazolinepropanoic acid, 3,4-dihydro-2-oxo-4-phenyl-3-[1-(phenylmethyl)-4-piperidinyl]-, methyl ester (CA INDEX NAME)



RN 265328-95-8 CAPLUS
CN 1(2H)-Quinazolineacetic acid, 3,4-dihydro-2-oxo-4-phenyl-3-[1-(phenylmethyl)-4-piperidinyl]-, methyl ester (CA INDEX NAME)



RN 265328-96-9 CAPLUS
CN 1(2H)-Quinazolinebutanenitrile, 3,4-dihydro-2-oxo-4-phenyl-3-[1-(phenylmethyl)-4-piperidinyl]- (CA INDEX NAME)

L5 ANSWER 55 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 265328-97-0 CAPLUS
CN 2(1H)-Quinazolinone, 3,4-dihydro-1-(2-hydroxyethyl)-4-phenyl-3-[1-(phenylmethyl)-4-piperidinyl]- (CA INDEX NAME)



RN 265328-99-2 CAPLUS
CN 2(1H)-Quinazolinone, 3,4-dihydro-1-(3-hydroxypropyl)-4-phenyl-3-[1-(phenylmethyl)-4-piperidinyl]- (CA INDEX NAME)



RN 265329-00-8 CAPLUS
CN 2(1H)-Quinazolinone, 1-(3-aminopropyl)-3,4-dihydro-4-phenyl-3-[1-(phenylmethyl)-4-piperidinyl]- (CA INDEX NAME)



RN 265329-02-0 CAPLUS
CN 1(2H)-Quinazolinepropanoic acid, 3,4-dihydro-2-oxo-4-phenyl-3-[1-(phenylmethyl)-4-piperidinyl]- (CA INDEX NAME)

L5 ANSWER 55 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 265329-03-1 CAPLUS
CN 1(2H)-Quinazolineacetic acid, 3,4-dihydro-2-oxo-4-phenyl-3-[1-(phenylmethyl)-4-piperidinyl]- (CA INDEX NAME)



IT 265328-90-3
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of quinazolinone derivs. having anticholinergic activity as muscarine receptor antagonists for treatment of urinary incontinence)
RN 265328-90-3 CAPLUS
CN 2(1H)-Quinazolinone, 1-[2-[[(1,1-dimethylethyl)dimethylsilyl]oxy]ethyl]-3,4-dihydro-3-[1-[[3-(hydroxymethyl)phenyl]methyl]-4-piperidinyl]-4-phenyl- (CA INDEX NAME)



IT 265328-98-1P 265329-01-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of quinazolinone derivs. having anticholinergic activity as muscarine receptor antagonists for treatment of urinary incontinence)
RN 265328-98-1 CAPLUS
CN 2(1H)-Quinazolinone, 3,4-dihydro-4-phenyl-3-[1-(phenylmethyl)-4-

L5 ANSWER 55 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
piperidinyl]-1-[2-[(tetrahydro-2H-pyran-2-yl)oxy]ethyl]- (CA INDEX NAME)



RN 265329-01-9 CAPLUS
CN 1H-Isoindole-1,3(2H)-dione, 2-[3-[3,4-dihydro-2-oxo-4-phenyl-3-[1-(phenylmethyl)-4-piperidinyl]-1(2H)-quinazolinyl]propyl]- (CA INDEX NAME)



REFERENCE COUNT: 58 THERE ARE 58 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 56 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2000:104748 CAPLUS
DOCUMENT NUMBER: 132:273834
TITLE: Critical point representations of electron density maps for the comparison of benzodiazepine-type ligands
AUTHOR(S): Leherte, Laurence; Meurice, Nathalie; Vercauteren, Daniel P.
CORPORATE SOURCE: Laboratoire de Physico-Chimie Informatique, Facultes Universitaires Notre-Dame de la Paix, Namur, B-5000, Belg.
SOURCE: Journal of Chemical Information and Computer Sciences (2000), 40(3), 816-832
CODEN: JCISD8; ISSN: 0095-2338
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English

AB A procedure for the comparison of three-dimensional electron d. distributions is proposed for similarity searches between pharmacol. ligands at various levels of crystallog. resolution First, a graph representation of mol. electron d. distributions is generated using a critical point anal. approach. Pairwise as well as multiple comparisons between the obtained graphs of critical points are then carried out using a Monte Carlo/simulated annealing technique, and results are compared with genetic algorithm solns.

IT 20927-53-1
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(citical point representations of electron d. maps for the comparison of benzodiazepine-type ligands)
RN 20927-53-1 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-1-methyl-4-phenyl- (CA INDEX NAME)



REFERENCE COUNT: 53 THERE ARE 53 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 57 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1998:723797 CAPLUS
DOCUMENT NUMBER: 129:330739
TITLE: Farnesyltransferase inhibiting quinazolinones
INVENTOR(S): Angibaud, Patrick Rene; Venet, Marc Gaston; Freyne, Eddy Jean Edgard
PATENT ASSIGNEE(S): Janssen Pharmaceutica N.V., Belg.
SOURCE: PCT Int. Appl., 38 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9849157	A1	19981105	WO 1998-EP2357	19980417
W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2288140	A1	19981105	CA 1998-2288140	19980417
CA 2288140	C	20070403		
AU 9876460	A	19981124	AU 1998-76460	19980417
AU 738628	B2	20010920		
EP 977750	A1	20000209	EP 1998-924161	19980417
EP 977750	B1	20070704		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, AL, MK				
BR 9809398	A	20000613	BR 1998-9398	19980417
TR 9902606	T2	20000721	TR 1999-2606	19980417
NZ 336233	A	20010126	NZ 1998-336233	19980417
HU 2000001122	A2	20010428	HU 2000-1122	19980417
HU 2000001122	A3	20020328		
JP 2001522364	T	20011113	JP 1998-546561	19980417
IL 130363	A	20020814	IL 1998-130363	19980417
CN 1094937	B	20021127	CN 1998-804366	19980417
RU 2205831	C2	20030610	RU 1999-124815	19980417
PL 190944	B1	20060228	PL 1998-336468	19980417
CZ 296959	B6	20060816	CZ 1999-3717	19980417
AT 366250	T	20070715	AT 1998-924161	19980417
ES 2289783	T3	20080201	ES 1998-924161	19980417
ZA 9803504	A	19991025	ZA 1998-3504	19980424
NO 9905169	A	19991227	NO 1999-5169	19991022
NO 317576	B1	20041115		
MX 9909763	A	20000430	MX 1999-9763	19991022
US 6177432	B1	20010123	US 1999-403705	19991022
US 6358961	B1	20020319	US 2000-687153	20001013
US 20020049327	A1	20020425	US 2000-725391	20001129
US 6444812	B2	20020903		

PRIORITY APPLN. INFO.: EP 1997-201259 A 19970425
EP 1997-200708 A 19970310
EP 1997-200709 A 19970310

L5 ANSWER 57 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
WO 1998-EP2357 W 19980417
US 1999-403705 A1 19991022
US 1999-380856 A3 19991220

OTHER SOURCE(S): MARPAT 129:330739
GI



I

AB The title compds. I [the dotted line represents an optional bond; X = O, S; R1, R2 = H, hydroxy, halo, cyano, C1-6alkyl, trihalomethyl, trihalomethoxy, C2-6alkenyl, C1-6alkyloxy, hydroxyC1-6alkyloxy, C1-6alkyloxyC1-6alkyloxy, C1-6alkyloxycarbonyl, aminoC1-6alkyloxy, mono- or di(C1-6alkyl)aminoC1-6alkyloxy, Ar1, Ar1C1-6alkyl, Ar1oxy, Ar1C1-6alkyloxy; or when on adjacent positions R1 and R2 taken together may form a bivalent radical; R3, R4 = H, halo, cyano, C1-6alkyl, C1-6alkyloxy, Ar1oxy, C1-6alkylthio, di(C1-6alkyl)amino, trihalomethyl, trihalomethoxy; R5 = H, halo, cyano, optionally substituted C1-6alkyl, C1-6alkyloxycarbonyl, Ar1; or a radical of the formula -OR10, -SR10, -NR11R12; R6 is an optionally substituted imidazolyl moiety; R7 = H, C1-6alkyl provided that the dotted line does not represent a bond; R8 = H, C1-6alkyl or Ar2CH2 or Het1CH2; R9 = H, C1-6alkyl, C1-6alkyloxy, halo, or R8 and R9 taken together may form a bivalent radical; Ar1 and Ar2 are optionally substituted Ph and Het1 is optionally substituted pyridinyl], having farnesyltransferase inhibiting activity, were prepared E.g., reaction of 6-[chloro(4-chlorophenyl)methyl]-4-(3-chlorophenyl)-3,4-dihydro-2(1H)-quinazolinone and imidazole gave 44.5% 4-(3-chlorophenyl)-6-[(4-chlorophenyl)-1H-imidazol-1-ylmethyl]-3,4-dihydro-2(1H)-quinazolinone.

IT 215034-62-1P 215034-65-4P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of farnesyltransferase inhibiting quinazolinones)
RN 215034-62-1 CAPLUS
CN 2(1H)-Quinazolinone, 4-(3-chlorophenyl)-6-[(4-chlorophenyl)hydroxy(1-methyl-1H-imidazol-5-yl)methyl]-1-methyl- (CA INDEX NAME)

L5 ANSWER 57 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 215034-65-4 CAPLUS
CN 2(1H)-Quinazolinone, 6-[chloro(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methyl- (CA INDEX NAME)



IT 215034-60-9P 215034-61-0P 215034-64-3P
215034-66-5P 215034-68-7P 215034-69-8P
215034-70-1P 215034-71-2P 215034-72-3P
215034-73-4P 215034-78-9P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of farnesyltransferase inhibiting quinazolinones)
RN 215034-60-9 CAPLUS
CN 2(1H)-Quinazolinone, 4-(3-chlorophenyl)-6-[(4-chlorophenyl)-1H-imidazol-1-ylmethyl]-1-methyl- (CA INDEX NAME)

L5 ANSWER 57 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 215034-61-0 CAPLUS
CN 2(1H)-Quinazolinone, 4-(3-chlorophenyl)-6-[(4-chlorophenyl)-1H-imidazol-1-ylmethyl]-1-(4-pyridinylmethyl)- (CA INDEX NAME)



RN 215034-64-3 CAPLUS
CN 2(1H)-Quinazolinone, 4-(3-chlorophenyl)-6-[(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-1-methyl-, ethanedioate (1:1) (CA INDEX NAME)

CM 1

CRN 215034-63-2
CMF C26 H20 Cl2 N4 O

L5 ANSWER 57 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



CM 2

CRN 144-62-7
CMF C2 H2 O4

RN 215034-66-5 CAPLUS
CN 2(1H)-Quinazolinone, 6-[amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methyl- (CA INDEX NAME)



RN 215034-68-7 CAPLUS
CN 2(1H)-Quinazolinone, 4-(3-chlorophenyl)-6-[(4-chlorophenyl)-1H-imidazol-1-ylmethyl]-3,4-dihydro-1-methyl- (CA INDEX NAME)

L5 ANSWER 57 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 215034-69-8 CAPLUS
CN 2(1H)-Quinazolinone, 4-(3-chlorophenyl)-6-[(4-chlorophenyl)-1H-imidazol-1-ylmethyl]-3,4-dihydro-1,3-dimethyl- (CA INDEX NAME)



RN 215034-70-1 CAPLUS
CN 2(1H)-Quinazolinone, 4-(3-chlorophenyl)-6-[(4-chlorophenyl)-1H-imidazol-1-ylmethyl]-3-ethyl-3,4-dihydro-1-methyl- (CA INDEX NAME)



RN 215034-71-2 CAPLUS

L5 ANSWER 57 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
CN 2(1H)-Quinazolinone, 4-(3-chlorophenyl)-6-[(4-chlorophenyl)hydroxy(1-methyl-1H-imidazol-5-yl)methyl]-3,4-dihydro-1-methyl- (CA INDEX NAME)



RN 215034-72-3 CAPLUS
CN 2(1H)-Quinazolinone, 4-(3-chlorophenyl)-6-[(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-3,4-dihydro-1-methyl- (CA INDEX NAME)



RN 215034-73-4 CAPLUS
CN 2(1H)-Quinazolinone, 4-(3-chlorophenyl)-6-[(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-3,4-dihydro-1,3-dimethyl- (CA INDEX NAME)

L5 ANSWER 57 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 215034-78-9 CAPLUS
CN 2(1H)-Quinazolinone, 6-[amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-3,4-dihydro-1,3-dimethyl- (CA INDEX NAME)



IT 215034-85-8P 215034-86-9P 215034-87-0P
215034-88-1P 215034-89-2P 215034-90-5P
215034-91-6P 215034-92-7P 215034-93-8P
215034-94-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of farnesyltransferase inhibiting quinazolinones)
RN 215034-85-8 CAPLUS
CN 2(1H)-Quinazolinone,
4-(3-chlorophenyl)-6-[2-(4-chlorophenyl)-1,3-dioxolan-2-yl]-1-methyl- (CA INDEX NAME)

L5 ANSWER 57 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 215034-86-9 CAPLUS
CN 2(1H)-Quinazolinone, 6-(4-chlorobenzoyl)-4-(3-chlorophenyl)-1-methyl- (CA
INDEX NAME)



RN 215034-87-0 CAPLUS
CN 2(1H)-Quinazolinone,
4-(3-chlorophenyl)-6-[(4-chlorophenyl)hydroxymethyl]-3,4-dihydro-1-methyl- (CA INDEX NAME)



RN 215034-88-1 CAPLUS
CN 2(1H)-Quinazolinone, 6-[chloro(4-chlorophenyl)methyl]-4-(3-chlorophenyl)-3,4-dihydro-1-methyl- (CA INDEX NAME)

L5 ANSWER 57 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 215034-89-2 CAPLUS
CN 2(1H)-Quinazolinone,
4-(3-chlorophenyl)-6-[2-(4-chlorophenyl)-1,3-dioxolan-2-yl]-3,4-dihydro-1-methyl- (CA INDEX NAME)



RN 215034-90-5 CAPLUS
CN 2(1H)-Quinazolinone,
4-(3-chlorophenyl)-6-[2-(4-chlorophenyl)-1,3-dioxolan-2-yl]-3,4-dihydro-1,3-dimethyl- (CA INDEX NAME)



RN 215034-91-6 CAPLUS
CN 2(1H)-Quinazolinone, 6-(4-chlorobenzoyl)-4-(3-chlorophenyl)-3,4-dihydro-1,3-dimethyl- (CA INDEX NAME)

L5 ANSWER 57 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 215034-92-7 CAPLUS
CN 2(1H)-Quinazolinone,
4-(3-chlorophenyl)-6-[2-(4-chlorophenyl)-1,3-dioxolan-
2-yl]-1-(ethoxymethyl)- (CA INDEX NAME)



RN 215034-93-8 CAPLUS
CN 2(1H)-Quinazolinone,
4-(3-chlorophenyl)-6-[2-(4-chlorophenyl)-1,3-dioxolan-
2-yl]-1-(ethoxymethyl)-3,4-dihydro- (CA INDEX NAME)



L5 ANSWER 58 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1998:682113 CAPLUS
DOCUMENT NUMBER: 129:299893
TITLE: Means of ascertaining an individual's risk profile for atherosclerotic disease based on systemic inflammation marker levels
INVENTOR(S): Ridker, Paul; Hennekens, Charles H.
PATENT ASSIGNEE(S): Brigham and Women's Hospital, Inc., USA
SOURCE: PCT Int. Appl., 48 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9843630	A1	19981008	WO 1998-US6613	19980402
W: AU, CA, JP				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
CA 2285091	A1	19981008	CA 1998-2285091	19980402
AU 9871008	A	19981022	AU 1998-71008	19980402
EP 1003501	A1	20000531	EP 1998-917992	19980402
EP 1003501	B1	20050309		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2001525058	T	20011204	JP 1998-542023	19980402
JP 3805381	B2	20060802		
JP 2003128582	A	20030508	JP 2002-220353	19980402
EP 1493439	A1	20050105	EP 2004-10424	19980402
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY				
AT 290375	T	20050315	AT 1998-917992	19980402
PT 1003501	T	20050729	PT 1998-917992	19980402
ES 2239801	T3	20051001	ES 1998-917992	19980402

PRIORITY APPLN. INFO.:			
	US 1997-41950P	P	19970402
	US 1997-43039P	P	19970402
	US 1998-70894P	P	19980109
	EP 1998-917992	A3	19980402
	JP 1998-542023	A3	19980402
	WO 1998-US6613	W	19980402

AB The invention involves methods for characterizing an individual's risk profile of developing a future cardiovascular disorder by obtaining a level of the marker of systemic inflammation in the individual. The invention also involves methods for evaluating the likelihood that an individual will benefit from treatment with an agent for reducing the risk of future cardiovascular disorder. The primary basis for this invention is evidence from the Physicians' Health Study, a large scale, randomized, double-blind, placebo-controlled trial of aspirin and β-carotene in the primary prevention of cardiovascular disease conducted among 22,000

L5 ANSWER 57 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

RN 215034-94-9 CAPLUS
CN 2(1H)-Quinazolinone,
4-(3-chlorophenyl)-6-[2-(4-chlorophenyl)-1,3-dioxolan-
2-yl]-1-(ethoxymethyl)-3,4-dihydro-3-methyl- (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 58 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
apparently healthy men. In that trial, baseline level of C-reactive protein, a marker for underlying systemic inflammation, was found to det. the future risk of myocardial infarction and stroke, independent of a large series of lipid and non-lipid risk factors. Baseline C-reactive protein level was not assocd. with venous thrombosis, a vascular event generally not assocd. with atherosclerosis. Further, the data indicate that the magnitude of benefit that apparently healthy individuals can expect from prophylactic aspirin is dependent in large part upon baseline level of C-reactive protein.

IT 22760-18-5, Proquazone 37554-40-8, Fluquazone
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(systemic inflammation marker level in evaluation of cardiovascular disorder risk reduction by)

RN 22760-18-5 CAPLUS
CN 2(1H)-Quinazolinone, 7-methyl-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)



RN 37554-40-8 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-4-phenyl-1-(2,2,2-trifluoroethyl)- (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 59 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1998:613444 CAPLUS
DOCUMENT NUMBER: 129:265466
TITLE: Spray formulations of antihyperalgesic opiates and method of treating topical hyperalgesic conditions therewith
INVENTOR(S): Maycock, Alan L.; Chang, An-chih; Farrar, John J.; Balogh, Imre
PATENT ASSIGNEE(S): Adolor Corp., USA
SOURCE: U.S., 8 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5811078	A	19980922	US 1997-818559	19970314
US 5798093	A	19980825	US 1997-892389	19970714
PRIORITY APPLN. INFO.:			US 1997-818559	A2 19970314

OTHER SOURCE(S): MARPAT 129:265466
AB Spray formulations of anti-hyperalgesic opiates comprise an anti-hyperalgesic opiate having a peripheral selectivity of 251 to 1,280 in an aqueous alc. mixture containing up to 15% ethanol, propanol, and/or isopropanol. Thus, 100 g of 4-(p-chlorophenyl)-4-hydroxy-N,N-dimethyl-α,α-diphenyl-1-piperidinebutyramide was dissolved in 2 L of a 5 % ethanol/95 % water mixture with agitation and the solution was transferred to a pump action spray bottle.
IT 22760-18-5, Proquazone
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(topical sprays containing anti-hyperalgesic opiates and active ingredients to promote wound healing)
RN 22760-18-5 CAPLUS
CN 2(1H)-Quinazolinone, 7-methyl-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 60 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1998:317133 CAPLUS
DOCUMENT NUMBER: 129:81647
TITLE: Thermal decomposition of tert-butyl o-(phenoxy)- and o-(anilino)phenyliminoxyperacetates
AUTHOR(S): Calestani, Gianluca; Leardini, Rino; McNab, Hamish; Nanni, Daniele; Zanardi, Giuseppe
CORPORATE SOURCE: Dipartimento di Chimica Generale ed Inorganica, Anal. Chim. Fis., Universita di Parma, Parma, I-43100, Italy
SOURCE: Journal of the Chemical Society, Perkin Transactions 1: Organic and Bio-Organic Chemistry (1998), (11), 1813-1824
CODEN: JCPRB4; ISSN: 0300-922X
PUBLISHER: Royal Society of Chemistry
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 129:81647
AB Some o-phenoxy- and o-anilino-substituted aryliminyl radicals were generated by thermal decomposition of suitable tert-Bu iminoxyperacetates. The iminyls show no disposition to give 7-membered cyclization on the Ph group. In some cases, products were found that can be rationalized through a 1,6-spirocyclization of the iminyl radicals followed by homolytic 1,5-migration of the Ph group from the aminic to the iminic nitrogen: this seems to be the first instance of such a process. Evidence was found for the formation of imines through hydrogen abstraction by the iminyls; with two o-phenoxy-substituted peresters these imines have been unexpectedly isolated. The reactions have also afforded significant-in some cases major-amts. of other products (acridine, quinazolinone and indole derivs.) presumably deriving from carbon radicals: mechanisms are suggested to account for the formation of these compds. The structure of a quinazolinone derivative was determined by X-ray crystallog. anal.
IT 209413-03-6P
RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 209413-03-6 CAPLUS
CN 2(1H)-Quinazolinone, 1,4-diphenyl- (CA INDEX NAME)



REFERENCE COUNT: 108 THERE ARE 108 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 61 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1998:122276 CAPLUS
DOCUMENT NUMBER: 128:204858
TITLE: Ureas in organic synthesis. XII. Synthesis of 2-amino-5-chlorobenzhydrylureas and their heterocyclization
AUTHOR(S): Bakibaev, A. A.; Shtrykova, V. V.; Vostretsov, S. N.
CORPORATE SOURCE: Tomsk Polytechnic University, Tomsk, Russia
SOURCE: Russian Journal of Organic Chemistry (Translation of Zhurnal Organicheskoi Khimii) (1997), 33(4), 457-459
CODEN: RJOCEQ; ISSN: 1070-4280
PUBLISHER: MAIK Nauka/Interperiodica Publishing
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 128:204858
AB A synthetic method was developed for biol. active 2-amino-5-chlorobenzhydrylureas based on reaction of the corresponding benzhydrols with urea in sulfuric acid. The 2-amino-5-chlorobenzhydrylureas were cyclized to 1-substituted 1,2,3,4-tetrahydro-4-phenyl-6-chloroquinazolin-2-ones.
IT 26772-95-2P 203788-16-3P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and heterocyclization of aminochlorobenzhydrylureas)
RN 26772-95-2 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-3,4-dihydro-1-methyl-4-phenyl- (CA INDEX NAME)



RN 203788-16-3 CAPLUS
CN 2(1H)-Quinazolinone, 1-acetyl-6-chloro-3,4-dihydro-4-phenyl- (CA INDEX NAME)



REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 62 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1997:545615 CAPLUS
DOCUMENT NUMBER: 127:199619
TITLE: Development of a genetic algorithm method especially designed for the comparison of molecular models: application to the elucidation of the benzodiazepine receptor pharmacophore
AUTHOR(S): Meurice, Nathalie; Leherte, Laurence; Vercauteren, Daniel P.; Bourguignon, Jean-Jacques; Wermuth, Camille G.
CORPORATE SOURCE: Laboratoire de Physico-Chimie Informatique, Facultes Universitaires, Namur, B-5000, Belg.
SOURCE: Computer-Assisted Lead Finding and Optimization: Current Tools for Medicinal Chemistry, [European Symposium on Quantitative Structure-Activity Relationships], 11th, Lausanne, Sept. 1-6, 1996 (1997)
, Meeting Date 1996, 499-509. Editor(s): Van de Waterbeemd, Han; Testa, Bernard; Folkers, Gerd. Verlag Helvetica Chimica Acta: Basel, Switz.
CODEN: 64VEAH
DOCUMENT TYPE: Conference
LANGUAGE: English
AB Since the three-dimensional mol. structure of the benzodiazepine receptors is not yet unequivocaly known, the direct elucidation of the interaction mode between their active binding sites and their potent ligands is rather difficult. The comparison of selected ligands is thus an indirect approach which could help to determine the pharmacophore elements. In the present work, ligands for the benzodiazepine receptors are characterized using electron d. maps at medium resolution, reconstructed from calculated structure factors using crystallog. simulation programs. As the obtained three-dimensional maps are rather complex, they then can be simplified by a topol. anal. in order to represent the ligands as connected graphs. An original genetic algorithm method is finally elaborated and implemented to carry out graph comparison. The design of the algorithm implies appropriate and efficient coding and evaluation of the generated graph superimpositions. The major aim of this study consists in determining the nature and arrangement of the mol. fragments taking part in the binding of ligands to their benzodiazepine receptor sites.
IT 20927-53-1
RL: PRP (Properties)
(benzodiazepine receptor pharmacophore determination by genetic algorithm method)
RN 20927-53-1 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-1-methyl-4-phenyl- (CA INDEX NAME)

L5 ANSWER 62 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



L5 ANSWER 63 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1997:480840 CAPLUS
DOCUMENT NUMBER: 127:108921
TITLE: Preparation of (aminoalkyl)-substituted benzo-heterocyclic compounds with antimycotic and antihypercholesteremic activities
INVENTOR(S): Aebi, Johannes; Lengsfeld, Hans; Dehmlow, Henrietta; Morand, Olivier; Himber, Jacques; Schmid, Gerard; Maerki, Hans-Peter; Ji, Yu-Hua
PATENT ASSIGNEE(S): F. Hoffmann-La Roche Ag, Switz.
SOURCE: Eur. Pat. Appl., 40 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 778271	A2	19970611	EP 1996-119172	19961129
EP 778271	A3	20000322		
R: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
CA 2190708	A1	19970609	CA 1996-2190708	19961119
JP 09176123	A	19970708	JP 1996-326555	19961206
CN 1161328	A	19971008	CN 1996-121501	19961206
CN 1067991	B	20010704		
US 5856503	A	19990105	US 1996-762867	19961206
BR 9605906	A	19980818	BR 1996-5906	19961209
PRIORITY APPLN. INFO.:			CH 1995-3480 A	19951208

OTHER SOURCE(S): MARPAT 127:108921
GI



I

AB The title compds. [I; dotted line = optional double bond; M = (un)substituted heterocyclic atom grouping; Q = (un)substituted cycloalkyl, (un)substituted alkenyl, (un)substituted alkadienyl, (un)substituted 4-(aminoalkyl)phenyl, etc.; R = (un)substituted aminoalkyl; T = H, alkyl, (un)substituted NH2, CONH2, NO2, CF3, OH], useful as antimycotics and antihypercholesteremics, are prepared and I-containing formulations presented. Thus, allyl[6-[3-(4-bromophenyl)benzo[d]isothiazol-6-yloxy]hexyl]methylamine fumarate, prepared in 4 steps from benzyl mercaptan, demonstrated a IC50 of 3.3 nM for 2,3-oxidosqualene-lanosterol cyclase.
IT 192442-83-4P

L5 ANSWER 63 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of (aminoalkyl)-substituted benzo-heterocyclic compds. with antimycotic and antihypercholesteremic activities)
RN 192442-83-4 CAPLUS
CN 2(1H)-Quinazolinone, 4-(4-bromophenyl)-1-methyl-7-[[6-(methyl-2-propenylamino)hexyl]oxy]- (9CI) (CA INDEX NAME)



L5 ANSWER 64 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1997:332024 CAPLUS
DOCUMENT NUMBER: 126:308827
TITLE: Peripherally active anti-hyperalgesic opiates
INVENTOR(S): Yaksh, Tony L.; Farrar, John J.; Maycock, Alan L.; Lewis, Michael E.; Dow, Gordon J.
PATENT ASSIGNEE(S): Regents of the University of California, USA; Adolor Corporation
SOURCE: PCT Int. Appl., 317 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9709973	A2	19970320	WO 1996-US14727	19960912
WO 9709973	A3	19970605		
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG				
US 5849761	A	19981215	US 1995-528510	19950912
CA 2229814	A1	19970320	CA 1996-2229814	19960912
CA 2229814	C	20011204		
CA 2356097	A1	19970320	CA 1996-2356097	19960912
AU 9670710	A	19970401	AU 1996-70710	19960912
AU 727982	B2	20010104		
EP 852494	A2	19980715	EP 1996-931567	19960912
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI				
BR 9610345	A	19990601	BR 1996-10345	19960912
JP 11512438	T	19991026	JP 1997-512136	19960912
JP 3553083	B2	20040811		
JP 2002069004	A	20020308	JP 2001-224729	19960912
NO 9800700	A	19980512	NO 1998-700	19980219
PRIORITY APPLN. INFO.:			US 1995-528510 A	19950912
			CA 1996-2229814 A3	19960912
			JP 1997-512136 A3	19960912
			WO 1996-US14727 W	19960912

OTHER SOURCE(S): MARPAT 126:308827
AB Compns. and methods using the compns. for treatment of peripheral hyperalgesia are provided. The compns. contain an anti-hyperalgesia effective amount of one or more compds. that directly or indirectly interact with peripheral opiate receptors, but that do not, upon topical or local administration, elicit substantial central nervous system effects. The anti-diarrheal compound loperamide-HCl is preferred for use in the compns. and methods.
IT 22760-18-5, Proquazone
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(peripherally active anti-hyperalgesic opiates)

L5 ANSWER 64 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
RN 22760-18-5 CAPLUS
CN 2(1H)-Quinazolinone, 7-methyl-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)



L5 ANSWER 65 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1996:756296 CAPLUS
DOCUMENT NUMBER: 126:14758
TITLE: Compositions and methods to prevent toxicity induced by nonsteroidal antiinflammatory drugs
INVENTOR(S): Garvey, David S.; Letts, L. Gordon; Renfroe, H. Burt; Tam, Sang W.
PATENT ASSIGNEE(S): Nitromed, Inc., USA; Garvey, David S.; Letts, L. Gordon; Renfroe, H. Burt; Tam, Sang W.
SOURCE: PCT Int. Appl., 99 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9632946	A1	19961024	WO 1996-US4931	19960411
W: AU, CA, JP, US				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
US 6051588	A	20000418	US 1995-425090	19950419
US 5703073	A	19971230	US 1995-543208	19951013
AU 9654493	A	19961107	AU 1996-54493	19960411
AU 710951	B2	19990930		
EP 821589	A1	19980204	EP 1996-911685	19960411
R: CH, DE, FR, GB, IT, LI, SE				
JP 11509519	T	19990824	JP 1996-531797	19960411
US 6043232	A	20000328	US 1999-235802	19990122
US 6143734	A	20001107	US 2000-495251	20000131
AU 773374	B2	20040520	AU 2001-91447	20011121

PRIORITY APPLN. INFO.:
US 1995-425090 A 19950419
US 1995-543208 A 19951013
WO 1996-US4931 W 19960411
US 1997-899238 A3 19970723
US 1999-235802 A1 19990122
AU 1999-65551 A3 19991230

OTHER SOURCE(S): MARPAT 126:14758
AB Nonsteroidal antiinflammatory drugs which have been substituted with a nitrogen monoxide group; compns. comprising: (i) a nonsteroidal antiinflammatory drug, which can optionally be substituted with a nitrogen monoxide group and (ii) a compound that directly donates, transfers or releases a nitrogen monoxide group (preferably as a charged species, particularly nitrosonium); and methods of treatment of inflammation, pain, gastrointestinal lesions and/or fever using the compns. are disclosed. The compds. and compns. protect against the gastrointestinal, renal and other toxicities that are otherwise induced by nonsteroidal

L5 ANSWER 65 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
antiinflammatory drugs. Prepn. of compds. of the invention is included, as are comparative in vivo analgesic,antiinflammatory, and gastric lesion activities.
IT 22760-18-5, Proquazone
RL: ADV (Adverse effect, including toxicity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(NO-substituted nonsteroidal antiinflammatory compound preparation for compns.
and methods to prevent toxicity induced by nonsteroidal antiinflammatory drugs)
RN 22760-18-5 CAPLUS
CN 2(1H)-Quinazolinone, 7-methyl-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)



L5 ANSWER 66 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1996:752409 CAPLUS
DOCUMENT NUMBER: 126:152212
TITLE: Liquid and subcritical CO2 separations of enantiomers on a broadly applicable polysiloxane chiral stationary phase
AUTHOR(S): Pirkle, William H.; Brice, L. Jonathan; Terfloth, Gerald J.
CORPORATE SOURCE: School of Chem. Sci., Univ. of Illinois, Urbana, IL, 61801, USA
SOURCE: Journal of Chromatography, A (1996), 753(1), 109-119
CODEN: JCRAEY; ISSN: 0021-9673
PUBLISHER: Elsevier
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Incorporation of chiral selector into a polysiloxane which is then immobilized on silica affords a chiral stationary phase (CSP) capable of resolving a broad array of enantiomers by either HPLC or supercrit. fluid chromatog. (SFC). Like its brush-type analog, the com. version of which is known as the Whelk-O 1, CSP 1, the polyWhelk-O, is stable to normal and reversed-phase conditions and to a wide range of temps., mobile phases and additives. In most cases, the polyWhelk-O affords greater enantioselectivity and less retention than does the brush-type Whelk-O 1 under the same conditions. An extensive collection of sepns. of the enantiomers of a variety of types of compds. is presented to illustrate the scope and level of performance typically afforded by the polyWhelk-O columns.
IT 26772-87-2 186296-36-6 186296-37-7
RL: ANT (Analyte); ANST (Analytical study)
(enantiomer separation by HPLC or supercrit. fluid chromatog. using subcrit.
and supercrit. carbon dioxide and polyWhelk-O chiral stationary phase)
RN 26772-87-2 CAPLUS
CN 2(1H)-Quinazolinone, 3,4-dihydro-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)



RN 186296-36-6 CAPLUS
CN 2(1H)-Quinazolinone, 3,4-dihydro-1-(1-methylethyl)-4-phenyl-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 66 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 186296-37-7 CAPLUS
CN 2(1H)-Quinazolinone, 3,4-dihydro-1-(1-methylethyl)-4-phenyl-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 67 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



L5 ANSWER 67 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1996:599048 CAPLUS
DOCUMENT NUMBER: 125:230824
ORIGINAL REFERENCE NO.: 125:42957a,42960a
TITLE: Nonsteroidal anti-inflammatory nanoparticles
INVENTOR(S): Franson, Nancy M.; Snyder, Donald R.
PATENT ASSIGNEE(S): Nanosystems L.L.C., USA
SOURCE: PCT Int. Appl., 20 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9624336	A1	19960815	WO 1996-US1801	19960208
W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN				
US 5591456	A	19970107	US 1995-386790	19950210
AU 9648667	A	19960827	AU 1996-48667	19960208
PRIORITY APPLN. INFO.:			US 1995-386790	A 19950210
			WO 1996-US1801	W 19960208

AB Dispersible particles consisting essentially of crystalline nonsteroidal anti-inflammatory analgesics having hydroxypropyl cellulose adsorbed on the surface thereof in an amount sufficient to maintain an effective average particle size of ≤1000 nm, exhibit unexpectedly reduced gastric irritation following oral administration and/or hastened onset of action. Naproxen 300 g was dispersed into a solution containing 30 g hydroxypropyl cellulose in 670 g water and the dispersion was spray-dried to a dry powder. The powder was filled into capsules to a strength of 250 mg naproxen/capsule.
IT 22760-18-5, Proquazone
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(nonsteroidal anti-inflammatory nanoparticles modified with hydroxypropyl cellulose)
RN 22760-18-5 CAPLUS
CN 2(1H)-Quinazolinone, 7-methyl-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)

L5 ANSWER 68 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1996:366053 CAPLUS
DOCUMENT NUMBER: 125:41845
ORIGINAL REFERENCE NO.: 125:7945a,7948a
TITLE: Nanoparticulate NSAID compositions
INVENTOR(S): Eickhoff, W. Mark; Engers, David A.; Mueller, Karl R.
PATENT ASSIGNEE(S): Nanosystem L.L.C., USA
SOURCE: U.S., 5 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5518738	A	19960521	US 1995-385614	19950209
CA 2212779	A1	19960815	CA 1996-2212779	19960118
CA 2212779	C	20030506		
WO 9624339	A1	19960815	WO 1996-US797	19960118
W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN				
AU 9649009	A	19960827	AU 1996-49009	19960118
EP 808156	A1	19971126	EP 1996-905181	19960118
EP 808156	B1	19981216		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE				
JP 10513198	T	19981215	JP 1996-524268	19960118
JP 3710818	B2	20051026		
AT 174506	T	19990115	AT 1996-905181	19960118
ES 2125099	T3	19990216	ES 1996-905181	19960118
PRIORITY APPLN. INFO.:			US 1995-385614	A 19950209
			WO 1996-US797	W 19960118

AB A composition comprising a crystalline nonsteroidal antiinflammatory drug (NSAID) having polyvinylpyrrolidone adsorbed on the surface thereof in an amount sufficient to maintain an effective average particle size of less than about 1000 nm, hygroscopic sugar and sodium lauryl sulfate exhibit greatly reduced gastric irritation following oral administration and/or hastened onset of action due to the substantial redispersion of the solid formulation to nanoparticles in gastric fluid.
IT 22760-18-5, Proquazone
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(nanoparticulate nonsteroidal antiinflammatory drug compns.)
RN 22760-18-5 CAPLUS
CN 2(1H)-Quinazolinone, 7-methyl-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)

L5 ANSWER 68 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



L5 ANSWER 69 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1994:613141 CAPLUS
DOCUMENT NUMBER: 121:213141
ORIGINAL REFERENCE NO.: 121:38667a,38670a
TITLE: Use of derivative spectrophotometry and Griess reaction for the assay of four antiinflammatory drugs
AUTHOR(S): Barary, Magda H.; Blaih, Salah M.; Abdine, Heba H.; El-Sayed, Mahmoud A.
CORPORATE SOURCE: Faculty Pharmacy, University Alexandria, Alexandria, Egypt
SOURCE: Mansoura Journal of Pharmaceutical Sciences (1994), 10(1), 1-17
CODEN: MJPSEO; ISSN: 1110-1318
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Two spectrophotometric methods were developed for the assay of four anti-inflammatory drugs: fentiazac, flufenamic acid, tiaprofenic acid and proquazone in their various dosage forms. The first method depends on the measurement of absorbances (Amax), first and second derivative (1D and 2D).

The second method utilizes Griess reaction where the acidic anti-inflammatory drugs (fentiazac and tiaprofenic acid) react with sodium nitrite releasing an equivalent amount of nitrous acid. The latter reacts with p-nitroaniline (PNA) and the coupling reagent 1-naphthylamine (1-NA) to form an orange pigment, exhibiting λ max at 462 nm.

IT 22760-18-5, Proquazone
RL: ANT (Analyte); ANST (Analytical study)
(determination of anti-inflammatory drugs by derivative spectrophotometry based on Griess reaction)

RN 22760-18-5 CAPLUS
CN 2(1H)-Quinazolinone, 7-methyl-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)



L5 ANSWER 70 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1994:418065 CAPLUS
DOCUMENT NUMBER: 121:18065
ORIGINAL REFERENCE NO.: 121:3323a,3326a
TITLE: Pharmaceutical composition for inhibiting tumor necrosis factor production
INVENTOR(S): Irie, Kenji; Ueda, Yataka; Fujiwara, Norio
PATENT ASSIGNEE(S): Sumitomo Pharmaceuticals Co., Ltd., Japan
SOURCE: PCT Int. Appl., 51 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9407498	A1	19940414	WO 1993-JP1443	19931007
W: CA, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
JP 06192099	A	19940712	JP 1993-276189	19931006
EP 664128	A1	19950726	EP 1993-922048	19931007
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, NL, PT, SE				
US 5646154	A	19970708	US 1995-411595	19950512
PRIORITY APPLN. INFO.:			JP 1992-296457 A	19921007
			WO 1993-JP1443 W	19931007

OTHER SOURCE(S): MARPAT 121:18065
GI



AB Forty-three quinazoline derivs. of I significantly inhibit the biosynthesis of tumor necrosis factors in mouse i.p. macrophages. Apparently, the derivs. are effective in treating diseases caused by tumor necrosis factors.

IT 23441-64-7 33443-30-0 33453-22-4
33453-23-5 36942-71-9 37555-05-8
49830-89-9 59253-25-7 59253-26-8
155602-72-5
RL: BIOL (Biological study)
(tumor necrosis factor inhibition by)

RN 23441-64-7 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-1-ethyl-4-phenyl- (CA INDEX NAME)

L5 ANSWER 70 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 33443-30-0 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-1-(2-cyclohexylethyl)-4-phenyl- (CA INDEX NAME)



RN 33453-22-4 CAPLUS
CN 2(1H)-Quinazolinone, 1-(cyclopropylmethyl)-4-phenyl- (CA INDEX NAME)



RN 33453-23-5 CAPLUS
CN 2(1H)-Quinazolinone, 1-(cyclopropylmethyl)-6-methoxy-4-phenyl- (CA INDEX NAME)

L5 ANSWER 70 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 36942-71-9 CAPLUS
CN 2(1H)-Quinazolinone,
1-(cyclopropylmethyl)-3,4-dihydro-6-methoxy-4-phenyl-
(CA INDEX NAME)



RN 37555-05-8 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-1-[(2-fluorophenyl)methyl]-4-phenyl- (CA INDEX NAME)



RN 49830-89-9 CAPLUS
CN 2(1H)-Quinazolinone, 6-methoxy-4-phenyl-1-(2,2,2-trifluoroethyl)- (CA

L5 ANSWER 70 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



L5 ANSWER 70 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
INDEX NAME)



RN 59253-25-7 CAPLUS
CN 2(1H)-Quinazolinone,
1-(cyclopropylmethyl)-3,4-dihydro-7-methoxy-4-phenyl-
(CA INDEX NAME)



RN 59253-26-8 CAPLUS
CN 2(1H)-Quinazolinone, 1-(cyclopropylmethyl)-3,4-dihydro-6-(methylthio)-4-phenyl- (CA INDEX NAME)



RN 155602-72-5 CAPLUS
CN Piperidine, 1-[(6-chloro-2-oxo-4-phenyl-1(2H)-quinazolinyl)acetyl]-(9CI)
(CA INDEX NAME)

L5 ANSWER 71 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1994:144167 CAPLUS
DOCUMENT NUMBER: 120:144167
ORIGINAL REFERENCE NO.: 120:25227a,25230a
TITLE: Surface-modified nonsteroidal anti-inflammatory drug (NSAID) nanoparticles
INVENTOR(S): Liversidge, Gary G.; Conzentino, Philip; Cundy, Kenneth C.; Sarpotdar, Pramod P.
PATENT ASSIGNEE(S): Sterling Winthrop Inc., USA
SOURCE: PCT Int. Appl., 27 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 5
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9325190	A1	19931223	WO 1993-US5082	19930601
W: AU, CA, HU, JP				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU 9343964	A	19940104	AU 1993-43964	19930601
AU 677783	B2	19970508		
EP 644755	A1	19950329	EP 1993-914224	19930601
EP 644755	B1	19970319		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
HU 70952	A2	19951128	HU 1994-3543	19930601
JP 08501073	T	19960206	JP 1994-501515	19930601
AT 150297	T	19970415	AT 1993-914224	19930601
ES 2101323	T3	19970701	ES 1993-914224	19930601
CA 2118517	C	20031014	CA 1993-2118517	19930601
US 5552160	A	19960903	US 1995-402662	19950313
PRIORITY APPLN. INFO.:			US 1992-897193 A	19920610
			US 1991-647105 A2	19910125
			WO 1993-US5082 A	19930601

AB Dispersible particles consist of a crystalline NSAID having a surface modifier
adsorbed on the surface thereof in an amount sufficient to maintain an effective average particle size of less than about 400 nm. Pharmaceutical
compns. containing the particles exhibit reduced gastric irritation following
oral administration and/or hastened onset of action. A nanoparticulate dispersion containing naproxen and Pluronic F-68 was prepared using zirconia
beads.
IT 22760-18-5, Proquazone
RL: PRP (Properties)
(surfactant adsorption on surface of, oral compns. containing)
RN 22760-18-5 CAPLUS
CN 2(1H)-Quinazolinone, 7-methyl-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)

L5 ANSWER 71 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



L5 ANSWER 72 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1992:612423 CAPLUS
DOCUMENT NUMBER: 117:212423
ORIGINAL REFERENCE NO.: 117:36695a,36698a
TITLE: Synthesis and renal vasodilator activity of substituted [4-alkyl(aryl)-2-oxoquinazolin-1-yl]alkanoic acids
AUTHOR(S): Russell, R. K.; Appollina, M. A.; Bandurco, V.; Combs,
D. W.; Kanojia, R. M.; Mallory, R.; Malloy, E.; McNally, J. J.; Mulvey, D. M.; et al.
CORPORATE SOURCE: Div. Med. Chem., R. W. Johnson Pharm. Res. Inst., Raritan, NJ, 08869-0602, USA
SOURCE: European Journal of Medicinal Chemistry (1992), 27(3),
277-84
CODEN: EJMCA5; ISSN: 0223-5234
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



AB The synthesis and cardiovascular evaluation of a novel series of title acids and their esters I [R = H, 6,7-(MeO)2, 6,7-, 7,8-, or 5,6-(HO)2, 6,7-(KO)2; R1 = H, K, Me, cyclohexyl; R2 = Me, Et, Pr, Me2CH, Ph, 4-FC6H4;
n = 1-4] as renal vasodilators is presented. I [R = 6,7-(HO)2, R1 = H, R2
= Me, n = 2] was a potent and selective renal vasodilator.

IT 143697-69-2P 143697-71-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reaction with hydrobromic acid)

RN 143697-69-2 CAPLUS
CN 1(2H)-Quinazolinepropanoic acid, 6,7-dimethoxy-2-oxo-4-phenyl-, methyl ester (CA INDEX NAME)

L5 ANSWER 72 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 143697-71-6 CAPLUS
CN 1(2H)-Quinazolinepropanoic acid, 4-(4-fluorophenyl)-6,7-dimethoxy-2-oxo-, methyl ester (CA INDEX NAME)



IT 143697-70-5P 143697-72-7P 144139-40-2P
144139-41-3P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and renal vasodilator activity of)

RN 143697-70-5 CAPLUS
CN 1(2H)-Quinazolinepropanoic acid, 6,7-dihydroxy-2-oxo-4-phenyl- (CA INDEX NAME)



RN 143697-72-7 CAPLUS
CN 1(2H)-Quinazolinepropanoic acid, 4-(4-fluorophenyl)-6,7-dihydroxy-2-oxo- (CA INDEX NAME)

L5 ANSWER 72 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 144139-40-2 CAPLUS
CN 1(2H)-Quinazolinepropanoic acid, 6,7-dihydroxy-2-oxo-4-phenyl-, monohydrobromide (9CI) (CA INDEX NAME)



● HBr

RN 144139-41-3 CAPLUS
CN 1(2H)-Quinazolinepropanoic acid, 4-(4-fluorophenyl)-6,7-dihydroxy-2-oxo-, monohydrobromide (9CI) (CA INDEX NAME)



● HBr

L5 ANSWER 72 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

L5 ANSWER 73 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1992:402498 CAPLUS
DOCUMENT NUMBER: 117:2498
ORIGINAL REFERENCE NO.: 117:531a,534a
TITLE: A QSAR model of teratogenesis
AUTHOR(S): Gombar, Vijay K.; Borgstedt, Harold H.; Enslein, Kurt;
Hart, Jeffrey B.; Blake, Benjamin W.
CORPORATE SOURCE: Health Des., Inc., Rochester, NY, 14604, USA
SOURCE: Quantitative Structure-Activity Relationships (1991), 10(4), 306-32
CODEN: QSARDI; ISSN: 0931-8771
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Four related QSAR models of teratogenesis in exptl. animals have been developed: one each for heteroarom., carboarom., alicyclic and acyclic compds. The nos. of compds. in these models range from 40 (for the alicyclic model) to 144 (for the carboarom. model). As determined by cross-validation using the leave-one-out, or jackknife, technique, the accuracy of the models in discriminating between teratogens and nonteratogens ranges from 92.4% to 96%. A single overall assessment of exptl. teratogenesis was chosen as the biol. endpoint; taking into account such factors as dosage, maternal toxicity, and affected organ systems remain to be subjects of further studies.
IT 40507-23-1, Fluproquazone
RL: ADV (Adverse effect, including toxicity); PRP (Properties); BIOL (Biological study)
(teratogenesis in laboratory animals from, QSAR model of)
RN 40507-23-1 CAPLUS
CN 2(1H)-Quinazolinone, 4-(4-fluorophenyl)-7-methyl-1-(1-methylethyl)- (CA INDEX NAME)



L5 ANSWER 74 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1992:400277 CAPLUS
DOCUMENT NUMBER: 117:277
ORIGINAL REFERENCE NO.: 117:43a,46a
TITLE: Mechanism of allergic cross-reactions. I. Multispecific binding of ligands to a mouse monoclonal anti-DNP IgE antibody
AUTHOR(S): Varga, Janos M.; Kalchschmid, Gertrud; Klein, Georg F.; Fritsch, Peter
CORPORATE SOURCE: Dep. Dermatol., Univ. Innsbruck, Innsbruck, 6020, Austria
SOURCE: Molecular Immunology (1991), 28(6), 641-54
CODEN: MOIMD5; ISSN: 0161-5890
DOCUMENT TYPE: Journal
LANGUAGE: English
AB A recently developed solid-phase binding assay was used to investigate the specificity of ligand binding to a mouse monoclonal anti-dinitrophenyl IgE (I). All DNP-amino acids, that were tested inhibited the binding of the radio-labeled I to DNP covalently attached to polystyrene microplates; however, the concentration for 50% inhibition varied within four orders of magnitude, DNP-L-serine being the most and DNP-L-proline the least potent inhibitor. In addition to DNP analogs, a large number of drugs and other compds. were tested for their ability to compete with DNP for the binding site of I. At the concentration used for screening, 59% of compds. had no significant inhibition; 19% inhibited the binding of I more than 50%. Several families of compds. (tetracyclines, polymyxins, phenothiazines, salicylates, and quinones) that were effective competitors were found. Within these families, changes in the functional groups attached to the family stem had major effects on the affinity of ligand binding. The occurrence frequencies of interactions of ligands with I is in good agreement with the semi-empirical model for multispecific antibody-ligand interactions.
IT 22760-18-5
RL: BIOL (Biological study)
(binding of, to anti-dinitrophenol monoclonal antibody, allergic cross-reaction mechanism in relation to)
RN 22760-18-5 CAPLUS
CN 2(1H)-Quinazolinone, 7-methyl-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)



L5 ANSWER 75 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1991:623028 CAPLUS
DOCUMENT NUMBER: 115:223028
ORIGINAL REFERENCE NO.: 115:37779a,37782a
TITLE: Aspirin-like drugs, ethanol-induced rat gastric injury and mucosal eicosanoid release
AUTHOR(S): Trautmann, Marion; Peskar, Brigitta M.; Peskar, Bernhard A.
CORPORATE SOURCE: Dep. Exp. Clin. Med., Ruhr-Univ., Bochum, D-4630/1, Germany
SOURCE: European Journal of Pharmacology (1991), 201(1), 53-8
CODEN: EJPHAZ; ISSN: 0014-2999
DOCUMENT TYPE: Journal
LANGUAGE: English
AB The effect of oral administration of various nonsteroidal anti-inflammatory drugs on ethanol-induced rat gastric injury and mucosal release of leukotriene C4, 6-keto-prostaglandin F1α and 15-hydroxy-5,8,11,13-eicosatetraenoic acid was investigated. It was found that besides sodium salicylate and high doses of aspirin, other salicylate type drugs, such as diflunisal, 4-aminosalicylic acid, 2,4-dihydroxybenzoic acid and Me salicylate, and several non-acidic compds., such as proquazone, benzydamine and paracetamol, were gastroprotective. All these drugs inhibited ex vivo leukotriene C4 formation by ethanol-stimulated gastric mucosa. However, naproxen, lonazolac, ibuprofen, gentisic acid, and 5-aminosalicylic acid also inhibited leukotriene C4 formation, but were not protective. Gastroprotection was independent of 6-keto-prostaglandin F1α formation. Both protective and non-protective drugs inhibited the ethanol-stimulated, but not the basal, release of 15-hydroxy-5,8,11,13-eicosatetraenoic acid. The results indicate that the differential effects of various nonsteroidal anti-inflammatory drugs on gastroprotection against ethanol are not correlated with specific effects on mucosal cyclooxygenase, 5-lipoxygenase or 15-lipoxygenase activity.
IT 22760-18-5, Proquazone
RL: BIOL (Biological study)
(ethanol-induced gastric injury and mucosal eicosanoid release response to)
RN 22760-18-5 CAPLUS
CN 2(1H)-Quinazolinone, 7-methyl-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)



L5 ANSWER 76 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1991:488777 CAPLUS
DOCUMENT NUMBER: 115:88777
ORIGINAL REFERENCE NO.: 115:15175a,15178a
TITLE: Substances to improve the recovery of annexins during analysis
INVENTOR(S): Roemisch, Juergen; Auerbach, Bernhard; Pelzer, Hermann
PATENT ASSIGNEE(S): Behringwerke A.-G., Germany
SOURCE: Eur. Pat. Appl., 6 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 433927	A2	19910626	EP 1990-124304	19901215
EP 433927	A3	19930203		
EP 433927	B1	19950920		
R: AT, BE, CH, DE, ES, FR, GB, IT, LI, LU, NL, SE				
DE 3942081	A1	19910627	DE 1989-3942081	19891220
AT 128239	T	19951015	AT 1990-124304	19901215
ES 2078289	T3	19951216	ES 1990-124304	19901215
CA 2032751	A1	19910621	CA 1990-2032751	19901219
AU 9068233	A	19910627	AU 1990-68233	19901219
AU 647431	B2	19940324		
JP 04208857	A	19920730	JP 1990-417897	19901219
JP 2972353	B2	19991108		
US 5589395	A	19961231	US 1993-46908	19930415
PRIORITY APPLN. INFO.:			DE 1989-3942081 A	19891220
			US 1990-629718 B1	19901218

AB A medium which stabilizes annexins for anal. studies contains an anticoagulant, a chelating agent, and ≥1 platelet aggregation inhibitor (e.g. chloroquine, quinacrine, dibucaine). Thus, human blood was drawn into a solution containing 134 mM EDTA, 16 mM hydroxychloroquine sulfate, and 20,000 units heparin/L for determination of the platelet factor 4 and placental protein 4 concns. by immunoassay.
IT 22760-18-5, Proquazone
RL: BIOL (Biological study)
(annexin stabilization with, in anal.)
RN 22760-18-5 CAPLUS
CN 2(1H)-Quinazolinone, 7-methyl-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)

L5 ANSWER 76 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



L5 ANSWER 77 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1991:240162 CAPLUS
DOCUMENT NUMBER: 114:240162
ORIGINAL REFERENCE NO.: 114:40325a,40328a
TITLE: Effects of nonsteroidal antiphlogistics on mouse ear edema induced with dithranol
AUTHOR(S): Gabor, Miklos; Razga, Z.
CORPORATE SOURCE: Inst. Pharmacodyn., Albert Szent-Gyorgyi Med. Univ., Szeged, H-6720, Hung.
SOURCE: Acta Physiologica Hungarica (1990), 75(4), 287-91
CODEN: APHHDU; ISSN: 0231-424X
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Mouse ear edema induced with dithranol in mice of the CFLP strain was decreased significantly, in a concentration-dependent manner, by the oral administration of the following nonsteroids 60 min before induction of the edema: piroxicam, proquazone, azapropazone, nifluminic acid, and phenylbutazone. An approx. 50% inhibitory effect could be attained with the following doses: 3.3 mg/kg piroxicam, 5 mg/kg proquazone, 5 mg/kg azapropazone, and 1 mg/kg nifluminic acid. Administration of the largest dose (30 mg/kg) of phenylbutazone, used for comparison, resulted in an edema decrease of 41%.
IT 22760-18-5, Proquazone
RL: BIOL (Biological study)
(edema response to)
RN 22760-18-5 CAPLUS
CN 2(1H)-Quinazolinone, 7-methyl-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)



L5 ANSWER 78 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1991:220616 CAPLUS
DOCUMENT NUMBER: 114:220616
ORIGINAL REFERENCE NO.: 114:36949a,36952a
TITLE: Comprehensive drug screening in urine using solid-phase extraction and combined TLC and GC/MS identification
AUTHOR(S): Lillsunde, P.; Korte, T.
CORPORATE SOURCE: Dep. Biochem., Natl. Public Health Inst., Helsinki, SF-00300, Finland
SOURCE: Journal of Analytical Toxicology (1991), 15(2), 71-81
CODEN: JATOD3; ISSN: 0146-4760
DOCUMENT TYPE: Journal
LANGUAGE: English
AB A simple and sensitive identification system for the detection of a broad spectrum of drugs is described. ChemElut extraction tubes were used for the isolation of drugs from human urine. Specimens were screened by TLC and confirmed by GC/mass spectrometry. Special procedures for buprenorphine, cannabinoids, cocaine, LSD, morphine, phencyclidine, halogenated hydrocarbons, paracetamol, and alcs. were used. This system is useful for screening samples in misuse, impaired driving, poisoning, and other forensic cases. It covers about 300 substances including all potentially abused drugs and their metabolites.
IT 22760-18-5, Proquazone
RL: ANT (Analyte); ANST (Analytical study)
(determination of, in urine of humans, by TLC and GC and mass spectrometry)
RN 22760-18-5 CAPLUS
CN 2(1H)-Quinazolinone, 7-methyl-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)



L5 ANSWER 79 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1991:143330 CAPLUS
DOCUMENT NUMBER: 114:143330
ORIGINAL REFERENCE NO.: 114:24325a
TITLE: Synthesis of derivatives of 2-hydrazino-1,4- or 3,4-dihydroquinazolines
AUTHOR(S): Richter, P.; Oertel, F.
CORPORATE SOURCE: Fach. Pharm., Ernst-Moritz-Arndt-Univ., Greifswald, O-2200, Germany
SOURCE: Pharmazie (1990), 45(10), 721-4
CODEN: PHARAT; ISSN: 0031-7144
DOCUMENT TYPE: Journal
LANGUAGE: German
OTHER SOURCE(S): CASREACT 114:143330
GI



I

AB Hydrazinolysis of 1H-1,4- or 3H-3,4-dihydro-2-(alkylthio)-6-chloro-4-phenylquinazolines gave the title compds. I (R = H, Me) or 6-chloro-3,4-diphenyl-2-hydrazino-3H-2,4-dihydroquinazoline hydrochloride.
The reaction of 6-chloro-1-methyl-4-phenyl-2-thioxo-1,2,3,4-tetrahydroquinazoline with MeI gave 6-chloro-1-methyl-2-(methylthio)-4-phenyl-1,4-dihydroquinazoline which upon elimination of MeSH gave 6-chloro-1-methyl-2-oxo-4-phenyl-1,2,3,4-tetrahydroquinazoline.
IT 26920-08-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and alkylation or oxidation of)
RN 26920-08-1 CAPLUS
CN 2(1H)-Quinazolinethione, 6-chloro-3,4-dihydro-1-methyl-4-phenyl- (CA INDEX NAME)



IT 132735-19-4P

L5 ANSWER 79 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. and hydrazinolysis of)
RN 132735-19-4 CAPLUS
CN Quinazoline, 6-chloro-2-(ethylthio)-1,4-dihydro-1-methyl-4-phenyl-, monohydriodide (9CI) (CA INDEX NAME)



● HI

IT 26772-95-2P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 26772-95-2 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-3,4-dihydro-1-methyl-4-phenyl- (CA INDEX NAME)



L5 ANSWER 80 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1990:618250 CAPLUS
DOCUMENT NUMBER: 113:218250
ORIGINAL REFERENCE NO.: 113:36757a,36760a
TITLE: γ-Butyrolactone solubilizer for antirheumatic drugs
INVENTOR(S): Klosa, Josef; Kroeger, Hans
PATENT ASSIGNEE(S): Germany
SOURCE: Ger. Offen., 4 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 3836863	A1	19900503	DE 1988-3836863	19881027
PRIORITY APPLN. INFO.:			DE 1988-3836863	19881027

AB γ-Butyrolactone is a solubilizer for antirheumatic drugs, such as ibuprofen, indomethacin and piroxicam. A lotion comprised 1 g ibuprofen, 10 g menthol, 10 mL perfume, 15 mL Emulgol, 100 mL γ-butyrolactone, 10 mL lactic acid, and 200 mL EtOH.
IT 22760-18-5
RL: PROC (Process)
(formulations of, γ-butyrolactone solubilizer in)
RN 22760-18-5 CAPLUS
CN 2(1H)-Quinazolinone, 7-methyl-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)



L5 ANSWER 81 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1990:478315 CAPLUS
DOCUMENT NUMBER: 113:78315
ORIGINAL REFERENCE NO.: 113:13251a,13254a
TITLE: Photochemical reactions of 4-phenylquinazolin-2-ones
AUTHOR(S): Nishio, Takehiko; Kameyama, Satoshi; Omote, Yoshimori;
Kashima, Choji
CORPORATE SOURCE: Dep. Chem., Univ. Tsukuba, Tsukuba, 305, Japan
SOURCE: Heterocycles (1990), 30(1, Spec. Issue), 493-500
CODEN: HTCYAM; ISSN: 0385-5414
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 113:78315
GI



I II

AB Irradiation of 4-phenylquinazolin-2-ones I (R = Me, Et) in the presence of hydrogen donor such as xanthene, sulfide, and acyclic or cyclic ethers, gave the C-C bonded 1:1-adducts II (R = Me, Et, R1R2 = g-xanthenyl, CH2CH2, X = O; R1 = R2 = Me, X = S; R = Me, R1 = R2 = Me, X = O, R1R2 = CH2OCH2, X = O) via hydrogen atom abstraction of the excited imino N of I,
while irradiation of I in the presence of Et3N gave the reduced 3,4-dihydroquinazolin-2-ones.
IT 17629-04-8 26831-07-2
RL: RCT (Reactant); RACT (Reactant or reagent)
(photolysis of, in presence of hydrogen donors, carbon-carbon bond formation in)
RN 17629-04-8 CAPLUS
CN 2(1H)-Quinazolinone, 1-methyl-4-phenyl- (CA INDEX NAME)



RN 26831-07-2 CAPLUS
CN 2(1H)-Quinazolinone, 1-ethyl-4-phenyl- (CA INDEX NAME)

L5 ANSWER 81 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



IT 26824-66-8P 70724-06-0P 128487-74-1P
128487-75-2P 128487-76-3P 128487-77-4P
128487-78-5P 128487-79-6P 128487-80-9P
128487-81-0P 128487-82-1P 128487-83-2P
128487-84-3P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 26824-66-8 CAPLUS
CN 2(1H)-Quinazolinone, 3,4-dihydro-1-methyl-4-phenyl- (CA INDEX NAME)



RN 70724-06-0 CAPLUS
CN 2(1H)-Quinazolinone, 1-ethyl-3,4-dihydro-4-phenyl- (CA INDEX NAME)



RN 128487-74-1 CAPLUS
CN 2(1H)-Quinazolinone, 3,4-dihydro-1-methyl-4-phenyl-4-(9H-xanthen-9-yl)-
(CA INDEX NAME)

L5 ANSWER 81 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 128487-78-5 CAPLUS
CN 2(1H)-Quinazolinone, 4-(1,4-dioxan-2-yl)-3,4-dihydro-1-methyl-4-phenyl-
(CA INDEX NAME)



RN 128487-79-6 CAPLUS
CN 2(1H)-Quinazolinone, 1-ethyl-3,4-dihydro-4-phenyl-4-(9H-xanthen-9-yl)-
(CA INDEX NAME)



RN 128487-80-9 CAPLUS
CN 2(1H)-Quinazolinone,
1-ethyl-4-[1-(ethylthio)ethyl]-3,4-dihydro-4-phenyl-,
(R*,R*)- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L5 ANSWER 81 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 128487-75-2 CAPLUS
CN 2(1H)-Quinazolinone, 4-(1-ethoxyethyl)-3,4-dihydro-1-methyl-4-phenyl-,
(R*,R*)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 128487-76-3 CAPLUS
CN 2(1H)-Quinazolinone,
4-[1-(ethylthio)ethyl]-3,4-dihydro-1-methyl-4-phenyl-
, (R*,R*)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 128487-77-4 CAPLUS
CN 2(1H)-Quinazolinone, 3,4-dihydro-1-methyl-4-phenyl-4-(tetrahydro-2-
furanyl)- (CA INDEX NAME)

L5 ANSWER 81 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 128487-81-0 CAPLUS
CN 2(1H)-Quinazolinone,
1-ethyl-3,4-dihydro-4-phenyl-4-(tetrahydro-2-furanyl)-
(CA INDEX NAME)



RN 128487-82-1 CAPLUS
CN 2(1H)-Quinazolinone, 4-(1-ethoxyethyl)-3,4-dihydro-1-methyl-4-phenyl-,
(R*,S*)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 128487-83-2 CAPLUS
CN 2(1H)-Quinazolinone,
4-[1-(ethylthio)ethyl]-3,4-dihydro-1-methyl-4-phenyl-
, (R*,S*)- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L5 ANSWER 81 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 128487-84-3 CAPLUS
CN 2(1H)-Quinazolinone, 1-ethyl-4-[1-(ethylthio)ethyl]-3,4-dihydro-4-phenyl-, (R*,S*)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L5 ANSWER 82 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1990:69616 CAPLUS
DOCUMENT NUMBER: 112:69616
ORIGINAL REFERENCE NO.: 112:11675a,11678a
TITLE: Quantitation by computerized visual image analysis of gastric mucosal lesions induced in mice and rats by non-steroidal anti-inflammatory drugs
AUTHOR(S): Rainsford, K. D.
CORPORATE SOURCE: Anti-Inflammatory Res. Unit, Strangeways Res. Lab., Cambridge, UK
SOURCE: Acta Physiologica Hungarica (1989), 73(2-3), 371-8
CODEN: APHHDU; ISSN: 0231-424X
DOCUMENT TYPE: Journal
LANGUAGE: English
AB A method is described for the quant. determination of gastric mucosal lesions induced by non-steroidal anti-inflammatory drugs in mice and rats. The area and number of gastric lesions present in formalin-fixed, glycerol-cleared mucosa is determined by computerized visual image anal. using instrumentation as described. The method is also applied to the determination of the protective effects of anti-ulcer agents (e.g. prostaglandin E2, pirenzepine). Thus this method affords unambiguous sensitive and determination of the percentage area of the mucosa damaged and the number of the lesions.
IT 22760-18-5
RL: BIOL (Biological study)
(gastric mucosal lesion induced by, evaluation of)
RN 22760-18-5 CAPLUS
CN 2(1H)-Quinazolinone, 7-methyl-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)



L5 ANSWER 83 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1990:42458 CAPLUS
DOCUMENT NUMBER: 112:42458
ORIGINAL REFERENCE NO.: 112:7203a,7206a
TITLE: Solid surfactant solutions of active ingredients in sugar esters
AUTHOR(S): Hahn, Lorenz; Sucker, Heinz
CORPORATE SOURCE: Sandoz A.-G., Basel, CH-4002, Switz.
SOURCE: Pharmaceutical Research (1989), 6(11), 958-60
CODEN: PHREEB; ISSN: 0724-8741
DOCUMENT TYPE: Journal
LANGUAGE: English
AB The penetration of solid solns. of ciclosporin as model solubilizate in water-soluble sugar esters, which are solid, biodegradable, and nontoxic surfactants, was described. Sugar esters were excellent solubilizers for poorly water-soluble drugs such as ciclosporin. Such systems are suitable for the preparation of solid dosage forms for the purpose of oral administration. Addition of water to the solid solns. yields clear solns. of the solubilizate.
IT 22760-18-5, Proquazone
RL: BIOL (Biological study)
(solubilizers for, sugar esters as, in solid solns. for pharmaceutical dosage forms)
RN 22760-18-5 CAPLUS
CN 2(1H)-Quinazolinone, 7-methyl-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)



L5 ANSWER 84 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1989:625090 CAPLUS
DOCUMENT NUMBER: 111:225090
ORIGINAL REFERENCE NO.: 111:37185a,37188a
TITLE: Role of low Km cyclic AMP phosphodiesterase inhibition in tracheal relaxation and bronchodilation in the guinea pig
AUTHOR(S): Harris, Alex L.; Connell, Mary J.; Ferguson, Edward W.; Wallace, Annette M.; Gordon, Robert J.; Pagani, Edward D.; Silver, Paul J.
CORPORATE SOURCE: Dep. Pharmacol., Sterling Res. Group, Rensselaer, NY, USA
SOURCE: Journal of Pharmacology and Experimental Therapeutics (1989), 251(1), 199-206
CODEN: JPETAB; ISSN: 0022-3565
DOCUMENT TYPE: Journal
LANGUAGE: English
AB The relationship between inhibition of the rolipram-sensitive and the CI-930-sensitive low Km cAMP-specific phosphodiesterase (PDE) isoenzymes (PDE IIIRO and PDE IIIC, resp.) and bronchomotor tone was examined in the guinea pig. Rolipram and CI-930 exhibited biphasic concentration-response relations for relaxation of carbachol-, histamine-, and LTD4-contracted trachea. However, each agent produced a monophasic (sigmoidal) concentration-response curve when tested in the presence of a fixed concentration (3 μM) of the other. The same relations were observed for inhibition of tracheal peak III PDE isolated via DEAE-cellulose chromatog. Whereas CI-930 was approx. equipotent in inhibiting PDE IIIC and relaxing rolipram-pretreated trachea, rolipram was substantially more potent (EC50 = 0.02 μM) in relaxing CI-930-pretreated trachea than in inhibiting CI-930-pretreated PDE III (PDE IIIRO, IC50 = 2.6 μM). Among a series of PDE inhibitors, there was a correlation between PDE IIIC inhibition (i.e., PDE III in the presence of rolipram) and rolipram-pretreated tracheal relaxation, but not between PDE IIIRO inhibition and CI-930-pretreated tracheal relaxation. Nine of the PDE inhibitors used in this study have been reported to displace rolipram from a high-affinity binding site in rat brain. A correlation between relaxation of CI-930-pretreated trachea and displacement of rolipram binding by these agents was observed between in vivo bronchodilation (inhibition of histamine-induced bronchoconstriction) and PDE IIIC inhibition ropipram-displacing potency, and relaxation of CI-930-pretreated trachea, but not PDE IIIRO inhibition. These data suggest that in the guinea pig, PDE IIIC inhibition produces bronchodilation whereas rolipram-induced bronchodilation is associated with a high-affinity binding site, which may or may not be the PDE IIIRO isoenzyme.
IT 22760-18-5, Proquazone
RL: BIOL (Biological study)
(airway relaxation by, as phosphodiesterase inhibitor)
RN 22760-18-5 CAPLUS
CN 2(1H)-Quinazolinone, 7-methyl-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)

L5 ANSWER 84 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



L5 ANSWER 85 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1989:601638 CAPLUS
DOCUMENT NUMBER: 111:201638
ORIGINAL REFERENCE NO.: 111:33393a,33396a
TITLE: Intravenous pharmaceutical solutions containing poorly water-soluble peptides and polyol monoesters of C6-18-fatty acids as solubilizers
INVENTOR(S): Hahn, Lorenz
PATENT ASSIGNEE(S): Sandoz-Patent-G.m.b.H., Fed. Rep. Ger.; Novartis AG
SOURCE: Ger. Offen., 11 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 3830494	A1	19890323	DE 1988-3830494	19880908
DE 3830494	B4	20060518		
HU 49494	A2	19891030	HU 1988-4518	19880901
HU 205010	B	19920330		
FR 2620336	A1	19890317	FR 1988-11953	19880912
FR 2620336	B1	19911025		
BE 1001204	A5	19890816	BE 1988-1044	19880912
CH 683672	A5	19940429	CH 1988-3398	19880912
FI 8804192	A	19890316	FI 1988-4192	19880913
FI 94837	B	19950731		
FI 94837	C	19951110		
NO 8804052	A	19890316	NO 1988-4052	19880913
NO 179434	B	19960701		
NO 179434	C	19961009		
SE 8803221	A	19890316	SE 1988-3221	19880913
SE 503279	C2	19960513		
AU 8822172	A	19890427	AU 1988-22172	19880913
AU 628787	B2	19920924		
GB 2209671	A	19890524	GB 1988-21443	19880913
GB 2209671	B	19911113		
CA 1338775	C	19961210	CA 1988-577214	19880913
DK 8805111	A	19890316	DK 1988-5111	19880914
DK 175132	B1	20040614		
JP 01151526	A	19890614	JP 1988-231396	19880914
JP 3090666	B2	20000925		
AT 8802249	A	19920815	AT 1988-2249	19880914
AT 395819	B	19930325		
KR 131084	B1	19980417	KR 1988-11874	19880914
NL 8802275	A	19890403	NL 1988-2275	19880915
NL 195094	C	20031217		
ES 2012118	A6	19900301	ES 1988-2831	19880915
ZA 8806885	A	19900530	ZA 1988-6885	19880915
US 5756450	A	19980526	US 1994-335523	19941107

PRIORITY APPLN. INFO.: DE 1987-3730909 A1 19870915
DE 1988-3802355 A1 19880127

L5 ANSWER 85 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

US 1988-243577	B2	19880913
GB 1989-2898	A	19890209
GB 1989-2901	A	19890209
GB 1989-3147	A	19890213
GB 1989-3663	A	19890217
US 1990-478187	B1	19900209
US 1991-791844	B1	19911114
US 1992-947224	B1	19920918

AB Water-soluble polyol monoesters of saturated or unsatd. C6-18-fatty acids are used as solubilizing agents for i.v. solns. of bioactive peptides which are poorly water-soluble or poorly soluble in aqueous media or in water-miscible solvents. Specific monoesters are saccharose monolaurate and raffinose monolaurate. L-1695 (>80% saccharose monolaurate) having a hydrophile-lipophile balance of 12.3 (1000 mg) and Sandimmun (i.e. cyclosporin) (160 mg) were dissolved in EtOH and the solvent was removed to give a powder. A paste was prepared from a solid solution containing 25 mg Sandimmun and 198.75 mg viscous paraffin and filled into hard gelatin capsules. The release profile at 37° in water was 3%, 65% and 98% after 5, 30 and 120 min, resp. The monoesters solubilize the peptide in a satisfactory manner and the addition of water effects the formation of a micellar solution from which the active agent is directly bioavailable.
IT 22760-18-5
RL: BIOL (Biological study)
(pharmaceutical injections containing polyol fatty acid monoesters and)
RN 22760-18-5 CAPLUS
CN 2(1H)-Quinazolinone, 7-methyl-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)



L5 ANSWER 86 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1989:546447 CAPLUS
DOCUMENT NUMBER: 111:146447
ORIGINAL REFERENCE NO.: 111:24261a,24264a
TITLE: Comparative study of nonsteroidal inflammation inhibitors, using a new combined method
AUTHOR(S): Gabor, Miklos; Razga, Zsolt
CORPORATE SOURCE: Gyogyszerhatastani Intez., Szent-Gyorgyi Albert Orvostud. Egy., Szeged, Hung.
SOURCE: Kiserletes Orvostudomany (1989), 41(3), 236-9
CODEN: KIORAH; ISSN: 0023-1878
DOCUMENT TYPE: Journal
LANGUAGE: Hungarian
AB The simultaneous inhibition of croton oil-induced ear edema and carrageenan-induced paw edema by 4 nonsteroidal anti-inflammatory agents was studied in rats. Piroxicam at 10 mg/kg caused 42.3 and 52.9% inhibition of the 2 types of edema, resp. Phenylbutazone at 90 mg/kg caused 36.8 and 44.6% inhibition, proquazone at 100 mg/kg caused 28.3 and 57.6% inhibition, and azapropazone at 200 mg/kg caused 20.5 and 46.8% inhibition, resp.
IT 22760-18-5, Proquazone
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES
(Uses)
(inflammation inhibition by, in edema models)
RN 22760-18-5 CAPLUS
CN 2(1H)-Quinazolinone, 7-methyl-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)



L5 ANSWER 87 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1989:546446 CAPLUS
DOCUMENT NUMBER: 111:146446
ORIGINAL REFERENCE NO.: 111:24261a,24264a
TITLE: Effect of nonsteroidal inflammation inhibitors on dithranol-induced mouse ear edema
AUTHOR(S): Gabor, Miklos; Razga, Zsolt
CORPORATE SOURCE: Gyogyszerhatastani Intez., Szent-Gyorgyi Albert Orvostud. Egy., Szeged, Hung.
SOURCE: Kiserletes Orvostudomany (1989), 41(3), 232-5
CODEN: KIORAH; ISSN: 0023-1878
DOCUMENT TYPE: Journal
LANGUAGE: Hungarian
AB Dithranol-induced mouse ear edema inhibition by 5 nonsteroidal inflammation inhibitors was studied by the edema disk method. The edema inhibition (%) was dose-dependent: piroxicam (15.5% and 3.3 mg/kg), phenylbutazone (41.4% and 30 mg/kg), proquazone (48.7% and 5.0 mg/kg), azapropazone (48.9% and 5.0 mg/kg), and niflumic acid (51.2% and 1.0 mg/kg). The inhibition mechanism is discussed.
IT 22760-18-5, Proquazone
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES
(Uses)
(inflammation inhibition by, in edema model)
RN 22760-18-5 CAPLUS
CN 2(1H)-Quinazolinone, 7-methyl-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)



L5 ANSWER 88 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1989:546445 CAPLUS
DOCUMENT NUMBER: 111:146445
ORIGINAL REFERENCE NO.: 111:24261a,24264a
TITLE: Effect of nonsteroidal inflammation inhibitors on croton oil-induced edema in the mouse ear
AUTHOR(S): Gabor, Miklos; Razga, Zsolt
CORPORATE SOURCE: Gyogyszerhatastani Intez., Szent-Gyorgyi Albert Orvostud., Szeged, Hung.
SOURCE: Kiserletes Orvostudomany (1989), 41(3), 228-31
CODEN: KIORAH; ISSN: 0023-1878
DOCUMENT TYPE: Journal
LANGUAGE: Hungarian
AB Croton oil-induced mouse ear edema inhibition by 5 nonsteroidal oral inflammation inhibitors was studied by the edema disk method. The edema inhibition (%) was dose-dependent: piroxicam (48.6% and 10 mg/kg), phenylbutazone (22.4% and 90 mg/kg), proquazone (35.9% and 10 mg/kg), azapropazone (33.8% and 50 mg/kg), and niflumic acid (32.6% and 10 mg/kg).
IT 22760-18-5, Proquazone
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES
(Uses)
(inflammation inhibition by, in ear edema model)
RN 22760-18-5 CAPLUS
CN 2(1H)-Quinazolinone, 7-methyl-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)



L5 ANSWER 89 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1989:540485 CAPLUS
DOCUMENT NUMBER: 111:140485
ORIGINAL REFERENCE NO.: 111:23385a,23388a
TITLE: Anti-inflammatory pharmaceuticals containing Ginkgo biloba extracts or ginkgolides and nonsteroidal inflammation inhibitors
INVENTOR(S): Bauer, Johann
PATENT ASSIGNEE(S): Oxo Chemie G.m.b.H., Fed. Rep. Ger.
SOURCE: PCT Int. Appl., 21 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 8806889	A1	19880922	WO 1988-DE132	19880309
W: JP, US				
DE 3707532	A1	19890309	DE 1987-3707532	19870309
DE 3707532	C2	19980528		
EP 293563	A1	19881207	EP 1988-103748	19880309
R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
JP 01502983	T	19891012	JP 1988-502181	19880309
PRIORITY APPLN. INFO.:			DE 1987-3707532 A	19870309
			WO 1988-DE132 W	19880309

OTHER SOURCE(S): MARPAT 111:140485
AB Pharmaceuticals contain Ginkgo biloba extract or ≥1 ginkgolides and ≥1 inflammation inhibitors. A patient suffering from third degree burns were treated with an infusion containing 10 mg ginkgo flavone glycosides, 500 mg sorbitol, 0.450 g DL-lysine monoacetyl salicylate, 0.5 g glycine, and 150 mg pentoxifylline. Pain subsided 10 min after begining of the treatment, a glaze-like scab formed that remained dry and free of infection.
IT 22760-18-5
RL: BIOL (Biological study)
(antiinflammatory pharmaceuticals containing Ginkgo biloba exts. and)
RN 22760-18-5 CAPLUS
CN 2(1H)-Quinazolinone, 7-methyl-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)



L5 ANSWER 90 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1989:526638 CAPLUS
DOCUMENT NUMBER: 111:126638
ORIGINAL REFERENCE NO.: 111:21007a,21010a
TITLE: Influence of nonsteroidal antiphlogistics on mouse ear inflammation induced with croton oil
AUTHOR(S): Gabor, M.; Razga, Zs.
CORPORATE SOURCE: Dep. Pharmacodyn., Albert Szent-Gyorgyi Med. Univ., Szeged, Hung.
SOURCE: Archives Internationales de Pharmacodynamie et de Therapie (1989), 299, 241-6
CODEN: AIPTAK; ISSN: 0003-9780
DOCUMENT TYPE: Journal
LANGUAGE: English
AB The edema disk technique was used to study the effects of orally administered nonsteroidal inflammation inhibitors (piroxicam, phenylbutazone, proquazone, azapropazone, and niflumic acid) on the inflammation induced by croton oil in the mouse ear. This method was suitable for the detection of an anti-inflammatory effect. The drugs caused inhibition in a dose-dependent manner. Edema inhibition of .apprx.50% was achieved with a dose of 10 mg piroxicam/kg; inhibition of >30% necessitated the administration of proquazone or niflumic acid at 10 mg/kg or azapropazone at 50 mg/kg. Following administration of 90 mg phenylbutazone/kg, an inhibition of only 22.4% was observed
IT 22760-18-5, Proquazone
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES
(Uses)
(inflammation inhibition by)
RN 22760-18-5 CAPLUS
CN 2(1H)-Quinazolinone, 7-methyl-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)



L5 ANSWER 91 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1989:526394 CAPLUS
DOCUMENT NUMBER: 111:126394
ORIGINAL REFERENCE NO.: 111:20959a,20962a
TITLE: Structure of peptidamidobenzophenone and peptidamidobenzhydrol metabolites
AUTHOR(S): Zinkovskii, V. G.; Golovenko, N. Ya.; Totrova, M. Yu.; Rudenko, O. P.
CORPORATE SOURCE: Odessa Gos. Univ., Odessa, USSR
SOURCE: Khimiko-Farmatsevticheskii Zhurnal (1989), 23(6), 651-5
CODEN: KHFZAN; ISSN: 0023-1134
DOCUMENT TYPE: Journal
LANGUAGE: Russian
GI



AB The metabolism of 5-bromo-2-peptidaminobenzophenone (I; R1 = H, Me; R2 = Gly-Gly, Gly-Gly-Z, Gly-Ala-Z) and 5-bromo-2-peptidaminobenzhydrol (II) was studied in mice and rats. The metabolism involved N-demethylation, hydroxylation, hydrolysis, and methoxylations. Some of the metabolites had a benzodiazepine structure which may explain the psychotropic benzodiazepine-like activities of I and II.
IT 64820-54-8
RL: BIOL (Biological study)
(as metabolite of bromopeptidamidobenzophenones or bromopeptidamidobenzhydrol)
RN 64820-54-8 CAPLUS
CN 2(1H)-Quinazolinone, 6-bromo-1-methyl-4-phenyl- (CA INDEX NAME)



L5 ANSWER 92 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1989:199224 CAPLUS
DOCUMENT NUMBER: 110:199224
ORIGINAL REFERENCE NO.: 110:32979a,32982a
TITLE: Pharmaceutical injectable hydrosols containing water-insoluble active agents
INVENTOR(S): List, Martin; Sucker, Heinz
PATENT ASSIGNEE(S): Sandoz S. A., Switz.
SOURCE: Fr. Demande, 26 pp.
CODEN: FRXXBL
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
FR 2608427	A1	19880624	FR 1987-17792	19871217
FR 2608427	B1	19910208		
NL 8702998	A	19880718	NL 1987-2998	19871211
NL 194638	B	20020603		
NL 194638	C	20021004		
HU 52941	A2	19900928	HU 1987-5601	19871211
HU 205861	B	19920728		
DE 3742473	A1	19880728	DE 1987-3742473	19871215
DE 3742473	C2	19981119		
CH 679451	A5	19920228	CH 1987-4885	19871215
DK 8706641	A	19880620	DK 1987-6641	19871217
DK 173319	B1	20000724		
SE 8705043	A	19880620	SE 1987-5043	19871217
SE 503020	C2	19960311		
GB 2200048	A	19880727	GB 1987-29404	19871217
GB 2200048	B	19910206		
BE 1000848	A3	19890418	BE 1987-1461	19871217
DD 281344	A5	19900808	DD 1987-310651	19871217
IL 84855	A	19920329	IL 1987-84855	19871217
CA 1308656	C	19921013	CA 1987-554625	19871217
AT 8703330	A	19931215	AT 1987-3330	19871217
AT 397914	B	19940825		
AU 8782828	A	19880623	AU 1987-82828	19871218
AU 606908	B2	19910221		
JP 63165312	A	19880708	JP 1987-322622	19871218
ZA 8709533	A	19890830	ZA 1987-9533	19871218
ES 2028492	A6	19920701	ES 1987-3635	19871218
US 5389382	A	19950214	US 1991-642106	19910116
DK 173345	B1	20000807	DK 2000-266	20000221

PRIORITY APPLN. INFO.: DE 1986-3643392 A 19861219
US 1987-134337 B1 19871217
US 1989-436147 B1 19891113

AB I.v. pharmaceutical hydrosols have the form of aqueous suspensions or dry compns. that may be resuspended in aqueous medium; the hydrosols comprise the pharmacol. active agent in a solid, particulate form. A solution containing 1 g

L5 ANSWER 92 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
Et cellulose-N7, 0.4 g darodipine (I), and 40 mL 94% EtOH was stirred rapidly into 200 mL H2O, EtOH was evapd., and the particles thus formed were isolated by filtration. The particle size was 0.116 μm and the polydispersion factor was 28%. A soln. contained the above formulation (2 mg I) and isotonic glucose, and a 100 μg/kg dose I was administered to rabbits by injection. As a result, pulse, blood pressure, ventricular blood pressure, cardiac contractility, cardiac output, and peripheral blood circulation were the same as those in a control receiving an injection contg. I, EtOH, and polyethylene glycol.
IT 22760-18-5, Proquazone
RL: BIOL (Biological study)
(pharmaceutical injectable hydrosols containing)
RN 22760-18-5 CAPLUS
CN 2(1H)-Quinazolinone, 7-methyl-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)



L5 ANSWER 93 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1989:128359 CAPLUS
DOCUMENT NUMBER: 110:128359
ORIGINAL REFERENCE NO.: 110:20999a,21002a
TITLE: Effect of peripheral benzodiazepine receptor ligands on the contraction of isolated heart atrium and papillary muscle of rats
AUTHOR(S): Saano, Veijo; Raty, Markku; MacDonald, Ewen
CORPORATE SOURCE: Dep. Pharmacol. Toxicol., Univ. Kuopio, Kuopio, SF-70211, Finland
SOURCE: Pharmacology & Toxicology (Oxford, United Kingdom) (1989), 64(1), 147-9
CODEN: PHTOEH; ISSN: 0901-9928
DOCUMENT TYPE: Journal
LANGUAGE: English
AB The affinities of 14 ligands for peripheral benzodiazepine receptors in the rat heart (determined by inhibition of [3H]Ro 5-4864 binding) and their effects on the elec. stimulated contractions of the isolated atrium and papillary muscle were determined The potencies in altering the contractile force were independent of the receptor d. in various regions of the heart.
This lack of correlation between finding affinity and contractile effects suggests that the peripheral benzodiazepine receptors are not involved in the actions of these ligands on the heart.
IT 22760-18-5, Proquazone
RL: BIOL (Biological study)
(heart contraction response to, benzodiazepine receptors in relation to)
RN 22760-18-5 CAPLUS
CN 2(1H)-Quinazolinone, 7-methyl-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)



L5 ANSWER 94 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1989:87909 CAPLUS
DOCUMENT NUMBER: 110:87909
ORIGINAL REFERENCE NO.: 110:14353a,14356a
TITLE: Drug distribution in the body: in vitro prediction and physiological interpretation
AUTHOR(S): Hinderling, P. H.
CORPORATE SOURCE: Dep. Pharmacol., Univ. Basel, Basel, 4056, Switz.
SOURCE: Progress in Pharmacology (1988), 6(4), 1-30
CODEN: PRPHDB; ISSN: 0340-465X
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Human and animal data reported in the literature for drugs on unbound steady state volume of distribution (Vu,ss), blood cell/buffer partitioning (Ke/b), ratio of bound to unbound fraction in plasma (R), octanol/buffer partition coefficient (P), and pKa were collected. The data were critically evaluated in accordance with defined selection criteria. After selection, values on Vu,ss, Ke/b, R, P and pKa were available for 36-38 basic and 15 acidic drugs in humans and on 12 barbituric acid derivs. in rats. Regression anal. were performed with Vu,ss, on each of Ke/B, R, P and pKa to test if a reliable in vitro prediction of drug distribution in vivo is possible and if the values obtained for the parameters Ke/b and Vu,ss have physiol. meaning. Significant correlations existed between Vu,ss and each of Ke/b, R and P for the tested bases in humans and for the acids in rats. Significant correlations were also found between Vu,ss and each of Ke/b and R for the studied acids in humans, whereas Vu,ss apparently did not depend on P. Among the in vitro predictors tested, Ke/b was the most reliable with a precision of prediction ranging between 22-50% suggesting that prospective <in vitro> distribution forecasting based on Ke/b is possible. The bases studied in humans and the barbituric acid derivs. investigated in rats had unrestricted cellular access, were distributed throughout the total body water and exerted addnl. binding and/or partitioning. In contrast, several of the acids tested in humans showed restricted cellular uptake. Lipophilicity was the major determinant for the unspecific cellular binding/partitioning of the bases and acids with unrestricted cell penetration. The largest fractions of the drugs resided within the cells in the bound/partitioned form explaining why P was a reliable in vitro predictor of drug distribution in vivo for bases and acids with unrestricted cellular uptake. With the bases tested in humans, the blood cells contained 0.2-4.2% of the total, plasma unbound amts. present in the body at steady state, whereas with the acids in humans and barbituric acids in rats, these percentages ranged resp. between 0.4-43.9 and 12.7-30.4%. These results suggested that acidic compds. with unrestricted cellular uptake can exhibit higher relative affinities to blood cells than bases. The regression of Vu,ss on Ke/b yielded values for total body water and extracellular space, which were in agreement with the generally accepted values for these physiol. vols. in humans and rats. It cannot be ruled out that these ests. and the similar values obtained in the present study are both subject to bias. Indications are however, that this possible bias is small.

IT 22760-18-5, Proquazone
RL: BIOL (Biological study)
(distribution of, process simulation of, in humans)
RN 22760-18-5 CAPLUS
CN 2(1H)-Quinazolinone, 7-methyl-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)



L5 ANSWER 95 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1989:82619 CAPLUS
DOCUMENT NUMBER: 110:82619
ORIGINAL REFERENCE NO.: 110:13545a,13548a
TITLE: Differential pulse polarographic determination of proquazone
AUTHOR(S): Temizer, Aytekin; Kir, Sedef; Onar, A. Nur
CORPORATE SOURCE: Fac. Pharm., Hacettepe Univ., Ankara, 06100, Turk.
SOURCE: Indian Journal of Chemistry, Section A: Inorganic, Physical, Theoretical & Analytical (1988), 27A(9), 825-6
CODEN: IJCADU; ISSN: 0376-4710
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



I

AB The differential pulse polarog. behavior of proquazone (I) was investigated in different media. The compns. of electrolytes, height of the mercury column, temperature and the other parameters were so selected that the determination of this drug can be accomplished down to below ppm level. The reduction of I to proquazole is a reversible reaction and occurs with one electron transfer.

IT 22760-18-5, Proquazone
RL: ANT (Analyte); ANST (Analytical study)
(determination of, in capsules by differential pulse polarog.)
RN 22760-18-5 CAPLUS
CN 2(1H)-Quinazolinone, 7-methyl-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)



IT 119053-59-7, Proquazole
RL: ANST (Analytical study)
(proquazone electrochem. reduction product)
RN 119053-59-7 CAPLUS
CN 2-Quinazolinol, 1,2-dihydro-7-methyl-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)



L5 ANSWER 96 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1988:570400 CAPLUS
DOCUMENT NUMBER: 109:170400
ORIGINAL REFERENCE NO.: 109:28267a,28270a
TITLE: Acid and alkaline hydrolysis of 2-amino-7-chloro-5-phenyl-1,3,4-benzotriazepines
AUTHOR(S): Richter, P.; Schleuder, M.; Stiebert, Petra
CORPORATE SOURCE: Sekt. Pharm., Ernst-Moritz-Arndt-Univ., Greifswald, Ger. Dem. Rep.
SOURCE: Pharmazie (1988), 43(5), 362
CODEN: PHARAT; ISSN: 0031-7144
DOCUMENT TYPE: Journal
LANGUAGE: German
OTHER SOURCE(S): CASREACT 109:170400
GI



AB The hydrolysis of title compds. I (R = H, Me) and II in refluxing HCl gave quinazolines III (R = H, Me) and IV, resp. III (R = H, Me) were hydrolyzed to give quinazolinone V (R1 = H), whereas the hydrolysis of IV gave V (R1 = Me). Refluxing I (R = H, Me) and II in ethanolic KOH gave V (R1 = H and Me, resp.).
IT 20927-53-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and ring cleavage of)
RN 20927-53-1 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-1-methyl-4-phenyl- (CA INDEX NAME)

L5 ANSWER 96 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



L5 ANSWER 97 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1988:510393 CAPLUS
DOCUMENT NUMBER: 109:110393
ORIGINAL REFERENCE NO.: 109:18395a,18398a
TITLE: Synthesis of 5-phenyl-2-thioxo-1,3,4-benzotriazepines
AUTHOR(S): Richter, P.; Morgenstern, O.; Besch, Anita
CORPORATE SOURCE: Sekt. Pharm., Ernst-Moritz-Arndt-Univ., Greifswald, Ger. Dem. Rep.
SOURCE: Pharmazie (1988), 43(1), 5-10
CODEN: PHARAT; ISSN: 0031-7144
DOCUMENT TYPE: Journal
LANGUAGE: German
OTHER SOURCE(S): CASREACT 109:110393
GI



AB The synthesis of the title compds. I (R1 = H, Me, R2 = H, Cl, R3 = H, Me, CH2CH2OH) is achieved by reaction of 2-isothiocyanato- or 2-aroxythiocarbonylaminobenzophenones with alkylhydrazines, by thermal cyclization of 2-aminobenzophenone thiosemicarbazones or -methylthio thiocarbonylhydrazones and by heating the 2-oxo-5-phenyl-1,3,4-benzotriazepines with phosphorus(V) sulfide.
IT 94990-70-2P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 94990-70-2 CAPLUS
CN 2(1H)-Quinazolinethione, 3-amino-6-chloro-3,4-dihydro-4-hydroxy-1-methyl-4-phenyl- (CA INDEX NAME)



L5 ANSWER 98 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1988:431713 CAPLUS
DOCUMENT NUMBER: 109:31713
ORIGINAL REFERENCE NO.: 109:5237a,5240a
TITLE: Interaction of O-(β-hydroxyethyl)rutin (HR) with nonsteroidal inflammation inhibitors
AUTHOR(S): Gabor, Miklos; Engi, Etelka
CORPORATE SOURCE: Gyogyszerhatastani Intez., Szegedi Orvostudo. Egy., Szeged, Hung.
SOURCE: Kiserletes Orvostudomany (1988), 40(1), 9-14
CODEN: KIORAH; ISSN: 0023-1878
DOCUMENT TYPE: Journal
LANGUAGE: Hungarian
AB The interaction of nonsteroidal inflammation inhibitors with HR was studied in rats. Carrageenan-induced foot edema was reduced by HR at 100 mg/kg, proquazone at 5 mg/kg, niflumic acid at 5 mg/kg and piroxicam at 2.5 mg/kg. HR had anti-inflammatory effects alone and potentiated the effects of the other drugs.
IT 22760-18-5, Proquazone
RL: BIOL (Biological study)
(inflammation inhibition by hydroxyethylrutin and)
RN 22760-18-5 CAPLUS
CN 2(1H)-Quinazolinone, 7-methyl-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)



L5 ANSWER 99 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1988:105947 CAPLUS
DOCUMENT NUMBER: 108:105947
ORIGINAL REFERENCE NO.: 108:17199a,17202a
TITLE: The inhibitory effect of some nonsteroidal anti-inflammatory compounds on calmodulin dependent cAMP phosphodiesterase and structure-activity relationships
AUTHOR(S): Nebioglu, Dogu; Kocer, Zeliha; Buyukbinbol, Erdem; Aktan, Fugen; Nebioglu, Serpil
CORPORATE SOURCE: Eczacilik Fak., A. U., Ankara, Turk.
SOURCE: Biyokimya Dergisi (1987), 12(1), 31-9
CODEN: BIDEDV; ISSN: 0250-4685
DOCUMENT TYPE: Journal
LANGUAGE: Turkish
AB The inhibitory effects of proquazone, flufenamic acid, and aspirin on calmodulin-dependent cAMP phosphodiesterase were determined with respect to lipophilicity and the mol. connectivity index. Some relations between structure and inhibitory activity are described.
IT 22760-18-5
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(cAMP phosphodiesterase inhibition by, structure in relation to)
RN 22760-18-5 CAPLUS
CN 2(1H)-Quinazolinone, 7-methyl-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)



L5 ANSWER 100 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1988:87613 CAPLUS
DOCUMENT NUMBER: 108:87613
ORIGINAL REFERENCE NO.: 108:14271a,14274a
TITLE: Binding of non-steroid anti-inflammatory drugs and warfarin to liver tissue of rabbits in vitro
AUTHOR(S): Tesseromatis, Christine; Fichtl, Buckard; Kurz, Hermann
CORPORATE SOURCE: Dep. Pharmacol., Univ. Munich, Munich, Fed. Rep. Ger.
SOURCE: European Journal of Drug Metabolism and Pharmacokinetics (1987), 12(3), 161-7
CODEN: EJDPD2; ISSN: 0398-7639
DOCUMENT TYPE: Journal
LANGUAGE: English
AB For warfarin and several non-steroidal anti-inflammatory drugs (NSAID), i.e. acetylsalicylic acid, ibuprofen, ketoprofen, and oxyphenbutazone, there was no difference between the free drug concns. in the homogenized and in non-homogenized samples from rabbit liver. This suggests that the binding of these drugs to liver tissue was not altered by homogenization. Whether NSAIDS interfere with binding of warfarin to liver tissue was studied. Acetylsalicylic acid, flubiprofen, ibuprofen, ketoprofen, oxyphenbutazone, and proquazone markedly increased the free concentration of warfarin both in liver slices and homogenates. The extent of displacement did not differ between slices and homogenates.
IT 22760-18-5
RL: BIOL (Biological study)
(binding of, by liver, warfarin interaction with)
RN 22760-18-5 CAPLUS
CN 2(1H)-Quinazolinone, 7-methyl-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)



L5 ANSWER 101 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1988:101 CAPLUS
DOCUMENT NUMBER: 108:101
ORIGINAL REFERENCE NO.: 108:7a,10a
TITLE: Comparative evaluation of equilibrium dialysis methods employing biological and artificial membranes for the determination of protein binding of drugs
AUTHOR(S): Hinderling, P. H.
CORPORATE SOURCE: Biocent., Univ. Basel, Basel, CH-4056, Switz.
SOURCE: Therapeutic Drug Monitoring (1987), 9(3), 331-6
CODEN: TDMODV; ISSN: 0163-4356
DOCUMENT TYPE: Journal
LANGUAGE: English
AB The performances of the conventional equilibrium dialysis method using artificial membranes (AED) and of an alternative equilibrium dialysis method employing biol. membranes of red blood cells (BED) were compared. Plasma protein binding values by AED and BED were available for a total of 22 nonelectrolytic and electrolytic compds., including the entire possible range of binding values. Plots of the mean plasma unbound fractions as obtained by AED and BED for the compds. studied could be fitted by a straight line with slope and intercept not different from unity and 0, resp. Also, the precision of the 2 methods appeared to be similar. However, the times required to reach equilibrium dialysis were different: with BED and AED, this time span ranged 2-45 and 180-960 min, resp. Overall, the BED method offers an advantage over the AED procedure: it is less time consuming and hence possibly more reliable.
IT 22760-18-5, Proquazone
RL: BIOL (Biological study)
(binding of, to plasma proteins, equilibrium dialysis using membranes for evaluation of)
RN 22760-18-5 CAPLUS
CN 2(1H)-Quinazolinone, 7-methyl-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)



L5 ANSWER 102 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1987:597373 CAPLUS
DOCUMENT NUMBER: 107:197373
ORIGINAL REFERENCE NO.: 107:31643a,31646a
TITLE: 1,4-Benzodiazepines and 1,5-diazocines. Part IX. Effects of para- and meta-fluoro substitution of the 5-phenyl ring on its solution-state conformation in lactam-type 5-phenyl-1,4-benzodiazepines
AUTHOR(S): Finner, Emil; Zeugner, Horst
CORPORATE SOURCE: Pharm. Div., Kali-Chem. A.-G., Hannover, D-3000, Fed. Rep. Ger.
SOURCE: Archiv der Pharmazie (Weinheim, Germany) (1987), 320(2), 179-82
CODEN: ARPMAS; ISSN: 0365-6233
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



I

AB NMR data for benzodiazepines (I; R = H, p-F, m-F) are reported. Conformation effects caused by the F substituents are discussed. While I (R = H, p-F) exhibit only signals for a single rotational conformer, I (R = m-F) exhibits signals of two rotational isomers. Rotational barriers were determined
IT 110953-83-8 110953-84-9
RL: PRP (Properties)
(conformation anal. of)
RN 110953-83-8 CAPLUS
CN 2(1H)-Quinazolinone, 4-(4-fluorophenyl)-1-methyl-6-nitro- (CA INDEX NAME)



RN 110953-84-9 CAPLUS
CN 2(1H)-Quinazolinone, 4-(3-fluorophenyl)-1-methyl-6-nitro- (CA INDEX NAME)

L5 ANSWER 102 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



L5 ANSWER 103 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1987:432439 CAPLUS
DOCUMENT NUMBER: 107:32439
ORIGINAL REFERENCE NO.: 107:5267a,5270a
TITLE: Proquazone. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in rheumatic diseases and pain states
AUTHOR(S): Clissold, Stephen P.; Beresford, Rosemary
CORPORATE SOURCE: ADIS Drug Inf. Serv., Auckland, N. Z.
SOURCE: Drugs (1987), 33(5), 478-502
CODEN: DRUGAY; ISSN: 0012-6667
DOCUMENT TYPE: Journal; General Review
LANGUAGE: English
AB A review with approx. 90 refs.
IT 22760-18-5, Proquazone
RL: BIOL (Biological study)
(pharmacodynamic and pharmacokinetic properties of, in humans and laboratory animals)
RN 22760-18-5 CAPLUS
CN 2(1H)-Quinazolinone, 7-methyl-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)



L5 ANSWER 104 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1987:138377 CAPLUS
DOCUMENT NUMBER: 106:138377
ORIGINAL REFERENCE NO.: 106:22581a,22584a
TITLE: Synthesis of quinazolines
AUTHOR(S): Bergman, Jan; Brynolf, Anna; Elman, Bjoern; Vuorinen, Eino
CORPORATE SOURCE: Dep. Org. Chem., R. Inst. Technol., Stockholm, S-100 44, Swed.
SOURCE: Tetrahedron (1986), 42(13), 3697-706
CODEN: TETRAB; ISSN: 0040-4020
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 106:138377
AB Reaction of RMgX (R = Me, Et, Ph, 4-MeC6H4, Me2CH, Bu; X = Cl, Br, iodo) with 2-H2NC6H4CN gave the intermediate 2-H2NC6H4CR:N- (I), which were cyclized to quinazolines by reaction with carbonyl compds. (e.g., acid chlorides, anhydrides, formates, and oxalates). Reaction of I with aldehydes, e.g. PhCHO, gave 1,2-dihydroquinazolines, which were readily dehydrogenated. Reaction of I with ClCO2Me gave 4-phenyl-2-quinazolinone, which was reduced to 3,4-dihydro-4-phenyl-2-quinazolinone by NaBH4 in AcOH.
IT 107289-00-9P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 107289-00-9 CAPLUS
CN 2(1H)-Quinazolinone, 4-phenyl-1-(phenylmethyl)- (CA INDEX NAME)



L5 ANSWER 105 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1987:119363 CAPLUS
DOCUMENT NUMBER: 106:119363
ORIGINAL REFERENCE NO.: 106:19487a,19490a
TITLE: Carbon dioxide: a reagent for the simultaneous protection of nucleophilic centers and the activation of alternative locations to electrophilic attack. Part III. A new synthetic method for the ortho-substitution of N-monoalkylanilines
AUTHOR(S): Katritzky, Alan R.; Fan, Wei Qiang; Akutagawa, Kunihiko
CORPORATE SOURCE: Dep. Chem., Univ. Florida, Gainesville, FL, 32611, USA
SOURCE: Tetrahedron (1986), 42(14), 4027-34
CODEN: TETRAB; ISSN: 0040-4020
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 106:119363
AB N-Methyl- and N-ethylaniline were regiospecifically converted to ortho-substituted derivs., using CO2 both for N-protection and as an intermediate carbanion stabilizing group, and Me3CLi to lithiate the ortho-C atom. The resulting Li N-(o-substituted phenyl)-N-methyl- and -N-ethylcarbamates underwent acid catalyzed decarboxylation under mild conditions. No α-substituted products were detected. I.e., lithiation of PhNMeCO2Li (I) and then addition of BzH followed by acid hydrolysis gave 60% o-PhCH(OH)C6H4NHMe. I was prepared by the reaction of PhNMeLi and CO2.
IT 26831-07-2P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 26831-07-2 CAPLUS
CN 2(1H)-Quinazolinone, 1-ethyl-4-phenyl- (CA INDEX NAME)



L5 ANSWER 106 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1986:508511 CAPLUS
DOCUMENT NUMBER: 105:108511
ORIGINAL REFERENCE NO.: 105:17419a,17420a
TITLE: Treating dysmenorrhea with 4-aryl-quinazolinone composition
INVENTOR(S): Von Graffenried, Beat; Nuesch, Erich
PATENT ASSIGNEE(S): Sandoz A.-G., Switz.
SOURCE: Pat. Specif. (Aust.), 11 pp.
CODEN: ALXXAP
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
AU 550009	B2	19860227	AU 1981-71301	19810603
AU 8171301	A	19811210		
BE 889046	A1	19811202	BE 1981-10239	19810602
JP 57014532	A	19820125	JP 1981-85553	19810603
PRIORITY APPLN. INFO.:			GB 1980-18328 A	19800604

GI



I

AB Title compds. (I; R0=C1-6 alkyl or haloalkyl, allyl, propargyl, cyclopropylmethyl; R=H, C1-4 alkyl, alkoxy, alkylthio, or alkylamino, F, Cl, Br, NO2, NH2, dialkylamino; R1=H, F, Cl, Br, C1-4 alkyl or alkoxy; or RR1=OCH2O; R2=H, F, Cl, Br, C1-4 alkyl or alkoxy, OH, CF3; R3=H, F, Cl, C1-4 alkyl) are useful for treatment of dysmenorrhea. For example, fluproquazone (I; R0=CHMe2, R=7-Me, R1=R3=H, R2=4'-F) provided good to very good improvement at 50mg 3 times a day in patients with primary dysmenorrhea.
IT 40507-23-1
RL: BIOL (Biological study)
(dysmenorrhea treatment with)
RN 40507-23-1 CAPLUS
CN 2(1H)-Quinazolinone, 4-(4-fluorophenyl)-7-methyl-1-(1-methylethyl)- (CA INDEX NAME)

L5 ANSWER 106 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



L5 ANSWER 107 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1986:507690 CAPLUS
DOCUMENT NUMBER: 105:107690
ORIGINAL REFERENCE NO.: 105:17265a,17268a
TITLE: A method for measuring specific activities of carbon-14-labeled compounds by gas chromatography-mass spectrometry-computer system
AUTHOR(S): Kanamaru, Hiroshi; Takai, Ryozo; Horiba, Masao; Nakatsuka, Iwao; Yoshitake, Akira
CORPORATE SOURCE: Takarazuka Res. Cent., Sumitomo Chem. Co., Ltd., Takarazuka, Japan
SOURCE: Radioisotopes (1985), 34(2), 67-71
CODEN: RAISAB; ISSN: 0033-8303
DOCUMENT TYPE: Journal
LANGUAGE: English
AB A method was developed for measuring specific activities of 14C-labeled compds. by gas chromatog.-mass spectrometry-computer system. A precise and accurate determination for specific activities of various 14C-labeled compds. is possible. The method is convenient and applicable to small amts. of samples as well as volatile compds. The anal. of the mass spectra provides information on the labeling patterns and synthetic procedures of the analyzed materials.
IT 103915-58-8
RL: ANST (Analytical study)
(determination of specific activity of, by gas chromatog.-mass spectrometry-computer system)
RN 103915-58-8 CAPLUS
CN 2(1H)-Quinazolinone-4-14C, 1-(cyclopropylmethyl)-6-methoxy-4-phenyl-(9CI) (CA INDEX NAME)



L5 ANSWER 108 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1986:472596 CAPLUS
DOCUMENT NUMBER: 105:72596
ORIGINAL REFERENCE NO.: 105:11649a,11652a
TITLE: Affinity of various compounds for benzodiazepine binding sites in rat brain, heart and kidneys in vitro
AUTHOR(S): Saano, V.
CORPORATE SOURCE: Dep. Pharmacol. Toxicol., Univ. Kuopio, Kuopio, SF-70211, Finland
SOURCE: Acta Pharmacologica et Toxicologica (1986), 58(5), 333-8
CODEN: APTOA6; ISSN: 0001-6683
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Binding of several psychoactive, antiinflammatory, antihypertensive, and antiarrhythmic drugs to central and peripheral benzodiazepine (BZ) binding sites was studied in the brain, heart and kidneys of rats. Diazepam [439-14-5] exhibited the highest affinity for all binding sites (Ki values at 0.01 μM level); another 1,4-BZ, oxazepam [604-75-1] had markedly lower affinity for peripheral binding sites (Ki 21-37 μM). Non-BZ compds. had low affinity for central BZ receptors; proquazone [22760-18-5] was the most potent (Ki 9.5 μM). The affinities of non-BZ compds. were higher for peripheral BZ binding sites. The Ki value for proquazone was approx. 0.1 μM; and many other antiinflammatory agents, and the vasodilators cyclandelate [456-59-7] and nifedipine [21829-25-4], produced Ki values in the micromolar level. β-Blocking drugs, and several other antihypertensive and antiarrhythmic agents lacked affinity for both central and peripheral BZ binding sites. According to the results, the affinity for peripheral binding sites is independent of an affinity for central BZ receptors. Non-BZ compds. that bound to brain BZ receptors bound with equal affinity to both BZ1 and BZ2 subgroups of receptors. The compds. with affinity for peripheral BZ binding sites did not select between heart and kidneys, which suggests that these organs have similar binding sites. The role of the peripheral BZ binding sites has not yet been established. The findings of the study allow the selection of a more varied group of ligands to be used when investigating the physiol. significance of these binding sites.
IT 22760-18-5
RL: PROC (Process)
(binding of, to benzodiazepine receptors of brain and heart and kidney)
RN 22760-18-5 CAPLUS
CN 2(1H)-Quinazolinone, 7-methyl-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)



L5 ANSWER 108 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

L5 ANSWER 109 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1986:218797 CAPLUS
DOCUMENT NUMBER: 104:218797
ORIGINAL REFERENCE NO.: 104:34517a,34520a
TITLE: Rat study comparing the anti-inflammatory and ulcerogenic activities of azapropazone with those of other nonsteroidal anti-inflammatory drugs
AUTHOR(S): Jahn, U.
CORPORATE SOURCE: Abt. Biol., Siegfried A.-G., Zofingen, CH-4800, Switz.
SOURCE: Arthritis + Rheuma (1985), 7(1), 21-7
CODEN: ARRHER; ISSN: 0176-5167
DOCUMENT TYPE: Journal
LANGUAGE: German

AB Comparative evaluations of the anti-inflammatory and ulcerogenic activities of a number of nonsteroidal anti-inflammatory drugs in the rat have shown azapropazone (I) [13539-59-8] to occupy an intermediate position in inhibiting carrageenan-induced edema of the paw. I does, however, have a very low adverse effect on the gastric mucosa, and a comparison of the ED50 values for inhibition of edema and ulcerogenic activity (ulcerogenic index) places it at the top when compared to the other tested prepns. Possible reasons for this placement are discussed.

IT 22760-18-5
RL: BIOL (Biological study)
(anti-inflammatory and ulcerogenic activities of, azapropazone comparison with)

RN 22760-18-5 CAPLUS
CN 2(1H)-Quinazolinone, 7-methyl-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)



L5 ANSWER 110 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1986:142260 CAPLUS
DOCUMENT NUMBER: 104:142260
ORIGINAL REFERENCE NO.: 104:22327a,22330a
TITLE: 4-Arylquinazolinone compositions
INVENTOR(S): Skrifvars, Bo Viktor
PATENT ASSIGNEE(S): Sandoz A.-G., Switz.
SOURCE: Pat. Specif. (Aust.), 12 pp.
CODEN: ALXXAP
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
AU 545003	B2	19850627	AU 1980-61836	19800828
AU 8061836	A	19810319		
BE 884935	A1	19810227	BE 1980-9939	19800827
JP 56036418	A	19810409	JP 1980-119678	19800828
PRIORITY APPLN. INFO.:			CH 1979-7871 A	19790830

GI



I

AB Arylquinazolines are described that have the general structure I (R0 = C≤6 alkyl, allyl, propargyl, cyclopropylmethyl; R = H, C≤4 alkyl, C≤4 alkoxy, F, Cl, Br, NO2, NH2, C≤4 substituted alkyl; R1 = H, F, Cl, Br, C≤4 alkyl, or alkoxy; or R and R1 together form 6,7-methylenedioxy; Y = H, F, Cl, Br, C≤4 alkyl, C≤4 alkoxy, OH, or trifluoromethyl; Y1 = H, F, Cl, Br, C≤4 alkyl) for treating connective autoimmune diseases. The most preferred compds. are II (Proquazone; I where R0 = iso-Pr, Y = Y1 = H, R = 7-Me, R1 = H) and III (RF 46-790; I where R0 = iso-Pr, Y = 4-F, Y0 = H, R = 7-Me, R1 = H). These compds. may be given with other known treatments (e.g., prednisone). II was given (300 mg capsule) to 8 active systemic lupus erythematosus (SLE) patients. Prednisone (4-10 mg/day) was also given to all patients except 1. Inclusion of II with prednisone resulted in good clin. improvement in half of the patients. II alone improved the chemical condition of 1 patient. II was discontinued on appearance of allergic reactions in 2 patients and diarrhea in 1 patient. Substitution of III (40 mg/day) for II resulted in a decrease in IgM level and mitochondrial and smooth muscle antibody titers.

IT 22760-18-5 40507-23-1
RL: BIOL (Biological study)

L5 ANSWER 110 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
(autoimmune diseases treatment with)

RN 22760-18-5 CAPLUS
CN 2(1H)-Quinazolinone, 7-methyl-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)



RN 40507-23-1 CAPLUS
CN 2(1H)-Quinazolinone, 4-(4-fluorophenyl)-7-methyl-1-(1-methylethyl)- (CA INDEX NAME)



L5 ANSWER 111 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1986:139402 CAPLUS
DOCUMENT NUMBER: 104:139402
ORIGINAL REFERENCE NO.: 104:21885a,21888a
TITLE: Chromogenic 4,4-diaryldihydroquinazolones
INVENTOR(S): Berneth, Horst; Brack, Alfred
PATENT ASSIGNEE(S): Bayer A.-G. , Fed. Rep. Ger.
SOURCE: Ger. Offen., 51 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 3420799	A1	19851205	DE 1984-3420799	19840604
US 4695633	A	19870922	US 1985-735477	19850517
EP 164018	A2	19851211	EP 1985-106253	19850522
EP 164018	A3	19881019		
EP 164018	B1	19901031		
R: CH, DE, FR, GB, LI				
JP 61017573	A	19860125	JP 1985-116837	19850531
JP 05033700	B	19930520		
PRIORITY APPLN. INFO.:			DE 1984-3420799 A	19840604

OTHER SOURCE(S): MARPAT 104:139402
GI


I


II

AB Chromogenic 4,4-diaryldihydroquinaqolones (R = H, alkyl, cycloalkyl, aralkyl, or a member of a bridge to the ortho-C of the adjacent ring; R1 = H, alkyl, cycloalkyl, aralkyl, aryl, heteroalkyl, or heteroaryl; R2, R3, R4 = H, halo, alkyl, aryl, alkanoylamino, aroylamino, NR5R6, OR7, or SR7 and ≥1 of R2, R3, R4 is NR5R6, OR7, or SR7 where R5, R6, R7 is H, alkyl, cycloalkyl, aralkyl, aryl, or the remaining member of a bridge to an ortho benzene C atom; and R5 R6 together can form a heteroatom-containing 5- or 6-membered ring) are described for use as color formers in heat- or pressure-sensitive copying materials. Thus, a paper support was coated with a mixture of a dispersion containing Bisphenol A 32, ethylenedistearylamide

L5 ANSWER 111 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
3.8, kaolin 89, 88% hydrolyzed poly(vinyl alc.) 20 g, and water 55 mL and a dispersion contg. II 6, 88% hydrolyzed poly(vinyl alc.) 3 g, and water 60 mL at 5.5 g/m2 (dry) and then the paper was contacted with a heated ball-point pen to give an intensive blue color having good lightfastness and sublimation resistance.
IT 101152-54-9P
RL: PREP (Preparation)
(preparation and color-former applications of, in pressure-sensitive copying and thermal recording)
RN 101152-54-9 CAPLUS
CN Benzonitrile, 4-[4,4-bis[4-(dimethylamino)phenyl]-6-ethoxy-1,4-dihydro-2-oxo-1-phenyl-3(2H)-quinazolinyl]- (CA INDEX NAME)



L5 ANSWER 112 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1986:49698 CAPLUS
DOCUMENT NUMBER: 104:49698
ORIGINAL REFERENCE NO.: 104:8005a,8008a
TITLE: Modulation of leukotriene and prostaglandin production from mouse peritoneal macrophages
AUTHOR(S): Brune, K.; Peskar, B. A.
CORPORATE SOURCE: Dep. Pharmacol. Toxicol., Univ. Erlangen-Nuernberg, Erlangen, D-8520, Fed. Rep. Ger.
SOURCE: Prostaglandins Other Eicosanoids Cardiovasc. Syst., Proc. Int. Symp. Prostaglandins, 2nd (1985), Meeting Date 1984, 559-63. Editor(s): Schroer, Karsten. Karger: Basel, Switz.
CODEN: 54GRA4
DOCUMENT TYPE: Conference
LANGUAGE: English
AB Mouse peritoneal macrophages responded to different stimuli with either prostaglandin (PG) or PG and leukotriene (LT) release. The tumor promoter TPA induced PGE2 release in a dose-dependent manner starting at 10-9 mol/L and reaching a plateau at 10-6 mol/L. A measurable production of LTC4-like immunoreactivity was observed only at concns. ≥10-7 mol/L. In contrast, ionophore A23187 initiated both PG and LT release, with maximum release of LT at 10-6 mol/L. Acidic anti-inflammatory and analgesic drugs inhibited TPA-induced PG production Benoxaprofen and indomethacin reduced the release of PG, whereas indomethacin tended to enhance LT release. The non-acidic analgesics 4-methylaminoantipyrine and proquazone both reduced PG production and enhanced LT release. The exptl. compds. BS 755 C and NDGA inhibited both PG and LT production at high concns. In macrophages stimulated by ionophore A23187, BS 755 C inhibited the production of PGE2 and LTC4, whereas NDGA at a lower concentration (10-6 mol/L) inhibited LTC4 but had no effect on PGE2 release. Higher concns. of NDGA (10-4 and 10-5 mol/L) however, inhibited the release of both PGE2 and LTC4. Benoxaprofen, indomethacin, acetylsalicylic acid, naproxen, diflunisal, proquazone, 4-methylamino-antipyrine and paracetamol inhibited PG production but enhanced LT production, whereas nafazatrom inhibited LTC4, but simultaneously enhanced PGE2 production
IT 22760-18-5
RL: BIOL (Biological study)
(leukotriene and prostaglandin formation by macrophage response to)
RN 22760-18-5 CAPLUS
CN 2(1H)-Quinazolinone, 7-methyl-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)

L5 ANSWER 112 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



L5 ANSWER 113 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1985:589062 CAPLUS
DOCUMENT NUMBER: 103:189062
ORIGINAL REFERENCE NO.: 103:30257a,30260a
TITLE: Determination of proquazone and its m-hydroxy metabolite by high-performance liquid chromatography. Clinical application: pharmacokinetics of proquazone in children with juvenile rheumatoid arthritis
AUTHOR(S): Lemplainen, Matti; Makela, Anna Liisa
CORPORATE SOURCE: Dep. Clin. Chem., Univ. Cent. Hosp., Turku, Finland
SOURCE: Journal of Chromatography (1985), 341(1), 105-13
CODEN: JOCRAM; ISSN: 0021-9673
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



I, R=H
II, R=OH

AB A method for the determination of proquazone (I) [22760-18-5] and its m-hydroxy metabolite (II) [65765-07-3] in serum and urine by reversed-phase HPLC is described. The technique is based on a single extraction of the unchanged drug, its metabolite and an internal standard from serum or urine with CHCl3. The column was packed with μBondapak C18 and the mobile phase was MeCN-H2O (50:50) (pH 3). The detection limits for proquazone and its metabolite were 0.02 μmol/L using 500 μL of sample. For the determination of the total m-hydroxy metabolite only 100 μL of sample are needed. The method described is suitable for routine clin. and pharmacokinetic studies. The clin. application of this method suggests that the pharmacokinetics of proquazone in adults and children are similar.
IT 65765-07-3
RL: BIOL (Biological study)
(determination of as proquazone metabolite by HPLC)
RN 65765-07-3 CAPLUS
CN 2(1H)-Quinazolinone, 4-(3-hydroxyphenyl)-7-methyl-1-(1-methylethyl)- (CA INDEX NAME)

L5 ANSWER 113 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



IT 22760-18-5
RL: ANT (Analyte); ANST (Analytical study)
(determination of, in human blood and urine by HPLC, pharmacokinetics in relation to)
RN 22760-18-5 CAPLUS
CN 2(1H)-Quinazolinone, 7-methyl-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)



L5 ANSWER 114 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1985:553587 CAPLUS
DOCUMENT NUMBER: 103:153587
ORIGINAL REFERENCE NO.: 103:24455a,24458a
TITLE: Modulation by drugs of leukotriene and prostaglandin production from mouse peritoneal macrophages
AUTHOR(S): Brune, K.; Peskar, B. A.
CORPORATE SOURCE: Dep. Pharmacol. Toxicol., Univ. Erlangen-Nuernberg, Erlangen, D-8520, Fed. Rep. Ger.
SOURCE: International Journal of Tissue Reactions (1985), 7(2), 97-103
CODEN: IJTEDP; ISSN: 0250-0868
DOCUMENT TYPE: Journal
LANGUAGE: English
AB In mouse peritoneal macrophages, the tumor promoter 12-O-tetradecanoylphorbol-13-acetate, despite initiating the release of prostaglandin E2 [363-24-6], had little effect on the release of leukotriene C4 [72025-60-6] like-immunoreactivity. The divalent cation ionophore A 23187 [52665-69-7] at concns. between 10-6 and 10-8 mol/L initiated prostaglandin as well as leukotriene release. This prostaglandin and leukotriene release could be modulated by drugs. Nonsteroidal antiinflammatory drugs inhibited prostaglandin release but enhanced leukotriene production The exptl. compound BW 755C [66000-40-6] inhibited prostaglandin and leukotriene production, whereas the antithrombic compound nafazatrom [59040-30-1] inhibited the production of leukotriene C4-like immunoreactivity but enhanced the prostaglandin E2 production Nordihydroguaiaretic acid [500-38-9] inhibited prostaglandin and leukotriene production The results show that the metabolism of arachidonic acid [506-32-1] in macrophages via the cyclooxygenase [39391-18-9] or the lipoxygenase [9029-60-1] pathway is dependent on the stimulus applied. Both pathways can be inhibited conjointly or selectively by drugs. The exptl. system described may be used for assessing the potency of drugs to inhibit the lipoxygenase and the cyclooxygenase pathway of arachidonic acid metabolism
IT 22760-18-5
RL: BIOL (Biological study)
(leukotriene and prostaglandin formation by peritoneal macrophage response to)
RN 22760-18-5 CAPLUS
CN 2(1H)-Quinazolinone, 7-methyl-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)



L5 ANSWER 115 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1985:547238 CAPLUS
DOCUMENT NUMBER: 103:147238
ORIGINAL REFERENCE NO.: 103:23519a,23522a
TITLE: Analytical study of piroxicam
AUTHOR(S): Vire, J. C.; Kauffmann, J. M.; Braun, J.; Patriarche, G. J.
CORPORATE SOURCE: Inst. Pharm., Univ. Libre Bruxelles, Brussels, 1050, Belg.
SOURCE: Journal de Pharmacie de Belgique (1985), 40(3), 133-8
CODEN: JPBEAJ; ISSN: 0047-2166
DOCUMENT TYPE: Journal
LANGUAGE: French
GI



I

AB Piroxicam (I) [36322-90-4] was determined in pharmaceuticals by differential pulse polarog. The method allowed the determination of I at a concentration of 37 μg/L with a detection limit of 5 x 10-8M. I could be differentiated in the presence of other nonsteroidal antiiflammatory agents, niflumic acid [4394-00-7], ketoprofen [22071-15-4], tolmetine [26171-23-3], sulindac [38194-50-2], indomethacin [53-86-1], oxametacin [27035-30-9], and proquazone [22760-18-5]. In addition formulation excipients did not interfere in the determination I was also determined in urine.
IT 22760-18-5
RL: ANST (Analytical study)
(piroxicam determination in presence of, by polarog.)
RN 22760-18-5 CAPLUS
CN 2(1H)-Quinazolinone, 7-methyl-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)



L5 ANSWER 116 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1985:509871 CAPLUS
DOCUMENT NUMBER: 103:109871
ORIGINAL REFERENCE NO.: 103:17535a,17538a
TITLE: Preparation of suppositories by compression
AUTHOR(S): Riva, A.; Surer, H.
CORPORATE SOURCE: Wander A.-G., Bern, CH-3001, Switz.
SOURCE: Rectal Ther., Proc. Symp. Advantages Probl. Encountered Rectal Ther. (1984), Meeting Date 1983, 123-8. Editor(s): Glas, B.; De Blaey, C. J. Prous: Barcelona, Spain.
CODEN: 53RVAU
DOCUMENT TYPE: Conference
LANGUAGE: French
AB Suppositories are obtained by compression of granules prepared with or without glidants such as poly(vinylpyrrolidone) [9003-39-8], CM-cellulose [9004-32-4], gelatin, and hydroxypropyl cellulose [9004-64-2]. Agglomeration by sintering or partial melting method is used. Suppocire AM [64104-39-8], NA 5 [97956-19-9] and NA 10 [97956-20-2], Witepsol H 15 [12699-05-7], H 35 [78171-14-9] and H 5 [64104-48-9], Novata BD [85682-19-5] and BB [97955-94-7], Massa estarinum BC [64366-62-7], E [55818-76-3], and 299 [59112-43-5] were used as the suppository bases. Both in vitro release and bioavailability (in humans and animals) of Tonopan [97883-63-1], Optalidon [60382-50-5], Biarison [22760-18-5] and propyphenazone [479-92-5] were determined The suppositories prepared with 4% poly(vinylpyrrolidone) showed the slowest release. The bioavailability of the suppositories obtained by compression was at least equal to that obtained by the fusion method.
IT 22760-18-5
RL: BIOL (Biological study)
(suppositories containing, manufacture of, compression method in)
RN 22760-18-5 CAPLUS
CN 2(1H)-Quinazolinone, 7-methyl-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)



L5 ANSWER 117 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1985:400299 CAPLUS
DOCUMENT NUMBER: 103:299
ORIGINAL REFERENCE NO.: 103:55a,58a
TITLE: Anti-inflammatory activity of SL-573 [cyproquazone]
AUTHOR(S): Koga, Yoshihiko; Yanagi, Yoshikazu
CORPORATE SOURCE: Takarazuka Res. Cent., Sumitomo Chem. Co., Ltd., Japan
SOURCE: Ensho (1984), 4(4), 309-10
CODEN: ENSHEE; ISSN: 0389-4290
DOCUMENT TYPE: Journal
LANGUAGE: Japanese
GI



AB In addition to its patent antiinflammatory effect, SL-573 (I) [33453-23-5] also showed analgesic and antipyretic effects without causing significant damage to gastrointestinal tract. SL-573 strongly inhibited cyclooxygenase [39391-18-9] activity and leukocyte function, but only slightly inhibited lipoxygenase [9029-60-1] activity. Thus, SL-573 appears to be a new type of anti-inflammatory drug.
IT 33453-23-5
RL: BIOL (Biological study)
(anti-inflammatory activity of, mechanism of)
RN 33453-23-5 CAPLUS
CN 2(1H)-Quinazolinone, 1-(cyclopropylmethyl)-6-methoxy-4-phenyl- (CA INDEX NAME)



L5 ANSWER 118 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1985:95620 CAPLUS
DOCUMENT NUMBER: 102:95620
ORIGINAL REFERENCE NO.: 102:15041a,15044a
TITLE: Acid hydrolysis of 5-phenyl-1,3,4-benzotriazepines
AUTHOR(S): Schleuder, M.; Butzki, Susanne; Richter, P.
CORPORATE SOURCE: Sekt. Pharm., Ernst-Moritz-Arndt-Univ., Greifswald, DDR-2200, Ger. Dem. Rep.
SOURCE: Pharmazie (1984), 39(7), 505-6
CODEN: PHARAT; ISSN: 0031-7144
DOCUMENT TYPE: Journal
LANGUAGE: German
GI



AB Refluxing benzotriazepinethiones I (R = Me, R1 = H;, R = H, R1 = H, Me) in dilute aqueous HCl resulted in ring cleavage and contraction, giving 5,2-Cl(RNH)C6H3COPh and hydroxyquinazolinethiones II. Acid hydrolysis of I (R = Me, R1 = H) also gave the 2-oxo derivative
IT 94990-70-2P
RL: FORM (Formation, nonpreparative); PREP (Preparation)
(formation of, in benzotriazepinethione derivative acid hydrolysis)
RN 94990-70-2 CAPLUS
CN 2(1H)-Quinazolinethione, 3-amino-6-chloro-3,4-dihydro-4-hydroxy-1-methyl-4-phenyl- (CA INDEX NAME)



L5 ANSWER 119 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1985:72551 CAPLUS
DOCUMENT NUMBER: 102:72551
ORIGINAL REFERENCE NO.: 102:11247a,11250a
TITLE: Molecular mechanisms of the gastric toxicity of antirheumatic drugs
AUTHOR(S): Aehringhaus, U.; Weiler, H.; Peskar, B. A.; Peskar, B. M.
CORPORATE SOURCE: Dep. Pharmacol. Toxicol., Ruhr-Univ., Bochum, 4630, Fed. Rep. Ger.
SOURCE: Archives of Toxicology, Supplement (1984), 7(Dis. Metab. Reprod. Toxic Response Drugs Other Chem.), 323-7
CODEN: ATSUDG; ISSN: 0171-9750
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Proquazone (I) [22760-18-5] was considerably more effective than indomethacin (II) [53-86-1] in inhibiting the release of PGE2 [363-24-6] from a whole cell preparation of human gastric mucosa incubated in vitro. This indicates that I, which is less ulcerogenic than II, is a potent inhibitor of human gastric mucosal cyclooxygenase [39391-18-9]. Contrary to the in vitro results, the lower incidence of gastrointestinal side effects of I as compared with II is not correlated with a less pronounced inhibition of prostaglandin formation in vivo, and addnl. factors have to account for differences in ulcerogenic potency. In further expts., the capacity of guinea pig gastric mucosa to synthesize leukotriene C4 [72025-60-6]-like immunoreactivity was demonstrated. Thus, it seems possible that increased formation of lipoxygenase products in the presence of nonsteroidal antiinflammatory drugs could contribute to the gastric toxicity of these drugs.
IT 22760-18-5
RL: BIOL (Biological study)
(prostaglandin metabolism in human gastric mucosa response to, ulcerogenic potency in relation to)
RN 22760-18-5 CAPLUS
CN 2(1H)-Quinazolinone, 7-methyl-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)



L5 ANSWER 120 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1984:583640 CAPLUS
DOCUMENT NUMBER: 101:183640
ORIGINAL REFERENCE NO.: 101:27621a,27624a
TITLE: Antiinflammatory activity of N-(2-benzoylphenyl)alanine derivatives
AUTHOR(S): Walsh, David A.; Sleevi, Mark C.; Sancilio, Lawrence F.
CORPORATE SOURCE: Dep. Chem. Res., A. H. Robins Co., Richmond, VA, 23261-6609, USA
SOURCE: Journal of Medicinal Chemistry (1984), 27(10), 1317-21
CODEN: JMCMAR; ISSN: 0022-2623
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



I II

AB N-(2-Benzoylphenyl)alanine derivs. I (R1 = H, Cl, Me, MeO; R2 = H, Br, Cl, MeO, etc.) and analogs II (R = NHCH2CO2H, NHCH(CH3)CO2H, OCH(CH3)CO2H, etc.) were prepared by acylation of the appropriate aminobenzophenone and tested for antiinflammatory activity in the Evans blue-carrageenan-induced pleural effusion rat model; the active compds. were further tested for activity against adjuvant-induced arthritis in rats. I; R1 = R2 = H showed antiinflammatory activity in the pleurisy model at 100 mg/kg; 1 compound was weakly active against adjuvant-induced arthritis. The antiinflammatory potency of some of the compds. was studied in relation to prostaglandin synthetase [9055-65-6] inhibition and compared with the effects of indomethacin. Structure-activity relations are discussed.
IT 91409-57-3P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation and antiinflammatory activity of)
RN 91409-57-3 CAPLUS
CN 1(2H)-Quinazolineacetic acid, α,7-dimethyl-2-oxo-4-phenyl- (CA INDEX NAME)

L5 ANSWER 120 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



IT 91409-76-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and hydrolysis of)
RN 91409-76-6 CAPLUS
CN 1(2H)-Quinazolineacetic acid, α,7-dimethyl-2-oxo-4-phenyl-, ethyl ester (CA INDEX NAME)



L5 ANSWER 121 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1984:530703 CAPLUS
DOCUMENT NUMBER: 101:130703
ORIGINAL REFERENCE NO.: 101:19889a,19892a
TITLE: Quinazoline derivatives and acid adducts
PATENT ASSIGNEE(S): Sumitomo Chemical Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 11 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 59055876	A	19840331	JP 1982-165890	19820922
PRIORITY APPLN. INFO.:			JP 1982-165890	19820922

OTHER SOURCE(S): CASREACT 101:130703
GI



I II III

AB Sixteen quinazoline derivs. (I; R = aryl, 2-pyridyl, 2-pyrimidinyl; R1 = H, PhCH2, alkyl, etc.; R2R3 = O; R1R2 = bond; R3 = alkoxy, aryloxy, PhCH2O, cycloalkoxy; R4,R5 = H, R4R5 = bond; Z = alkylene), effective antianxiety agents at 5-100 mg/day in adults, were prepared Thus, a mixture of II 3.9, III 3.1, and Na2CO3 2 g in DMF was heated 7 h at 140-150° to give 33.9% I HCl [R = 2-pyrimidinyl; R1 = cyclopropylmethyl; R2R3 = O; R4R5 = bond, Z = (CH2)4] after treatment with 3% HCl.
IT 91852-65-2P 91852-66-3P 91852-67-4P
91852-68-5P 91852-69-6P 91852-70-9P
91852-71-0P 91852-72-1P 91852-73-2P
91852-76-5P 91852-77-6P 91852-79-8P
91852-80-1P 91852-81-2P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 91852-65-2 CAPLUS

L5 ANSWER 121 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
CN 2(1H)-Quinazolinone, 1-(cyclopropylmethyl)-4-phenyl-6-[4-[4-(2-pyrimidinyl)-1-piperazinyl]butoxy]-, hydrochloride (9CI) (CA INDEX NAME)



RN 91852-66-3 CAPLUS
CN 2(1H)-Quinazolinone, 1-(cyclopropylmethyl)-4-phenyl-6-[3-[4-(2-pyrimidinyl)-1-piperazinyl]propoxy]- (CA INDEX NAME)



RN 91852-67-4 CAPLUS
CN 2(1H)-Quinazolinone, 1-(cyclopropylmethyl)-4-phenyl-6-[2-[4-(2-pyrimidinyl)-1-piperazinyl]ethoxy]-, hydrochloride (9CI) (CA INDEX NAME)

L5 ANSWER 121 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



●x HCl

RN 91852-68-5 CAPLUS
CN 2(1H)-Quinazolinone,
1-(cyclopropylmethyl)-3,4-dihydro-4-phenyl-6-[4-[4-(2-pyrimidinyl)-1-piperazinyl]butoxy]- (CA INDEX NAME)



RN 91852-69-6 CAPLUS
CN 2(1H)-Quinazolinone,
1-(cyclopropylmethyl)-3,4-dihydro-4-phenyl-6-[3-[4-(2-pyrimidinyl)-1-piperazinyl]propoxy]- (CA INDEX NAME)

L5 ANSWER 121 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 91852-70-9 CAPLUS
CN 2(1H)-Quinazolinone,
1-(cyclopropylmethyl)-3,4-dihydro-4-phenyl-6-[2-[4-(2-pyrimidinyl)-1-piperazinyl]ethoxy]-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 91852-71-0 CAPLUS
CN 2(1H)-Quinazolinone, 1-methyl-4-phenyl-6-[3-[4-(2-pyrimidinyl)-1-piperazinyl]propoxy]- (CA INDEX NAME)



L5 ANSWER 121 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

RN 91852-72-1 CAPLUS
CN 2(1H)-Quinazolinone, 4-phenyl-1-(phenylmethyl)-6-[3-[4-(2-pyrimidinyl)-1-piperazinyl]propoxy]- (CA INDEX NAME)



RN 91852-73-2 CAPLUS
CN 2(1H)-Quinazolinone, 3,4-dihydro-4-phenyl-1-(phenylmethyl)-6-[3-[4-(2-pyrimidinyl)-1-piperazinyl]propoxy]- (CA INDEX NAME)



RN 91852-76-5 CAPLUS
CN 2(1H)-Quinazolinone, 1-(cyclopropylmethyl)-4-phenyl-6-[3-(4-phenyl-1-piperazinyl)propoxy]- (CA INDEX NAME)



RN 91852-77-6 CAPLUS
CN 2(1H)-Quinazolinone,
1-(cyclopropylmethyl)-4-phenyl-6-[3-[4-(2-pyridinyl)-1-piperazinyl]propoxy]- (CA INDEX NAME)

L5 ANSWER 121 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 91852-79-8 CAPLUS
CN 2(1H)-Quinazolinone, 1-(cyclopropylmethyl)-6-[2-hydroxy-3-[4-(2-pyrimidinyl)-1-piperazinyl]propoxy]-4-phenyl-, compd. with 2,4,6-trinitrophenol (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 91852-78-7
CMF C29 H32 N6 O3



CM 2

CRN 88-89-1
CMF C6 H3 N3 O7



RN 91852-80-1 CAPLUS
CN 2(1H)-Quinazolinone, 1-(cyclopropylmethyl)-3,4-dihydro-4-phenyl-6-[3-(4-phenyl-1-piperazinyl)propoxy]- (CA INDEX NAME)

L5 ANSWER 121 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 91852-81-2 CAPLUS
CN 2(1H)-Quinazolinone, 1-(cyclopropylmethyl)-3,4-dihydro-4-phenyl-6-[3-[4-(2-pyridinyl)-1-piperazinyl]propoxy]- (CA INDEX NAME)



IT 91852-64-1
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of, with pyrimidinylpiperazine)
RN 91852-64-1 CAPLUS
CN 2(1H)-Quinazolinone, 6-(4-bromobutoxy)-1-(cyclopropylmethyl)-4-phenyl- (CA INDEX NAME)



L5 ANSWER 121 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

L5 ANSWER 122 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1984:497691 CAPLUS
DOCUMENT NUMBER: 101:97691
ORIGINAL REFERENCE NO.: 101:14867a,14870a
TITLE: Analgesic combinations
INVENTOR(S): Cooper, Stephen A.
PATENT ASSIGNEE(S): Sandoz A.-G., Switz.
SOURCE: PCT Int. Appl., 17 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 8402273	A1	19840621	WO 1983-EP326	19831207
W: AU, DK, HU, JP				
AU 8423352	A	19840705	AU 1984-23352	19831207
JP 60500016	T	19850110	JP 1984-500121	19831207
HU 35519	A2	19850729	HU 1984-281	19831207
HU 196126	B	19881028		
IL 70407	A	19900319	IL 1983-70407	19831208
EP 111456	A1	19840620	EP 1983-810581	19831209
EP 111456	B1	19890712		
R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
ZA 8309196	A	19850731	ZA 1983-9196	19831209
CA 1237077	A1	19880524	CA 1983-442921	19831209
AT 44461	T	19890715	AT 1983-810581	19831209
DK 8403745	A	19840801	DK 1984-3745	19840801
US 4599359	A	19860708	US 1984-668896	19841107
US 4794112	A	19881227	US 1986-829571	19860214

PRIORITY APPLN. INFO.: US 1982-448290 A 19821209
WO 1983-EP326 A 19831207
EP 1983-810581 A 19831209
US 1984-586566 A2 19840306
US 1984-586567 A1 19840306
US 1985-753014 A1 19850708

AB An analgesic combination for oral or rectal administration contains hydroxyine [68-88-2] or its salts and at least 1 of a nonsteroidal anti-inflammatory analgesic and/or acetaminophen [103-90-2]. Capsules were prepared containing 200 mg ibuprofen [15687-27-1] and 50 mg hydroxyzine pamoate [10246-75-0]. Clin. tests were given showing the synergistic effects of the combinations compared to administration of the single compds.

IT 22760-18-5
RL: BIOL (Biological study)
(analgesic pharmaceuticals containing hydroxyzine)
RN 22760-18-5 CAPLUS
CN 2(1H)-Quinazolinone, 7-methyl-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)

L5 ANSWER 122 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



L5 ANSWER 123 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1984:483714 CAPLUS
DOCUMENT NUMBER: 101:83714
ORIGINAL REFERENCE NO.: 101:12729a,12732a
TITLE: Effect of proquazone and indomethacin on gastric prostaglandin synthesis in vitro and in vivo
AUTHOR(S): Weiler, Horst; Meyer, Christiane; Froehlich, Juergen; Peskar, Brigitta M.
CORPORATE SOURCE: Dep. Gastroenterol., Univ. Freiburg, Freiburg, D-7800, Fed. Rep. Ger.
SOURCE: Agents and Actions (1984), 15(1-2), 93-5
CODEN: AGACBH; ISSN: 0065-4299
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Although proquazone [22760-18-5] is less ulcerogenic than indomethacin [53-86-1] in rat and man, it inhibits gastric mucosal synthesis of 6-keto-PGF1α [58962-34-8] more effectively in both species in vitro. The more pronounced inhibitory activity of proquazone can be observed on formation of 6-keto-PGF1α from endogenous substrate by fragments of gastric mucosa as well as on conversion of exogenous arachidonic acid by a microsomal fraction of mucosal homogenates indicating high affinity of proquazone for gastric mucosal cyclooxygenase [39391-18-9]. After oral administration, however, both drugs exhibit equal inhibitory potency on gastric formation of 6-keto-PGF1α in the rat. Apparently, the pharmacokinetic properties of nonsteroidal antiinflammatory drugs contribute to their inhibitory action on gastric prostaglandin formation in vivo. The ulcerogenic effects of these drugs result not only from inhibition of the gastric prostaglandin system but also from their effects on other processes and other enzyme systems.
IT 22760-18-5
RL: BIOL (Biological study)
(ulcer induced by, prostaglandin metabolism in)
RN 22760-18-5 CAPLUS
CN 2(1H)-Quinazolinone, 7-methyl-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)



L5 ANSWER 124 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



L5 ANSWER 124 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1984:445309 CAPLUS
DOCUMENT NUMBER: 101:45309
ORIGINAL REFERENCE NO.: 101:6959a,6962a
TITLE: Polarography of heterocyclics. 16. Polarographic studies on 1,3,4-benzotriazepine series
AUTHOR(S): Pflegel, Peter; Kuehmstedt, Christa; Richter, Peter
CORPORATE SOURCE: Sekt. Pharm., Ernst-Moritz-Arndt-Univ., Greifswald, DDR-2200, Ger. Dem. Rep.
SOURCE: Wissenschaftliche Zeitschrift der Ernst-Moritz-Arndt-Universitaet Greifswald, Mathematisch-Naturwissenschaftliche Reihe (1982), 31(2), 37-40
CODEN: WZEMAX; ISSN: 0138-2853
DOCUMENT TYPE: Journal
LANGUAGE: German
GI



I

AB Polarog. of the title compds. was carried out in Britton-Robinson buffers in 30% EtOH and interpretation of the reduction mechanism given. For example in I (X = O, R = H; X = O, R = Me; X = S, R = H; X = S, R = Me) cathodic diffusion-controlled 4e/4H waves were obtained with the 1st 2 members and 2e/2H waves were obtained with the latter 2 members over a pH range 2-7. In addition these 2 latter compds. yield le wares caused by formation of the Hg salt. In some cases, depending on the concentration, a dimer may be formed.
IT 77485-01-9P
RL: PREP (Preparation)
(formation of, electrochem.)
RN 77485-01-9 CAPLUS
CN [1,1'(2H,2'H)-Biquinazoline]-2,2'-dithione, 6,6'-dichloro-4,4'-diphenyl- (CA INDEX NAME)

L5 ANSWER 125 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1984:150596 CAPLUS
DOCUMENT NUMBER: 100:150596
ORIGINAL REFERENCE NO.: 100:22813a,22816a
TITLE: Pharmacokinetics of the antirheumatic proquazone in healthy humans
AUTHOR(S): Hinderling, Peter H.; Roos, Andre
CORPORATE SOURCE: Dep. Pharmacol., Univ. Basel, Basel, 4056, Switz.
SOURCE: Journal of Pharmaceutical Sciences (1984), 73(3), 332-40
CODEN: JPMSAE; ISSN: 0022-3549
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



I

AB The pharmacokinetics of proquazone (I) [22760-18-5] and of the measured metabolites in healthy humans after i.v. administration and after the 300-mg oral dose were 1st order, whereas deviations from linear kinetics were observed at the 900-mg oral dose level. The apparent half-lives of the α,β, and γ phases of proquazone in plasma were 2, 14, and 76 min, resp., after i.v. administration. The total clearance of proquazone was 700 mL/min, which indicated a high hepatic extraction The apparent volume of distribution at steady state was 40 L, implying extensive binding or partitioning of the lipophilic drug in the tissues. Unchanged proquazone (<0.001%), the m-hydroxy metabolite [65765-07-3] (<1.0%), and the conjugated m-hydroxy metabolite (20%) were renally excreted after i.v. administration. The extent of absorption of proquazone was .apprx.7% and was entirely the result of a large 1st-pass effect. Digital computer anal. of the data after i.v. administration was performed with a linear 3-compartment model. A model-independent approach was used in the anal. of the peroral data.
IT 22760-18-5
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(pharmacokinetics of, in humans)
RN 22760-18-5 CAPLUS
CN 2(1H)-Quinazolinone, 7-methyl-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)

L5 ANSWER 125 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



IT 65765-07-3 65765-07-3D, conjugates
RL: BIOL (Biological study)
(proquazone metabolite, formation of, in humans)
RN 65765-07-3 CAPLUS
CN 2(1H)-Quinazolinone, 4-(3-hydroxyphenyl)-7-methyl-1-(1-methylethyl)- (CA INDEX NAME)



RN 65765-07-3 CAPLUS
CN 2(1H)-Quinazolinone, 4-(3-hydroxyphenyl)-7-methyl-1-(1-methylethyl)- (CA INDEX NAME)



L5 ANSWER 126 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1984:126930 CAPLUS
DOCUMENT NUMBER: 100:126930
ORIGINAL REFERENCE NO.: 100:19261a,19264a
TITLE: Compressed suppositories
INVENTOR(S): De Buman, Alain; Riva, Aldo; Sucker, Heinz
PATENT ASSIGNEE(S): Sandoz, Inc., Switz.
SOURCE: Patentschrift (Switz.), 3 pp.
CODEN: SWXXAS
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CH 640410	A5	19840113	CH 1979-3191	19790405
PRIORITY APPLN. INFO.:			CH 1979-3191	19790405

AB Suppositories with a saturated glyceride base, an active ingredient, and no
binder are prepared by compression at ≤10°. Thus, propyphenazone [479-92-5] 18.75, butalbital [77-26-9] 7.5, and caffeine [58-08-2] 3.75 kg were mixed, passed through a 0.3-mm-mesh screen, and kneaded with 70 kg Witepsol H15 [12699-05-7], then the mass chilled with cold water for 10 min. The temperature of the circulating water was raised to
40°, and the mass was stirred for 10 min until it aggregated into large clumps. The 28-30° mass was cooled to 4°, granulated through a 1.6-mm-mesh screen, and compressed at -10 to +5° at a rate of 100,000 suppositories/h.
IT 22760-18-5
RL: BIOL (Biological study)
(compressed suppositories containing, manufacture of)
RN 22760-18-5 CAPLUS
CN 2(1H)-Quinazolinone, 7-methyl-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)



L5 ANSWER 127 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1984:374 CAPLUS
DOCUMENT NUMBER: 100:374
ORIGINAL REFERENCE NO.: 100:59a,62a
TITLE: Inhibitory effect of a new nonsteroidal anti-inflammatory drug, 6-methoxy-4-phenyl-1-(2,2,2-trifluoroethyl)-2-(1H)-quinazolinone, on prostaglandin
biosynthesis
AUTHOR(S): Nishikawa, Takashige; Terada, Hiroji; Okamoto, Hiroshi; Tsujimoto, Akira
CORPORATE SOURCE: Sch. Dent., Hiroshima Univ., Hiroshima, 734, Japan
SOURCE: Hiroshima Daigaku Shigaku Zasshi (1983), 15(1), 187-92
CODEN: HUDJAN; ISSN: 0046-7472
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



I

AB The inhibition of prostaglandin biosynthesis by 6-methoxy-4-phenyl-1-(2,2,2-trifluoroethy)-2-(1H)-quinazolinone (SX)(I) [49830-89-9] was determined using microsomes of rabbit renal medullae as enzyme sources and
1-14C-labeled arachidonic acid as a substrate in comparison with those by indomethacin and other nonsteroidal antiinflammatory drugs. The relative inhibitory potency of SX was very similar to that of indomethacin. The inhibition of prostaglandin biosynthesis by SX decreased concomitantly with an increase of substrate concentration This response resembled that of
indomethacin. The inhibitory activity of indomethacin and diclofenac but not SX was significantly potentiated by preincubation with microsomal enzymes. The inhibition by SX was reversible although that by indomethacin was irreversible. The inhibition of prostaglandin biosynthesis by indomethacin was time-dependent when the enzymes were pre-incubated with drug, but such change was not observed with SX. Furthermore, SX prevented the progressive increase in the irreversible inhibition by indomethacin.
IT 49830-89-9
RL: BIOL (Biological study)
(prostaglandin formation inhibition by)
RN 49830-89-9 CAPLUS
CN 2(1H)-Quinazolinone, 6-methoxy-4-phenyl-1-(2,2,2-trifluoroethyl)- (CA INDEX NAME)

L5 ANSWER 127 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



L5 ANSWER 128 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1983:533457 CAPLUS
DOCUMENT NUMBER: 99:133457
ORIGINAL REFERENCE NO.: 99:20376h,20377a
TITLE: TXA2-antagonistic properties of agents affecting prostaglandin synthesis or the cyclic nucleotide system in human platelets
AUTHOR(S): Kangasaho, Mauno; Vapaatalo, Heikki
CORPORATE SOURCE: Dep. Biomed. Sci., Univ. Tampere, Tampere, SF-33100, Finland
SOURCE: Acta Pharmacologica et Toxicologica (1983), 53(2), 130-4
CODEN: APTOA6; ISSN: 0001-6683
DOCUMENT TYPE: Journal
LANGUAGE: English
AB PG E1 [745-65-3] and PGE2 [363-24-6] as well as 3-isobutyl-1-methylxanthine [57576-52-0], Na nitroprusside [14402-89-2], dibutyryl cyclic AMP [362-74-3] and N-0164 [60787-00-0] inhibited platelet aggregation induced by the TX A2 [57576-52-0]-mimetic prostaglandin endoperoxide analog U46619. Non-steroidal anti-inflammatory agents, acetylsalicylic acid [50-78-2], indomethacin [53-86-1], tolfenamic acid [13710-19-5], flumizole [36740-73-5], nictindole [36504-64-0], and proquazone [22760-18-5] did not demonstrate any antagonistic actions on U46619-induced aggregation at concns. causing inhibition of prostaglandin/thromboxane synthesis-dependent forms of platelet aggregation. Comparing with the effects of the different test substances on ADP- or arachidonic acid-induced platelet aggregation, it can be suggested that PGE1 and PGE2 as well as 3-isobutyl-1-methylxanthine, nitroprusside, and dibutyryl cyclic AMP are functional antagonists and N-0164 is a receptor level antagonist of TXA2 in platelets.
IT 22760-18-5
RL: BIOL (Biological study)
(platelet aggregation of humans response to)
RN 22760-18-5 CAPLUS
CN 2(1H)-Quinazolinone, 7-methyl-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)



L5 ANSWER 129 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1983:533409 CAPLUS
DOCUMENT NUMBER: 99:133409
ORIGINAL REFERENCE NO.: 99:20361a,20364a
TITLE: Effects of various substances on two types of inflammatory reaction in animals
AUTHOR(S): Hertz, F.; Chevrier, M. M.; DeFeudis, F. V.
CORPORATE SOURCE: Dep. Biol., UPSA, Rueil-Malmaison, 92506, Fr.
SOURCE: General Pharmacology (1983), 14(4), 419-27
CODEN: GEPHDP; ISSN: 0306-3623
DOCUMENT TYPE: Journal
LANGUAGE: English
AB The effects of various substances, including nonsteroidal anti-inflammatory agents, a corticoid, phenols, immunomodulators and Au salts, were studied using 2 types of acute inflammatory reaction; a nonspecific reaction (carrageenan-induced edema) and an immune reaction (reversed passive Arthus reaction in the rat or active Arthus reaction in the mouse). The active Arthus model appears to be more selective than the passive reversed Arthus model, which is itself less sensitive than the carrageenan model. The active Arthus reaction might be useful for secondary screening of mols. that act on mechanisms modulating the intervention of complement and the various functions of polymorphonuclear leukocytes, and the passive Arthus reaction appears to be more suitable for preliminary screening. The activities of the different substances studied are discussed in terms of their modes of action and toxicity.
IT 22760-18-5
RL: BIOL (Biological study)
(anti-inflammatory acitivity of, inflammation models in relation to)
RN 22760-18-5 CAPLUS
CN 2(1H)-Quinazolinone, 7-methyl-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)



L5 ANSWER 130 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1983:505086 CAPLUS
DOCUMENT NUMBER: 99:105086
ORIGINAL REFERENCE NO.: 99:16173a,16176a
TITLE: Heterocyclic 8π-systems. 15. Studies on indole 2,3-oxides: synthesis of 3-hydroxyindoles via intramolecular Wittig rearrangement of 1,2-dihydro-4H-3,1-benzoxazines
AUTHOR(S): Schmidt, Richard R.; Beitzke, Bernhard
CORPORATE SOURCE: Fak. Chem., Univ. Konstanz, Konstanz, D-7750, Fed. Rep. Ger.
SOURCE: Chemische Berichte (1983), 116(6), 2115-35
CODEN: CHBEAM; ISSN: 0009-2940
DOCUMENT TYPE: Journal
LANGUAGE: German
OTHER SOURCE(S): CASREACT 99:105086
GI



I

II



III

IV

AB Base-catalyzed ring contraction of benzoxazines I (R = H, Me, OMe, F, CF3, R1 = H; R = Me, R1 = Cl) with KNH2-NH3 gave 3-hydroxyindoles II. The FSO3Me salts of I gave cis-III diastereospecifically on treatment with NaOEt under kinetically controlled conditions. II thermolyzed via quinonimine intermediates. In strong base III underwent a supra-suprafacial Wittig rearrangement to 3-hydroxyindolines IV. An intermediate close ion pair is proposed for this rearrangement.
IT 26920-07-0P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 26920-07-0 CAPLUS
CN 2(1H)-Quinazolinethione, 3,4-dihydro-1-methyl-4-phenyl- (CA INDEX NAME)

L5 ANSWER 130 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



L5 ANSWER 131 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1983:488147 CAPLUS
DOCUMENT NUMBER: 99:88147
ORIGINAL REFERENCE NO.: 99:13601a,13604a
TITLE: Synthesis, structure and properties of 4-phenylquinazolin-2-ones with fluorine-containing substituents
AUTHOR(S): Gordiichuk, G. N.; Andronati, S. A.; Voronina, T. A.; Rakhmankulova, I. Kh.; Terent'ev, P. B.; Sharbatyan, P. A.; Yavorskii, A. S.
CORPORATE SOURCE: Fiz.-Khim. Inst., Kiev, USSR
SOURCE: Fiziologicheski Aktivnye Veshchestva (1982), 14, 36-9
CODEN: FAVUAI; ISSN: 0533-1153
DOCUMENT TYPE: Journal
LANGUAGE: Russian
OTHER SOURCE(S): CASREACT 99:88147
GI



I

AB I [R = H, R1 = CHF2SO2 (II), CF3S (III), CF3O (IV), CHF2S (V), CHF2O (VI);
R = Me, R1 = CHF2SO2 (VII), CF3SO2 (VIII), CHF2O (IX), CF3O (X), CF3S (XI), CHF2S] were prepared The analgesic activity of I (R = H) increased symbatically with the value of the Hammett substituent constant for R1, i.e.
II « III .simeq. IV < V .simeq. VI. The analgesic activities of I (R = Me) increased in the order VII < VIII < IX < X .simeq. XI; sedative activities increased in the order VII < VIII < XI < X .simeq. IX.
IT 79885-39-5P 86815-84-1P 86815-85-2P
86815-86-3P 86815-87-4P 86815-88-5P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation and analgesic activity of)
RN 79885-39-5 CAPLUS
CN 2(1H)-Quinazolinone, 6-[(difluoromethyl)thio]-1-methyl-4-phenyl- (CA INDEX NAME)

L5 ANSWER 131 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 86815-84-1 CAPLUS
CN 2(1H)-Quinazolinone, 6-(difluoromethoxy)-1-methyl-4-phenyl- (CA INDEX NAME)



RN 86815-85-2 CAPLUS
CN 2(1H)-Quinazolinone, 1-methyl-4-phenyl-6-(trifluoromethoxy)- (CA INDEX NAME)



RN 86815-86-3 CAPLUS
CN 2(1H)-Quinazolinone, 1-methyl-4-phenyl-6-[(trifluoromethyl)thio]- (CA INDEX NAME)



L5 ANSWER 131 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

RN 86815-87-4 CAPLUS
CN 2(1H)-Quinazolinone, 6-[(difluoromethyl)sulfonyl]-1-methyl-4-phenyl- (CA INDEX NAME)



RN 86815-88-5 CAPLUS
CN 2(1H)-Quinazolinone, 1-methyl-4-phenyl-6-[(trifluoromethyl)sulfonyl]-(CA
INDEX NAME)



L5 ANSWER 132 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1983:405643 CAPLUS
DOCUMENT NUMBER: 99:5643
ORIGINAL REFERENCE NO.: 99:1033a,1036a
TITLE: Quinazolinone derivative
INVENTOR(S): Foguet Ambros, Rafael; Ortiz Hernandez, Jose A.
PATENT ASSIGNEE(S): Ferrer Internacional S. A., Spain
SOURCE: Span., 9 pp.
CODEN: SPXXAD
DOCUMENT TYPE: Patent
LANGUAGE: Spanish
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
ES 509087	A1	19830101	ES 1982-509087	19820112
PRIORITY APPLN. INFO.:			ES 1982-509087	19820112

GI



I

AB The analgesic and antiinflammatory (no data) quinazolinone (I) was prepared
by converting 4,2-Me(Me2CHNH)C6H3COC6H4F-4 to its oxime and cyclizing the latter with COCl2 or ClCO2Et to the N-oxide of I which was treated with PCl3 to give I.
IT 86111-60-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reduction of)
RN 86111-60-6 CAPLUS
CN 2(1H)-Quinazolinone, 4-(4-fluorophenyl)-7-methyl-1-(1-methylethyl)-, 3-oxide (CA INDEX NAME)

L5 ANSWER 132 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



IT 40507-23-1P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 40507-23-1 CAPLUS
CN 2(1H)-Quinazolinone, 4-(4-fluorophenyl)-7-methyl-1-(1-methylethyl)- (CA INDEX NAME)



L5 ANSWER 133 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1983:198135 CAPLUS
DOCUMENT NUMBER: 98:198135
ORIGINAL REFERENCE NO.: 98:30119a,30122a
TITLE: 1-Alkyl-4-aryl-3,4-dihydro-2(1H)-quinazolinones and thiones. Synthesis and proton-NMR spectra
AUTHOR(S): Houlihan, William J.; Cooke, George; Denzer, Max; Nicoletti, Joseph
CORPORATE SOURCE: Sandoz, Inc., East Hanover, NJ, 07936, USA
SOURCE: Journal of Heterocyclic Chemistry (1982), 19(6), 1453-6
CODEN: JHTCAD; ISSN: 0022-152X
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 98:198135
GI



AB Alkylaryldihydroquinazolines I and II (Z = O, S; R = Me, Et, Me2CH; R1 = H, Me, F3C, Me2CH, NO2, CO2H, etc.) were prepared by a modification of the
Pictet-Spengler reaction that involves treatment of an N-alkyl-N-arylurea or thiourea with R1C6H4CHO in the presence of MeSO3H. The NMR spectra of these compds. had unusual methylenedioxy and iso-Pr signals.
IT 26772-90-7P 26772-96-3P 26772-97-4P
26772-98-5P 26772-99-6P 26773-01-3P
37749-76-1P 85575-61-7P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 26772-90-7 CAPLUS
CN 2(1H)-Quinazolinone, 3,4-dihydro-7-methyl-1-(1-methylethyl)-4-phenyl- (CA
INDEX NAME)



L5 ANSWER 133 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

RN 26772-96-3 CAPLUS
CN 2(1H)-Quinazolinone, 3,4-dihydro-6,7-dimethyl-1-(1-methylethyl)-4-phenyl-
(CA INDEX NAME)



RN 26772-97-4 CAPLUS
CN 2(1H)-Quinazolinone, 3,4-dihydro-6-methoxy-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)



RN 26772-98-5 CAPLUS
CN 2(1H)-Quinazolinone, 3,4-dihydro-6-methoxy-1-(1-methylethyl)-4-(4-methylphenyl)- (CA INDEX NAME)



RN 26772-99-6 CAPLUS
CN 2(1H)-Quinazolinone, 3,4-dihydro-6-methoxy-1-(1-methylethyl)-4-(3-methylphenyl)- (CA INDEX NAME)

L5 ANSWER 133 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 26773-01-3 CAPLUS
CN 2(1H)-Quinazolinone, 4-(2,6-dichlorophenyl)-3,4-dihydro-6-methoxy-1-(1-methylethyl)- (CA INDEX NAME)



RN 37749-76-1 CAPLUS
CN 2(1H)-Quinazolinone, 3,4-dihydro-6-methoxy-1-(1-methylethyl)-4-[4-(1-methylethyl)phenyl]- (CA INDEX NAME)



RN 85575-61-7 CAPLUS
CN 2(1H)-Quinazolinone, 3,4-dihydro-6-methoxy-1-(1-methylethyl)-4-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)

L5 ANSWER 133 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



L5 ANSWER 134 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1983:154839 CAPLUS
DOCUMENT NUMBER: 98:154839
ORIGINAL REFERENCE NO.: 98:23377a,23380a
TITLE: Effect of antiinflammatory drugs on endotoxin-induced diarrhea in mice
AUTHOR(S): Tsurumi, Kaito; Fujimura, Hajime
CORPORATE SOURCE: Sch. Med., Gifu Univ., Gifu, 500, Japan
SOURCE: Japanese Journal of Pharmacology (1983), 33(1), 165-73
CODEN: JJPAAZ; ISSN: 0021-5198
DOCUMENT TYPE: Journal
LANGUAGE: English

AB The effects of various nonsteroidal antiinflammatory drugs (NSAID) and steroidal antiinflammatory drugs (SAID) on endotoxin (ETX)-induced diarrhea were studied in mice. ETX given orally did not induce diarrhea, but it induced diarrhea after parenteral administration, especially after i.v. injection. All NSAID and SAID tested inhibited ETX-induced diarrhea at dose levels similar to or lower than those commonly producing an acute antiinflammatory effect. The antidiarrheal effects were found in not only acidic NSAID, but also in basic NSAID and SAID which did not inhibit UV erythema, acute death induced by arachidonic acid injection, and PGs biosynthesis. Thus, this test using ETX-induced diarrhea in mice may be used as a new and desirable method for screening or evaluating antiinflammatory drugs. The diarrhogenic action of ETX may be attributed to inhibition of PGs biosynthesis.

IT 22760-18-5
RL: BIOL (Biological study)
(endotoxin-induced diarrhea response to, antiinflammatory activity in relation to)

RN 22760-18-5 CAPLUS
CN 2(1H)-Quinazolinone, 7-methyl-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)



L5 ANSWER 135 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1983:126047 CAPLUS
DOCUMENT NUMBER: 98:126047
ORIGINAL REFERENCE NO.: 98:19211a,19214a
TITLE: Polarography of heterocyclics. 14. Polarography of 7-chloro-5-phenyl-2-thioxo-1H-2,3-dihydro-1,3,4-benzotriazepines
AUTHOR(S): Pflegel, P.; Kuehmstedt, Christa; Richter, P.; Gerisch, Karin
CORPORATE SOURCE: Sekt. Pharm., Ernst-Moritz-Arndt-Univ., Greifswald, DDR-2200, Ger. Dem. Rep.
SOURCE: Pharmazie (1982), 37(10), 714-17
CODEN: PHARAT; ISSN: 0031-7144
DOCUMENT TYPE: Journal
LANGUAGE: German
GI



I II



III

AB Polarog. reduction of benzotriazepines I (R = H, Me; R1R1 = bond) gave quinazoline II by a 2e/2e reaction, via 2e product I (R1 = H). At pH >10, I (R = H, R1R1 = bond) was reduced by a 2e/1e mechanism to the bis-quinazoline III. III was formed in addition to II in a concentration-dependent competitive reaction at pH 4.7.

IT 77485-01-9P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, by reductive polarog. of benzotriazepinethione)

RN 77485-01-9 CAPLUS
CN [1,1'(2H,2'H)-Biquinazoline]-2,2'-dithione, 6,6'-dichloro-4,4'-diphenyl- (CA INDEX NAME)

L5 ANSWER 135 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



L5 ANSWER 136 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1983:84433 CAPLUS
DOCUMENT NUMBER: 98:84433
ORIGINAL REFERENCE NO.: 98:12813a,12816a
TITLE: A screening test for pharmaceuticals, drugs and insecticides with reversed-phase liquid chromatography
- retention data of 560 compounds
AUTHOR(S): Daldrup, T.; Michalke, P.; Boehme, W.
CORPORATE SOURCE: Inst. Rechtsmed., Univ. Duesseldorf, Duesseldorf, Fed.
Rep. Ger.
SOURCE: Chromatography Newsletter (1982), 10(1), 1-7
CODEN: CHNLAZ; ISSN: 0095-2214
DOCUMENT TYPE: Journal
LANGUAGE: English
AB High-performance reversed-phase liquid chromatog. retention data are given.
The relative retention times were calculated as the ratio of retention times
of compound and reference compound 5-(p-methylphenyl)-5-phenylhydantoin. The UV
detector wavelength was 220 nm, where most of the compds. gave a good response. The sensitivity of the method for each compound is rated from very good to bad. Two solvent programs and a prepacked column C-18 SIL-X-10 were used for the anal.
IT 22760-18-5
RL: ANT (Analyte); ANST (Analytical study)
(determination of, by reversed-phase high-performance liquid chromatog.)
RN 22760-18-5 CAPLUS
CN 2(1H)-Quinazolinone, 7-methyl-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)



L5 ANSWER 137 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1983:16712 CAPLUS
DOCUMENT NUMBER: 98:16712
ORIGINAL REFERENCE NO.: 98:2711a,2714a
TITLE: 2(1H)-Quinazolinone derivatives
PATENT ASSIGNEE(S): Sumitomo Chemical Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 25 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 57095966	A	19820615	JP 1980-171521	19801204
PRIORITY APPLN. INFO.:			JP 1980-171521	19801204

GI



AB Quinazolinones I [R = H, alkanoyloxy, aroyloxy, etc.; Z = divalent (un)saturated hydrocarbon residues; Z1 = O, S, SO, SO2; R1 = H, halo, alkyl;
R2 = aryl, alkyl; R3 = H; R4 = H, (hydroxy)alkyl, alkoxycarbonyl, etc.; R3, R4 may form a bond; R5 = H, (cyclo)alkyl, alkenyl, etc.; Z2 = O, S] were prepared and had serum hypolipenic, vasodilating, platelet aggregation
inhibitory, and anti-allergic activities (no data). Thus, 6 g 1-cyclopropylmethyl-6-hydroxy-4-phenyl-2(1H)-quinazolinone was stirred with 1.5 g NaOMe in DMF 10 min, 3.67 g Me2C:CHCH2Br added with ice cooling, and the whole heated 3 h at 145° to give 5.5 g 1-cyclopropylmethyl-6-(3-methyl-2-butenyloxy)-4-phenyl-2(1H)-quinazolinone.
IT 73052-30-9
RL: RCT (Reactant); RACT (Reactant or reagent)
(etherification of)
RN 73052-30-9 CAPLUS
CN 2(1H)-Quinazolinone, 1-(cyclopropylmethyl)-6-hydroxy-4-phenyl- (CA INDEX NAME)

L5 ANSWER 137 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



IT 83770-14-3P 83770-15-4P 83770-16-5P
83770-17-6P 83770-18-7P 83770-19-8P
83770-20-1P 83770-21-2P 83770-22-3P
83770-23-4P 83770-24-5P 83770-25-6P
83770-26-7P 83770-27-8P 83770-28-9P
83770-29-0P 83770-30-3P 83770-31-4P
83770-32-5P 83770-33-6P 83770-34-7P
83770-35-8P 83770-36-9P 83770-38-1P
83770-39-2P 83770-40-5P 83770-41-6P
83770-42-7P 83770-43-8P 83770-44-9P
83770-45-0P 83770-47-2P 83770-48-3P
83770-49-4P 83770-50-7P 83770-51-8P
83770-52-9P 83770-53-0P 83770-54-1P
83770-55-2P 83770-56-3P 83770-57-4P
83770-58-5P 83770-59-6P 83770-60-9P
83770-61-0P 83770-62-1P 83770-63-2P
83770-64-3P 83770-65-4P 83770-66-5P
83770-67-6P 83784-53-6P 83784-54-7P
83817-80-5P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 83770-14-3 CAPLUS
CN 2(1H)-Quinazolinone, 1-(cyclopropylmethyl)-6-[(3-methyl-2-butenyl)oxy]-4-phenyl- (9CI) (CA INDEX NAME)



RN 83770-15-4 CAPLUS
CN 2(1H)-Quinazolinone, 6-[[4-(acetyloxy)-2-methyl-2-butenyl]oxy]-1-(cyclopropylmethyl)-4-phenyl- (9CI) (CA INDEX NAME)

L5 ANSWER 137 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 83770-16-5 CAPLUS
CN 2(1H)-Quinazolinone, 1-(cyclopropylmethyl)-6-[(1,5-dimethyl-4-hexenyl)oxy]-4-phenyl- (9CI) (CA INDEX NAME)



RN 83770-17-6 CAPLUS
CN 2(1H)-Quinazolinone, 1-(cyclopropylmethyl)-6-[(3,7-dimethyl-2,6-octadienyl)oxy]-4-phenyl-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 83770-18-7 CAPLUS
CN 2(1H)-Quinazolinone, 1-(cyclopropylmethyl)-4-phenyl-6-[(3,7,11-trimethyl-2,6,10-dodecatrienyl)oxy]- (9CI) (CA INDEX NAME)

L5 ANSWER 137 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 83770-19-8 CAPLUS
CN 2(1H)-Quinazolinone, 1-(cyclopropylmethyl)-6-(3-methylbutoxy)-4-phenyl- (CA INDEX NAME)



RN 83770-20-1 CAPLUS
CN 2(1H)-Quinazolinone, 1-(cyclopropylmethyl)-6-(heptyloxy)-4-phenyl- (CA INDEX NAME)



RN 83770-21-2 CAPLUS
CN 2(1H)-Quinazolinone, 1-(cyclopropylmethyl)-6-(1,3-dimethylbutoxy)-4-phenyl- (CA INDEX NAME)

L5 ANSWER 137 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 83770-25-6 CAPLUS
CN 2(1H)-Quinazolinone, 1-(cyclopropylmethyl)-6-[(4-methoxyphenyl)methoxy]-4-phenyl- (CA INDEX NAME)



RN 83770-26-7 CAPLUS
CN Pentanenitrile, 5-[[1-(cyclopropylmethyl)-1,2-dihydro-2-oxo-4-phenyl-6-quinazolinyl]oxy]- (CA INDEX NAME)



RN 83770-27-8 CAPLUS
CN 2(1H)-Quinazolinone, 6-[(3-methyl-2-butenyl)oxy]-4-phenyl-1-propyl- (9CI) (CA INDEX NAME)

L5 ANSWER 137 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 83770-22-3 CAPLUS
CN 2(1H)-Quinazolinone, 1-(cyclopropylmethyl)-6-(nonyloxy)-4-phenyl- (CA INDEX NAME)



RN 83770-23-4 CAPLUS
CN 2(1H)-Quinazolinone, 1-(cyclopropylmethyl)-6-(decyloxy)-4-phenyl- (CA INDEX NAME)



RN 83770-24-5 CAPLUS
CN 2(1H)-Quinazolinone, 6-(cyclohexylmethoxy)-1-(cyclopropylmethyl)-4-phenyl- (CA INDEX NAME)

L5 ANSWER 137 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 83770-28-9 CAPLUS
CN 2(1H)-Quinazolinone, 1-methyl-6-[(3-methyl-2-butenyl)oxy]-4-phenyl- (9CI) (CA INDEX NAME)



RN 83770-29-0 CAPLUS
CN 2(1H)-Quinazolinone, 6-[(3-methyl-2-butenyl)oxy]-4-phenyl-1-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)



RN 83770-30-3 CAPLUS
CN 2(1H)-Quinazolinone, 1-(cyclopropylmethyl)-7-[(3-methyl-2-butenyl)oxy]-4-phenyl- (9CI) (CA INDEX NAME)



L5 ANSWER 137 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

RN 83770-31-4 CAPLUS
CN 2(1H)-Quinazolinone, 6-(pentyloxy)-4-phenyl-1-(2,2,2-trifluoroethyl)-(CA
INDEX NAME)



RN 83770-32-5 CAPLUS
CN 2(1H)-Quinazolinone, 1-(cyclopropylmethyl)-6-(octyloxy)-4-phenyl- (CA INDEX NAME)



RN 83770-33-6 CAPLUS
CN 2(1H)-Quinazolinone, 1-(cyclopropylmethyl)-6-(pentyloxy)-4-phenyl- (CA INDEX NAME)



RN 83770-34-7 CAPLUS
CN 2(1H)-Quinazolinone, 1-(cyclopropylmethyl)-6-(hexyloxy)-4-phenyl- (CA

L5 ANSWER 137 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 83770-39-2 CAPLUS
CN 2(1H)-Quinazolinone,
1-(cyclopropylmethyl)-6-[2-(3-methylphenyl)ethoxy]-4-
phenyl- (CA INDEX NAME)



RN 83770-40-5 CAPLUS
CN 2(1H)-Quinazolinone, 1-(cyclopropylmethyl)-7-(pentyloxy)-4-phenyl- (CA INDEX NAME)



RN 83770-41-6 CAPLUS
CN 2(1H)-Quinazolinone, 1-(cyclopropylmethyl)-7-(pentylthio)-4-phenyl- (CA INDEX NAME)

L5 ANSWER 137 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
INDEX NAME)



RN 83770-35-8 CAPLUS
CN 2(1H)-Quinazolinone,
1-(cyclopropylmethyl)-6-[(3-methyl-2-butenyl)thio]-4-
phenyl- (9CI) (CA INDEX NAME)



RN 83770-36-9 CAPLUS
CN 2(1H)-Quinazolinone, 1-ethyl-7-[(3-methyl-2-butenyl)oxy]-4-phenyl- (9CI) (CA INDEX NAME)



RN 83770-38-1 CAPLUS
CN 2(1H)-Quinazolinone, 1-(cyclopropylmethyl)-6-(pentylthio)-4-phenyl- (CA INDEX NAME)

L5 ANSWER 137 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 83770-42-7 CAPLUS
CN 2-Butenal, 4-[[1-(cyclopropylmethyl)-1,2-dihydro-2-oxo-4-phenyl-6-quinazolinyl]oxy]-3-methyl- (CA INDEX NAME)



RN 83770-43-8 CAPLUS
CN 2-Butenoic acid, 4-[[1-(cyclopropylmethyl)-1,2-dihydro-2-oxo-4-phenyl-6-quinazolinyl]oxy]-3-methyl- (CA INDEX NAME)



RN 83770-44-9 CAPLUS
CN 2(1H)-Quinazolinone, 1-(cyclopropylmethyl)-6-(pentylsulfonyl)-4-phenyl-(CA INDEX NAME)

L5 ANSWER 137 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 83770-45-0 CAPLUS
CN 1(2H)-Quinazolineacetic acid, 6-[(3-methyl-2-butenyl)oxy]-2-oxo-4-phenyl- (9CI) (CA INDEX NAME)



RN 83770-47-2 CAPLUS
CN Hexanoic acid, 6-[[6-[(3-methyl-2-butenyl)oxy]-2-oxo-4-phenyl-1(2H)-quinazolinyl]oxy]-, ethyl ester (9CI) (CA INDEX NAME)



RN 83770-48-3 CAPLUS
CN Hexanoic acid, 6-[[1-(cyclopropylmethyl)-1,2-dihydro-2-oxo-4-phenyl-6-quinazolinyl]oxy]-, ethyl ester (CA INDEX NAME)

L5 ANSWER 137 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 83770-49-4 CAPLUS
CN Hexanoic acid, 6-[(1,2-dihydro-2-oxo-1-pentyl-4-phenyl-7-quinazolinyl)oxy]-, ethyl ester (CA INDEX NAME)



RN 83770-50-7 CAPLUS
CN Hexanoic acid, 6-[(1,2-dihydro-2-oxo-1-pentyl-4-phenyl-7-quinazolinyl)oxy]- (CA INDEX NAME)



RN 83770-51-8 CAPLUS
CN Hexanoic acid, 6-[[1-(cyclopropylmethyl)-1,2-dihydro-2-oxo-4-phenyl-6-quinazolinyl]oxy]- (CA INDEX NAME)

L5 ANSWER 137 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 83770-52-9 CAPLUS
CN 1(2H)-Quinazolinehexanoic acid, 6-[(3-methyl-2-butenyl)oxy]-2-oxo-4-phenyl- (9CI) (CA INDEX NAME)



RN 83770-53-0 CAPLUS
CN Pentanoic acid, 5-[[1-(cyclopropylmethyl)-1,2,3,4-tetrahydro-2-oxo-4-phenyl-6-quinazolinyl]oxy]-2,2-dimethyl- (CA INDEX NAME)



RN 83770-54-1 CAPLUS
CN Hexanamide, 6-[[1-(cyclopropylmethyl)-1,2-dihydro-2-oxo-4-phenyl-6-quinazolinyl]oxy]-N-(2-hydroxyethyl)- (CA INDEX NAME)

L5 ANSWER 137 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 83770-55-2 CAPLUS
CN Morpholine, 4-[6-[[1-(cyclopropylmethyl)-1,2-dihydro-2-oxo-4-phenyl-6-quinazolinyl]oxy]-1-oxohexyl]- (9CI) (CA INDEX NAME)



RN 83770-56-3 CAPLUS
CN 3(2H)-Quinazolineacetic acid, 1-(cyclopropylmethyl)-1,4-dihydro-6-[(3-methyl-2-butenyl)oxy]-2-oxo-4-phenyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 83770-57-4 CAPLUS
CN 3(2H)-Quinazolineacetic acid, 1-(cyclopropylmethyl)-1,4-dihydro-6-[(3-methyl-2-butenyl)oxy]-2-oxo-4-phenyl- (9CI) (CA INDEX NAME)

L5 ANSWER 137 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 83770-58-5 CAPLUS
CN Butanoic acid, 4-[[1-(cyclopropylmethyl)-1,2-dihydro-2-oxo-4-phenyl-6-quinazolinyl]oxy]-2-hydroxy-3,3-dimethyl- (CA INDEX NAME)



RN 83770-59-6 CAPLUS
CN 2(1H)-Quinazolinone, 6-[[4-(acetyloxy)-3-methyl-2-butenyl]oxy]-1-(cyclopropylmethyl)-4-phenyl- (9CI) (CA INDEX NAME)



RN 83770-60-9 CAPLUS
CN 2(1H)-Quinazolinone, 1-(cyclopropylmethyl)-6-[(4-hydroxy-3-methyl-2-butenyl)oxy]-4-phenyl- (9CI) (CA INDEX NAME)

L5 ANSWER 137 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 83770-64-3 CAPLUS
CN 1(2H)-Quinazolinebutanoic acid, 6-[(3-methyl-2-butenyl)oxy]-2-oxo-4-phenyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 83770-65-4 CAPLUS
CN 1(2H)-Quinazolinepropanoic acid, 6-[(3-methyl-2-butenyl)oxy]-2-oxo-4-phenyl- (9CI) (CA INDEX NAME)



RN 83770-66-5 CAPLUS
CN 2(1H)-Quinazolinone, 6-[[4-(acetyloxy)-3-methyl-2-butenyl]oxy]-1-(3-methyl-2-butenyl)-4-phenyl- (9CI) (CA INDEX NAME)

L5 ANSWER 137 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 83770-61-0 CAPLUS
CN 2-Butenal, 4-[[1-(cyclopropylmethyl)-1,2-dihydro-2-oxo-4-phenyl-6-quinazolinyl]oxy]-2-methyl- (CA INDEX NAME)



RN 83770-62-1 CAPLUS
CN 2-Butenoic acid, 4-[[1-(cyclopropylmethyl)-1,2-dihydro-2-oxo-4-phenyl-6-quinazolinyl]oxy]-2-methyl- (CA INDEX NAME)



RN 83770-63-2 CAPLUS
CN 3-Pyridinecarboxylic acid, 4-[[1-(cyclopropylmethyl)-1,2-dihydro-2-oxo-4-phenyl-6-quinazolinyl]oxy]-2-methyl-2-butenyl ester (9CI) (CA INDEX NAME)

L5 ANSWER 137 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 83770-67-6 CAPLUS
CN 2-Butenoic acid, 4-[[1,2-dihydro-1-(3-methyl-2-butenyl)-2-oxo-4-phenyl-6-quinazolinyl]oxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 83784-53-6 CAPLUS
CN 2(1H)-Quinazolinone, 1-(cyclopropylmethyl)-6-[(3-methyl-3-butenyl)oxy]-4-phenyl- (9CI) (CA INDEX NAME)



RN 83784-54-7 CAPLUS
CN 2(1H)-Quinazolinone, 6-[(4-hydroxy-3-methyl-2-butenyl)oxy]-1-(3-methyl-2-butenyl)-4-phenyl- (9CI) (CA INDEX NAME)



L5 ANSWER 137 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
RN 83817-80-5 CAPLUS
CN 2(1H)-Quinazolinone, 1-(cyclopropylmethyl)-4-phenyl-6-(phenylmethoxy)- (CA INDEX NAME)



L5 ANSWER 138 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1982:556139 CAPLUS
DOCUMENT NUMBER: 97:156139
ORIGINAL REFERENCE NO.: 97:25853a,25856a
TITLE: Effects of nonsteroidal antiinflammatory drugs on rat gastric mucosal phosphodiesterase activity
AUTHOR(S): Silvola, J.; Kangasaho, M.; Tokola, O.; Vapaatalo, H.
CORPORATE SOURCE: Dep. Biomed. Sci., Univ. Tampere, Tampere, SF-33101/10, Finland
SOURCE: Agents and Actions (1982), 12(4), 516-20
CODEN: AGACBH; ISSN: 0065-4299
DOCUMENT TYPE: Journal
LANGUAGE: English
AB The effects of acetylsalicylic acid [50-78-2], diclofenac [15307-86-5], ibuprofen [15687-27-1], indomethacin [53-86-1], naproxen [22204-53-1], phenylbutazone [50-33-9], proquazone [22760-18-5], fluproquazone (RF 46-790 N) [40507-23-1], sulindac [38194-50-2], sulindac sulfide [49627-27-2], and tolfenamic acid [13710-19-5] were compared on rat gastric mucosal cyclic nucleotide phosphodiesterase (PDEs) [9040-59-9]. Some of the drugs inhibited PDEs effectively, the Ki values being clearly lower than those of theophylline.
Mostly the type of inhibition was apparently competitive. Acetylsalicylic acid and ibuprofen were ineffective. No unambiguous correlation between the inhibition of mucosal PDEs and clin. observed gastric irritation was found. However, the inhibition of PDEs may modulate gastric side effects of nonsteroidal antiinflammatory drugs.
IT 22760-18-5 40507-23-1
RL: BIOL (Biological study)
(cyclic nucleotide phosphodiesterase of stomach mucosa response to)
RN 22760-18-5 CAPLUS
CN 2(1H)-Quinazolinone, 7-methyl-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)



RN 40507-23-1 CAPLUS
CN 2(1H)-Quinazolinone, 4-(4-fluorophenyl)-7-methyl-1-(1-methylethyl)- (CA INDEX NAME)

L5 ANSWER 138 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



L5 ANSWER 139 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1982:503745 CAPLUS
DOCUMENT NUMBER: 97:103745
ORIGINAL REFERENCE NO.: 97:17083a,17086a
TITLE: GLC-ECD determination of 1-(2-hydroxyethyl)-3-hydroxy-7-chloro-1,3-dihydro-5-(O-fluorophenyl)-2H-1,4-benzodiazepin-2-one (SAS 643) in plasma and urine and identification of its main biotransformation products
AUTHOR(S): Mardente, Salvatore; Bicchi, Carlo; Nano, G. Mario
CORPORATE SOURCE: Anal. Res. Dep., Schiapparelli Farm. S.p.A., Turin, Italy
SOURCE: Therapeutic Drug Monitoring (1981), 3(4), 351-6
CODEN: TDMODV; ISSN: 0163-4356
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



I

AB A gas-liquid chromatog.-electron-capture detection method for rapid, accurate determination of SAS 643 (I) [40762-15-0] in plasma and urine is described. The drug was extracted from biol. fluid with benzene and converted to the O,O'-bistrimethylsilyl derivative with bis(trimethylsilyl) trifluoroacetamide. The glucuronide form of the drug was extracted after hydrolysis with β-glucuronidase. Nimetazepam was used as internal standard Moreover, some metabolites such as glucuronide and the N-1-dealkylated [17617-60-6] and N-1-yl-acetic [82780-99-2] products were identified. All compds. were confirmed by thin-layer chromatog. mass spectroscopy, and gas-liquid chromatog.-mass spectroscopy by comparison with reference products.
IT 37554-38-4
RL: ANT (Analyte); ANST (Analytical study)
(determination of, as benzodiazepinone derivative metabolite, in human by gas liquid chromatog.)
RN 37554-38-4 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-4-(2-fluorophenyl)-1-(2-hydroxyethyl)- (CA INDEX NAME)

L5 ANSWER 139 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



L5 ANSWER 140 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1982:155263 CAPLUS
DOCUMENT NUMBER: 96:155263
ORIGINAL REFERENCE NO.: 96:25382h,25383a
TITLE: Prevention of the platelet alpha-granule release reaction by membrane-active drugs
AUTHOR(S): Prowse, Christopher; Pepper, Duncan; Dawes, Joan
CORPORATE SOURCE: Edinburgh South-East Scotland Reg. Blood Transfus. Serv., R. Infirm., Edinburgh, UK
SOURCE: Thrombosis Research (1982), 25(3), 219-27
CODEN: THBRAA; ISSN: 0049-3848
DOCUMENT TYPE: Journal
LANGUAGE: English
AB A range of membrane-active drugs were tested for their ability to prevent β-thromboglobulin and platelet factor 4 release from freshly collected blood platelets. While all the drugs tested could inhibit collagen-induced platelet aggregation, only a few, notably procaine [59-46-1] and the antimalarial drugs chloroquine [54-05-7], hydroxychloroquine [118-42-3], camoquine [86-42-0] and quinacrine (mepacrine) [83-89-6], effectively prevented the α-granule release reaction.
IT 22760-18-5
RL: BIOL (Biological study)
(α-granule release by blood platelet response to, antithrombotic activity in relation to)
RN 22760-18-5 CAPLUS
CN 2(1H)-Quinazolinone, 7-methyl-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)



L5 ANSWER 141 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1982:129806 CAPLUS
DOCUMENT NUMBER: 96:129806
ORIGINAL REFERENCE NO.: 96:21205a,21208a
TITLE: Use of an analgesic and nonhormonal, antiinflammatory agent in the treatment of microvascular diseases
INVENTOR(S): Ringold, Howard J.; Waterbury, L. David
PATENT ASSIGNEE(S): Syntex Corp. , USA
SOURCE: Ger. Offen., 16 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 3026402	A1	19820204	DE 1980-3026402	19800711
JP 57032218	A	19820220	JP 1980-103214	19800729
PRIORITY APPLN. INFO.:			DE 1980-3026402 A	19800711

AB The microvascular diseases of man and mammals, especially of the skin, kidney, and retina, as a result of the complications of diabetes mellitus, are treated with a nonhormonal antiinflammatory analgesic. Thus, rats made diabetic with streptozotocin were fed a lab chow diet, or the diet containing 0.05% ibuprofen [15687-27-1] (50 mg/kg/day) or 0.015% naproxen [22204-53-1] (15 mg/kg/day) for 3 wk, and fluorescein was injected. One hour later, the penetration of fluorescein into the vitreous humor was measured. Both drugs reduced the penetration to normal levels, as compared to more than twice normal values in untreated diabetic rats. Preparation of tablets containing these ingredients is described.
IT 22760-18-5
RL: BIOL (Biological study)
(diabetic angiopathy treatment with)
RN 22760-18-5 CAPLUS
CN 2(1H)-Quinazolinone, 7-methyl-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)



L5 ANSWER 142 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1982:97404 CAPLUS
DOCUMENT NUMBER: 96:97404
ORIGINAL REFERENCE NO.: 96:15825a,15828a
TITLE: Heterogeneity of biochemical actions among vasodilators
AUTHOR(S): Greenslade, Forrest C.; Scott, Cynthia K.; Newquist, Kathryn L.; Krider, Kathryn M.; Chasin, Mark
CORPORATE SOURCE: Div. Biochem. Res., Ortho Pharm. Corp., Raritan, NJ, 08869, USA
SOURCE: Journal of Pharmaceutical Sciences (1982), 71(1), 94-100
CODEN: JPMSAE; ISSN: 0022-3549
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Thirty-four vasodilators were screened in 3 in vitro biochem. assays related to smooth muscle excitation-contraction coupling: binding to β1-, β2-, and α-adrenergic receptors, inhibition of phosphodiesterase activity, and antagonism of Ca accumulation. The results indicate that vasodilators should not be considered as a single drug class since they act on various mechanisms related to coupling of neuronal excitation to muscular contractility.
IT 22760-18-5
RL: BIOL (Biological study)
(vasodilation by, mechanism of)
RN 22760-18-5 CAPLUS
CN 2(1H)-Quinazolinone, 7-methyl-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)



L5 ANSWER 143 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1982:69021 CAPLUS
DOCUMENT NUMBER: 96:69021
ORIGINAL REFERENCE NO.: 96:11345a,11348a
TITLE: 2(1H)-Quinazolinone derivatives
PATENT ASSIGNEE(S): Sumitomo Chemical Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 10 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 56113769	A	19810907	JP 1980-17041	19800213
PRIORITY APPLN. INFO.:			JP 1980-17041 A	19800213

OTHER SOURCE(S): CASREACT 96:69021
GI



AB 2(1H)-Quinazolinones I [R, R1 = EtOCH2CH2O, Ph; HOCH2CH2, Ph; EtOCH2CH2O, H; Me2CHOCH2CH2O, Ph; HO(CH2)5O, Ph; 2,3-epoxypropoxy, Ph; EtOCH2CH(OH)CH2O, Ph; PhOCH2CH(OH)CH2O, Ph] and II [R2 = EtOCH2CH2O, HO(CH2)5O] were prepared and had antiinflammatory, analgesic, and platelet aggregation inhibitory activities (no data). Thus, etherification of 7.8 g EtOCH2CH2Br with 5 g I (R = OH, R1 = Ph) and aqueous NaOH 9 h at 90-5° gave 4.12 g I (R = EtOCH2CH2O, R1 = Ph) (III). Refluxing 1 g III with NaBH4 in EtOH 30 min gave 0.8 g II (R2 = EtOCH2CH2O).
IT 73052-30-9
RL: RCT (Reactant); RACT (Reactant or reagent)
(etherification of, with ethoxyethyl bromide)
RN 73052-30-9 CAPLUS
CN 2(1H)-Quinazolinone, 1-(cyclopropylmethyl)-6-hydroxy-4-phenyl- (CA INDEX NAME)

L5 ANSWER 143 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



IT 80591-27-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reduction of)
RN 80591-27-1 CAPLUS
CN 2(1H)-Quinazolinone, 1-(cyclopropylmethyl)-6-(2-ethoxyethoxy)-4-phenyl- (CA INDEX NAME)



IT 80591-28-2P 80591-29-3P 80591-31-7P
80591-32-8P 80591-33-9P 80591-34-0P
80591-35-1P 80591-36-2P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 80591-28-2 CAPLUS
CN 2(1H)-Quinazolinone, 1-(cyclopropylmethyl)-6-(2-ethoxyethoxy)-3,4-dihydro-4-phenyl- (CA INDEX NAME)

L5 ANSWER 143 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 80591-29-3 CAPLUS
CN 2(1H)-Quinazolinone, 1-(cyclopropylmethyl)-6-(2-hydroxyethyl)-4-phenyl- (CA INDEX NAME)



RN 80591-31-7 CAPLUS
CN 2(1H)-Quinazolinone, 1-(cyclopropylmethyl)-6-[2-(1-methylethoxy)ethoxy]-4-phenyl- (CA INDEX NAME)



RN 80591-32-8 CAPLUS
CN 2(1H)-Quinazolinone, 1-(cyclopropylmethyl)-6-[(5-hydroxypentyl)oxy]-4-phenyl- (CA INDEX NAME)

L5 ANSWER 143 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 80591-33-9 CAPLUS
CN 2(1H)-Quinazolinone, 1-(cyclopropylmethyl)-6-(oxiranylmethoxy)-4-phenyl- (9CI) (CA INDEX NAME)



RN 80591-34-0 CAPLUS
CN 2(1H)-Quinazolinone, 1-(cyclopropylmethyl)-6-(3-ethoxy-2-hydroxypropoxy)-4-phenyl- (CA INDEX NAME)



RN 80591-35-1 CAPLUS
CN 2(1H)-Quinazolinone, 1-(cyclopropylmethyl)-6-(2-hydroxy-3-phenoxypropoxy)-4-phenyl- (CA INDEX NAME)

L5 ANSWER 143 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 80591-36-2 CAPLUS
CN 2(1H)-Quinazolinone, 1-(cyclopropylmethyl)-3,4-dihydro-6-[(5-hydroxypentyl)oxy]-4-phenyl- (CA INDEX NAME)



L5 ANSWER 144 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1982:29498 CAPLUS
DOCUMENT NUMBER: 96:29498
ORIGINAL REFERENCE NO.: 96:4801a
TITLE: Combination of TLC, GLC (OV 1 and OV 17) and HPLC (RP 18) for a rapid detection of drugs, intoxicants and related compounds
AUTHOR(S): Daldrup, T.; Susanto, F.; Michalke, P.
CORPORATE SOURCE: Inst. Rechtsmed., Univ. Duesseldorf, Duesseldorf, D-4000, Fed. Rep. Ger.
SOURCE: Fresenius' Zeitschrift fuer Analytische Chemie (1981), 308(5), 413-27
CODEN: ZACFAU; ISSN: 0016-1152
DOCUMENT TYPE: Journal
LANGUAGE: German
AB Relative retention times for 570 drugs and related compds. on 8 chromatog. systems were reported. TLC employing silica gel plates, gas chromatog. employing 3% OV-1 on Chromosorb W-HP, and reversed-phase high-pressure chromatog. employing octadecylsilanized columns were described.
IT 22760-18-5
RL: ANT (Analyte); ANST (Analytical study)
(determination of, by chromatog.)
RN 22760-18-5 CAPLUS
CN 2(1H)-Quinazolinone, 7-methyl-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)



L5 ANSWER 145 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1982:27946 CAPLUS
DOCUMENT NUMBER: 96:27946
ORIGINAL REFERENCE NO.: 96:4500h,4501a
TITLE: Tormosyl
AUTHOR(S): Kranz, Otto
CORPORATE SOURCE: Sandoz Ltd., Basel, Switz.
SOURCE: Drugs Made in Germany (1981), 24(3), 81-4, 86-8
CODEN: DRMGAS; ISSN: 0012-6683
DOCUMENT TYPE: Journal; General Review
LANGUAGE: English
GI



AB A review with 15 refs. of the pharmacokinetics of the analgesic tormosyl (I) [40507-23-1].
IT 40507-23-1
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(pharmacokinetics of, in humans and laboratory animals)
RN 40507-23-1 CAPLUS
CN 2(1H)-Quinazolinone, 4-(4-fluorophenyl)-7-methyl-1-(1-methylethyl)- (CA INDEX NAME)



L5 ANSWER 146 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1982:24742 CAPLUS
DOCUMENT NUMBER: 96:24742
ORIGINAL REFERENCE NO.: 96:4029a,4032a
TITLE: Percutaneous absorption of griseofulvin and proquazone in the rat and in isolated human skin
AUTHOR(S): Franz, J. M.; Gaillard, A.; Maibach, H. I.; Schweitzer, A.
CORPORATE SOURCE: Div. Biopharm., Sandoz Ltd., Basel, CH-4002, Switz.
SOURCE: Archives of Dermatological Research (1981), 271(3), 275-82
CODEN: ADREDL; ISSN: 0340-3696
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Ointments containing griseofulvin [126-07-8] and proquazone [22760-18-5], resp., were made up of monoglycerides of medium chain length and an aprotic solvent, glycerinformal. The ointments were applied topically on the back of bile cannulated rats. The total amount absorbed percutaneously and the permeability consts. of both drugs were considerably higher for the ointments than for simple solns. of the drugs without monoglycerides. Distribution of the labeled drugs in rat skin was demonstrated by microautoradiog. Concns. of the drugs in the different layers of human skin together with the medium flow rates were determined 16 h after administration of the ointments onto isolated human skin. Monoglycerides of medium chain length significantly enhanced the permeability of the stratum corneum for solutes.
IT 22760-18-5
RL: BIOL (Biological study)
(skin absorption of, from ointments, monoglycerides and glycerinformal effect on)
RN 22760-18-5 CAPLUS
CN 2(1H)-Quinazolinone, 7-methyl-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)



L5 ANSWER 147 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1982:20054 CAPLUS
DOCUMENT NUMBER: 96:20054
ORIGINAL REFERENCE NO.: 96:3339a,3342a
TITLE: Synthetic studies on quinazoline derivatives. II. The reactions of 2-trichloro- and 2-trifluoroacetamidobenzophenones with primary amines
AUTHOR(S): Yamamoto, Michihiro; Yamamoto, Hisao
CORPORATE SOURCE: Pharm. Div., Sumitomo Chem. Co., Ltd., Takatsukasa, 665, Japan
SOURCE: Chemical & Pharmaceutical Bulletin (1981), 29(8), 2135-56
CODEN: CPBTAL; ISSN: 0009-2363
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 96:20054
GI


II


III


IV


V


VI

AB The reaction of 5-chloro-2-trichloroacetamidobenzophenone (I) with several primary alkylamines in Me2SO gave high yields of the quinazolinones II (R = Me, Et, Pr, Et2NCH2CH2, morpholinoethyl, PhCH2, etc.), which were formed by base-catalyzed and/or thermal cyclization and simultaneous rearrangement of the isomeric 5-chloro-2-trichloroacetamidobenzophenone alkylimines III. Both compds. II and III were obtained when the reaction was effected in benzene. Treatment of the compound I with bulky amines such as Me2CHNH2 and cyclohexylamine gave, under similar conditions, the corresponding benzophenone imines III (R = Me2C, cyclohexyl) exclusively, and these could be transformed into II on heating in pyridine. The reaction of N-substituted trichloroacetamidobenzophenones with N-(2-aminoethyl)morpholine as well as NH3/Me2SO yielded the 1-alkylaminobenzophenone imines, IV (R = Me, R1 = H, morpholinoethyl; R = cyclopropylmethyl, R1 = H) which on treatment with Cl3CCOCl were readily cyclized to give the corresponding 1-substituted 4-trichloromethylquinazolinones. The trichloromethyl group of the 1-unsubstituted quinazolinones II were easily displaced by a nucleophile such as hydride, alkoxide or hydroxide under base catalysis to give the 3,4-dihydro-2(1H)-quinazolinone derivs., e.g. V. The NaBH4 redn. of III (R = Me) at room temp. mainly afforded the trichloroacetamidobenzhydrylamine, which underwent thermal cyclization to the quinazolinone V. In contrast, the reaction of 5-chloro-2-trifluoroacetamidobenzophenone with some primary alkylamines in Me2SO produced the trifluoroacetamidobenzophenone alkylimines, which on treatment with NaBH4 could be converted only to 3-substituted 6-chloro-3,4-dihydro-4-phenyl-2-trifluoromethylquinazolines. These procedures were successfully utilized in syntheses of the imidazo[1,2-c]quinazolinone (VI), oxazolo[3,2-c]quinazolinones, and 1,3-oxazino[3,2-c]quinazolinone.

IT 80170-89-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and deacetylation of)
RN 80170-89-4 CAPLUS
CN 2(1H)-Quinazolinone, 1-acetyl-6-chloro-3,4-dihydro-3-methyl-4-phenyl-4-(trichloromethyl)- (CA INDEX NAME)



IT 80170-86-1P 80170-87-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and hydrolysis of)
RN 80170-86-1 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-3,4-dihydro-1-methyl-4-phenyl-4-(trichloromethyl)- (CA INDEX NAME)

L5 ANSWER 147 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 80170-87-2 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-1-(cyclopropylmethyl)-3,4-dihydro-4-phenyl-4-(trichloromethyl)- (CA INDEX NAME)



IT 20927-53-1P 26772-95-2P 33453-19-9P
36942-76-4P 41230-84-6P 80170-72-5P
80170-73-6P 80170-74-7P 80170-75-8P
80170-88-3P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 20927-53-1 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-1-methyl-4-phenyl- (CA INDEX NAME)



RN 26772-95-2 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-3,4-dihydro-1-methyl-4-phenyl- (CA INDEX NAME)

L5 ANSWER 147 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 33453-19-9 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-1-(cyclopropylmethyl)-4-phenyl- (CA INDEX NAME)



RN 36942-76-4 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-1-(cyclopropylmethyl)-3,4-dihydro-4-phenyl-(CA INDEX NAME)



RN 41230-84-6 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-1-(cyclopropylmethyl)-3-ethyl-3,4-dihydro-4-phenyl- (CA INDEX NAME)

L5 ANSWER 147 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 80170-72-5 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-3,4-dihydro-1-methyl-3-[2-(4-morpholinyl)ethyl]-4-phenyl-, (2Z)-2-butenedioate (1:1) (CA INDEX NAME)

CM 1

CRN 80170-71-4
CMF C21 H24 Cl N3 O2



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



RN 80170-73-6 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-3-ethyl-3,4-dihydro-1-methyl-4-phenyl- (CA INDEX NAME)

L5 ANSWER 147 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



L5 ANSWER 147 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 80170-74-7 CAPLUS
CN 2(1H)-Quinazolinone, 1-acetyl-6-chloro-3,4-dihydro-3-methyl-4-phenyl- (CA INDEX NAME)



RN 80170-75-8 CAPLUS
CN 2(1H)-Quinazolinone, 1-acetyl-6-chloro-3-[2-(diethylamino)ethyl]-3,4-dihydro-4-phenyl- (CA INDEX NAME)



RN 80170-88-3 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-3,4-dihydro-1-methyl-3-[2-(4-morpholinyl)ethyl]-4-phenyl-4-(trichloromethyl)- (CA INDEX NAME)

L5 ANSWER 148 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1982:15063 CAPLUS
DOCUMENT NUMBER: 96:15063
ORIGINAL REFERENCE NO.: 96:2487a,2490a
TITLE: Reduction of inflammatory brain edema by nonsteroidal antiinflammatory drugs
AUTHOR(S): Levine, Seymour; Casner, Nancy; Compitello, Robert; Saad, Ahmed M.; Plakogiannis, Fotios M.
CORPORATE SOURCE: Pathol. Dep., New York Med. Coll., Valhalla, NY, 10595, USA
SOURCE: Experimental Neurology (1981), 74(2), 370-8
CODEN: EXNEAC; ISSN: 0014-4886
DOCUMENT TYPE: Journal
LANGUAGE: English

AB After the implantation of Cu-wire into the right cerebral hemispheres of rats, the resulting inflammation and necrosis were accompanied by severe edema with water content increased from .apprx.79% to 81-82%. Treatment with dexamethasone [50-02-2] after the implantation and on the next 3 days caused marked reduction in the edema. Alleviation of edema, albeit of lesser degree, was obtained with the common analgesic-antipyretic drug, acetaminophen [103-90-2]. This result was not due to adrenal stimulation. The drug penetrated the brain and reached slightly higher concns. in the edematous right hemisphere than in the relatively normal left hemisphere. Encouraging results were also obtained with acetophenetidin [62-44-2] and benoxaprofen [51234-28-7], but not with other nonsteroidal antiinflammatory drugs. The mechanism for the beneficial effects of acetaminophen is unknown but it probably does not involve inhibition of prostaglandin synthesis.

IT 22760-18-5 40507-23-1
RL: BIOL (Biological study)
(brain edema response to)

RN 22760-18-5 CAPLUS
CN 2(1H)-Quinazolinone, 7-methyl-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)



RN 40507-23-1 CAPLUS
CN 2(1H)-Quinazolinone, 4-(4-fluorophenyl)-7-methyl-1-(1-methylethyl)- (CA INDEX NAME)

L5 ANSWER 148 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



L5 ANSWER 149 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1981:603865 CAPLUS
DOCUMENT NUMBER: 95:203865
ORIGINAL REFERENCE NO.: 95:34065a,34068a
TITLE: Synthesis and pharmacological properties of 4-phenylquinazolin-2-ones
AUTHOR(S): Voronina, T. A.; Gordichuk, G. N.; Andronati, S. A.; Garibova, T. L.; Zhilina, Z. I.
CORPORATE SOURCE: Nauchno-Issled. Inst. Farmakol., Moscow, USSR
SOURCE: Khimiko-Farmatsevticheskii Zhurnal (1981), 15(7), 55-7
CODEN: KHFZAN; ISSN: 0023-1134
DOCUMENT TYPE: Journal
LANGUAGE: Russian
GI



AB Twelve quinazolinones I (R1 = H, Br, Cl, OCHF2, OCF3, SCHF2, Me, SCF3, SO2CHF2, SO2CF3; R2 = H, Me) were prepared E.g., treatment of benzophenone II with NH3 gave 38% quinazolinone I (R1 = SCF3, R2 = H). I showed antagonism to corazol, hyposedative properties, antispasmodic activity, weak muscle relaxant activity and low toxicity. The pharmacol. properties of I were not inferior to those of chloridiazepoxide and lonetil.

IT 20927-53-1P 79885-38-4P 79885-39-5P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and pharmacol. properties of)

RN 20927-53-1 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-1-methyl-4-phenyl- (CA INDEX NAME)



RN 79885-38-4 CAPLUS
CN 2(1H)-Quinazolinone, 1-(difluoromethoxy)-4-phenyl- (CA INDEX NAME)

L5 ANSWER 149 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 79885-39-5 CAPLUS
CN 2(1H)-Quinazolinone, 6-[(difluoromethyl)thio]-1-methyl-4-phenyl- (CA INDEX NAME)



L5 ANSWER 150 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1981:549409 CAPLUS
DOCUMENT NUMBER: 95:149409
ORIGINAL REFERENCE NO.: 95:24991a,24994a
TITLE: Mass spectral studies of 4-phenyl-2(1H)-quinazolinones
AUTHOR(S): Kamal, Ahmed; Sattur, P. B.
CORPORATE SOURCE: Reg. Res. Lab., Hyderabad, 500 009, India
SOURCE: Indian Journal of Chemistry, Section B: Organic Chemistry Including Medicinal Chemistry (1981), 20B(7), 600-1
CODEN: IJSBDB; ISSN: 0376-4699
DOCUMENT TYPE: Journal
LANGUAGE: English
AB 4-Phenyl-2(1H)-quinazolinones with no substituent on N-1 fragment via loss of 2 H• radicals and a CO mol. When N-1 carries a Me group, only 1 H atom is lost to give the (M-1) ion, which fragments further via expulsion of Me•; direct loss of the HCO• radical from the mol. ion is also observed Fragmentation pathways proposed are supported by D labeling and by the presence of metastable peaks.

IT 17629-04-8 79246-07-4 79313-40-9 79313-41-0
RL: PRP (Properties)
(mass spectrum of)

RN 17629-04-8 CAPLUS
CN 2(1H)-Quinazolinone, 1-methyl-4-phenyl- (CA INDEX NAME)



RN 79246-07-4 CAPLUS
CN 2(1H)-Quinazolinone, 1-(methyl-d3)-4-phenyl- (9CI) (CA INDEX NAME)



RN 79313-40-9 CAPLUS
CN 2(1H)-Quinazolinone, 1-methyl-4-phenyl-, monochloro deriv. (9CI) (CA INDEX NAME)

L5 ANSWER 150 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



D1—Cl

RN 79313-41-0 CAPLUS
CN 2(1H)-Quinazolinone, 1-methyl-4-phenyl-, dichloro deriv. (9CI) (CA INDEX NAME)



2 (D1—Cl)

L5 ANSWER 151 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
RN 22760-18-5 CAPLUS
CN 2(1H)-Quinazolinone, 7-methyl-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)



L5 ANSWER 151 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1981:526251 CAPLUS
DOCUMENT NUMBER: 95:126251
ORIGINAL REFERENCE NO.: 95:21039a,21042a
TITLE: Use of thromboxane-synthetase inhibiting compounds in the treatment of obesity and the lowering of insulin levels
INVENTOR(S): Hamilton, James G.; Lands, William E. M.; Sullivan, Ann Clare; Tobias, Lawrence D.; Triscari, Joseph
PATENT ASSIGNEE(S): Hoffmann-La Roche, F., und Co. A.-G., Switz.
SOURCE: Eur. Pat. Appl., 18 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 28410	A1	19810513	EP 1980-106714	19801031
EP 28410	B1	19870930		
R: AT, BE, CH, DE, FR, GB, IT, LU, NL, SE				
ZA 8006531	A	19810624	ZA 1980-6531	19801023
NL 8005946	A	19810601	NL 1980-5946	19801029
JP 56097267	A	19810805	JP 1980-152400	19801031
DE 3041090	A1	19810903	DE 1980-3041090	19801031
AT 29964	T	19871015	AT 1980-106714	19801031
AU 8064056	A	19810507	AU 1980-64056	19801103
AU 531604	B2	19830901		
US 4500540	A	19850219	US 1982-387721	19820611
US 4591594	A	19860527	US 1984-680706	19841212
US 4731363	A	19880315	US 1986-819319	19860116

PRIORITY APPLN. INFO.: US 1979-90850 A 19791102
US 1979-90941 A 19791102
US 1979-107484 A 19791226
EP 1980-106714 A 19801031
US 1982-387721 A3 19820611
US 1984-680706 A3 19841212

OTHER SOURCE(S): MARPAT 95:126251
AB Thromboxane synthetase inhibitors such as imidazoles, 3-substituted pyrimidines, substituted indoles, 4-substituted pyrimidines, a substituted pyrazolidinedione and a substituted quinazolinone are effective in the treatment of obesity and in decreasing insulin levels in diabetic rats. Thus, 1-(2-isopropylphenyl)imidazole [25364-40-3] and 3-(imidazolomethyl)indole [19714-15-9] were effective compds. in decreasing body weight, food intake, and blood insulin concentration
IT 22760-18-5
RL: BIOL (Biological study)
(insulin and obesity reduction by, diabetes in relation to)

L5 ANSWER 152 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1981:508820 CAPLUS
DOCUMENT NUMBER: 95:108820
ORIGINAL REFERENCE NO.: 95:18125a,18128a
TITLE: Renal function and laboratory safety parameters after two weeks' administration of fluproquazone to man
AUTHOR(S): Crawford, M.; Thiel, G.
CORPORATE SOURCE: Int. Clin. Res., Sandoz Ltd., Basel, Switz.
SOURCE: Arzneimittel-Forschung (1981), 31(5A), 912-14
CODEN: ARZNAD; ISSN: 0004-4172
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



I

AB Tormosyl (fluproquazone)(I) [40507-23-1] given for 14 days (100 mg 3 times daily) to 6 healthy male volunteers produced no clin. relevant effects upon the subjects renal function, urine microscopic findings, blood coagulation status, or upon their general well-being as shown by a range of laboratory safety tests including haematol. profile and blood and urine biochem. Minor and transient side effects mainly affecting the gastrointestinal system were seen in 4 subjects.
IT 40507-23-1
RL: BIOL (Biological study)
(kidney function response to)
RN 40507-23-1 CAPLUS
CN 2(1H)-Quinazolinone, 4-(4-fluorophenyl)-7-methyl-1-(1-methylethyl)- (CA INDEX NAME)



L5 ANSWER 152 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

L5 ANSWER 153 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1981:508591 CAPLUS
DOCUMENT NUMBER: 95:108591
ORIGINAL REFERENCE NO.: 95:18069a,18072a
TITLE: Toxicological evaluation of fluproquazone
AUTHOR(S): Ruettimann, G.; Schoen, H.; Madoerin, M.; Van Ryzin, R. J.; Richardson, B. P.; Matter, B. E.
CORPORATE SOURCE: Preclin. Res. Toxicol., Sandoz Ltd., Basel, Switz.
SOURCE: Arzneimittel-Forschung (1981), 31(5A), 882-92
CODEN: ARZNAD; ISSN: 0004-4172
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



I

AB The toxicol. characteristics of Tormosyl (fluproquazone)(I) [40507-23-1] an analgesic with distinct antiinflammatory properties, were evaluated in acute and chronic toxicity studies as well as in reproduction toxicity, carcinogenicity and mutagenicity studies. The following overall results were obtained: the acute oral toxicity in mice, rats, and rabbits is of low order. In the chronic oral studies I was generally well tolerated when given to rats and dogs for 13 wk, to dogs and monkeys for 52 wk, to mice for 78 wk and to rats for 104 wk. In particular, there was no indication of gastrointestinal irritations or lesions in any of these studies. In dogs and rats showed the major target organs for I toxicity was the liver and kidney, where mild, reversible changes were observed These findings were considerably less severe than those found with several other antiphlogistic-analgesic compds. In the reproduction toxicity studies, the only drug-related effects seen in expts. on female fertility or peri- and postnatal development in rats were a prolongation of pregnancy and an impairment of delivery leading to an increased perinatal mortality. These findings may be related to an inhibition of prostaglandin synthesis by I. Similar effects are known to occur after administration of other inhibitors of prostaglandin synthesis. In rats and rabbits I did not reveal any embryolethal or tetratogenic effects. I had no mutagenic effects in either the micronucleus test and the dominant-lethal test using mice, or in the Ames-Test using Salmonella typhimurium. I has no carcinogenic potential in rats and mice.
IT 40507-23-1
RL: ADV (Adverse effect, including toxicity); BIOL (Biological study)

L5 ANSWER 153 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
(toxicity of)
RN 40507-23-1 CAPLUS
CN 2(1H)-Quinazolinone, 4-(4-fluorophenyl)-7-methyl-1-(1-methylethyl)- (CA INDEX NAME)



L5 ANSWER 154 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1981:508590 CAPLUS
DOCUMENT NUMBER: 95:108590
ORIGINAL REFERENCE NO.: 95:18069a,18072a
TITLE: The pharmacodynamic properties of fluproquazone
AUTHOR(S): Hill, R. C.; Foote, R. W.; Roemer, D.
CORPORATE SOURCE: Preclin. Res. Dep., Sandoz Ltd., Basel, Switz.
SOURCE: Arzneimittel-Forschung (1981), 31(5A), 873-82
CODEN: ARZNAD; ISSN: 0004-4172
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



I

AB Tormosyl (fluproquazone)(I) [40507-23-1] is a potent analgesic and antipyretic compound with antiinflammatory properties. It is effective in a variety of animal species, is active after oral and parenteral administration, and has a duration of action of several hours. I is many times more potent than acetylsalicylic acid (ASA) and generally resembles the clin. active ibuprofen and indoprofen in its pharmacodynamic effects. I is a very strong inhibitor of collagen and arachidonic acid-induced platelet aggregation. It causes mild central nervous system depressant effects in rodents only in very high doses and does not produce phys. dependence when administered i.v. over a period of 4 wk to rhesus monkeys. In the anesthetized dog, I causes minimal cardiovascular changes. In fasted rats, I is 3 times more ulcerogenic than ASA and ibuprofen and about half as potent as indoprofen, whereas after repeated administration for 5 consecutive days, I is by far the least toxic of the 4 compds. tested. At 3 times the acute UD50 (ulcerogenic dose), I does not produce any petechial hemorrhages and even after repeated administration of over 6 times the acute UD50 it only causes tiny gastric lesions. Comparison of the doses of the test compds. needed to cause analgesia and to inhibit yeast-induced pyrexia with the doses required to produce gastric lesions after acute and following repeated administration in the rat clearly shows that I has the greatest safety margin. It is evident from the results that the pharmacodynamic effects of I are due to a marked inhibition of the synthesis of prostaglandins and their metabolites as the order of potency of I and the 3 reference compds. in the prostaglandin synthetase assay correlates reasonably well with the rank order recorded in other tests.
IT 40507-23-1
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES

L5 ANSWER 154 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
(Uses)
(pharmacol. of)
RN 40507-23-1 CAPLUS
CN 2(1H)-Quinazolinone, 4-(4-fluorophenyl)-7-methyl-1-(1-methylethyl)- (CA INDEX NAME)



L5 ANSWER 155 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1981:508347 CAPLUS
DOCUMENT NUMBER: 95:108347
ORIGINAL REFERENCE NO.: 95:18009a,18012a
TITLE: The biotransformation of fluproquazone in man and several animal species
AUTHOR(S): Orwig, B. A.; Dugger, H. A.; Bhuta, S. I.; Talbot, K. C.; Schwarz, H. J.
CORPORATE SOURCE: Drug Metab. Sect., Sandoz, Inc., East Hanover, NJ, USA
SOURCE: Arzneimittel-Forschung (1981), 31(5A), 904-11
CODEN: ARZNAD; ISSN: 0004-4172
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



I

AB The biotransformation of tormosyl (fluproquazone)(I) [40507-23-1] was investigated in man, mouse, rat, rabbit, and dog. Single oral doses of [3H]fluproquazone (15 mg/kg) were administered to the animals. Human volunteers received 100 mg [3H]fluproquazone 3 times daily for 5 days (3.8 mg/kg). The human urinary metabolites of fluproquazone were separated and purified by a combination of extraction and liquid chromatog. on reversed-phase columns. Definitive structures were assigned to 5 metabolites. Fluproquazone and its metabolites were characterized and quantitated in the blood, urine, and feces of man, mouse, rat, rabbit, and dog by high-pressure liquid chromatog. coupled to a radioactivity monitor or by reverse isotope dilution anal. Significant quantities of fluproquazone were noted in the blood of all species. Two biotransformation pathways were identified. The major pathway was sequential oxidation with or without conjugation of the 7-Me group; aromatic hydroxylation and conjugation were a minor pathway.
IT 40507-23-1
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(metabolism of)

L5 ANSWER 155 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
RN 40507-23-1 CAPLUS
CN 2(1H)-Quinazolinone, 4-(4-fluorophenyl)-7-methyl-1-(1-methylethyl)- (CA INDEX NAME)



IT 79039-54-6 79039-55-7
RL: BIOL (Biological study)
(preparation as fluproquazone metabolite)
RN 79039-54-6 CAPLUS
CN 7-Quinazolinecarboxylic acid, 4-(4-fluorophenyl)-1,2-dihydro-1-(1-methylethyl)-2-oxo- (CA INDEX NAME)



RN 79039-55-7 CAPLUS
CN 2(1H)-Quinazolinone, 4-(4-fluorophenyl)-7-(hydroxymethyl)-1-(1-methylethyl)- (CA INDEX NAME)



L5 ANSWER 155 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

L5 ANSWER 156 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1981:508346 CAPLUS
DOCUMENT NUMBER: 95:108346
ORIGINAL REFERENCE NO.: 95:18009a,18012a
TITLE: Absorption, distribution, and excretion of fluproquazone in several animal species
AUTHOR(S): Williams, J. I.; Bhuta, S. I.; Jaffe, J. M.; Migdalof, B. H.; Schwarz, H. J.; Talbot, K. C.; Brouillard, J. F.; Donatsch, P.; Hodel, C.; et al.
CORPORATE SOURCE: Drug Metab. Sect., Sandoz, Inc., East Hanover, NJ, USA
SOURCE: Arzneimittel-Forschung (1981), 31(5A), 897-904
CODEN: ARZNAD; ISSN: 0004-4172
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



I

AB Single oral doses of 3H-labeled Tormosyl (fluproquazone)(I) [40507-23-1], were administered to mice, rats, rabbits, and dogs (10 and/or 15 mg/kg). I.v. doses were administered to rats at 1.5 mg/kg and to mice, rabbits and dogs at 5 mg/kg. Multiple oral doses of non-radiolabeled I were studied in the rat (15 and 45 mg/kg/day) and dog (5, 15, and 50 mg/kg/day). I-14C was administered orally to rats (10 mg/kg) for whole-body autoradiog. studies. I was well absorbed in all species but the dog in which .apprx.50% of the dose was absorbed. Peak blood concns. of radioactivity were measured at 30 min (mouse) and 2-4 h (rat, rabbit, dog). Radioactivity was present in all tissues examined after oral or i.v. administration to mice and rats. Except for liver and kidney, which had higher concns., most tissue levels were in the range of the corresponding blood levels. No evidence of accumulation or retention in any tissue was noted. Elimination of radioactivity from blood and tissues was significantly faster in male rats than in females. In the rat chronic administration resulted in changes in pharmacokinetic parameters, possibly due to enzyme induction. Pharmacokinetic parameters did not change after chronic administration in the dog. Radioactivity was transmitted to the fetuses of orally dosed pregnant rats and rabbits. I and its metabolites were secreted in the milk of orally dosed lactating rats at concns. greater than those of the blood and were transferred to the nursing neonates. Excretion in urine and feces was rapid in all species after both oral and i.v. dosing. Urinary excretion was the major excretory pathway in the mouse and rabbit and fecal excretion was dominant

L5 ANSWER 156 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
in rat and dog.
IT 40507-23-1
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(metabolism and pharmacokinetics of, species in relation to)
RN 40507-23-1 CAPLUS
CN 2(1H)-Quinazolinone, 4-(4-fluorophenyl)-7-methyl-1-(1-methylethyl)- (CA INDEX NAME)



L5 ANSWER 157 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1981:508276 CAPLUS
DOCUMENT NUMBER: 95:108276
ORIGINAL REFERENCE NO.: 95:17993a,17996a
TITLE: An automated fluorimetric method for the determination of fluproquazone in plasma and urine
AUTHOR(S): Pacha, W.; Delaborde, C.; Keller, H. P.; Meier, J.; Rietsch, H.
CORPORATE SOURCE: Div. Pharm. Res. Dev., Sandoz Ltd., Basel, Switz.
SOURCE: Arzneimittel-Forschung (1981), 31(5A), 893-6
CODEN: ARZNAD; ISSN: 0004-4172
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



I

AB A rapid and sensitive fluorimetric assay was developed for the quant. determination of Tormosyl (fluproquazone)(I) [40507-23-1] in plasma and urine. The unchanged drug was extracted from alkalinized plasma or urine into n-heptane containing 0-1.5% isoamyl alc. followed by a back extraction into 5 N HCl. After oxidation with potassium persulfate the fluorescence measurements were taken at 326 nm excitation and 520 nm emission. Detection limits were about 15 ng/mL plasma and 6 ng/mL urine, using 1 mL plasma and 2 mL urine, resp. The automated assay had a 5 times higher sample capacity and better reproducibility than the manual assay. The method was applied to animal studies including assays in milk and proved to be suitable in human studies after oral doses in the therapeutical range.
IT 40507-23-1
RL: ANT (Analyte); ANST (Analytical study)
(determination of, in plasma and urine by fluorometry)
RN 40507-23-1 CAPLUS
CN 2(1H)-Quinazolinone, 4-(4-fluorophenyl)-7-methyl-1-(1-methylethyl)- (CA INDEX NAME)

L5 ANSWER 157 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



L5 ANSWER 158 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1981:490873 CAPLUS
DOCUMENT NUMBER: 95:90873
ORIGINAL REFERENCE NO.: 95:15179a,15182a
TITLE: Effects of fluproquazone on platelet aggregation in man
AUTHOR(S): Beveridge, T.; Crawford, M.
CORPORATE SOURCE: Clin. Res. Dep., Sandoz Ltd., Basel, Switz.
SOURCE: Arzneimittel-Forschung (1981), 31(5A), 937-40
CODEN: ARZNAD; ISSN: 0004-4172
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



I

AB Turbidimetric investigations on platelets from healthy volunteers showed inhibitory effects Tormosyl (fluproquazone)(I) [40507-23-1] and acetylsalicylic acid (ASA) on both the extent and the velocity of aggregation induced by collagen. The threshold concentration of arachidonic acid
needed to induce aggregation was also raised after fluproquazone was given
to donors. Whereas the inhibitory effects of fluproquazone disappear within 24 h, the qual. similar effects of ASA are much longer lasting (72-96 h). There is no evidence for enhancement of the effects of fluproquazone following 4 days of administration (100 mg, 3 times daily).
IT 40507-23-1
RL: BIOL (Biological study)
(platelet aggregation response to)
RN 40507-23-1 CAPLUS
CN 2(1H)-Quinazolinone, 4-(4-fluorophenyl)-7-methyl-1-(1-methylethyl)- (CA INDEX NAME)

L5 ANSWER 158 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



L5 ANSWER 159 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1981:216539 CAPLUS
DOCUMENT NUMBER: 94:216539
ORIGINAL REFERENCE NO.: 94:35307a,35310a
TITLE: Polarographic reduction of 7-chloro-5-phenyl-2-thioxo-1H-2,3-dihydro-1,3,4-benzotriazepine
AUTHOR(S): Pflegel, P.; Kuehmstedt, Christa; Richter, P.
CORPORATE SOURCE: Sekt. Pharm., Ernst-Moritz-Arndt-Univ. Greifswald, Greifswald, Ger. Dem. Rep.
SOURCE: Pharmazie (1981), 36(1), 65-6
CODEN: PHARAT; ISSN: 0031-7144
DOCUMENT TYPE: Journal
LANGUAGE: German
AB The title compound was prepared using a known method and the reduction was carried
out using a previously described apparatus and method. To carry out the reduction
50 mg of 7-chloro-5-phenyl-2-thioxo-1H-2,3-dihydro-1,3,4-benzotriazepine [73549-45-8] was dissolved in 70 mL EtOH and brought to pH 4.6 with acetate buffer. After 1-2 h reduction
bis(6-chloro-4-phenyl-2-thioxo-1,2-dihydroquinazolin-1-yl) (I) [77485-01-9] precipitated from the solution
The reduction continued for a total of 5 h at which time I was separated and dried
as was also 3-chloro-4-phenyl-2-thioxo-1,2,3,4-tetrahydroquinazoline [77485-02-0].
IT 77485-01-9P
RL: RCT (Reactant); PREP (Preparation); RACT (Reactant or reagent)
(synthesis of, by electrochem. reduction)
RN 77485-01-9 CAPLUS
CN [1,1'(2H,2'H)-Biquinazoline]-2,2'-dithione, 6,6'-dichloro-4,4'-diphenyl- (CA INDEX NAME)



L5 ANSWER 160 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1981:202650 CAPLUS
DOCUMENT NUMBER: 94:202650
ORIGINAL REFERENCE NO.: 94:33047a,33050a
TITLE: The toxicology profile of the antiinflammatory drug proquazone in animals
AUTHOR(S): Van Ryzin, R. J.; Trapold, J. H.
CORPORATE SOURCE: Sandoz Pharm., East Hanover, NJ, 07936, USA
SOURCE: Drug and Chemical Toxicology (1977) (1980), 3(4), 361-79
CODEN: DCTODJ; ISSN: 0148-0545
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



I

AB Proquazone (I) [22760-18-5] is a chemical distinctive non-steroidal antiinflammatory drug (NSAID) and is orally effective as an antiinflammatory, analgesic and anti-pyretic in animals. As with other NSAID's the main toxic effect was gastrointestinal irritation with sequela. Comparative relative potency of proquazone with other NSAID's with regard to gastrointestinal effects was: rat-indomethacin > naproxen =
proquazone > phenylbutazone; dog-indomethacin > naproxen > proquazone > phenylbutazone. In addition to gastrointestinal effects in minipigs, inflammatory renal changes occurred; renal changes also occurred in pigs treated with phenylbutazone. No evidence of carcinogenicity was seen in rodent oncogenicity studies. Evidence of teratogenicity was not seen in rat and rabbit teratol. studies. In reproduction/perinatal studies in rats
dose levels that induced intestinal lesions in the dams resulted in decreased survival of young to weaning. A major human metabolite of proquazone, the m-hydroxy [65765-07-3] derivative, was shown to be less toxic than the parent compound
IT 65765-07-3
RL: BIOL (Biological study)
(as proquazone metabolite.)
RN 65765-07-3 CAPLUS
CN 2(1H)-Quinazolinone, 4-(3-hydroxyphenyl)-7-methyl-1-(1-methylethyl)- (CA INDEX NAME)

L5 ANSWER 160 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



IT 22760-18-5
RL: ADV (Adverse effect, including toxicity); BIOL (Biological study)
(toxicity of)
RN 22760-18-5 CAPLUS
CN 2(1H)-Quinazolinone, 7-methyl-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)



L5 ANSWER 161 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1981:149992 CAPLUS
DOCUMENT NUMBER: 94:149992
ORIGINAL REFERENCE NO.: 94:24379a,24382a
TITLE: Protein binding and erythrocyte partitioning of the antirheumatic proquazone
AUTHOR(S): Roos, Andre; Hinderling, Peter H.
CORPORATE SOURCE: Biocent., Univ. Basel, Basel, 4056, Switz.
SOURCE: Journal of Pharmaceutical Sciences (1981), 70(3), 252-7
CODEN: JPMSAE; ISSN: 0022-3549
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



I

AB The kinetics of proquazone (I) [22760-18-5], a new nonacidic nonsteroidal antiinflammatory drug, was investigated by equilibrium dialysis and red blood partitioning methods on human blood and its subcompartments: erythrocytes, plasma, and plasma water. The binding of this lipophilic compound to plasma proteins and albumin was high (98%) and was not concentration-dependent or altered in the presence of large concns. of metabolites. The plasma protein binding of proquazone increased with increasing pH. The apparent solubility of the hydrophobic drug was largely increased in buffers in which albumin was admixed in high concns. Albumin as a biol. solubilizer permits i.v. administration of significantly larger amts. of the drug. The erythrocyte-buffer partition coefficient averaged 5.5 and was pH dependent. Equilibrium between red blood cells and the buffer was obtained quickly after drug addition (<2 min). The erythrocyte-plasma partition coefficient value of 0.09 indicated that only unbound drug partitions into red cells.
IT 22760-18-5
RL: PROC (Process)
(erythrocyte partitioning and protein binding of)
RN 22760-18-5 CAPLUS
CN 2(1H)-Quinazolinone, 7-methyl-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)

L5 ANSWER 161 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



L5 ANSWER 162 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1981:149864 CAPLUS
DOCUMENT NUMBER: 94:149864
ORIGINAL REFERENCE NO.: 94:24347a,24350a
TITLE: Application of column switching in high-performance liquid chromatography to on-line sample preparation for complex separations
AUTHOR(S): Erni, F.; Keller, H. P.; Morin, C.; Schmitt, M.
CORPORATE SOURCE: Anal. Res. Dev., Sandoz Ltd., Basel, Switz.
SOURCE: Journal of Chromatography (1981), 204, 65-76
CODEN: JOCRAM; ISSN: 0021-9673
DOCUMENT TYPE: Journal
LANGUAGE: English
AB A flexible column-switching set-up for high-performance liquid chromatog. (HPLC) which uses 2 6-port valves as switching devices is presented. The apparatus is suitable for automation and can easily be put together from com. available components. The arrangement can be used for different kinds of cuts (front-cut, heart-cut, end-cut), for back-flushing, and for on-line concentration Varying the separation parameters with gradient elution and/or different stationary phases in the sub-separation systems offers many possibilities, including 2-dimensional HPLC. The set-up presented proved to be valuable both during optimization and for routine work. Applications of this technique to the anal. of biol. samples (animal feed, urine, plasma, etc.) for drugs are discussed. They demonstrate that a chromatog. clean-up is very efficient and may be the method of choice when the compds. to be analyzed are chemical labile and when there is a high risk of artifact formation with classical clean-up techniques.
IT 40507-23-1
RL: ANT (Analyte); ANST (Analytical study)
(determination of, in feed by high-performance liquid chromatog. with column switching)
RN 40507-23-1 CAPLUS
CN 2(1H)-Quinazolinone, 4-(4-fluorophenyl)-7-methyl-1-(1-methylethyl)- (CA INDEX NAME)



L5 ANSWER 163 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1981:121593 CAPLUS
DOCUMENT NUMBER: 94:121593
ORIGINAL REFERENCE NO.: 94:19891a,19894a
TITLE: 1,4-Disubstituted-1,2-dihydroquinazolin-1-ones
PATENT ASSIGNEE(S): Shionogi and Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 3 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 55141472	A	19801105	JP 1979-50628	19790423
PRIORITY APPLN. INFO.:			JP 1979-50628 A	19790423

OTHER SOURCE(S): CASREACT 94:121593
GI



I II

AB Quinazolinones I (R = H, alkyl, alkoxy, halogen; R1 = alkyl, alkoxy, halogen; R2 = H, halogen) were prepared Thus, refluxing 5.34 g aminobenzophenone II (R3 = H) in 70 mL CHCl3 with 12.9 mL 2.45 M BrCN in MeCN gave 5.11 g II (R3 = CN), which was treated with 2 N HCl at 100° to give I (R = 7-Me, R1 = Me2CH, R2 = Ph).
IT 17629-04-8P 22760-18-5P 40507-23-1P
76854-08-5P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 17629-04-8 CAPLUS
CN 2(1H)-Quinazolinone, 1-methyl-4-phenyl- (CA INDEX NAME)



RN 22760-18-5 CAPLUS

L5 ANSWER 163 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
CN 2(1H)-Quinazolinone, 7-methyl-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)



RN 40507-23-1 CAPLUS
CN 2(1H)-Quinazolinone, 4-(4-fluorophenyl)-7-methyl-1-(1-methylethyl)- (CA INDEX NAME)



RN 76854-08-5 CAPLUS
CN 2(1H)-Quinazolinone, 8-methoxy-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)



L5 ANSWER 164 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1981:121443 CAPLUS
DOCUMENT NUMBER: 94:121443
ORIGINAL REFERENCE NO.: 94:19859a,19862a
TITLE: A new route to 4-phenyl-2(1H)-quinazolinones; reactions of 2-aminobenzophenones with chlorosulfonyl isocyanate
AUTHOR(S): Kamal, Ahmed; Rao, K Rama; Sattur, P. B.
CORPORATE SOURCE: Reg. Res. Lab., Hyderabad, 500009, India
SOURCE: Synthetic Communications (1980), 10(10), 799-804
CODEN: SYNCAV; ISSN: 0039-7911
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 94:121443
GI



I II

AB Phenylquinazolinones I (R = H, Me; R1, R2 = H, Cl) were prepared in 66-81% yield by condensing aminobenzophenones II with ClO2SNCO.
IT 17629-04-8P 20927-53-1P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 17629-04-8 CAPLUS
CN 2(1H)-Quinazolinone, 1-methyl-4-phenyl- (CA INDEX NAME)



RN 20927-53-1 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-1-methyl-4-phenyl- (CA INDEX NAME)

L5 ANSWER 164 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



L5 ANSWER 165 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1981:114296 CAPLUS
DOCUMENT NUMBER: 94:114296
ORIGINAL REFERENCE NO.: 94:18527a,18530a
TITLE: A radioassay for proteolytic cleavage of isolated cartilage proteoglycan. 2. Inhibition of human leukocyte elastase and cathepsin G by antiinflammatory drugs
AUTHOR(S): Stephens, R. W.; Walton, E. A.; Ghosh, P.; Taylor, T. K. F.; Gramse, M.; Havemann, K.
CORPORATE SOURCE: Raymond Purves Res. Lab., R. North Shore Hosp., Sydney, Australia
SOURCE: Arzneimittel-Forschung (1980), 30(12), 2108-12
CODEN: ARZNAD; ISSN: 0004-4172
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Twenty nonsteroidal antiinflammatory drugs and other agents were evaluated for their effectiveness in directly inhibiting the proteolytic activity of human leukocyte elastase and cathepsin G. The proteolysis of hide powder azure by leukocyte granule exts. was used for initial testing, and selected drugs were then studied further using a radioassay of the proteolysis of isolated proteoglycan by purified leukocyte elastase and cathepsin G. The results indicated that at drug concns. likely to be attained in vivo, phenylbutazone may significantly inhibit elastase, while gold thiomalate and Arteparon (mucopolysaccharide polysulfonic acid ester) could limit the action of cathepsin G. Oleic acid may provide a useful starting point for development of agents specifically designed to inhibit cartilage erosion.
IT 22760-18-5
RL: BIOL (Biological study)
(cathepsin G and elastase of leukocytes response to, cartilage proteoglycan cleavage in relation to)
RN 22760-18-5 CAPLUS
CN 2(1H)-Quinazolinone, 7-methyl-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)



L5 ANSWER 166 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1981:7766 CAPLUS
DOCUMENT NUMBER: 94:7766
ORIGINAL REFERENCE NO.: 94:1311a
TITLE: Pharmaceutical for treating a benign prostate adenoma
PATENT ASSIGNEE(S): Roecar Holdings (Netherlands Antilles) N.V., Neth.
SOURCE: Fr. Demande, 9 pp.
CODEN: FRXXBL
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
FR 2437838	A1	19800430	FR 1978-23535	19780809
PRIORITY APPLN. INFO.:			DE 1978-2832531 A	19780725

OTHER SOURCE(S): MARPAT 94:7766
AB Compds. such as salicylic acid derivs., capable of inhibiting or reducing the biosynthesis of prostaglandins are used effectively in the treatment of benign prostate adenoma. Among the compds. used were acetylsalicylic acid [50-78-2] (3000-6000 mg), mephenaminic acid [61-68-7] (1000 mg), diclofenac [15307-86-5] (75-150 mg), azapropazone [13539-59-8] (900-1800 mg), sulindac [38194-50-2] (300-400 mg), and proquazone [22760-18-5] (600-1200 mg).
IT 22760-18-5
RL: BIOL (Biological study)
(benign prostate adenoma treatment by)
RN 22760-18-5 CAPLUS
CN 2(1H)-Quinazolinone, 7-methyl-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)



L5 ANSWER 167 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1981:554 CAPLUS
DOCUMENT NUMBER: 94:554
ORIGINAL REFERENCE NO.: 94:122h,123a
TITLE: Modification of EAE by nonsteroidal anti-inflammatory drugs
AUTHOR(S): Bolton, C.; Cuzner, M. L.
CORPORATE SOURCE: Inst. Neurol., Natl. Hosp., London, WC1 3BG, UK
SOURCE: Suppr. Exp. Allerg. Encephalomyelitis Mult. Scler., [Proc. Liversedge Symp.] (1980), Meeting Date 1979, 189-97. Editor(s): Davison, Alan Nelson; Cuzner, M. L. Academic: London, Engl.
CODEN: 44LDAA
DOCUMENT TYPE: Conference
LANGUAGE: English
GI



I

AB In guinea pigs with hyperacute exptl. allergic encephalomyelitis (EAE) prophylactic or therapeutic administration of the nonsteroidal antiinflammatory drugs indomethacin [53-86-1], flurbiprofen [5104-49-4], and RF 46-790 [40507-23-1] increased the severity of the disease. However, 16,16-dimethyl PGE2 (I) [39746-25-3] inhibited it. The suppressive effect could not be repeated with prostaglandin precursors or with drugs which increased the conversion to E-type prostaglandins. The lymphotoxic drug cyclosporin A [59865-13-3] was the most effective immunosuppressant and had greater prophylactic than therapeutic activity.
IT 40507-23-1
RL: BIOL (Biological study)
(encephalomyelitis response to)
RN 40507-23-1 CAPLUS
CN 2(1H)-Quinazolinone, 4-(4-fluorophenyl)-7-methyl-1-(1-methylethyl)- (CA INDEX NAME)

L5 ANSWER 167 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



L5 ANSWER 168 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1981:51 CAPLUS
DOCUMENT NUMBER: 94:51
ORIGINAL REFERENCE NO.: 94:3a,6a
TITLE: High-performance liquid chromatographic column switching technique in the analysis of medicated feed for an automated clean-up procedure
AUTHOR(S): Gfeller, J. C.; Stockmeyer, M.
CORPORATE SOURCE: Pharm. Dep., Sandoz Ltd., Basel, CH-4002, Switz.
SOURCE: Journal of Chromatography (1980), 198(2), 162-8
CODEN: JOCRAM; ISSN: 0021-9673
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



AB A high-performance liquid chromatog. column switching technique for sample clean-up treatment was used for the determination of Fluorproquazone (I) [40507-23-1] in medicated feed. Methanol was used for the extraction of I from feed. The samples were chromatographed on a LiChrosorb RP-8 column with a mobile phase consisting of MeOH-AcOH and a LiChrosorb RP-18 column was used for the sample clean-up. The sample exts. were treated on a pre-column with different methanolic mobile phases before separation on the anal. column. Water was used for the clean-up procedure. I was detected at 240 nm. The limit of detection was .apprx.5 ppm. Recovery studies of spiked feed exts. indicate a recovery ≥95%. Samples were stable for up to 2 wk at temps. from -25° - 23°. The column switching technique for sample clean-up treatment is very efficient for the determination of I in medicated feed. The method is simple, sensitive, reproducible, and rapid.
IT 40507-23-1
RL: ANT (Analyte); ANST (Analytical study)
(determination of, in feed by high-performance liquid chromatog. column switching technique)
RN 40507-23-1 CAPLUS
CN 2(1H)-Quinazolinone, 4-(4-fluorophenyl)-7-methyl-1-(1-methylethyl)- (CA INDEX NAME)

L5 ANSWER 168 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



L5 ANSWER 169 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1980:604682 CAPLUS
DOCUMENT NUMBER: 93:204682
ORIGINAL REFERENCE NO.: 93:32665a,32668a
TITLE: Quinazolinone derivatives
PATENT ASSIGNEE(S): Rousssel-UCLAF, Fr.
SOURCE: Jpn. Tokkyo Koho, 6 pp.
CODEN: JAXXAD
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 55005505	B	19800207	JP 1971-89492	19711111
PRIORITY APPLN. INFO.:			JP 1971-89492 A	19711111

GI



AB Quinazolinone derivs. (I; R = NH2, CN, CO2H, alkoxycarbonyl), effective antiinflammatants and analgesics at 100 mg-2.5 g/day in adults, were prepared Thus, 9.8 g I (R = NO2) in HCl was reduced with 27 g SnCl2 to give 380 mg I (R = NH2), which (5 g) was diazotized with NaNO2 in HNO3 and treated with CuCN solution to give 1.80 g I (R = CN) (II). Hydrolysis of 5.4 g II in refluxing HCl gave 70% acid (I; R = CO2H), which (2.4 g) was esterified with CH2N2 in CH2Cl2 to give 80% Me ester (I; R = CO2Me).
IT 75388-60-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and cyanation of)
RN 75388-60-2 CAPLUS
CN 2(1H)-Quinazolinone, 6-amino-1-methyl-4-phenyl- (CA INDEX NAME)



IT 75388-61-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

L5 ANSWER 169 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
(prepn. and hydrolysis of)
RN 75388-61-3 CAPLUS
CN 6-Quinazolinecarbonitrile, 1,2-dihydro-1-methyl-2-oxo-4-phenyl- (CA INDEX NAME)



IT 75388-62-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and methylation of)
RN 75388-62-4 CAPLUS
CN 6-Quinazolinecarboxylic acid, 1,2-dihydro-1-methyl-2-oxo-4-phenyl- (CA INDEX NAME)



IT 75388-63-5P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 75388-63-5 CAPLUS
CN 6-Quinazolinecarboxylic acid, 1,2-dihydro-1-methyl-2-oxo-4-phenyl-, methyl ester (CA INDEX NAME)



IT 26953-46-8
RL: RCT (Reactant); RACT (Reactant or reagent)
(reduction of)
RN 26953-46-8 CAPLUS

L5 ANSWER 169 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
CN 2(1H)-Quinazolinone, 1-methyl-6-nitro-4-phenyl- (CA INDEX NAME)



L5 ANSWER 170 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1980:586401 CAPLUS
DOCUMENT NUMBER: 93:186401
ORIGINAL REFERENCE NO.: 93:29719a,29722a
TITLE: 1-Polyhaloalkyl-2(1H)quinazolinone derivatives
INVENTOR(S): Inaba, Shigeho; Ishizumi, Kikuo; Mori, Kazuo; Yamamoto, Hisao; Yamamoto, Michihiro
PATENT ASSIGNEE(S): Sumitomo Chemical Co., Ltd., Japan
SOURCE: U.S., 6 pp. Cont.-in-part of U.S. Ser. No. 153,031, abandoned.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 4202895	A	19800513	US 1974-479464	19740614
PRIORITY APPLN. INFO.:			US 1971-153031	A2 19710604

OTHER SOURCE(S): MARPAT 93:186401
GI



I

AB The quinazolinones I (R = C2-3 polyalkyl containing 2 F atoms; R1, R2, R3 = H, C1-4 alkyl, C1-4 alkoxy, NO2, F3C, halo) were prepared Thus, 5.13 g 4-phenyl-6-chloro-2(1H)-quinazolinone was treated with F3CCH2I to give 3-5 g I (R = F3CCH2, R1 = 6-Cl, R2 = R3 = H) (II) and 2 g 2-(2,2,2-trifluoroethoxy)-4-phenyl-6-chloroquinazoline; II was also prepared by cyclization of 5,2-Cl(F3CCH2NH)C6H3COPh with Et carbamate. I were antiinflammatory and analgesic (no data).
IT 36943-01-8 59253-64-4 59253-65-5
74856-20-5 74856-21-6
RL: RCT (Reactant); RACT (Reactant or reagent)
(dehydrogenation of)
RN 36943-01-8 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-3,4-dihydro-4-phenyl-1-(2,2,2-trifluoroethyl)- (CA INDEX NAME)

L5 ANSWER 170 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 59253-64-4 CAPLUS
CN 2(1H)-Quinazolinone, 3,4-dihydro-6-methoxy-4-phenyl-1-(2,2,2-trifluoroethyl)- (CA INDEX NAME)



RN 59253-65-5 CAPLUS
CN 2(1H)-Quinazolinone, 3,4-dihydro-6-nitro-4-phenyl-1-(2,2,2-trifluoroethyl)- (CA INDEX NAME)



RN 74856-20-5 CAPLUS
CN 2(1H)-Quinazolinone, 1-(1,1-difluoroethyl)-3,4-dihydro-6-nitro-4-phenyl- (CA INDEX NAME)



RN 74856-21-6 CAPLUS
CN 2(1H)-Quinazolinone, 3,4-dihydro-6-methoxy-4-phenyl-1-(2,2,2-

L5 ANSWER 170 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
trichloroethyl)- (CA INDEX NAME)



IT 63930-33-6
RL: RCT (Reactant); RACT (Reactant or reagent)
(oxidation of)
RN 63930-33-6 CAPLUS
CN 2(1H)-Quinazolinethione, 6-chloro-3,4-dihydro-4-phenyl-1-(2,2,2-trifluoroethyl)- (CA INDEX NAME)



IT 37554-40-8P 40852-44-6P 40852-52-6P
49830-89-9P 52505-75-6P 59253-70-2P
74856-11-4P 74856-13-6P 74856-15-8P
74856-16-9P 74856-25-0P 74856-26-1P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 37554-40-8 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-4-phenyl-1-(2,2,2-trifluoroethyl)- (CA INDEX NAME)



RN 40852-44-6 CAPLUS
CN 2(1H)-Quinazolinone, 6-nitro-4-phenyl-1-(2,2,2-trifluoroethyl)- (CA INDEX
NAME)

L5 ANSWER 170 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 40852-52-6 CAPLUS
CN 2(1H)-Quinazolinone, 4-phenyl-1-(2,2,2-trifluoroethyl)- (CA INDEX NAME)



RN 49830-89-9 CAPLUS
CN 2(1H)-Quinazolinone, 6-methoxy-4-phenyl-1-(2,2,2-trifluoroethyl)- (CA INDEX NAME)



RN 52505-75-6 CAPLUS
CN 2(1H)-Quinazolinone, 6-methyl-1-(2,2,3,3,3-pentafluoropropyl)-4-phenyl- (CA INDEX NAME)



L5 ANSWER 170 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 74856-16-9 CAPLUS
CN 2(1H)-Quinazolinone, 6-methoxy-4-phenyl-1-(2,2,2-trichloroethyl)- (CA INDEX NAME)



RN 74856-25-0 CAPLUS
CN 2(1H)-Quinazolinone, 6-bromo-4-phenyl-1-(2,2,2-trifluoroethyl)- (CA INDEX NAME)



RN 74856-26-1 CAPLUS
CN 2(1H)-Quinazolinone, 6,8-dichloro-4-phenyl-1-(2,2,2-trifluoroethyl)- (CA INDEX NAME)



L5 ANSWER 170 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 59253-70-2 CAPLUS
CN 2(1H)-Quinazolinone, 6-methyl-4-phenyl-1-(2,2,2-trifluoroethyl)- (CA INDEX NAME)



RN 74856-11-4 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-4-(2-fluorophenyl)-1-(2,2,2-trifluoroethyl)- (CA INDEX NAME)



RN 74856-13-6 CAPLUS
CN 2(1H)-Quinazolinone, 4-phenyl-1-(2,2,2-trifluoroethyl)-6-(trifluoromethyl)- (CA INDEX NAME)

RN 74856-15-8 CAPLUS
CN 2(1H)-Quinazolinone, 1-(1,1-difluoroethyl)-6-nitro-4-phenyl- (CA INDEX NAME)

L5 ANSWER 171 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1980:560979 CAPLUS
DOCUMENT NUMBER: 93:160979
ORIGINAL REFERENCE NO.: 93:25497a,25500a
TITLE: Effects of wortmannines, cyclo-oxgenase inhibitors, and dexamethasone on enzyme secretion by macrophages
AUTHOR(S): Baggiolini, M.; Dewald, B.; Schnyder, J.
CORPORATE SOURCE: Preclin. Res., Sandoz Ltd., Basel, Switz.
SOURCE: British Journal of Pharmacology (1980), 69(2), 269P-270P
CODEN: BJPCBM; ISSN: 0007-1188
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Dexamethasone [50-02-2] (0.1 or 1.0 mM) blocked plasminogen (I) [9001-91-6] activator secretion and reproducibly lowered release of lysosomal glycosides by 40-80% from mouse peritoneal macrophages. Wortmannin (II) derivs. (1-10 μM) also blocked I activator secretion and also lowered lysozyme release, but had virtually no effect on lysosomal hydrolases, and did not inhibit cyclooxygenase. Indomethacin [53-86-1], diclofenac [15307-86-5], and proquazone [22760-18-5] (all 0.1-1.0 μM) all enhanced I activator secretion by 40-100%, but the release of the other enzymes was unchanged. Steroidal and nonsteroidal antiinflammatory compds. had opposite effects on I activator secretion by macrophages. In this respect, the effects of II derivs. resemble those of glucocorticosteroids.

IT 22760-18-5
RL: BIOL (Biological study)
(plasminogen activator secretion by macrophages enhancement by)

RN 22760-18-5 CAPLUS
CN 2(1H)-Quinazolinone, 7-methyl-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)



L5 ANSWER 172 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1980:555856 CAPLUS
DOCUMENT NUMBER: 93:155856
ORIGINAL REFERENCE NO.: 93:24735a,24738a
TITLE: Pharmaceutical administration forms
INVENTOR(S): DeBuman, Alain; Riva, Aldo; Sucker, Heinz
PATENT ASSIGNEE(S): Sandoz-Patent-G.m.b.H., Switz.
SOURCE: Ger. Offen., 13 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2914163	A1	19800410	DE 1979-2914163	19790407
DE 2914163	C2	19821118		
ES 479565	A1	19790716	ES 1979-479565	19790411
FR 2437204	A1	19800425	FR 1979-9158	19790411
FR 2437204	B1	19850726		
AT 7902699	A	19831015	AT 1979-2699	19790411
AT 374680	B	19840525		
NL 7903065	A	19800401	NL 1979-3065	19790419
JP 55049310	A	19800409	JP 1979-51997	19790425
JP 62027046	B	19870612		
DK 7903933	A	19800330	DK 1979-3933	19790920
SE 7907795	A	19800330	SE 1979-7795	19790920
SE 439243	B	19850610		
SE 439243	C	19850919		
FI 68762	B	19850731	FI 1979-2927	19790920
FI 68762	C	19851111		
NO 7903034	A	19800401	NO 1979-3034	19790921
NO 153553	B	19860106		
NO 153553	C	19860416		
CA 1134268	A1	19821026	CA 1979-336504	19790927
AU 7951287	A	19800403	AU 1979-51287	19790928
AU 530954	B2	19830804		
DD 146248	A5	19810204	DD 1979-215888	19790928
HU 22627	A2	19820628	HU 1979-SA3201	19790928
HU 180291	B	19830228		
CS 219258	B2	19830325	CS 1979-6590	19790928

PRIORITY APPLN. INFO.: CH 1978-10194 A 19780929

AB Suppositories are prepared by compression at low temps. (<10°) to avoid problems associated with high temperature m.-molding processes, e.g., drug decomposition and sedimentation. There is no need for binders in the concns.
The humidity should be controlled to avoid H2O crystallization propyphenazone [479-92-5], butalbital [77-26-9] and anhydrous caffeine [58-08-2] were mixed, sieved, and mixed and stirred with pulverized Witepsol H15 with cooling (H2O). The cooling H2O was heated to 40°. Large lumps were formed upon continued stirring. The mass was removed and cooled to 40, sieved to a 1.6 mm mesh granulate and compressed at -10 to 5° to give suppositories.
IT 22760-18-5
RL: BIOL (Biological study)
(suppositories containing, cold compression of)
RN 22760-18-5 CAPLUS
CN 2(1H)-Quinazolinone, 7-methyl-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)



L5 ANSWER 173 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1980:525572 CAPLUS
DOCUMENT NUMBER: 93:125572
ORIGINAL REFERENCE NO.: 93:19873a,19876a
TITLE: Study on small intestine lesions induced by nonsteroidal anti-inflammatory drugs. I. Effect of single administration of various nonsteroidal anti-inflammatory drugs and influence of fasting or bile-duct ligation on it in rats
AUTHOR(S): Kyuki, Kohei
CORPORATE SOURCE: Sch. Med., Gifu Univ., Gifu, Japan
SOURCE: Gifu Daigaku Igakubu Kiyo (1980), 28(2), 141-51
CODEN: GDIKAN; ISSN: 0072-4521
DOCUMENT TYPE: Journal
LANGUAGE: Japanese

AB At 48 h following oral or parental administration of nonsteroidal antiinflammatory drugs to rats, the indole, phenylacetic acid, and anthranillic acid derivs. produced intestinal ulcers, whereas the pyrazolidinedione derivs., salicylates, and basic compds. had no effect. The active compds. were indomethacin [53-86-1], ketoprofen, ibuprofen [15687-27-1], diclofenac-Na [15307-79-6], flufenamic acid [530-78-9], mefenamic acid [61-68-7], TAI-284 [28968-09-4], and benoxaprofen [51234-28-7], whereas the inactive compds. were phenylbutazone [50-33-9], oxyphenbutazone [129-20-4], Na salicylate [54-21-7], salicylic acid [69-72-7], aspirin [50-78-2], mepirizone [20326-12-9], and proquazone [22760-18-5]. Thus, intestinal lesions may be produced by different mechanisms then stomach ulcers. Thus, intestinal lesions caused by parental administration of the nonsteroidal antiinflammatory drugs were similar to those produced by oral administration. The intestinal lesions were decreased by starvation of the rat and were prevented by ligation of the bile duct. Thus, biliary excretion and enterohepatic circulation of nonsteroidal antiinflammatory drugs is the important factor in causing intestinal lesions.
IT 22760-18-5
RL: BIOL (Biological study)
(intestinal lesions in relation to)
RN 22760-18-5 CAPLUS
CN 2(1H)-Quinazolinone, 7-methyl-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)



L5 ANSWER 174 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1980:514469 CAPLUS
DOCUMENT NUMBER: 93:114469
ORIGINAL REFERENCE NO.: 93:18329a,18332a
TITLE: 1,4-Benzodiazepines and 1,5-benzodiazocines. III. Oxidation of a 2-(chloromethyl)-1,4-benzodiazepine derivative
AUTHOR(S): Milkowski, W.; Hueschens, R.; Kuchenbecker, H.
CORPORATE SOURCE: Sparte Pharma, Kali-Chem. A.-G., Hannover, D-3000, Fed. Rep. Ger.
SOURCE: Journal of Heterocyclic Chemistry (1980), 17(2), 373-6
CODEN: JHTCAD; ISSN: 0022-152X
DOCUMENT TYPE: Journal
LANGUAGE: German
OTHER SOURCE(S): CASREACT 93:114469

AB 7-Chloro-1-methyl-2-chloromethyl-5-phenyl-2,3-dihydro-1H-1,4-benzodiazepine is oxidized with KMnO4 and chromic acid. The products of oxidation are discussed. With KMnO4 in dilute HCl, the main product is the 7-chloro-1-methyl-5-phenyl-1,3-dihydro-2H-1,4-benzodiazepine-2-one whereas with chromic anhydride/pyridine the addnl. oxidation at C3 increases and the N-Me group is affected to a larger extent.
IT 20927-53-1P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 20927-53-1 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-1-methyl-4-phenyl- (CA INDEX NAME)



L5 ANSWER 175 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1980:453892 CAPLUS
DOCUMENT NUMBER: 93:53892
ORIGINAL REFERENCE NO.: 93:8747a,8750a
TITLE: Dependence of area under the curve on proquazone particle size and in vitro dissolution rate
AUTHOR(S): Nimmerfall, Fritz; Rosenthaler, Joachim
CORPORATE SOURCE: Pharm. Dep., Sandoz Ltd., Basel, Switz.
SOURCE: Journal of Pharmaceutical Sciences (1980), 69(5), 605-7
CODEN: JPMSAE; ISSN: 0022-3549
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



I

AB The in vitro dissoln. and GI absorption of various sieve fractions of proquazone (I) [22760-18-5] were studied (particle-size ranges of 45-74, 160-300, and 500-1000 μm). The dissoln. rates of prepns. F45, F160, and F500 were determined in vitro in a flow-through assembly in artificial gastric juice at 37°. The time required for 63% of the maximum amount of soluble drug to pass into solution was characterized by the dissoln. variable τD. The in vitro dissoln. rates for the prepns. differed significantly in the order τD.F45 < τD.F160 < τD.F500. After oral administration of 300 mg of the fractions to each of 8 rhesus monkeys, the area under the plasma level-time curve (AUC) differed significantly in the order AUCF45 > AUCF160 > AUCF500. The dissoln. rate increased with decreasing particle size. The AUC increased with decreasing particle size and with increasing dissoln. rate. These results indicate that the dissoln. rate probably dets. the extent of absorption when dissoln. is rate limiting.
IT 22760-18-5
RL: BIOL (Biological study)
(dissoln. and bioavailability of various particle size fractions of)
RN 22760-18-5 CAPLUS
CN 2(1H)-Quinazolinone, 7-methyl-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)

L5 ANSWER 175 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



L5 ANSWER 176 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1980:418889 CAPLUS
DOCUMENT NUMBER: 93:18889
ORIGINAL REFERENCE NO.: 93:3071a,3074a
TITLE: The effect of antacid and food on the absorption of proquazone (Biarison) in man
AUTHOR(S): Ohnhaus, E. E.
CORPORATE SOURCE: Dep. Med., Univ. Bern, Bern, Switz.
SOURCE: International Journal of Clinical Pharmacology, Therapy and Toxicology (1980), 18(3), 136-9
CODEN: IJCPB5; ISSN: 0300-9718
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



I

AB The effect of food and antacid was studied on the absorption of proquazone (I) [22760-18-5] in healthy volunteers when administered orally as a single dose. Each subject received, in a randomized cross-over sequence, 600 mg I after a 10 h overnight fast, 15 min after 20 mL of an antacid (Maaloxan), and 15 min after a standard breakfast. The only effect of antacid, compared to fasting, was to slow the rate of absorption without appreciably altering the extent of absorption. Food, on the other hand, markedly increased the maximal plasma concentration and also the area under the plasma concentration/time curve. Administration of I with or after food should be doubly advantageous for the patient, as it ought to offer protection from local gastrointestinal irritation and at the same time lead to an enhanced bioavailability.
IT 22760-18-5
RL: BIOL (Biological study)
(absorption of, by intestine, antacids and food effect on)
RN 22760-18-5 CAPLUS
CN 2(1H)-Quinazolinone, 7-methyl-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)

L5 ANSWER 176 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



L5 ANSWER 177 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1980:408203 CAPLUS
DOCUMENT NUMBER: 93:8203
ORIGINAL REFERENCE NO.: 93:1511a,1514a
TITLE: 2(1H)-Quinazolinethione derivatives
INVENTOR(S): Tamura, Takamitsu; Kawasaki, Tomomi; Kita, Yasuyuki
PATENT ASSIGNEE(S): Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 11 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 54144386	A	19791110	JP 1978-53009	19780502
JP 61021473	B	19860527		
PRIORITY APPLN. INFO.:			JP 1978-53009 A	19780502

GI



I II

AB Eighteen title derivs. I (R = H, alkyl, alkenyl, alkynyl, substituted alkyl, etc.; R1 = H, Ph, aryl, cycloalkyl, heterocyclic; R2, R3 = H, NO2, NH2, alkyl, etc.) were prepared by reaction of II with Ph3P(SCN)2. I had antiinflammatory, analgesic, and antibacterial activities (no data). Thus, 492.5 mg 2-H2NC6H4COPh in CH2Cl2 was added to 3 mmol Ph3P(SCN)2 in CH2Cl2 at -40° under N, the mixture kept 1 h at -40°, and stirred overnight to give 524 mg I (R = R2 = R3 = H, R1 = Ph).

IT 26824-98-6P 26920-10-5P 26920-12-7P
26920-15-0P 26930-57-4P 33443-28-6P
53720-97-1P 53720-98-2P 53720-99-3P
53721-00-9P 53721-01-0P 73877-20-0P
73877-21-1P 73877-22-2P 73877-23-3P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 26824-98-6 CAPLUS
CN 2(1H)-Quinazolinethione, 4-phenyl-1-(2-propenyl)- (9CI) (CA INDEX NAME)

L5 ANSWER 177 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 26920-10-5 CAPLUS
CN 2(1H)-Quinazolinethione, 1-ethyl-6-nitro-4-phenyl- (CA INDEX NAME)



RN 26920-12-7 CAPLUS
CN 2(1H)-Quinazolinethione, 6-chloro-1-methyl-4-phenyl- (CA INDEX NAME)



RN 26920-15-0 CAPLUS
CN 2(1H)-Quinazolinethione, 1-methyl-4-phenyl- (CA INDEX NAME)



RN 26930-57-4 CAPLUS
CN 2(1H)-Quinazolinethione, 1-ethyl-4-phenyl- (CA INDEX NAME)

L5 ANSWER 177 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 33443-28-6 CAPLUS
CN 2(1H)-Quinazolinethione, 6-chloro-1-(cyclopropylmethyl)-4-phenyl- (CA INDEX NAME)



RN 53720-97-1 CAPLUS
CN 2(1H)-Quinazolinethione, 1-(cyclopropylmethyl)-6-methoxy-4-phenyl- (CA INDEX NAME)



RN 53720-98-2 CAPLUS
CN 2(1H)-Quinazolinethione, 1-(cyclopropylmethyl)-6-nitro-4-phenyl- (CA INDEX NAME)

L5 ANSWER 177 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 53720-99-3 CAPLUS
CN 2(1H)-Quinazolinethione, 1-(cyclopropylmethyl)-7-methyl-4-phenyl- (CA INDEX NAME)



RN 53721-00-9 CAPLUS
CN 2(1H)-Quinazolinethione, 1-(cyclopropylmethyl)-6-(methylthio)-4-phenyl- (CA INDEX NAME)



RN 53721-01-0 CAPLUS
CN 2(1H)-Quinazolinethione, 1-(cyclopropylmethyl)-4-phenyl- (CA INDEX NAME)

L5 ANSWER 177 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 73877-20-0 CAPLUS
CN 2(1H)-Quinazolinethione, 1-(2-methylpropyl)-4-phenyl- (CA INDEX NAME)



RN 73877-21-1 CAPLUS
CN 2(1H)-Quinazolinethione, 7-methyl-1-(2-methylpropyl)-4-phenyl- (CA INDEX NAME)



RN 73877-22-2 CAPLUS
CN 2(1H)-Quinazolinethione, 1-(2-methylpropyl)-7-(methylthio)-4-phenyl- (CA INDEX NAME)

L5 ANSWER 177 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 73877-23-3 CAPLUS
CN 2(1H)-Quinazolinethione, 6-methoxy-1-(2-methylpropyl)-4-phenyl- (CA INDEX NAME)



L5 ANSWER 178 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER:	1980:128950 CAPLUS
DOCUMENT NUMBER:	92:128950
ORIGINAL REFERENCE NO.:	92:21038h,21039a
TITLE:	Quinazolines
INVENTOR(S):	Ott, Hans
PATENT ASSIGNEE(S):	Sandoz A.-G., Switz.
SOURCE:	Rom., 5 pp. CODEN: RUXXA3
DOCUMENT TYPE:	Patent
LANGUAGE:	Romanian
FAMILY ACC. NUM. COUNT:	1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
RO 53491	A1	19781115	RO 1968-50070	19680611
CS 157638	B2	19740916	CS 1968-981	19680605
CS 157639	B2	19740916	CS 1973-982	19731219

PRIORITY APPLN. INFO.: RO 1968-50070 19680611

GI



AB Phenylquinazolines I (R = H, F, Bu, Cl; R1 = H, halo, HO, alkyl, C1-4 alkyl), having antiinflammatory, antipyretic, and analgesic activities (no data), were prepared Thus, refluxing 4-phenylquinazoline with MeI 8 h gave 1-methyl-4-phenylquinazolinium iodide, whose oxidation gave I (R-R2 = H).

IT 17629-04-8P 20927-53-1P 23441-88-5P
26824-77-1P 26824-94-2P 26824-96-4P
26824-97-5P 26831-06-1P 26831-08-3P
26940-07-8P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 17629-04-8 CAPLUS
CN 2(1H)-Quinazolinone, 1-methyl-4-phenyl- (CA INDEX NAME)

L5 ANSWER 178 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 20927-53-1 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-1-methyl-4-phenyl- (CA INDEX NAME)



RN 23441-88-5 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-4-(2-chlorophenyl)-1-methyl- (CA INDEX NAME)



RN 26824-77-1 CAPLUS
CN 2(1H)-Quinazolinone, 4-(2,6-dimethoxyphenyl)-1-methyl- (CA INDEX NAME)



RN 26824-94-2 CAPLUS

L5 ANSWER 178 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
CN 2(1H)-Quinazolinone, 4-(3-chlorophenyl)-1-methyl- (CA INDEX NAME)



RN 26824-96-4 CAPLUS
CN 2(1H)-Quinazolinone, 4-(2,3-dimethylphenyl)-1-methyl- (CA INDEX NAME)



RN 26824-97-5 CAPLUS
CN 2(1H)-Quinazolinone, 4-(4-hydroxyphenyl)-1-methyl- (CA INDEX NAME)



RN 26831-06-1 CAPLUS
CN 2(1H)-Quinazolinone, 4-(4-chlorophenyl)-1-methyl- (CA INDEX NAME)

L5 ANSWER 178 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 26831-08-3 CAPLUS
CN 2(1H)-Quinazolinone, 4-(4-methoxyphenyl)-1-methyl- (CA INDEX NAME)



RN 26940-07-8 CAPLUS
CN 2(1H)-Quinazolinone, 1-methyl-4-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)



L5 ANSWER 179 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1980:121782 CAPLUS
DOCUMENT NUMBER: 92:121782
ORIGINAL REFERENCE NO.: 92:19713a,19716a
TITLE: General pharmacological studies on ciproquazone (SL-573) and its metabolites
AUTHOR(S): Miyagishi, Akira; Tsuda, Masafumi; Hara, Yoichi; Nakatani, Hiroshi
CORPORATE SOURCE: Res. Dep., Sumitomo Chem. Co., Ltd., Hyogo, 665, Japan
SOURCE: Oyo Yakuri (1979), 18(1), 9-22
CODEN: OYYAA2; ISSN: 0369-8033
DOCUMENT TYPE: Journal
LANGUAGE: Japanese
GI



I

AB The antiinflammatory drug SL-573 (I) [33453-23-5] (>1 mg/kg, i.v.) given to cats decreased blood pressure and the R-R interval in the EKG pattern, increased heart rate, cardiac activity, but had no significant effect on the pos. inotropic and chronotropic responses. In isolated guinea pig ileum, I induced contraction, but in isolated vas deferens I inhibited the contraction. I and its metabolites had no marked
effect on the movement of small intestine.
IT 73052-29-6 73052-30-9
RL: BIOL (Biological study)
(as ciproquazone metabolite, pharmacol. of)
RN 73052-29-6 CAPLUS
CN 2(1H)-Quinazolinone, 1-(cyclopropylmethyl)-4-(4-hydroxyphenyl)-6-methoxy- (CA INDEX NAME)

L5 ANSWER 179 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 73052-30-9 CAPLUS
CN 2(1H)-Quinazolinone, 1-(cyclopropylmethyl)-6-hydroxy-4-phenyl- (CA INDEX NAME)



IT 33453-23-5
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmacol. of)
RN 33453-23-5 CAPLUS
CN 2(1H)-Quinazolinone, 1-(cyclopropylmethyl)-6-methoxy-4-phenyl- (CA INDEX NAME)

L5 ANSWER 179 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



L5 ANSWER 180 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1980:41989 CAPLUS
DOCUMENT NUMBER: 92:41989
ORIGINAL REFERENCE NO.: 92:7013a,7016a
TITLE: Quinazoline derivatives
INVENTOR(S): Hardtmann, Goetz Eduard; Schwarz, Hans Jakob; Papp, Eugene Anthony
PATENT ASSIGNEE(S): Sandoz-Patent-G.m.b.H., Switz.
SOURCE: Ger. Offen., 32 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2809210	A1	19790906	DE 1978-2809210	19780303
PRIORITY APPLN. INFO.:			DE 1978-2809210 A	19780303

GI



I

AB The antiinflammatory (no data) compds. I (R = H, F, Cl, Br, OH, alkoxy, acyloxy; R1 = alkyl, cycloalkylalkyl, haloalkyl; R2 = CO2H, CH2OH, H, F, Cl, Br, NO2, alkyl; R3 = H, F, Cl, Br; R4 = H, F, Cl, Br, OH, CF3, alkoxy) were prepared Thus, I (R = R3 = R4 = H, R1 = Me2CH, R2 = 7-Me) was brominated with N-bromosuccinimide to give I (R2 = CHBr2), with was hydrolyzed to I (R2 = CO2H).

IT 22760-18-5 65765-08-4
RL: RCT (Reactant); RACT (Reactant or reagent)
(bromination of)

RN 22760-18-5 CAPLUS
CN 2(1H)-Quinazolinone, 7-methyl-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)

L5 ANSWER 180 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 65765-08-4 CAPLUS
CN 2(1H)-Quinazolinone, 4-[3-(acetyloxy)phenyl]-7-methyl-1-(1-methylethyl)- (CA INDEX NAME)



IT 65765-06-2
RL: RCT (Reactant); RACT (Reactant or reagent)
(oxidation and bromination of)

RN 65765-06-2 CAPLUS
CN 2(1H)-Quinazolinone, 4-(3-methoxyphenyl)-7-methyl-1-(1-methylethyl)- (CA INDEX NAME)



IT 65765-07-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and acetylation of)

RN 65765-07-3 CAPLUS
CN 2(1H)-Quinazolinone, 4-(3-hydroxyphenyl)-7-methyl-1-(1-methylethyl)- (CA INDEX NAME)

L5 ANSWER 180 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



IT 50817-66-8P 65765-09-5P 72410-31-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and hydrolysis of)

RN 50817-66-8 CAPLUS
CN 2(1H)-Quinazolinone, 7-(bromomethyl)-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)



RN 65765-09-5 CAPLUS
CN 2(1H)-Quinazolinone, 4-[3-(acetyloxy)phenyl]-7-(bromomethyl)-1-(1-methylethyl)- (CA INDEX NAME)



RN 72410-31-2 CAPLUS
CN 2(1H)-Quinazolinone, 7-(dibromomethyl)-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)

L5 ANSWER 180 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



IT 65765-05-1P 65765-11-9P 66154-89-0P
66154-91-4P 69104-02-5P 72410-32-3P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 65765-05-1 CAPLUS
CN 2(1H)-Quinazolinone, 3,4-dihydro-4-(3-methoxyphenyl)-7-methyl-1-(1-methylethyl)- (CA INDEX NAME)



RN 65765-11-9 CAPLUS
CN 2(1H)-Quinazolinone, 7-(hydroxymethyl)-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)



RN 66154-89-0 CAPLUS
CN 7-Quinazolinecarboxylic acid, 1,2-dihydro-4-(3-methoxyphenyl)-1-(1-methylethyl)-2-oxo- (CA INDEX NAME)

L5 ANSWER 180 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 66154-91-4 CAPLUS
CN 7-Quinazolinecarboxylic acid, 1,2-dihydro-4-(3-hydroxyphenyl)-1-(1-methylethyl)-2-oxo- (CA INDEX NAME)



RN 69104-02-5 CAPLUS
CN 7-Quinazolinecarboxylic acid, 1,2-dihydro-1-(1-methylethyl)-2-oxo-4-phenyl- (CA INDEX NAME)



RN 72410-32-3 CAPLUS
CN 2(1H)-Quinazolinone, 7-(hydroxymethyl)-4-(3-hydroxyphenyl)-1-(1-methylethyl)- (CA INDEX NAME)

L5 ANSWER 180 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



L5 ANSWER 181 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1980:41979 CAPLUS
DOCUMENT NUMBER: 92:41979
ORIGINAL REFERENCE NO.: 92:7009a,7012a
TITLE: Quinazolinones
INVENTOR(S): Ott, Hans
PATENT ASSIGNEE(S): Sandoz A.-G., Switz.
SOURCE: Rom., 4 pp.
CODEN: RUXXA3
DOCUMENT TYPE: Patent
LANGUAGE: Romanian
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
RO 53396	A1	19781015	RO 1968-56975	19680611
PRIORITY APPLN. INFO.:			RO 1968-56975 A	19680611

GI



AB Benzophenones I (R = H, F, Cl, Br; R1 = alkyl, allyl, methylallyl, propargyl; R2 = H, OH, alkoxy, alkyl, CF3; R3 = H, halo, OH, alkyl, alkoxy) were treated with H2NCO2Et and ZnCl2 to give quinazolinones II, useful as analgesics, antipyretics, and antiinflammatory agents (no data).
A mixture of 2-(MeNH)C6H4COPh, H2NCO2Et, and ZnCl2 was heated at 180-90° to give II (R = R2 = R3 = H, R1 = Me).

IT 17629-04-8P 20927-53-1P 23441-64-7P
23441-88-5P 26772-86-1P 26824-71-5P
26824-77-1P 26824-80-6P 26824-81-7P
26824-82-8P 26824-84-0P 26824-94-2P
26824-96-4P 26824-97-5P 26831-06-1P
26831-07-2P 26831-08-3P 26831-09-4P
26831-11-8P 26940-07-8P 27524-92-1P
27524-93-2P 27529-23-3P 27559-10-0P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 17629-04-8 CAPLUS
CN 2(1H)-Quinazolinone, 1-methyl-4-phenyl- (CA INDEX NAME)

L5 ANSWER 181 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 20927-53-1 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-1-methyl-4-phenyl- (CA INDEX NAME)



RN 23441-64-7 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-1-ethyl-4-phenyl- (CA INDEX NAME)



RN 23441-88-5 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-4-(2-chlorophenyl)-1-methyl- (CA INDEX NAME)



L5 ANSWER 181 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 26824-81-7 CAPLUS
CN 2(1H)-Quinazolinone, 1-butyl-4-phenyl- (CA INDEX NAME)



RN 26824-82-8 CAPLUS
CN 2(1H)-Quinazolinone, 1-pentyl-4-phenyl- (CA INDEX NAME)



RN 26824-84-0 CAPLUS
CN 2(1H)-Quinazolinone, 4-phenyl-1-(2-propynyl)- (8CI, 9CI) (CA INDEX NAME)



RN 26824-94-2 CAPLUS
CN 2(1H)-Quinazolinone, 4-(3-chlorophenyl)-1-methyl- (CA INDEX NAME)

L5 ANSWER 181 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

RN 26772-86-1 CAPLUS
CN 2(1H)-Quinazolinone, 1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)



RN 26824-71-5 CAPLUS
CN 2(1H)-Quinazolinone, 4-phenyl-1-(2-propenyl)- (9CI) (CA INDEX NAME)



RN 26824-77-1 CAPLUS
CN 2(1H)-Quinazolinone, 4-(2,6-dimethoxyphenyl)-1-methyl- (CA INDEX NAME)



RN 26824-80-6 CAPLUS
CN 2(1H)-Quinazolinone, 4-phenyl-1-propyl- (CA INDEX NAME)

L5 ANSWER 181 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 26824-96-4 CAPLUS
CN 2(1H)-Quinazolinone, 4-(2,3-dimethylphenyl)-1-methyl- (CA INDEX NAME)



RN 26824-97-5 CAPLUS
CN 2(1H)-Quinazolinone, 4-(4-hydroxyphenyl)-1-methyl- (CA INDEX NAME)



RN 26831-06-1 CAPLUS
CN 2(1H)-Quinazolinone, 4-(4-chlorophenyl)-1-methyl- (CA INDEX NAME)

L5 ANSWER 181 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 26831-07-2 CAPLUS
CN 2(1H)-Quinazolinone, 1-ethyl-4-phenyl- (CA INDEX NAME)



RN 26831-08-3 CAPLUS
CN 2(1H)-Quinazolinone, 4-(4-methoxyphenyl)-1-methyl- (CA INDEX NAME)



RN 26831-09-4 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-4-(2-chlorophenyl)-1-(1-methylethyl)- (CA INDEX NAME)

L5 ANSWER 181 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 27524-93-2 CAPLUS
CN 2(1H)-Quinazolinone, 7-chloro-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)



RN 27529-23-3 CAPLUS
CN 2(1H)-Quinazolinone, 1-(2-methyl-2-propenyl)-4-phenyl- (9CI) (CA INDEX NAME)



RN 27559-10-0 CAPLUS
CN 2(1H)-Quinazolinone, 1-(2-methylpropyl)-4-phenyl- (CA INDEX NAME)

L5 ANSWER 181 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 26831-11-8 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)



RN 26940-07-8 CAPLUS
CN 2(1H)-Quinazolinone, 1-methyl-4-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 27524-92-1 CAPLUS
CN 2(1H)-Quinazolinone, 1-(1-methylethyl)-4-(4-methylphenyl)- (CA INDEX NAME)

L5 ANSWER 181 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



L5 ANSWER 182 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1979:581345 CAPLUS
DOCUMENT NUMBER: 91:181345
ORIGINAL REFERENCE NO.: 91:29133a,29136a
TITLE: Biopharmaceutical studies of lipid-containing oral dosage forms: relationship between drug absorption rate and digestibility of vehicles
AUTHOR(S): Yamahira, Yoshiya; Noguchi, Takeshi; Takenaka, Hiroshi; Maeda, Tadao
CORPORATE SOURCE: Pharm. Div., Sumitomo Chem. Co., Ltd., Ibaraki, 567, Japan
SOURCE: International Journal of Pharmaceutics (1979), 3(1), 23-31
CODEN: IJPHDE; ISSN: 0378-5173
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



I

AB The gastrointestinal absorption characteristics of a drug in a lipid-containing oral dosage form were studied in rats in relation to digestibility of lipids. SL-512 (I) [70857-50-0] was selected as a model of a lipid soluble drug with very low water solubility Medium chain triglyceride (MCT) was employed as a model of a well digestible lipid and N-α-methylbenzyllinoleamide (II) [14417-88-0] as model of a poorly digestible lipid. The in vitro release experiment of I from lipid vehicle to the water phase showed a strong affinity of I to vehicle lipids. In an oral administration study of lipid prepns. to rats, the serum level of I was much higher from an MCT preparation than from an II preparation In an in situ recirculation experiment I was not absorbed from lipid vehicles, although it was easily adsorbed from the aqueous solution These facts suggest that digestion of the lipid was a major premise for absorption of I. In an intraduodenal administration study the serum levels of I from MCT and corn oil prepns. were depressed by ligation of the bile duct. Thus, the decrease of the amount of the lipid by digestion in the gut was important for the absorption of I in lipids.
IT 70857-50-0
RL: BIOL (Biological study)

L5 ANSWER 182 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
(lipid oral dosage form contg., gastrointestinal absorption of)
RN 70857-50-0 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-1-cyclopropyl-4-phenyl- (CA INDEX NAME)



L5 ANSWER 183 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1979:551347 CAPLUS
DOCUMENT NUMBER: 91:151347
ORIGINAL REFERENCE NO.: 91:24289a,24292a
TITLE: Autoradiographic methods for the evaluation of ulcerogenic effects of antiinflammatory drugs
AUTHOR(S): Brune, K.; Gubler, H.; Schweitzer, A.
CORPORATE SOURCE: Dep. Pharmacol., Univ. Basel, Basel, CH-4056, Switz.
SOURCE: Pharmacology & Therapeutics (1979), 5(1-3), 199-207
CODEN: PHTHDT; ISSN: 0163-7258
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



I

AB Autoradiog. methods were used to monitor the absorption and distribution of nonsteroidal antiinflammatory drugs (NSAID) in rats. After oral administration, the acidic drug acetylsalicylic acid (I) [50-78-2] was absorbed rapidly and concentrated in a few parietal cells of the stomach while the nonacidic drug, proquazone [22760-18-5] remained in the stomach lumen for hours without entering the stomach wall in measurable amts. The effects observed may be correlated with the ulcerogenic effects both compds. exert on the stomach. While ulcer formation due to salicylates took place within the 1st h after administration, reached a peak at 3 h and thereafter declined, with proquazone only minor mucosal damage of the stomach was observed and was most pronounced at 6 h after administration.. Thus, acidic NSAIDs may rapidly enter functioning parietal cells of the stomach by nonionic diffusion, get trapped in the neutral environment of the cell interior and destroy these cells by osmotic and acidic shock thereby forming the initial focus of ulcer formation..
IT 22760-18-5
RL: BIOL (Biological study)
(ulcerogenic activity of, method for evaluation of)
RN 22760-18-5 CAPLUS
CN 2(1H)-Quinazolinone, 7-methyl-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)



L5 ANSWER 183 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

L5 ANSWER 184 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1979:483493 CAPLUS
DOCUMENT NUMBER: 91:83493
ORIGINAL REFERENCE NO.: 91:13419a,13422a
TITLE: Studies on the prednisolone-sparing effect of proquazone
AUTHOR(S): Mathies, H.; Wolff, E.
CORPORATE SOURCE: I. Med. Klin., Rheuma-Zent., Regensburg, D-8403, Fed. Rep. Ger.
SOURCE: MMW, Muenchener Medizinische Wochenschrift (1979), 121(13), 459-60
CODEN: MMMWD7; ISSN: 0341-3098
DOCUMENT TYPE: Journal
LANGUAGE: German
GI



I

AB Proquazone (I) [22760-18-5] (300 mg 4 times daily) given orally to polyarthritic patients treated with prednisolone [50-24-8] produced an average steroid-sparing effect amounting to 52.2% of the previously required prednisolone daily dose.
IT 22760-18-5
RL: PRP (Properties)
(prednisolone-sparing effect of, in arthritis)
RN 22760-18-5 CAPLUS
CN 2(1H)-Quinazolinone, 7-methyl-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)



L5 ANSWER 185 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
CN 2(1H)-Quinazolinone, 6-chloro-1-cyclopropyl-4-phenyl- (CA INDEX NAME)



L5 ANSWER 185 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1979:478837 CAPLUS
DOCUMENT NUMBER: 91:78837
ORIGINAL REFERENCE NO.: 91:12677a,12680a
TITLE: Evaluation of lipid-containing oral dosage forms in rats
AUTHOR(S): Yamahira, Yoshiya; Noguchi, Tetsuo; Noguchi, Takeshi; Takenaka, Hiroshi; Maeda, Tadao
CORPORATE SOURCE: Pharm. Div., Sumitomo Chem. Co., Ltd., Ibaraki, 567, Japan
SOURCE: Journal of Pharmacobio-Dynamics (1979), 2(1), 52-9
CODEN: JOPHDQ; ISSN: 0386-846X
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



I

AB A novel method for evaluation of oral lipid formulation in rats, which enabled a reduced dose level to 2 mcl/rat with satisfactory accuracy, was presented. The dose level was fairly comparable to that of clin. unit dose such a soft capsule on μL/kg (lipid dose/body weight) basis. Lipid-containing oral dosage forms were evaluated. A new antiinflammatory agent SL-512 (I) [70857-50-0] was selected as a model of poorly water soluble drug. A medium chain triglyceride was mostly used as a lipid vehicle. The characteristics of the lipid formulation were estimated by measuring the gastric emptying rate of the drug or sometimes combined with that remaining in the intestine in rats. These results basically consisted of those obtained from 20 μL/rat dosing expts. previously reported. By reducing the dose level to 2 μL/rat, the drug absorption was less affected by the dosage form factors such as the drug concentration in the preparation or the digestibility of lipid vehicle. In this method compared with an aqueous suspension, the drug absorption of the lipid formulation was less variable and less affected by the concomitant food intake.
IT 70857-50-0
RL: BIOL (Biological study)
(lipid-containing oral dosage forms, evaluation of)
RN 70857-50-0 CAPLUS

L5 ANSWER 186 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1979:468399 CAPLUS
DOCUMENT NUMBER: 91:68399
ORIGINAL REFERENCE NO.: 91:10933a,10936a
TITLE: The biochemical mode of action of proquazone with particular regard to connective tissue metabolism. (Biochemical studies to test its antiinflammatory properties)
AUTHOR(S): Stuhlsatz, H. W.; Greiling, H.
CORPORATE SOURCE: Med. Fak., Rheinisch-Westfael. Tech. Hochsch. Aachen, Aachen, 5100, Fed. Rep. Ger.
SOURCE: Zeitschrift fuer Rheumatologie (1979), 38(3-4), 99-105
CODEN: ZRHMBQ; ISSN: 0340-1855
DOCUMENT TYPE: Journal
LANGUAGE: German
GI



I

AB Since an increased biosynthesis of proteoglycans can be observed in the anabolic phase of inflammation, the mechanism of action of the antiinflammatory drug proquazone (I) [22760-18-5] was studied by determining its effect on the incorporation of 35SO42- and glucosamine-3H into proteochondroitin sulfate and proteokeratan sulfate in calf cornea. I (2.7 + 10-4M) inhibited the incorporation of both labels into both proteoglycans. A mechanism is proposed in which I inhibits the core protein synthesis of proteoglycans and the secondary biosynthesis of the glycosaminoglycan chains. The action of antiinflammatory drugs is probably based on an inhibitory effect on proteoglycan synthesis in the anabolic phase of inflammation.
IT 22760-18-5
RL: BIOL (Biological study)
(proteoglycan formation by connective tissue inhibition by, inflammation inhibition in relation to)
RN 22760-18-5 CAPLUS
CN 2(1H)-Quinazolinone, 7-methyl-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)



L5 ANSWER 186 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

L5 ANSWER 187 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1979:456946 CAPLUS
DOCUMENT NUMBER: 91:56946
ORIGINAL REFERENCE NO.: 91:9227a,9230a
TITLE: Cyclic guanidines. VI. Synthesis of hypoglycemic tricyclic guanidines
AUTHOR(S): Kosasayama, Akira; Higashi, Kunio; Ishikawa, Fumiyoshi
CORPORATE SOURCE: Res. Inst., Daiichi Seiyaku Co., Ltd., Tokyo, 132, Japan
SOURCE: Chemical & Pharmaceutical Bulletin (1979), 27(4), 880-92
CODEN: CPBTAL; ISSN: 0009-2363
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 91:56946
GI



I, X=NH
II, X=S
III, X=O

AB Synthesis of linear and angular tricyclic guanidine derivs., imidazo- or pyrimido[2,1-b]- or [1,2-a]quinazoline derivs., is described. Cyclization of 2-(ω-chloroalkyl)-4-phenyl-3,4-dihydroquinazolines gave two, difficult to isolate. 2-Aminobenzhydrylaminoalkanols obtained from 2-aminobenzophenone were converted to linear tricyclic guanidine derivs., e.g. I (n = 2,3), and other tricyclic compds. II and III (n = 2,3). Reaction of 2-benzoylaminoalkanols also gave angular products. Most of the tricyclic guanidine derivs. showed a hypoglycemic activity.

IT 70888-47-0P 70888-48-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and chlorination of)

RN 70888-47-0 CAPLUS
CN 2(1H)-Quinazolinone, 3,4-dihydro-1-(2-hydroxyethyl)-4-phenyl- (CA INDEX NAME)



L5 ANSWER 187 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

RN 70888-48-1 CAPLUS
CN 2(1H)-Quinazolinone, 3,4-dihydro-1-(3-hydroxypropyl)-4-phenyl- (CA INDEX NAME)



IT 70888-52-7P 70888-53-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and cyclization of)

RN 70888-52-7 CAPLUS
CN 1(4H)-Quinazolineethanol, 2-(methylthio)-4-phenyl-, monohydriodide (9CI) (CA INDEX NAME)



● HI

RN 70888-53-8 CAPLUS
CN 1(4H)-Quinazolinepropanol, 2-(methylthio)-4-phenyl-, monohydriodide (9CI) (CA INDEX NAME)



● HI

IT 68210-70-8P 70888-46-9P

L5 ANSWER 187 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. and methylation of)

RN 68210-70-8 CAPLUS
CN 2(1H)-Quinazolinethione, 3,4-dihydro-1-(2-hydroxyethyl)-4-phenyl- (CA INDEX NAME)



RN 70888-46-9 CAPLUS
CN 2(1H)-Quinazolinethione, 3,4-dihydro-1-(3-hydroxypropyl)-4-phenyl- (CA INDEX NAME)



IT 70888-49-2P 70888-50-5P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 70888-49-2 CAPLUS
CN 2(1H)-Quinazolinone, 1-(2-chloroethyl)-3,4-dihydro-4-phenyl- (CA INDEX NAME)



RN 70888-50-5 CAPLUS
CN 2(1H)-Quinazolinone, 1-(3-chloropropyl)-3,4-dihydro-4-phenyl- (CA INDEX NAME)

L5 ANSWER 187 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



L5 ANSWER 188 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1979:439516 CAPLUS
DOCUMENT NUMBER: 91:39516
ORIGINAL REFERENCE NO.: 91:6449a,6452a
TITLE: Quinazolinone oxides
PATENT ASSIGNEE(S): du Pont de Nemours, E. I., and Co., USA
SOURCE: Jpn. Kokai Tokkyo Koho, 11 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 54005988	A	19790117	JP 1978-73679	19780616
DK 7801763	A	19781217	DK 1978-1763	19780424
AU 7837092	A	19791220	AU 1978-37092	19780614
CA 1094068	A1	19810120	CA 1978-305471	19780614
NO 7802087	A	19781219	NO 1978-2087	19780615
EP 149	A1	19790110	EP 1978-100163	19780615
R: BE, CH, DE, FR, GB, LU, NL, SE				
ZA 7803438	A	19790627	ZA 1978-3438	19780615
ES 470828	A1	19791001	ES 1978-470828	19780615
AT 7804366	A	19810115	AT 1978-4366	19780615
SU 797575	A3	19810115	SU 1978-2627504	19780615
FI 7801928	A	19781217	FI 1978-1928	19780616
PL 113420	B1	19801231	PL 1978-207682	19780616
US 4258187	A	19810324	US 1978-959626	19781113

PRIORITY APPLN. INFO.: US 1977-807076 A 19770616

OTHER SOURCE(S): MARPAT 91:39516
GI



I III IV

AB Aminobenzophenones I (R = H, Me; R1 = Cl, Br, NO2, CF3; R2 = H, Br, Cl; R3 = H) were acylated with R4NCO [R4 = (halo)hydrocarbyl] to give I (R3 = CONHR4) (II) and (or) III. II or III were treated with NH2OH.HCl to give quinazolinone N-oxides IV. Thus, refluxing I (R1 = Cl, R = R2 = R3 = H) in CH2Cl2 with MeNCO 2 days gave 96% corresponding III, which was refluxed with NH2OH.HCl in EtOH 187 h to give 83% corresponding IV.

IT 70547-51-2P

L5 ANSWER 188 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. and reaction with hydroxylamine, quinazolinone N-oxide from)

RN 70547-51-2 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-3,4-dihydro-4-hydroxy-1,3-dimethyl-4-phenyl- (CA INDEX NAME)



IT 70296-98-9P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 70296-98-9 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-1-methyl-4-phenyl-, 3-oxide (CA INDEX NAME)



L5 ANSWER 189 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1979:439425 CAPLUS
DOCUMENT NUMBER: 91:39425
ORIGINAL REFERENCE NO.: 91:6429a,6432a
TITLE: A direct synthesis of 1-alkyl-3,4-dihydro-2-oxo-4,7-diphenylpyrrolo(1H,3H,6H)[3,4-d]pyrimidines. A new hydride-transfer reaction
AUTHOR(S): Tarzia, Giorgio; Panzone, Giambattista
CORPORATE SOURCE: Lab. Ric., Gruppo Lepetit S.p.A., Milan, 20158, Italy
SOURCE: Gazzetta Chimica Italiana (1978), 108(11-12), 591-5
CODEN: GCITA9; ISSN: 0016-5603
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



I II

AB Heating 4-(dialkylamino)-3-benzoylpyrroles I (R = H, R1 = Me, Ph; or R = R1 = Me) and urea at 200° for 2 h resulted in a redox reaction to give the title pyrrolopyrimidines II along with aldehydes R1CHO. 2-(Et2N)C6H4COPh reacted similarly. The hydride-transfer nature of the reaction was demonstrated by D-labeling expts.

IT 70724-06-0P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 70724-06-0 CAPLUS
CN 2(1H)-Quinazolinone, 1-ethyl-3,4-dihydro-4-phenyl- (CA INDEX NAME)



IT 26831-07-2

RL: RCT (Reactant); RACT (Reactant or reagent)
(reduction of)

RN 26831-07-2 CAPLUS
CN 2(1H)-Quinazolinone, 1-ethyl-4-phenyl- (CA INDEX NAME)

L5 ANSWER 189 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



L5 ANSWER 190 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1979:420538 CAPLUS
DOCUMENT NUMBER: 91:20538
ORIGINAL REFERENCE NO.: 91:3441a,3444a
TITLE: Nitroquinazolinone compounds having antiviral properties
INVENTOR(S): Yamamoto, Michihiro; Morooka, Shigeaki; Koshiba, Masao; Komatsu, Toshiaki; Noguchi, Hiroshi; Inaba, Shigeho; Yamamoto, Hisao
PATENT ASSIGNEE(S): Sumitomo Chemical Co., Ltd., Japan
SOURCE: U.S., 10 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 4146717	A	19790327	US 1974-454284	19740325
PRIORITY APPLN. INFO.:			US 1972-242241	A2 19720407

OTHER SOURCE(S): MARPAT 91:20538
GI



I

AB The nitroquinazoline I (R1 = Ph, thienyl; R2 = furyl, 2-thienyl, pyridyl, tetrahydrofuryl, tetrahydro-2-pyranyl) were prepared Thus, 4-phenyl-6-nitro-2(1H)-quinazolinone was treated with tetrahydrofurfuryl bromide to give mainly 1-(tetrahydrofurfuryl)-4-phenyl-6-nitro-2(1H)quinazolinone (II) and some 2-(tetrahydrofurfuryloxy)-4-phenyl-6-nitroquinazoline. The min. inhibtory concentration of II on vaccinia virus multiplication in chick embryo fibroblast cell culture was 1.0 erg/mL.

IT 70413-14-8
RL: RCT (Reactant); RACT (Reactant or reagent)
(nitration of)
RN 70413-14-8 CAPLUS
CN 2(1H)-Quinazolinone, 4-phenyl-1-(2-pyridinylmethyl)- (CA INDEX NAME)

L5 ANSWER 190 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



IT 70413-13-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and dehydrogenation of)
RN 70413-13-7 CAPLUS
CN 2(1H)-Quinazolinone, 3,4-dihydro-6-nitro-4-phenyl-1-(2-thienylmethyl)- (CA INDEX NAME)



IT 40852-50-4P 40852-51-5P 40852-54-8P
40852-56-0P 40852-57-1P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation and virucidal activity of)
RN 40852-50-4 CAPLUS
CN 2(1H)-Quinazolinone, 6-nitro-4-phenyl-1-[(tetrahydro-2-furanyl)methyl]- (CA INDEX NAME)

L5 ANSWER 190 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 40852-51-5 CAPLUS
CN 2(1H)-Quinazolinone, 6-nitro-4-phenyl-1-[(tetrahydro-2H-pyran-2-yl)methyl]- (CA INDEX NAME)



RN 40852-54-8 CAPLUS
CN 2(1H)-Quinazolinone, 1-(2-furanylmethyl)-6-nitro-4-phenyl- (CA INDEX NAME)



RN 40852-56-0 CAPLUS
CN 2(1H)-Quinazolinone, 6-nitro-4-phenyl-1-(2-pyridinylmethyl)- (CA INDEX NAME)

L5 ANSWER 190 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 40852-57-1 CAPLUS
CN 2(1H)-Quinazolinone, 6-nitro-4-phenyl-1-(2-thienylmethyl)- (CA INDEX NAME)



IT 40852-55-9P 70413-12-6P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 40852-55-9 CAPLUS
CN 2(1H)-Quinazolinone, 1-[(2,3-dihydro-1,4-benzodioxin-2-yl)methyl]-6-nitro-4-phenyl- (CA INDEX NAME)

L5 ANSWER 190 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 70413-12-6 CAPLUS
CN 2(1H)-Quinazolinone, 6-nitro-1-(oxiranylmethyl)-4-phenyl- (9CI) (CA INDEX NAME)



IT 33890-29-8 37554-37-3 37555-03-6
40852-28-6 40852-31-1 40852-33-3
40852-34-4 40852-35-5 40852-36-6
40852-37-7 40852-38-8 40852-40-2
40852-42-4 40852-49-1 41190-30-1
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(virucidal activity of)
RN 33890-29-8 CAPLUS
CN 2(1H)-Quinazolinone, 1-(cyclopropylmethyl)-6-nitro-4-phenyl- (CA INDEX NAME)

L5 ANSWER 190 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 37554-37-3 CAPLUS
CN 2(1H)-Quinazolinone, 1-(2-ethoxyethyl)-6-nitro-4-phenyl- (CA INDEX NAME)



RN 37555-03-6 CAPLUS
CN 2(1H)-Quinazolinone, 6-nitro-4-phenyl-1-(phenylmethyl)- (CA INDEX NAME)



RN 40852-28-6 CAPLUS
CN 2(1H)-Quinazolinone, 1-[(2-chlorophenyl)methyl]-6-nitro-4-phenyl- (CA INDEX NAME)

L5 ANSWER 190 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 40852-31-1 CAPLUS
CN 2(1H)-Quinazolinone, 4-(2-chlorophenyl)-1-(cyclopropylmethyl)-6-nitro- (CA INDEX NAME)



RN 40852-33-3 CAPLUS
CN 2(1H)-Quinazolinone, 1-(cyclopentylmethyl)-6-nitro-4-phenyl- (CA INDEX NAME)



RN 40852-34-4 CAPLUS
CN 2(1H)-Quinazolinone, 1-(cyclohexylmethyl)-6-nitro-4-phenyl- (CA INDEX NAME)

L5 ANSWER 190 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 40852-35-5 CAPLUS
CN 2(1H)-Quinazolinone, 1-(cycloheptylmethyl)-6-nitro-4-phenyl- (CA INDEX NAME)



RN 40852-36-6 CAPLUS
CN 2(1H)-Quinazolinone, 1-(cyclooctylmethyl)-6-nitro-4-phenyl- (CA INDEX NAME)



L5 ANSWER 190 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
CN 2(1H)-Quinazolinone, 1-[(methylthio)methyl]-6-nitro-4-phenyl- (CA INDEX NAME)



RN 40852-49-1 CAPLUS
CN 1(2H)-Quinazolineacetamide, N,N-diethyl-6-nitro-2-oxo-4-phenyl- (CA INDEX NAME)



RN 41190-30-1 CAPLUS
CN 2(1H)-Quinazolinone, 1-[(2-methylphenyl)methyl]-6-nitro-4-phenyl- (CA INDEX NAME)



L5 ANSWER 190 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

RN 40852-37-7 CAPLUS
CN 2(1H)-Quinazolinone, 1-(2-cyclohexylethyl)-6-nitro-4-phenyl- (CA INDEX NAME)



RN 40852-38-8 CAPLUS
CN 2(1H)-Quinazolinone, 1-cyclohexyl-6-nitro-4-phenyl- (CA INDEX NAME)



RN 40852-40-2 CAPLUS
CN 2(1H)-Quinazolinone, 1-[2-(1-methylethoxy)ethyl]-6-nitro-4-phenyl- (CA INDEX NAME)



RN 40852-42-4 CAPLUS

L5 ANSWER 191 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1979:420537 CAPLUS
DOCUMENT NUMBER: 91:20537
ORIGINAL REFERENCE NO.: 91:3441a,3444a
TITLE: 4-Arylquinazolin-2(1H)-ones
INVENTOR(S): Smith, Joseph Antonio
PATENT ASSIGNEE(S): Sandoz-Patent-G.m.b.H., Fed. Rep. Ger.
SOURCE: Ger. Offen., 17 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2837403	A1	19790308	DE 1978-2837403	19780828
CH 642638	A5	19840430	CH 1978-9045	19780825
FI 7802619	A	19790307	FI 1978-2619	19780828
FI 66362	B	19840629		
FI 66362	C	19841010		
DK 7803820	A	19790307	DK 1978-3820	19780829
DK 144999	B	19820726		
DK 144999	C	19821213		
NO 7802945	A	19790307	NO 1978-2945	19780829
SE 7809098	A	19790307	SE 1978-9098	19780829
GB 2003873	A	19790321	GB 1978-35143	19780831
GB 2003873	B	19820310		
FR 2401917	A1	19790330	FR 1978-25162	19780831
FR 2401917	B1	19821217		
NL 7808981	A	19790308	NL 1978-8981	19780901
BE 870185	A1	19790305	BE 1978-190237	19780904
JP 54055583	A	19790502	JP 1978-107691	19780904
IL 55492	A	19820831	IL 1978-55492	19780904
ES 473103	A1	19790401	ES 1978-473103	19780905
DD 138657	A5	19791114	DD 1978-207656	19780905
AU 7839571	A	19800313	AU 1978-39571	19780905
AU 523728	B2	19820812		
PL 114207	B1	19810131	PL 1978-209423	19780905
CA 1111847	A1	19811103	CA 1978-310645	19780905
SU 900810	A3	19820123	SU 1978-2658400	19780905
HU 26336	A2	19830928	HU 1978-SA3133	19780905
HU 183018	B	19840428		
AT 7806399	A	19840315	AT 1978-6399	19780905
AT 376211	B	19841025		
ZA 7805061	A	19800430	ZA 1978-5061	19780906

PRIORITY APPLN. INFO.: US 1977-830411 A 19770906

GI



I II

L5 ANSWER 191 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
AB The quinazolines I (R = C1-8 hydrocarbon moiety optionally substituted by 1,2, or 3 F, Cl, or Br; R2 = monocyclic aryl; R2 = R3 = H, F, Cl, Br, C1-3 alkyl or alkoxy; R2R3 = OCH2O) were prepared by the dehydrogenation of II with S in the presence of a metal oxide, hydroxide, or salt, especially those of Ca, Fe, or Zn but not Mg, Al, or alkali metals. Thus, II (R = Me2CH, R1 = Ph, R2 = 7-Me, R3 = 4) reacted with S in p-cymene in the presence of FeO to give I (Rs same).
IT 22760-18-5P 40507-23-1P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 22760-18-5 CAPLUS
CN 2(1H)-Quinazolinone, 7-methyl-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)



RN 40507-23-1 CAPLUS
CN 2(1H)-Quinazolinone, 4-(4-fluorophenyl)-7-methyl-1-(1-methylethyl)- (CA INDEX NAME)



L5 ANSWER 192 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



L5 ANSWER 192 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1979:413542 CAPLUS
DOCUMENT NUMBER: 91:13542
ORIGINAL REFERENCE NO.: 91:2179a,2182a
TITLE: Studies on the mechanism of action of 1-(cyclopropylmethyl)-4-phenyl-6-methoxy-2(1H)-quinazolinone (SL-573). Its effect on several functions of rat polymorphonuclear leukocytes and mast cells
AUTHOR(S): Yanagi, Yoshikazu; Koga, Yoshihiko; Inukai, Toshiya
CORPORATE SOURCE: Res. Dep., Sumitomo Chem. Co., Ltd., Takarazuka, 665, Japan
SOURCE: Nippon Yakurigaku Zasshi (1979), 75(1), 45-52
CODEN: NYKZAU; ISSN: 0015-5691
DOCUMENT TYPE: Journal
LANGUAGE: Japanese
GI



I

AB SL-573 (I) [33453-23-5] was tested for its effect on the chemotaxis, phagocytosis, phagocytosis-stimulated O uptake and lysosomal enzyme release of rat polymorphonuclear leukocytes and on histamine [51-45-6] release from rat mast cells. I was a potent inhibitor of phagocytosis-stimulated O uptake. The inhibitory activity of I was 17 times that of indomethacin (IM) and >40 times that of ibuprofen (IP), mepirizole (MP), and aspirin (AS). In chemotaxis, I showed 50% inhibition at 58 μM, while IC50 values of IM, IP, MP and AS were 31, 68, 370, and 460 μM, resp. The inhibitory effect of I on lysosomal enzyme release was 49.5% at 100 μM, which was more potent than that of IM. In histamine release from mast cells, I showed more potent inhibitory activity than IM, IP, AS, and MP.
IT 33453-23-5
RL: BIOL (Biological study)
(histamine release by mast cell and polymorphonuclear leukocyte response to)
RN 33453-23-5 CAPLUS
CN 2(1H)-Quinazolinone, 1-(cyclopropylmethyl)-6-methoxy-4-phenyl- (CA INDEX NAME)

L5 ANSWER 193 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1979:405252 CAPLUS
DOCUMENT NUMBER: 91:5252
ORIGINAL REFERENCE NO.: 91:987a,990a
TITLE: Hydroxyquinazolines and their use as intermediates for pharmaceutical agents
INVENTOR(S): Middleton, William J.
PATENT ASSIGNEE(S): du Pont de Nemours, E. I., and Co., USA
SOURCE: U.S., 10 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 4141895	A	19790227	US 1977-807077	19770616
PRIORITY APPLN. INFO.:			US 1977-807077 A	19770616

OTHER SOURCE(S): MARPAT 91:5252
GI



I II

AB One hydroxyquinazoline I (R = Br, Cl, NO2, CF3; R1 = H, Br, Cl, F; R2 = Cl, Br) and its diastereoisomer were prepared as intermediates for benzodiazepines II (R's the same), which are tranquilizers, sedatives, and muscle relaxants (no data). Thus, 5,2-Cl(H2N)C6H3COPh was N-formylated with HCO2H (93% yield), the product 5,2-Cl(OCHNH)C6H3COPh N-methylated with NaH and MeI (70% yield), and the resulting 5,2-Cl(OCHNMe)COPh treated with NH3 and ZnCl2 in MeOH to give 76% 5,2-Cl(MeNH)C6H3C(:NH)Ph (III). Cyclization of III with FClCHCOCl in CH2Cl2 at 25-40° gave 49% I (R = R2 = Cl, R1 = H) as a mixture of diastereoisomers. Stirring I (R = R2 = Cl, R1 = H) with NaH in THF gave 22% II (R = Cl, R1 = H). Cyclizing III with FClCHCOCl in the presence of NaH in THF gave 34% II (R = Cl, R1 = H).
IT 70395-32-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and ring expansion of)
RN 70395-32-3 CAPLUS
CN 2-Quinazolinol, 6-chloro-2-(chlorofluoromethyl)-1,2-dihydro-1-methyl-4-phenyl-, (R*,R*)- (9CI) (CA INDEX NAME)

L5 ANSWER 193 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

Relative stereochemistry.



IT 70395-33-4P 70395-37-8P 70395-38-9P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 70395-33-4 CAPLUS
CN 2-Quinazolinol, 6-chloro-2-(chlorofluoromethyl)-1,2-dihydro-1-methyl-4-phenyl-, (R*,S*)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 70395-37-8 CAPLUS
CN Quinazoline, 6-chloro-2-(chlorofluoromethyl)-2-ethoxy-1,2-dihydro-1-methyl-4-phenyl-, (R*,R*)- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L5 ANSWER 193 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 70395-38-9 CAPLUS
CN Quinazoline, 6-chloro-2-(chlorofluoromethyl)-2-ethoxy-1,2-dihydro-1-methyl-4-phenyl-, (R*,S*)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L5 ANSWER 194 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1979:204132 CAPLUS
DOCUMENT NUMBER: 90:204132
ORIGINAL REFERENCE NO.: 90:32485a,32488a
TITLE: Imidazo- and pyrimido[2,1-b]quinazolines
INVENTOR(S): Yamamoto, Michihiro; Koshiba, Masao; Aono, Shunzji
PATENT ASSIGNEE(S): Sumitomo Chemical Co., Ltd., Japan
SOURCE: Ger. Offen., 21 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2838846	A1	19790315	DE 1978-2838846	19780906
JP 54048797	A	19790417	JP 1977-107643	19770906
FR 2401924	A1	19790330	FR 1978-25459	19780905
FR 2401924	B1	19810508		
US 4228167	A	19801014	US 1978-939869	19780905
CA 1106371	A1	19810804	CA 1978-310634	19780905
CH 636876	A5	19830630	CH 1978-9313	19780905
GB 2018761	A	19791024	GB 1978-35735	19780906
GB 2018761	B	19820310		
AU 505635	B1	19791129	AU 1978-39581	19780906

PRIORITY APPLN. INFO.: JP 1977-107643 A 19770906

OTHER SOURCE(S): MARPAT 90:204132
GI



I

AB The title compds. I (R = H, C1-3 alkyl; R1-R3 = H, halogen, C1-3 alkyl or alkoxy; R4 = C1-5 aliphatic group, aralkyl, cycloalkylalkyl; R5 = H, OH; m = 1, 2; n = 1, 2) were prepared for use as vasodilators and diuretics (test data tabulated). Thus, 6-chloro-1,4-dihydro-2-(2-hydroxyethylamino)-1-butyl-4-phenylquinazoline was refluxed with POCl3 to give I (Rn = R2 = R3 = R5 = H, R1 = 7-Cl, R4 = Bu, n = 1).
IT 70217-44-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reaction of, with aminoethanol)
RN 70217-44-6 CAPLUS
CN Quinazoline, 1-butyl-6-chloro-1,4-dihydro-2-(methylthio)-4-phenyl-, monohydriodide (9CI) (CA INDEX NAME)

L5 ANSWER 194 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



● HI

IT 70217-53-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reaction of, with aminopropanol)
RN 70217-53-7 CAPLUS
CN Quinazoline, 6-chloro-1,4-dihydro-1-methyl-2-(methylthio)-4-phenyl-, monohydriodide (9CI) (CA INDEX NAME)



● HI

IT 26920-08-1 70217-43-5
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of, with Me iodide)
RN 26920-08-1 CAPLUS
CN 2(1H)-Quinazolinethione, 6-chloro-3,4-dihydro-1-methyl-4-phenyl- (CA INDEX NAME)



RN 70217-43-5 CAPLUS
CN 2(1H)-Quinazolinethione, 1-butyl-6-chloro-3,4-dihydro-4-phenyl- (CA INDEX

L5 ANSWER 194 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
NAME)



L5 ANSWER 195 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1979:204128 CAPLUS
DOCUMENT NUMBER: 90:204128
ORIGINAL REFERENCE NO.: 90:32485a,32488a
TITLE: Quinazolinone oxides
PATENT ASSIGNEE(S): du Pont de Nemours, E. I., and Co., USA
SOURCE: Jpn. Kokai Tokkyo Koho, 8 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 54005989	A	19790117	JP 1978-73680	19780616
US 4160092	A	19790703	US 1977-807074	19770616
DK 7801764	A	19781217	DK 1978-1764	19780424
NO 7802086	A	19781219	NO 1978-2086	19780615
EP 148	A1	19790110	EP 1978-100162	19780615
R: BE, CH, DE, FR, GB, LU, NL, SE				
ZA 7803440	A	19790627	ZA 1978-3440	19780615
ES 470829	A1	19791001	ES 1978-470829	19780615
AU 7837138	A	19791220	AU 1978-37138	19780615
AT 7804367	A	19800315	AT 1978-4367	19780615
AT 359057	B	19801027		
FI 7801929	A	19781217	FI 1978-1929	19780616
SU 731893	A3	19800430	SU 1978-2626798	19780616
PRIORITY APPLN. INFO.:			US 1977-807074 A	19770616

OTHER SOURCE(S): MARPAT 90:204128
GI



I II

AB Quinazolinone oxides (I, R = H, R1 = Cl, Br, NO2, CF3; R2 = H, Br, Cl) were N-methylated with MeI to give I (R = Me), the alkali metal salts of which were hydrolyzed to give anti-oximes II. Thus, I (R = H, R1 = Cl, R2 = H) was heated with NaH in DMF at 60° and stirred with MeI 2 h at room temperature to give 58% I (R = Me). This was refluxed with NaH-EtOH 2 h to give 69% II (R1 = Cl, R2 = H).
IT 70296-98-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT

L5 ANSWER 195 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
(Reactant or reagent)
(prepn. and hydrolytic ring cleavage of, benzophenone anti-oxime deriv.
from)
RN 70296-98-9 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-1-methyl-4-phenyl-, 3-oxide (CA INDEX NAME)



IT 70297-00-6P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 70297-00-6 CAPLUS
CN 2(1H)-Quinazolinone, 6-bromo-1-methyl-4-phenyl-, 3-oxide (CA INDEX NAME)



L5 ANSWER 196 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1979:203899 CAPLUS
DOCUMENT NUMBER: 90:203899
ORIGINAL REFERENCE NO.: 90:32437a,32440a
TITLE: Synthetic studies on quinazoline derivatives. I. Formation of 2(1H)-quinazolinones from the reaction of
2-trihaloacetamidophenyl ketones with ammonia
AUTHOR(S): Yamamoto, Michihiro; Inaba, Shigeho; Yamamoto, Hisao
CORPORATE SOURCE: Res. Dev. Cent., Sumitomo Chem. Co., Ltd., Takarazuka,
Japan
SOURCE: Chemical & Pharmaceutical Bulletin (1978), 26(6), 1633-51
CODEN: CPBTAL; ISSN: 0009-2363
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 90:203899
GI



I II

AB The trihaloacetamidophenyl ketones I (R = H, Me, Et, Me2CH, alkyl, PhCH2, EtOCH2CH2, CF3CH2, cyclopropylmethyl; R1 = H,Cl; R2 = Cl,H; R3 = H, halo, MeSO2, CF3, Ac, CO2Me, CN, Me, MeO, NO2; R2 R3 = OCH2O; R4 = H, NO2; R5 = Ph, 2-thienyl, 2-furyl, 2-pyridyl, 2-ClC6H4, 3-ClC6H4, 2-FC6H4, 2-MeC6H4, cyclohexyl, Me; X = Cl, Br, F)(50 compds.), which were also prepared, were readily converted to the corresponding quinazolinone II via treatment with NH3, via loss of the trihalomethyl groups. Treatment of I (R = R1 = R2 = R4 = H, R3 = Cl, R5 = Ph, X = Cl) with NH4OAc in Me2SO gave II in quant. yield, whereas I (R = R1 = R2 = R4 = H, R3 = Cl, R5 = Ph, X = F) gave 6-chloro-4-phenyl-1-(trifluoromethyl)quinazoline. N-substituted derivs. of 2-trichloroacetamidobenzophenones yielded 4-phenyl-2H-3,1-benzoxazin-2-ones or 2-aminobenzophenone imines, depending on reaction conditions. The trichloroacetanilides containing EtO2C, CN, or H groups in the ortho position were converted to the corresponding cyclic or acyclic ureas. Mechanisms for their formations were proposed. In the case of the trichloroacetanilides bearing an ethoxycarbonyl, cyano or H in the o-position, the corresponding cyclic or acyclic ureas were obtained by this reaction. Mechanisms for their formations are proposed.
IT 20927-53-1P 23441-64-7P 23441-66-9P
23465-52-3P 26313-51-9P 26831-11-8P
26953-46-8P 33453-19-9P 33453-23-5P
33890-29-8P 37554-40-8P 37555-10-5P
49830-89-9P

L5 ANSWER 196 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)
RN 20927-53-1 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-1-methyl-4-phenyl- (CA INDEX NAME)



RN 23441-64-7 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-1-ethyl-4-phenyl- (CA INDEX NAME)



RN 23441-66-9 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-4-phenyl-1-(2-propenyl)- (9CI) (CA INDEX NAME)



RN 23465-52-3 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-4-phenyl-1-(phenylmethyl)- (CA INDEX NAME)

L5 ANSWER 196 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 26313-51-9 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-1-(2-ethoxyethyl)-4-(2-fluorophenyl)- (CA INDEX NAME)



RN 26831-11-8 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)



RN 26953-46-8 CAPLUS
CN 2(1H)-Quinazolinone, 1-methyl-6-nitro-4-phenyl- (CA INDEX NAME)

L5 ANSWER 196 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 33453-19-9 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-1-(cyclopropylmethyl)-4-phenyl- (CA INDEX NAME)



RN 33453-23-5 CAPLUS
CN 2(1H)-Quinazolinone, 1-(cyclopropylmethyl)-6-methoxy-4-phenyl- (CA INDEX NAME)



RN 33890-29-8 CAPLUS
CN 2(1H)-Quinazolinone, 1-(cyclopropylmethyl)-6-nitro-4-phenyl- (CA INDEX NAME)

L5 ANSWER 196 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 37554-40-8 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-4-phenyl-1-(2,2,2-trifluoroethyl)- (CA INDEX NAME)



RN 37555-10-5 CAPLUS
CN 2(1H)-Quinazolinone, 8-chloro-1-(cyclopropylmethyl)-4-phenyl- (CA INDEX NAME)



RN 49830-89-9 CAPLUS
CN 2(1H)-Quinazolinone, 6-methoxy-4-phenyl-1-(2,2,2-trifluoroethyl)- (CA INDEX NAME)

L5 ANSWER 196 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



L5 ANSWER 197 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1979:168542 CAPLUS
DOCUMENT NUMBER: 90:168542
ORIGINAL REFERENCE NO.: 90:26759a,26762a
TITLE: A new convenient synthesis of 2-thioxo-1,2-dihydroquinazolines
AUTHOR(S): Tamura, Yasumitsu; Kawasaki, Tomomi; Tanio, Masami; Kita, Yasuyuki
CORPORATE SOURCE: Fac. Pharm. Sci., Osaka Univ., Suita, Japan
SOURCE: Synthesis (1979), (2), 120-1
CODEN: SYNTBF; ISSN: 0039-7881
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 90:168542
GI



AB Treating o-acylanilines I (R = Ph, R1 = H, Et, Me2CH; R2 = H, Cl; or R = Me, R1 = R2 = H) with Ph3P(SCN)2 in CH2Cl2 under N at -40° with warming to room temperature gave 62-88% quinazolinethiones II.

IT 26824-68-0P 26930-57-4P 69964-51-8P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 26824-68-0 CAPLUS
CN 2(1H)-Quinazolinethione, 1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)



RN 26930-57-4 CAPLUS
CN 2(1H)-Quinazolinethione, 1-ethyl-4-phenyl- (CA INDEX NAME)

L5 ANSWER 197 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 69964-51-8 CAPLUS
CN 2(1H)-Quinazolinethione, 6-chloro-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)



L5 ANSWER 198 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1979:162097 CAPLUS
DOCUMENT NUMBER: 90:162097
ORIGINAL REFERENCE NO.: 90:25631a,25634a
TITLE: Antipyretic activity of 1-cyclopropylmethyl-4-phenyl-6-methoxy-2(1H)-quinazolinone (SL-573). II
AUTHOR(S): Yanagi, Yoshikazu; Kurokawa, Hiroshi; Nagao, Yasuko; Inukai, Toshiya
CORPORATE SOURCE: Pharm. Div., Sumitomo Chem. Co., Ltd., Takarazuka, Japan
SOURCE: Nippon Yakurigaku Zasshi (1978), 74(8), 981-90
CODEN: NYKZAU; ISSN: 0015-5691
DOCUMENT TYPE: Journal
LANGUAGE: Japanese
GI



AB Antipyretic activity of SL-573 (I) [33453-23-5] was not influenced by age and sex difference in rats. The combined effect of other drugs on the antipyretic activity of I was examined Cefazolin Na [27164-46-1], ampicillin Na [69-52-3], codeine phosphate [52-28-8], hydrochlorothiazide [58-93-5], and haloperidol [52-86-8] did not show any significant effect on the antipyretic activity of I. Diazepam [439-14-5] itself showed antipyretic activity, and its combined use with I resulted in an additive effect. I also showed antipyretic activity in mice with fever induced by yeast, as was seen in rats. I diminished the hyperthermic response to bacterial endotoxin and leukocytic pyrogen in rats, but not to 2,4-dinitrophenol. Addnl., I did not inhibit the bacterial endotoxin-induced production of leukocytic pyrogen and its release in saline medium. I, therefore, is considered to be a centrally acting antipyretic. I.v. injection of prostaglandin E2 and arachidonic acid induced a hyperthermia in mice. I inhibited prostaglandin-induced biosynthesis from arachidonic acid; the prostaglandin biosynthesis inhibition may be one of the main mechanisms of antipyretic action of I.

IT 33453-23-5
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(antipyretic activity of)

RN 33453-23-5 CAPLUS
CN 2(1H)-Quinazolinone, 1-(cyclopropylmethyl)-6-methoxy-4-phenyl- (CA INDEX NAME)

L5 ANSWER 198 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



L5 ANSWER 199 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1979:66517 CAPLUS
DOCUMENT NUMBER: 90:66517
ORIGINAL REFERENCE NO.: 90:10431a,10434a
TITLE: 2(1H)-quinazolinones as novel non-acidic anti-inflammatory agents
AUTHOR(S): Ott, Hans
CORPORATE SOURCE: Med. Chem. Res. Dep., Sandoz Ltd., Basel, Switz.
SOURCE: Scandinavian Journal of Rheumatology, Supplement (1978), 21(Proquazone), 5-7
CODEN: SJRSAS; ISSN: 0301-3847
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



I

AB Chemical modification of 1-methyl-4-phenyl-2(1H)-quinazolinone produced proquazone (I) [22760-18-5], an antiinflammatory agent comparable to indomethacin. Pharmacol. activity of eight I analogs was compared with that of phenylbutazone and indomethacin, and mol. structure-biol. activity relationship discussed.

IT 22760-18-5 22760-25-4 23441-64-7
26772-86-1 26831-07-2 27524-93-2
28340-57-0 28340-64-9
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(antiinflammatory activity of)

RN 22760-18-5 CAPLUS
CN 2(1H)-Quinazolinone, 7-methyl-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)



RN 22760-25-4 CAPLUS

L5 ANSWER 199 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

CN 2(1H)-Quinazolinone, 7-methoxy-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)



RN 23441-64-7 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-1-ethyl-4-phenyl- (CA INDEX NAME)



RN 26772-86-1 CAPLUS
CN 2(1H)-Quinazolinone, 1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)



RN 26831-07-2 CAPLUS
CN 2(1H)-Quinazolinone, 1-ethyl-4-phenyl- (CA INDEX NAME)



RN 27524-93-2 CAPLUS
CN 2(1H)-Quinazolinone, 7-chloro-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)

L5 ANSWER 199 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 28340-57-0 CAPLUS
CN 2(1H)-Quinazolinone, 6-(dimethylamino)-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)



RN 28340-64-9 CAPLUS
CN 2(1H)-Quinazolinone, 7-(dimethylamino)-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)



L5 ANSWER 200 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1979:66455 CAPLUS
DOCUMENT NUMBER: 90:66455
ORIGINAL REFERENCE NO.: 90:10415a,10418a
TITLE: The distribution of proquazone and three of its metabolites in serum and synovial fluid
AUTHOR(S): Ott, H.; Meier, J.
CORPORATE SOURCE: Serv. Rheumatol. Phys. Med., Hop. Communal, Basel, Switz.
SOURCE: Scandinavian Journal of Rheumatology, Supplement (1978), 21(Proquazone), 12-14
CODEN: SJRSAS; ISSN: 0301-3847
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



I

AB Proquazone (I) [22760-18-5] (600 mg, orally) given to patients with hydrarthrosis of the knee was rapidly absorbed and metabolized, but high concns. were still found in the synovial fluid and serum up to 7 h after intake. Considerable variations were observed among patients. The concns. were generally lower in the synovial fluid than in the serum. Distribution of I metabolites in these body fluids is described.
IT 65765-07-3 66154-91-4 69104-02-5
RL: BIOL (Biological study)
(as proquazone metabolite)
RN 65765-07-3 CAPLUS
CN 2(1H)-Quinazolinone, 4-(3-hydroxyphenyl)-7-methyl-1-(1-methylethyl)- (CA INDEX NAME)



RN 66154-91-4 CAPLUS
CN 7-Quinazolinecarboxylic acid, 1,2-dihydro-4-(3-hydroxyphenyl)-1-(1-methylethyl)-2-oxo- (CA INDEX NAME)



RN 69104-02-5 CAPLUS
CN 7-Quinazolinecarboxylic acid, 1,2-dihydro-1-(1-methylethyl)-2-oxo-4-phenyl- (CA INDEX NAME)



IT 22760-18-5
RL: BIOL (Biological study)
(of serum and synovial fluid)
RN 22760-18-5 CAPLUS
CN 2(1H)-Quinazolinone, 7-methyl-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)



L5 ANSWER 201 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1979:48551 CAPLUS
DOCUMENT NUMBER: 90:48551
ORIGINAL REFERENCE NO.: 90:7681a,7684a
TITLE: Effect of 1-cyclopropylmethyl-4-phenyl-6-methoxy-2(1H)-quinazolinone (SL-573) on uric acid metabolism and urinary excretion in rats and mice
AUTHOR(S): Iwata, Heitaroh; Iwaki, Hideo; Gyotoku, Tomochika; Aisaka, Akira
CORPORATE SOURCE: Fac. Pharm. Sci., Osaka Univ., Osaka, Japan
SOURCE: Oyo Yakuri (1978), 16(1), 17-22
CODEN: OYYAA2; ISSN: 0369-8033
DOCUMENT TYPE: Journal
LANGUAGE: Japanese
GI



I

AB The oral administration of SL-573 (I) [33453-23-5] at 100 mg/kg increased urinary uric acid [69-93-2] excretion in rats, mice, and rats treated with uric acid. Serum uric acid was not affected. I increased urine volume in rats. I showed no influence on the activity of xanthine oxidase and uricase. Apparently, I has no effect on uric acid metabolism, but markedly affects urinary uric acid excretion.
IT 33453-23-5
RL: BIOL (Biological study)
(urate metabolism response to)
RN 33453-23-5 CAPLUS
CN 2(1H)-Quinazolinone, 1-(cyclopropylmethyl)-6-methoxy-4-phenyl- (CA INDEX NAME)



L5 ANSWER 202 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1979:48363 CAPLUS
DOCUMENT NUMBER: 90:48363
ORIGINAL REFERENCE NO.: 90:7637a,7640a
TITLE: Anti-inflammatory activity of SL-573
AUTHOR(S): Yanagi, Yoshikazu; Awata, Hiroshi; Koga, Yoshihiko; Kurokawa, Hiroshi; Inukai, Toshiya
CORPORATE SOURCE: Pharm. Div., Sumitomo Chem. Co., Ltd., Takarazuka, Japan
SOURCE: Nippon Yakurigaku Zasshi (1978), 74(6), 749-62
CODEN: NYKZAU; ISSN: 0015-5691
DOCUMENT TYPE: Journal
LANGUAGE: Japanese
GI



I

AB In the carrageenin-induced edema test in rats, the antiinflammatory effect of SL-573 (I) [33453-23-5] was 1.6 times that of phenylbutazone (II) and ibuprofen (III), 3.3 that of mefenamic acid (IV), and 6.7 times that of mepirizole (V). In the yeast-induced edema test in rats, I showed equal activity with III and 4 times that of V. In the dextran-induced edema test in rats, the antiinflammatory activity of I was significantly higher than those of III and V. I showed no antiinflammatory activity in the formalin-induced edema test in rats. I markedly inhibited the AcOH-induced increase in capillary permeability in mice. I showed equipotent activity with II in the adjuvant arthritis test in rats, but had little effect on the healing of skin wounds. The effect of I on the carrageenin-induced edema was not diminished in the adrenalectomized rats. The gastric hemorrhagic effect of I was significantly less than that usually seen with nonsteroidal antiinflammatory drugs. I did not induce intestinal perforation even at a dose of 800 mg/kg. Addnl., I showed a protective effect against the indomethacin-induced intestinal lesions.
IT 33453-23-5
RL: BIOL (Biological study)
(antiinflammatory pharmacol. of)
RN 33453-23-5 CAPLUS
CN 2(1H)-Quinazolinone, 1-(cyclopropylmethyl)-6-methoxy-4-phenyl- (CA INDEX NAME)

L5 ANSWER 202 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



L5 ANSWER 203 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1979:48362 CAPLUS
DOCUMENT NUMBER: 90:48362
ORIGINAL REFERENCE NO.: 90:7637a,7640a
TITLE: Analgetic and antipyretic activity of SL-573
AUTHOR(S): Yanagi, Yoshikazu; Kurokawa, Hiroshi; Koga, Yoshihiko; Awata, Hiroshi; Inukai, Toshiya
CORPORATE SOURCE: Pharm. Div., Sumitomo Chem. Co., Ltd., Takarazuka, Japan
SOURCE: Nippon Yakurigaku Zasshi (1978), 74(6), 735-47
CODEN: NYKZAU; ISSN: 0015-5691
DOCUMENT TYPE: Journal
LANGUAGE: Japanese
GI



I

AB Analgesic potency of SL-573 (I) [33453-23-5] was between that of indomethacin and aminopyrine (II) in chemical stimulation tests. Compared to II, the analgesic activity of I was 3.2 times in phenylquinone writhing test, 4.1 times in the acetic acid writhing test, and 6.3 times in the Randall-Selitto test. The analgesic activity of I was not evident in the mech. or heat stimulation test and was not antagonized by naloxone. I showed no antagonistic effect to morphine. Tolerance to the analgesic activity of I was not observed I had no effect on the evoked potentials recorded from cells in the central pain pathway and the site of analgesic effect was considered to be in peripheral sites of the sensory neurons. The antipyretic activity of I was equal to that of II in febrile rabbits and 4 times that of II in febrile rats. I did not affect normal body temperature of rabbits and rats. I appeared to have antipyretic-analgesic activity of the same magnitude as that of codeine.

IT 33453-23-5
RL: BIOL (Biological study)
(analgesic and antipyretic activities of)

RN 33453-23-5 CAPLUS
CN 2(1H)-Quinazolinone, 1-(cyclopropylmethyl)-6-methoxy-4-phenyl- (CA INDEX NAME)

L5 ANSWER 203 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



L5 ANSWER 204 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1979:34076 CAPLUS
DOCUMENT NUMBER: 90:34076
ORIGINAL REFERENCE NO.: 90:5399a,5402a
TITLE: Influence of proquazone (Biarison) on the levels of complement components (C3 and C4) in synovial fluid and on IgM in serum in patients with active rheumatoid arthritis. A preliminary report
AUTHOR(S): Skrifvars, Bo
CORPORATE SOURCE: Dep. Med. IV, Helsinki Univ. Cent. Hosp., Helsinki, Finland
SOURCE: Scandinavian Journal of Rheumatology, Supplement (1978), 21(Proquazone), 40-2
CODEN: SJRSAS; ISSN: 0301-3847
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



I

AB Proquazone (I) [22760-18-5] (600-900 mg/day) administered for 4-7 wk to patients with erosive rheumatoid arhthritis increased the C3 and/or C4 levels in the synovial fluid but not in the serum. The patients with psoriasis arthropathy did not show any reaction. Of the Igs measured, only IgM in serum was increased in the patients, but the level decreased during I treatment.

IT 22760-18-5
RL: BIOL (Biological study)
(complements of synovial fluid and Igs of blood serum response to, in arthritis)

RN 22760-18-5 CAPLUS
CN 2(1H)-Quinazolinone, 7-methyl-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)



L5 ANSWER 205 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1979:33638 CAPLUS
DOCUMENT NUMBER: 90:33638
ORIGINAL REFERENCE NO.: 90:5299a,5302a
TITLE: Pharmacological properties of proquazone
AUTHOR(S): Gubler, H. U.; Baggiolini, M.
CORPORATE SOURCE: Res. Inst. Wander, Bern, Switz.
SOURCE: Scandinavian Journal of Rheumatology, Supplement (1978), 21(Proquazone), 8-11
CODEN: SJRSAS; ISSN: 0301-3847
DOCUMENT TYPE: Journal; General Review
LANGUAGE: English
GI



I

AB A review with 14 refs. on pharmacol. properties of proquazone (I) [22760-18-5].
IT 22760-18-5
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmacol. of)
RN 22760-18-5 CAPLUS
CN 2(1H)-Quinazolinone, 7-methyl-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)



L5 ANSWER 206 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1978:597584 CAPLUS
DOCUMENT NUMBER: 89:197584
ORIGINAL REFERENCE NO.: 89:30719a,30722a
TITLE: Tricyclic hetero condensed ring compounds
INVENTOR(S): Ishikawa, Fumiyoshi; Kosasayama, Akira; Abiko, Kazushi
PATENT ASSIGNEE(S): Daiichi Seiyaku Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 6 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 53044593	A	19780421	JP 1976-116784	19760929
JP 60039074	B	19850904		

PRIORITY APPLN. INFO.: JP 1976-116784 A 19760929

GI For diagram(s), see printed CA Issue.
AB Fifteen title compds. I [X = N:, S, CH2; X1 = N:, NR (R = H, alkyl), O, S, CH2; at least either X or X1 has an N atom; n = 2-4] and their salts were prepared I had hypotensive (stronger than that of tolbutamide) and blood platelet aggregation inhibitory activities. Thus, heating 1-(2-hydroxyethyl)-4-phenyl-1,2,3,4-tetrahydro-2-quinazolinethione and MeSO3H 15 min at 130-40° gave, 5-phenyl-1,2-dihydro-5H-thiazolo[3,2-a]quinazoline (as the HCl salt).
IT 68210-70-8
RL: RCT (Reactant); RACT (Reactant or reagent)
(cyclization of, thiazoloquinazoline derivative from)
RN 68210-70-8 CAPLUS
CN 2(1H)-Quinazolinethione, 3,4-dihydro-1-(2-hydroxyethyl)-4-phenyl- (CA INDEX NAME)



L5 ANSWER 207 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1978:517635 CAPLUS
DOCUMENT NUMBER: 89:117635
ORIGINAL REFERENCE NO.: 89:18095a,18098a
TITLE: Photochemical decomposition of 1,4-benzodiazepines. Diazepam
AUTHOR(S): Cornelissen, P. J. G.; Beijersbergen van Henegouwen, G. M. J.; Gerritsma, K. W.
CORPORATE SOURCE: Gorlaeus Lab., State Univ. Leiden, Leiden, Neth.
SOURCE: International Journal of Pharmaceutics (1978), 1(3), 173-81
CODEN: IJPHDE; ISSN: 0378-5173
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



I

AB A methanolic solution of diazepam (I) [439-14-5], irradiated with UV light (254 nm) for 17 h led to the formation of benzophenones, 4-phenylquinazolines, 4-phenylquinazolones, and glycine [56-40-6]. The percentage of the compds. formed depended on the solvent, concentration of the solution, irradiation time, intensity, and the wavelength of light. Under the investigated conditions, benzophenones 8, 4-phenylquinazolinones 15, and 4-phenylquinazolines 70% were formed.
IT 17629-04-8 20927-53-1
RL: BIOL (Biological study)
(diazepam photochem. decomposition product)
RN 17629-04-8 CAPLUS
CN 2(1H)-Quinazolinone, 1-methyl-4-phenyl- (CA INDEX NAME)



RN 20927-53-1 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-1-methyl-4-phenyl- (CA INDEX NAME)

L5 ANSWER 207 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



L5 ANSWER 208 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1978:517624 CAPLUS
DOCUMENT NUMBER: 89:117624
ORIGINAL REFERENCE NO.: 89:18091a,18094a
TITLE: Physicochemical study of some psychotropic drugs. I. Investigation of the Romanian product diazepam
AUTHOR(S): Predescu, Irina; Barza, Paraschiva; Macovschi, M.
CORPORATE SOURCE: Lab. Chim. Fiz. Coloidala, Fac. Farm., Bucharest, Rom.
SOURCE: Farmacia (Bucharest, Romania) (1977), 25(4), 241-6
CODEN: FRMBAZ; ISSN: 0014-8237
DOCUMENT TYPE: Journal
LANGUAGE: Romanian
GI



II III

AB HCl(1N) decomposed diazepam (I) [439-14-5] by 10% within 10 days yielding 2-methylamino-5-chlorobenzophenone (II) [1022-13-5]. In 0.1N H2SO4, the above benzophenone and 1-methyl-4-phenyl-6-chloro-2-quinazolinone (III) [20927-53-1] were formed. In water, I was stable at 65° for 2 h. I was separated from oxazepam, nitrazepam, and chlorodiazepoxide by thin-layer chromatog. using 1 of 4 solvent systems.
IT 20927-53-1
RL: BIOL (Biological study)
(diazepam oxidation product)
RN 20927-53-1 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-1-methyl-4-phenyl- (CA INDEX NAME)



L5 ANSWER 209 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1978:509565 CAPLUS
DOCUMENT NUMBER: 89:109565
ORIGINAL REFERENCE NO.: 89:16893a,16896a
TITLE: 4-Phenyl-2(1H)-quinazolinones
INVENTOR(S): Gamboni, Guido; Schmid, Walter; Sutter, Alfred
PATENT ASSIGNEE(S): Sandoz-Patent-G.m.b.H., Fed. Rep. Ger.
SOURCE: Ger. Offen., 10 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2753970	A1	19780615	DE 1977-2753970	19771203
CH 625512	A5	19810930	CH 1976-15619	19761213
FI 7703659	A	19780614	FI 1977-3659	19771202
FI 64358	B	19830729		
FI 64358	C	19831110		
DK 7705408	A	19780614	DK 1977-5408	19771205
DK 143025	B	19810316		
DK 143025	C	19810928		
NO 7704147	A	19780614	NO 1977-4147	19771205
NO 147484	B	19830110		
NO 147484	C	19830420		
SE 7713742	A	19780614	SE 1977-13742	19771205
SE 442996	B	19860210		
SE 442996	C	19860529		
FR 2373534	A1	19780707	FR 1977-36661	19771206
FR 2373534	B1	19830114		
GB 1592687	A	19810708	GB 1977-51144	19771208
NL 7713651	A	19780615	NL 1977-13651	19771209
CA 1091229	A1	19801209	CA 1977-292750	19771209
BE 861775	A1	19780612	BE 1977-183388	19771212
JP 53077077	A	19780708	JP 1977-148230	19771212
JP 61043349	B	19860926		
DD 133327	A5	19781227	DD 1977-202556	19771212
ES 464966	A1	19790101	ES 1977-464966	19771212
AU 7731438	A	19790621	AU 1977-31438	19771212
AU 517193	B2	19810716		
CS 196409	B2	19800331	CS 1977-8309	19771212
HU 19087	A2	19801128	HU 1977-SA3080	19771212
HU 176875	B	19810528		
SU 793391	A3	19801230	SU 1977-2552353	19771212
IL 53588	A	19811130	IL 1977-53588	19771212
AT 7708846	A	19821115	AT 1977-8846	19771212
AT 371450	B	19830627		
ZA 7707425	A	19790725	ZA 1977-7425	19771213
US 4236006	A	19801125	US 1979-8328	19790201

PRIORITY APPLN. INFO.: CH 1976-15619 A 19761213
US 1977-861426 A1 19771213

OTHER SOURCE(S): MARPAT 89:109565

L5 ANSWER 209 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
GI



I II

AB The title compds. I (R = H, halo, alkyl, alkoxy, CF3; n = 1, 2; R1 = C1-5 aliphatic group; R2 = R3 = H, halo, alkyl, alkylthio, alkoxy, NO2, CF3) were prepared by the cyclization of II with urea or alkyl carbamates in the presence of acid. Thus, 2,5-BzMeC6H3NHCHMe2 was refluxed with urea and BzOH in PhMe to give I (Rn = H, R1 = Me2CH, R2 = 7-Me, R3 = H). I are useful as antiinflammatory agents (no data).
IT 22760-18-5P 40507-23-1P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 22760-18-5 CAPLUS
CN 2(1H)-Quinazolinone, 7-methyl-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)



RN 40507-23-1 CAPLUS
CN 2(1H)-Quinazolinone, 4-(4-fluorophenyl)-7-methyl-1-(1-methylethyl)- (CA INDEX NAME)



L5 ANSWER 209 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

L5 ANSWER 210 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1978:499805 CAPLUS
DOCUMENT NUMBER: 89:99805
ORIGINAL REFERENCE NO.: 89:15127a,15130a
TITLE: Inhibition of prostaglandin biosynthesis in rat small intestine by SL-573
AUTHOR(S): Yanagi, Yoshikazu
CORPORATE SOURCE: Res. Dev. Cent., Sumitomo Chem. Co. Ltd., Hyogo, Japan
SOURCE: Biochemical Pharmacology (1978), 27(5), 723-8
CODEN: BCPCA6; ISSN: 0006-2952
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Prostaglandin formation by the 20,000-g supernatant of rat small intestine was reversibly inhibited by SL-573 [33453-23-5] (5-20 μg/mL) and indomethacin [53-86-1] (2.0-14 μg/mL). The concns. giving 50% inhibition of prostaglandin formation were 9.1 and 5.6 μg/mL for SL-573 and indomethacin, resp. Both compds. inhibited formation of all products to the same degree, suggesting that the drugs inhibited the cyclooxygenase. The possible relation between prostaglandin biosynthesis inhibition and ulcer formation is discussed.
IT 33453-23-5
RL: BIOL (Biological study)
(prostaglandin formation in response to, in small intestine, ulcer formation in relation to)
RN 33453-23-5 CAPLUS
CN 2(1H)-Quinazolinone, 1-(cyclopropylmethyl)-6-methoxy-4-phenyl- (CA INDEX NAME)



L5 ANSWER 211 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1978:470825 CAPLUS
DOCUMENT NUMBER: 89:70825
ORIGINAL REFERENCE NO.: 89:10827a,10830a
TITLE: In-vivo effects of anti-inflammatory and other drugs on granulocyte emigration in the rabbit skin collection chamber
AUTHOR(S): Borel, J. F.; Feurer, Camille
CORPORATE SOURCE: Biol. Med. Res. Div., Sandoz Ltd., Basel, Switz.
SOURCE: Journal of Pathology (1978), 124(2), 85-93
CODEN: JPTLAS; ISSN: 0022-3417
DOCUMENT TYPE: Journal
LANGUAGE: English
AB A method for measuring localized leukocyte mobilization under in-vivo conditions with a plastic skin collection-chamber adapted to the rabbit ear was used for assessing the effects of antiinflammatory and other agents on granulocyte emigration. Studies on the effect of oral drug administration to rabbits indicated that most antiinflammatory drugs, 2 cystostatic agents (cyclophosphamide [50-18-0] and colchicine [64-86-8]), but none of the other compds. exhibiting antihistaminic, β-adrenolytic or neuroleptic properties, inhibited granulocyte mobilization. The results after topical application of some of these agents into the chamber correlated well with those obtained after oral treatment. This technique may thus prove useful in selecting new compds. inhibiting granulocyte mobilization in acute inflammation reactions.
IT 22760-18-5
RL: BIOL (Biological study)
(granulocyte emigration inhibition by)
RN 22760-18-5 CAPLUS
CN 2(1H)-Quinazolinone, 7-methyl-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)



L5 ANSWER 212 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1978:443474 CAPLUS
DOCUMENT NUMBER: 89:43474
ORIGINAL REFERENCE NO.: 89:6765a,6768a
TITLE: 3,4-Dihydro-2(1H)-quinazoline derivatives
INVENTOR(S): Yamamoto, Michihiro; Koshiba, Masao; Yamamoto, Hisao
PATENT ASSIGNEE(S): Sumitomo Chemical Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 5 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 53005180	A	19780118	JP 1976-78780	19760701
PRIORITY APPLN. INFO.:			JP 1976-78780 A	19760701

GI



AB Title derivs. I [R, R1, R2 = cyclopropyl (Q), Me, H; Q, Et, H; Q, Et, Me; Q, Me, Et; H, Me, Et; resp.] were prepared by quaternization of II with R1X (X = iodine, Br) followed by reaction of the resulting quinazolinium salts III with H2O or alcs. R2OH. I had antiinflammatory, hypoglycemic, histamine H2 receptor-inhibiting, and antitrichomonas activities (no data). Thus, refluxing 2.2 g II (R = Q) with 20 mL EtI 17 h gave 1.9 g III (R = Q, R1 = Me, X = iodine), which (0.1 g) was stirred in 10 mL H2O 30 min at 50-60° to give I (R = Q, R1 = Me, R2 = H) quant.
IT 66478-73-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reaction with water or alcs.)
RN 66478-73-7 CAPLUS
CN Quinazolinium, 6-chloro-1-(cyclopropylmethyl)-1,2-dihydro-3-methyl-2-oxo-4-phenyl-, iodide (9CI) (CA INDEX NAME)

L5 ANSWER 212 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



● I-

IT 41230-84-6P 66478-74-8P 66478-75-9P
66478-76-0P 66835-50-5P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 41230-84-6 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-1-(cyclopropylmethyl)-3-ethyl-3,4-dihydro-4-phenyl- (CA INDEX NAME)



RN 66478-74-8 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-1-(cyclopropylmethyl)-3-ethyl-3,4-dihydro-4-methyl-4-phenyl- (CA INDEX NAME)



L5 ANSWER 212 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
RN 66478-75-9 CAPLUS
CN 2(1H)-Quinazolinone,
6-chloro-1-(cyclopropylmethyl)-4-ethyl-3,4-dihydro-3-
methyl-4-phenyl- (CA INDEX NAME)



RN 66478-76-0 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-4-ethyl-3,4-dihydro-1,3-dimethyl-4-phenyl-
(CA INDEX NAME)



RN 66835-50-5 CAPLUS
CN 2(1H)-Quinazolinone,
6-chloro-1-(cyclopropylmethyl)-3,4-dihydro-3-methyl-4-
phenyl- (CA INDEX NAME)



IT 33453-19-9
RL: RCT (Reactant); RACT (Reactant or reagent)

L5 ANSWER 212 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
(quaternization of, by Et iodide)
RN 33453-19-9 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-1-(cyclopropylmethyl)-4-phenyl- (CA INDEX
NAME)



L5 ANSWER 213 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1978:436864 CAPLUS
DOCUMENT NUMBER: 89:36864
ORIGINAL REFERENCE NO.: 89:5611a,5614a
TITLE: Analgesic and antiinflammatory activity of Biarison. Clinical experimental studies
AUTHOR(S): Gabka, J.
CORPORATE SOURCE: Schlossparkklinikhotel, Berlin, Fed. Rep. Ger.
SOURCE: Muenchener Medizinische Wochenschrift (1978), 120(10),
331-4
CODEN: MMWOAU; ISSN: 0027-2973
DOCUMENT TYPE: Journal
LANGUAGE: German
AB In human subjects, Biarison (I) [22760-18-5] (600 mg) increased the threshold to pain (elec. stimulation of the teeth) by 22.3 mA after 75
min, compared with a maximum increase of 18 mA in subjects given indomethacin
(100 mg); no differences in antiinflammatory activity between I (900 mg/day) and indomethacin (140 mg/day) were observed in postoperative edema.
IT 22760-18-5
RL: BIOL (Biological study)
(analgesia and inflammation inhibition by)
RN 22760-18-5 CAPLUS
CN 2(1H)-Quinazolinone, 7-methyl-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)



L5 ANSWER 214 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1978:163999 CAPLUS
DOCUMENT NUMBER: 88:163999
ORIGINAL REFERENCE NO.: 88:25725a,25728a
TITLE: Proquazone (Sandoz 43-715), an unusually potent inhibitor of the platelet release reaction and malondialdehyde formation
AUTHOR(S): Zucker, Marjorie B.
CORPORATE SOURCE: Dep. Pathol., New York Univ. Med. Cent., New York, NY,
USA
SOURCE: Proceedings of the Society for Experimental Biology and Medicine (1977), 156(2), 209-12
CODEN: PSEBAA; ISSN: 0037-9727
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



I

AB Although Sandoz 43-715 (proquazone) [22760-18-5] is not an acid, its action on platelets is similar to that of a typical acidic NSAID: I inhibited the release reaction and associated production of malondialdehyde [542-78-9] without affecting primary aggregation caused by ADP or epinephrine, and it failed to inhibit the collagen-induced release which remained after maximum inhibition by aspirin. It is unusually
active; it may have an effect in vitro at 11 nM, and is at least 50 times more active than indomethacin in preventing collagen-induced release from human platelets.
IT 22760-18-5
RL: BIOL (Biological study)
(platelet secretion inhibition by)
RN 22760-18-5 CAPLUS
CN 2(1H)-Quinazolinone, 7-methyl-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)



L5 ANSWER 215 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1978:163540 CAPLUS
DOCUMENT NUMBER: 88:163540
ORIGINAL REFERENCE NO.: 88:25645a,25648a
TITLE: Proquazone
AUTHOR(S): Alhadeff, M.
CORPORATE SOURCE: Spain
SOURCE: Drugs of Today (1977), 13(12), 531-7
CODEN: MDACAP; ISSN: 0025-7656
DOCUMENT TYPE: Journal; General Review
LANGUAGE: English/Spanish
GI



I

AB A review with 15 refs. is given on proquazone (I) [22760-18-5], a nonsteroidal antiinflammatory drug. This nonnarcotic analgesic was rapidly absorbed after oral administration, and was effective in the treatment of inflammations or rheumatic-type symptoms.
IT 22760-18-5
RL: PROC (Process)
(pharmacol. evaluation of)
RN 22760-18-5 CAPLUS
CN 2(1H)-Quinazolinone, 7-methyl-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)



L5 ANSWER 216 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1978:145925 CAPLUS
DOCUMENT NUMBER: 88:145925
ORIGINAL REFERENCE NO.: 88:22875a
TITLE: Salicylic acid and proquazone: the differences in absorption and biodistribution explain their different
profile of side-effects
AUTHOR(S): Schweitzer, Alain; Brune, Kay
CORPORATE SOURCE: Dep. Pharm., Sandoz A.-G., Basel, Switz.
SOURCE: Perspect. Inflammation, Proc. Int. Meet., 3rd (1977), 353-60. Editor(s): Willoughby, Derek A.; Giroud, J. P.; Velo, G. P. Univ. Park Press: Baltimore, Md.
CODEN: 37LBAE
DOCUMENT TYPE: Conference
LANGUAGE: English
AB After oral administration to young rats, both salicylic acid [69-72-7] and proquazone [22760-18-5] accumulated in inflamed tissue and in the kidney. However, only salicylic acid accumulated in the glandular and nonglandular part of the stomach. Proquazone remained in the lumen of the stomach. There was a relation between absorption of salicylic acid by the stomach and cell damage. Proquazone did not cause stomach damage, indicating that it may be an inflammation inhibitor with fewer side effects than salicylic acid.
IT 22760-18-5
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(metabolism of, stomach accumulation in, chemical damage in relation to)
RN 22760-18-5 CAPLUS
CN 2(1H)-Quinazolinone, 7-methyl-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)



L5 ANSWER 217 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1978:141601 CAPLUS
DOCUMENT NUMBER: 88:141601
ORIGINAL REFERENCE NO.: 88:22213a,22216a
TITLE: Physico-chemical properties and stabilities of prazepam
AUTHOR(S): Doi, Tadashi; Okajima, Akemi; Ohkawa, Yasushi; Yoneda, Michiaki; Nagai, Hidetaka
CORPORATE SOURCE: Inst. Biol. Sci., Sumitomo Chem. Co., Ltd., Takarazuka, Japan
SOURCE: Iyakuhin Kenkyu (1978), 9(1), 205-15
CODEN: IYKEDH; ISSN: 0287-0894
DOCUMENT TYPE: Journal
LANGUAGE: Japanese
GI



I

AB Solid prazepam (I) [2955-38-6] was stable at room temperature for 24 mo and at 60° for 3 mo. In solns., I was stable at pH >4. I was highly soluble in CHCl3 and Me2CO, moderately soluble in MeOH and EtOH, but practically insol. in H2O. The maximum UV absorption of I in H2SO4 and anhydrous EtOH was at 243 nm (ε = 2.62 + 101), 285 nm (ε = 1.24 + 101) and 365 nm (ε = 3.33 + 103). Characteristics of other spectrophotometric properties were also described. PKa value of I was 2.99. I can be determined by the nonaq. titration method.
IT 33453-19-9
RL: ANT (Analyte); ANST (Analytical study)
(gas chromatog. of)
RN 33453-19-9 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-1-(cyclopropylmethyl)-4-phenyl- (CA INDEX NAME)

L5 ANSWER 217 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



L5 ANSWER 218 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1978:105408 CAPLUS
DOCUMENT NUMBER: 88:105408
ORIGINAL REFERENCE NO.: 88:16545a,16548a
TITLE: Hydroxymethyl-substituted-2(1H)-quinazolinones
INVENTOR(S): Papp, Eugene A.
PATENT ASSIGNEE(S): Sandoz, Inc., USA
SOURCE: U.S., 6 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 4064246	A	19771220	US 1976-731336	19761012
DE 2735920	A1	19780223	DE 1977-2735920	19770810
BE 857974	A1	19780220	BE 1977-180323	19770819
FR 2362132	A1	19780317	FR 1977-25370	19770819

PRIORITY APPLN. INFO.: US 1976-716135 A 19760820
US 1976-716136 A 19760820
US 1976-716138 A 19760820
US 1976-731336 A 19761012

GI



I II

AB Quinazolinones I (R = H, F, Cl; R1 = alkyl, cycloalkyl; R2 = H, F, Cl, Br, alkoxy, HO; R3 = H, F, Cl, alkoxy) (2 compds.) were prepared Thus, successive bromination of II and hydrolysis gave I (R = R3 = H, R1 = Me2CH, R2 = 3-HO, and HOCH2 at C-7). These compds. are useful as antiinflammatory agents at 3-200 mg/kg orally.

IT 22760-18-5
RL: RCT (Reactant); RACT (Reactant or reagent)
(bromination of)
RN 22760-18-5 CAPLUS
CN 2(1H)-Quinazolinone, 7-methyl-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)

L5 ANSWER 218 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

IT 65765-05-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and dehydrogenation of)
RN 65765-05-1 CAPLUS
CN 2(1H)-Quinazolinone, 3,4-dihydro-4-(3-methoxyphenyl)-7-methyl-1-(1-methylethyl)- (CA INDEX NAME)



IT 65765-06-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and demethylation of)
RN 65765-06-2 CAPLUS
CN 2(1H)-Quinazolinone, 4-(3-methoxyphenyl)-7-methyl-1-(1-methylethyl)- (CA INDEX NAME)



IT 50817-66-8P 65765-09-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and hydrolysis of)
RN 50817-66-8 CAPLUS
CN 2(1H)-Quinazolinone, 7-(bromomethyl)-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)

L5 ANSWER 218 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



IT 65765-07-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and acetylation of)
RN 65765-07-3 CAPLUS
CN 2(1H)-Quinazolinone, 4-(3-hydroxyphenyl)-7-methyl-1-(1-methylethyl)- (CA INDEX NAME)



IT 65765-08-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and bromination of)
RN 65765-08-4 CAPLUS
CN 2(1H)-Quinazolinone, 4-[3-(acetyloxy)phenyl]-7-methyl-1-(1-methylethyl)- (CA INDEX NAME)



L5 ANSWER 218 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 65765-09-5 CAPLUS
CN 2(1H)-Quinazolinone, 4-[3-(acetyloxy)phenyl]-7-(bromomethyl)-1-(1-methylethyl)- (CA INDEX NAME)



IT 65765-10-8P 65765-11-9P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 65765-10-8 CAPLUS
CN 2(1H)-Quinazolinone, 4-[3-(acetyloxy)phenyl]-7-(hydroxymethyl)-1-(1-methylethyl)- (CA INDEX NAME)



RN 65765-11-9 CAPLUS
CN 2(1H)-Quinazolinone, 7-(hydroxymethyl)-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)

L5 ANSWER 218 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



L5 ANSWER 219 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1978:83526 CAPLUS
DOCUMENT NUMBER: 88:83526
ORIGINAL REFERENCE NO.: 88:13077a,13080a
TITLE: A comparison of the effect of proquazone, a new non-steroidal antiinflammatory compound, and acetylsalicyclic acid on blood platelet function in vitro and in vivo
AUTHOR(S): Holmes, I. B.
CORPORATE SOURCE: Biol. Med. Res. Div., Sandoz Ltd., Basel, Switz.
SOURCE: Archives Internationales de Pharmacodynamie et de Therapie (1977), 228(1), 136-52
CODEN: AIPTAK; ISSN: 0003-9780
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



I

AB Platelet aggregation induced by collagen and arachidonic acid in vitro was inhibited in a dose-dependent manner by proquazone (I) [22760-18-5] and acetylsalicylic acid [50-78-2]. On the basis of concentration for 50% inhibition (IC50), I was between 22 and 830 times more potent than acetylsalicylic acid. That I inhibits the platelet release reaction was indicated by suppression of collagen-induced serotonin release from preloaded platelets (IC50 = 0.15 - 0.35 μM). Primary ADP-induced aggregation was influenced by I only at high concns. Following oral drug administration to rabbits, aggregation induced by collagen in vitro was markedly inhibited. The dose producing 50% inhibition (ID50) was 3.4 and 15.3 mg/kg for I and acetylsalicylic acid, resp. Collagen-induced decrease in rat circulating platelet count was reduced following oral administration of I or acetylsalicylic acid. In these expts., I (ID30 = 5.0 mg/kg) was 6.7 times more potent than acetylsalicylic acid. I.v. injected I inhibited collagen-induced bronchoconstriction in the guinea-pig, which is thought to be caused by vasoactive substances released from aggregating platelets. On the basis of the ID50, I (5.8 μg/kg) was 140 times more active than acetylsalicylic acid. The duration of action of I in vivo was clearly shorter than that of acetylsalicylic acid. Nevertheless, significant inhibitory activity was still observed in the rat 6 to 16 h after oral administration.

IT 22760-18-5
RL: BIOL (Biological study)
(blood platelet aggregation response to)

RN 22760-18-5 CAPLUS
CN 2(1H)-Quinazolinone, 7-methyl-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)

L5 ANSWER 219 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



L5 ANSWER 220 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1978:61720 CAPLUS
DOCUMENT NUMBER: 88:61720
ORIGINAL REFERENCE NO.: 88:9739a,9742a
TITLE: Carbon-13 nuclear magnetic resonance studies of anti-inflammatory 2(1H)-quinazolinones
AUTHOR(S): Masai, Naruhito; Kimura, Michio; Yamamoto, Michihiro; Hirohashi, Toshiyuki; Yamamoto, Hisao
CORPORATE SOURCE: Inst. Biol. Sci., Sumitomo Chem. Co., Ltd., Hyogo, Japan
SOURCE: Chemical & Pharmaceutical Bulletin (1977), 25(11), 3018-22
CODEN: CPBTAL; ISSN: 0009-2363
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



I

AB The 13C NMR spectra of twelve 1-cyclopropylmethyl-4-phenyl-2(1H)-quinazolinones including a potent anti-inflammatory agent SL-573 (I) were investigated, and the all carbon resonances were assigned mainly by the off-resonance technique, substituent effects on the 4-Ph groups and 13C-19F couplings. Good correlations were found between Hammett parameters σp and the 13C chemical shifts of the parasubstituted quinazolinone frame carbons in spite of the large dihedral angles between the quinazolinone and Ph ring planes (42.8° for I).

IT 33453-22-4 33453-23-5 59253-47-3
59253-49-5 63930-21-2 65386-95-0
65386-96-1 65386-97-2 65386-98-3
65386-99-4 65387-00-0 65387-01-1
RL: PRP (Properties)
(carbon-13 NMR of)

RN 33453-22-4 CAPLUS
CN 2(1H)-Quinazolinone, 1-(cyclopropylmethyl)-4-phenyl- (CA INDEX NAME)



L5 ANSWER 220 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

RN 33453-23-5 CAPLUS
CN 2(1H)-Quinazolinone, 1-(cyclopropylmethyl)-6-methoxy-4-phenyl- (CA INDEX NAME)



RN 59253-47-3 CAPLUS
CN 2(1H)-Quinazolinone, 1-(cyclopropylmethyl)-6-methoxy-4-(4-nitrophenyl)- (CA INDEX NAME)



RN 59253-49-5 CAPLUS
CN 2(1H)-Quinazolinone, 1-(cyclopropylmethyl)-6-methoxy-4-(4-methylphenyl)- (CA INDEX NAME)

L5 ANSWER 220 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 63930-21-2 CAPLUS
CN 2(1H)-Quinazolinone, 1-(cyclopropylmethyl)-6-methoxy-4-(4-methoxyphenyl)- (CA INDEX NAME)



RN 65386-95-0 CAPLUS
CN 2(1H)-Quinazolinone, 4-(2-chlorophenyl)-1-(cyclopropylmethyl)-6-methoxy- (CA INDEX NAME)

L5 ANSWER 220 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 65386-96-1 CAPLUS
CN 2(1H)-Quinazolinone, 4-(2-bromophenyl)-1-(cyclopropylmethyl)-6-methoxy- (CA INDEX NAME)



RN 65386-97-2 CAPLUS
CN 2(1H)-Quinazolinone, 1-(cyclopropylmethyl)-6-methoxy-4-(2-nitrophenyl)- (CA INDEX NAME)



RN 65386-98-3 CAPLUS
CN 2(1H)-Quinazolinone, 1-(cyclopropylmethyl)-6-methoxy-4-(2-methoxyphenyl)-

L5 ANSWER 220 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
(CA INDEX NAME)



RN 65386-99-4 CAPLUS
CN 2(1H)-Quinazolinone, 1-(cyclopropylmethyl)-4-(4-fluorophenyl)-6-methoxy- (CA INDEX NAME)



RN 65387-00-0 CAPLUS
CN 2(1H)-Quinazolinone, 4-(4-chlorophenyl)-1-(cyclopropylmethyl)-6-methoxy- (CA INDEX NAME)

L5 ANSWER 220 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 65387-01-1 CAPLUS
CN 2(1H)-Quinazolinone, 4-(4-bromophenyl)-1-(cyclopropylmethyl)-6-methoxy- (CA INDEX NAME)



L5 ANSWER 221 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1978:6829 CAPLUS
DOCUMENT NUMBER: 88:6829
ORIGINAL REFERENCE NO.: 88:1161a,1164a
TITLE: 1,4-Benzodiazepines, their cyclic homologs and analogs. XXVI. Synthesis, structure, and properties of some 4-phenylquinazoline derivatives
AUTHOR(S): Bogatskii, A. V.; Andronati, S. A.; Zhilina, Z. I.; Danilina, N. I.
CORPORATE SOURCE: Inst. Obshch. Neorg. Khim., Odessa, USSR
SOURCE: Zhurnal Organicheskoi Khimii (1977), 13(8), 1773-80
CODEN: ZORKAE; ISSN: 0514-7492
DOCUMENT TYPE: Journal
LANGUAGE: Russian
OTHER SOURCE(S): CASREACT 88:6829
GI



AB Quinazoline derivs. I (R = H, R1 = Cl, Br, NO2, H, Me, SCHF2, OCHF2, SO2CHF2, OCF3; R2 = Ph, o-ClC6H4; X = O) were obtained in 25-90% yields by cyclization of II with urea or by acylation of II with Cl3CCOCl to give an acylamino intermediate which was cyclized with NH3. Treatment of I with P2S5 gave 30-5% I (R = H; R1 = Cl, Br, Me, H; R2 = Ph; X = S); methylation of I gave 40-55% I (R = Me; R1 = Cl, Br, NO2, H, Me; R2 = Ph; X = O). Chlorination of I with PCl5 gave 60-8% III (R1 = Cl, Br, Me, H; R2 = Ph; R3 = Cl) which were treated with N2H4 to give 35-40% III (R3 = NHNH2). Cyclization of the latter by NaNO2-AcOH yielded 50-60% IV (R1 = Cl, Br, Me, H; R2 = Ph).
IT 17629-04-8P 20927-53-1P 26953-46-8P
50817-26-0P 64820-54-8P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 17629-04-8 CAPLUS
CN 2(1H)-Quinazolinone, 1-methyl-4-phenyl- (CA INDEX NAME)

L5 ANSWER 221 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 20927-53-1 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-1-methyl-4-phenyl- (CA INDEX NAME)



RN 26953-46-8 CAPLUS
CN 2(1H)-Quinazolinone, 1-methyl-6-nitro-4-phenyl- (CA INDEX NAME)



RN 50817-26-0 CAPLUS
CN 2(1H)-Quinazolinone, 1,6-dimethyl-4-phenyl- (CA INDEX NAME)



RN 64820-54-8 CAPLUS
CN 2(1H)-Quinazolinone, 6-bromo-1-methyl-4-phenyl- (CA INDEX NAME)

L5 ANSWER 221 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



L5 ANSWER 222 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1977:552263 CAPLUS
DOCUMENT NUMBER: 87:152263
ORIGINAL REFERENCE NO.: 87:24103a,24106a
TITLE: 3,4-Dihydro-2(1H)-quinazolinone derivatives
INVENTOR(S): Yamamoto, Michihiro; Katayama, Shigenari; Koshiba, Masao; Yamamoto, Hisao
PATENT ASSIGNEE(S): Sumitomo Chemical Co., Ltd., Japan
SOURCE: Ger. Offen., 8 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2702530	A1	19770728	DE 1977-2702530	19770121
JP 52091885	A	19770802	JP 1976-6920	19760123
US 4048168	A	19770913	US 1976-754640	19761227
NL 7614574	A	19770726	NL 1976-14574	19761230
FR 2338934	A1	19770819	FR 1977-1170	19770117
FR 2338934	B1	19801219		
AT 7700227	A	19790415	AT 1977-227	19770117
AT 353276	B	19791112		
SE 7700533	A	19770724	SE 1977-533	19770119
SE 422324	B	19820301		
SE 422324	C	19820610		
DK 7700222	A	19770724	DK 1977-222	19770120
DK 141064	B	19800107		
DK 141064	C	19800623		
CA 1069505	A1	19800108	CA 1977-270156	19770120
HU 174389	B	19791228	HU 1977-SU937	19770121
CH 625231	A5	19810915	CH 1977-788	19770121

PRIORITY APPLN. INFO.: JP 1976-6920 A 19760123

GI



I

AB The title compds. I (R = H, F, Cl, HCF2, CF3; R1 = H, R2 = Me, MeO; R2R2 = OCH2O; R3 = Ph, 2-thienyl) were prepared for use as analgesics and antiphlogistics (no data). Thus, 4-MeOC6H4N(CONH2)CH2CF3 was refluxed with BzH and ZnCl2 in xylene to give 62% I (R = F, R1 = H, R2 = MeO, R3 = Ph).
IT 59253-64-4P 59253-67-7P 63930-36-9P

L5 ANSWER 222 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 64323-94-0 CAPLUS
CN 2(1H)-Quinazolinone, 1-(2,2-difluoroethyl)-3,4-dihydro-6-methoxy-4-phenyl- (CA INDEX NAME)



RN 64597-44-0 CAPLUS
CN 2(1H)-Quinazolinone, 3,4-dihydro-6-methoxy-4-phenyl-1-(2,2,3,3-tetrafluoropropyl)- (CA INDEX NAME)



L5 ANSWER 222 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
63930-38-1P 64323-94-0P 64597-44-0P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)
RN 59253-64-4 CAPLUS
CN 2(1H)-Quinazolinone, 3,4-dihydro-6-methoxy-4-phenyl-1-(2,2,2-trifluoroethyl)- (CA INDEX NAME)



RN 59253-67-7 CAPLUS
CN 2(1H)-Quinazolinone, 3,4-dihydro-6-methyl-1-(2,2,3,3,3-pentafluoropropyl)-4-phenyl- (CA INDEX NAME)



RN 63930-36-9 CAPLUS
CN 2(1H)-Quinazolinone, 1-(2-chloro-2,2-difluoroethyl)-3,4-dihydro-6-methoxy-4-phenyl- (CA INDEX NAME)



RN 63930-38-1 CAPLUS
CN 2(1H)-Quinazolinone, 3,4-dihydro-6-methoxy-1-(2,2,3,3,3-pentafluoropropyl)-4-phenyl- (CA INDEX NAME)

L5 ANSWER 223 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1977:517899 CAPLUS
DOCUMENT NUMBER: 87:117899
ORIGINAL REFERENCE NO.: 87:18725a,18728a
TITLE: 2(1H)-Quinazolinones and -thiones
INVENTOR(S): Yamamoto, Michihiro; Katayama, Shigenari; Koshiba, Masao; Yamamoto, Hisao
PATENT ASSIGNEE(S): Sumitomo Chemical Co., Ltd., Japan
SOURCE: Ger. Offen., 11 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2656156	A1	19770623	DE 1976-2656156	19761210
JP 52071483	A	19770614	JP 1975-148279	19751211
NL 7613307	A	19770614	NL 1976-13307	19761130
US 4387223	A	19830607	US 1976-748145	19761206
FR 2376142	A1	19780728	FR 1976-36740	19761207
FR 2376142	B1	19790420		
HU 173530	B	19790628	HU 1976-SU934	19761208
DK 7605530	A	19770612	DK 1976-5530	19761209
DK 138989	B	19781127		
DK 138989	C	19790514		
SE 7613839	A	19770612	SE 1976-13839	19761209
SE 422578	B	19820315		
SE 422578	C	19820624		
CH 602667	A5	19780731	CH 1976-15505	19761209
CA 1068694	A1	19791224	CA 1976-267562	19761209
AT 7609159	A	19790315	AT 1976-9159	19761210
AT 352737	B	19791010		

PRIORITY APPLN. INFO.: JP 1975-148279 A 19751211

OTHER SOURCE(S): CASREACT 87:117899; MARPAT 87:117899
GI



I II

AB The title compds. I (R = cyclopropylmetyl, PhCH2, Et, allyl, F3CCH2, etc.; R1 = R2 = H, Me, CF3, Ac, NO2, etc.; R3 = Ph, furyl, thienyl; Z = O, S) were prepared by refluxing II with S in o-Cl2C6H4. I are useful as analgesics, antiphlogistics, and virucides (no data).
IT 26772-90-7 26772-97-4 26824-74-8
26920-08-1 36942-67-3 36942-69-5
36942-70-8 36942-71-9 36942-76-4
36943-01-8 52568-15-7 59253-22-4
59253-24-6 59253-25-7 59253-26-8

L5 ANSWER 223 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
59253-27-9 59253-28-0 59253-29-1
59253-30-4 59253-31-5 59253-32-6
59253-34-8 59253-35-9 59253-39-3
59253-40-6 59253-54-2 59253-55-3
59253-56-4 59253-57-5 59253-58-6
59253-59-7 59253-61-1 59253-63-3
59253-64-4 59253-65-5 59253-66-6
59253-68-8 63611-94-9 63930-25-6
63930-26-7 63930-27-8 63930-28-9
63930-29-0 63930-30-3 63930-31-4
63930-32-5 63930-33-6 63930-34-7
63930-36-9 63930-38-1
RL: RCT (Reactant); RACT (Reactant or reagent)
(dehydrogenation of)

RN 26772-90-7 CAPLUS
CN 2(1H)-Quinazolinone, 3,4-dihydro-7-methyl-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)



RN 26772-97-4 CAPLUS
CN 2(1H)-Quinazolinone, 3,4-dihydro-6-methoxy-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)



RN 26824-74-8 CAPLUS
CN 2(1H)-Quinazolinethione, 3,4-dihydro-7-methyl-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)

L5 ANSWER 223 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 26920-08-1 CAPLUS
CN 2(1H)-Quinazolinethione, 6-chloro-3,4-dihydro-1-methyl-4-phenyl- (CA INDEX NAME)



RN 36942-67-3 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-1-(2-ethoxyethyl)-4-(2-fluorophenyl)-3,4-dihydro- (CA INDEX NAME)



RN 36942-69-5 CAPLUS
CN 2(1H)-Quinazolinone, 1-(cyclopropylmethyl)-3,4-dihydro-6-nitro-4-phenyl- (CA INDEX NAME)

L5 ANSWER 223 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 36942-70-8 CAPLUS
CN 2(1H)-Quinazolinone, 1-(cyclopropylmethyl)-3,4-dihydro-4-phenyl-6-(trifluoromethyl)- (CA INDEX NAME)



RN 36942-71-9 CAPLUS
CN 2(1H)-Quinazolinone, 1-(cyclopropylmethyl)-3,4-dihydro-6-methoxy-4-phenyl- (CA INDEX NAME)



RN 36942-76-4 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-1-(cyclopropylmethyl)-3,4-dihydro-4-phenyl- (CA INDEX NAME)

L5 ANSWER 223 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 36943-01-8 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-3,4-dihydro-4-phenyl-1-(2,2,2-trifluoroethyl)- (CA INDEX NAME)



RN 52568-15-7 CAPLUS
CN 2(1H)-Quinazolinone, 1-[2-(acetyloxy)ethyl]-3,4-dihydro-6-methoxy-4-phenyl- (CA INDEX NAME)



RN 59253-22-4 CAPLUS
CN 2(1H)-Quinazolinone, 1-(cyclopropylmethyl)-3,4-dihydro-4-phenyl- (CA INDEX NAME)

L5 ANSWER 223 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 59253-24-6 CAPLUS
CN 2(1H)-Quinazolinone,
1-(cyclopropylmethyl)-3,4-dihydro-7-methyl-4-phenyl-
(CA INDEX NAME)



RN 59253-25-7 CAPLUS
CN 2(1H)-Quinazolinone,
1-(cyclopropylmethyl)-3,4-dihydro-7-methoxy-4-phenyl-
(CA INDEX NAME)



RN 59253-26-8 CAPLUS
CN 2(1H)-Quinazolinone, 1-(cyclopropylmethyl)-3,4-dihydro-6-(methylthio)-4-
phenyl- (CA INDEX NAME)

L5 ANSWER 223 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 59253-27-9 CAPLUS
CN 2(1H)-Quinazolinone,
1-(cyclopropylmethyl)-3,4-dihydro-6-(methylsulfonyl)-
4-phenyl- (CA INDEX NAME)



RN 59253-28-0 CAPLUS
CN 2(1H)-Quinazolinone,
6-acetyl-1-(cyclopropylmethyl)-3,4-dihydro-4-phenyl-
(CA INDEX NAME)



RN 59253-29-1 CAPLUS
CN 2(1H)-Quinazolinone, 6,8-dichloro-1-(cyclopropylmethyl)-3,4-dihydro-4-

L5 ANSWER 223 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
phenyl- (CA INDEX NAME)



RN 59253-30-4 CAPLUS
CN 2(1H)-Quinazolinone,
6-chloro-1-(cyclopropylmethyl)-4-(2-fluorophenyl)-3,4-
dihydro- (CA INDEX NAME)



RN 59253-31-5 CAPLUS
CN 2(1H)-Quinazolinone, 1-(cyclopropylmethyl)-3,4-dihydro-6-methoxy-4-(4-
nitrophenyl)- (CA INDEX NAME)



L5 ANSWER 223 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

RN 59253-32-6 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-1-(cyclopropylmethyl)-3,4-dihydro-4-(2-
methylphenyl)- (CA INDEX NAME)



RN 59253-34-8 CAPLUS
CN 2(1H)-Quinazolinone, 1-(cyclohexylmethyl)-3,4-dihydro-6-nitro-4-phenyl-
(CA INDEX NAME)



RN 59253-35-9 CAPLUS
CN 2(1H)-Quinazolinone, 1-cyclohexyl-3,4-dihydro-6-nitro-4-phenyl- (CA
INDEX
NAME)



L5 ANSWER 223 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
RN 59253-39-3 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-1-ethyl-3,4-dihydro-4-phenyl- (CA INDEX NAME)



RN 59253-40-6 CAPLUS
CN 2(1H)-Quinazolinone, 3,4-dihydro-7-methoxy-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)



RN 59253-54-2 CAPLUS
CN 2(1H)-Quinazolinone, 6-(dimethylamino)-3,4-dihydro-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)



RN 59253-55-3 CAPLUS
CN 2(1H)-Quinazolinone, 3,4-dihydro-6-nitro-4-phenyl-1-(2-propenyl)- (9CI) (CA INDEX NAME)

L5 ANSWER 223 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 59253-56-4 CAPLUS
CN 2(1H)-Quinazolinone, 3,4-dihydro-6-nitro-4-phenyl-1-(phenylmethyl)- (CA INDEX NAME)



RN 59253-57-5 CAPLUS
CN 2(1H)-Quinazolinone, 3,4-dihydro-1-[(2-methylphenyl)methyl]-6-nitro-4-phenyl- (CA INDEX NAME)



RN 59253-58-6 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-3,4-dihydro-1-(methoxymethyl)-4-phenyl- (CA
INDEX NAME)

L5 ANSWER 223 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 59253-59-7 CAPLUS
CN 2(1H)-Quinazolinone, 1-(2-ethoxyethyl)-3,4-dihydro-6-nitro-4-phenyl- (CA INDEX NAME)



RN 59253-61-1 CAPLUS
CN 2(1H)-Quinazolinone, 1-(2-chloroethyl)-3,4-dihydro-6-nitro-4-phenyl- (CA INDEX NAME)



RN 59253-63-3 CAPLUS
CN 2(1H)-Quinazolinone, 3,4-dihydro-4-phenyl-1-(2,2,2-trifluoroethyl)- (CA INDEX NAME)



RN 59253-64-4 CAPLUS
CN 2(1H)-Quinazolinone, 3,4-dihydro-6-methoxy-4-phenyl-1-(2,2,2-trifluoroethyl)- (CA INDEX NAME)

L5 ANSWER 223 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 59253-65-5 CAPLUS
CN 2(1H)-Quinazolinone,
3,4-dihydro-6-nitro-4-phenyl-1-(2,2,2-trifluoroethyl)-
(CA INDEX NAME)



RN 59253-66-6 CAPLUS
CN 2(1H)-Quinazolinone, 3,4-dihydro-6-methyl-4-phenyl-1-(2,2,2-trifluoroethyl)- (CA INDEX NAME)



RN 59253-68-8 CAPLUS
CN 2(1H)-Quinazolinone, 3,4-dihydro-1-(2-hydroxyethyl)-6-nitro-4-phenyl- (CA
INDEX NAME)



L5 ANSWER 223 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
RN 63611-94-9 CAPLUS
CN 2(1H)-Quinazolinone, 1-(cyclopropylmethyl)-3,4-dihydro-6-methoxy-4-(4-methoxyphenyl)- (CA INDEX NAME)



RN 63930-25-6 CAPLUS
CN 2(1H)-Quinazolinethione, 1-(cyclopropylmethyl)-3,4-dihydro-6-methoxy-4-phenyl- (CA INDEX NAME)



RN 63930-26-7 CAPLUS
CN 2(1H)-Quinazolinethione, 1-ethyl-3,4-dihydro-4-phenyl- (CA INDEX NAME)



RN 63930-27-8 CAPLUS

L5 ANSWER 223 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
CN 2(1H)-Quinazolinethione, 6-chloro-1-(cyclopropylmethyl)-3,4-dihydro-4-phenyl- (CA INDEX NAME)



RN 63930-28-9 CAPLUS
CN 2(1H)-Quinazolinethione, 1-(cyclopropylmethyl)-3,4-dihydro-7-methyl-4-phenyl- (CA INDEX NAME)



RN 63930-29-0 CAPLUS
CN 2(1H)-Quinazolinethione, 1-(cyclopropylmethyl)-3,4-dihydro-4-phenyl- (CA INDEX NAME)



RN 63930-30-3 CAPLUS
CN 2(1H)-Quinazolinethione, 1-(cyclopropylmethyl)-3,4-dihydro-6-(methylthio)-

L5 ANSWER 223 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
4-phenyl- (CA INDEX NAME)



RN 63930-31-4 CAPLUS
CN 2(1H)-Quinazolinethione, 1-(cyclopropylmethyl)-3,4-dihydro-7-methoxy-4-phenyl- (CA INDEX NAME)



RN 63930-32-5 CAPLUS
CN 2(1H)-Quinazolinethione, 1-(cyclopropylmethyl)-3,4-dihydro-6-nitro-4-phenyl- (CA INDEX NAME)



RN 63930-33-6 CAPLUS
CN 2(1H)-Quinazolinethione, 6-chloro-3,4-dihydro-4-phenyl-1-(2,2,2-trifluoroethyl)- (CA INDEX NAME)

L5 ANSWER 223 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 63930-34-7 CAPLUS
CN 2(1H)-Quinazolinethione, 3,4-dihydro-6-methoxy-4-phenyl-1-(2,2,2-trifluoroethyl)- (CA INDEX NAME)



RN 63930-36-9 CAPLUS
CN 2(1H)-Quinazolinone, 1-(2-chloro-2,2-difluoroethyl)-3,4-dihydro-6-methoxy-4-phenyl- (CA INDEX NAME)



RN 63930-38-1 CAPLUS
CN 2(1H)-Quinazolinone, 3,4-dihydro-6-methoxy-1-(2,2,3,3,3-pentafluoropropyl)-4-phenyl- (CA INDEX NAME)



IT 22760-18-5P 22760-25-4P 23441-64-7P

L5 ANSWER 223 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
26313-51-9P 26824-69-1P 26824-70-4P
26920-12-7P 26930-57-4P 28340-57-0P
33443-20-8P 33443-28-6P 33443-33-3P
33443-35-5P 33453-19-9P 33453-22-4P
33453-23-5P 33890-29-8P 37554-35-1P
37554-37-3P 37554-39-5P 37554-40-8P
37554-98-6P 37555-03-6P 37555-17-2P
40852-34-4P 40852-38-8P 40852-44-6P
40852-52-6P 41190-30-1P 49830-63-9P
49830-89-9P 52568-07-7P 52568-22-6P
53720-97-1P 53720-98-2P 53720-99-3P
53721-00-9P 53721-01-0P 59253-44-0P
59253-45-1P 59253-46-2P 59253-47-3P
59253-48-4P 59253-70-2P 63930-18-7P
63930-19-8P 63930-20-1P 63930-21-2P
63930-22-3P 63930-24-5P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)

RN 22760-18-5 CAPLUS
CN 2(1H)-Quinazolinone, 7-methyl-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)



RN 22760-25-4 CAPLUS
CN 2(1H)-Quinazolinone, 7-methoxy-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)



RN 23441-64-7 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-1-ethyl-4-phenyl- (CA INDEX NAME)

L5 ANSWER 223 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 26920-12-7 CAPLUS
CN 2(1H)-Quinazolinethione, 6-chloro-1-methyl-4-phenyl- (CA INDEX NAME)



RN 26930-57-4 CAPLUS
CN 2(1H)-Quinazolinethione, 1-ethyl-4-phenyl- (CA INDEX NAME)



RN 28340-57-0 CAPLUS
CN 2(1H)-Quinazolinone, 6-(dimethylamino)-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)



RN 33443-20-8 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-1-(cyclopropylmethyl)-4-(2-fluorophenyl)- (CA INDEX NAME)

L5 ANSWER 223 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 26313-51-9 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-1-(2-ethoxyethyl)-4-(2-fluorophenyl)- (CA INDEX NAME)



RN 26824-69-1 CAPLUS
CN 2(1H)-Quinazolinethione, 7-methyl-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)



RN 26824-70-4 CAPLUS
CN 2(1H)-Quinazolinone, 6-methoxy-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)

L5 ANSWER 223 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 33443-28-6 CAPLUS
CN 2(1H)-Quinazolinethione, 6-chloro-1-(cyclopropylmethyl)-4-phenyl- (CA INDEX NAME)



RN 33443-33-3 CAPLUS
CN 2(1H)-Quinazolinone, 1-(cyclopropylmethyl)-4-phenyl-6-(trifluoromethyl)- (CA INDEX NAME)



RN 33443-35-5 CAPLUS
CN 2(1H)-Quinazolinone, 6,8-dichloro-1-(cyclopropylmethyl)-4-phenyl- (CA INDEX NAME)

L5 ANSWER 223 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 33453-19-9 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-1-(cyclopropylmethyl)-4-phenyl- (CA INDEX NAME)



RN 33453-22-4 CAPLUS
CN 2(1H)-Quinazolinone, 1-(cyclopropylmethyl)-4-phenyl- (CA INDEX NAME)



RN 33453-23-5 CAPLUS
CN 2(1H)-Quinazolinone, 1-(cyclopropylmethyl)-6-methoxy-4-phenyl- (CA INDEX NAME)

L5 ANSWER 223 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 33890-29-8 CAPLUS
CN 2(1H)-Quinazolinone, 1-(cyclopropylmethyl)-6-nitro-4-phenyl- (CA INDEX NAME)



RN 37554-35-1 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-1-(methoxymethyl)-4-phenyl- (CA INDEX NAME)



RN 37554-37-3 CAPLUS
CN 2(1H)-Quinazolinone, 1-(2-ethoxyethyl)-6-nitro-4-phenyl- (CA INDEX NAME)

L5 ANSWER 223 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 37554-39-5 CAPLUS
CN 2(1H)-Quinazolinone, 1-(2-hydroxyethyl)-6-nitro-4-phenyl- (CA INDEX NAME)



RN 37554-40-8 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-4-phenyl-1-(2,2,2-trifluoroethyl)- (CA INDEX NAME)



RN 37554-98-6 CAPLUS
CN 2(1H)-Quinazolinone, 6-nitro-4-phenyl-1-(2-propenyl)- (9CI) (CA INDEX NAME)



RN 37555-03-6 CAPLUS
CN 2(1H)-Quinazolinone, 6-nitro-4-phenyl-1-(phenylmethyl)- (CA INDEX NAME)

L5 ANSWER 223 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 37555-17-2 CAPLUS
CN 2(1H)-Quinazolinone, 1-(cyclopropylmethyl)-6-(methylsulfonyl)-4-phenyl- (CA INDEX NAME)



RN 40852-34-4 CAPLUS
CN 2(1H)-Quinazolinone, 1-(cyclohexylmethyl)-6-nitro-4-phenyl- (CA INDEX NAME)



RN 40852-38-8 CAPLUS
CN 2(1H)-Quinazolinone, 1-cyclohexyl-6-nitro-4-phenyl- (CA INDEX NAME)

L5 ANSWER 223 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 40852-44-6 CAPLUS
CN 2(1H)-Quinazolinone, 6-nitro-4-phenyl-1-(2,2,2-trifluoroethyl)- (CA INDEX NAME)



RN 40852-52-6 CAPLUS
CN 2(1H)-Quinazolinone, 4-phenyl-1-(2,2,2-trifluoroethyl)- (CA INDEX NAME)



RN 41190-30-1 CAPLUS
CN 2(1H)-Quinazolinone, 1-[(2-methylphenyl)methyl]-6-nitro-4-phenyl- (CA INDEX NAME)

L5 ANSWER 223 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 52568-22-6 CAPLUS
CN 2(1H)-Quinazolinone, 1-(2-chloroethyl)-6-nitro-4-phenyl- (CA INDEX NAME)



RN 53720-97-1 CAPLUS
CN 2(1H)-Quinazolinethione, 1-(cyclopropylmethyl)-6-methoxy-4-phenyl- (CA INDEX NAME)



RN 53720-98-2 CAPLUS
CN 2(1H)-Quinazolinethione, 1-(cyclopropylmethyl)-6-nitro-4-phenyl- (CA INDEX NAME)



L5 ANSWER 223 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 49830-63-9 CAPLUS
CN 2(1H)-Quinazolinone, 1-(cyclopropylmethyl)-6-(methylthio)-4-phenyl- (CA INDEX NAME)



RN 49830-89-9 CAPLUS
CN 2(1H)-Quinazolinone, 6-methoxy-4-phenyl-1-(2,2,2-trifluoroethyl)- (CA INDEX NAME)



RN 52568-07-7 CAPLUS
CN 2(1H)-Quinazolinone, 1-[2-(acetyloxy)ethyl]-6-methoxy-4-phenyl- (CA INDEX NAME)

L5 ANSWER 223 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

RN 53720-99-3 CAPLUS
CN 2(1H)-Quinazolinethione, 1-(cyclopropylmethyl)-7-methyl-4-phenyl- (CA INDEX NAME)



RN 53721-00-9 CAPLUS
CN 2(1H)-Quinazolinethione, 1-(cyclopropylmethyl)-6-(methylthio)-4-phenyl- (CA INDEX NAME)



RN 53721-01-0 CAPLUS
CN 2(1H)-Quinazolinethione, 1-(cyclopropylmethyl)-4-phenyl- (CA INDEX NAME)



RN 59253-44-0 CAPLUS
CN 2(1H)-Quinazolinone, 1-(cyclopropylmethyl)-7-methyl-4-phenyl- (CA INDEX NAME)

L5 ANSWER 223 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 59253-45-1 CAPLUS
CN 2(1H)-Quinazolinone, 1-(cyclopropylmethyl)-7-methoxy-4-phenyl- (CA INDEX NAME)



RN 59253-46-2 CAPLUS
CN 2(1H)-Quinazolinone, 6-acetyl-1-(cyclopropylmethyl)-4-phenyl- (CA INDEX NAME)



RN 59253-47-3 CAPLUS
CN 2(1H)-Quinazolinone, 1-(cyclopropylmethyl)-6-methoxy-4-(4-nitrophenyl)- (CA INDEX NAME)

L5 ANSWER 223 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 59253-48-4 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-1-(cyclopropylmethyl)-4-(2-methylphenyl)- (CA INDEX NAME)



RN 59253-70-2 CAPLUS
CN 2(1H)-Quinazolinone, 6-methyl-4-phenyl-1-(2,2,2-trifluoroethyl)- (CA INDEX NAME)



RN 63930-18-7 CAPLUS

L5 ANSWER 223 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
CN 2(1H)-Quinazolinethione, 1-(cyclopropylmethyl)-7-methoxy-4-phenyl- (CA INDEX NAME)



RN 63930-19-8 CAPLUS
CN 2(1H)-Quinazolinethione, 6-chloro-4-phenyl-1-(2,2,2-trifluoroethyl)- (CA INDEX NAME)



RN 63930-20-1 CAPLUS
CN 2(1H)-Quinazolinethione, 6-methoxy-4-phenyl-1-(2,2,2-trifluoroethyl)- (CA INDEX NAME)



RN 63930-21-2 CAPLUS
CN 2(1H)-Quinazolinone, 1-(cyclopropylmethyl)-6-methoxy-4-(4-methoxyphenyl)- (CA INDEX NAME)

L5 ANSWER 223 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 63930-22-3 CAPLUS
CN 2(1H)-Quinazolinone, 1-(2-chloro-2,2-difluoroethyl)-6-methoxy-4-phenyl- (CA INDEX NAME)



RN 63930-24-5 CAPLUS
CN 2(1H)-Quinazolinone, 6-methoxy-1-(2,2,3,3,3-pentafluoropropyl)-4-phenyl- (CA INDEX NAME)



L5 ANSWER 224 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1977:511873 CAPLUS
DOCUMENT NUMBER: 87:111873
ORIGINAL REFERENCE NO.: 87:17705a,17708a
TITLE: On the interaction between the anti-inflammatory substance proquazone (RU 43-715) and phenprocoumone
AUTHOR(S): Vinazzer, H.
CORPORATE SOURCE: Blood Coagulation Lab., Linz, Austria
SOURCE: International Journal of Clinical Pharmacology and Biopharmacy (1977), 15(5), 214-16
CODEN: IJCBDX; ISSN: 0340-0026
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



AB The antiinflammatory drug proquazone (I) [22760-18-5] had no influence on the degree of hypocoagulability in patients anticoagulated with phenprocoumone (II) [435-97-2]. Administration of I for 2 weeks did not statistically affect the Quick percent, coagulation factors II, VII, and X, or the platelet aggregation induced by collagen or epinephrine. Many antiinflammatory agents decreased the blood clotting ability of patients receiving oral anticoagulants to below therapeutic levels, resulting in increased bleeding and(or) hemorrhagic tendencies.
IT 22760-18-5
RL: BIOL (Biological study)
(blood coagulation response to phenprocoumone and)
RN 22760-18-5 CAPLUS
CN 2(1H)-Quinazolinone, 7-methyl-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)



L5 ANSWER 225 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1977:485043 CAPLUS
DOCUMENT NUMBER: 87:85043
ORIGINAL REFERENCE NO.: 87:13535a,13538a
TITLE: 3,4-Dihydro-2(1H)-quinazolinones and -quinazolinethiones
INVENTOR(S): Yamamoto, Michihiro; Katayama, Shigenari; Koshiba, Masao; Yamamoto, Hisao
PATENT ASSIGNEE(S): Sumitomo Chemical Co., Ltd., Japan
SOURCE: Ger. Offen., 10 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2647853	A1	19770505	DE 1976-2647853	19761022
JP 52051379	A	19770425	JP 1975-128578	19751024
JP 54016513	B	19790622		
NL 7611210	A	19770426	NL 1976-11210	19761011
NL 166934	B	19810515		
NL 166934	C	19811015		
US 4202974	A	19800513	US 1976-731574	19761012
AT 353796	B	19791210	AT 1976-7709	19761015
AT 7607709	A	19790515		
FR 2328700	A1	19770520	FR 1976-31342	19761019
FR 2328700	B1	19790302		
SE 7611693	A	19770425	SE 1976-11693	19761021
SE 422577	B	19820315		
SE 422577	C	19820624		
CH 601259	A5	19780630	CH 1976-13318	19761021
DK 7604809	A	19770425	DK 1976-4809	19761022
CA 1049521	A1	19790227	CA 1976-263980	19761022
HU 173529	B	19790628	HU 1976-SU932	19761022

PRIORITY APPLN. INFO.: JP 1975-128578 A 19751024

OTHER SOURCE(S): MARPAT 87:85043
GI



AB Antiinflammatory and analgesic (no data) quinazolinones I (R = OMe, Me, SMe, R1 = H, R2 = cyclopropylmethyl, R3 = Ph; R = OMe, R1 = H, R2 = cyclopropylmethyl, R3 = 2-FC6H4, 4-FC6H4, 4-ClC6H4, 2-MeC6H4, 4-MeOC6H4, 2-thienyl; R = H, R1 = OMe, Me, RR1 = OCH2O, R2 = cyclopropylmethyl, R3 =

L5 ANSWER 225 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
Ph; R = OMe, R1 = H, R2 = Et, CHMe2, R3 = Ph; R = SMe, R1 = H, R2 = cyclopropylmethyl, R3 = 2-thienyl; R = H, R1 = Me, RR1 = OCH2O, R2 = CHMe2, R3 = Ph) were prepd. by cyclizing the ureas II with R3CHO in the presence of HBr.
IT 26772-90-7P 26772-97-4P 36942-71-9P
36942-72-0P 59253-24-6P 59253-25-7P
59253-26-8P 63611-90-5P 63611-91-6P
63611-92-7P 63611-93-8P 63611-94-9P
63611-96-1P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 26772-90-7 CAPLUS
CN 2(1H)-Quinazolinone, 3,4-dihydro-7-methyl-1-(1-methylethyl)-4-phenyl- (CA
INDEX NAME)



RN 26772-97-4 CAPLUS
CN 2(1H)-Quinazolinone, 3,4-dihydro-6-methoxy-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)



RN 36942-71-9 CAPLUS
CN 2(1H)-Quinazolinone,
1-(cyclopropylmethyl)-3,4-dihydro-6-methoxy-4-phenyl-
(CA INDEX NAME)

L5 ANSWER 225 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 36942-72-0 CAPLUS
CN 2(1H)-Quinazolinone,
1-(cyclopropylmethyl)-3,4-dihydro-6-methyl-4-phenyl-
(CA INDEX NAME)



RN 59253-24-6 CAPLUS
CN 2(1H)-Quinazolinone,
1-(cyclopropylmethyl)-3,4-dihydro-7-methyl-4-phenyl-
(CA INDEX NAME)



RN 59253-25-7 CAPLUS
CN 2(1H)-Quinazolinone,
1-(cyclopropylmethyl)-3,4-dihydro-7-methoxy-4-phenyl-
(CA INDEX NAME)

L5 ANSWER 225 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 59253-26-8 CAPLUS
CN 2(1H)-Quinazolinone, 1-(cyclopropylmethyl)-3,4-dihydro-6-(methylthio)-4-phenyl- (CA INDEX NAME)



RN 63611-90-5 CAPLUS
CN 2(1H)-Quinazolinone, 1-(cyclopropylmethyl)-4-(2-fluorophenyl)-3,4-dihydro-6-methoxy- (CA INDEX NAME)



RN 63611-91-6 CAPLUS
CN 2(1H)-Quinazolinone, 1-(cyclopropylmethyl)-4-(4-fluorophenyl)-3,4-dihydro-

L5 ANSWER 225 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 63611-94-9 CAPLUS
CN 2(1H)-Quinazolinone, 1-(cyclopropylmethyl)-3,4-dihydro-6-methoxy-4-(4-methoxyphenyl)- (CA INDEX NAME)



RN 63611-96-1 CAPLUS
CN 2(1H)-Quinazolinone, 1-ethyl-3,4-dihydro-6-methoxy-4-phenyl- (CA INDEX NAME)



L5 ANSWER 225 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
6-methoxy- (CA INDEX NAME)



RN 63611-92-7 CAPLUS
CN 2(1H)-Quinazolinone, 4-(4-chlorophenyl)-1-(cyclopropylmethyl)-3,4-dihydro-6-methoxy- (CA INDEX NAME)



RN 63611-93-8 CAPLUS
CN 2(1H)-Quinazolinone, 1-(cyclopropylmethyl)-3,4-dihydro-6-methoxy-4-(2-methylphenyl)- (CA INDEX NAME)

L5 ANSWER 226 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1977:485037 CAPLUS
DOCUMENT NUMBER: 87:85037
ORIGINAL REFERENCE NO.: 87:13535a,13538a
TITLE: 1-Cyclopropylmethyl-4-phenyl-6-chloro-2(1H)-quinazolinone
INVENTOR(S): Yamamoto, Michihiro; Koshiba, Masao; Ishizumi, Kikuo; Mori, Kazuo; Yamamoto, Hisao
PATENT ASSIGNEE(S): Sumitomo Chemical Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 4 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 52017482	A	19770209	JP 1975-91372	19750725
PRIORITY APPLN. INFO.:			JP 1975-91372 A	19750725

GI



AB Cyclization of I with (PhO)2P(O)N3 gave II. Thus, 0.5 g Et3N and 1.4 g (PhO)2P(O)N3 were added to 1.79 g I in Me2CO and the whole was stirred 6 h at room temperature to give 86% II. II had antiinflammatory, analgesic, uric acid-excretion stimulating, and antiviral activities (no data).
IT 33453-19-9P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 33453-19-9 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-1-(cyclopropylmethyl)-4-phenyl- (CA INDEX NAME)

L5 ANSWER 226 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



L5 ANSWER 227 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1977:467489 CAPLUS
DOCUMENT NUMBER: 87:67489
ORIGINAL REFERENCE NO.: 87:10725a,10728a
TITLE: Mass spectra of trisubstituted 1,2,3,4,-tetrahydro-1,5-benzodiazocin-2-ones
AUTHOR(S): Sharbatyan, P. A.; Terent'ev, P. B.; Andronati, S. A.; Bogatskii, A. V.; Rudenko, O. P.; Danilin, V. V.
CORPORATE SOURCE: Mosk. Gos. Univ., Moscow, USSR
SOURCE: Khimiya Geterotsiklicheskikh Soedinenii (1977), (4), 529-36
CODEN: KGSSAQ; ISSN: 0132-6244
DOCUMENT TYPE: Journal
LANGUAGE: Russian
GI



I

AB The mass spectral fragmentation of I (R = H, Me, Cl, Br; R1 = Me, Et, Pr, Bu; R2 = H, Cl) occurred first by loss of C2H4 and then by loss of H•, NCO•, or CO. Loss of ketene with ring contraction also occurred.

IT 20927-53-1
RL: PRP (Properties)
(mass spectrum of)

RN 20927-53-1 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-1-methyl-4-phenyl- (CA INDEX NAME)



L5 ANSWER 227 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

L5 ANSWER 228 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1977:444242 CAPLUS
DOCUMENT NUMBER: 87:44242
ORIGINAL REFERENCE NO.: 87:6945a,6948a
TITLE: Pharmaceutical composition for the prevention of a gastrointestinal ulcer provoked by a nonsteroid antiinflammatory agent
INVENTOR(S): Yamamoto, Hisao; Komatsu, Toshiaki; Awata, Hiroshi
PATENT ASSIGNEE(S): Sumitomo Chemical Co., Ltd., Japan
SOURCE: Belg., 19 pp.
CODEN: BEXXAL
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
BE 843242	A1	19761018	BE 1976-168174	19760622
JP 52001036	A	19770106	JP 1976-61613	19760526
JP 54016509	B	19790622		
NL 7606494	A	19761227	NL 1976-6494	19760616
AU 499021	B2	19790405	AU 1976-15066	19760618
FR 2315281	A1	19770121	FR 1976-18763	19760621
FR 2315281	B1	19790427		
CA 1062615	A1	19790918	CA 1976-255289	19760621
ZA 7603700	A	19770525	ZA 1976-3700	19760622
IL 49867	A	19800131	IL 1976-49867	19760622
US 4247554	A	19810127	US 1977-795887	19770511
PRIORITY APPLN. INFO.:			US 1975-589573 A	19750623

OTHER SOURCE(S): MARPAT 87:44242
GI



I II

AB Pharmaceutical compns. comprise a nonsteroidal antiinflammatory agent and an ulcer-preventing quinaozolinone I where R' = alkyl C1-3, cyclopropylmethyl, or 2,2,2-trifluoroethyl, R2 = halogen, alkyl C1-3, or alcoxy C1-3, R3 = Ph or thienyl. For example, with an oral 5% gum arabic suspension containing indomethacin [53-86-1] (10 mg/kg) and 1-cyclopropylmethyl-4-phenyl-6-methoxy-2-(1H)-quinazolinone (II) [33453-23-5] (50 mg/kg) no intestinal perforations occurred.

IT 20927-53-1P 23441-64-7P 33453-19-9P
33453-23-5P 37554-40-8P 49830-89-9P
59253-44-0P 59253-45-1P
RL: PREP (Preparation)
(ulcer formation from nonsteroidal antiinflammatory agent inhibition by)

RN 20927-53-1 CAPLUS

L5 ANSWER 228 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
CN 2(1H)-Quinazolinone, 6-chloro-1-methyl-4-phenyl- (CA INDEX NAME)



RN 23441-64-7 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-1-ethyl-4-phenyl- (CA INDEX NAME)



RN 33453-19-9 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-1-(cyclopropylmethyl)-4-phenyl- (CA INDEX NAME)



RN 33453-23-5 CAPLUS
CN 2(1H)-Quinazolinone, 1-(cyclopropylmethyl)-6-methoxy-4-phenyl- (CA INDEX NAME)

L5 ANSWER 228 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 59253-45-1 CAPLUS
CN 2(1H)-Quinazolinone, 1-(cyclopropylmethyl)-7-methoxy-4-phenyl- (CA INDEX NAME)



L5 ANSWER 228 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 37554-40-8 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-4-phenyl-1-(2,2,2-trifluoroethyl)- (CA INDEX NAME)



RN 49830-89-9 CAPLUS
CN 2(1H)-Quinazolinone, 6-methoxy-4-phenyl-1-(2,2,2-trifluoroethyl)- (CA INDEX NAME)



RN 59253-44-0 CAPLUS
CN 2(1H)-Quinazolinone, 1-(cyclopropylmethyl)-7-methyl-4-phenyl- (CA INDEX NAME)

L5 ANSWER 229 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1977:115372 CAPLUS
DOCUMENT NUMBER: 86:115372
ORIGINAL REFERENCE NO.: 86:18177a,18180a
TITLE: Quinazolinone-containing antiinflammatory agents
INVENTOR(S): Yamamoto, Hisao; Komatsu, Toshiaki; Awata, Hiroshi
PATENT ASSIGNEE(S): Sumitomo Chemical Co., Ltd., Japan
SOURCE: Ger. Offen., 19 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2627914	A1	19770113	DE 1976-2627914	19760622
JP 52001036	A	19770106	JP 1976-61613	19760526
JP 54016509	B	19790622		
NL 7606494	A	19761227	NL 1976-6494	19760616
AU 499021	B2	19790405	AU 1976-15066	19760618
FR 2315281	A1	19770121	FR 1976-18763	19760621
FR 2315281	B1	19790427		
CA 1062615	A1	19790918	CA 1976-255289	19760621
ZA 7603700	A	19770525	ZA 1976-3700	19760622
IL 49867	A	19800131	IL 1976-49867	19760622
US 4247554	A	19810127	US 1977-795887	19770511
PRIORITY APPLN. INFO.:			US 1975-589573 A	19750623

GI



I

AB The quinazolinone derivs. I (R1 = C1-3 alkyl, cyclopropylmethyl or F3CCH2CH2; R2 = halogen, C1-3 alkyl or C1-3 alkoxy; R3 = Ph or thienyl) or their salts showed antiinflammatory activity and can be used in combination with non-steroidal inflammation inhibitors. For example, 9 quinazolinone derivs. administered orally at 1 ml/100 g as 5% solns. in gum arabic inhibited or prevented indomethacin [53-86-1]-induced perforations in the intestines. Combined administration of 1-cyclopropylmethyl-4-phenyl-6-methoxy-2(1H)-quinazolinone [33453-23-5] and either indomethacin or phenylbutazone [50-33-9] gave an additive antiinflammatory effect against carrageenan-induced local edema in the rat hind foot.
IT 20927-53-1 23441-64-7 33453-19-9
33453-23-5 37554-40-8 49830-89-9
59253-44-0 59253-45-1
RL: BAC (Biological activity or effector, except adverse); BSU (Biological

L5 ANSWER 229 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
study, unclassified); THU (Therapeutic use); BIOL (Biological study);
USES
(Uses)
(antiinflammatory activity of)
RN 20927-53-1 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-1-methyl-4-phenyl- (CA INDEX NAME)



RN 23441-64-7 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-1-ethyl-4-phenyl- (CA INDEX NAME)



RN 33453-19-9 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-1-(cyclopropylmethyl)-4-phenyl- (CA INDEX NAME)



RN 33453-23-5 CAPLUS
CN 2(1H)-Quinazolinone, 1-(cyclopropylmethyl)-6-methoxy-4-phenyl- (CA INDEX NAME)

L5 ANSWER 229 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 59253-45-1 CAPLUS
CN 2(1H)-Quinazolinone, 1-(cyclopropylmethyl)-7-methoxy-4-phenyl- (CA INDEX NAME)



L5 ANSWER 229 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 37554-40-8 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-4-phenyl-1-(2,2,2-trifluoroethyl)- (CA INDEX NAME)



RN 49830-89-9 CAPLUS
CN 2(1H)-Quinazolinone, 6-methoxy-4-phenyl-1-(2,2,2-trifluoroethyl)- (CA INDEX NAME)



RN 59253-44-0 CAPLUS
CN 2(1H)-Quinazolinone, 1-(cyclopropylmethyl)-7-methyl-4-phenyl- (CA INDEX NAME)

L5 ANSWER 230 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1977:10917 CAPLUS
DOCUMENT NUMBER: 86:10917
ORIGINAL REFERENCE NO.: 86:1757a,1760a
TITLE: The crystal and molecular structure of an anti-inflammatory agent, 1-(cyclopropylmethyl)-4-phenyl-6-methoxy-2(1H)-quinazolinone (SL-573)
AUTHOR(S): Kimura, Michio; Hirohashi, Toshiyuki; Yamamoto, Hisao
CORPORATE SOURCE: Inst. Biol. Sci., Sumitomo Chem. Co., Ltd., Takarazuka, Japan
SOURCE: Bulletin of the Chemical Society of Japan (1976), 49(10), 2696-700
CODEN: BCSJA8; ISSN: 0009-2673
DOCUMENT TYPE: Journal
LANGUAGE: English
AB The crystal structure of the title compound (SL-573), crystallized from an
ethyl acetate solution, was determined by single-crystal x-ray diffraction. The
crystals are monoclinic, space group P21/a, a 17.395(11), b 8.371(5), c 10.871(7) Å, β 99°56(4)', and Z = 4. The intensities were measured visually from equi-inclination integrated Weissenberg photographs
taken with Cu Kα radiation. The structure was solved by the symbolic addition method. The final R factor was 0.119 for 3284 reflections.
The mols. are placed in pairs around the centers of symmetry and are linked by van der Waals' distances less than 3.94 Å. The dihedral angle between the quinazoline and Ph ring planes is 42.8°.
IT 33453-23-5
RL: PRP (Properties)
(crystal structure of)
RN 33453-23-5 CAPLUS
CN 2(1H)-Quinazolinone, 1-(cyclopropylmethyl)-6-methoxy-4-phenyl- (CA INDEX NAME)



L5 ANSWER 231 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1976:560153 CAPLUS
Correction of: 1974:477959
DOCUMENT NUMBER: 85:160153
Correction of: 81:77959
ORIGINAL REFERENCE NO.: 85:25645a,25648a
TITLE: Quinazolinones
INVENTOR(S): Ishizumi, Kikuo; Mori, Kazuo; Yamamoto, Michihiro; Koshiba, Masao; Inaba, Shigeho; Yamamoto, Hisao
PATENT ASSIGNEE(S): Sumitomo Chemical Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 8 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 48080583	A	19731029	JP 1972-12977	19720205
JP 54026555	B	19790904		

PRIORITY APPLN. INFO.: JP 1972-12977 A 19720205

GI



I II

AB The title compds. (I) were prepared by hydrolyzing or by heating acyl ureas
II (R1-R3 = H, halogen, CF3, NO2, alkyl, or alkoxy; R4 = H, alkyl, polyhaloalkyl, or cycloalkylalkyl; R5 = H, alkyl, Ph, alkoxy, benzyloxy, NH2, carboxyl, carbamoyl, or alkoxycarbonyl). E.g., 1.92 g II (R1 = 4-Cl,
R2 = R3 = H, R4 = Me, R5 = Et) in EtOH was refluxed 30 min with 5 ml 20% NaOH to give I (R1 = 6-Cl, R2 = R3 = H, R4 = Me). Similarly prepared was I
(R1, R2, R3, and R4 given): 6-Cl, H, o-F, H.
IT 20927-53-1P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 20927-53-1 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-1-methyl-4-phenyl- (CA INDEX NAME)

L5 ANSWER 231 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



L5 ANSWER 232 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1976:542144 CAPLUS
DOCUMENT NUMBER: 85:142144
ORIGINAL REFERENCE NO.: 85:22797a,22800a
TITLE: Mass spectrometry of 1,4-benzodiazepines
AUTHOR(S): Rendic, S.; Klasinc, L.; Sunjic, V.; Kajfez, F.; Kramer, V.; Mildner, P.
CORPORATE SOURCE: Compagnia Ric. Chem., Chiasso, Switz.
SOURCE: Biomedical Mass Spectrometry (1975), 2(2), 97-106
CODEN: BMSYAL; ISSN: 0306-042X
DOCUMENT TYPE: Journal
LANGUAGE: English
AB The mass spectra of 4 chiral 1,4-benzodiazepine-2-ones, 3 of their in vitro biohydroxylation products, and 6 achiral 1,4-benzodiazepinones are reported and their fragmentation paths discussed. Derivs. with C-3 substituents were useful for determination of fragmentation paths at low resolution.
IT 20927-53-1
RL: PRP (Properties)
(mass spectrum of)
RN 20927-53-1 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-1-methyl-4-phenyl- (CA INDEX NAME)



L5 ANSWER 233 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1976:487535 CAPLUS
DOCUMENT NUMBER: 85:87535
ORIGINAL REFERENCE NO.: 85:13983a,13986a
TITLE: Quantitative determination of quinazolinone derivatives
INVENTOR(S): Hasegawa, Masatoshi; Maeda, Tadao; Takenaka, Hiroshi; Noguchi, Takeshi; Yamahira, Yoshiya
PATENT ASSIGNEE(S): Sumitomo Chemical Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 4 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 51025193	A	19760301	JP 1974-97697	19740826

PRIORITY APPLN. INFO.: JP 1974-97697 A 19740826

GI



I

AB Quinazolin-2-ones or quinazoline-2,4-diones are determined in body fluids by
electron-capture gas chromatog. Thus, 5 μl SL 573 (1-cyclopropylmethyl-4-phenyl-6-methoxy-2(1H)-quinazolinone)(I) [33453-23-5] (1 μg/ml benzene) was determined by electron-capture gas chromatog. (column temperature 270°; detector temperature 310°; chromosorb W AW DMCS column packing; N carrier gas). The retention time was 4.5 min.
IT 22760-18-5 33443-22-0 33453-22-4
33453-23-5 53720-97-1 59253-44-0
RL: ANT (Analyte); ANST (Analytical study)
(determination of, in blood and urine, by gas chromatog.)
RN 22760-18-5 CAPLUS
CN 2(1H)-Quinazolinone, 7-methyl-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)



L5 ANSWER 233 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
RN 33443-22-0 CAPLUS
CN 2(1H)-Quinazolinone, 1-(cyclopropylmethyl)-4-(4-methylphenyl)- (CA INDEX NAME)



RN 33453-22-4 CAPLUS
CN 2(1H)-Quinazolinone, 1-(cyclopropylmethyl)-4-phenyl- (CA INDEX NAME)



RN 33453-23-5 CAPLUS
CN 2(1H)-Quinazolinone, 1-(cyclopropylmethyl)-6-methoxy-4-phenyl- (CA INDEX NAME)

L5 ANSWER 233 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 53720-97-1 CAPLUS
CN 2(1H)-Quinazolinethione, 1-(cyclopropylmethyl)-6-methoxy-4-phenyl- (CA INDEX NAME)



RN 59253-44-0 CAPLUS
CN 2(1H)-Quinazolinone, 1-(cyclopropylmethyl)-7-methyl-4-phenyl- (CA INDEX NAME)



L5 ANSWER 234 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1976:456473 CAPLUS
DOCUMENT NUMBER: 85:56473
ORIGINAL REFERENCE NO.: 85:9051a,9054a
TITLE: Inhibition of prostaglandin biosynthesis by SL-573
AUTHOR(S): Yanagi, Yoshikazu; Komatsu, Toshiaki
CORPORATE SOURCE: Res. Dev. Cent., Sumitomo Chem. Co. Ltd., Hyogo, Japan
SOURCE: Biochemical Pharmacology (1976), 25(8), 937-41
CODEN: BCPCA6; ISSN: 0006-2952
DOCUMENT TYPE: Journal
LANGUAGE: English
AB SL 573 [33453-23-5] (0.5-10 μg/ml) inhibited prostaglandin biosynthesis from labeled arachidonic acid using bovine seminal vesicle microsomes as enzyme sources. The relative inhibitory potencies of indomethacin [53-86-1] (0.06-2.0 μg/ml), SL 573, and aspirin [50-78-2] (100-800 μg/ml) were 1000, 227, and 1.0 resp. The inhibition by SL 573 was reversible, whereas that of indomethacin and aspirin was irreversible.
SL 573 prevented the progressive increase of the irreversible inhibition of indomethacin and aspirin.
IT 33453-23-5
RL: BIOL (Biological study)
(prostaglandin formation by seminal vesicle microsome inhibition by)
RN 33453-23-5 CAPLUS
CN 2(1H)-Quinazolinone, 1-(cyclopropylmethyl)-6-methoxy-4-phenyl- (CA INDEX NAME)



L5 ANSWER 235 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1976:433065 CAPLUS
DOCUMENT NUMBER: 85:33065
ORIGINAL REFERENCE NO.: 85:5369a,5372a
TITLE: Quinazolinone derivatives
INVENTOR(S): Ishizumi, Kikuo; Mori, Kazuo; Inaba, Shigoho; Yamamoto, Hisao
PATENT ASSIGNEE(S): Sumitomo Chemical Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 4 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 50151887	A	19751206	JP 1974-61684	19740530
JP 59019098	B	19840502		
SE 7506140	A	19751201	SE 1975-6140	19750529
SE 414403	B	19800728		
SE 414403	C	19801113		
NL 7506338	A	19751202	NL 1975-6338	19750529
CA 1047967	A1	19790206	CA 1975-228044	19750529
CH 599172	A5	19780512	CH 1975-7026	19750530

PRIORITY APPLN. INFO.: JP 1974-61684 A 19740530

GI



I, XX^1=C:N
II, XX^1=CHNH

AB Quinazolinones I (R = halo, alkoxy) were prepared by photodehydrogenation of dihydroquinazolinones II. I are antiviral, antiinflammatory and uric acid excretion stimulating agents (no data). Thus, 1 g II (R = 6-Cl) in Me2SO was uv-irradiated 50 hr to give 0.87 g I (R = 6-Cl). Also prepared was I (R = 6-MeO).
IT 59253-25-7 59695-55-5
RL: RCT (Reactant); RACT (Reactant or reagent)
(photodehydrogenation of)
RN 59253-25-7 CAPLUS
CN 2(1H)-Quinazolinone, 1-(cyclopropylmethyl)-3,4-dihydro-7-methoxy-4-phenyl- (CA INDEX NAME)

L5 ANSWER 235 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 59695-55-5 CAPLUS
CN 2(1H)-Quinazolinone, 7-chloro-1-(cyclopropylmethyl)-3,4-dihydro-4-phenyl- (CA INDEX NAME)



IT 37555-09-2P 59253-45-1P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 37555-09-2 CAPLUS
CN 2(1H)-Quinazolinone, 7-chloro-1-(cyclopropylmethyl)-4-phenyl- (CA INDEX NAME)



RN 59253-45-1 CAPLUS

L5 ANSWER 235 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
CN 2(1H)-Quinazolinone, 1-(cyclopropylmethyl)-7-methoxy-4-phenyl- (CA INDEX NAME)



L5 ANSWER 236 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1976:421431 CAPLUS
DOCUMENT NUMBER: 85:21431
ORIGINAL REFERENCE NO.: 85:3509a,3512a
TITLE: 4-Phenyl-2(1H)-quinazolinones
INVENTOR(S): Ishizumi, Kikuo; Mori, Kazuo; Inaba, Shigeho; Yamamoto, Hisao
PATENT ASSIGNEE(S): Sumitomo Chemical Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 8 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 50148372	A	19751127	JP 1974-52446	19740510
JP 57060341	B	19821218		

PRIORITY APPLN. INFO.: JP 1974-52446 A 19740510

GI



AB 4-Phenyl-2(1H)-quinazolinones I (R1-R3 = H, halo, CF3, NO2, alkylsulfonyl, alkyl, alkoxy, alkylthio; R4 = H, alkyl, aralkyl, alkanoyloxyalkyl, alkoxyalkyl, polyhaloalkyl, cycloalkyl, tetrahydropyranylmethyl, pyridylmethyl, furylmethyl, thienylmethyl) are prepared by cyclizing 2-aminobenzophenones II with ClCONCO or ClCON:CCl2. Thus, 0.2 g 2-(methylamino)-5-chlorobenzophenone was stirred with 0.39 g ClCON:CCl2 in Et2O 2 hr to give I (R1 = 6-Cl, R2 = R3 = H, R4 = Me), also prepared from ClCONCO. ClCON:CCl2 was prepared by photochem. chlorination of MeNCO in Cl3C6H3 at 100°.
IT 20927-53-1P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 20927-53-1 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-1-methyl-4-phenyl- (CA INDEX NAME)

L5 ANSWER 236 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



L5 ANSWER 237 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1976:180277 CAPLUS
DOCUMENT NUMBER: 84:180277
ORIGINAL REFERENCE NO.: 84:29223a,29226a
TITLE: Quinazolin-2-ones from 3,4-dihydroquinazolin-2-ones
INVENTOR(S): Yamamoto, Michihiro; Morooka, Shigeaki; Koshiba, Masao; Inaba, Shigeho; Yamamoto, Hisao
PATENT ASSIGNEE(S): Sumitomo Chemical Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 6 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 51008287	A	19760123	JP 1974-80506	19740713
JP 54016506	B	19790622		
NL 7507921	A	19760115	NL 1975-7921	19750703
AT 7505257	A	19770815	AT 1975-5257	19750708
SE 7507922	A	19760114	SE 1975-7922	19750710
SE 414404	B	19800728		
SE 414404	C	19801113		
HU 170223	B	19770428	HU 1975-SU895	19750710
CH 612186	A5	19790713	CH 1975-9028	19750710
DK 7503180	A	19760114	DK 1975-3180	19750711
CA 1046063	A1	19790109	CA 1975-231296	19750711

PRIORITY APPLN. INFO.: JP 1974-80506 A 19740713

GI



I II

AB Quinazolinones I [R1, and R2 = H, halo, alkyl, alkoxy, MeS, MeSO2, NO2, CF3, COMe, MeNHCO, or R1R2 = OCH2O; R3 = Ph, halophenyl, nitrophenyl, tolyl, C6H4OMe-p, pyridyl, thienyl; R4 = alkyl, alkenyl, cyclohexyl, cycloalkylmethyl, haloalkyl] were prepared by treating dihydroquinazolinones II with Cl or Br in the presence or absence of a base. Thus, 3.08 g II (R1 = 6-MeO, R2 = H, R3 = Ph, R4 = cyclopropylmethyl) in dioxane was treated dropwise with 2.3 g Br at 75-80° for 6 hr to give 3.8 g I.HBr (same substituents). Similar oxidation with NaOCl in MeOH gave 2.9 g its base. Among 48 more I prepared were R1-R4 given): 6-Cl, H, Ph, CH2CF3; R1R2 = 7,8-OCH2O, Ph, cyclopropylmethyl; 6-Cl, H, 2-pyridyl, cyclopropylmethyl; and 6-MeO, H, 2-thienyl, CH2CF3.

IT 26772-90-7 26772-95-2 26772-97-4
36942-67-3 36942-69-5 36942-70-8
36942-71-9 36942-76-4 36943-01-8
59253-22-4 59253-23-5 59253-24-6
59253-25-7 59253-26-8 59253-27-9
59253-28-0 59253-29-1 59253-30-4
59253-31-5 59253-32-6 59253-33-7
59253-34-8 59253-35-9 59253-37-1
59253-38-2 59253-39-3 59253-40-6
59253-41-7 59253-53-1 59253-54-2
59253-55-3 59253-56-4 59253-57-5
59253-58-6 59253-59-7 59253-60-0
59253-61-1 59253-62-2 59253-63-3
59253-64-4 59253-65-5 59253-66-6
59253-67-7 59253-68-8 59295-63-5
RL: RCT (Reactant); RACT (Reactant or reagent)
(dehydrogenation of)

RN 26772-90-7 CAPLUS
CN 2(1H)-Quinazolinone, 3,4-dihydro-7-methyl-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)



RN 26772-95-2 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-3,4-dihydro-1-methyl-4-phenyl- (CA INDEX NAME)



RN 26772-97-4 CAPLUS
CN 2(1H)-Quinazolinone, 3,4-dihydro-6-methoxy-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)

L5 ANSWER 237 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 36942-67-3 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-1-(2-ethoxyethyl)-4-(2-fluorophenyl)-3,4-dihydro- (CA INDEX NAME)



RN 36942-69-5 CAPLUS
CN 2(1H)-Quinazolinone, 1-(cyclopropylmethyl)-3,4-dihydro-6-nitro-4-phenyl- (CA INDEX NAME)



RN 36942-70-8 CAPLUS
CN 2(1H)-Quinazolinone, 1-(cyclopropylmethyl)-3,4-dihydro-4-phenyl-6-(trifluoromethyl)- (CA INDEX NAME)

L5 ANSWER 237 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 36942-71-9 CAPLUS
CN 2(1H)-Quinazolinone, 1-(cyclopropylmethyl)-3,4-dihydro-6-methoxy-4-phenyl- (CA INDEX NAME)



RN 36942-76-4 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-1-(cyclopropylmethyl)-3,4-dihydro-4-phenyl- (CA INDEX NAME)



RN 36943-01-8 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-3,4-dihydro-4-phenyl-1-(2,2,2-trifluoroethyl)- (CA INDEX NAME)

L5 ANSWER 237 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 59253-22-4 CAPLUS
CN 2(1H)-Quinazolinone, 1-(cyclopropylmethyl)-3,4-dihydro-4-phenyl- (CA INDEX NAME)



RN 59253-23-5 CAPLUS
CN 2(1H)-Quinazolinone, 6-bromo-1-(cyclopropylmethyl)-3,4-dihydro-4-phenyl- (CA INDEX NAME)



RN 59253-24-6 CAPLUS
CN 2(1H)-Quinazolinone, 1-(cyclopropylmethyl)-3,4-dihydro-7-methyl-4-phenyl- (CA INDEX NAME)

L5 ANSWER 237 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 59253-25-7 CAPLUS
CN 2(1H)-Quinazolinone, 1-(cyclopropylmethyl)-3,4-dihydro-7-methoxy-4-phenyl- (CA INDEX NAME)



RN 59253-26-8 CAPLUS
CN 2(1H)-Quinazolinone, 1-(cyclopropylmethyl)-3,4-dihydro-6-(methylthio)-4-phenyl- (CA INDEX NAME)



RN 59253-27-9 CAPLUS
CN 2(1H)-Quinazolinone, 1-(cyclopropylmethyl)-3,4-dihydro-6-(methylsulfonyl)-4-phenyl- (CA INDEX NAME)

L5 ANSWER 237 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 59253-28-0 CAPLUS
CN 2(1H)-Quinazolinone, 6-acetyl-1-(cyclopropylmethyl)-3,4-dihydro-4-phenyl- (CA INDEX NAME)



RN 59253-29-1 CAPLUS
CN 2(1H)-Quinazolinone, 6,8-dichloro-1-(cyclopropylmethyl)-3,4-dihydro-4-phenyl- (CA INDEX NAME)



RN 59253-30-4 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-1-(cyclopropylmethyl)-4-(2-fluorophenyl)-3,4-dihydro- (CA INDEX NAME)

L5 ANSWER 237 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 59253-31-5 CAPLUS
CN 2(1H)-Quinazolinone, 1-(cyclopropylmethyl)-3,4-dihydro-6-methoxy-4-(4-nitrophenyl)- (CA INDEX NAME)



RN 59253-32-6 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-1-(cyclopropylmethyl)-3,4-dihydro-4-(2-methylphenyl)- (CA INDEX NAME)



L5 ANSWER 237 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
RN 59253-33-7 CAPLUS
CN 2(1H)-Quinazolinone, 1-(cyclopropylmethyl)-3,4-dihydro-6-methoxy-4-(4-methylphenyl)- (CA INDEX NAME)



RN 59253-34-8 CAPLUS
CN 2(1H)-Quinazolinone, 1-(cyclohexylmethyl)-3,4-dihydro-6-nitro-4-phenyl- (CA INDEX NAME)



RN 59253-35-9 CAPLUS
CN 2(1H)-Quinazolinone, 1-cyclohexyl-3,4-dihydro-6-nitro-4-phenyl- (CA INDEX NAME)

L5 ANSWER 237 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 59253-37-1 CAPLUS
CN 2(1H)-Quinazolinone, 3,4-dihydro-1-methyl-6-nitro-4-phenyl- (CA INDEX NAME)



RN 59253-38-2 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-3,4-dihydro-4-(4-methoxyphenyl)-1-methyl- (CA INDEX NAME)



RN 59253-39-3 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-1-ethyl-3,4-dihydro-4-phenyl- (CA INDEX NAME)

L5 ANSWER 237 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 59253-40-6 CAPLUS
CN 2(1H)-Quinazolinone, 3,4-dihydro-7-methoxy-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)



RN 59253-41-7 CAPLUS
CN 2(1H)-Quinazolinone, 3,4-dihydro-1-(1-methylethyl)-6-nitro-4-phenyl- (CA INDEX NAME)



RN 59253-53-1 CAPLUS
CN 2(1H)-Quinazolinone, 3,4-dihydro-5,7-dimethyl-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)



RN 59253-54-2 CAPLUS
CN 2(1H)-Quinazolinone, 6-(dimethylamino)-3,4-dihydro-1-(1-methylethyl)-4-

L5 ANSWER 237 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
phenyl- (CA INDEX NAME)



RN 59253-55-3 CAPLUS
CN 2(1H)-Quinazolinone, 3,4-dihydro-6-nitro-4-phenyl-1-(2-propenyl)- (9CI) (CA INDEX NAME)



RN 59253-56-4 CAPLUS
CN 2(1H)-Quinazolinone, 3,4-dihydro-6-nitro-4-phenyl-1-(phenylmethyl)- (CA INDEX NAME)



RN 59253-57-5 CAPLUS
CN 2(1H)-Quinazolinone, 3,4-dihydro-1-[(2-methylphenyl)methyl]-6-nitro-4-phenyl- (CA INDEX NAME)

L5 ANSWER 237 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 59253-58-6 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-3,4-dihydro-1-(methoxymethyl)-4-phenyl- (CA
INDEX NAME)



RN 59253-59-7 CAPLUS
CN 2(1H)-Quinazolinone, 1-(2-ethoxyethyl)-3,4-dihydro-6-nitro-4-phenyl- (CA INDEX NAME)



RN 59253-60-0 CAPLUS
CN 2(1H)-Quinazolinone, 3,4-dihydro-1-[2-(1-methylethoxy)ethyl]-6-nitro-4-phenyl- (CA INDEX NAME)

L5 ANSWER 237 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 59253-61-1 CAPLUS
CN 2(1H)-Quinazolinone, 1-(2-chloroethyl)-3,4-dihydro-6-nitro-4-phenyl- (CA INDEX NAME)



RN 59253-62-2 CAPLUS
CN 2(1H)-Quinazolinone, 1-(2,2-difluoroethyl)-3,4-dihydro-6-nitro-4-phenyl- (CA INDEX NAME)



RN 59253-63-3 CAPLUS
CN 2(1H)-Quinazolinone, 3,4-dihydro-4-phenyl-1-(2,2,2-trifluoroethyl)- (CA INDEX NAME)



L5 ANSWER 237 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

RN 59253-64-4 CAPLUS
CN 2(1H)-Quinazolinone, 3,4-dihydro-6-methoxy-4-phenyl-1-(2,2,2-trifluoroethyl)- (CA INDEX NAME)



RN 59253-65-5 CAPLUS
CN 2(1H)-Quinazolinone,
3,4-dihydro-6-nitro-4-phenyl-1-(2,2,2-trifluoroethyl)-
(CA INDEX NAME)



RN 59253-66-6 CAPLUS
CN 2(1H)-Quinazolinone, 3,4-dihydro-6-methyl-4-phenyl-1-(2,2,2-trifluoroethyl)- (CA INDEX NAME)



RN 59253-67-7 CAPLUS
CN 2(1H)-Quinazolinone,
3,4-dihydro-6-methyl-1-(2,2,3,3,3-pentafluoropropyl)-
4-phenyl- (CA INDEX NAME)

L5 ANSWER 237 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 59253-68-8 CAPLUS
CN 2(1H)-Quinazolinone, 3,4-dihydro-1-(2-hydroxyethyl)-6-nitro-4-phenyl- (CA
INDEX NAME)



RN 59295-63-5 CAPLUS
CN 2(1H)-Quinazolinone, 6-acetyl-3,4-dihydro-1-methyl-4-phenyl- (CA INDEX NAME)



IT 20927-53-1P 22760-18-5P 22760-25-4P
22760-27-6P 22760-60-7P 23441-64-7P
23441-78-3P 26313-51-9P 26824-70-4P
26953-46-8P 28340-57-0P 33443-20-8P
33443-33-3P 33443-35-5P 33453-19-9P
33453-20-2P 33453-22-4P 33453-23-5P
33890-29-8P 37554-35-1P 37554-37-3P
37554-39-5P 37554-40-8P 37554-98-6P
37555-03-6P 37555-17-2P 40852-34-4P
40852-38-8P 40852-40-2P 40852-44-6P
40852-52-6P 41190-30-1P 49830-63-9P
49830-89-9P 52505-75-6P 52568-22-6P
56984-09-9P 59253-44-0P 59253-45-1P
59253-46-2P 59253-47-3P 59253-48-4P
59253-49-5P 59253-69-9P 59253-70-2P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

L5 ANSWER 237 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
RN 20927-53-1 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-1-methyl-4-phenyl- (CA INDEX NAME)



RN 22760-18-5 CAPLUS
CN 2(1H)-Quinazolinone, 7-methyl-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)



RN 22760-25-4 CAPLUS
CN 2(1H)-Quinazolinone, 7-methoxy-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)



RN 22760-27-6 CAPLUS
CN 2(1H)-Quinazolinone, 5,7-dimethyl-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)

L5 ANSWER 237 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 26313-51-9 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-1-(2-ethoxyethyl)-4-(2-fluorophenyl)- (CA INDEX NAME)



RN 26824-70-4 CAPLUS
CN 2(1H)-Quinazolinone, 6-methoxy-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)



RN 26953-46-8 CAPLUS
CN 2(1H)-Quinazolinone, 1-methyl-6-nitro-4-phenyl- (CA INDEX NAME)

L5 ANSWER 237 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 22760-60-7 CAPLUS
CN 2(1H)-Quinazolinone, 1-(1-methylethyl)-6-nitro-4-phenyl- (CA INDEX NAME)



RN 23441-64-7 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-1-ethyl-4-phenyl- (CA INDEX NAME)



RN 23441-78-3 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-4-(4-methoxyphenyl)-1-methyl- (CA INDEX NAME)

L5 ANSWER 237 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 28340-57-0 CAPLUS
CN 2(1H)-Quinazolinone, 6-(dimethylamino)-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)



RN 33443-20-8 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-1-(cyclopropylmethyl)-4-(2-fluorophenyl)- (CA INDEX NAME)



RN 33443-33-3 CAPLUS
CN 2(1H)-Quinazolinone, 1-(cyclopropylmethyl)-4-phenyl-6-(trifluoromethyl)- (CA INDEX NAME)

L5 ANSWER 237 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 33443-35-5 CAPLUS
CN 2(1H)-Quinazolinone, 6,8-dichloro-1-(cyclopropylmethyl)-4-phenyl- (CA INDEX NAME)



RN 33453-19-9 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-1-(cyclopropylmethyl)-4-phenyl- (CA INDEX NAME)



RN 33453-20-2 CAPLUS
CN 2(1H)-Quinazolinone, 6-bromo-1-(cyclopropylmethyl)-4-phenyl- (CA INDEX NAME)

L5 ANSWER 237 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 33453-22-4 CAPLUS
CN 2(1H)-Quinazolinone, 1-(cyclopropylmethyl)-4-phenyl- (CA INDEX NAME)



RN 33453-23-5 CAPLUS
CN 2(1H)-Quinazolinone, 1-(cyclopropylmethyl)-6-methoxy-4-phenyl- (CA INDEX NAME)



RN 33890-29-8 CAPLUS
CN 2(1H)-Quinazolinone, 1-(cyclopropylmethyl)-6-nitro-4-phenyl- (CA INDEX NAME)

L5 ANSWER 237 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 37554-35-1 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-1-(methoxymethyl)-4-phenyl- (CA INDEX NAME)



RN 37554-37-3 CAPLUS
CN 2(1H)-Quinazolinone, 1-(2-ethoxyethyl)-6-nitro-4-phenyl- (CA INDEX NAME)



RN 37554-39-5 CAPLUS
CN 2(1H)-Quinazolinone, 1-(2-hydroxyethyl)-6-nitro-4-phenyl- (CA INDEX NAME)



RN 37554-40-8 CAPLUS

L5 ANSWER 237 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
CN 2(1H)-Quinazolinone, 6-chloro-4-phenyl-1-(2,2,2-trifluoroethyl)- (CA INDEX NAME)



RN 37554-98-6 CAPLUS
CN 2(1H)-Quinazolinone, 6-nitro-4-phenyl-1-(2-propenyl)- (9CI) (CA INDEX NAME)



RN 37555-03-6 CAPLUS
CN 2(1H)-Quinazolinone, 6-nitro-4-phenyl-1-(phenylmethyl)- (CA INDEX NAME)



RN 37555-17-2 CAPLUS
CN 2(1H)-Quinazolinone, 1-(cyclopropylmethyl)-6-(methylsulfonyl)-4-phenyl- (CA INDEX NAME)

L5 ANSWER 237 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 40852-34-4 CAPLUS
CN 2(1H)-Quinazolinone, 1-(cyclohexylmethyl)-6-nitro-4-phenyl- (CA INDEX NAME)



RN 40852-38-8 CAPLUS
CN 2(1H)-Quinazolinone, 1-cyclohexyl-6-nitro-4-phenyl- (CA INDEX NAME)



RN 40852-40-2 CAPLUS
CN 2(1H)-Quinazolinone, 1-[2-(1-methylethoxy)ethyl]-6-nitro-4-phenyl- (CA INDEX NAME)

L5 ANSWER 237 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 49830-63-9 CAPLUS
CN 2(1H)-Quinazolinone, 1-(cyclopropylmethyl)-6-(methylthio)-4-phenyl- (CA INDEX NAME)



RN 49830-89-9 CAPLUS
CN 2(1H)-Quinazolinone, 6-methoxy-4-phenyl-1-(2,2,2-trifluoroethyl)- (CA INDEX NAME)



RN 52505-75-6 CAPLUS
CN 2(1H)-Quinazolinone, 6-methyl-1-(2,2,3,3,3-pentafluoropropyl)-4-phenyl- (CA INDEX NAME)

L5 ANSWER 237 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 40852-44-6 CAPLUS
CN 2(1H)-Quinazolinone, 6-nitro-4-phenyl-1-(2,2,2-trifluoroethyl)- (CA INDEX NAME)



RN 40852-52-6 CAPLUS
CN 2(1H)-Quinazolinone, 4-phenyl-1-(2,2,2-trifluoroethyl)- (CA INDEX NAME)



RN 41190-30-1 CAPLUS
CN 2(1H)-Quinazolinone, 1-[(2-methylphenyl)methyl]-6-nitro-4-phenyl- (CA INDEX NAME)

L5 ANSWER 237 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 52568-22-6 CAPLUS
CN 2(1H)-Quinazolinone, 1-(2-chloroethyl)-6-nitro-4-phenyl- (CA INDEX NAME)



RN 56984-09-9 CAPLUS
CN 2(1H)-Quinazolinone, 6-acetyl-1-methyl-4-phenyl- (CA INDEX NAME)



RN 59253-44-0 CAPLUS
CN 2(1H)-Quinazolinone, 1-(cyclopropylmethyl)-7-methyl-4-phenyl- (CA INDEX NAME)



RN 59253-45-1 CAPLUS
CN 2(1H)-Quinazolinone, 1-(cyclopropylmethyl)-7-methoxy-4-phenyl- (CA INDEX

L5 ANSWER 237 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
NAME)



RN 59253-46-2 CAPLUS
CN 2(1H)-Quinazolinone, 6-acetyl-1-(cyclopropylmethyl)-4-phenyl- (CA INDEX NAME)



RN 59253-47-3 CAPLUS
CN 2(1H)-Quinazolinone, 1-(cyclopropylmethyl)-6-methoxy-4-(4-nitrophenyl)- (CA INDEX NAME)

L5 ANSWER 237 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 59253-48-4 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-1-(cyclopropylmethyl)-4-(2-methylphenyl)- (CA INDEX NAME)



RN 59253-49-5 CAPLUS
CN 2(1H)-Quinazolinone, 1-(cyclopropylmethyl)-6-methoxy-4-(4-methylphenyl)- (CA INDEX NAME)

L5 ANSWER 237 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 59253-69-9 CAPLUS
CN 2(1H)-Quinazolinone, 1-(2,2-difluoroethyl)-6-nitro-4-phenyl- (CA INDEX NAME)



RN 59253-70-2 CAPLUS
CN 2(1H)-Quinazolinone, 6-methyl-4-phenyl-1-(2,2,2-trifluoroethyl)- (CA INDEX NAME)



L5 ANSWER 238 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1976:180271 CAPLUS
DOCUMENT NUMBER: 84:180271
ORIGINAL REFERENCE NO.: 84:29223a,29226a
TITLE: 3,4-Dihydro-2(1H)-quinazolinones and their salts
INVENTOR(S): Inaba, Shigeho; Yamamoto, Michihiro; Ishizumi, Kikuo; Mori, Kazuo; Koshiba, Masao; Yamamoto, Hisao
PATENT ASSIGNEE(S): Sumitomo Chemical Co., Ltd., Japan
SOURCE: Ger. Offen., 15 pp. Division of Ger. Offen. 2,162,327.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 6
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2166327	A1	19731031	DE 1971-2166327	19711215
DE 2166327	B2	19760729		
DE 2166327	C3	19770331		
JP 49040476	B	19741102	JP 1971-1477	19710119
SU 439979	A3	19740815	SU 1971-1727687	19711221
PL 83081	B1	19751231	PL 1971-152411	19711222
PRIORITY APPLN. INFO.:			JP 1971-1477 A	19710119
			JP 1971-34897 A	19710521

GI



AB 2(1H)-quinazolinone (I, R = CH2CH2OH) was obtained by reductive cyclization of II by NaBH4 in DMF. Analogously obtained were I [R = CH2CH2OAc, PhCH2, CH2CH2NEt2, (CH2)3NMe2, 2-morpholinoethyl]. I were useful as analgesics, inflammation-inhibitors, and as central nervous system depressants.
IT 41230-82-4P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 41230-82-4 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-1-(cyclopropylmethyl)-3-[2-(diethylamino)ethyl]-3,4-dihydro-4-phenyl- (CA INDEX NAME)

L5 ANSWER 238 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



L5 ANSWER 239 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1976:164840 CAPLUS
DOCUMENT NUMBER: 84:164840
ORIGINAL REFERENCE NO.: 84:26771a,26774a
TITLE: Quinazolinones
INVENTOR(S): Inaba, Shigeho; Yamamoto, Michihiro; Ishizumi, Kikuo; Mori, Kazuo; Koshiba, Masao; Yamamoto, Hisao
PATENT ASSIGNEE(S): Sumitomo Chemical Co., Ltd., Japan
SOURCE: Ger. Offen., 26 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 6
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2162327	A	19720713	DE 1971-2162327	19711215
DE 2162327	B2	19750130		
DE 2162327	C3	19750918		
JP 48034598	B	19731022	JP 1970-118332	19701223
JP 49040476	B	19741102	JP 1971-1477	19710119
SU 475774	A3	19750630	SU 1971-1754058	19710612
AT 310177	B	19730925	AT 1972-8983	19710712
AT 310178	B	19730925	AT 1972-8984	19710712
SU 439980	A3	19740815	SU 1971-1754056	19710712
CH 563995	A5	19750715	CH 1975-358	19710712
CH 564539	A5	19750731	CH 1975-357	19710712
CS 181665	B2	19780331	CS 1971-5097	19710712
CS 181693	B2	19780331	CS 1975-7829	19710712
AU 7136921	A	19730621	AU 1971-36921	19711215
GB 1344658	A	19740123	GB 1971-58305	19711215
FR 2118932	A5	19720804	FR 1971-45497	19711217
FR 2118932	B1	19751010		
CH 560198	A5	19750327	CH 1971-18583	19711220
DK 129996	B	19741209	DK 1971-6269	19711221
SE 405729	B	19781227	SE 1971-16425	19711221
SE 405729	C	19790405		
BE 777102	A1	19720414	BE 1971-112022	19711222
NL 7117652	A	19720627	NL 1971-17652	19711222
DD 95845	A5	19730220	DD 1971-159807	19711222
PL 83081	B1	19751231	PL 1971-152411	19711222
CA 981672	A1	19760113	CA 1971-130858	19711222
HU 163789	B	19731027	HU 1971-SU704	19711223
ES 419267	A1	19761101	ES 1973-419267	19731002
ES 419266	A1	19770101	ES 1973-419266	19731002

PRIORITY APPLN. INFO.: JP 1970-118332 A 19701223
JP 1971-1477 A 19710119
JP 1971-34897 A 19710521

GI

L5 ANSWER 239 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



AB Quinazolinones I (R = H, R1 = Et, CH2CH2OH, Me, CH2CH2OAc, CH2Ph, C6H4Me-4, CH2CH2NEt2, (CH2)3NMe2, morpholinoethyl, R2 = Cl; R = Me, R1 = cyclopropylmethyl, R2 = Cl; R = cyclopropylmethyl, R1 = Et, CH2CH2NEt2, R2 = Cl; R = Et, R1 = CH2CH2NEt2, R2 = Cl; R = CHMe2, R1 = (CH2)3NMe2, R2 = H; R = Me, R1 = CH2CH2NMe2, R2 = H) were prepared for use as central nervous system depressants, inflammation inhibitors, analgesics, uricosurics, and bactericides (no data). Thus 2,5-Cl3CCONH(Cl)C6H4Bz was treated with EtNH2·HCl and 2,5-Cl3CCONH(Cl)C6H4CPh:NEt subjected to reductive cyclization with NaBH4 to give I (R = H, R1 = Et, R2 = Cl).

IT 36942-76-4
RL: RCT (Reactant); RACT (Reactant or reagent)
(alkylation of)

RN 36942-76-4 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-1-(cyclopropylmethyl)-3,4-dihydro-4-phenyl- (CA INDEX NAME)



IT 26772-91-8P 37665-54-6P 41230-80-2P 41230-82-4P 41230-84-6P 59128-74-4P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 26772-91-8 CAPLUS
CN 2(1H)-Quinazolinone, 3-[3-(dimethylamino)propyl]-3,4-dihydro-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)

L5 ANSWER 239 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 37665-54-6 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-3-(cyclopropylmethyl)-1-methyl-4-phenyl- (9CI) (CA INDEX NAME)



RN 41230-80-2 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-3-[2-(diethylamino)ethyl]-1-ethyl-3,4-dihydro-4-phenyl-, monohydriodide (9CI) (CA INDEX NAME)



● HI

RN 41230-82-4 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-1-(cyclopropylmethyl)-3-[2-(diethylamino)ethyl]-3,4-dihydro-4-phenyl- (CA INDEX NAME)

L5 ANSWER 239 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 41230-84-6 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-1-(cyclopropylmethyl)-3-ethyl-3,4-dihydro-4-phenyl- (CA INDEX NAME)



RN 59128-74-4 CAPLUS
CN 2(1H)-Quinazolinone, 3-[2-(dimethylamino)ethyl]-3,4-dihydro-1-methyl-4-phenyl-, (2Z)-2-butenedioate (9CI) (CA INDEX NAME)

CM 1

CRN 37665-55-7
CMF C19 H23 N3 O



CM 2

L5 ANSWER 239 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



L5 ANSWER 240 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1976:95677 CAPLUS
DOCUMENT NUMBER: 84:95677
ORIGINAL REFERENCE NO.: 84:15553a,15556a
TITLE: Luminescence determination of pharmaceuticals of the tetrahydrocarbazole, carbazole, and 1,4-benzodiazepine class
AUTHOR(S): De Silva, J. Arthur F.; Strojny, Norman; Stika, Katherine
CORPORATE SOURCE: Dep. Biochem. Drug Metab., Hoffmann-La Roche Inc., Nutley, NJ, USA
SOURCE: Analytical Chemistry (1976), 48(1), 144-55
CODEN: ANCHAM; ISSN: 0003-2700
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Luminescence studies were performed on thin-layer chromatog. plates at 77°K and also with a Farrand Mark I Spectrofluorometer which was modified to accommodate a com. available phosphoroscope. The apparatus was used to obtain fluorescence and phosphorescence spectra at 77°K of selected tetrahydrocarbazoles, and carbazoles, 1,4-benzodiazepines. Some of the results were verified on other com. available phosphorimeters, and the modified instrument was equal to or better in spectral quality, sensitivity, and precision. The simple modification employed greatly extends the utility of this instrument for cryogenic luminescence research.
IT 20927-53-1
RL: PRP (Properties)
(luminescence of, low temperature)
RN 20927-53-1 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-1-methyl-4-phenyl- (CA INDEX NAME)



L5 ANSWER 241 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1976:4921 CAPLUS
DOCUMENT NUMBER: 84:4921
ORIGINAL REFERENCE NO.: 84:833a,836a
TITLE: Benzodiazepines. X. Oxidation of tetrahydro-1,4-benzodiazepine derivatives
AUTHOR(S): Ishizumi, Kikuo; Mori, Kazuo; Inaba, Shigeho; Yamamoto, Hisao
CORPORATE SOURCE: Pharm. Div., Sumitomo Chem. Co., Ltd., Takarazuka, Japan
SOURCE: Chemical & Pharmaceutical Bulletin (1975), 23(9), 2169-73
CODEN: CPBTAL; ISSN: 0009-2363
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 84:4921
GI For diagram(s), see printed CA Issue.
AB By uv irradiation in Me2SO or Me2CO tetrahydro-1,4-benzodiazepines I (R = H, Me, X = O; R = Me, X = H2) and 6-chloro-1-cyclopropylmethyl-4-phenyl-1,2,3,4-tetrahydroquinazolin-2-one were oxidized to the corresponding dihydro compds. II and III. I (R = Me, X = O) was prepared from 4-acetyl-7-cloro-1-methyl-2,3,4,5-tetrahydro-5-phenyl-1H-1,4-benzodiazepine by oxidation with KMnO4 followed by acid hydrolysis. Other types of 4-acylbenzodiazepine derivs. were also oxidized.
IT 36942-76-4
RL: RCT (Reactant); RACT (Reactant or reagent)
(oxidation of)
RN 36942-76-4 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-1-(cyclopropylmethyl)-3,4-dihydro-4-phenyl- (CA INDEX NAME)



IT 33453-19-9P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 33453-19-9 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-1-(cyclopropylmethyl)-4-phenyl- (CA INDEX NAME)

L5 ANSWER 241 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



L5 ANSWER 242 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1975:514470 CAPLUS
DOCUMENT NUMBER: 83:114470
ORIGINAL REFERENCE NO.: 83:17987a,17990a
TITLE: Quinazolinones
INVENTOR(S): Yamamoto, Michihiro; Morooka, Shigeaki; Koshiba, Masao; Inaba, Shigeho; Yamamoto, Hisao
PATENT ASSIGNEE(S): Sumitomo Chemical Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 5 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 50071686	A	19750613	JP 1973-123128	19731031
PRIORITY APPLN. INFO.:			JP 1973-123128 A	19731031

GI For diagram(s), see printed CA Issue.

AB Quinazolines (I, R = H, alkyl, haloalkyl, cyclohexylalkyl, R1 = H, alkyl, R2 = Ph), were prepared by cyclization of II (R4 = trihalomethyl, CN, alkoxy, halogen) with NH3 or by reacting III with a reactive carbamic acid ester or salt. Thus, 22.3 g 2-(trichloroacetamido)-5-acetylbenzophenone in 250 ml Me2SO was treated with 9 g NH4OAc at 90° for 2 hr to give 12.4 g I (R = H, R1CO = 6-MeCO, R2 = Ph). I (R = Me, R1CO = 6-Ac, R2 = Ph) was similarly prepared I were useful as antiinflammatory agents and virucides.

IT 56984-09-9P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 56984-09-9 CAPLUS
CN 2(1H)-Quinazolinone, 6-acetyl-1-methyl-4-phenyl- (CA INDEX NAME)



L5 ANSWER 243 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1975:458866 CAPLUS
DOCUMENT NUMBER: 83:58866
ORIGINAL REFERENCE NO.: 83:9295a,9298a
TITLE: Morpholino-substituted 2(1H)-quinazolinones
INVENTOR(S): Ott, Hans
PATENT ASSIGNEE(S): Sandoz-Wander, Inc., USA
SOURCE: U.S., 6 pp. Division of U.S. 3,819,625.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 3876640	A	19750408	US 1974-458545	19740408
US 3642791	A	19720215	US 1969-849863	19690813
US 3819625	A	19740625	US 1971-177154	19710901
PRIORITY APPLN. INFO.:			US 1969-849863 A3	19690813
			US 1971-177154 A3	19710901

GI For diagram(s), see printed CA Issue.

AB Antiinflammatory (no data) quinazolinones I (R = H, R1 = morpholino; R = morpholino, R1 = H, Me) were prepared by either (a) treatment of benzophenonimine II with COCl2 or (b) cycloaddn. of benzophenone III with urethane followed successively by nitration, hydrogenation, and cycloaddn. with (BrCH2CH2)2O. Treatment of 1-chloro-4-morpholino-2-nitrobenzene with CuCN and then successive reduction with Fe-HCl, isopropylation, and treatment with PhLi gave II.

IT 25509-39-1P 28340-78-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and cyclization of, with bis(bromoethyl) ether)

RN 25509-39-1 CAPLUS
CN 2(1H)-Quinazolinone, 6-amino-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)



RN 28340-78-5 CAPLUS
CN 2(1H)-Quinazolinone, 6-amino-7-methyl-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)

L5 ANSWER 243 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



IT 28340-53-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and hydrogenation of)

RN 28340-53-6 CAPLUS
CN 2(1H)-Quinazolinone, 7-methyl-1-(1-methylethyl)-6-nitro-4-phenyl- (CA INDEX NAME)



IT 22760-18-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and nitration of)

RN 22760-18-5 CAPLUS
CN 2(1H)-Quinazolinone, 7-methyl-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)



IT 22760-60-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reduction of)

RN 22760-60-7 CAPLUS
CN 2(1H)-Quinazolinone, 1-(1-methylethyl)-6-nitro-4-phenyl- (CA INDEX NAME)

L5 ANSWER 243 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



IT 28340-74-1P 28340-77-4P 28340-79-6P
56158-73-7P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 28340-74-1 CAPLUS
CN 2(1H)-Quinazolinone, 1-(1-methylethyl)-7-(4-morpholinyl)-4-phenyl- (CA INDEX NAME)



RN 28340-77-4 CAPLUS
CN 2(1H)-Quinazolinone, 1-(1-methylethyl)-6-(4-morpholinyl)-4-phenyl- (CA INDEX NAME)



RN 28340-79-6 CAPLUS
CN 2(1H)-Quinazolinone,
7-methyl-1-(1-methylethyl)-6-(4-morpholinyl)-4-phenyl-
(CA INDEX NAME)

L5 ANSWER 243 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 56158-73-7 CAPLUS
CN 2(1H)-Quinazolinone, 1-(1-methylethyl)-7-(4-morpholinyl)-4-phenyl-, monohydrochloride (9CI) (CA INDEX NAME)



L5 ANSWER 244 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1975:428267 CAPLUS
DOCUMENT NUMBER: 83:28267
ORIGINAL REFERENCE NO.: 83:4533a,4536a
TITLE: Quinazolinones
INVENTOR(S): Yamamoto, Michihiro; Morooka, Shigeaki; Koshiba, Masao; Inaba, Shigeho; Yamamoto, Hisao
PATENT ASSIGNEE(S): Sumitomo Chemical Co., Ltd.
SOURCE: Jpn. Kokai Tokkyo Koho, 6 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 49110681	A	19741022	JP 1973-27486	19730307
PRIORITY APPLN. INFO.:			JP 1973-27486 A	19730307

GI For diagram(s), see printed CA Issue.
AB Quinazolinones I (R1 = alkoxycarbonyl, CN, CONR3R4, where R3 and R4 = H, alkyl, or NR3R4 = 5- or 6-membered saturated heterocycle which may contain other hetero atoms; R2 = optionally substituted phenyl, pyridyl; R = H, alkyl, alkenyl) were prepared by (A) cyclizing trihaloacetamides II (X = halo) with NH3, (B) cyclizing amines III with reactive carbamate esters, HOCN, or its salts, or (C) alkylating 1-unsubstituted analogs I (R = H) with reactive esters of alcs. ROH (except when R = H). I have uricosuric, antiinflammatory, and antiviral activities (no data). Thus, 8 g 2-trichloroacetamido-5-(methoxycarbonyl)benzophenone was stirred with 3.9 g NH4OAc in 50 ml Me2SO at room temperature for 16 hr to give 5.55 g I (R1 = 6-CO2Me, R2 = Ph, R = H). Among 5 more I (R2 = Ph) prepared were (6-R1, R, and method given): CN, H, A; CONH2, H, B; CO2Me, cyclopropylmethyl, C; CN, cyclopropylmethyl, C. The 1-N-alkylation (method C) was accompanied by 2-O-alkylation.
IT 49830-65-1P 56017-59-5P 56017-60-8P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and uricosuric, antiinflammatory and antiviral activities of)
RN 49830-65-1 CAPLUS
CN 6-Quinazolinecarboxylic acid, 1-(cyclopropylmethyl)-1,2-dihydro-2-oxo-4-phenyl-, methyl ester (CA INDEX NAME)

L5 ANSWER 244 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 56017-59-5 CAPLUS
CN 6-Quinazolinecarbonitrile, 1-(cyclopropylmethyl)-1,2-dihydro-2-oxo-4-phenyl- (CA INDEX NAME)



RN 56017-60-8 CAPLUS
CN 6-Quinazolinecarboxamide, 1,2-dihydro-1-methyl-2-oxo-4-phenyl- (CA INDEX NAME)



L5 ANSWER 245 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1975:410139 CAPLUS
DOCUMENT NUMBER: 83:10139
ORIGINAL REFERENCE NO.: 83:1705a,1708a
TITLE: Quinazolinone compounds
PATENT ASSIGNEE(S): Sumitomo Chemical Co., Ltd., Japan
SOURCE: Neth. Appl., 16 pp.
CODEN: NAXXAN
DOCUMENT TYPE: Patent
LANGUAGE: Dutch
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
NL 7304967	A	19741014	NL 1973-4967		19730410
PRIORITY APPLN. INFO.:			NL 1973-4967	A	19730410

GI For diagram(s), see printed CA Issue.
AB Antiinflammatory and analgesic (no date) quinazolinones I(R = Me, R1 = H, R2 = Cl; R = H, R1 = F, R2 = Cl; R = R1 = H, R2 = NO2) were prepared Thus
1-methyl-3-phenyl-5-chloro-2-indolecarbonyl azide was treated with EtOH and the Et carbamate oxidized to 2,4-Bz(Cl)C6H3NMeCONHCO2Et, which on basic hydrolysis gave I(R = Me, R1 = H, R2 = Cl).
IT 20927-53-1P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 20927-53-1 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-1-methyl-4-phenyl- (CA INDEX NAME)



L5 ANSWER 246 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1975:401450 CAPLUS
DOCUMENT NUMBER: 83:1450
ORIGINAL REFERENCE NO.: 83:295a,298a
TITLE: Metabolic rearrangements of 1,4-benzodiazepine derivatives
AUTHOR(S): Schwandt, H. J.; Sadee, W.; Beyer, K. H.
CORPORATE SOURCE: Fachber. Pharm., Freie Univ. Berlin, Berlin, Fed. Rep.
Ger.
SOURCE: Xenobiotica (1974), 4(12), 733-41
CODEN: XENOBH; ISSN: 0049-8254
DOCUMENT TYPE: Journal
LANGUAGE: English
GI For diagram(s), see printed CA Issue.
AB The metabolism of equimolar amts. (.apprx.1 mg) of 1,4-benzodiazepine derivs.,
e.g. diazepam (I) [439-14-5], by rat liver microsomal prepns. showed that the extent of metabolic rearrangement to quinazolines depended on the structure of the diazepine ring. Thus, 3-hydroxy derivs. were metabolic precursors in quinazolinone formation whereas 3-oxo derivs. were not metabolic intermediates. In addition to quinazolinones, 3-Me analogs of I
also gave 2-acetylquinazoline [13132-91-7] and 2-ethan-α-olquinazoline [55281-43-1] as major metabolites. Schemes for the sequence
and mechanism of metabolic steps in quinazolinone formation are presented.
IT 20927-53-1
RL: PRP (Properties)
(benzodiazepine derivs. metabolic rearrangement to, in liver microsomal
prepns.)
RN 20927-53-1 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-1-methyl-4-phenyl- (CA INDEX NAME)



L5 ANSWER 247 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1975:171043 CAPLUS
DOCUMENT NUMBER: 82:171043
ORIGINAL REFERENCE NO.: 82:27345a,27348a
TITLE: 4-Phenyl-2-(1H)-quinazolinones
INVENTOR(S): Ishizumi, Kikuo; Mori, Kazuo; Yamamoto, Michihiro; Koshiba, Masao; Inaba, Shigeho; Yamamoto, Hisao
PATENT ASSIGNEE(S): Sumitomo Chemical Co., Ltd., Japan
SOURCE: Ger. Offen., 12 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
DE 2439454	A1	19750306	DE 1974-2439454		19740816
JP 50046680	A	19750425	JP 1973-93678		19730820
US 3953446	A	19760427	US 1974-494885		19740805
GB 1464033	A	19770209	GB 1974-35079		19740808
NL 7410775	A	19750224	NL 1974-10775		19740812
SE 7410424	A	19750221	SE 1974-10424		19740815
SE 409325	B	19790813			
FR 2245642	A1	19750425	FR 1974-28416		19740819
DK 7404424	A	19750428	DK 1974-4424		19740819
DK 134228	B	19761004			
CA 1019329	A1	19771018	CA 1974-207244		19740819
CH 601260	A5	19780630	CH 1974-11351		19740820
PRIORITY APPLN. INFO.:			JP 1973-93678	A	19730820

GI For diagram(s), see printed CA Issue.
AB Three quinazolinones (I) R = H, Me, R1 = H, F, R2 = Cl, O2N), useful as antiphlogistics, virucides, and drugs for the treatment of gout (no data),
were prepared by treatment of the azides II with oxidizing agents, i.e. CrO3
or ozone. Thus, 1-methyl-5-nitro-3-phenyl-2-indolecarboxylic acid reacted
successively with SOCl2 and NaN3 to give II (R = Me, R1 = H, R2 = O2N), which on treatment with aqueous CrO3 or ozone-containing O in AcOH gave I (R = Me,
R1 = H, R2 = O2N).
IT 20927-53-1P 26953-46-8P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 20927-53-1 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-1-methyl-4-phenyl- (CA INDEX NAME)



L5 ANSWER 247 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
RN 26953-46-8 CAPLUS
CN 2(1H)-Quinazolinone, 1-methyl-6-nitro-4-phenyl- (CA INDEX NAME)



L5 ANSWER 248 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1975:171012 CAPLUS
DOCUMENT NUMBER: 82:171012
ORIGINAL REFERENCE NO.: 82:27337a,27340a
TITLE: Quinazolinone derivatives having central nervous system, antiinflammatory and analgesic activities, and also useful as pharmaceutical agents
INVENTOR(S): Inaba, Shigeo; Yamamoto, Michihiro; Ishizumi, Kikuo; Mori, Kazuo; Koshiba, Masao; Yamamoto, Hisao
PATENT ASSIGNEE(S): Sumitomo Chemical Co., Ltd.
SOURCE: Jpn. Tokkyo Koho, 4 pp. Division of Japan. 73 34,598 (See Ger. 2,134,118, CA 77: 5515w).
CODEN: JAXXAD
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 49025270	B	19740628	JP 1973-40728	19730409
PRIORITY APPLN. INFO.:			JP 1973-40728	19730409

GI For diagram(s), see printed CA Issue.
AB Quinazolinones (I, R = cyclopropylmethyl, R1 = Et (II), CH2CH2NEt; R = CH2CF3, R1 = CH2OMe), useful as antiinflammatory agents at 100-200 mg/kg, were prepared by reacting I (R1 = H) with the appropriate alkyl halide in the presence of NaH. Thus, I (R = cyclopropylmethyl, R1 = H) (3.1 g) in 50 ml DMF containing 0.42 g 63% NaH was heated 30 min at 50°, and the mixture was treated with 3.1 g EtI at 60° for 4 hr to give II.
IT 36942-76-4 36943-01-8
RL: RCT (Reactant); RACT (Reactant or reagent)
(alkylation of)
RN 36942-76-4 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-1-(cyclopropylmethyl)-3,4-dihydro-4-phenyl- (CA INDEX NAME)



RN 36943-01-8 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-3,4-dihydro-4-phenyl-1-(2,2,2-trifluoroethyl)- (CA INDEX NAME)

L5 ANSWER 248 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



L5 ANSWER 248 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



IT 41230-82-4P 41230-84-6P 55577-43-0P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 41230-82-4 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-1-(cyclopropylmethyl)-3-[2-(diethylamino)ethyl]-3,4-dihydro-4-phenyl- (CA INDEX NAME)



RN 41230-84-6 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-1-(cyclopropylmethyl)-3-ethyl-3,4-dihydro-4-phenyl- (CA INDEX NAME)



RN 55577-43-0 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-3,4-dihydro-3-(methoxymethyl)-4-phenyl-1-(2,2,2-trifluoroethyl)- (CA INDEX NAME)

L5 ANSWER 249 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1975:156366 CAPLUS
DOCUMENT NUMBER: 82:156366
ORIGINAL REFERENCE NO.: 82:24969a,24972a
TITLE: 6-Nitro-4-phenyl-2(1H)-quinazolinones
INVENTOR(S): Yamamoto, Michihiro; Morooka, Shigeaki; Koshiba, Masao; Inaba, Shigeho; Yamamoto, Hisao
PATENT ASSIGNEE(S): Sumitomo Chemical Co., Ltd., Japan
SOURCE: Ger. Offen., 22 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2438849	A1	19750306	DE 1974-2438849	19740813
JP 50040584	A	19750414	JP 1973-91590	19730814
JP 57024789	B	19820526		
US 3970654	A	19760720	US 1974-493240	19740730
AU 7471927	A	19760205	AU 1974-71927	19740801
CA 1000699	A1	19761130	CA 1974-206126	19740801
GB 1474985	A	19770525	GB 1974-35076	19740808
NL 7410725	A	19750218	NL 1974-10725	19740809
CH 608008	A5	19781215	CH 1974-10897	19740809
BE 818784	A1	19741202	BE 1974-147551	19740813
SE 7410325	A	19750217	SE 1974-10325	19740813
SE 408553	C	19790927		
SE 408553	B	19790618		
FR 2240736	A1	19750314	FR 1974-28057	19740813
DK 7404318	A	19750421	DK 1974-4318	19740813
DK 134550	B	19761129		
AT 7406682	A	19761215	AT 1974-6682	19740814
AT 338275	B	19770810		
PRIORITY APPLN. INFO.:			JP 1973-91590 A	19730814

GI For diagram(s), see printed CA Issue.
AB Three quinazolinones I [R = 1-adamantylmethyl (II), 2-norbornylmethyl (III), or 2-(6,6-dimethylbicyclo[3.1.1]hept-2-en-2-yl)ethyl (IV)] were prepared and useful as virucides. Thus, 1-(1-adamantylmethyl)-3,4-dihydro-6-nitro-4-phenyl-2(1H)-quinazolinone was treated with KMnO4 in H2O and dioxane at room temperature to give II, which was also prepared by reaction of 2-[(1-adamantylmethyl)amino]-5-nitrobenzophenone with H2NCO2Et in the presence of ZnCl2 at 170-80°. I (R = H) in DMF reacted with NaH and 2-(bromomethyl)norbornane at reflux to give III and 6-nitro-2-(2-norbornylmethoxy)-4-phenylquinazoline. 2-[[(6,6-Dimethylbicyclo[3.1.1]hept-2-en-2-yl)ethyl]amino]-5-nitrobenzophenone imine reacted with COCl2 in C6H6 containing Et3N to give IV.
IT 55932-65-5
RL: RCT (Reactant); RACT (Reactant or reagent)
(oxidation of)
RN 55932-65-5 CAPLUS
CN 2(1H)-Quinazolinone, 3,4-dihydro-6-nitro-4-phenyl-1-(tricyclo[3.3.1.13,7]dec-1-ylmethyl)- (CA INDEX NAME)

L5 ANSWER 249 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



IT 55932-59-7P 55932-60-0P 55932-63-3P
55932-66-6P 56044-62-3P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 55932-59-7 CAPLUS
CN 2(1H)-Quinazolinone, 1-(bicyclo[2.2.1]hept-2-ylmethyl)-6-nitro-4-phenyl-
(CA INDEX NAME)



RN 55932-60-0 CAPLUS
CN 2(1H)-Quinazolinone,
1-(bicyclo[2.2.1]hept-2-ylmethoxy)-6-nitro-4-phenyl-
(CA INDEX NAME)



RN 55932-63-3 CAPLUS
CN 2(1H)-Quinazolinone,
1-[2-(6,6-dimethylbicyclo[3.1.1]hept-2-en-2-yl)ethyl]-

L5 ANSWER 249 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



L5 ANSWER 249 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
6-nitro-4-phenyl- (CA INDEX NAME)



RN 55932-66-6 CAPLUS
CN 2(1H)-Quinazolinone, 1-[2-(6,6-dimethylbicyclo[3.1.1]hept-2-en-2-
yl)ethoxy]-6-nitro-4-phenyl- (CA INDEX NAME)



RN 56044-62-3 CAPLUS
CN 2(1H)-Quinazolinone, 6-nitro-4-phenyl-1-(tricyclo[3.3.1.13,7]dec-1-
ylmethyl)- (CA INDEX NAME)

L5 ANSWER 250 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1975:156224 CAPLUS
DOCUMENT NUMBER: 82:156224
ORIGINAL REFERENCE NO.: 82:24937a,24940a
TITLE: 1,2,3-Benzotriazines
AUTHOR(S): Adger, Brian M.; Bradbury, Steven; Keating, Martin; Rees, Charles W.; Storr, Richard C.; Williams, Michael T.
CORPORATE SOURCE: Robert Robinson Lab., Univ. Liverpool, Liverpool, UK
SOURCE: Journal of the Chemical Society, Perkin Transactions 1: Organic and Bio-Organic Chemistry (1972-1999) (1975), (1), 31-40
CODEN: JCPRB4; ISSN: 0300-922X
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 82:156224
GI For diagram(s), see printed CA Issue.
AB 1,2,3-Benzotriazine and its 4-substituted derivs. were prepared by 3 methods. Oxidation of (o-aminophenyl) ketone hydrazones by Pb(OAc)4 in CH2Cl2, e.g. o-H2NC6H4CCMe with N2H4 gave after oxidation 47% triazine I. Oxidation of N-aminoquinazolinones by Pb(OAc)4, in CH2Cl2, e.g., II gave 23% triazine I. Oxidation of aminoindazoles by Pb(OAc)4 in CH2Cl2, e.g. 2-amino-3-methylindazole (III) gave 80% triazine I. The 1,2,3-benzotriazines underwent nucleophilic addition to the 3,4-bond. (O-Azidophenyl) ketones with N2H4 and AcOH in EtOH gave indazoles. E.g., o-N3C6H4CCMe gave 90% 3-methylindazole.
IT 55271-19-7P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 55271-19-7 CAPLUS
CN 2(1H)-Quinazolinone, 1-amino-4-phenyl- (CA INDEX NAME)



L5 ANSWER 251 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1975:140164 CAPLUS
DOCUMENT NUMBER: 82:140164
ORIGINAL REFERENCE NO.: 82:22399a,22402a
TITLE: 1-Hydroxyalkylquinazolinone derivatives
INVENTOR(S): Yamamoto, Michihiro; Morooka, Shigeaki; Koshiba, Masao; Inaba, Shigeho; Yamamoto, Hisao
PATENT ASSIGNEE(S): Sumitomo Chemical Co., Ltd.
SOURCE: Jpn. Kokai Tokkyo Koho, 7 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 49108087	A	19741014	JP 1973-19390	19730217
JP 55047035	B	19801127		

PRIORITY APPLN. INFO.: JP 1973-19390 A 19730217

GI For diagram(s), see printed CA Issue.
AB 1-Hydroxyalkylquinazolinone I [R = lower alkyl having 1-3 OH groups; R1 = H, halo, lower alkyl, lower alkoxy, NO2; R2 = Ph, lower alkyl, cycloalkyl, pyridyl, furyl, thienyl (II)] were prepared (1) by reacting I (R = H) with reactive esters of ROH, (2) by reacting III (R3 = trihalomethyl, cyano) with NH3, (3) by oxidizing IV, or (4) by hydrolyzing I (R = lower alkyl having 1-3 lower alkanoyloxy, lower haloalkanoyloxy, BzO, HCO2, ClCO2, H2NCO2, CH2:CHO, tetrahydropyranyloxy, lower alkylsulfonyloxy, arylsulfonyloxy, halo or having a cyclic ether bond). II had uric acid-excreting action (no data). Thus, a mixture of 3.1 g 4-phenyl-6-nitro-2(1H)-quinazolinone and 0.6 g 52% NaH in DMF was stirred 30 min at 55°, 1.9 g HOCH2CH2Br added, and the whole stirred 3 hr at 100° to give 1-(2-hydroxyethyl)-4-phenyl-6-nitro-2(1H)-quinazolinone. Also, 1-(2,3-dihydroxypropyl)-4-phenyl-6-nitro-2(1H)-quinazolinone was prepared
IT 37554-39-5P 55266-62-1P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 37554-39-5 CAPLUS
CN 2(1H)-Quinazolinone, 1-(2-hydroxyethyl)-6-nitro-4-phenyl- (CA INDEX NAME)



L5 ANSWER 251 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
RN 55266-62-1 CAPLUS
CN 2(1H)-Quinazolinone, 1-(2,3-dihydroxypropyl)-6-nitro-4-phenyl- (CA INDEX NAME)



L5 ANSWER 252 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1975:73020 CAPLUS
DOCUMENT NUMBER: 82:73020
ORIGINAL REFERENCE NO.: 82:11675a,11678a
TITLE: Quinazolinone compounds
INVENTOR(S): Ishizumi, Kikuo; Mori, Kazuo; Yamamoto, Michihiro; Yamamoto, Hisao; Koshiba, Masao; Inaba, Shigeho
PATENT ASSIGNEE(S): Sumitomo Chemical Co., Ltd.
SOURCE: Can., 25 pp.
CODEN: CAXXA4
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CA 949573	A1	19740618	CA 1973-168918	19730417

PRIORITY APPLN. INFO.: CA 1973-168918 A 19730417

OTHER SOURCE(S): MARPAT 82:73020
GI For diagram(s), see printed CA Issue.
AB The quinazolinones I (R = Me, R1 = H, R2 = Cl; R = H, R1 = F, R2 = Cl; R = R1 = H, R2 = NO2) were prepared by several methods. Thus, 1-methyl-3-phenyl-5-chloroindole-2-carboxylic azide was heated and then treated with PhCH2OH and the resulting carbamate oxidized with chromic anhydride to give 4,2-Cl(PhCO)C6H3NMeCONHCO2CH2Ph, which was cyclized with HCl to give I (R = Me, R1 = H, R2 = Cl).
IT 20927-53-1P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 20927-53-1 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-1-methyl-4-phenyl- (CA INDEX NAME)



L5 ANSWER 253 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1975:38472 CAPLUS
DOCUMENT NUMBER: 82:38472
ORIGINAL REFERENCE NO.: 82:6063a,6066a
TITLE: Quinazolines and 1,4-benzodiazepines. 69. 1-Vinyl-1,4-benzodiazepin-2-ones and 1-vinylquinazolin-2(1H)-ones
AUTHOR(S): Walser, A.; Fryer, R. I.
CORPORATE SOURCE: Chem. Res. Dep., Hoffmann-La Roche Inc., Nutley, NJ, USA
SOURCE: Journal of Medicinal Chemistry (1974), 17(11), 1228-30
CODEN: JMCMAR; ISSN: 0022-2623
DOCUMENT TYPE: Journal
LANGUAGE: English
GI For diagram(s), see printed CA Issue.
AB One-vinyl analogs of benzodiazepine tranquilizers such as 7-chloro-5-(2-fluorophenyl)-1,3-dihydro-1-vinyl-2H-1,4-benzodiazepin-2-one (I) [53514-78-6] had greater central nervous activity than diazepam [439-14-5]. The 4-oxides were less active than the corresponding 4-deoxy derivs. Several other benzodiazepine derivs. had activities close to that of diazepam, whereas analogs of quinazoline were inactive. I was prepared from 7-chloro-1-(2-diethylaminoethyl)-5-(2-fluorophenyl)-1,3-dihydro-2H-1,4-benzodiazepin-2-one [17617-23-1] by oxidation to the ω-oxide [53514-87-7] and thermolysis.
IT 53514-85-5P 53514-86-6P 53579-80-9P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and tranquilizer activity of)
RN 53514-85-5 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-1-[2-(dimethylamino)ethyl]-4-phenyl- (CA INDEX NAME)



RN 53514-86-6 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-1-[2-(dimethyloxidoamino)ethyl]-4-phenyl- (9CI) (CA INDEX NAME)

L5 ANSWER 253 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 53579-80-9 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-1-ethenyl-4-phenyl- (CA INDEX NAME)



L5 ANSWER 254 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1974:563569 CAPLUS
DOCUMENT NUMBER: 81:163569
ORIGINAL REFERENCE NO.: 81:25223a,25226a
TITLE: Uricosuric agent
INVENTOR(S): Yamamoto, Michihiro; Aoono, Shunji; Nakatani, Hiroshi;
Morooka, Shigeaki; Koshiba, Masao; Inaha, Shigeho; Aisaka, Akira; Yamamoto, Hisao
PATENT ASSIGNEE(S): Sumitomo Chemical Co., Ltd.
SOURCE: U.S., 7 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 3812257	A	19740521	US 1972-242215	19720407
PRIORITY APPLN. INFO.:			US 1972-242215 A	19720407

AB Uric acid [69-93-2] content of the body can be controlled by administering a quinazoline derivative (I), where R is H, lower alkyl, lower alkenyl, aralkyl, cycloalkyl, lower cycloalkylalkyl, lower alkoxyalkyl, lower alkanoyloxyalkyl, or lower alkylthioalkyl; R1 and R2 are individually H, lower alkyl, lower alkoxy, trifluoromethyl, nitro, lower alkylthio, lower alkylsulfonyl, or halogen; Z is an O or S atom, and A is -C(R3):N-, where R3 is Ph, substituted Ph, cycloalkyl, pyridyl, pyrrolyl, furyl, or thienyl. An example of a quinazoline derivative is 1-methyl-4-phenyl-6-chloro-2(1H)-quinazolinone [20927-53-1].
IT 20927-53-1 26313-51-9 26831-11-8 33443-22-0 33443-33-3 33453-23-5 33453-24-6 33890-29-8 36942-76-4 37554-27-1 37554-35-1 37554-37-3 37554-98-6 37555-10-5 37555-17-2 40852-50-4 52505-76-7
RL: BIOL (Biological study)
(uricosuric agent)
RN 20927-53-1 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-1-methyl-4-phenyl- (CA INDEX NAME)



L5 ANSWER 254 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
RN 26313-51-9 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-1-(2-ethoxyethyl)-4-(2-fluorophenyl)- (CA INDEX NAME)



RN 26831-11-8 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)



RN 33443-22-0 CAPLUS
CN 2(1H)-Quinazolinone, 1-(cyclopropylmethyl)-4-(4-methylphenyl)- (CA INDEX NAME)



RN 33443-33-3 CAPLUS
CN 2(1H)-Quinazolinone, 1-(cyclopropylmethyl)-4-phenyl-6-(trifluoromethyl)- (CA INDEX NAME)

L5 ANSWER 254 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 33453-23-5 CAPLUS
CN 2(1H)-Quinazolinone, 1-(cyclopropylmethyl)-6-methoxy-4-phenyl- (CA INDEX NAME)



RN 33453-24-6 CAPLUS
CN 2(1H)-Quinazolinone, 1-(cyclopropylmethyl)-6-methyl-4-phenyl- (CA INDEX NAME)



RN 33890-29-8 CAPLUS
CN 2(1H)-Quinazolinone, 1-(cyclopropylmethyl)-6-nitro-4-phenyl- (CA INDEX NAME)

L5 ANSWER 254 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 36942-76-4 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-1-(cyclopropylmethyl)-3,4-dihydro-4-phenyl- (CA INDEX NAME)



RN 37554-27-1 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-1-(cyclopropylmethyl)-4-(4-methoxyphenyl)- (CA INDEX NAME)



L5 ANSWER 254 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 37555-17-2 CAPLUS
CN 2(1H)-Quinazolinone, 1-(cyclopropylmethyl)-6-(methylsulfonyl)-4-phenyl- (CA INDEX NAME)



RN 40852-50-4 CAPLUS
CN 2(1H)-Quinazolinone, 6-nitro-4-phenyl-1-[(tetrahydro-2-furanyl)methyl]- (CA INDEX NAME)



RN 52505-76-7 CAPLUS
CN 2(1H)-Quinazolinone, 1-[2-(acetyloxy)ethyl]-6-chloro-4-phenyl- (CA INDEX NAME)

L5 ANSWER 254 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

RN 37554-35-1 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-1-(methoxymethyl)-4-phenyl- (CA INDEX NAME)



RN 37554-37-3 CAPLUS
CN 2(1H)-Quinazolinone, 1-(2-ethoxyethyl)-6-nitro-4-phenyl- (CA INDEX NAME)



RN 37554-98-6 CAPLUS
CN 2(1H)-Quinazolinone, 6-nitro-4-phenyl-1-(2-propenyl)- (9CI) (CA INDEX NAME)



RN 37555-10-5 CAPLUS
CN 2(1H)-Quinazolinone, 8-chloro-1-(cyclopropylmethyl)-4-phenyl- (CA INDEX NAME)

L5 ANSWER 254 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



L5 ANSWER 255 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1974:520685 CAPLUS
DOCUMENT NUMBER: 81:120685
ORIGINAL REFERENCE NO.: 81:19090h,19091a
TITLE: 1-Substituted 4-phenyl-2 (1H)-quinazolinones
INVENTOR(S): Yamamoto, Michihiro; Ishizumi, Kikuo; Mori, Kazuo; Koshiba, Masao; Inaba, Shigeho; Yamamoto, Hisao
PATENT ASSIGNEE(S): Sumitomo Chemical Co., Ltd.
SOURCE: Jpn. Kokai Tokkyo Koho, 3 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
JP 49030384	A	19740318	JP 1972-70264		19720712
PRIORITY APPLN. INFO.:			JP 1972-70264	A	19720712

GI For diagram(s), see printed CA Issue.
AB Quinazolinones I (R = lower alkyl, lower alkenyl, lower cycloalkylalkyl, lower polyhaloalkyl, lower alkoxyalkyl, lower alkanoyloxyalkyl, aralkyl; R1, R2, and R3 = H, lower alkyl, lower alkoxy, CF3, NO2, MeS, MeSO2, halo) are prepared by treating 2(1H)-quinazolinone 3-oxides (II) with reactive esters of alcs. ROH. I are analgesic and antiinflammatory agents. Thus, 0.73 g 4-phenyl-6-chloro-2(1H)-quinazolinone 3-oxide was treated with 0.2 g 63% NaH in DMF and heated with 0.75 g cyclopropylmethyl bromide at 100° for 10 hr to give I (R = cyclopropylmethyl, R1 = 6-Cl, R2 = R3 = H).
IT 33453-19-9P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation and analgesic and antiinflammatory activity of)
RN 33453-19-9 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-1-(cyclopropylmethyl)-4-phenyl- (CA INDEX NAME)



L5 ANSWER 255 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

L5 ANSWER 256 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1974:520677 CAPLUS
DOCUMENT NUMBER: 81:120677
ORIGINAL REFERENCE NO.: 81:19087a,19090a
TITLE: Antiphlogistic and analgesic 1-(cyclopropylmethyl)-2(1H)-quinazolinethiones
INVENTOR(S): Inaba, Shigeho; Yamamoto, Michihiro; Ishizumi, Kikuo; Mori, Kazuo; Yamamoto, Hisao
PATENT ASSIGNEE(S): Sumitomo Chemical Co., Ltd.
SOURCE: Ger. Offen., 19 pp. Division of Ger. Offen. 2,037,693 (CA 75;49123e).
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
DE 2065611	A1	19740627	DE 1970-2065611		19700729
DE 2065611	C3	19781102			
PRIORITY APPLN. INFO.:			DE 1970-2065611	A	19700729

GI For diagram(s), see printed CA Issue.
AB Six quinazolines I (R = cyclopropylmethyl; Z = S; R1 = 6-Cl, 6-MeO, 6-O2N, 7-Me, 6-MeS, or H), which had antiphlogistic activities on oral administration in rats and were useful as analgesics, were prepared either by cyclization of II with MCNS (M = Na, K, or NH4) in AcOH at 55-65°, or by N-alkylation of I (R = H), or by sulfuration of I (Z = O) with P2S5 in boiling pyridine.
IT 33890-29-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and sulfuration of)
RN 33890-29-8 CAPLUS
CN 2(1H)-Quinazolinone, 1-(cyclopropylmethyl)-6-nitro-4-phenyl- (CA INDEX NAME)



IT 33443-28-6P 53720-97-1P 53720-98-2P
53720-99-3P 53721-00-9P 53721-01-0P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 33443-28-6 CAPLUS
CN 2(1H)-Quinazolinethione, 6-chloro-1-(cyclopropylmethyl)-4-phenyl- (CA INDEX NAME)



RN 53720-97-1 CAPLUS
CN 2(1H)-Quinazolinethione, 1-(cyclopropylmethyl)-6-methoxy-4-phenyl- (CA INDEX NAME)



RN 53720-98-2 CAPLUS
CN 2(1H)-Quinazolinethione, 1-(cyclopropylmethyl)-6-nitro-4-phenyl- (CA INDEX NAME)



RN 53720-99-3 CAPLUS
CN 2(1H)-Quinazolinethione, 1-(cyclopropylmethyl)-7-methyl-4-phenyl- (CA INDEX NAME)

L5 ANSWER 256 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 53721-00-9 CAPLUS
CN 2(1H)-Quinazolinethione, 1-(cyclopropylmethyl)-6-(methylthio)-4-phenyl- (CA INDEX NAME)



RN 53721-01-0 CAPLUS
CN 2(1H)-Quinazolinethione, 1-(cyclopropylmethyl)-4-phenyl- (CA INDEX NAME)



IT 33453-23-5
RL: RCT (Reactant); RACT (Reactant or reagent)
(sulfuration by phosphorus pentasulfide of)
RN 33453-23-5 CAPLUS
CN 2(1H)-Quinazolinone, 1-(cyclopropylmethyl)-6-methoxy-4-phenyl- (CA INDEX NAME)

L5 ANSWER 256 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



L5 ANSWER 257 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1974:505182 CAPLUS
DOCUMENT NUMBER: 81:105182
ORIGINAL REFERENCE NO.: 81:16627a,16630a
TITLE: Quinazolines. II. Oxidation of 2-aminoindoles and related compounds
AUTHOR(S): Ishizumi, Kikuo; Inaba, Shigeho; Yamamoto, Hisao
CORPORATE SOURCE: Pharm. Div., Sumitomo Chem. Co., Ltd., Takarazuka, Japan
SOURCE: Journal of Organic Chemistry (1974), 39(17), 2581-7
CODEN: JOCEAH; ISSN: 0022-3263
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 81:105182
GI For diagram(s), see printed CA Issue.
AB Ozonolysis of 2-aminoindole I (R = NH2, R1 = Me, R2 = H, R3 = Cl) in HOAc gave a mixture of the 2-imino-3-indolinol II (R = Cl) (85%) and the quinazolinone III (R1 = Me, R2 = H, R3 = Cl) (1%). I (R = NH2, R1 = H, R2
= F, R3 = Cl) gave only 2-amino-3H-indol-3-ol IV. Ozonolysis of I (R = NH2, R1 = Me, R2 = H, R3 = Cl) in CCl4 gave only III (R1 = Me, R2 = H, R3 = Cl). Chromic acid oxidation of urethanes I (R = MeO2CNH, EtO2CNH, PhCH2O2CNH) gave the corresponding allophanates, which were hydrolyzed with base or acid to give III. Indole-2-carboxylic acid azides I (R = CON3) gave III (R1 = Me, R2 = H, R3 = Cl, NO2) (44 and 41%, resp.) and small amts. of II (R = Cl, NO2) by chromic acid oxidation, whereas I (R = NCO) yielded mainly II (R = Cl, NO2) (47 and 64% resp) together with III (R1 = Me, R2 = H, R3 = Cl, NO2) (4 and 6%, resp.). Chromic acid oxidation of
I (R = CON3, R1 = H, R2 = F, R3 = Cl) gave 4,2-Cl(o-FC6H4CO) C6H3NHCOCON3. Ozonolysis of I (R = NCO, R1 = Me, R2 = H, R3 = Cl) gave the 1,2,4-dioxazol-3-one V. Hofmann reaction of I (R = CO-NH2, R1 = Me, R2 = H, R3 = Cl) with aqueous NaOBr in THF gave III (R1 = Me, R2 = H, R3 = Cl), but a similar reaction with aq NaOCl gave the oxindoles VI (R = H2NCO, Cl).
IT 20927-53-1P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 20927-53-1 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-1-methyl-4-phenyl- (CA INDEX NAME)



L5 ANSWER 258 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1974:499206 CAPLUS
DOCUMENT NUMBER: 81:99206
ORIGINAL REFERENCE NO.: 81:15653a,15656a
TITLE: Stereoselectivity in enzymic biotransformation of chiral and achiral 1,3-dihydro-2H-1,4-benzodiazepin-2-ones
AUTHOR(S): Rendic, S.; Sunjic, V.; Kajfez, F.; Klasinc, L.; Mildner, P.
CORPORATE SOURCE: CRC Compagnia Ric. Chim. S. A., Chiasso, Switz.
SOURCE: Chimia (1974), 28(5), 232-4
CODEN: CHIMAD; ISSN: 0009-4293
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Enzymic biotransformation in rat liver 9000 g supernatant of chiral 1,4-benzodiazepin-2-one derivs. (I) possessing a center of chirality in position 3 appears to be stereospecific for hydroxylation in aromatic rings,
but not for hydroxylation in position 3 or N1-demethylation.
IT 20927-53-1
RL: FORM (Formation, nonpreparative)
(formation of, in benzodiazepinone derivative biotransformation)
RN 20927-53-1 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-1-methyl-4-phenyl- (CA INDEX NAME)



L5 ANSWER 259 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1974:491467 CAPLUS
DOCUMENT NUMBER: 81:91467
ORIGINAL REFERENCE NO.: 81:14497a,14500a
TITLE: Quinazolines. III. Curtius and Hofmann reactions of 2'-benzoyloxanilic acids. Novel syntheses of quinazolinones
AUTHOR(S): Ishizumi, Kikuo; Inaba, Shigeho; Yamamoto, Hisao
CORPORATE SOURCE: Pharm. Div., Sumitomo Chem. Co., Ltd., Takarazuka, Japan
SOURCE: Journal of Organic Chemistry (1974), 39(17), 2587-91
CODEN: JOCEAH; ISSN: 0022-3263
DOCUMENT TYPE: Journal
LANGUAGE: English
GI For diagram(s), see printed CA Issue.
AB N-Substituted 2'-benzoyloxaniloyl chlorides I, prepared from the reaction of
the corresponding 2-aminobenzophenones II and oxalyl chloride, were converted through their azides III to quinazolinones IV (R1 = Me, CH2CH2OAc, H, cyclopropylmethyl; R2 = Cl, NO2; R3 = H, F) in good yields by treatment with aqueous NaN3. I (R1 = H, R2 = Cl, R3 = F) gave the corresponding III, which was identical with the product of chromic acid oxidation of the corresponding indole-2-carboxylic acid azide. For the Hofmann reaction, N-(2-benzoylphenyl)oxamides V (R1 = H, Me, cyclopropylmethyl; R2 = Cl, NO2) were prepared from the corresponding I by
treatment with NH3. Similar reaction of I (R1 = Me, R2 = NO2, R3 = H) with NH3 led to a mixture of the corresponding IV and 2-hydroxy-1-methyl-6-
nitro-4-phenylquinazoline. The desired oxamide V (R1 = Me, R2 = NO2), however, was obtained by chromic acid oxidation of indole-2-carboxamide VI.
N-Alkyl-substituted oxamides V (R1 = Me, cyclopropylmethyl; R2 = Cl, NO2) were converted to the corresponding quinazolinones IV in satisfactory yields either by treatment with aqueous NaOBr in THF, or with NaOBr in MeOH.
IT 20927-53-1P 26953-46-8P 33453-19-9P
49830-84-4P 51806-15-6P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 20927-53-1 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-1-methyl-4-phenyl- (CA INDEX NAME)



RN 26953-46-8 CAPLUS
CN 2(1H)-Quinazolinone, 1-methyl-6-nitro-4-phenyl- (CA INDEX NAME)

L5 ANSWER 259 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



L5 ANSWER 259 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 33453-19-9 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-1-(cyclopropylmethyl)-4-phenyl- (CA INDEX NAME)



RN 49830-84-4 CAPLUS
CN 2(1H)-Quinazolinone, 1-[2-(acetyloxy)ethyl]-6-nitro-4-phenyl- (CA INDEX NAME)



RN 51806-15-6 CAPLUS
CN 2-Quinazolinol, 1,2-dihydro-1-methyl-6-nitro-4-phenyl- (CA INDEX NAME)

L5 ANSWER 260 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1974:477959 CAPLUS
DOCUMENT NUMBER: 81:77959
ORIGINAL REFERENCE NO.: 81:12403a,12406a
TITLE: Quinazolinones
INVENTOR(S): Ishizumi, Kikuo; Mori, Kazuo; Yamamoto, Michihiro; Koshiba, Masao; Inaba, Shigeho; Yamamoto, Hisao
PATENT ASSIGNEE(S): Sumitomo Chemical Co., Ltd.
SOURCE: Jpn. Kokai Tokkyo Koho, 8 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 48080533	B4	19731029	JP 1972-12977	19720205

GI For diagram(s), see printed CA Issue.
AB The title compds. (I) were prepared by hydrolyzing or by heating acyl ureas
II (R1-R3 = H, halogen, CF3, NO2, alkyl, or alkoxy; R4 = H, alkyl, polyhaloalkyl, or cycloalkylalkyl; R5 = H, alkyl, Ph, alkoxy, benzyloxy, NH2, carboxyl, carbamoyl, or alkoxycarbonyl). E.g., 1.92 g II (R1 = 4-Cl,
R2 = R3 = H, R4 = Me, R5 = Et) in EtOH was refluxed 30 min with 5 ml 20% NaOH to give I (R1 = 6-Cl, R2 = R3 = H, R4 = Me). Similarly prepared was I
(R1, R2, R3, and R4 given): 6-Cl, H, o-G, H. Correction CA 80:37151c.
IT 20927-53-1P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 20927-53-1 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-1-methyl-4-phenyl- (CA INDEX NAME)



L5 ANSWER 261 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1974:477956 CAPLUS
DOCUMENT NUMBER: 81:77956
ORIGINAL REFERENCE NO.: 81:12403a,12406a
TITLE: Quinazoline derivatives
INVENTOR(S): Ishizumi, Kikuo; Mori, Kazuo; Yamamoto, Michihiro; Koshiba, Masao; Inaba, Shigeho; Yamamoto, Hisao
PATENT ASSIGNEE(S): Sumitomo Chemical Co., Ltd.
SOURCE: Jpn. Kokai Tokkyo Koho, 7 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 49031680	A	19740322	JP 1972-73250	19720720
JP 54018269	B	19790706		
CA 949574	A1	19740618	CA 1973-176081	19730710
DK 132430	B	19751208	DK 1973-3835	19730710
US 3910911	A	19751007	US 1973-378555	19730712
CH 585730	A5	19770315	CH 1973-10525	19730718
NL 7310055	A	19740122	NL 1973-10055	19730719
AT 7306373	A	19750815	AT 1973-6373	19730719
AT 329570	B	19760525		
PL 91618	B1	19770331	PL 1973-164172	19730719
FI 58639	B	19801128	FI 1973-2282	19730719
FI 58639	C	19810310		
HU 166497	B	19750328	HU 1973-SU827	19730720
PRIORITY APPLN. INFO.:			JP 1972-73250 A	19720720

GI For diagram(s), see printed CA Issue.
AB Antiinflammatory quinazolinones (I, R1,R2,R3 = H, halo, CF3, NO2, lower alkylsulfonyl, lower alkyl, lower alkoxy; R4 = H, lower alkyl aralkyl, lower alkanoyloxyalkyl, lower alkoxyalkyl, polyhaloalkyl, cycloalkylalkyl) were prepared by reaction of oxamide derivs. (II) with halogens in the presence of bases or with hypohalous acid salts (e.g., NaOCl). Thus, 1 g N-(2-benzoyl-4-chlorophenyl)-N-methyloxamide in THF was added to a mixture of 2.4 g NaOH and 1.92 g Br in H2O at -7° and stirred 2 hr to give 0.49 g 1-methyl-4-phenyl-6-chloro-2(1H)-quinazolinone.
IT 20927-53-1P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 20927-53-1 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-1-methyl-4-phenyl- (CA INDEX NAME)

L5 ANSWER 261 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



L5 ANSWER 262 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1974:454444 CAPLUS
DOCUMENT NUMBER: 81:54444
ORIGINAL REFERENCE NO.: 81:8643a,8646a
TITLE: Glycerides for orally administrable pharmaceuticals
INVENTOR(S): Nakamura, Toshio; Maeda, Tadao; Takenaka, Hiroshi; Yamahira, Yoshiya; Noguchi, Takeshi; Hasegawa, Masatoshi; Harada, Zenzo
PATENT ASSIGNEE(S): Sumitomo Chemical Co., Ltd.
SOURCE: Ger. Offen., 11 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2357389	A1	19740522	DE 1973-2357389	19731116
JP 49071127	A	19740710	JP 1972-116021	19721118
GB 1432784	A	19760422	GB 1973-52734	19731113
BE 807312	A1	19740301	BE 1973-137740	19731114
AU 7362543	A	19750515	AU 1973-62543	19731115
FR 2206943	A1	19740614	FR 1973-40923	19731116
PRIORITY APPLN. INFO.:			JP 1972-116021 A	19721118

AB The gastrointestinal absorbability of pharmaceuticals, e.g. indomethacin (I), diazepam, pentazocine, or griseofulvin, was improved by addition of a triglyceride (II) containing caproic acid 1-2, caprylic acid 75-80, capric acid 17-23, and lauric acid 1%. Thus, the blood level of I 8 hr after oral administration of 150 mg I alone or 150 mg I + 1.5 g II was 5.4 or 14.3 μg/ml, resp.
IT 33453-19-9
RL: BIOL (Biological study)
(intestinal absorption of, glyceride composition for improvement of)
RN 33453-19-9 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-1-(cyclopropylmethyl)-4-phenyl- (CA INDEX NAME)



L5 ANSWER 263 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1974:449698 CAPLUS
DOCUMENT NUMBER: 81:49698
ORIGINAL REFERENCE NO.: 81:7939a,7942a
TITLE: Quinazolinethione derivative
INVENTOR(S): Inaba, Shigeho; Yamamoto, Michihiro; Ishizumi, Kikuo; Mori, Kazuo; Kashiba, Masao; Yamamoto, Hisao
PATENT ASSIGNEE(S): Sumitomo Chemical Co., Ltd.
SOURCE: Jpn. Tokkyo Koho, 3 pp.
CODEN: JAXXAD
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 48043355	B	19731218	JP 1970-53648	19700619
PRIORITY APPLN. INFO.:			JP 1970-53648	19700619

GI For diagram(s), see printed CA Issue.
AB The quinazolinethione I was prepared by cyclization of 2-[(cyclopropylmethyl)amino]-5-chlorobenzo-phenone with NaSCN in HOAc. I was an inflammation inhibitor and sedative.
IT 33443-28-6P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 33443-28-6 CAPLUS
CN 2(1H)-Quinazolinethione, 6-chloro-1-(cyclopropylmethyl)-4-phenyl- (CA INDEX NAME)



L5 ANSWER 264 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1974:403965 CAPLUS
DOCUMENT NUMBER: 81:3965
ORIGINAL REFERENCE NO.: 81:651a,654a
TITLE: Pharmacologically active quinazolones
INVENTOR(S): Yamamoto, Michihiro; Moorooka, Shigeaki; Koshiba, Masao; Inaba, Shigeho; Yamamoto, Hisao
PATENT ASSIGNEE(S): Sumitomo Chemical Co., Ltd.
SOURCE: Ger. Offen., 32 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2337285	A1	19740214	DE 1973-2337285	19730723
JP 49035390	A	19740401	JP 1972-74460	19720724
JP 55037554	B	19800929		
US 3895395	A	19750715	US 1973-376163	19730703
GB 1401723	A	19750730	GB 1973-31895	19730704
AU 7357830	A	19750109	AU 1973-57830	19730706
CA 1005059	A1	19770208	CA 1973-176083	19730710
FR 2193599	A1	19740222	FR 1973-26499	19730719
CH 588471	A5	19770615	CH 1973-10601	19730719
CH 590245	A5	19770729	CH 1976-11940	19730719
BE 802662	A1	19731116	BE 1973-133751	19730723
NL 7310217	A	19740128	NL 1973-10217	19730723
AT 7306485	A	19750715	AT 1973-6485	19730723
AT 329067	B	19760426		
AT 7502649	A	19750715	AT 1973-264975	19730723
HU 167053	B	19750728	HU 1973-SU828	19730723

PRIORITY APPLN. INFO.: JP 1972-74460 A 19720724

GI For diagram(s), see printed CA Issue.
AB Quinazolinones I (R = CH2CH2O2CR2; R1 = NO2, R2 = Me, CMe3, cyclopropyl, Et, CHMe2, CH:CH2, CHCl2, CH2OMe, CH2OH, NEt2; R = CH2 H2OAc, R1 = Cl, Br, Me, OMe) were prepared by treating I (R = H) with ClCH2CH2O2CR2. The 2-(acyloxyethoxy)-quinazolines, formed as by-products, were separated I were uricosuric, antiphlogistic, and antiinflammatory.
IT 37554-39-5
RL: RCT (Reactant); RACT (Reactant or reagent)
(acetylation of)
RN 37554-39-5 CAPLUS
CN 2(1H)-Quinazolinone, 1-(2-hydroxyethyl)-6-nitro-4-phenyl- (CA INDEX NAME)

L5 ANSWER 264 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
CN 2(1H)-Quinazolinone, 1-[2-(acetyloxy)ethyl]-6-bromo-4-phenyl- (CA INDEX NAME)



RN 49830-84-4 CAPLUS
CN 2(1H)-Quinazolinone, 1-[2-(acetyloxy)ethyl]-6-nitro-4-phenyl- (CA INDEX NAME)



RN 49830-85-5 CAPLUS
CN Propanoic acid, 2-methyl-, 2-(6-nitro-2-oxo-4-phenyl-1(2H)-quinazolinyl)ethyl ester (CA INDEX NAME)



RN 49830-86-6 CAPLUS
CN Acetic acid, dichloro-, 2-(6-nitro-2-oxo-4-phenyl-1(2H)-quinazolinyl)ethyl ester (9CI) (CA INDEX NAME)

L5 ANSWER 264 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



IT 52568-14-6
RL: RCT (Reactant); RACT (Reactant or reagent)
(acyloxyethylation of)
RN 52568-14-6 CAPLUS
CN 2(1H)-Quinazolinone, 1-(2-bromoethyl)-6-nitro-4-phenyl- (CA INDEX NAME)



IT 52568-15-7
RL: RCT (Reactant); RACT (Reactant or reagent)
(dehydrogenation of)
RN 52568-15-7 CAPLUS
CN 2(1H)-Quinazolinone, 1-[2-(acetyloxy)ethyl]-3,4-dihydro-6-methoxy-4-phenyl- (CA INDEX NAME)



IT 49830-83-3P 49830-84-4P 49830-85-5P
49830-86-6P 52505-76-7P 52568-05-5P
52568-07-7P 52568-16-8P 52568-17-9P
52568-18-0P 52568-19-1P 52568-20-4P
52568-23-7P 52568-24-8P 52761-64-5P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 49830-83-3 CAPLUS

L5 ANSWER 264 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 52505-76-7 CAPLUS
CN 2(1H)-Quinazolinone, 1-[2-(acetyloxy)ethyl]-6-chloro-4-phenyl- (CA INDEX NAME)



RN 52505-05-5 CAPLUS
CN 2(1H)-Quinazolinone, 1-[2-(acetyloxy)ethyl]-6-methyl-4-phenyl- (CA INDEX NAME)



RN 52568-07-7 CAPLUS
CN 2(1H)-Quinazolinone, 1-[2-(acetyloxy)ethyl]-6-methoxy-4-phenyl- (CA INDEX NAME)



L5 ANSWER 264 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
RN 52568-16-8 CAPLUS
CN Cyclopropanecarboxylic acid, 2-(6-nitro-2-oxo-4-phenyl-1(2H)-quinazolinyl)ethyl ester (CA INDEX NAME)



RN 52568-17-9 CAPLUS
CN 2(1H)-Quinazolinone, 6-nitro-1-[2-(1-oxopropoxy)ethyl]-4-phenyl- (CA INDEX NAME)



RN 52568-18-0 CAPLUS
CN 2-Propenoic acid, 2-(6-nitro-2-oxo-4-phenyl-1(2H)-quinazolinyl)ethyl ester
(CA INDEX NAME)

L5 ANSWER 264 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 52568-19-1 CAPLUS
CN Acetic acid, methoxy-, 2-(6-nitro-2-oxo-4-phenyl-1(2H)-quinazolinyl)ethyl ester (9CI) (CA INDEX NAME)



RN 52568-20-4 CAPLUS
CN 2(1H)-Quinazolinone, 1-[2-(acetyloxy)ethyl]-6-(methylsulfonyl)-4-phenyl- (CA INDEX NAME)



RN 52568-23-7 CAPLUS
CN Acetic acid, hydroxy-, 2-(6-nitro-2-oxo-4-phenyl-1(2H)-quinazolinyl)ethyl ester (9CI) (CA INDEX NAME)

L5 ANSWER 264 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 52568-24-8 CAPLUS
CN Carbamic acid, diethyl-, 2-(6-nitro-2-oxo-4-phenyl-1(2H)-quinazolinyl)ethyl ester (9CI) (CA INDEX NAME)



RN 52761-64-5 CAPLUS
CN Propanoic acid, 2,2-dimethyl-, (6-nitro-2-oxo-4-phenyl-1(2H)-quinazolinyl)methyl ester (CA INDEX NAME)



IT 52568-22-6
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of, with glycolate)
RN 52568-22-6 CAPLUS
CN 2(1H)-Quinazolinone, 1-(2-chloroethyl)-6-nitro-4-phenyl- (CA INDEX NAME)

L5 ANSWER 264 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



L5 ANSWER 265 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1974:146193 CAPLUS
DOCUMENT NUMBER: 80:146193
ORIGINAL REFERENCE NO.: 80:23597a,23600a
TITLE: Quinazolinones
INVENTOR(S): Ishizumi, Kikuo; Mori, Kazuo; Yamamoto, Michihiro; Koshiba, Masao; Inaba, Shigeho; Yamamoto, Hisao
PATENT ASSIGNEE(S): Sumitomo Chemical Co., Ltd.
SOURCE: Ger. Offen., 15 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2345030	A1	19740321	DE 1973-2345030	19730906
JP 49045085	A	19740427	JP 1972-90225	19720907
JP 55005506	B	19800207		
DK 131779	B	19750901	DK 1973-4855	19730904
AT 7307668	A	19750915	AT 1973-7668	19730904
AT 330189	B	19760625		
GB 1398448	A	19750618	GB 1973-41815	19730905
US 3926993	A	19751216	US 1973-394542	19730905
CH 586208	A5	19770331	CH 1973-12756	19730905
NL 7312257	A	19740311	NL 1973-12257	19730906
CA 949575	A1	19740618	CA 1973-180457	19730906
HU 167054	B	19750728	HU 1973-SU839	19730906
PRIORITY APPLN. INFO.:			JP 1972-90225 A	19720907

GI For diagram(s), see printed CA Issue.
AB Forty-seven quinazolinones I (R = e.g. H, Me AcOCH2CH2, cyclopropylmethyl, Me2CH, CF3CH2, or tetrahydrofurfuryl; R1 = e.g. Cl, NO2, CF3, or iodo; R2 = e.g. H or MeO; R3 = e.g. Cl or F), useful as antiphlogistic, virucidal, and uricosuric agents, were prepared by successive reaction of the aminobenzophenones II with (ClCO)2 and NaN3.
IT 17629-04-8P 20927-53-1P 22760-18-5P
22760-25-4P 22760-60-7P 23441-74-9P
25508-93-4P 25509-57-3P 26313-42-8P
26953-46-8P 33443-20-8P 33443-30-0P
33443-33-3P 33443-35-5P 33453-19-9P
33453-20-2P 33453-23-5P 33890-29-8P
37554-37-3P 37554-40-8P 37554-75-9P
37555-03-6P 37555-17-2P 40852-31-1P
40852-33-3P 40852-34-4P 40852-38-8P
40852-50-4P 40852-51-5P 40852-54-8P
40852-56-0P 40852-57-1P 49830-63-9P
49830-84-4P 50817-26-0P 52505-74-5P
52505-75-6P 52505-76-7P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 17629-04-8 CAPLUS
CN 2(1H)-Quinazolinone, 1-methyl-4-phenyl- (CA INDEX NAME)

L5 ANSWER 265 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
RN 22760-60-7 CAPLUS
CN 2(1H)-Quinazolinone, 1-(1-methylethyl)-6-nitro-4-phenyl- (CA INDEX NAME)



RN 23441-74-9 CAPLUS
CN 2(1H)-Quinazolinone, 6-methoxy-1-methyl-4-phenyl- (CA INDEX NAME)



RN 25508-93-4 CAPLUS
CN 2(1H)-Quinazolinone, 1-ethyl-6-nitro-4-phenyl- (CA INDEX NAME)



RN 25509-57-3 CAPLUS
CN 2(1H)-Quinazolinone, 6,7-dimethoxy-1-methyl-4-phenyl- (CA INDEX NAME)



RN 26313-42-8 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-1-ethyl-4-(2-methylphenyl)- (CA INDEX NAME)

L5 ANSWER 265 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 20927-53-1 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-1-methyl-4-phenyl- (CA INDEX NAME)



RN 22760-18-5 CAPLUS
CN 2(1H)-Quinazolinone, 7-methyl-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)



RN 22760-25-4 CAPLUS
CN 2(1H)-Quinazolinone, 7-methoxy-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)



L5 ANSWER 265 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 26953-46-8 CAPLUS
CN 2(1H)-Quinazolinone, 1-methyl-6-nitro-4-phenyl- (CA INDEX NAME)



RN 33443-20-8 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-1-(cyclopropylmethyl)-4-(2-fluorophenyl)- (CA INDEX NAME)



RN 33443-30-0 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-1-(2-cyclohexylethyl)-4-phenyl- (CA INDEX NAME)

L5 ANSWER 265 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 33443-33-3 CAPLUS
CN 2(1H)-Quinazolinone, 1-(cyclopropylmethyl)-4-phenyl-6-(trifluoromethyl)- (CA INDEX NAME)



RN 33443-35-5 CAPLUS
CN 2(1H)-Quinazolinone, 6,8-dichloro-1-(cyclopropylmethyl)-4-phenyl- (CA INDEX NAME)



RN 33453-19-9 CAPLUS

L5 ANSWER 265 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
CN 2(1H)-Quinazolinone, 6-chloro-1-(cyclopropylmethyl)-4-phenyl- (CA INDEX NAME)



RN 33453-20-2 CAPLUS
CN 2(1H)-Quinazolinone, 6-bromo-1-(cyclopropylmethyl)-4-phenyl- (CA INDEX NAME)



RN 33453-23-5 CAPLUS
CN 2(1H)-Quinazolinone, 1-(cyclopropylmethyl)-6-methoxy-4-phenyl- (CA INDEX NAME)



RN 33890-29-8 CAPLUS
CN 2(1H)-Quinazolinone, 1-(cyclopropylmethyl)-6-nitro-4-phenyl- (CA INDEX

L5 ANSWER 265 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
NAME)



RN 37554-37-3 CAPLUS
CN 2(1H)-Quinazolinone, 1-(2-ethoxyethyl)-6-nitro-4-phenyl- (CA INDEX NAME)



RN 37554-40-8 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-4-phenyl-1-(2,2,2-trifluoroethyl)- (CA INDEX NAME)



RN 37554-75-9 CAPLUS
CN 2(1H)-Quinazolinone, 6-iodo-1-methyl-4-phenyl- (CA INDEX NAME)



L5 ANSWER 265 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
RN 37555-03-6 CAPLUS
CN 2(1H)-Quinazolinone, 6-nitro-4-phenyl-1-(phenylmethyl)- (CA INDEX NAME)



RN 37555-17-2 CAPLUS
CN 2(1H)-Quinazolinone, 1-(cyclopropylmethyl)-6-(methylsulfonyl)-4-phenyl- (CA INDEX NAME)



RN 40852-31-1 CAPLUS
CN 2(1H)-Quinazolinone, 4-(2-chlorophenyl)-1-(cyclopropylmethyl)-6-nitro- (CA INDEX NAME)



RN 40852-33-3 CAPLUS
CN 2(1H)-Quinazolinone, 1-(cyclopentylmethyl)-6-nitro-4-phenyl- (CA INDEX NAME)

L5 ANSWER 265 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 40852-34-4 CAPLUS
CN 2(1H)-Quinazolinone, 1-(cyclohexylmethyl)-6-nitro-4-phenyl- (CA INDEX NAME)



RN 40852-38-8 CAPLUS
CN 2(1H)-Quinazolinone, 1-cyclohexyl-6-nitro-4-phenyl- (CA INDEX NAME)



RN 40852-50-4 CAPLUS
CN 2(1H)-Quinazolinone, 6-nitro-4-phenyl-1-[(tetrahydro-2-furanyl)methyl]- (CA INDEX NAME)

L5 ANSWER 265 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 40852-51-5 CAPLUS
CN 2(1H)-Quinazolinone, 6-nitro-4-phenyl-1-[(tetrahydro-2H-pyran-2-yl)methyl]- (CA INDEX NAME)



RN 40852-54-8 CAPLUS
CN 2(1H)-Quinazolinone, 1-(2-furanylmethyl)-6-nitro-4-phenyl- (CA INDEX NAME)



L5 ANSWER 265 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
RN 40852-56-0 CAPLUS
CN 2(1H)-Quinazolinone, 6-nitro-4-phenyl-1-(2-pyridinylmethyl)- (CA INDEX NAME)



RN 40852-57-1 CAPLUS
CN 2(1H)-Quinazolinone, 6-nitro-4-phenyl-1-(2-thienylmethyl)- (CA INDEX NAME)



RN 49830-63-9 CAPLUS
CN 2(1H)-Quinazolinone, 1-(cyclopropylmethyl)-6-(methylthio)-4-phenyl- (CA INDEX NAME)



RN 49830-84-4 CAPLUS
CN 2(1H)-Quinazolinone, 1-[2-(acetyloxy)ethyl]-6-nitro-4-phenyl- (CA INDEX

L5 ANSWER 265 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
NAME)



RN 50817-26-0 CAPLUS
CN 2(1H)-Quinazolinone, 1,6-dimethyl-4-phenyl- (CA INDEX NAME)



RN 52505-74-5 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-1-(2-methylpropyl)-4-phenyl- (CA INDEX NAME)



RN 52505-75-6 CAPLUS
CN 2(1H)-Quinazolinone, 6-methyl-1-(2,2,3,3,3-pentafluoropropyl)-4-phenyl- (CA INDEX NAME)



RN 52505-76-7 CAPLUS
CN 2(1H)-Quinazolinone, 1-[2-(acetyloxy)ethyl]-6-chloro-4-phenyl- (CA INDEX

L5 ANSWER 265 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
NAME)



L5 ANSWER 266 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1974:120987 CAPLUS
DOCUMENT NUMBER: 80:120987
ORIGINAL REFERENCE NO.: 80:19479a,19482a
TITLE: Quinazoline derivatives
INVENTOR(S): Ishizumi, Kikuo; Mori, Kazuo; Yamamoto, Michihiro; Koshiba, Masao; Inaba, Shigeo; Yamamoto, Hisao
PATENT ASSIGNEE(S): Sumitomo Chemical Co., Ltd.
SOURCE: Jpn. Kokai Tokkyo Koho, 6 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 48097881	A	19731213	JP 1972-29984	19720324
JP 54026556	B	19790904		
NL 7304100	A	19730926	NL 1973-4100	19730323
AT 7302584	A	19750615	AT 1973-2584	19730323
AT 328456	B	19760325		
CH 567003	A5	19750930	CH 1973-4221	19730323
US 3925382	A	19751209	US 1973-344400	19730323
DK 132890	B	19760223	DK 1973-1616	19730323
PL 91818	B1	19770331	PL 1973-161447	19730324
PRIORITY APPLN. INFO.:			JP 1972-29984 A	19720324

GI For diagram(s), see printed CA Issue.
AB The quinazolines (R1 = H, aralkyl, lower alkyl, polyhaloalkyl, lower alkanoyloxyalkyl, or cycloalkylalkyl; R2 and R3 = H, halogen, CF3, NO2, lower alkyl, or lower alkoxy) were prepared by hydrolysis or reduction of 2-acylaminoindoles (II; R4 = H, lower alkyl, Ph, lower alkoxy, PhCH2O) or by the hydrolysis of 2-isocyanatoindoles (III) followed by oxidation of 2-aminoindoles IV. I are antiinflammatory agents. Thus, 15 g V (R1 = Me, R2 = H, R3 = 5-Cl) (VI) in PhCH2OH-PhMe was refluxed to give 8 g 1-methyl-3-phenyl-5-chloroindole-2-carbamic acid benzyl ester, which (2.8g) in EtOH containing concentrated HCl was hydrogenated in the presence of Pd-C catalyst to give 1.96 g 1-methyl-2-amino-3-phenyl-5-chloroindole-HCl (VII.HCl). VII was suspended in CCl4 and oxidized at -5° with O3 to give I (R1 = Me, R2 = H, R3 = 6-Cl) (VIII). VI was kept in a desiccator at room temperature for 40 days, to give III (R1 = Me, R2 = H, R3 = 5-Cl) quant., which (5 g) in C6H6-aqueous NaOH was refluxed to give 3.38 g VII. VII and KOH-Br was stirred at 65° to give VIII.
IT 20927-53-1P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation and antiinflammatory activity of)
RN 20927-53-1 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-1-methyl-4-phenyl- (CA INDEX NAME)

L5 ANSWER 266 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



L5 ANSWER 267 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1974:96008 CAPLUS
DOCUMENT NUMBER: 80:96008
ORIGINAL REFERENCE NO.: 80:15447a,15450a
TITLE: Quinazolinone derivatives
INVENTOR(S): Ishizumi, Kikuo; Mori, Kazuo; Yamamoto, Michihiro; Koshiba, Masao; Inaba, Shigeho; Yamamoto, Hisae
PATENT ASSIGNEE(S): Sumitomo Chemical Co., Ltd.
SOURCE: Jpn. Kokai Tokkyo Koho, 6 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 48099186	A	19731215	JP 1972-32966	19720331
JP 54027356	B	19790910		
AT 7302679	A	19750315	AT 1973-2679	19730327
AT 326668	B	19751229		
US 3923710	A	19751202	US 1973-346037	19730329
NL 7304437	A	19731002	NL 1973-4437	19730330
CA 949572	A1	19740618	CA 1973-167590	19730330
HU 166021	B	19741228	HU 1973-SU810	19730330
DK 132948	B	19760301	DK 1973-1758	19730330
PL 91816	B1	19770331	PL 1973-161616	19730330
CH 589070	A5	19770630	CH 1973-4636	19730330
PRIORITY APPLN. INFO.:			JP 1972-32966 A	19720331

OTHER SOURCE(S): MARPAT 80:96008
GI For diagram(s), see printed CA Issue.
AB Antiinflammatory quinazolinone derivs. (I; R1, R2, R3 = H, halo, CF3, NO2, lower alkyl, lower alkoxy; R4 = H, lower alkyl, aralkyl, lower alkanoyloxyalkyl, lower alkoxyalkyl, polyhaloalkyl, cycloalkylalkyl) were prepared by reacting indole-2-isocyanate derivs. (II, R5 = OCN) (III) with oxidizing agents (e.g., Br, O3, CrO3). III were obtained by rearrangement of azide derivs. (II, R5 = N3CO) (IV). E.g., heating 2 g IV (R1 = 5-Cl, R2 = R3 = H, R4 = Me) in C6H6 5 min at 50-60° gave III (R1 = 5-Cl, R2 = R3 = H, R4 = Me) (V). V (1.42 g) was added to an aqueous mixture of KOH 1.7 and Br 1 g <0°, the mixture stirred 30 min <0°, 1 hr at room temperature, and 1 hr at 70-80° to give I (R1 = 6-Cl, R2 = R3 = H, R4 = Me).
IT 20927-53-1P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 20927-53-1 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-1-methyl-4-phenyl- (CA INDEX NAME)

L5 ANSWER 267 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



L5 ANSWER 268 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1974:59911 CAPLUS
DOCUMENT NUMBER: 80:59911
ORIGINAL REFERENCE NO.: 80:9717a,9720a
TITLE: Syntheses of 2(1H)-quinazolinone-4-14C derivatives
AUTHOR(S): Yoshitake, A.; Makari, Y.; Kawahara, K.; Endo, M.
CORPORATE SOURCE: Pharm. Div., Sumito Chem. Co., Ltd., Takarazuka, Japan
SOURCE: Journal of Labelled Compounds (1973), 9(3), 537-44
CODEN: JLCAAI; ISSN: 0022-2135
DOCUMENT TYPE: Journal
LANGUAGE: English
GI For diagram(s), see printed CA Issue.
AB 1-(Cyclopropylmethyl)-6-methoxy-4-phenyl-2(1H)-quinazolinone (I, R = MeO) (SL-573) and 1-Cyclopropylmethyl-6-nitro-4-phenyl-2(1H)-quinazolinone (I, R = O2N) (SL-522), each labeled with carbon-14 at C-4 position were synthesized for use in metabolic studies. The syntheses were achieved by two types of reaction sequences. Overall radiochem. yields of SL-573-4-14C and SL-522-4-14C were 35% and 17% from carbon dioxide-14C, and their specific activities were 5.52 mCi/mmole and 3.31 mCi/mmole, resp.
IT 51126-57-9P 51126-58-0P 51126-60-4P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 51126-57-9 CAPLUS
CN 2(1H)-Quinazolinone-4-14C, 6-acetyl-1-(cyclopropylmethyl)-3,4-dihydro-4-phenyl- (9CI) (CA INDEX NAME)



RN 51126-58-0 CAPLUS
CN 2(1H)-Quinazolinone-4-14C, 6-acetyl-1-(cyclopropylmethyl)-4-phenyl- (9CI)
(CA INDEX NAME)

L5 ANSWER 268 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 51126-60-4 CAPLUS
CN 2(1H)-Quinazolinone-4-14C, 1-(cyclopropylmethyl)-6-nitro-1-phenyl- (9CI) (CA INDEX NAME)



L5 ANSWER 269 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1974:37151 CAPLUS
DOCUMENT NUMBER: 80:37151
ORIGINAL REFERENCE NO.: 80:6103a,6106a
TITLE: Quinazolinones
INVENTOR(S): Ishizumi, Kikuo; Mori, Kazuo; Yamamoto, Michihiro; Koshiba, Masao; Inaba, Shigeho; Yamamoto, Hisao
PATENT ASSIGNEE(S): Sumitomo Chemical Co., Ltd.
SOURCE: Jpn. Kokai Tokkyo Koho, 8 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 47012977	B4	19731029	JP 1972-12977	19720205

GI For diagram(s), see printed CA Issue.
AB The title compds. (I) were prepared by hydrolyzing or by heating acyl ureas (II) where R1-3 = H, halogen, CF3, NO2, alkyl, or alkoxy; R4 = H, alkyl, polyhaloalkyl, or cycloalkylalkyl; R5 = H, alkyl, Ph, alkoxy, benzyloxy, NH2, carboxyl, carbamoyl, or alkoxycarbonyl. E.g., 1.92 g II (R1 = 4-Cl, R2 = R3 = H, R4 = Me, R5 = Et) in EtOH was refluxed 30 min with 5 ml 20% NaOH to give I (R1 = 6-Cl, R2 = R3 = H, R4 = Me). Similarly prepared was I(R1, R2, R3, and R4 given): 6-Cl, H, 0-F, H.
IT 20927-53-1P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 20927-53-1 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-1-methyl-4-phenyl- (CA INDEX NAME)



L5 ANSWER 270 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1974:3460 CAPLUS
DOCUMENT NUMBER: 80:3460
ORIGINAL REFERENCE NO.: 80:607a,610a
TITLE: Novel quinazoline derivatives. II. A new antiinflammatory agent, SL-512
AUTHOR(S): Yamamoto, Hisao; Saito, Chiharu; Inaba, Shigeho; Awata, Hiroshi; Yamamoto, Michihiro; Sakai, Yuriko; Komatsu, Toshiaki
CORPORATE SOURCE: Takarazuka Res. Lab., Sumitomo Chem. Co., Ltd., Osaka, Japan
SOURCE: Arzneimittel-Forschung (1973), 23(9), 1266-71
CODEN: ARZNAD; ISSN: 0004-4172
DOCUMENT TYPE: Journal
LANGUAGE: English
GI For diagram(s), see printed CA Issue.
AB SL-512 (I) was prepared from the indole II by 2 methods: either by successive conversion into III, oxidation with CrO3 to give 4,2-Cl(PhCO)C6H3NRCOCO2Et (IV, R = A), hydrolysis to give 4,2-Cl(PhCO)C6H3NHR (V, R = A), and ring closure with KOCN to give I or by successive oxidation with CrO3 to give IV (R = H), hydrolysis to give V (R = H), reaction with urea to give VI, which on reaction with ABr gave I. The antiinflammatory effects of I on acute inflammation models were about twice to 4 times more potent than those of mefenamic acid or benzyldiamine and almost equal to phenylbutazone. I had also marked analgesic and antipyretic activities. Effects of I on adjuvant-induced arthritis were also exhibited, but it did not inhibit granuloma formation. Acute toxicity and intestinal perforating activity of I were remarkably weaker than those of other antiinflammatory agents.
IT 33453-19-9P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and inflammation inhibiting effects of)
RN 33453-19-9 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-1-(cyclopropylmethyl)-4-phenyl- (CA INDEX NAME)



L5 ANSWER 270 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

L5 ANSWER 271 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1973:549319 CAPLUS
DOCUMENT NUMBER: 79:149319
ORIGINAL REFERENCE NO.: 79:24175a,24178a
TITLE: 2(1H)-Quinazolinone derivatives as uricosurics
INVENTOR(S): Yamamoto, Michihiro; Morooka, Shigeaki; Koshiba, Masao; Aono, Shunji; Aisaka, Akira; Inabe, Shigeho; Nakatani, Hiroshi; Yamamoto, Hisao
PATENT ASSIGNEE(S): Sumitomo Chemical Co., Ltd.
SOURCE: Ger. Offen., 28 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2307808	A1	19730830	DE 1973-2307808	19730216
JP 48085719	A	19731113	JP 1972-17442	19720218
BE 795519	A1	19730618	BE 1973-127723	19730216
FR 2181744	A2	19731207	FR 1973-5627	19730216
FR 2181745	A2	19731207	FR 1973-5628	19730216
FR 2181746	A2	19731207	FR 1973-5629	19730216
AU 7352299	A	19740822	AU 1973-52299	19730219
PRIORITY APPLN. INFO.:			JP 1972-17442 A	19720218

GI For diagram(s), see printed CA Issue.
AB Fifty quinazolinone derivs. [I and II, e.g. R = Me, allyl, cyclopropylmethyl, CH2OMe, CH2CH2SMe, 2,3-epoxypropyl, (CH2)4OH, CH2CH2NEt2, CH2CF3, or (1-methylcyclohexyl)methyl; R1 = Ph, 3-ClC6H4, cyclohexyl, 2-pyridyl, or 2-thienyl; R2 = Me, Cl, Br, O2N, MeO, H2N, MeS, MeSO2, or MeO2C; R3 = H or Me; or R2R3 = OCH2O; R4 = H; R5 = H or CH2CH2NEt2; or R4R5 = OCH2CH2, O(CH2)3, NMeCH2CH2, or NH(CH2)3] or their hydrochlorides increased uric acid excretion of mice and were useful for the treatment of gout. I and II were more effective than probenecid, e.g. 100 mg I (R = CH2CH2OAc, R1 = Ph, R2 = O2N, R3 = H)/kg mice (orally) caused the excretion of 100 µg uric acid/100 g body weight
IT 20927-53-1 22760-18-5 26831-11-8
33453-20-2 33453-23-5 33453-24-6
33890-29-8 36942-70-8 37554-27-1
37554-35-1 37554-37-3 37554-39-5
37554-75-9 37554-98-6 37555-03-6
37555-17-2 38018-35-8 38634-47-8
40852-39-9 40852-49-1 42285-56-3
49830-54-8 49830-57-1 49830-63-9
49830-65-1 49830-72-0 49830-74-2
49830-82-2 49830-83-3 49830-84-4
49830-85-5 49830-86-6 49830-87-7
49830-89-9 49830-91-3
RL: BIOL (Biological study)
(uricosuric)
RN 20927-53-1 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-1-methyl-4-phenyl- (CA INDEX NAME)

L5 ANSWER 271 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 22760-18-5 CAPLUS
CN 2(1H)-Quinazolinone, 7-methyl-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)



RN 26831-11-8 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)



RN 33453-20-2 CAPLUS
CN 2(1H)-Quinazolinone, 6-bromo-1-(cyclopropylmethyl)-4-phenyl- (CA INDEX NAME)



L5 ANSWER 271 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
RN 33453-23-5 CAPLUS
CN 2(1H)-Quinazolinone, 1-(cyclopropylmethyl)-6-methoxy-4-phenyl- (CA INDEX NAME)



RN 33453-24-6 CAPLUS
CN 2(1H)-Quinazolinone, 1-(cyclopropylmethyl)-6-methyl-4-phenyl- (CA INDEX NAME)



RN 33890-29-8 CAPLUS
CN 2(1H)-Quinazolinone, 1-(cyclopropylmethyl)-6-nitro-4-phenyl- (CA INDEX NAME)



RN 36942-70-8 CAPLUS

L5 ANSWER 271 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
CN 2(1H)-Quinazolinone, 1-(2-ethoxyethyl)-6-nitro-4-phenyl- (CA INDEX NAME)



RN 37554-39-5 CAPLUS
CN 2(1H)-Quinazolinone, 1-(2-hydroxyethyl)-6-nitro-4-phenyl- (CA INDEX NAME)



RN 37554-75-9 CAPLUS
CN 2(1H)-Quinazolinone, 6-iodo-1-methyl-4-phenyl- (CA INDEX NAME)



RN 37554-98-6 CAPLUS
CN 2(1H)-Quinazolinone, 6-nitro-4-phenyl-1-(2-propenyl)- (9CI) (CA INDEX NAME)



RN 37555-03-6 CAPLUS
CN 2(1H)-Quinazolinone, 6-nitro-4-phenyl-1-(phenylmethyl)- (CA INDEX NAME)

L5 ANSWER 271 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
CN 2(1H)-Quinazolinone, 1-(cyclopropylmethyl)-3,4-dihydro-4-phenyl-6-(trifluoromethyl)- (CA INDEX NAME)



RN 37554-27-1 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-1-(cyclopropylmethyl)-4-(4-methoxyphenyl)- (CA INDEX NAME)



RN 37554-35-1 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-1-(methoxymethyl)-4-phenyl- (CA INDEX NAME)



RN 37554-37-3 CAPLUS

L5 ANSWER 271 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 37555-17-2 CAPLUS
CN 2(1H)-Quinazolinone, 1-(cyclopropylmethyl)-6-(methylsulfonyl)-4-phenyl- (CA INDEX NAME)



RN 38018-35-8 CAPLUS
CN 2(1H)-Quinazolinone, 1-[2-(methylthio)ethyl]-6-nitro-4-phenyl- (CA INDEX NAME)



RN 38634-47-8 CAPLUS
CN 2(1H)-Quinazolinone, 6-amino-1-(cyclopropylmethyl)-4-phenyl- (CA INDEX NAME)

L5 ANSWER 271 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 40852-39-9 CAPLUS
CN 2(1H)-Quinazolinone, 1-(methoxymethyl)-6-nitro-4-phenyl- (CA INDEX NAME)



RN 40852-49-1 CAPLUS
CN 1(2H)-Quinazolineacetamide, N,N-diethyl-6-nitro-2-oxo-4-phenyl- (CA INDEX
NAME)



RN 42285-56-3 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-1-(oxiranylmethyl)-4-phenyl- (9CI) (CA INDEX NAME)

L5 ANSWER 271 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 49830-54-8 CAPLUS
CN 2(1H)-Quinazolinone, 1-(2-methyl-2-propenyl)-6-nitro-4-phenyl- (9CI) (CA INDEX NAME)



RN 49830-57-1 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-4-(3-chlorophenyl)-1-(cyclopropylmethyl)-
(CA INDEX NAME)



RN 49830-63-9 CAPLUS
CN 2(1H)-Quinazolinone, 1-(cyclopropylmethyl)-6-(methylthio)-4-phenyl- (CA INDEX NAME)

L5 ANSWER 271 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 49830-65-1 CAPLUS
CN 6-Quinazolinecarboxylic acid, 1-(cyclopropylmethyl)-1,2-dihydro-2-oxo-4-phenyl-, methyl ester (CA INDEX NAME)



RN 49830-72-0 CAPLUS
CN 2(1H)-Quinazolinone, 1-(cyclobutylmethyl)-6-nitro-4-phenyl- (CA INDEX NAME)



RN 49830-74-2 CAPLUS
CN 2(1H)-Quinazolinone, 6-bromo-1-(methoxymethyl)-4-phenyl- (CA INDEX NAME)

L5 ANSWER 271 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 49830-82-2 CAPLUS
CN 2(1H)-Quinazolinone, 1-(2-hydroxybutyl)-6-methoxy-4-phenyl- (CA INDEX NAME)



RN 49830-83-3 CAPLUS
CN 2(1H)-Quinazolinone, 1-[2-(acetyloxy)ethyl]-6-bromo-4-phenyl- (CA INDEX NAME)



RN 49830-84-4 CAPLUS
CN 2(1H)-Quinazolinone, 1-[2-(acetyloxy)ethyl]-6-nitro-4-phenyl- (CA INDEX NAME)



RN 49830-85-5 CAPLUS

L5 ANSWER 271 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
CN Propanoic acid, 2-methyl-, 2-(6-nitro-2-oxo-4-phenyl-1(2H)-quinazolinyl)ethyl ester (CA INDEX NAME)



RN 49830-86-6 CAPLUS
CN Acetic acid, dichloro-, 2-(6-nitro-2-oxo-4-phenyl-1(2H)-quinazolinyl)ethyl ester (9CI) (CA INDEX NAME)



RN 49830-87-7 CAPLUS
CN 2(1H)-Quinazolinone, 1-[2-(diethylamino)ethyl]-6-nitro-4-phenyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 49830-89-9 CAPLUS
CN 2(1H)-Quinazolinone, 6-methoxy-4-phenyl-1-(2,2,2-trifluoroethyl)- (CA INDEX NAME)



RN 49830-91-3 CAPLUS
CN 2(1H)-Quinazolinone, 3,4-dihydro-1-[(1-methylcyclohexyl)methyl]-6-nitro-4-phenyl- (CA INDEX NAME)



L5 ANSWER 272 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1973:537109 CAPLUS
DOCUMENT NUMBER: 79:137109
ORIGINAL REFERENCE NO.: 79:22225a,22228a
TITLE: Quinazolines and 1,4-benzodiazepines. LIX. Preparation of pyrrolo[2,1-c]-1,4-benzodiazepines
AUTHOR(S): Walser, Armin; Silverman, Gladys; Fryer, R. Ian
CORPORATE SOURCE: Chem. Res. Dep., Hoffmann-La Roche Inc., Nutley, NJ, USA
SOURCE: Journal of Organic Chemistry (1973), 38(20), 3502-7
CODEN: JOCEAH; ISSN: 0022-3263
DOCUMENT TYPE: Journal
LANGUAGE: English
GI For diagram(s), see printed CA Issue.
AB Substituted 7-chloro-5,10-dihydro-5-phenyl-11H-pyrrolo[2,1-c][1,4]benzodiazepines (I) were obtained from treatment of the corresponding 3-allylbenzodiazepine 4-oxides (II) with Ac2O.
IT 20927-53-1P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 20927-53-1 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-1-methyl-4-phenyl- (CA INDEX NAME)



L5 ANSWER 273 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1973:515618 CAPLUS
DOCUMENT NUMBER: 79:115618
ORIGINAL REFERENCE NO.: 79:18779a,18782a
TITLE: Quinazoline derivatives
INVENTOR(S): Yamamoto, Michihiro; Ishizumi, Kikuo; Mori, Kazuo; Inaba, Shigeho; Yamamoto, Hisao
PATENT ASSIGNEE(S): Sumitomo Chemical Co., Ltd.
SOURCE: Jpn. Tokkyo Koho, 5 pp.
CODEN: JAXXAD
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 6
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 48021956	B	19730702	JP 1970-114461	19701211
CH 572472	A5	19760213	CH 1971-15572	19711026
DD 95382	A5	19730212	DD 1971-158657	19711029
HU 163176	B	19730628	HU 1971-SU688	19711029
SE 7600767	A	19760126	SE 1976-767	19760126
SE 431206	B	19840123		
SE 431206	C	19840503		

PRIORITY APPLN. INFO.:		
JP 1970-96304	A	19701030
JP 1970-96305	A	19701030
JP 1970-96306	A	19701030
JP 1970-110689	A	19701211
JP 1970-114461	A	19701211
JP 1970-129965	A	19701228
JP 1971-6400	A	19710213

GI For diagram(s), see printed CA Issue.
AB The quinazolines I [R1, R2 = H, lower alkyl, lower alkoxy, NO2, CF3, lower alkylthio, lower alkylsulfonyl, or halogen; R3 = Ph, halophenyl, lower alkylphenyl, lower alkoxyphenyl, trifluoromethylphenyl, lower cycloalkyl, or thienyl; R = lower alkyl, lower alkenyl, CH.tplbond.CCH2, aralkyl, lower cycloalkyl, lower cycloalkylalkyl, lower alkoxyalkyl, lower trihalomethylalkyl, or CnH2nNR4R5 (n = 1-4, R4, R5 = lower alkyl); Z = O or S] were prepared by reaction of II with halogenating agents to give III (X = Cl or Br), followed by the reaction with an organo-metallic compound I are analgesics, antiinflammatory agents, and agents acting on the central nervous system. Thus, a mixture of 4.2 g II (R1 = H, R2 = 6-Cl, R = Me, Z = O), PCl5, and POCl3 was refluxed 5 hr to give III (R1 = H, R2 = 6-Cl, R = Me, Z = O, X = Cl), which was treated with PhMgBr from 25 g PhBr) in THF to give I (R1 = H, R2 = 6-Cl, R = Me, R3 = Ph, Z = O). Among 60 I similarly prepared were the following (R1, R2, R, R3, and Z given): H, 6-Cl, Me, Ph, S; H, 6-Cl, cyclopropylmethyl, Ph, S; H, H, iso-Pr, Ph, S; H, 5-Cl, Me, Ph, O.

L5 ANSWER 273 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
IT 20927-53-1P 23441-90-9P 26824-68-0P
26920-12-7P 33443-28-6P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 20927-53-1 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-1-methyl-4-phenyl- (CA INDEX NAME)



RN 23441-90-9 CAPLUS
CN 2(1H)-Quinazolinone, 5-chloro-1-methyl-4-phenyl- (CA INDEX NAME)



RN 26824-68-0 CAPLUS
CN 2(1H)-Quinazolinethione, 1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)



RN 26920-12-7 CAPLUS
CN 2(1H)-Quinazolinethione, 6-chloro-1-methyl-4-phenyl- (CA INDEX NAME)

L5 ANSWER 273 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 33443-28-6 CAPLUS
CN 2(1H)-Quinazolinethione, 6-chloro-1-(cyclopropylmethyl)-4-phenyl- (CA INDEX NAME)



L5 ANSWER 274 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1973:505283 CAPLUS
DOCUMENT NUMBER: 79:105283
ORIGINAL REFERENCE NO.: 79:17079a,17082a
TITLE: Quinazolinones
INVENTOR(S): Yamamoto, Michihiro; Morooka, Shigeaki; Koshiba, Masao; Inaba, Shigeho; Yamamoto, Hisao
PATENT ASSIGNEE(S): Sumitomo Chemical Co., Ltd.
SOURCE: Jpn. Kokai Tokkyo Koho, 5 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 48049779	A	19730713	JP 1971-84861	19711026
JP 49048957	B	19741224		
US 3812118	A	19740521	US 1972-259691	19720605
AT 317226	B	19740826	AT 1972-8886	19721017
NL 7214449	A	19730501	NL 1972-14449	19721025
DK 129350	B	19740930	DK 1972-5290	19721025
HU 166019	B	19741228	HU 1972-SU782	19721025
CA 996557	A1	19760907	CA 1972-154815	19721025
CH 581630	A5	19761115	CH 1972-15570	19721025
SE 397679	B	19771114	SE 1972-13782	19721025
PRIORITY APPLN. INFO.:			JP 1971-84861 A	19711026

GI For diagram(s), see printed CA Issue.
AB The title compds. (I) were prepared by treating 2-carbamoylindoles (II) with halogen in the presence of alkali. Thus, Br was added to aqueous KOH and the mixture heated at 80° with II (R1 = 5-Cl, R2 = H, R3 = Ph, R4 = Me) to give I (R1 = 6-Cl, R2 = H, R3 = Ph, R4 = Me). Among .apprx.50 I similarly prepared were (R1, R2, R3, and R4 given): 5-Cl, H, Ph, Me; 6-Cl, H, p-MeOC6H4, Me; Me, Me, Ph, Et; 6-Cl, H, Ph, 3,3-dimethylallyl; 6-NO2, H, Ph, 2-morpholinoethyl.
IT 20927-53-1P 23441-78-3P 23441-90-9P
37554-43-1P 37555-00-3P 49796-77-2P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 20927-53-1 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-1-methyl-4-phenyl- (CA INDEX NAME)



RN 23441-78-3 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-4-(4-methoxyphenyl)-1-methyl- (CA INDEX NAME)

L5 ANSWER 274 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 23441-90-9 CAPLUS
CN 2(1H)-Quinazolinone, 5-chloro-1-methyl-4-phenyl- (CA INDEX NAME)



RN 37554-43-1 CAPLUS
CN 2(1H)-Quinazolinone, 1-[2-(4-morpholinyl)ethyl]-6-nitro-4-phenyl- (CA INDEX NAME)



RN 37555-00-3 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-1-(3-methyl-2-butenyl)-4-phenyl- (9CI) (CA INDEX NAME)

L5 ANSWER 274 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 49796-77-2 CAPLUS
CN 2(1H)-Quinazolinone, 1-ethyldimethyl-4-phenyl- (9CI) (CA INDEX NAME)



2 (D1—Me)

L5 ANSWER 275 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1973:492268 CAPLUS
DOCUMENT NUMBER: 79:92268
ORIGINAL REFERENCE NO.: 79:14991a,14994a
TITLE: Quinazoline derivatives
INVENTOR(S): Yamamoto, Michihiro; Ishizumi, Kikuo; Mori, Kazuo; Inaba, Shigeho; Yamamoto, Hisao
PATENT ASSIGNEE(S): Sumitomo Chemical Co., Ltd.
SOURCE: Jpn. Tokkyo Koho, 5 pp.
CODEN: JAXXAD
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 6
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 48021955	B	19730702	JP 1970-110689	19701211
CH 572472	A5	19760213	CH 1971-15572	19711026
CH 574418	A5	19760415	CH 1975-12093	19711026
DD 95382	A5	19730212	DD 1971-158657	19711029
HU 163176	B	19730628	HU 1971-SU688	19711029
AT 313909	B	19740311	AT 1973-1779	19711029
SE 410188	B	19791001	SE 1971-13749	19711029
DK 7500228	A	19750804	DK 1975-228	19750124
DK 134401	B	19761101		
SE 7600767	A	19760126	SE 1976-767	19760126
SE 431206	B	19840123		
SE 431206	C	19840503		
FI 59797	B	19810630	FI 1978-1641	19780524
FI 59797	C	19811012		

PRIORITY APPLN. INFO.:

JP 1970-96304	A	19701030
JP 1970-96305	A	19701030
JP 1970-96306	A	19701030
JP 1970-110689	A	19701211
JP 1970-114461	A	19701211
JP 1970-129965	A	19701228
JP 1971-6400	A	19710213
DK 1971-5233	A	19711027
FI 1971-3074	A	19711028

GI For diagram(s), see printed CA Issue.
AB Title derivs. I were prepared by treating the corresponding 4-oxo compds. with organic Mg halides or organic Li compds., followed by H2O or lower alcs., and then heating. I had antiinflammatory, analgesic, and central nervous actions. E.g., refluxing PhMgBr and 5 g 1-(cyclopropylmethyl)-6-chloro-2,-

L5 ANSWER 275 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
4(1H,3H)-quinazolinedione 4 hr, addn. of 100 ml MeOH at 0° and 50 ml 20% MeOH-HCl, and stirring 1 hr at room temp. gave 1-(cyclopropylmethyl)-3,4-dihydro-4-methoxy-4-phenyl-6-chloro-2(1H)-quinazolinone (II). Heating II 30 min at 220° and silica gel chromatog. gave I (R = cyclopropylmethyl, R1 = Ph, R2 = R4 = R5 = H, R3 = Cl, Z = O). Also, I of the same type were prepd. (R to R5 and Z given): Me, Ph, H, MeO, H, H, O; Et, o-MeC6H4, H, Cl, H, H, O; CH2:CHCH2, Ph, H, NO2, H, H, O; cyclohexylmethyl, Ph, H, Cl, H, H, O; and Me, Ph, H, Cl, H, H, S. Some 58 other I were also prepd.
IT 23441-74-9P 26313-42-8P 26920-12-7P
33453-19-9P 33512-31-1P 37554-98-6P
43107-59-1P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 23441-74-9 CAPLUS
CN 2(1H)-Quinazolinone, 6-methoxy-1-methyl-4-phenyl- (CA INDEX NAME)



RN 26313-42-8 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-1-ethyl-4-(2-methylphenyl)- (CA INDEX NAME)



RN 26920-12-7 CAPLUS
CN 2(1H)-Quinazolinethione, 6-chloro-1-methyl-4-phenyl- (CA INDEX NAME)



L5 ANSWER 275 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
RN 33453-19-9 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-1-(cyclopropylmethyl)-4-phenyl- (CA INDEX NAME)



RN 33512-31-1 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-1-(cyclohexylmethyl)-4-phenyl- (CA INDEX NAME)



RN 37554-98-6 CAPLUS
CN 2(1H)-Quinazolinone, 6-nitro-4-phenyl-1-(2-propenyl)- (9CI) (CA INDEX NAME)



RN 43107-59-1 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-1-(cyclopropylmethyl)-3,4-dihydro-4-methoxy-4-phenyl- (CA INDEX NAME)

L5 ANSWER 275 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



L5 ANSWER 276 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1973:492267 CAPLUS
DOCUMENT NUMBER: 79:92267
ORIGINAL REFERENCE NO.: 79:14991a,14994a
TITLE: Quinazolinone derivatives
INVENTOR(S): Inaba, Shigeho; Yamamoto, Michihiro; Ishizumi, Kikuo; Mori, Kazuo; Yamamoto, Hisao
PATENT ASSIGNEE(S): Sumitomo Chemical Co., Ltd.
SOURCE: Jpn. Tokkyo Koho, 5 pp.
CODEN: JAXXAD
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 6
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 48021953	B	19730702	JP 1970-96304	19701030
CH 572472	A5	19760213	CH 1971-15572	19711026
DK 130294	B	19750203	DK 1971-5233	19711027
DD 95382	A5	19730212	DD 1971-158657	19711029
HU 163176	B	19730628	HU 1971-SU688	19711029
AT 312615	B	19740110	AT 1971-9371	19711029
SE 410188	B	19791001	SE 1971-13749	19711029
SE 7600767	A	19760126	SE 1976-767	19760126
SE 431206	B	19840123		
SE 431206	C	19840503		

PRIORITY APPLN. INFO.:

JP 1970-96304	A	19701030
JP 1970-96305	A	19701030
JP 1970-96306	A	19701030
JP 1970-110689	A	19701211
JP 1970-114461	A	19701211
JP 1970-129965	A	19701228
JP 1971-6400	A	19710213

GI For diagram(s), see printed CA Issue.

AB The quinazolinones I were prepared by treating 2-alkoxycarbonylaminophenyl ketones with NH3. I had antiinflammatory, analgesic, and central nervous actions. E.g., 3 ml Me2SO4 was dropped to a mixture of 5.8 g 2-(methoxycarbonylamino)-5-chlorobenzophenone and 3 g 50% NaOH in acetone and the whole kept stirred 2 hr at room temperature to give 2-(N-methylmethoxycarbonylamino)-5-chlorobenzophenone (II). A mixture of 1.52 g II, Me2SO, 4 g AcONH4, and 0.6 g KOH was heated 20 hr at 130° to give I (R = Me, R1 = Ph, R2 = R4 = H, R3 = Cl). Also, I (R to R4 given) were prepared: Me, Ph, Cl, H, H; Me, Ph, H, H, Cl; Me, Ph, H, I, H; Me, Ph, H, MeO, H; Me, Ph, H, CF3, H. Some 70 other I were similarly prepared

IT 20927-53-1P 23441-63-6P 23441-74-9P

L5 ANSWER 276 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

23441-90-9P 23536-81-4P 37554-75-9P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)

RN 20927-53-1 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-1-methyl-4-phenyl- (CA INDEX NAME)



RN 23441-63-6 CAPLUS
CN 2(1H)-Quinazolinone, 7-chloro-1-methyl-4-phenyl- (CA INDEX NAME)



RN 23441-74-9 CAPLUS
CN 2(1H)-Quinazolinone, 6-methoxy-1-methyl-4-phenyl- (CA INDEX NAME)



RN 23441-90-9 CAPLUS
CN 2(1H)-Quinazolinone, 5-chloro-1-methyl-4-phenyl- (CA INDEX NAME)



L5 ANSWER 276 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

RN 23536-81-4 CAPLUS
CN 2(1H)-Quinazolinone, 1-methyl-4-phenyl-6-(trifluoromethyl)- (CA INDEX NAME)



RN 37554-75-9 CAPLUS
CN 2(1H)-Quinazolinone, 6-iodo-1-methyl-4-phenyl- (CA INDEX NAME)



L5 ANSWER 277 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1973:466396 CAPLUS
DOCUMENT NUMBER: 79:66396
ORIGINAL REFERENCE NO.: 79:10735a,10738a
TITLE: Quinazolinones
INVENTOR(S): Yamamoto, Michihiro; Ishizumi, Kikuo; Mori, Kazuo; Inaba, Shigeho; Yamamoto, Hisao
PATENT ASSIGNEE(S): Sumitomo Chemical Co., Ltd.
SOURCE: Jpn. Kokai Tokkyo Koho, 5 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 48040787	A	19730615	JP 1971-78059	19711004
JP 50013271	B	19750519		
PRIORITY APPLN. INFO.:			JP 1971-78059 A	19711004

GI For diagram(s), see printed CA Issue.
AB The title compds. (I), antiinflammatory and analgesic drugs, were prepared by treating benzhydrols with carbamates or cyanates followed by oxidation E.g., 2-(2,2,2-trifluoroethylamino)-5-chlorobenzhydrol was heated 3 hr at 200° with Et carbamate in the presence of ZnCl2 and the resulting 1-(2,2,2-trifluoroethyl)-4-phenyl-6-chloro-3,4-dihydro-2(1H)-quinazolinone oxidized with KMnO4 in dioxane to give I (R1 = CH2CF3, R2 = Ph, R3 = 6-Cl). Among 23 more I similarly prepared were the following (R1, R2, and R3 given): cyclopropylmethyl, Ph, 6-Cl; cyclopropylmethyl, Ph, 8-Cl; cyclopropylmethyl, p-tolyl, 6-Cl; cyclopropylmethyl, 2-pyridyl, 6-Cl; cyclopropylmethyl, Ph, 6-Me.
IT 33453-19-9P 33453-24-6P 37554-40-8P 37555-10-5P 42026-39-1P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 33453-19-9 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-1-(cyclopropylmethyl)-4-phenyl- (CA INDEX NAME)



L5 ANSWER 277 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



L5 ANSWER 277 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

RN 33453-24-6 CAPLUS
CN 2(1H)-Quinazolinone, 1-(cyclopropylmethyl)-6-methyl-4-phenyl- (CA INDEX NAME)



RN 37554-40-8 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-4-phenyl-1-(2,2,2-trifluoroethyl)- (CA INDEX NAME)



RN 37555-10-5 CAPLUS
CN 2(1H)-Quinazolinone, 8-chloro-1-(cyclopropylmethyl)-4-phenyl- (CA INDEX NAME)



RN 42026-39-1 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-1-(cyclopropylmethyl)-4-(4-methylphenyl)- (CA INDEX NAME)

L5 ANSWER 278 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1973:466384 CAPLUS
DOCUMENT NUMBER: 79:66384
ORIGINAL REFERENCE NO.: 79:10731a,10734a
TITLE: Quinazolinones
INVENTOR(S): Yamamoto, Michihiro; Morooka, Shigeaki; Koshiba, Masao; Inaba, Shigeho; Yamamoto, Hisao
PATENT ASSIGNEE(S): Sumitomo Chemical Co., Ltd.
SOURCE: Jpn. Kokai Tokkyo Koho, 7 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 48044279	A	19730626	JP 1971-81181	19711014
JP 50013272	B	19750519		
AU 7245877	A	19740228	AU 1972-45877	19720823
GB 1394191	A	19750514	GB 1972-39296	19720823
DE 2242375	A1	19730315	DE 1972-2242375	19720829
DE 2242375	B2	19740905		
DE 2242375	C3	19750430		
AT 7207429	A	19750415	AT 1972-7429	19720829
AT 327199	B	19760126		
AT 7401520	A	19750415	AT 1972-152074	19720829
CH 579562	A5	19760915	CH 1972-12739	19720829
SE 395453	B	19770815	SE 1972-11231	19720830
SU 640663	A3	19781230	SU 1972-1823902	19720830
BE 788213	A1	19730228	BE 1972-121515	19720831
NL 7211867	A	19730305	NL 1972-11867	19720831
HU 166496	B	19750328	HU 1972-SU834	19720831
CA 1006161	A1	19770301	CA 1972-150694	19720831
DK 133507	B	19760531	DK 1973-6806	19731214
PRIORITY APPLN. INFO.:			JP 1971-67669 A	19710901
			JP 1971-81181 A	19711014
			JP 1972-18220 A	19720221
			JP 1972-20356 A	19720228

GI For diagram(s), see printed CA Issue.
AB The title compds. (I), antiinflammatory and antiviral drugs, were prepared from the corresponding 1-unsubstituted compds. Thus, 4-phenyl-6-chloro-2(1H)-quinazolinone in DMF was warmed with NaH and warmed further with epibromohydrin to give I (R = 2,3-epoxypropyl). Similarly prepared was I (R = tetrahydrofurfuryl). This was also prepared by a ring closure of 2-(tetrahydrofurfurylamino)-5-nitrobenzophenone or of 2-[N-(tetrahydrofurfuryl)trichloroacetamido]-5-nitrobenzophenone.
IT 42285-56-3P 42285-57-4P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 42285-56-3 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-1-(oxiranylmethyl)-4-phenyl- (9CI) (CA INDEX NAME)

L5 ANSWER 278 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 42285-57-4 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-4-phenyl-1-[(tetrahydro-2-furanyl)methyl]- (CA INDEX NAME)



L5 ANSWER 279 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1973:453357 CAPLUS
DOCUMENT NUMBER: 79:53357
ORIGINAL REFERENCE NO.: 79:8615a,8618a
TITLE: 1-Alkyl-4-phenyl-2(1H)-quinazolinones
INVENTOR(S): Denzer, Max
PATENT ASSIGNEE(S): Sandoz Ltd.
SOURCE: Ger. Offen., 12 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 7
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2253165	A1	19730524	DE 1972-2253165	19721030
US 3793324	A	19740219	US 1971-200141	19711118
BE 782985	A4	19721103	BE 1972-117070	19720503
BE 785283	A4	19721222	BE 1972-119041	19720622
CA 983501	A1	19760210	CA 1972-145389	19720622
CH 574942	A5	19760430	CH 1972-15469	19721023
DK 130972	B	19750512	DK 1972-5264	19721024
FR 2160385	A1	19730629	FR 1972-37751	19721025
NO 136361	B	19770516	NO 1972-3829	19721025
SE 412391	B	19800303	SE 1972-13849	19721026
SE 412391	C	19800619		
FI 57402	B	19800430	FI 1972-2971	19721026
FI 57402	C	19800811		
NL 7214565	A	19730522	NL 1972-14565	19721027
BE 790804	A1	19730430	BE 1972-123684	19721031
DD 100950	A5	19731012	DD 1972-166584	19721031
AU 7248360	A	19740502	AU 1972-48360	19721031
HU 165128	B	19740628	HU 1972-SA2416	19721031
GB 1385420	A	19750226	GB 1972-50104	19721031
CA 976165	A1	19751014	CA 1972-155222	19721031
ES 408156	A1	19760201	ES 1972-408156	19721031
PL 85287	B1	19760430	PL 1972-158570	19721031
CS 182229	B2	19780428	CS 1972-7326	19721031
RO 63386	A1	19780815	RO 1972-72684	19721031
ZA 7207760	A	19740626	ZA 1972-7760	19721101
JP 49132091	A	19741218	JP 1972-108936	19721101
JP 55016424	B	19800501		
AT 7209644	A	19770215	AT 1972-9644	19721113
AT 339313	B	19771010		
SU 474985	A3	19750625	SU 1972-1855788	19721117

PRIORITY APPLN. INFO.:

US 1971-200141	A	19711118
BE 1970-759671	A	19701130
US 1971-140990	A	19710506
US 1971-141011	A	19710506
US 1971-156460	A	19710624

L5 ANSWER 279 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

GI For diagram(s), see printed CA Issue.

AB Fourteen title compds. I (R = Me, CHMe2, HC.tplbond.CCH2, Et, CH2:CHCH2, CH2:CMeCH2; R1 = H, 4-Cl, 4-Me, 4-MeO, 3-CF3; R2 = HMe; R3 = H, Me, CF3, NO2, Br, MeO, Cl; R4 = H, Me, Cl), useful as antiinflammatory agents, were prepared by refluxing 2, (alkylamino)benzophenones with >3 equivs. urea in the presence of HOAc.

IT 22760-18-5P 22760-22-1P 22760-23-2P
22760-27-6P 25508-89-8P 25508-91-2P
25508-93-4P 26824-70-4P 26831-06-1P
26940-07-8P 27524-92-1P 27529-23-3P
42211-83-6P 42314-12-5P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 22760-18-5 CAPLUS
CN 2(1H)-Quinazolinone, 7-methyl-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)



RN 22760-22-1 CAPLUS
CN 2(1H)-Quinazolinone, 4-(4-methoxyphenyl)-7-methyl-1-(1-methylethyl)- (CA INDEX NAME)



RN 22760-23-2 CAPLUS
CN 2(1H)-Quinazolinone, 6,7-dichloro-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)

L5 ANSWER 279 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 22760-27-6 CAPLUS
CN 2(1H)-Quinazolinone, 5,7-dimethyl-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)



RN 25508-89-8 CAPLUS
CN 2(1H)-Quinazolinone, 6,7-dimethyl-4-phenyl-1-(2-propynyl)- (8CI, 9CI) (CA INDEX NAME)



RN 25508-91-2 CAPLUS
CN 2(1H)-Quinazolinone, 1-ethyl-4-phenyl-6-(trifluoromethyl)- (CA INDEX NAME)



RN 25508-93-4 CAPLUS
CN 2(1H)-Quinazolinone, 1-ethyl-6-nitro-4-phenyl- (CA INDEX NAME)

L5 ANSWER 279 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 26824-70-4 CAPLUS
CN 2(1H)-Quinazolinone, 6-methoxy-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)



RN 26831-06-1 CAPLUS
CN 2(1H)-Quinazolinone, 4-(4-chlorophenyl)-1-methyl- (CA INDEX NAME)



RN 26940-07-8 CAPLUS
CN 2(1H)-Quinazolinone, 1-methyl-4-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)

L5 ANSWER 279 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 42314-12-5 CAPLUS
CN 2(1H)-Quinazolinone, 7-chloro-4-phenyl-1-(2-propenyl)- (9CI) (CA INDEX NAME)



L5 ANSWER 279 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 27524-92-1 CAPLUS
CN 2(1H)-Quinazolinone, 1-(1-methylethyl)-4-(4-methylphenyl)- (CA INDEX NAME)



RN 27529-23-3 CAPLUS
CN 2(1H)-Quinazolinone, 1-(2-methyl-2-propenyl)-4-phenyl- (9CI) (CA INDEX NAME)



RN 42211-83-6 CAPLUS
CN 2(1H)-Quinazolinone, 6-bromo-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)

L5 ANSWER 280 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1973:453354 CAPLUS
DOCUMENT NUMBER: 79:53354
ORIGINAL REFERENCE NO.: 79:8615a,8618a
TITLE: Quinazoline derivatives
PATENT ASSIGNEE(S): Sumitomo Chemical Co., Ltd.
SOURCE: Fr. Demande, 10 pp.
CODEN: FRXXBL
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
FR 2141574	A1	19730126	FR 1971-21908	19710616
FR 2141574	B1	19740830		
PRIORITY APPLN. INFO.:			FR 1971-21908 A	19710616

GI For diagram(s), see printed CA Issue.
AB The quinazoline I was prepared by N-acylating 2,4-Bz(Cl)C6H3NHCH2CF3 with CCl3COCl and cyclizing the 2,4-Bz(Cl)C6H3N(COCCl3)CH2CF3 with NH3.
IT 37554-40-8P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 37554-40-8 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-4-phenyl-1-(2,2,2-trifluoroethyl)- (CA INDEX NAME)



L5 ANSWER 281 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1973:432084 CAPLUS
DOCUMENT NUMBER: 79:32084
ORIGINAL REFERENCE NO.: 79:5209a,5212a
TITLE: Quinazoline derivatives
INVENTOR(S): Inaba, Shigeho; Yamamoto, Michihiro; Ishizumi, Kikuo; Mori, Kazuo; Yamamoto, Hisao
PATENT ASSIGNEE(S): Sumitomo Chemical Co., Ltd.
SOURCE: Jpn. Tokkyo Koho, 3 pp.
CODEN: JAXXAD
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 48008118	B4	19730312	JP 1970-96306	19701030

GI For diagram(s), see printed CA Issue.
AB Novel quinazoline derivs. (I, A = -C(R3):N- or -CH(R3)NH-, R3 = Ph, halophenyl, lower alkoxyphenyl, lower alkylphenyl, CF3C6H4, cycloalkyl, pyridyl, furyl, or thienyl, R1, R2 = H, lower alkyl, alkoxy, NO2, CF3, alkylthio, alkylsulfonyl, or halo, and R is lower cycloalkyl) were prepared by hydrolysis of the corresponding 2-thioxo- or 2-imino- derivative in H2O, alc. dioxan, or Me2SO, containing acid or alkali. 1-Cyclopropylmethyl-4-phenyl-6-chloro-1H-quinazolin-2-one, m.p. 172-3°, and 25 other compds. were prepared and they showed antiinflammatory, analgesic, and central nerve actions. They are also useful as intermediates in the preparation of pharmaceutics.
IT 33453-19-9P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 33453-19-9 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-1-(cyclopropylmethyl)-4-phenyl- (CA INDEX NAME)



L5 ANSWER 282 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1973:432079 CAPLUS
DOCUMENT NUMBER: 79:32079
ORIGINAL REFERENCE NO.: 79:5209a,5212a
TITLE: Synthesis of quinazolinone derivatives
INVENTOR(S): Inaba, Shigeho; Yamamoto, Michihiro; Ishizumi, Kikuo; Mori, Kazuo; Yamamoto, Hisao
PATENT ASSIGNEE(S): Sumitomo Chemical Co., Ltd.
SOURCE: Jpn. Tokkyo Koho, 3 pp.
CODEN: JAXXAD
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 48008117	B4	19730312	JP 1970-96305	19701030

GI For diagram(s), see printed CA Issue.
AB Novel 1H-quinazolin-2-one derivs. (I, R1, R2 = H, lower alkyl, alkoxy, NO2, CF3, alkylthio, alkylsulfonyl, or halo, R3 is Ph, halophenyl, alkoxyphenyl, CF3C6H4, cycloalkyl, pyridyl, furyl, or thienyl, and R is lower cycloalkylalkyl) were prepared by oxidation of 1H-quinazoline-2-thione derivs. (II, where A is -C(R3):N- or -CH(R3)NH-) with NaMnO4, KMnO4, H2O2, HC(O)OO3H, or MeC(O)OO3H, in the presence or absence of NaOH, KOH, or Ca(OH)2, in H2O, MeOH, EtOH, iso-PrOH, C6H6, toluene, Et2O, THF, dioxane, or Me2CO. 1-Cyclopropylmethyl-4-phenyl-1H-quinazolin-2-one and 27 compds. were prepared which are useful as intermediate for manufacture of pharmaceutics, and they all showed anti-inflammatory, analgesic, and central nerve actions.
IT 33453-22-4P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 33453-22-4 CAPLUS
CN 2(1H)-Quinazolinone, 1-(cyclopropylmethyl)-4-phenyl- (CA INDEX NAME)



L5 ANSWER 283 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1973:159659 CAPLUS
DOCUMENT NUMBER: 78:159659
ORIGINAL REFERENCE NO.: 78:25643a,25646a
TITLE: Dihydroquinazolinone derivatives
INVENTOR(S): Yamamoto, Michihiro; Ishizumi, Kikuo; Mori, Kazuo; Koshiba, Masao; Inaba, Shigeho; Yamamoto, Hisao
PATENT ASSIGNEE(S): Sumitomo Chemical Co., Ltd.
SOURCE: Jpn. Kokai Tokkyo Koho, 7 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 48000585	B4	19730106	JP 1971-34897	19710521

GI For diagram(s), see printed CA Issue.
AB The title compds. (I) exhibiting central nervous, antiinflammatory, and analgesic actions, were prepared Thus, 3-[2-(diethylamino)ethyl]-4-phenyl-6-chloro-3,4-dihydro-2 (1H)-quinazolinone in DMF was warmed with NaH and stirred 4 hr at 100° with EtI to give I.HI [R1 = Et, R2 = 2-(diethylamino)ethyl, X = Cl]. Similarly prepared were I [R1,R2, and X given): Me, 2-(dimethylamino)ethyl, H; cyclopropylmethyl, 2-(diethylamino)ethyl, Cl; Me, cyclopropylmethyl, Cl; cyclopropylmethyl, Et, Cl].
IT 37665-54-6P 37665-55-7P 41230-80-2P 41230-82-4P 41230-84-6P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 37665-54-6 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-3-(cyclopropylmethyl)-1-methyl-4-phenyl- (9CI) (CA INDEX NAME)



RN 37665-55-7 CAPLUS
CN 2(1H)-Quinazolinone, 3-[2-(dimethylamino)ethyl]-3,4-dihydro-1-methyl-4-phenyl- (CA INDEX NAME)

L5 ANSWER 283 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 41230-80-2 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-3-[2-(diethylamino)ethyl]-1-ethyl-3,4-dihydro-4-phenyl-, monohydriodide (9CI) (CA INDEX NAME)



● HI

RN 41230-82-4 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-1-(cyclopropylmethyl)-3-[2-(diethylamino)ethyl]-3,4-dihydro-4-phenyl- (CA INDEX NAME)



RN 41230-84-6 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-1-(cyclopropylmethyl)-3-ethyl-3,4-dihydro-4-phenyl- (CA INDEX NAME)

L5 ANSWER 283 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



L5 ANSWER 284 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1973:136327 CAPLUS
DOCUMENT NUMBER: 78:136327
ORIGINAL REFERENCE NO.: 78:21905a,21908a
TITLE: 1,6-Disubstituted 4-phenyl-2(1H)-quinazolinones
INVENTOR(S): Yamamoto, Michihiro; Ishizumi, Kikuo; Mori, Kazuo; Koshiba, Masao; Inaba, Shigeho; Yamamoto, Hisao
PATENT ASSIGNEE(S): Sumitomo Chemical Co., Ltd.
SOURCE: Jpn. Kokai Tokkyo Koho, 4 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 48014685	A	19730223	JP 1971-49741	19710705
FI 57101	B	19800229	FI 1972-1901	19720704
FI 57101	C	19800610		
PRIORITY APPLN. INFO.:			JP 1971-49741 A	19710705

AB The title compds. (I), useful as antiinflammatory, analgesic, and central nervous system drugs, were prepared by treating the corresponding benzophenones with NH3. E.g., 2-(N-methylcyanocarbonylamino)-5-chlorobenzophenone in EtOH was let stand 3 days with saturated ethanolic NH3 to give I (R1 = Me, R2 = Cl). Similarly prepared were the following I (R1 and R2 given): Me, NO2; allyl, Cl.

IT 20927-53-1P 23441-66-9P 26953-46-8P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 20927-53-1 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-1-methyl-4-phenyl- (CA INDEX NAME)



RN 23441-66-9 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-4-phenyl-1-(2-propenyl)- (9CI) (CA INDEX NAME)

L5 ANSWER 284 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 26953-46-8 CAPLUS
CN 2(1H)-Quinazolinone, 1-methyl-6-nitro-4-phenyl- (CA INDEX NAME)



L5 ANSWER 285 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1973:136326 CAPLUS
DOCUMENT NUMBER: 78:136326
ORIGINAL REFERENCE NO.: 78:21905a,21908a
TITLE: Quinazolinone derivatives
INVENTOR(S): Inaba, Shigeho; Yamamoti, Michihiro; Ishizumi, Kikuo; Mori, Kazuo; Yamamoto, Hisao
PATENT ASSIGNEE(S): Sumitomo Chemical Co., Ltd.
SOURCE: Brit., 4 pp.
CODEN: BRXXAA
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
GB 1307202	A	19730214	GB 1971-28026	19710615
PRIORITY APPLN. INFO.:			GB 1971-28026 A	19710615

AB 1-(2,2,2-Trifluoroethyl)-4-phenyl-6-chloro-2(1H)-quinazolinone (I), useful as an inflammation inhibitor, was prepared by trichloroacetylation of 5',2-Cl(CF3CH2NH)C6H3

IT 37554-40-8
RL: RCT (Reactant); RACT (Reactant or reagent)
(inflammation inhibitor)

RN 37554-40-8 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-4-phenyl-1-(2,2,2-trifluoroethyl)- (CA INDEX NAME)



L5 ANSWER 286 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1973:124626 CAPLUS
DOCUMENT NUMBER: 78:124626
ORIGINAL REFERENCE NO.: 78:20027a,20030a
TITLE: Quinazoline derivatives
INVENTOR(S): Inaba, Shigeho; Yamamoto, Michihiro; Ishizumi, Kikuo; Mori, Kazuo; Yamamoto, Hisao
PATENT ASSIGNEE(S): Sumitomo Chemical Co., Ltd.
SOURCE: S. African, 14 pp.
CODEN: SFXXAB
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
ZA 7103886		19720731	ZA 1971-3886	19710615

GI For diagram(s), see printed CA Issue.
AB (Trifluoroethyl)quinazolinone I, possessing antiinflammatory activity, was prepared by condensing Cl3CCOCl with 2,5-(CF3CH2- NR)ClC6H3COPh (II; R = H) in refluxing Et2O containing Et3N to give II (R = CCl3CO); the latter underwent ring closure with NH4OAc in refluxing EtOH to yield I.
IT 37554-40-8P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation and antiinflammatory activity of)
RN 37554-40-8 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-4-phenyl-1-(2,2,2-trifluoroethyl)- (CA INDEX NAME)



L5 ANSWER 287 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1973:111362 CAPLUS
DOCUMENT NUMBER: 78:111362
ORIGINAL REFERENCE NO.: 78:17883a,17886a
TITLE: 1-Cycloalkylmethyl-4-phenyl-2(1H)-quinazolinones
INVENTOR(S): Inaba, Shigeho; Yamamoto, Michihiro; Ishizumi, Kikuo; Mori, Kazuo; Yamamoto, Hisao
PATENT ASSIGNEE(S): Sumitomo Chemical Co., Ltd.
SOURCE: Jpn. Tokkyo Koho, 3 pp.
CODEN: JAXXAD
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 47048395	B4	19721206	JP 1970-79752	19700910

GI For diagram(s), see printed CA Issue.
AB About 16 quinazolinones (I, n= 2-5; X = 6-Cl, F, Br, Me, MeO, NO2, CF3, 6,7-Cl2; Y = H, o-F, Cl, p-Me), with central nervous system activities, were prepared by cyclization of 2-(cycloathylmethylamino)benzophenone imines with cOCl2-Et3N, N,N'-carbonyldiimidazole, and ClCO2Et. Thus, 10% COCl2 in C6H6 was added to 2-(cyclopropylmethylamino)-5-chlorobenzophenone imine and Et3N in C6H6 and the mixture stirred 0.5 hr to give I (n = 2, X = 6-Cl, Y = H).
IT 33453-19-9P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 33453-19-9 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-1-(cyclopropylmethyl)-4-phenyl- (CA INDEX NAME)



L5 ANSWER 288 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1973:111347 CAPLUS
DOCUMENT NUMBER: 78:111347
ORIGINAL REFERENCE NO.: 78:17879a,17882a
TITLE: 1-Cycloalkylmethyl-4-phenyl-2(1H)-quinazolinones
INVENTOR(S): Inaba, Shigeho; Yamamoto, Michihiro; Ishizumi, Kikuo; Mori, Kazuo; Koshiba, Masao; Yamamoto, Hisao
PATENT ASSIGNEE(S): Sumitomo Chemical Co., Ltd.
SOURCE: Jpn. Tokkyo Koho, 4 pp.
CODEN: JAXXAD
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 47048396	B4	19721206	JP 1970-80173	19700911
CA 949570			CA	

GI For diagram(s), see printed CA Issue.
AB About 16 quinazolinones (I, n = 2-5; X = 6-Cl, F, Br, Me, MeO, NO2, CF3, 6,7-Cl2; Y = H, o-F, Cl, p-Me) were prepared by oxidation of II, III, or IV with KMnO4. Thus, I (n = 2, X = 6-Cl, Y = H) was obtained by oxidizing II (same substituents) in dioxane with aqueous KMnO4 at room temperature for 30 min.
IT 36942-76-4
RL: RCT (Reactant); RACT (Reactant or reagent)
(oxidation of)
RN 36942-76-4 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-1-(cyclopropylmethyl)-3,4-dihydro-4-phenyl- (CA INDEX NAME)



IT 33453-19-9P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 33453-19-9 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-1-(cyclopropylmethyl)-4-phenyl- (CA INDEX NAME)

L5 ANSWER 288 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



L5 ANSWER 289 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1973:84440 CAPLUS
DOCUMENT NUMBER: 78:84440
ORIGINAL REFERENCE NO.: 78:13481a,13484a
TITLE: 1-(2,2,2-Trifluoroethyl)-4-phenyl-6-chloro-2(1H)-quinazolinone
INVENTOR(S): Yamamoto, Hisao; Inaba, Shigeho; Yamamoto, Michihiro; Ishizumi, Kikuo; Mori, Kazuo
PATENT ASSIGNEE(S): Sumitomo Chemical Co., Ltd.
SOURCE: Ger. Offen., 11 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2129103	A1	19730104	DE 1971-2129103	19710611
DE 2129103	B2	19740926		
DE 2129103	C3	19750619		

PRIORITY APPLN. INFO.: DE 1971-2129103 A 19710611

GI For diagram(s), see printed CA Issue.
AB Refluxing 5,2-Cl(CF3CH2NH)C6H3COPh with Cl3CCOCl in the presence of NEt3 for 4 hr in Et2O gave 5,2-Cl[CF3CH2N(COCCl3)] C6H3COPh, which on refluxing 10 hr with NH4OAc in EtOH gave the antiphlogistic title compound (I).
IT 37554-40-8P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 37554-40-8 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-4-phenyl-1-(2,2,2-trifluoroethyl)- (CA INDEX NAME)



L5 ANSWER 290 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1973:84283 CAPLUS
DOCUMENT NUMBER: 78:84283
ORIGINAL REFERENCE NO.: 78:13449a,13452a
TITLE: 1-Cyclopropylmethyl-4-phenyl-6-chloro-2(1H)-quinazolinethione
INVENTOR(S): Yamamoto, Michihiro; Ishizumi, Kikuo; Mori, Kazuo; Inaba, Shigeho; Yamamoto, Hisao
PATENT ASSIGNEE(S): Sumitomo Chemical Co., Ltd.
SOURCE: Jpn. Kokai Tokkyo Koho, 4 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 48000584	A	19730106	JP 1971-34849	19710521

PRIORITY APPLN. INFO.: JP 1971-34849 19710521

AB The antiinflammatory and analgesic title compound, was prepared in 3.15 g yield by refluxing a mixture of 3.4 g 1-cyclopropylmethyl-4-phenyl-6-chloro-2(1H)-quinazolinone and 11 g P2S5 in pyridine for 17 hr.
IT 33443-28-6P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 33443-28-6 CAPLUS
CN 2(1H)-Quinazolinethione, 6-chloro-1-(cyclopropylmethyl)-4-phenyl- (CA INDEX NAME)



L5 ANSWER 290 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



IT 33453-19-9
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of, with phosphorus pentasulfide)
RN 33453-19-9 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-1-(cyclopropylmethyl)-4-phenyl- (CA INDEX NAME)

L5 ANSWER 291 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1973:72196 CAPLUS
DOCUMENT NUMBER: 78:72196
ORIGINAL REFERENCE NO.: 78:11481a,11484a
TITLE: Quinazolinone derivatives
INVENTOR(S): Yamamoto, Michihiro; Ishizumi, Kikuo; Mori, Kazuo; Inaba, Shigeho; Yamamoto, Hisao
PATENT ASSIGNEE(S): Sumitomo Chemical Co., Ltd.
SOURCE: Jpn. Kokai Tokkyo Koho, 6 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 47042780	A	19721216	JP 1971-32324	19710513
SE 405728	C	19790405	SE 1972-6152	19720509
SE 405728	B	19781227		
CS 217952	B2	19830225	CS 1972-3173	19720511
NL 172154	B	19830216	NL 1972-6409	19720512
NL 172154	C	19830718		

PRIORITY APPLN. INFO.: JP 1971-32324 A 19710513
JP 1971-34894 A 19710521

GI For diagram(s), see printed CA Issue.
AB 4-Phenyl-6-chloro-2(1H)-quinazolinone (5.13 g) in DMF was heated 30 min at 100° with 62% NaH and further heated 8 hr at 140° with 10 g 2,2,2-trifluoroethyl iodide to give 3.5 g 1-(2,2,2-trifluoroethyl)-4-phenyl-6-chloro-2(1H)-quinazolinone (I) and 2 g 2-(2,2,2-trifluoroethoxy)-4-phenyl-6-chloroquinazoline. 2-(2,2,2-Trifluoroethylamino)-5-chlorobenzophenone was heated with KOCN in AcOH 20 hr at 60° to give I. 2-(2,2,2-Trifluoroethylamino)-5-chlorobenzophenone imine, Et3N, C6H6 and COCl2 was mixed to give I. The products were antiinflammatory, analgesic, and central nervous system depressants.
IT 37554-40-8P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 37554-40-8 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-4-phenyl-1-(2,2,2-trifluoroethyl)- (CA INDEX NAME)



L5 ANSWER 292 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1973:72190 CAPLUS
DOCUMENT NUMBER: 78:72190
ORIGINAL REFERENCE NO.: 78:11481a,11484a
TITLE: 1-(Dialkylaminoethyl)-4-phenyl-2(1H)-quinazolinones
INVENTOR(S): Inaba, Shigeho; Yamamoto, Michihiro; Ishizumi, Kikuo; Takahashi, Kei; Mori, Kazuo; Yamamoto, Hisao
PATENT ASSIGNEE(S): Sumitomo Chemical Co., Ltd.
SOURCE: Jpn. Tokkyo Koho, 3 pp.
CODEN: JAXKAD
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 47045755	B4	19721117	JP 1969-66336	19690821

GI For diagram(s), see printed CA Issue.
AB The title compds. (I) with a central nervous system activity were prepared by N-alkylation of the quinazoline ring. Thus, 4-(o-fluorophenyl)-6-chloro-2(1H)-quinazolinone was added to NaH in DMF and the mixture heated with ClCH2CH2NEt2 at 50° to give crystalline I.HCl (X = Cl, Y = F, R = Et). Also prepared were I (Y = H; X = NO2, R = Et; X = Me, NR2 = pyrrolidino; X = MeO, NR2 = piperidino; X = NO2, NR2 = morpholino).
IT 26313-52-0P 37554-43-1P 40069-71-4P
40069-72-5P 40069-73-6P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 26313-52-0 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-1-[2-(diethylamino)ethyl]-4-(2-fluorophenyl)-, monohydrochloride (9CI) (CA INDEX NAME)



RN 37554-43-1 CAPLUS
CN 2(1H)-Quinazolinone, 1-[2-(4-morpholinyl)ethyl]-6-nitro-4-phenyl- (CA INDEX NAME)

L5 ANSWER 292 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 40069-71-4 CAPLUS
CN 2(1H)-Quinazolinone, 1-[2-(diethylamino)ethyl]-6-nitro-4-phenyl- (CA INDEX NAME)



RN 40069-72-5 CAPLUS
CN 2(1H)-Quinazolinone, 6-methyl-4-phenyl-1-[2-(1-pyrrolidinyl)ethyl]- (CA INDEX NAME)



L5 ANSWER 292 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
RN 40069-73-6 CAPLUS
CN 2(1H)-Quinazolinone, 6-methoxy-4-phenyl-1-[2-(1-piperidinyl)ethyl]- (CA INDEX NAME)



L5 ANSWER 293 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1973:72179 CAPLUS
DOCUMENT NUMBER: 78:72179
ORIGINAL REFERENCE NO.: 78:11481a,11484a
TITLE: 4-Phenyl-6-nitro-2(1H)-quinazolinones
INVENTOR(S): Inaba, Shigeho; Takahashi, Kei; Yamamoto, Michihiro; Mori, Kazuo; Ishizumi, Kikuo; Yamamoto, Hisao
PATENT ASSIGNEE(S): Sumitomo Chemical Co., Ltd.
SOURCE: Ger. Offen., 9 pp. Division of Ger. Offen. 1,935,404 (CA 72;90494r).
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 1966509	A	19721221	DE 1969-1966509	19690711
US 3923803	A	19751202	US 1972-252947	19720512
US 252947	I5	19750128		

PRIORITY APPLN. INFO.: JP 1968-76377 A 19681018
JP 1968-50982 A 19680718
JP 1968-50983 A 19680718
US 1969-840856 A1 19690710

GI For diagram(s), see printed CA Issue.
AB The title compds. (I and II), which were used as antiphlogistic agents, were prepared by reaction of 5,2-O2N(RR1N)C6H3COPh (III, R1 = H) with C13CCOCl, followed by reaction of the isolated intermediates III (R1 = C13CCO) with 5% ethanolic NH3 in Me3COH 2 days at room temperature
IT 26953-46-8P 37555-03-6P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 26953-46-8 CAPLUS
CN 2(1H)-Quinazolinone, 1-methyl-6-nitro-4-phenyl- (CA INDEX NAME)



RN 37555-03-6 CAPLUS
CN 2(1H)-Quinazolinone, 6-nitro-4-phenyl-1-(phenylmethyl)- (CA INDEX NAME)

L5 ANSWER 293 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



L5 ANSWER 294 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1973:72041 CAPLUS
DOCUMENT NUMBER: 78:72041
ORIGINAL REFERENCE NO.: 78:11453a,11456a
TITLE: Novel quinazoline derivatives. I. Synthesis and preliminary pharmacological evaluation of an antiinflammatory agents SL-573
AUTHOR(S): Komatsu, Toshiaki; Awata, Hiroshi; Sakai, Yuriko; Inukai, Toshiya; Yamamoto, Michihiro; Inaba, Shigeho; Yamamoto, Hisao
CORPORATE SOURCE: Takarazuka Res. Lab., Sumitomo Chem. Co., Ltd., Osaka, Japan
SOURCE: Arzneimittel-Forschung (1972), 22(11), 1958-62
CODEN: ARZNAD; ISSN: 0004-4172
DOCUMENT TYPE: Journal
LANGUAGE: English
GI For diagram(s), see printed CA Issue.
AB The title compound (I) was prepared in 84.9% yield by reaction of p-MeOC6H4NH2 with cyclopropanecarbonyl chloride, LiAlH4 reduction, treatment of the resulting N-(cyclopropylmethyl)-p-anisidine with sodium cyanate in AcOH, ring closure of the resulting urea with BzH in PhMe in the presence of p-MeC6H4SO3H, and dehydrogenation. I had antiinflammatory and analgesic properties in rats and low toxicity, and was effective against adjuvant-induced arthritis.
IT 33453-23-5P 36942-71-9P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 33453-23-5 CAPLUS
CN 2(1H)-Quinazolinone, 1-(cyclopropylmethyl)-6-methoxy-4-phenyl- (CA INDEX NAME)



RN 36942-71-9 CAPLUS
CN 2(1H)-Quinazolinone, 1-(cyclopropylmethyl)-3,4-dihydro-6-methoxy-4-phenyl- (CA INDEX NAME)

L5 ANSWER 294 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



L5 ANSWER 295 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1973:62136 CAPLUS
DOCUMENT NUMBER: 78:62136
ORIGINAL REFERENCE NO.: 78:9825a,9828a
TITLE: New tablet disintegrating agent. Crosslinked poly(vinylpyrrolidinone)
AUTHOR(S): Kornblum, Saul S.; Stoopak, Samuel B.
CORPORATE SOURCE: Pharm. Res. Dev. Dep., Sandoz-Wander, Inc., East Hanover, NJ, USA
SOURCE: Journal of Pharmaceutical Sciences (1973), 62(1), 43-9
CODEN: JPMSAE; ISSN: 0022-3549
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Cross-linked poly(vinylpyrrolidone) (I) was studied for its disintegration property in comparison to starch USP and alginic acid. Certain phys. parameters of the disintegrants (maximum moisture sorption, hydration capacity, bulk d., and sp. surface area) were determined for the purpose of differentiating their relative efficiency. A linear relation existed when the maximum moisture sorption was plotted vs. the sp. surface area for each disintegrant. Capillary activity of cross-linked I for H2O appears responsible for its tablet disintegration property. Cross-linked I demonstrated superiority over starch USP and alginic acid in most of the exptl. tablet formulations made by either dry or wet granulation. A quinazolinone derivative was formulated into tablets employing each disintegrant to provide identical disintegration times, and these tablets were submitted to dissoln. rate anal. The dissoln. results showed some differences for those made by direct compression but no variation for wet granulated tablets.
IT 22760-18-5
RL: BIOL (Biological study)
(tablets, solubility of, disintegrants effect on)
RN 22760-18-5 CAPLUS
CN 2(1H)-Quinazolinone, 7-methyl-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)



L5 ANSWER 296 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1973:4278 CAPLUS
DOCUMENT NUMBER: 78:4278
ORIGINAL REFERENCE NO.: 78:719a,722a
TITLE: 1-Methyl-4-phenyl-6-nitro-2(1H)-quinazolinone
INVENTOR(S): Inaba, Shigeho; Yamamoto, Michihiro; Ishiguro, Kikuo; Takahashi, Kei; Mori, Kazuo; Yamamoto, Hisao
PATENT ASSIGNEE(S): Sumitomo Chemical Co., Ltd.
SOURCE: Jpn. Tokkyo Koho, 2 pp.
CODEN: JAXXAD
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 47040057	B4	19721009	JP 1969-88516	19691104

AB The title analgesic and antiinflammatory compound, was prepared in 1.4 g yield
by heating 2.6 g 2-(methylamino)-5-nitrobenzophenone (I) with Et carbamate
and ZnCl2. Using 2-(methylamino)-5-nitrobenzophenoneimine instead of I also gave the same compound
IT 26953-46-8P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 26953-46-8 CAPLUS
CN 2(1H)-Quinazolinone, 1-methyl-6-nitro-4-phenyl- (CA INDEX NAME)



L5 ANSWER 297 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1972:552212 CAPLUS
DOCUMENT NUMBER: 77:152212
ORIGINAL REFERENCE NO.: 77:25031a,25034a
TITLE: Quinazolinone derivatives
INVENTOR(S): Yamamoto, Michihiro; Ishizumi, Kikuo; Mori, Kazuo; Inaba, Shigeho; Yamamoto, Hisao
PATENT ASSIGNEE(S): Sumitomo Chemical Co., Ltd.
SOURCE: Jpn. Kokai Tokkyo Koho, 4 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 47018885	B4	19720918	JP 1971-6400	19710213

AB 1-(Cyclopropylmethyl)-4-phenyl-6-amino-2(1H)-quinazolinone, a central depressant, antiinflammatory, and analgesic, was prepared by reducing 1-(cyclopropylmethyl)-4-phenyl-6-nitro-2(1H)-quinazolinone in AcOH-H2O with Fe powder at 100° for 3 hr.
IT 38634-47-8P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 38634-47-8 CAPLUS
CN 2(1H)-Quinazolinone, 6-amino-1-(cyclopropylmethyl)-4-phenyl- (CA INDEX NAME)



L5 ANSWER 298 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1972:540132 CAPLUS
DOCUMENT NUMBER: 77:140132
ORIGINAL REFERENCE NO.: 77:23049a,23052a
TITLE: Quinazolinone derivatives
INVENTOR(S): Inaba, Shigeho; Yamamoto, Michihiro; Ishiguro, Kikuo; Takahashi, Kei; Mori, Kazuo; Yamamoto, Hisao
PATENT ASSIGNEE(S): Sumitomo Chemical Co., Ltd.
SOURCE: Jpn. Tokkyo Koho, 3 pp.
CODEN: JAXXAD
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 47027105	B4	19720720	JP 1969-89448	19691107

GI For diagram(s), see printed CA Issue.
AB The title compds. (I), central ner-vous system depressant, antiinflammatory agents, and analgesics, were prepared by treating (trichloroacetamido)benzophenones (II) with NH3. E.g., II (R1 = Me, R2 = NO2) in tert-BuOH was kept 2 days with ethanolic NH3 to give I (R1 = Me, R2 = NO2). Among 8 more I similarly prepared were the following (R1 and R2
given): Me, MeSO2; Me, CF3; Et, NO2; PhCH2, NO2; β-phen-ethyl, NO2.
IT 23441-83-0P 23536-81-4P 25508-93-4P
26953-46-8P 37555-03-6P 37677-75-1P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 23441-83-0 CAPLUS
CN 2(1H)-Quinazolinone, 1-methyl-6-(methylsulfonyl)-4-phenyl- (CA INDEX NAME)



RN 23536-81-4 CAPLUS
CN 2(1H)-Quinazolinone, 1-methyl-4-phenyl-6-(trifluoromethyl)- (CA INDEX NAME)



L5 ANSWER 298 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
RN 25508-93-4 CAPLUS
CN 2(1H)-Quinazolinone, 1-ethyl-6-nitro-4-phenyl- (CA INDEX NAME)



RN 26953-46-8 CAPLUS
CN 2(1H)-Quinazolinone, 1-methyl-6-nitro-4-phenyl- (CA INDEX NAME)



RN 37555-03-6 CAPLUS
CN 2(1H)-Quinazolinone, 6-nitro-4-phenyl-1-(phenylmethyl)- (CA INDEX NAME)



RN 37677-75-1 CAPLUS
CN 2(1H)-Quinazolinone, 6-nitro-4-phenyl-1-(2-phenylethyl)- (CA INDEX NAME)



L5 ANSWER 299 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1972:540129 CAPLUS
DOCUMENT NUMBER: 77:140129
ORIGINAL REFERENCE NO.: 77:23049a,23052a
TITLE: 2(1H)-Quinazolinones
INVENTOR(S): Yamamoto, Michihiro; Koshiba, Masao; Inaba, Shigeho; Yamamoto, Hisao
PATENT ASSIGNEE(S): Sumitomo Chemical Co., Ltd.
SOURCE: Ger. Offen., 21 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2159655	A	19720622	DE 1971-2159655	19711201
DE 2159655	B2	19751023		
DE 2159655	C3	19760526		
JP 51018423	B	19760609	JP 1970-109975	19701208
CH 558800	A	19750214	CH 1971-17413	19711130
CA 1002046	A1	19761221	CA 1971-128964	19711130
AU 7136340	A	19730607	AU 1971-36340	19711201
FR 2117301	A5	19720721	FR 1971-43282	19711202
AT 319919	B	19750110	AT 1971-10437	19711203
GB 1353789	A	19740522	GB 1971-56613	19711206
BE 776332	A1	19720404	BE 1971-111353	19711207
NL 7116769	A	19720612	NL 1971-16769	19711207
DD 95841	A5	19730220	DD 1971-159419	19711207
SU 517242	A3	19760605	SU 1971-1723376	19711207
SE 397518	B	19771107	SE 1971-15685	19711207
HU 163952	B	19731128	HU 1971-SU751	19711208
PRIORITY APPLN. INFO.:			JP 1970-109975 A	19701208

OTHER SOURCE(S): MARPAT 77:140129
GI For diagram(s), see printed CA Issue.
AB Sixty-seven title compds. [I, R = Me, Et, CHMe2, allyl, CH2-CH:CMe2, (CH2)3Cl, CH2Ph, CH2C6H4F-o, C3-6 cycloalkyl-methyl, cyclohexyl, CH2OMe, CH2CF3, cyclohexylethyl, OH, OEt, SMe, NEt2, morpholino, R1 = Ph, cyclohexyl, 2-thienyl, 2-pyridyl, o-ClC6H4, m-ClC6H4, o-FC6H4, o-MeC6H4, or p-MeO-C6H4; R2 = H, F, Cl, Br, I, CF3, MeO, MeS, MeSO2, O2N; R3 = H, 7-Me, 7-MeO, 7-Cl, 8-Cl or their HCl salts, useful as antiphlogistics, analgesics, or intermediates for pharmaceuticals, were prepared Thus, 5,2-Cl(NH2)C6H3COPh was treated with NaH and EtI and the product treated with Cl-CO2Et to give 2,5(EtO2CNEt)ClC6H3COPh, which was treated with AcONH4 and KOH to give I (R = Et, R1 = Ph, R2 = R3 = H).
IT 20927-53-1P 22760-16-3P 22760-18-5P
22760-25-4P 22760-60-7P 23441-64-7P
23441-66-9P 23441-71-6P 23441-78-3P
23441-81-8P 23441-83-0P 23441-88-5P
23465-52-3P 23465-55-6P 23536-81-4P
25508-87-6P 25508-91-2P 25508-93-4P
25509-43-7P 25509-45-9P 25509-55-1P
26313-42-8P 26313-51-9P 26772-86-1P
26831-11-8P 26953-46-8P 27247-21-8P

L5 ANSWER 299 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
33443-20-8P 33443-22-0P 33443-23-1P
33443-24-2P 33443-25-3P 33443-26-4P
33443-33-3P 33443-35-5P 33453-19-9P
33453-20-2P 33453-21-3P 33453-22-4P
33453-23-5P 33453-24-6P 33512-31-1P
33890-29-8P 37554-27-1P 37554-35-1P
37554-37-3P 37554-38-4P 37554-39-5P
37554-40-8P 37554-41-9P 37554-43-1P
37554-75-9P 37554-98-6P 37555-00-3P
37555-03-6P 37555-05-8P 37555-09-2P
37555-10-5P 37555-17-2P 37837-21-1P
38018-35-8P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)
RN 20927-53-1 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-1-methyl-4-phenyl- (CA INDEX NAME)



RN 22760-16-3 CAPLUS
CN 2(1H)-Quinazolinone, 6,7-dimethyl-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)



RN 22760-18-5 CAPLUS
CN 2(1H)-Quinazolinone, 7-methyl-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)

L5 ANSWER 299 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 22760-25-4 CAPLUS
CN 2(1H)-Quinazolinone, 7-methoxy-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)



RN 22760-60-7 CAPLUS
CN 2(1H)-Quinazolinone, 1-(1-methylethyl)-6-nitro-4-phenyl- (CA INDEX NAME)



RN 23441-64-7 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-1-ethyl-4-phenyl- (CA INDEX NAME)



RN 23441-66-9 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-4-phenyl-1-(2-propenyl)- (9CI) (CA INDEX NAME)

L5 ANSWER 299 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 23441-71-6 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-1-(3-chloropropyl)-4-phenyl- (CA INDEX NAME)



RN 23441-78-3 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-4-(4-methoxyphenyl)-1-methyl- (CA INDEX NAME)



RN 23441-81-8 CAPLUS
CN 2(1H)-Quinazolinone, 1-methyl-6-(methylthio)-4-phenyl- (CA INDEX NAME)



RN 23441-83-0 CAPLUS

L5 ANSWER 299 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
CN 2(1H)-Quinazolinone, 1-methyl-6-(methylsulfonyl)-4-phenyl- (CA INDEX NAME)



RN 23441-88-5 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-4-(2-chlorophenyl)-1-methyl- (CA INDEX NAME)



RN 23465-52-3 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-4-phenyl-1-(phenylmethyl)- (CA INDEX NAME)



RN 23465-55-6 CAPLUS
CN 2(1H)-Quinazolinone, 4-(3-chlorophenyl)-6-methoxy-1-methyl- (CA INDEX NAME)

L5 ANSWER 299 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 23536-81-4 CAPLUS
CN 2(1H)-Quinazolinone, 1-methyl-4-phenyl-6-(trifluoromethyl)- (CA INDEX NAME)



RN 25508-87-6 CAPLUS
CN 2(1H)-Quinazolinone, 1-ethyl-6,7-dimethyl-4-phenyl- (CA INDEX NAME)



RN 25508-91-2 CAPLUS
CN 2(1H)-Quinazolinone, 1-ethyl-4-phenyl-6-(trifluoromethyl)- (CA INDEX NAME)

L5 ANSWER 299 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 25508-93-4 CAPLUS
CN 2(1H)-Quinazolinone, 1-ethyl-6-nitro-4-phenyl- (CA INDEX NAME)



RN 25509-43-7 CAPLUS
CN 2(1H)-Quinazolinone, 1-ethyl-6-methyl-4-phenyl- (CA INDEX NAME)



RN 25509-45-9 CAPLUS
CN 2(1H)-Quinazolinone, 1-ethyl-6-(methylthio)-4-phenyl- (CA INDEX NAME)



RN 25509-55-1 CAPLUS
CN 2(1H)-Quinazolinone, 1-ethyl-6,7-dimethoxy-4-phenyl- (CA INDEX NAME)

L5 ANSWER 299 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 26313-42-8 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-1-ethyl-4-(2-methylphenyl)- (CA INDEX NAME)



RN 26313-51-9 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-1-(2-ethoxyethyl)-4-(2-fluorophenyl)- (CA INDEX NAME)



RN 26772-86-1 CAPLUS
CN 2(1H)-Quinazolinone, 1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)



L5 ANSWER 299 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
RN 26831-11-8 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)



RN 26953-46-8 CAPLUS
CN 2(1H)-Quinazolinone, 1-methyl-6-nitro-4-phenyl- (CA INDEX NAME)



RN 27247-21-8 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-1-[2-(diethylamino)ethyl]-4-(2-fluorophenyl)-, hydrochloride (9CI) (CA INDEX NAME)



RN 33443-20-8 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-1-(cyclopropylmethyl)-4-(2-fluorophenyl)- (CA INDEX NAME)

L5 ANSWER 299 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 33443-24-2 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-1-(cyclobutylmethyl)-4-phenyl- (CA INDEX NAME)



RN 33443-25-3 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-1-(cyclopentylmethyl)-4-phenyl- (CA INDEX NAME)



RN 33443-26-4 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-1-cyclohexyl-4-phenyl- (CA INDEX NAME)

L5 ANSWER 299 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 33443-22-0 CAPLUS
CN 2(1H)-Quinazolinone, 1-(cyclopropylmethyl)-4-(4-methylphenyl)- (CA INDEX NAME)



RN 33443-23-1 CAPLUS
CN 2(1H)-Quinazolinone, 6,7-dichloro-1-(cyclopropylmethyl)-4-phenyl- (CA INDEX NAME)

L5 ANSWER 299 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 33443-33-3 CAPLUS
CN 2(1H)-Quinazolinone, 1-(cyclopropylmethyl)-4-phenyl-6-(trifluoromethyl)- (CA INDEX NAME)



RN 33443-35-5 CAPLUS
CN 2(1H)-Quinazolinone, 6,8-dichloro-1-(cyclopropylmethyl)-4-phenyl- (CA INDEX NAME)



RN 33453-19-9 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-1-(cyclopropylmethyl)-4-phenyl- (CA INDEX NAME)

L5 ANSWER 299 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 33453-20-2 CAPLUS
CN 2(1H)-Quinazolinone, 6-bromo-1-(cyclopropylmethyl)-4-phenyl- (CA INDEX NAME)



RN 33453-21-3 CAPLUS
CN 2(1H)-Quinazolinone, 1-(cyclopropylmethyl)-6-fluoro-4-phenyl- (CA INDEX NAME)



RN 33453-22-4 CAPLUS
CN 2(1H)-Quinazolinone, 1-(cyclopropylmethyl)-4-phenyl- (CA INDEX NAME)

L5 ANSWER 299 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 33453-23-5 CAPLUS
CN 2(1H)-Quinazolinone, 1-(cyclopropylmethyl)-6-methoxy-4-phenyl- (CA INDEX NAME)



RN 33453-24-6 CAPLUS
CN 2(1H)-Quinazolinone, 1-(cyclopropylmethyl)-6-methyl-4-phenyl- (CA INDEX NAME)



RN 33512-31-1 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-1-(cyclohexylmethyl)-4-phenyl- (CA INDEX NAME)

L5 ANSWER 299 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 33890-29-8 CAPLUS
CN 2(1H)-Quinazolinone, 1-(cyclopropylmethyl)-6-nitro-4-phenyl- (CA INDEX NAME)



RN 37554-27-1 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-1-(cyclopropylmethyl)-4-(4-methoxyphenyl)- (CA INDEX NAME)



RN 37554-35-1 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-1-(methoxymethyl)-4-phenyl- (CA INDEX NAME)

L5 ANSWER 299 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 37554-37-3 CAPLUS
CN 2(1H)-Quinazolinone, 1-(2-ethoxyethyl)-6-nitro-4-phenyl- (CA INDEX NAME)



RN 37554-38-4 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-4-(2-fluorophenyl)-1-(2-hydroxyethyl)- (CA INDEX NAME)



RN 37554-39-5 CAPLUS
CN 2(1H)-Quinazolinone, 1-(2-hydroxyethyl)-6-nitro-4-phenyl- (CA INDEX NAME)



RN 37554-40-8 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-4-phenyl-1-(2,2,2-trifluoroethyl)- (CA

L5 ANSWER 299 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
INDEX NAME)



RN 37554-41-9 CAPLUS
CN 2(1H)-Quinazolinone, 1-[2-(diethylamino)ethyl]-6-nitro-4-phenyl-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 37554-43-1 CAPLUS
CN 2(1H)-Quinazolinone, 1-[2-(4-morpholinyl)ethyl]-6-nitro-4-phenyl- (CA INDEX NAME)



RN 37554-75-9 CAPLUS

L5 ANSWER 299 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
CN 2(1H)-Quinazolinone, 6-iodo-1-methyl-4-phenyl- (CA INDEX NAME)



RN 37554-98-6 CAPLUS
CN 2(1H)-Quinazolinone, 6-nitro-4-phenyl-1-(2-propenyl)- (9CI) (CA INDEX NAME)



RN 37555-00-3 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-1-(3-methyl-2-butenyl)-4-phenyl- (9CI) (CA INDEX NAME)



RN 37555-03-6 CAPLUS
CN 2(1H)-Quinazolinone, 6-nitro-4-phenyl-1-(phenylmethyl)- (CA INDEX NAME)

L5 ANSWER 299 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 37555-05-8 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-1-[(2-fluorophenyl)methyl]-4-phenyl- (CA INDEX NAME)



RN 37555-09-2 CAPLUS
CN 2(1H)-Quinazolinone, 7-chloro-1-(cyclopropylmethyl)-4-phenyl- (CA INDEX NAME)



RN 37555-10-5 CAPLUS
CN 2(1H)-Quinazolinone, 8-chloro-1-(cyclopropylmethyl)-4-phenyl- (CA INDEX NAME)

L5 ANSWER 299 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 37555-17-2 CAPLUS
CN 2(1H)-Quinazolinone, 1-(cyclopropylmethyl)-6-(methylsulfonyl)-4-phenyl- (CA INDEX NAME)



RN 37837-21-1 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-1-(cyclohexylethyl)-4-phenyl- (9CI) (CA INDEX NAME)



RN 38018-35-8 CAPLUS
CN 2(1H)-Quinazolinone, 1-[2-(methylthio)ethyl]-6-nitro-4-phenyl- (CA INDEX NAME)

L5 ANSWER 299 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



L5 ANSWER 300 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1972:540123 CAPLUS
DOCUMENT NUMBER: 77:140123
ORIGINAL REFERENCE NO.: 77:23049a,23052a
TITLE: Quinazolinone derivatives
INVENTOR(S): Yamamoto, Michihiro; Ishizumi, Kikuo; Mori, Kazuo; Koshiba, Masao; Inaba, Shigeho; Yamamoto, Hisao
PATENT ASSIGNEE(S): Sumitomo Chemical Co., Ltd.
SOURCE: Jpn. Kokai Tokkyo Koho, 8 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 47014183	B4	19720804	JP 1971-1477	19710119

GI For diagram(s), see printed CA Issue.
AB The title compds. (I), useful as antiinflammatory and analgesic drugs, were prepared E.g., 3.77 g 2-trichloroacetamido-5-chlorobenzophenone in EtOH was refluxed with EtNH2, HCl, and NEt3 to give 3.9 g α-(trichloro-acetamido)-5-chloro-α-phenylbenzylideneaminoethane (II). II (1.21 g) was reduced with NaBH4 in DMF to give 0.8 g I (R1 = H, R2 = Et, R3 = Cl). Among 8 I similarly prepared were the following (R1, R2, and R3 given): H, HOCH2CH2, Cl; H, Me, Cl; Me, cyclopropylmethyl, Cl; Me, Me2NCH2CH2, H; iso-Pr, Me2N(CH2)3, H.
IT 26772-91-8P 37665-54-6P 37665-55-7P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 26772-91-8 CAPLUS
CN 2(1H)-Quinazolinone, 3-[3-(dimethylamino)propyl]-3,4-dihydro-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)



RN 37665-54-6 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-3-(cyclopropylmethyl)-1-methyl-4-phenyl- (9CI) (CA INDEX NAME)

L5 ANSWER 300 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 37665-55-7 CAPLUS
CN 2(1H)-Quinazolinone, 3-[2-(dimethylamino)ethyl]-3,4-dihydro-1-methyl-4-phenyl- (CA INDEX NAME)



L5 ANSWER 301 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1972:514425 CAPLUS
DOCUMENT NUMBER: 77:114425
ORIGINAL REFERENCE NO.: 77:18857a,18860a
TITLE: Quinazolinone derivatives
INVENTOR(S): Inaba, Shigeho; Yamamoto, Michihiro; Ishiguro, Kikuo; Takahashi, Kei; Mori, Kazuo; Yamamoto, Hisao
PATENT ASSIGNEE(S): Sumitomo Chemical Co., Ltd.
SOURCE: Jpn. Tokkyo Koho, 8 pp.
CODEN: JAXXAD
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 47016305	B4	19720515	JP 1969-61872	19690804

GI For diagram(s), see printed CA Issue.
AB The title compds. (I), antiinflammatory drugs, were prepared by treating trihaloacetamidobenzo-phenones (II) with NH3. E.g., II (R1 = allyl, R2 - H, X = 5-Cl, Z = Cl) in CHCl3-EtOH was let stand with ethanolic NH3 to give I (R1 = allyl, R2 = H, X = 6-Cl). Among 23 I similarly prepared were the following (R1, R2, and X given): CH2CO2Me, H, 6-Cl; 2-EtOCH2CH2, H, 6-Cl; cyclopropylmethyl, H, 6-Me; 2-MeSCH2CH2, H, 6-NO2; cyclopropylmethyl, H, 6,8-Cl2.
IT 23441-66-9P 23465-54-5P 33443-35-5P 33453-24-6P 38018-33-6P 38018-35-8P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 23441-66-9 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-4-phenyl-1-(2-propenyl)- (9CI) (CA INDEX NAME)



RN 23465-54-5 CAPLUS
CN 1(2H)-Quinazolineacetic acid, 6-chloro-2-oxo-4-phenyl-, methyl ester (CA INDEX NAME)

L5 ANSWER 301 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 33443-35-5 CAPLUS
CN 2(1H)-Quinazolinone, 6,8-dichloro-1-(cyclopropylmethyl)-4-phenyl- (CA INDEX NAME)



RN 33453-24-6 CAPLUS
CN 2(1H)-Quinazolinone, 1-(cyclopropylmethyl)-6-methyl-4-phenyl- (CA INDEX NAME)



RN 38018-33-6 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-1-(2-ethoxyethyl)-4-phenyl- (CA INDEX NAME)

L5 ANSWER 301 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 38018-35-8 CAPLUS
CN 2(1H)-Quinazolinone, 1-[2-(methylthio)ethyl]-6-nitro-4-phenyl- (CA INDEX NAME)



L5 ANSWER 302 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1972:514422 CAPLUS
DOCUMENT NUMBER: 77:114422
ORIGINAL REFERENCE NO.: 77:18857a,18860a
TITLE: Synthesis of 2(1H)-quinazolinones
INVENTOR(S): Inaba, Shigeho; Yamamoto, Michihiro; Ishizumi, Kikuo; Mori, Kazuo; Yamamoto, Hisao
PATENT ASSIGNEE(S): Sumitomo Chemical Co., Ltd.
SOURCE: Jpn. Tokkyo Koho, 11 pp.
CODEN: JAXXAD
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 47021429	B4	19720616	JP 1970-6628	19700124

GI For diagram(s), see printed CA Issue.
AB The title compds. (I) with antiinflammatory and analgesic activities were prepared from the indole derivs. (II) by oxidation to give benzophenone derivs. (III), which were hydrolyzed to give 2-aminobenzophenone derivs., followed by condensation with X3CCO2H or X3CCOCl (X = halo) and cyclization using NH3. Thus a suspension of II (R1 = R3 = H, R2 = 5-Cl, R4 = CO2Et) in AcOH was treated with aqueous CrO3 solution at room temperature to give III (R1 = R3 = H, R2 = 4-Cl, R4 = CO2Et). Refluxing III in H2O containing NaOH gave 2-amino-5-chloro-benzophenone (IV). IV in benzene was treated with Cl3CCOCl to give 2-trichloroacetamide-5-chlorobenzophenone (V). A solution of V in MeOH in a sealed vessel was heated with 10% NH3 to give I (R1 = R3 = H, R2 = 5-Cl). Eight I (R1 = H, R2 = 5-Cl, R3 = o-F; R1 = Me, R2 = 5-Cl, R3 = H; R1 = CH2CH2OEt, R2 = 5-Cl, R3 = o-F; R1 = cyclopropylmethyl, R2 = 5-Cl, R3 = H; R1 = cyclopropylmethyl, R2 = 5-Cl, R3 = H) were similarly prepared
IT 23441-90-9P 36977-54-5P 36977-55-6P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 23441-90-9 CAPLUS
CN 2(1H)-Quinazolinone, 5-chloro-1-methyl-4-phenyl- (CA INDEX NAME)



RN 36977-54-5 CAPLUS
CN 2(1H)-Quinazolinone, 5-chloro-1-(2-ethoxyethyl)-4-(2-fluorophenyl)- (CA INDEX NAME)

L5 ANSWER 302 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 36977-55-6 CAPLUS
CN 2(1H)-Quinazolinone, 5-chloro-1-(cyclopropylmethyl)-4-phenyl- (CA INDEX NAME)



L5 ANSWER 303 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1972:501648 CAPLUS
DOCUMENT NUMBER: 77:101648
ORIGINAL REFERENCE NO.: 77:16762h,16763a
TITLE: Quinazolinones
INVENTOR(S): Inaba, Shigeho; Yamamoto, Michihiro; Ishizumi, Kikuo; Mori, Kazuo; Yamamoto, Hisao
PATENT ASSIGNEE(S): Sumitomo Chemical Co., Ltd.
SOURCE: Jpn. Tokkyo Koho, 5 pp.
CODEN: JAXXAD
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 47021430	B4	19720616	JP 1970-14069	19700217

GI For diagram(s), see printed CA Issue.
AB The title compds. (I) with antiinflammatory and analgesic activities were prepared from indole derivs. (II) by oxidation to give benzophenone derivs., followed by hydrolysis to give 2-aminobenzophenone derivs. and cyclization using HCNO or H2NCO2Et. Thus, II (R1 = (CH2)2OEt, R2 = CO2Et, R3 = o-5f) in AcOH was treated with aqueous CrO3 to give Et 2-(zome-fluorobenzoyl)-4chloro-N-(β-ethoxyethyl)oxanilate (III). Refluxing III in EtOH containing NaOH gave 2-(β-ethoxyethylamino)-5-chloro-2'-fluorobenzophenone, which was heated at 190-200° with H2NCO2Et and ZnCl2 to give I (R1 = (CH2)2OEt, R3 = o-F). Similarly, I (R1 = cyclopropylmethyl, R3 = H) was prepared from II (R2 = CN and CO2Et, resp.).
IT 33453-22-4P 37671-66-2P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 33453-22-4 CAPLUS
CN 2(1H)-Quinazolinone, 1-(cyclopropylmethyl)-4-phenyl- (CA INDEX NAME)



RN 37671-66-2 CAPLUS
CN 2(1H)-Quinazolinone, 1-(2-ethoxyethyl)-4-(2-fluorophenyl)- (CA INDEX NAME)

L5 ANSWER 303 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



L5 ANSWER 304 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1972:462021 CAPLUS
DOCUMENT NUMBER: 77:62021
ORIGINAL REFERENCE NO.: 77:10267a,10270a
TITLE: 2(1H)-Quinazolinones
INVENTOR(S): Ott, Hans
PATENT ASSIGNEE(S): Sandoz Ltd.
SOURCE: Patentschrift (Switz.), 4 pp.
CODEN: SWXXAS
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CH 520692	A	19720331	CH 1969-520692	19691031
PRIORITY APPLN. INFO.:			CH 1972-1879 A	19691031

GI For diagram(s), see printed CA Issue.
AB Isopropylamino-4-methyl-5-nitrobenzophenone, prepared by refluxing the corresponding 2-chloro compound with H2NCHMe2 in EtOH containing Cu and Cu chloride, was treated with NH4SCN in HOAc to give the title compound (I, X = S, R = O2N, R1 = Me), which was refluxed in dioxane and 25% NaOH to give I (X = O, R = O2N, R1 = Me). Ten addnl. I [X = O,S; R = H, Me2N, (Me2CH)2N, Et(Me2CH)N, morpholino; R1 = H, Me, Cl, Me2N, morpholino] were prepared similarly.
IT 28340-53-6P 28340-54-7P 28340-57-0P 28340-64-9P 28340-65-0P 28340-69-4P 28340-74-1P 28340-77-4P 28340-79-6P 37133-54-3P 37133-60-1P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 28340-53-6 CAPLUS
CN 2(1H)-Quinazolinone, 7-methyl-1-(1-methylethyl)-6-nitro-4-phenyl- (CA INDEX NAME)



RN 28340-54-7 CAPLUS
CN 2(1H)-Quinazolinone, 6-(dimethylamino)-7-methyl-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)

L5 ANSWER 304 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 28340-57-0 CAPLUS
CN 2(1H)-Quinazolinone, 6-(dimethylamino)-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)



RN 28340-64-9 CAPLUS
CN 2(1H)-Quinazolinone, 7-(dimethylamino)-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)



RN 28340-65-0 CAPLUS
CN 2(1H)-Quinazolinone, 6-[ethyl(1-methylethyl)amino]-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)



RN 28340-69-4 CAPLUS
CN 2(1H)-Quinazolinone, 7-chloro-6-(dimethylamino)-1-(1-methylethyl)-4-phenyl-

L5 ANSWER 304 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
(CA INDEX NAME)



RN 28340-74-1 CAPLUS
CN 2(1H)-Quinazolinone, 1-(1-methylethyl)-7-(4-morpholinyl)-4-phenyl- (CA INDEX NAME)



RN 28340-77-4 CAPLUS
CN 2(1H)-Quinazolinone, 1-(1-methylethyl)-6-(4-morpholinyl)-4-phenyl- (CA INDEX NAME)



RN 28340-79-6 CAPLUS
CN 2(1H)-Quinazolinone,
7-methyl-1-(1-methylethyl)-6-(4-morpholinyl)-4-phenyl-
(CA INDEX NAME)

L5 ANSWER 304 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 37133-54-3 CAPLUS
CN 2(1H)-Quinazolinone, 6-[bis(1-methylethyl)amino]-1-(1-methylethyl)-4-phenyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 37133-60-1 CAPLUS
CN 2(1H)-Quinazolinethione, 7-methyl-1-(1-methylethyl)-6-nitro-4-phenyl- (CA
INDEX NAME)



L5 ANSWER 305 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1972:448498 CAPLUS
DOCUMENT NUMBER: 77:48498
ORIGINAL REFERENCE NO.: 77:8050h,8051a
TITLE: 2(1H)-Quinazolinones
INVENTOR(S): Ott, Hans
PATENT ASSIGNEE(S): Sandoz Ltd.
SOURCE: Patentschrift (Switz.), 5 pp.
CODEN: SWXXAS
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
CH 520689	A	19720331	CH 1969-520689		19691031
PRIORITY APPLN. INFO.:			CH 1972-1876	A	19691031

GI For diagram(s), see printed CA Issue.
AB 4,2-Me(Me2CHNH)C6H4COPh, prepared from 4,2-Me(H2N)C6H3COPh and ICHMe2, was
treated with urethan at 190° for 1.5 hr to give quinazolinone (I, R = H, R1 = Me), which was nitrated with KNO3-H2SO4 at 0-5° for 10 min to give I (R = O2N, R1 = Me) (II). Stirring II in MeOH containing Raney
Ni and HCHO gave I (R = Me2N, R1 = Me). Nine addnl. I [R = Me2N, (Me2CH)2N, Et(Me2CH)N, H, morpholino; R1 = Me, H, NMe2, Cl, morpholino] were prepared analogously.
IT 22760-18-5P 28340-53-6P 28340-54-7P
28340-57-0P 28340-61-6P 28340-64-9P
28340-65-0P 28340-69-4P 28340-74-1P
28340-77-4P 28340-79-6P 37556-28-8P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 22760-18-5 CAPLUS
CN 2(1H)-Quinazolinone, 7-methyl-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)



RN 28340-53-6 CAPLUS
CN 2(1H)-Quinazolinone, 7-methyl-1-(1-methylethyl)-6-nitro-4-phenyl- (CA INDEX NAME)

L5 ANSWER 305 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 28340-54-7 CAPLUS
CN 2(1H)-Quinazolinone,
6-(dimethylamino)-7-methyl-1-(1-methylethyl)-4-phenyl-
(CA INDEX NAME)



RN 28340-57-0 CAPLUS
CN 2(1H)-Quinazolinone, 6-(dimethylamino)-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)



RN 28340-61-6 CAPLUS
CN 2(1H)-Quinazolinone, 6-[bis(1-methylethyl)amino]-1-(1-methylethyl)-4-phenyl-, hydrochloride (9CI) (CA INDEX NAME)

L5 ANSWER 305 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



●x HCl

RN 28340-64-9 CAPLUS
CN 2(1H)-Quinazolinone, 7-(dimethylamino)-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)



RN 28340-65-0 CAPLUS
CN 2(1H)-Quinazolinone, 6-[ethyl(1-methylethyl)amino]-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)



RN 28340-69-4 CAPLUS
CN 2(1H)-Quinazolinone,
7-chloro-6-(dimethylamino)-1-(1-methylethyl)-4-phenyl-
(CA INDEX NAME)

L5 ANSWER 305 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 37556-28-8 CAPLUS
CN 2(1H)-Quinazolinone, 6-(dimethylamino)-3,4-dihydro-7-methyl-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)



L5 ANSWER 305 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 28340-74-1 CAPLUS
CN 2(1H)-Quinazolinone, 1-(1-methylethyl)-7-(4-morpholinyl)-4-phenyl- (CA INDEX NAME)



RN 28340-77-4 CAPLUS
CN 2(1H)-Quinazolinone, 1-(1-methylethyl)-6-(4-morpholinyl)-4-phenyl- (CA INDEX NAME)



RN 28340-79-6 CAPLUS
CN 2(1H)-Quinazolinone,
7-methyl-1-(1-methylethyl)-6-(4-morpholinyl)-4-phenyl-
(CA INDEX NAME)

L5 ANSWER 306 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER:	1972:439252 CAPLUS
DOCUMENT NUMBER:	77:39252
ORIGINAL REFERENCE NO.:	77:6495a,6498a
TITLE:	Improving drug absorption in body fluids
INVENTOR(S):	Melliger, Guido W.
PATENT ASSIGNEE(S):	Sandoz Ltd.
SOURCE:	Ger. Offen., 17 pp. CODEN: GWXXBX
DOCUMENT TYPE:	Patent
LANGUAGE:	German
FAMILY ACC. NUM. COUNT:	1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2145325	A	19720323	DE 1971-2145325	19710910
NL 7112288	A	19720320	NL 1971-12288	19710907
BE 772594	A1	19720314	BE 1971-108156	19710914
FR 2106553	A5	19720505	FR 1971-33150	19710915
AU 7133517	A	19730322	AU 1971-33517	19710915
PRIORITY APPLN. INFO.:			US 1970-72829 A	19700916

AB The absorption of drugs which are insol. or practically insol. in body fluids, such as griseofulvin, ergot alkaloid, or phenylquinoxaline drugs, is improved by dissolving the drugs in urethane (I), adding poly(vinylpyrrolidone) (II), preferably in the ratio 2:3-3:2 I:II, and heating the solution to 30-120° until all I is evaporated If required the solution is absorbed on a suitable carrier, such as lactose before I is evaporated

IT 22760-18-5
RL: BIOL (Biological study)
(absorption of, by digestive tract, poly(vinylpyrrolidone) and urethane for promotion of)

RN 22760-18-5 CAPLUS
CN 2(1H)-Quinazolinone, 7-methyl-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)



L5 ANSWER 307 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1972:405515 CAPLUS
DOCUMENT NUMBER: 77:5515
ORIGINAL REFERENCE NO.: 77:971a,974a
TITLE: 3,4-Dihydro-2(1H)-quinazolinones
INVENTOR(S): Inaba, Shigeho; Yamamoto, Michihiro; Ishizumi, Kikuo; Mori, Kazuo; Koshiba, Masao; Yamamoto, Hisao
PATENT ASSIGNEE(S): Sumitomo Chemical Co., Ltd.
SOURCE: Ger. Offen., 21 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 6
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2134118	A	19720120	DE 1971-2134118	19710708
DE 2134118	B2	19740815		
DE 2134118	C3	19750410		
JP 48021951	B	19730702	JP 1970-61618	19700713
JP 48021954	B	19730702	JP 1970-98107	19701105
JP 48034598	B	19731022	JP 1970-118332	19701223
SU 475774	A3	19750630	SU 1971-1754058	19710612
DK 129348	B	19740930	DK 1971-3328	19710706
ZA 7104514	A	19720329	ZA 1971-4514	19710708
US 3829420	A	19740813	US 1971-160947	19710708
FR 2100890	A5	19720324	FR 1971-25249	19710709
FR 2100890	B1	19750606		
GB 1341247	A	19731219	GB 1971-32379	19710709
BE 769858	A1	19711116	BE 1971-105783	19710712
AU 7131101	A	19730118	AU 1971-31101	19710712
AT 310173	B	19730925	AT 1971-6053	19710712
AT 310177	B	19730925	AT 1972-8983	19710712
AT 310178	B	19730925	AT 1972-8984	19710712
SU 400095	A3	19731003	SU 1971-1686631	19710712
SU 439980	A3	19740815	SU 1971-1754056	19710712
ES 393186	A1	19740901	ES 1971-393186	19710712
CA 956958	A1	19741029	CA 1971-117977	19710712
CH 560693	A5	19750415	CH 1971-10229	19710712
CH 563995	A5	19750715	CH 1975-358	19710712
CH 564539	A5	19750731	CH 1975-357	19710712
SE 380019	B	19751027	SE 1971-9009	19710712
CS 181665	B2	19780331	CS 1971-5097	19710712
CS 181693	B2	19780331	CS 1975-7829	19710712
NL 7109637	A	19720117	NL 1971-9637	19710713
NL 169589	B	19820301		
NL 169589	C	19820802		
FR 2118932	A5	19720804	FR 1971-45497	19711217
FR 2118932	B1	19751010		
ES 419267	A1	19761101	ES 1973-419267	19731002
ES 419266	A1	19770101	ES 1973-419266	19731002

PRIORITY APPLN. INFO.: JP 1970-61618 A 19700713
JP 1970-96306 A 19701030

L5 ANSWER 307 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
JP 1970-98107 A 19701105
JP 1970-118332 A 19701223

GI For diagram(s), see printed CA Issue.
AB The title compds. (I, R = cyclopropyl, CF3, CH2NEt2, or CH2OEt; R1 = Ph, o-FC6H4, cyclohexyl, 2-pyridyl, or 2-thienyl; R2 = Cl, F, Me, MeO, NO2, or CF3), useful as antiphlogistic and analgesic agents or as intermediates for pharmaceuticals, were prepared by reduction of 2(1H)-quinazolinones. They could also be prepared by various other reactions, e.g. by condensation of RCH2(p-R2C6H4)NCONH2 with R1CHO. Thus, 6.22 g 1-(cyclopropylmethyl)-4-phenyl-6-chloro-2(1H)-quinazolinone in iso-PrOH was treated with NaBH4 for 2 hr at room temperature to give 6.25 g I (R = cyclopropyl, R1 = Ph, R2 = Cl). Similarly prepared were 12 addnl. I, e.g. (R-R2 given): CH2OEt, o-FC6H4, Cl; CF3, Ph, Cl; cyclopropyl, 2-thienyl, Cl; cyclopropyl, Ph,NO2.
IT 36942-66-2P 36942-67-3P 36942-68-4P
36942-69-5P 36942-70-8P 36942-71-9P
36942-72-0P 36942-73-1P 36942-74-2P
36942-76-4P 36943-01-8P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 36942-66-2 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-1-[2-(diethylamino)ethyl]-4-(2-fluorophenyl)-3,4-dihydro-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 36942-67-3 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-1-(2-ethoxyethyl)-4-(2-fluorophenyl)-3,4-dihydro- (CA INDEX NAME)

L5 ANSWER 307 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 36942-68-4 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-1-(2-ethoxyethyl)-3,4-dihydro-4-phenyl- (CA INDEX NAME)



RN 36942-69-5 CAPLUS
CN 2(1H)-Quinazolinone, 1-(cyclopropylmethyl)-3,4-dihydro-6-nitro-4-phenyl- (CA INDEX NAME)



RN 36942-70-8 CAPLUS
CN 2(1H)-Quinazolinone, 1-(cyclopropylmethyl)-3,4-dihydro-4-phenyl-6-(trifluoromethyl)- (CA INDEX NAME)

L5 ANSWER 307 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 36942-71-9 CAPLUS
CN 2(1H)-Quinazolinone, 1-(cyclopropylmethyl)-3,4-dihydro-6-methoxy-4-phenyl- (CA INDEX NAME)



RN 36942-72-0 CAPLUS
CN 2(1H)-Quinazolinone, 1-(cyclopropylmethyl)-3,4-dihydro-6-methyl-4-phenyl- (CA INDEX NAME)



RN 36942-73-1 CAPLUS
CN 2(1H)-Quinazolinone, 6,7-dichloro-1-(cyclopropylmethyl)-3,4-dihydro-4-phenyl- (CA INDEX NAME)

L5 ANSWER 307 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 36942-74-2 CAPLUS
CN 2(1H)-Quinazolinone,
1-(cyclopropylmethyl)-6-fluoro-3,4-dihydro-4-phenyl-
(CA INDEX NAME)



RN 36942-76-4 CAPLUS
CN 2(1H)-Quinazolinone,
6-chloro-1-(cyclopropylmethyl)-3,4-dihydro-4-phenyl-
(CA INDEX NAME)



RN 36943-01-8 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-3,4-dihydro-4-phenyl-1-(2,2,2-
trifluoroethyl)- (CA INDEX NAME)

L5 ANSWER 307 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



L5 ANSWER 308 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1972:127009 CAPLUS
DOCUMENT NUMBER: 76:127009
ORIGINAL REFERENCE NO.: 76:20569a,20572a
TITLE: Antiinflammatory morpholino-substituted 1-substituted-2(1H)-quinazolinones
INVENTOR(S): Ott, Hans
PATENT ASSIGNEE(S): Sandoz-Wander, Inc.
SOURCE: U.S., 5 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 3642791	A	19720215	US 1969-849863	19690813
US 3819625	A	19740625	US 1971-177154	19710901
US 3876640	A	19750408	US 1974-458545	19740408
PRIORITY APPLN. INFO.:			US 1969-849863 A3	19690813
			US 1971-177154 A3	19710901

GI For diagram(s), see printed CA Issue.
AB The title compds. [I, R = morpholino, R1 = H (II); R = H, R1 = morpholino;
and R = Me, R1 = morpholino] were antiinflammatants and analgesics. Thus,
III (R = PhC:NH, R1 = NHPr-iso) (IV) and Et3N was added to COCl2 in C6H6 at room temperature to give II, which was converted to the HCl salt. IV was
prepared from H2NC6H3(Cl)-NO2-4,3 by heating with [Br(CH2)2]O at 160° to give III (R = Cl, R1 = NO2); subsequent cyanation, reduction, and N-isopropylation to III (R = CN, R1 = NHPr-iso) (V); and treatment of V with PhLi.
IT 22760-18-5P 22760-60-7P 25509-39-1P 28340-53-6P 28340-74-1P 28340-75-2P 28340-77-4P 28340-78-5P 28340-79-6P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 22760-18-5 CAPLUS
CN 2(1H)-Quinazolinone, 7-methyl-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)



RN 22760-60-7 CAPLUS
CN 2(1H)-Quinazolinone, 1-(1-methylethyl)-6-nitro-4-phenyl- (CA INDEX NAME)

L5 ANSWER 308 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 25509-39-1 CAPLUS
CN 2(1H)-Quinazolinone, 6-amino-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)



RN 28340-53-6 CAPLUS
CN 2(1H)-Quinazolinone, 7-methyl-1-(1-methylethyl)-6-nitro-4-phenyl- (CA INDEX NAME)



RN 28340-74-1 CAPLUS
CN 2(1H)-Quinazolinone, 1-(1-methylethyl)-7-(4-morpholinyl)-4-phenyl- (CA INDEX NAME)



RN 28340-75-2 CAPLUS
CN 2(1H)-Quinazolinone, 1-(1-methylethyl)-7-(4-morpholinyl)-4-phenyl-, hydrochloride (9CI) (CA INDEX NAME)

L5 ANSWER 308 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



●x HCl

RN 28340-77-4 CAPLUS
CN 2(1H)-Quinazolinone, 1-(1-methylethyl)-6-(4-morpholinyl)-4-phenyl- (CA INDEX NAME)



RN 28340-78-5 CAPLUS
CN 2(1H)-Quinazolinone, 6-amino-7-methyl-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)



RN 28340-79-6 CAPLUS
CN 2(1H)-Quinazolinone, 7-methyl-1-(1-methylethyl)-6-(4-morpholinyl)-4-phenyl- (CA INDEX NAME)

L5 ANSWER 308 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



L5 ANSWER 309 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1972:34287 CAPLUS
DOCUMENT NUMBER: 76:34287
ORIGINAL REFERENCE NO.: 76:5555a,5558a
TITLE: New quinazoline derivatives
INVENTOR(S): Maruyama, Isamu; Yamamoto, Hisao
PATENT ASSIGNEE(S): Sumitomo Chemical Co., Ltd.
SOURCE: Jpn. Tokkyo Koho, 3 pp.
CODEN: JAXXAD
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 46039707	B4	19711122	JP	19690214

GI For diagram(s), see printed CA Issue.
AB I, useful as an antiinflammatory drug, was manufactured by reducing II. E.g., II (R1=Me, R2=6-Cl) in AcOH was hydrogenated over PtO to give I (R1=Me, R2=6-Cl). Similarly prepared was I (R1=iso-Pr, R2=7-Me).
IT 26772-90-7P 26772-95-2P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 26772-90-7 CAPLUS
CN 2(1H)-Quinazolinone, 3,4-dihydro-7-methyl-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)



RN 26772-95-2 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-3,4-dihydro-1-methyl-4-phenyl- (CA INDEX NAME)



L5 ANSWER 310 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1972:34286 CAPLUS
DOCUMENT NUMBER: 76:34286
ORIGINAL REFERENCE NO.: 76:5555a,5558a
TITLE: 1-Methyl-4-phenyl-6-chloro-1H-3,4-dihydroquinazolin-2-one-3-acetic acid
INVENTOR(S): Maruyama, Isamu; Yamamoto, Hisao
PATENT ASSIGNEE(S): Sumitomo Chemical Co., Ltd.
SOURCE: Jpn. Tokkyo Koho, 3 pp.
CODEN: JAXXAD
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 46039706	B4	19711122	JP	19690213

GI For diagram(s), see printed CA Issue.
AB The title product (I), useful as an antiinflammatory drug, was manufactured by heating 1-methyl-4-phenyl-6-chloro-3,4-dihydroquinazolin-2-(1H)-one in PhMe-DMF with NaH and BrCH2CO2Et followed by hydrolyzing with KOH.
IT 34954-53-5P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 34954-53-5 CAPLUS
CN 3(2H)-Quinazolineacetic acid, 6-chloro-1,4-dihydro-1-methyl-2-oxo-4-phenyl- (CA INDEX NAME)



L5 ANSWER 311 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1971:540877 CAPLUS
DOCUMENT NUMBER: 75:140877
ORIGINAL REFERENCE NO.: 75:22233a,22236a
TITLE: 1-Alkylquinazolinone derivatives
INVENTOR(S): Inaba, Shigeho; Yamamoto, Michihiro; Ishiguro, Kikuo; Takahashi, Kei; Mori, Kazuo; Yamamoto, Hisao
PATENT ASSIGNEE(S): Sumitomo Chemical Co., Ltd.
SOURCE: Jpn. Tokkyo Koho, 3 pp.
CODEN: JAXXAD
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 46029858	B4	19710831	JP	19681210

AB 1-Methyl-4-phenyl-6-nitro-2(1H)quinazolinone, useful as an antiinflammatory drug, was manufactured by methylating 4-phenyl-6-nitro-2(1H)-quinazolinone in DMF with MeI.
IT 26953-46-8P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 26953-46-8 CAPLUS
CN 2(1H)-Quinazolinone, 1-methyl-6-nitro-4-phenyl- (CA INDEX NAME)



L5 ANSWER 312 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1971:529828 CAPLUS
DOCUMENT NUMBER: 75:129828
ORIGINAL REFERENCE NO.: 75:20503a,20506a
TITLE: Antiinflammatory and analgesic quinazolinone derivatives
INVENTOR(S): Inaba, Shigeho; Yamamoto, Michihiro; Ishizumi, Kikuo; Mori, Kazuo; Yamamoto, Hisao
PATENT ASSIGNEE(S): Sumitomo Chemical Co., Ltd.
SOURCE: S. African, 50 pp.
CODEN: SFXXAB
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
ZA 7005270	A	19710428	ZA 1970-5270	19700730
FR 2060075	A1	19710611	FR 1970-28417	19700731
AT 301558	B	19720911	AT 1971-8857	19700731
SU 419034	A3	19740305	SU 1970-1677064	19700731
CS 177097	B2	19770729	CS 1970-4718	19700803
US 3767797	A	19731023	US 1972-297294	19721013
PRIORITY APPLN. INFO.:			JP 1969-61222	A 19690802
			JP 1969-61872	A 19690804
			JP 1969-70453	A 19690904
			JP 1969-102810	A 19691208
			JP 1969-98836	A 19691208
			JP 1969-99196	A 19691208
			JP 1970-6531	A 19700123
			JP 1970-6628	A 19700124
			JP 1970-14069	A 19700217
			US 1970-59337	A3 19700729

GI For diagram(s), see printed CA Issue.
AB 2-(Cyclopropylmethylamino)-5-chlorobenzophenone in AcOH is treated with KOCN to prepare 1-(cyclopropylmethyl)-4-phenyl-6-chloro-2(1H)-quinazolinone (I) which has 6 times the antiinflammatory activity of phenylbutazone and is much less toxic. 1-(Cyclopropylmethyl)-4-phenyl-6-chloro-2-(1H)-quinazolinethione is prepared similarly but with NaSCN instead of KOCN.
A DMF solution of 4-phenyl-6-chloro-2(1H)-quinazolinone is added to NaH in DMF and then treated with cyclopropylmethyl bromide to give a 2:1 mixture of I

L5 ANSWER 312 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
and 2-(cyclopropylmethoxy)-4-phenyl-6-chloroquinazoline. Also prepd. are the 2(1H)-quinazolinones II with R = cyclopropylmethyl, cyclobutylmethyl, cyclopentylmethyl, cyclohexylmethyl, cyclohexyl, or 2-cyclohexylethyl, R1 = Ph, o-FC6H4, o-ClC6H4, p-tolyl, or 2-pyridyl, R2 = H, Cl, Br, F, Me, CF3, MeO, or NO2, and R3 = H or Cl and the quinazolines III with n = 1,2,3, or 4 and with R1, R2, and R3 as described for II.
IT 33443-20-8P 33443-21-9P 33443-22-0P
33443-23-1P 33443-24-2P 33443-25-3P
33443-26-4P 33443-28-6P 33443-30-0P
33443-33-3P 33453-19-9P 33453-20-2P
33453-21-3P 33453-22-4P 33453-23-5P
33453-24-6P 33512-31-1P 33890-29-8P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 33443-20-8 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-1-(cyclopropylmethyl)-4-(2-fluorophenyl)- (CA INDEX NAME)



RN 33443-21-9 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-4-(o-chlorophenyl)-1-(cyclopropylmethyl)- (8CI) (CA INDEX NAME)



RN 33443-22-0 CAPLUS
CN 2(1H)-Quinazolinone, 1-(cyclopropylmethyl)-4-(4-methylphenyl)- (CA INDEX NAME)

L5 ANSWER 312 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 33443-23-1 CAPLUS
CN 2(1H)-Quinazolinone, 6,7-dichloro-1-(cyclopropylmethyl)-4-phenyl- (CA INDEX NAME)



RN 33443-24-2 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-1-(cyclobutylmethyl)-4-phenyl- (CA INDEX NAME)



RN 33443-25-3 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-1-(cyclopentylmethyl)-4-phenyl- (CA INDEX NAME)

L5 ANSWER 312 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 33443-26-4 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-1-cyclohexyl-4-phenyl- (CA INDEX NAME)



RN 33443-28-6 CAPLUS
CN 2(1H)-Quinazolinethione, 6-chloro-1-(cyclopropylmethyl)-4-phenyl- (CA INDEX NAME)



RN 33443-30-0 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-1-(2-cyclohexylethyl)-4-phenyl- (CA INDEX NAME)

L5 ANSWER 312 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 33443-33-3 CAPLUS
CN 2(1H)-Quinazolinone, 1-(cyclopropylmethyl)-4-phenyl-6-(trifluoromethyl)- (CA INDEX NAME)



RN 33453-19-9 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-1-(cyclopropylmethyl)-4-phenyl- (CA INDEX NAME)



RN 33453-20-2 CAPLUS

L5 ANSWER 312 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
CN 2(1H)-Quinazolinone, 6-bromo-1-(cyclopropylmethyl)-4-phenyl- (CA INDEX NAME)



RN 33453-21-3 CAPLUS
CN 2(1H)-Quinazolinone, 1-(cyclopropylmethyl)-6-fluoro-4-phenyl- (CA INDEX NAME)



RN 33453-22-4 CAPLUS
CN 2(1H)-Quinazolinone, 1-(cyclopropylmethyl)-4-phenyl- (CA INDEX NAME)



RN 33453-23-5 CAPLUS
CN 2(1H)-Quinazolinone, 1-(cyclopropylmethyl)-6-methoxy-4-phenyl- (CA INDEX NAME)

L5 ANSWER 312 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 33453-24-6 CAPLUS
CN 2(1H)-Quinazolinone, 1-(cyclopropylmethyl)-6-methyl-4-phenyl- (CA INDEX NAME)



RN 33512-31-1 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-1-(cyclohexylmethyl)-4-phenyl- (CA INDEX NAME)



RN 33890-29-8 CAPLUS
CN 2(1H)-Quinazolinone, 1-(cyclopropylmethyl)-6-nitro-4-phenyl- (CA INDEX NAME)

L5 ANSWER 312 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



L5 ANSWER 313 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1971:436104 CAPLUS
DOCUMENT NUMBER: 75:36104
ORIGINAL REFERENCE NO.: 75:5713a,5716a
TITLE: Heterocyclic compounds
INVENTOR(S): Masuda, Toru; Fujii, Shoichiro; Naito, Kenzo
PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd.
SOURCE: Jpn. Tokkyo Koho, 4 pp.
CODEN: JAXXAD
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 46015500	B4	19710426	JP	19681115

GI For diagram(s), see printed CA Issue.

AB I, useful as sedatives, are manufactured 7-Chloro-1,2-dihydro-1-methylaminocarbonyl-5-phenyl-3H-1,4-benzodiazepine (3.5 g) in 50 ml AcOH is kept 20 hr with 1 ml H2O to give I.AcOH (R1 = H, R2 = Me, R3 = Ph, R4 = Cl, X = O), m. 170-2° (decomposition); the free base m. 179-81° (decomposition) (MeOH). Similarly prepared are I (X, R1, R2, R3, R4, and m.p. [decomposition] given): O, H, Ph, Ph, Cl, 118-25°; O, H, Me, Ph, NO2, 200-1°; O, H, Me2N(CH2)3, Ph, Cl, 119-22°; S, H, Me, Ph, Cl, 179-81°; O, H, Et, Ph, Cl, 188-90°; O, H, Pr, Ph, Cl, - (monoacetate m. 101-5°); O, H, iso-Pr, Ph, Cl, - (triacetate m. 136-7°); O, H, iso-Bu, OH, Cl, - (monoacetate m. 153-5°); O, H, pentyl, Ph, NO2, - (monoacetate m. 162-3°); O, H, pentyl, p-tolyl, NO2, - (monoacetate m. 158-60°); O, Me, Me, Ph, NO2, - (nonahydrate m. 105-8°); O, H, cyanoethyl, Ph, Cl, - (triacetate m. 158-60°); O, H, hexyl, Ph, Cl, - (monoacetate m. 153-4°); O, H, PhCH2, Ph, Cl, 190-3°; O, H, CH2CO2Et, Ph, Cl, - (monoacetate m. 148-9°).

IT 32558-23-9P 32558-24-0P 32558-25-1P
32558-26-2P 32558-27-3P 32558-28-4P
32558-29-5P 32558-30-8P 32558-31-9P
32558-32-0P 32558-33-1P 32558-34-2P
32558-35-3P 32558-36-4P 32558-37-5P
32558-38-6P 32689-12-6P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 32558-23-9 CAPLUS
CN 2(1H)-Quinazolinone, 1-(2-aminoethyl)-6-chloro-3,4-dihydro-4-hydroxy-3-methyl-4-phenyl-, monoacetate (salt) (8CI) (CA INDEX NAME)

CM 1

CRN 32558-24-0
CMF C17 H18 Cl N3 O2

L5 ANSWER 313 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



CM 2

CRN 64-19-7
CMF C2 H4 O2

RN 32558-24-0 CAPLUS
CN 2(1H)-Quinazolinone, 1-(2-aminoethyl)-6-chloro-3,4-dihydro-4-hydroxy-3-methyl-4-phenyl- (CA INDEX NAME)



RN 32558-25-1 CAPLUS
CN 2(1H)-Quinazolinone, 1-(2-aminoethyl)-6-chloro-3,4-dihydro-4-hydroxy-3,4-diphenyl- (CA INDEX NAME)



RN 32558-26-2 CAPLUS
CN 2(1H)-Quinazolinone, 1-(2-aminoethyl)-3,4-dihydro-4-hydroxy-3-methyl-6-nitro-4-phenyl- (CA INDEX NAME)

L5 ANSWER 313 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 32558-27-3 CAPLUS
CN 2(1H)-Quinazolinone, 1-(2-aminoethyl)-6-chloro-3-[3-(dimethylamino)propyl]-3,4-dihydro-4-hydroxy-4-phenyl- (CA INDEX NAME)



RN 32558-28-4 CAPLUS
CN 2(1H)-Quinazolinethione, 1-(2-aminoethyl)-6-chloro-3,4-dihydro-4-hydroxy-3-methyl-4-phenyl- (CA INDEX NAME)



RN 32558-29-5 CAPLUS
CN 2(1H)-Quinazolinone, 1-(2-aminoethyl)-6-chloro-3-ethyl-3,4-dihydro-4-hydroxy-4-phenyl- (CA INDEX NAME)



RN 32558-30-8 CAPLUS

L5 ANSWER 313 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
CN 2(1H)-Quinazolinone, 1-(2-aminoethyl)-6-chloro-3,4-dihydro-4-hydroxy-4-phenyl-3-propyl-, monoacetate (salt) (8CI) (CA INDEX NAME)

CM 1

CRN 47416-36-4
CMF C19 H22 Cl N3 O2



CM 2

CRN 64-19-7
CMF C2 H4 O2

RN 32558-31-9 CAPLUS
CN 2(1H)-Quinazolinone, 1-(2-aminoethyl)-6-chloro-3,4-dihydro-4-hydroxy-3-isopropyl-4-phenyl-, triacetate (salt) (8CI) (CA INDEX NAME)

CM 1

CRN 47416-34-2
CMF C19 H22 Cl N3 O2



CM 2

CRN 64-19-7

L5 ANSWER 313 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
CMF C2 H4 O2

RN 32558-32-0 CAPLUS
CN 2(1H)-Quinazolinone, 1-(2-aminoethyl)-6-chloro-3,4-dihydro-4-hydroxy-3-isobutyl-4-phenyl-, monoacetate (salt) (8CI) (CA INDEX NAME)

CM 1

CRN 47467-96-9
CMF C20 H24 Cl N3 O2



CM 2

CRN 64-19-7
CMF C2 H4 O2

RN 32558-33-1 CAPLUS
CN 2(1H)-Quinazolinone, 1-(2-aminoethyl)-3,4-dihydro-4-hydroxy-6-nitro-3-pentyl-4-phenyl-, monoacetate (salt) (8CI) (CA INDEX NAME)

CM 1

CRN 47607-08-9
CMF C21 H26 N4 O4

L5 ANSWER 313 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



CM 2

CRN 64-19-7
CMF C2 H4 O2

RN 32558-34-2 CAPLUS
CN 2(1H)-Quinazolinone, 1-(2-aminoethyl)-3,4-dihydro-4-hydroxy-3-pentyl-4-p-tolyl-, monoacetate (salt) (8CI) (CA INDEX NAME)

CM 1

CRN 47522-66-7
CMF C22 H29 N3 O2



CM 2

CRN 64-19-7
CMF C2 H4 O2

L5 ANSWER 313 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
RN 32558-35-3 CAPLUS
CN 2(1H)-Quinazolinone, 1-(2-aminopropyl)-3,4-dihydro-4-hydroxy-3-methyl-6-nitro-4-phenyl- (CA INDEX NAME)



RN 32558-36-4 CAPLUS
CN 2(1H)-Quinazolinone, 1-(2-aminoethyl)-6-chloro-3-hexyl-3,4-dihydro-4-hydroxy-4-phenyl-, monoacetate (salt) (8CI) (CA INDEX NAME)

CM 1

CRN 47563-23-5
CMF C22 H28 Cl N3 O2



CM 2

CRN 64-19-7
CMF C2 H4 O2

RN 32558-37-5 CAPLUS
CN 2(1H)-Quinazolinone, 1-(2-aminoethyl)-3-benzyl-6-chloro-3,4-dihydro-4-hydroxy-4-phenyl- (8CI) (CA INDEX NAME)

L5 ANSWER 313 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 32558-38-6 CAPLUS
CN 3(2H)-Quinazolineacetic acid, 1-(2-aminoethyl)-6-chloro-1,4-dihydro-4-hydroxy-2-oxo-4-phenyl-, ethyl ester, monoacetate (salt) (8CI) (CA INDEX NAME)

CM 1

CRN 47563-22-4
CMF C20 H22 Cl N3 O4



CM 2

CRN 64-19-7
CMF C2 H4 O2

RN 32689-12-6 CAPLUS
CN 3(2H)-Quinazolinepropionitrile, 1-(2-aminoethyl)-6-chloro-1,4-dihydro-4-hydroxy-2-oxo-4-phenyl-, triacetate (salt) (8CI) (CA INDEX NAME)

CM 1

CRN 47467-97-0
CMF C19 H19 Cl N4 O2

L5 ANSWER 313 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



CM 2

CRN 64-19-7
CMF C2 H4 O2

L5 ANSWER 314 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1971:405845 CAPLUS
DOCUMENT NUMBER: 75:5845
ORIGINAL REFERENCE NO.: 75:971a,974a
TITLE: Thiocarbamide derivatives with tuberculostatic action.

I. Heterocyclic compounds with the thiocarbamide skeleton
AUTHOR(S): Solyom, Sandor; Koczka, Istvan; Toth, Gabor; Toldy, Lajos
CORPORATE SOURCE: Inst. Med. Res., Budapest, Hung.
SOURCE: Acta Chimica Academiae Scientiarum Hungaricae (1971), 68(1), 93-132
CODEN: ACASA2; ISSN: 0001-5407
DOCUMENT TYPE: Journal
LANGUAGE: German
GI For diagram(s), see printed CA Issue.
AB Heterocyclic thiocarbamoyl compds. including I-III (R = alkyl; R = substituted aryl; n = 1 or 2) as well as open-chain compds. R1NHCSNHCHRCO2H and RNHCSNH(CH2)3CO2H (103 compds.) were prepared from amino
acids and the corresponding isothiocyanates. The thiohydantoins I had antitubercular activity in vitro, but were highly toxic to mice. The diazepines II (n = 2) showed tranquilizing activity. The other compds. showed little or no antitubercular activity
IT 32262-36-5P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 32262-36-5 CAPLUS
CN 1(2H)-Quinazolinecarboxylic acid, 4-phenyl-2-thioxo-, ethyl ester (CA INDEX NAME)



L5 ANSWER 315 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1971:141687 CAPLUS
DOCUMENT NUMBER: 74:141687
ORIGINAL REFERENCE NO.: 74:22895a,22898a
TITLE: Reactions of 2,4(1H,3H)-quinazolinediones
AUTHOR(S): Elkaschef, Mohamed A. F.; Abdel-Megeid, Farouk M. E.; Mokhtar, Kamel E.; Zaki, Kamel E. M.
CORPORATE SOURCE: Nat. Res. Cent., Cairo, Egypt
SOURCE: Journal of the Chemical Society [Section] C: Organic (1971), (6), 1055-8
CODEN: JSOOAX; ISSN: 0022-4952
DOCUMENT TYPE: Journal
LANGUAGE: English
GI For diagram(s), see printed CA Issue.
AB 6-Chloro-3-phenyl-2,4(1H,3H)-quinazolinedione (I) reacted with PCl5 or POCl3 to give 2,6-dichloro-3-phenyl-4(3H)-quinazolinone (II). II reacted with NH4, N2H4, BuNH2, PhCH2NH2, and PhNH2 to give the corresponding 2-amino analogs. 3-Phenyl-2,4-(1H,3H)-quinazolinediones (I, III, and IV) reacted with PhMgBr to give 1,2,3,4-tetrahydro-2,4-diphenyl-2,4-quinazolinediols (V), and with EtMgBr to give 4-ethylidene-3,4-dihydro-2(1H)-quinazolinones (VI). The products of treating I with MeMgBr and p-MeOC6H4MgBr underwent dehydration to 6-chloro-3,4-dihydro-2-methyl-4-methylene-3-phenylquinazoline and 6-chloro-3,4-dihydro-2,4-bis(p-methoxyphenyl)-3-phenyl-4-quinazolinol, resp.
2,4(1H,3H)-Quinazolinedione
reacted with EtMgBr and PhMgBr to give 2,4-diethyl- and 2,4-diphenylquinazoline, resp.
IT 31730-58-2P 31730-59-3P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 31730-58-2 CAPLUS
CN 2,4-Quinazolinediol, 6-chloro-1,2,3,4-tetrahydro-1-methyl-2,3,4-triphenyl- (CA INDEX NAME)



RN 31730-59-3 CAPLUS
CN 2,4-Quinazolinediol, 6-chloro-1,2,3,4-tetrahydro-2,4-bis(p-methoxyphenyl)-1-methyl-3-phenyl- (8CI) (CA INDEX NAME)

L5 ANSWER 315 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



L5 ANSWER 316 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1971:125720 CAPLUS
DOCUMENT NUMBER: 74:125720
ORIGINAL REFERENCE NO.: 74:20315a,20318a
TITLE: Tertiary-butylamino-benzophenones, useful as intermediates in preparing pharmaceutically active 1-substituted-4-aryl-2(1H)-quinazolinones
INVENTOR(S): Coombs, Robert V.; Hardtmann, Goetz E.
PATENT ASSIGNEE(S): Sandoz-Wander, Inc.
SOURCE: U.S., 4 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 3541151	A	19701117	US 1968-787256	19681226
PRIORITY APPLN. INFO.:			US 1968-787256 A	19681226

GI For diagram(s), see printed CA Issue.

AB The title compds. (I) are prepared by thermal rearrangement of the corresponding 1-tert-butyl-3-aryl-2,1-benzisoxazoline (II). Thus, 5-chloro-6-methyl-3-phenyl-2,1-benzisoxazole in MeNO2 kept 60 hr at 20° with Me3COH and 60% aqueous HClO4 and diluted with anhydrous Et2O yielded 1-tert-butyl-5-chloro-6-methyl-3-phenyl-2,1-benzisoxazolium perchlorate (III), m. 183-5°. III in absolute alc. treated portionwise in 15 min with NaBH4 and the cooled mixture diluted with H2O gave 1-tert-butyl-5-chloro-6-methyl-3-phenyl-2,1-benzisoxazoline (IV), m. 114-15°. IV kept 4 hr at 160° and the brown oily product taken up in CH2Cl2, chromatographed on Al2O3 and eluted with CH2Cl2 gave 2-(tert-butylamino)-5-chloro-4-methylbenzophenone (V), m. 76-8°. V heated 2 days at 120° in a stainless steel cylinder with NH3 and ZnCl2 gave oily 2-(tert-butylamino)-5-chloro-4-methyl-benzophenonimine which with Et3N in C6H6 treated at 5-20° with 12% COCl2 in C6H6 and the residue on evaporation taken up in 0.5N Na2CO3 yielded the quinazolinone (VI, R = 6-Cl,7-Me, Y = H), m. 149-50°. V hydrogenated catalytically over Pd-C in 3:1 MeOH-EtOAc containing KOH gave 2-(tert-butylamino)-4-methylbenzhydrol, m. 57-63°, oxidized in C6H6 with Na2Cr2O7 in AcOH-H2SO4 at 0-5° to give oily I (R = 4-Me, Y = H), converted with NH3 in the presence of ZnCl2 to the corresponding imine, and transformed as above to the corresponding VI (R = 7-Me, Y = H), m. 141-3°. VI have antiinflammatory activity.

IT 31822-48-7P 31822-52-3P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 31822-48-7 CAPLUS
CN 2(1H)-Quinazolinone, 1-tert-butyl-6-chloro-7-methyl-4-phenyl- (8CI) (CA INDEX NAME)

L5 ANSWER 316 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 31822-52-3 CAPLUS
CN 2(1H)-Quinazolinone, 1-(1,1-dimethylethyl)-7-methyl-4-phenyl- (CA INDEX NAME)



L5 ANSWER 317 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1970:445541 CAPLUS
DOCUMENT NUMBER: 73:45541
ORIGINAL REFERENCE NO.: 73:7519a,7522a
TITLE: Antiinflammatory 1-alkyl-4-phenyl-2-quinazolines
INVENTOR(S): Ott, Hans
PATENT ASSIGNEE(S): Sandoz Ltd.
SOURCE: S. African, 35 pp.
CODEN: SFXXAB
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
ZA 6803396		19691127	ZA	19680527

GI For diagram(s), see printed CA Issue.

AB The title compds. (I), useful as antipyretic and analgesic agents, are prepared 4-Phenylquinazoline (II) (2 g) in 10 ml MeI kept overnight at 20° and refluxed 8 hr gave II.MeI (III), m. 200-1°. To a solution of 4 g KMnO4 in 150 ml H2O at 20° was slowly added a suspension of 5.7 g III in 300 ml dioxane, and the mixture kept 15 min to give I (R1 = Me, R2 = R3 = H) (IV), m. 142-3° (AcOEt-Et2O). III (18 g) in 500 ml EtOH and 250 ml CH2Cl2 was treated portionwise at room temperature with 6 g NaBH4, and the mixture kept 45 min to give 1-methyl-4-phenyl-1,2,3,4-tetrahydroquinazoline (V), oil. Oxidation of 12 g V in 500 ml dioxane with 13.2 g KMnO4 in 250 ml H2O at 20° gave IV, also prepared by heating a mixture of 1 g 2-MeNHC6H4Bz, 2 g H2NCO2Et, and 20 mg ZnCl2 1.25 hr at 180-90°. To 2.2 g 4-phenyl-2(1H)-quinazolinone in 50 ml AcNMe2 at 20° was added 0.75 g NaH (50% in oil) and the mixture stirred 15 min, treated with 4 ml EtI, stirred 0.5 hr, and heated 0.5 hr at 60° to give I (R1 = Et, R2 = R3 = H) (Va), m. 183-5° (AcOEt). I (R1 = Et, R2 = 6-Cl, R3 = H), m. 223-4° (AcOEt), was similarly prepared To ethereal 4-ClC6H4Li prepared from 0.96 g 4-BrC6H4Cl and 3.1 ml 1.6M BuLi in hexane was added 0.65 g quinazoline in 10 ml Et2O and the mixture stirred 10 min to give 4-(4-chlorophenyl)-3,4-dihydroquinazoline (VI), m. 166-7° (AcOEt). Oxidation of 5 g VI with 5.27 g KMnO4 gave 4-(4-chlorophenyl)quinazoline m. 122-3° (Et2O); methiodide (VII) m. 222-5°. Reduction of VII with NaBH4 and oxidation of the oily 1-methyl-4-(4-chlorophenyl)-1,2,3,4-tetrahydroquinazoline formed with KMnO4 gave I (R1 = Me, R2 = H, R3 = 4-Cl), m. 195°. The following quinazolinium iodides were prepared (substituents and m.p. given): 1-methyl-4-(4-methoxyphenyl)-, 228-32° (EtOH); 1-methyl-4-(2,6-dimethoxyphenyl)-, 198-202° (decomposition) (AcOH); 1-methyl-4-(3-chlorophenyl), m. 200-10°; 1-methyl-4-(3-trifluoromethylphenyl)-, -; and 1-methyl-4-(2,3-dimethylphenyl)-, 208-10°. Reduction and oxidation gave the following I (R1 = Me, R2 = H) (R3 and m.p. given): 4-MeO (VIII), 184° (AcOEt); 2,6-(MeO)2, 166-7° (AcOEt); 3-Cl, 95-6°, (Et2O-petroleum ether); 3-F3C, 165-7° (AcOEt-Et2O); and 2,3-Me2, 186-8°, AcOEt. The following I (R2 = R3 = H, R1 and m.p. given) were prepared: Pr, 131°; Bu, 103-4° (AcOEt-Et2O); C5H11, 121-2°; CH2:CHCH2, 159-60°; CH.tplbond.CCH2, 181° (EtOH). I (R1 = Me, R2 = 6-Cl, R3 = 2-Cl), m. 191-4°, was prepared by methylation of 6-chloro-4-(2-chlorophenyl)-2(1H)-

L5 ANSWER 317 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
quinazolinone. Refluxing a mixt. of 3 g VIII and 20 ml 48% aq. HBr 20 hr gave I (R1 = Me, R2 = H, R3 = 4-OH), m. 291-3° (AcOEt). By analogous methods were prepd. the following I [R1, R2, R3, and m.p. (AcOEt) given]: iso-Bu, H, H, 120-2°; CH2:CHCHMe, H, H, 142-3°; Et, 6-Cl, H, 163°; iso-Pr, H, H, 140°; iso-Pr, 6-Cl, H, 149-50° (Me2CO); iso-Pr, 6-Cl, 2-Cl, 147-9° (Et2O-petroleum ether); iso-Pr, H, 4-Me, 138-40° (Me2O); and iso-Pr, 7-Cl, H, 165-8°. Daily oral doses of I are in the range 37.5-300 mg. Typical tablets contain 50% by wt. Va.
IT 17629-04-8P 20927-53-1P 23441-64-7P
23441-88-5P 26772-86-1P 26824-71-5P
26824-77-1P 26824-80-6P 26824-81-7P
26824-82-8P 26824-84-0P 26824-94-2P
26824-96-4P 26824-97-5P 26831-06-1P
26831-07-2P 26831-08-3P 26831-09-4P
26831-11-8P 26940-07-8P 27524-92-1P
27524-93-2P 27529-23-3P 27559-10-0P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 17629-04-8 CAPLUS
CN 2(1H)-Quinazolinone, 1-methyl-4-phenyl- (CA INDEX NAME)



RN 20927-53-1 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-1-methyl-4-phenyl- (CA INDEX NAME)



RN 23441-64-7 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-1-ethyl-4-phenyl- (CA INDEX NAME)

L5 ANSWER 317 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 23441-88-5 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-4-(2-chlorophenyl)-1-methyl- (CA INDEX NAME)



RN 26772-86-1 CAPLUS
CN 2(1H)-Quinazolinone, 1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)



RN 26824-71-5 CAPLUS
CN 2(1H)-Quinazolinone, 4-phenyl-1-(2-propenyl)- (9CI) (CA INDEX NAME)



L5 ANSWER 317 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

RN 26824-77-1 CAPLUS
CN 2(1H)-Quinazolinone, 4-(2,6-dimethoxyphenyl)-1-methyl- (CA INDEX NAME)



RN 26824-80-6 CAPLUS
CN 2(1H)-Quinazolinone, 4-phenyl-1-propyl- (CA INDEX NAME)



RN 26824-81-7 CAPLUS
CN 2(1H)-Quinazolinone, 1-butyl-4-phenyl- (CA INDEX NAME)



RN 26824-82-8 CAPLUS
CN 2(1H)-Quinazolinone, 1-pentyl-4-phenyl- (CA INDEX NAME)



L5 ANSWER 317 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

RN 26824-84-0 CAPLUS
CN 2(1H)-Quinazolinone, 4-phenyl-1-(2-propynyl)- (8CI, 9CI) (CA INDEX NAME)



RN 26824-94-2 CAPLUS
CN 2(1H)-Quinazolinone, 4-(3-chlorophenyl)-1-methyl- (CA INDEX NAME)



RN 26824-96-4 CAPLUS
CN 2(1H)-Quinazolinone, 4-(2,3-dimethylphenyl)-1-methyl- (CA INDEX NAME)



RN 26824-97-5 CAPLUS
CN 2(1H)-Quinazolinone, 4-(4-hydroxyphenyl)-1-methyl- (CA INDEX NAME)

L5 ANSWER 317 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 26831-06-1 CAPLUS
CN 2(1H)-Quinazolinone, 4-(4-chlorophenyl)-1-methyl- (CA INDEX NAME)



RN 26831-07-2 CAPLUS
CN 2(1H)-Quinazolinone, 1-ethyl-4-phenyl- (CA INDEX NAME)



RN 26831-08-3 CAPLUS
CN 2(1H)-Quinazolinone, 4-(4-methoxyphenyl)-1-methyl- (CA INDEX NAME)

L5 ANSWER 317 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 26831-09-4 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-4-(2-chlorophenyl)-1-(1-methylethyl)- (CA INDEX NAME)



RN 26831-11-8 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)



RN 26940-07-8 CAPLUS
CN 2(1H)-Quinazolinone, 1-methyl-4-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)

L5 ANSWER 317 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 27524-92-1 CAPLUS
CN 2(1H)-Quinazolinone, 1-(1-methylethyl)-4-(4-methylphenyl)- (CA INDEX NAME)



RN 27524-93-2 CAPLUS
CN 2(1H)-Quinazolinone, 7-chloro-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)



RN 27529-23-3 CAPLUS
CN 2(1H)-Quinazolinone, 1-(2-methyl-2-propenyl)-4-phenyl- (9CI) (CA INDEX NAME)

L5 ANSWER 317 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 27559-10-0 CAPLUS
CN 2(1H)-Quinazolinone, 1-(2-methylpropyl)-4-phenyl- (CA INDEX NAME)



L5 ANSWER 318 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1970:100739 CAPLUS
DOCUMENT NUMBER: 72:100739
ORIGINAL REFERENCE NO.: 72:18281a,18284a
TITLE: Analgesic 1-methyl-4-(substituted-phenyl)-1H-quinazolin-2-ones
INVENTOR(S): Ott, Hans
PATENT ASSIGNEE(S): Sandoz Ltd.
SOURCE: Fr., 10 pp.
CODEN: FRXXAK
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 7
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
FR 1571271	A	19690620	FR 1967-1571271	19670828
CH 487902	A	19700331	CH 1967-487902	19670816
CH 489506	A	19700430	CH 1967-489506	19670816
CH 489507	A	19700430	CH 1967-489507	19670816
CH 489508	A	19700430	CH 1967-489508	19670816
GB 1195066	A	19700617	GB 1967-1195066	19670821
DE 1695769	B2	19790705	DE 1967-S111538	19670825
DE 1695769	C3	19800228		
ES 344534	A1	19681216	ES 1967-344534	19670828
CA 957375	A1	19741105	CA 1967-999345	19670905
ES 345400	A1	19690201	ES 1967-345400	19670923
FR 6835	M	19690331	FR 1967-6835	19671127
SE 325893	B	19700713	SE 1967-16389	19671129
AT 293391	B	19711011	AT 1967-10910	19671201
AT 293397	B	19711011	AT 1970-112	19671201
AT 293398	B	19711011	AT 1970-113	19671201
AT 299205	B	19720612	AT 1970-114	19671201
FI 49038	B	19741202	FI 1967-3490	19671229
NL 6800104	A	19681105	NL 1968-104	19680104
BE 714568	A	19681104	BE 1968-714568	19680502
US 3925548	A	19751209	US 1972-313531	19721208
US 313531	I5	19750128		
PRIORITY APPLN. INFO.:			US 1966-575511 A	19660829
			US 1967-636015 A	19670504
			US 1967-672739 A	19671004
			US 1968-707932 A2	19680226
			US 1968-741804 A2	19680701
			US 1968-775201 A3	19681112

OTHER SOURCE(S): MARPAT 72:100739
GI For diagram(s), see printed CA Issue.
AB The title compds. (I), antipyretics, analgesics, and antiinflammatory agents, are prepared Thus, 2 g 4-phenylquinazoline in 10 ml MeI gave 1-methyl-4-phenylquinazolinium iodide (II), m. 200-1°. KMnO4 (4 g) in 150 ml H2O was added to 5.7 g II in 300 ml to give 1-methyl-4-phenyl-2-(1H)-quinazolinone, (I, R1 = H, R2 = Me, Y = Ph) (Ia), m. 142-3°. II (18 g) in 500 ml EtOH and 250 cc CH2Cl2 with 6 g NaBH4 gave oily 1-methyl-4-phenyl-1,2,3,4-tetrahydroquinazoline (III, R1 = H, Y = Ph), which (12 g) in 500 cc dioxane was treated with 13.2 g KMnO4 in 250 cc H2O to give Ia, m. 142-3°. A mixt. of 1 g o-methylaminobenzophenone, 2 g H2NCO2Et, and 20 g ZnCl2 was kept at 180-90° to give Ia. AnH (50% in mineral 001) 0.7 5 g) was added to 2.2 g 4-phenyl-2-(1H)-quinazolinone in 50 cc Me2NCHO (DMF), and 4 cc EtI added to give 1-ethyl-4-phenyl-2-(1H)-quinazolinone (Ib), m. 183-5°. The following I were similarly prepd. (R1, R2, Y, and m.p. given): 6-Cl, Me, Ph, 223-4° (AcOEt); H, Pr, Ph, 131°; H, Bu, Ph, 103-4° (1:1 AcOEt-Et2-O); H, n-amyl, Ph, 121-2°; H, allyl, Ph, 159-60°; H, propargyl, Ph, 181° (EtOH); 6-Cl, Me, p-ClC6H4, 191-4°. To anethereal soln. of p-chlorophenyllithium, 0.65 g quinazoline in 10 cc Et2O was added to give 4-(p-chlorophenyl)-3,4-dihydroquinazoline, m. 166-7°. KMnO4 (5.27 g in 100 cc of H2O) was added to 5 g of this in 200 cc of dioxane to give 4-(p-chlorophenyl)quinazoline, m. 122-3°, which (4.5 g) in 55 cc MeI gave 1-methyl-4-(p-chlorophenyl)quinazolinium iodide (IV, R1 = H, Y = p-ClC6H4), m. 222-5°. The following IV were similarly prepd. (R1, Y, and m.p. given): H, p-MeOC6H4, 228-32° (EtOH); H, 2,6-dimethoxyphenyl, 198-202° (decompn.) (AcOEt); H, m-ClC6H4, 200-10°; H, m-(trifluoromethyl)phenyl, -; H, 2,3-dimethylphenyl, 208-10°. NaBH4 (3.5 g) was added in small portions to 6.7 g 1-methyl-4-(p-chlorophenyl)quinazolinium iodide in 200 ml of EtOH and 100 cc of CH2Cl2 to give oily 1-methyl-4-(p-chlorophenyl)-1,2,3,4-tetrahydroquinazoline (III, R1 = H, R2 = Me Y = p-chlorophenyl) (IIIb.) The following III were similarly prepd. (R1, Y, and H, p-MeOC6H4, oil; H, 2,6-dimethoxyphenyl, 157° (AcOEt); H, m.p. given): H, p-MeOC6H4, oil; H, 2,6-dimethoxyphenyl, 157° (AcOEt); H, m-ClC6H4, oil; H, m-(trifluoromethyl)phenyl, oil; H,2,3-dimethoxyphenyl, oil. A soln. of 0.625 g KMnO4 in 12 cc H2O was added to 0.5 g IIIb in 20 cc to give I (R1 = H, R2 = Me, Y = p-ClC6H4), m. 195°. The following I were similarly prepd. (R1, R2, Y, and m.p. given): H, Me, p-MeOC6H4, 184° (AcOEt); H, Me, 2,6-dimethoxyphenyl, 166-7° (AcOEt); H, Me, m-ClC6H4, 95-6° (Et2O-petroleum ether); H, Me, m-(trifluoromethyl)phenyl, 165-7° (AcOEt-Et2O); and H, Me, 2,3-dimethylphenyl, 186-8° (AcOEt). A mixt. of 3 g 4-(p-methoxyphenyl)-1-methyl-2(1H)-quinazolinone and 20 cc aq. 48% HBr was refluxed 20 hr to give 1-methyl-4-(p-hydroxyphenyl)-2-(1H)-quinazolinone, m. 291-3° (AcOEt).
IT 17629-04-8P 20927-53-1P 23441-88-5P
26824-71-5P 26824-77-1P 26824-80-6P
26824-81-7P 26824-82-8P 26824-84-0P
26824-94-2P 26824-96-4P 26824-97-5P
26831-06-1P 26831-07-2P 26831-08-3P
26940-07-8P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 17629-04-8 CAPLUS
CN 2(1H)-Quinazolinone, 1-methyl-4-phenyl- (CA INDEX NAME)



RN 20927-53-1 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-1-methyl-4-phenyl- (CA INDEX NAME)



RN 23441-88-5 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-4-(2-chlorophenyl)-1-methyl- (CA INDEX NAME)



RN 26824-71-5 CAPLUS
CN 2(1H)-Quinazolinone, 4-phenyl-1-(2-propenyl)- (9CI) (CA INDEX NAME)



RN 26824-77-1 CAPLUS
CN 2(1H)-Quinazolinone, 4-(2,6-dimethoxyphenyl)-1-methyl- (CA INDEX NAME)



RN 26824-80-6 CAPLUS
CN 2(1H)-Quinazolinone, 4-phenyl-1-propyl- (CA INDEX NAME)



RN 26824-81-7 CAPLUS
CN 2(1H)-Quinazolinone, 1-butyl-4-phenyl- (CA INDEX NAME)



RN 26824-82-8 CAPLUS
CN 2(1H)-Quinazolinone, 1-pentyl-4-phenyl- (CA INDEX NAME)



RN 26824-84-0 CAPLUS
CN 2(1H)-Quinazolinone, 4-phenyl-1-(2-propynyl)- (8CI, 9CI) (CA INDEX NAME)

L5 ANSWER 318 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 26824-94-2 CAPLUS
CN 2(1H)-Quinazolinone, 4-(3-chlorophenyl)-1-methyl- (CA INDEX NAME)



RN 26824-96-4 CAPLUS
CN 2(1H)-Quinazolinone, 4-(2,3-dimethylphenyl)-1-methyl- (CA INDEX NAME)



RN 26824-97-5 CAPLUS
CN 2(1H)-Quinazolinone, 4-(4-hydroxyphenyl)-1-methyl- (CA INDEX NAME)

L5 ANSWER 318 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 26940-07-8 CAPLUS
CN 2(1H)-Quinazolinone, 1-methyl-4-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)



L5 ANSWER 318 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 26831-06-1 CAPLUS
CN 2(1H)-Quinazolinone, 4-(4-chlorophenyl)-1-methyl- (CA INDEX NAME)



RN 26831-07-2 CAPLUS
CN 2(1H)-Quinazolinone, 1-ethyl-4-phenyl- (CA INDEX NAME)



RN 26831-08-3 CAPLUS
CN 2(1H)-Quinazolinone, 4-(4-methoxyphenyl)-1-methyl- (CA INDEX NAME)

L5 ANSWER 319 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1970:100737 CAPLUS
DOCUMENT NUMBER: 72:100737
ORIGINAL REFERENCE NO.: 72:18281a,18284a
TITLE: Antiinflammatory 1-alkyl-4-phenyl-2(1H)-quinazolinones
INVENTOR(S): Ott, Hans
PATENT ASSIGNEE(S): Sandoz Ltd.
SOURCE: Ger. Offen., 64 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 6
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 1932402	A	19700305	DE 1969-1932402	19690626
DE 1932402	B2	19800925		
DE 1932402	C3	19810903		
US 3549635	A	19701222	US 1968-741806	19680701
CH 514552	A	19711031	CH 1969-514552	19690612
CH 514553	A	19711031	CH 1969-514553	19690612
CH 514554	A	19711031	CH 1969-514554	19690612
CH 514603	A	19711031	CH 1969-514603	19690612
GB 1280551	A	19720705	GB 1969-1280551	19690613
GB 1280553	A	19720705	GB 1969-1280553	19690613
DK 129047	B	19740812	DK 1969-3228	19690616
RO 54693	A1	19730217	RO 1969-60372	19690628
RO 57329	A1	19750115	RO 1969-62546	19690628
RO 57381	A1	19750415	RO 1969-62545	19690628
IL 32505	A	19730330	IL 1969-32505	19690629
FR 2012061	A5	19700313	FR 1969-21994	19690630
ES 368946	A1	19710716	ES 1969-368946	19690630
BR 6910302	D0	19730208	BR 1969-210302	19690630
AT 306723	B	19730425	AT 1969-6237	19690630
AT 306731	B	19730425	AT 1971-5061	19690630
SU 396022	A3	19730828	SU 1969-1343969	19690630
SU 444367	A3	19740925	SU 1969-1493614	19690630
CA 956954	A1	19741029	CA 1969-55737	19690630
ZA 6904678	A	19710224	ZA 1969-4678	19690701
ES 379154	A1	19730201	ES 1970-379154	19700429
ES 379155	A1	19730201	ES 1970-379155	19700429
ES 379156	A1	19730201	ES 1970-379156	19700429
ES 379157	A1	19730201	ES 1970-379157	19700429
ES 379158	A1	19730201	ES 1970-379158	19700429
ES 379159	A1	19730201	ES 1970-379159	19700429
ES 379160	A1	19730201	ES 1970-379160	19700429
ES 381047	A1	19730316	ES 1970-381047	19700623
ES 381048	A1	19730401	ES 1970-381048	19700629
SE 7505420	A	19750512	SE 1975-5420	19750512

PRIORITY APPLN. INFO.:		
US 1968-741806	A	19680701
US 1968-741807	A	19680701
US 1968-787252	A	19681226
US 1968-787254	A	19681226
US 1969-816383	A	19690415

L5 ANSWER 319 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

US 1969-819435 A 19690425

US 1969-819450 A 19690425

US 1969-819451 A 19690425

GI For diagram(s), see printed CA Issue.

AB The title compds. (I) were prepared Thus, 100 g 4,3-Cl-(O2N)C6H3Me, 60 g CuCN, and 150 ml AcNMe2, was refluxed 4.5 hr to give 4,3-NC(O2N)C6H3Me, m. 96-7°, which was reduced with Fe-HCl in EtOH to give Ia, m. 88-90°. Ia (36 g), 120 ml iso-PrI, 36 g K2CO3, and 0.5 g powdered Cu was refluxed 8 days to give Ib. Ib (5.22 g) in 40 ml Et2O and 90 millimoles PhLi in 1:1 Et2O-C6H6 gave Ic; maleate m. 119-22°. Ic (5 g), 3 ml ClCO2Et, and 30 ml C6H6 was refluxed 2.5 hr (method A) to give I (R2 = iso-Pr, R3 = R4 = H, R5 = Me) (II), m. 137-8°. Ring closure of Ic to II was also performed by ClCO2Et in the presence of Et3N, by urethane in the absence of ZnCl2 (method B), by COCl2 (method C), and by 1,1'-carbonyldiimidazole (method D). II was also prepared from Id 10, NH4NCS 3.5, and BzCl 6.2 g in 100 ml Me2CO by refluxing 3 hr and hydrolyzing the 2-thione, m. 185-90°, with NaOH (method E). 3-MeC6H4-NHPr-iso (III), b51 109°, was prepared from m-toluidine, iso-PrI, and Et3N in PrOH. III, 4.1 g nitrourea, and 20 ml EtOH was heated on a steam bath 2 hr to give 3-MeC6H4N(Pr-iso)CONH2 (IV), m. 89-91°. IV (1 g), 0.4 g BzH, and 30 ml C6H6 in the presence of .apprx.10 mg p-MeC6H4SO3H was refluxed 22 hr to give the corresponding dihydroquinazolinone, m. 160°, which was dehydrogenated to II by refluxing with MgO2 (method F). III by method E gave the N'-benzoyl derivative, m. 112-13°, and 3-MeC6H4N(Pr-iso)CSNH2 (V), m. 126-7°. V (1 g), 2 g BzH, and 25 ml HCl-saturated C6H6 was refluxed 15 hr to give the corresponding dihydroquinazoline-2-thione, m. 125-7°, which was oxidized with KMnO4 to II (method G). Similarly prepared were the following I (R2, R3, R4, R5, m.p., and method given): Et, H, Me, Me, 176-80°, A and D; Et, H, CF3, H, 180°, A; Et, H, MeS, H, 150-1°, A; Me, H, MeO, MeO, 197-8°, A; Et, H, MeO, H, 138-42°, B; Et, H, NO2, H, 214-15°, B; Me, H, H, H (VI), 141-3°, B, C, and G; Me, H, Cl, H (VII), 223-4°, B, C, E, and F; Me, 4-Cl, H, H, 122-3°, C; Et, H, H, H, (VIII), 183-5°, C and E; Me, 4-Meo, H, H, 184°, C; iso-Pr, 2-Cl, Cl, H, 147-9°, C; iso-Pr, H, H, H (IX), 140°, C and E; iso-Pr, H, Cl, H, 149-50°, C; iso-Pr, H, NO2, H, 190-2°, C; iso-Pr, H, Me, H, 170-1°, C; iso-Pr, H, H, MeO, 137-8°, C; Et, H, H, Cl, 187-8°, C; iso-Pr, H, CN, H, 125-8°, D; iso-Pr, H, Me, Me (X), 135-7°, F; iso-Pr, H, MeO, H (XI), 140-3°, E; allyl, H, H, H (XII), 159-60°, E. 4-ClC6H4NH2 63.8, HC(OMe)3 28.9, and concentrated H2SO4 2 g was heated to give the N-formyl-N-methyl derivative, b20 130-40°, 80 g of which was refluxed 18 hr with 200 ml 10% HCl to give 4-ClC6H4NHMe, b40 143-4°. The latter and nitrourea formed the corresponding urea derivative, 0.5 g of which was refluxed 20 hr with 0.25 g BzH in the presence of p-MeC6H4SO3H and dehydrogenation of the resulting dihydro-quinazolinone, m. 184-7°, with MgO2 gave VII. Similarly prepd. was X dihydro deriv., m. 156-60°. 2-MeHNC6H4CHO (15 g) and 15 g urea was heated 15 hr at 150° under N to give 1-methyl-2(1H)-quinazolinone; hydrochloride (XIII) m. 233-5°. XIII (1 g), 200 ml tetrahydrofuran, and 5 ml 2M PhLi in 7:3 C6H6-Et2O at 25-30° gave the dihydroquinazolinone, m. 183-4°, which was oxidized with KMnO4 to give VI. 2-H2NC6H4Bz (20 g), 10 g Na2CO3, and 50 ml iso-PrI was refluxed 5 days to give 2-iso-PrHNC6H4Bz, 30 g of which was added to 11.3 g NH4NCS and 18.8 g BzCl in 100 ml Me2CO and refluxed 3 hr to give the 2-thione, m. 212-14°. Alk. hydrolysis of the latter gave IX. Similarly prepd. were the 2-thiones of VIII, m. 232-5°; of VII, m. 228-30°; of XI, m. 144-5°; and of XII, m. 180°. Ic and I have analgetic and antiinflammatory activities, resp.

IT 17629-04-8P 20927-53-1P 22760-16-3P
22760-17-4P 22760-18-5P 22760-25-4P
22760-60-7P 25508-87-6P 25508-91-2P
25508-93-4P 25509-41-5P 25509-43-7P
25509-57-3P 25509-61-9P 26772-86-1P
26772-90-7P 26772-95-2P 26772-96-3P
26824-56-6P 26824-66-8P 26824-68-0P
26824-69-1P 26824-70-4P 26824-71-5P
26824-74-8P 26831-06-1P 26831-07-2P
26831-08-3P 26831-09-4P 26831-11-8P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 17629-04-8 CAPLUS

CN 2(1H)-Quinazolinone, 1-methyl-4-phenyl- (CA INDEX NAME)



RN 20927-53-1 CAPLUS

CN 2(1H)-Quinazolinone, 6-chloro-1-methyl-4-phenyl- (CA INDEX NAME)



RN 22760-16-3 CAPLUS

CN 2(1H)-Quinazolinone, 6,7-dimethyl-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)



RN 22760-17-4 CAPLUS

CN 2(1H)-Quinazolinone, 6-methyl-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)



RN 22760-18-5 CAPLUS

CN 2(1H)-Quinazolinone, 7-methyl-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)



RN 22760-25-4 CAPLUS

CN 2(1H)-Quinazolinone, 7-methoxy-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)



RN 22760-60-7 CAPLUS

CN 2(1H)-Quinazolinone, 1-(1-methylethyl)-6-nitro-4-phenyl- (CA INDEX NAME)



RN 25508-87-6 CAPLUS

CN 2(1H)-Quinazolinone, 1-ethyl-6,7-dimethyl-4-phenyl- (CA INDEX NAME)



RN 25508-91-2 CAPLUS

CN 2(1H)-Quinazolinone, 1-ethyl-4-phenyl-6-(trifluoromethyl)- (CA INDEX NAME)



RN 25508-93-4 CAPLUS

CN 2(1H)-Quinazolinone, 1-ethyl-6-nitro-4-phenyl- (CA INDEX NAME)



RN 25509-41-5 CAPLUS

L5 ANSWER 319 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
CN 6-Quinazolinecarbonitrile, 1,2-dihydro-1-isopropyl-2-oxo-4-phenyl- (8CI) (CA INDEX NAME)



RN 25509-43-7 CAPLUS
CN 2(1H)-Quinazolinone, 1-ethyl-6-methyl-4-phenyl- (CA INDEX NAME)



RN 25509-57-3 CAPLUS
CN 2(1H)-Quinazolinone, 6,7-dimethoxy-1-methyl-4-phenyl- (CA INDEX NAME)



RN 25509-61-9 CAPLUS
CN 2(1H)-Quinazolinone, 1-ethyl-6-methoxy-4-phenyl- (CA INDEX NAME)



L5 ANSWER 319 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

RN 26772-86-1 CAPLUS
CN 2(1H)-Quinazolinone, 1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)



RN 26772-90-7 CAPLUS
CN 2(1H)-Quinazolinone, 3,4-dihydro-7-methyl-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)



RN 26772-95-2 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-3,4-dihydro-1-methyl-4-phenyl- (CA INDEX NAME)



RN 26772-96-3 CAPLUS
CN 2(1H)-Quinazolinone, 3,4-dihydro-6,7-dimethyl-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)

L5 ANSWER 319 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 26824-56-6 CAPLUS
CN 2(1H)-Quinazolinone, 7-chloro-1-ethyl-4-phenyl- (CA INDEX NAME)



RN 26824-66-8 CAPLUS
CN 2(1H)-Quinazolinone, 3,4-dihydro-1-methyl-4-phenyl- (CA INDEX NAME)



RN 26824-68-0 CAPLUS
CN 2(1H)-Quinazolinethione, 1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)



RN 26824-69-1 CAPLUS
CN 2(1H)-Quinazolinethione, 7-methyl-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)

L5 ANSWER 319 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 26824-70-4 CAPLUS
CN 2(1H)-Quinazolinone, 6-methoxy-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)



RN 26824-71-5 CAPLUS
CN 2(1H)-Quinazolinone, 4-phenyl-1-(2-propenyl)- (9CI) (CA INDEX NAME)



RN 26824-74-8 CAPLUS
CN 2(1H)-Quinazolinethione, 3,4-dihydro-7-methyl-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)



RN 26831-06-1 CAPLUS
CN 2(1H)-Quinazolinone, 4-(4-chlorophenyl)-1-methyl- (CA INDEX NAME)

L5 ANSWER 319 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 26831-07-2 CAPLUS
CN 2(1H)-Quinazolinone, 1-ethyl-4-phenyl- (CA INDEX NAME)



RN 26831-08-3 CAPLUS
CN 2(1H)-Quinazolinone, 4-(4-methoxyphenyl)-1-methyl- (CA INDEX NAME)



RN 26831-09-4 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-4-(2-chlorophenyl)-1-(1-methylethyl)- (CA INDEX NAME)

L5 ANSWER 319 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 26831-11-8 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-1-(1-methylethyl)-4-phenyl- (CA INDEX NAME)



L5 ANSWER 320 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1970:90494 CAPLUS
DOCUMENT NUMBER: 72:90494
ORIGINAL REFERENCE NO.: 72:16449a,16452a
TITLE: 4-Phenyl-6-chloro-2(1H)-quinazolinone
INVENTOR(S): Inaba, Shigeho; Yamamoto, Michihiro; Takahashi, Kei; Mori, Kazuo; Ishizumi, Kikuo; Yamamoto, Hisao
PATENT ASSIGNEE(S): Sumitomo Chemical Co., Ltd.
SOURCE: Ger. Offen., 19 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 1935404	A	19700122	DE 1969-1935404	19690711
DE 1935404	B2	19740620		
DE 1935404	C3	19750213		
FR 2013172	A5	19700327	FR 1969-23771	19690711
FR 2013172	B1	19730112		
GB 1251600	A	19711027	GB 1969-1251600	19690711
BR 6910753	D0	19730222	BR 1969-210753	19690716
BE 736215	A	19691231	BE 1969-736215	19690717
NL 6910984	A	19700120	NL 1969-10984	19690717
AT 297706	B	19720410	AT 1969-6909	19690717
AT 311317	B	19731112	AT 1971-4277	19690717
SU 417945	A3	19740228	SU 1969-1349827	19690717
SE 377567	B	19750714	SE 1969-10131	19690717
CH 515912	A	19711130	CH 1969-515912	19690718
CH 527201	A	19720831	CH 1969-527201	19690718
US 3923803	A	19751202	US 1972-252947	19720512
US 252947	I5	19750128		

PRIORITY APPLN. INFO.: JP 1968-50982 A 19680718
JP 1968-50983 A 19680718
JP 1968-76377 A 19681018
US 1969-840856 A1 19690710

GI For diagram(s), see printed CA Issue.
AB The antiinflammatory title compds. (I) were prepared from 2-aminobenzophenones by acylation with a trihaloacetic acid derivative followed by ring closure with alc. NH3. Thus, to 13.9 g 2-amino-5-chlorobenzophenone in 40 ml C6H6 was added 5.5 g CCl3COCl in 20 ml PhH to give 8.7 g 2-(trichloroacetamido)-5-chlorobenzophenone, m. 93-4°, which (5.7 g) kept 2 days in 200 ml MeOH and 50 g 10% NH3-MeOH gave 4-phenyl-6-chloro-2(1H)-quinazolinone, m. > 300°; Na salt m. >300°. Also prepared were I (R, R1, R2, and m.p. given): H, H, NO2, >300°; Me, H, Cl, 221-2°; CH2CH:CH2, H, Cl, 185-6°; H, H, OMe, 287°; Me, m-Cl, OMe, 199-200°; Et, o-Me, Cl, 174-5°; Me, H, OMe, 167-8°; CH2Ph, H, Cl, 183-4°; Me, H, CF3, 199-201°; Et, H, Cl, 167-8°; Me, p-Cl, Cl, 221-2°; CH2CH2OEt, o-F, Cl, 151-2°; CH2CH2NEt2, o-F, Cl, 223-4°. Also prepared was 4-phenyl-5-chloro-2(1H)quinazolinone, m. 284°.
IT 20927-53-1P 23441-64-7P 23441-66-9P 23441-74-9P 23441-92-1P 23465-52-3P

L5 ANSWER 320 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
23465-55-6P 23536-81-4P 26313-42-8P
26313-51-9P 27247-21-8P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)
RN 20927-53-1 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-1-methyl-4-phenyl- (CA INDEX NAME)



RN 23441-64-7 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-1-ethyl-4-phenyl- (CA INDEX NAME)



RN 23441-66-9 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-4-phenyl-1-(2-propenyl)- (9CI) (CA INDEX NAME)



RN 23441-74-9 CAPLUS
CN 2(1H)-Quinazolinone, 6-methoxy-1-methyl-4-phenyl- (CA INDEX NAME)

L5 ANSWER 320 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 23441-92-1 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-4-(p-chlorophenyl)-1-methyl- (8CI) (CA INDEX NAME)



RN 23465-52-3 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-4-phenyl-1-(phenylmethyl)- (CA INDEX NAME)



RN 23465-55-6 CAPLUS
CN 2(1H)-Quinazolinone, 4-(3-chlorophenyl)-6-methoxy-1-methyl- (CA INDEX NAME)

L5 ANSWER 320 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 27247-21-8 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-1-[2-(diethylamino)ethyl]-4-(2-fluorophenyl)-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

L5 ANSWER 320 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 23536-81-4 CAPLUS
CN 2(1H)-Quinazolinone, 1-methyl-4-phenyl-6-(trifluoromethyl)- (CA INDEX NAME)



RN 26313-42-8 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-1-ethyl-4-(2-methylphenyl)- (CA INDEX NAME)



RN 26313-51-9 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-1-(2-ethoxyethyl)-4-(2-fluorophenyl)- (CA INDEX NAME)

L5 ANSWER 321 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1970:66976 CAPLUS
DOCUMENT NUMBER: 72:66976
ORIGINAL REFERENCE NO.: 72:12235a,12238a
TITLE: Antiinflammatory quinazolinones
PATENT ASSIGNEE(S): Roussel-UCLAF
SOURCE: Fr. M., 7 pp.
CODEN: FMXXAJ
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
FR 6158		19680808	FR	19670518

OTHER SOURCE(S): MARPAT 72:66976
GI For diagram(s), see printed CA Issue.
AB 2-Quinazolinones I show useful antiinflammatory activity at a daily adult oral dose of 0.1-2 g daily. Heating a mixture of 9.4 g II, 3.84 g KCNO, and 96 ml AcOH at 60° 16 hr gave I (X = R2 = H, Y = 2-MeC6H4, R1 = Cl), (III), m. 267-8°. A mixture of 4.5 g III and 840 mg NaH (50% in oil) in 100 ml Me2NCHO was stirred until H evolution ceased, treated with 3.4 g MeI in 10 ml Me2NCHO and stirred 15 hr to give 3.125 g I (R1 = Cl, R2 = H, X = Me, Y = 2-MeC6H4), m. 212-13°. By similar methods were prepared 83.5% I (X = R2 = H, Y = Ph, R1 = OMe), m. 287° (MeOH). 75% I (R1 = OMe, R2 = H, X = Me, Y = Ph), m. 166°; I (X = R1 = H, Y = Ph, R2 = Cl), m. 286-7° (BuOH); I (R1 = H, R2 = Cl, X = Me, Y = Ph), m. 190° (EtOH); 46% I (R1 = Cl, R2 = H, X = Et, Y = Ph), m. 168° (PhMe); I (R1 = Cl, R2 = X = H, Y = 4-ClC6H4), m. 276°; I (R1 = Cl, R2 = H, X = Me, Y = 4-ClC6H4), m. 222° (PhMe). In the rat paw test, I showed good antiinflammatory activity in the oral dose range 10-50 mg/kg.
IT 23441-63-6P 23441-64-7P 23441-74-9P
23441-92-1P 23441-93-2P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 23441-63-6 CAPLUS
CN 2(1H)-Quinazolinone, 7-chloro-1-methyl-4-phenyl- (CA INDEX NAME)



RN 23441-64-7 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-1-ethyl-4-phenyl- (CA INDEX NAME)

L5 ANSWER 321 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 23441-74-9 CAPLUS
CN 2(1H)-Quinazolinone, 6-methoxy-1-methyl-4-phenyl- (CA INDEX NAME)



RN 23441-92-1 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-4-(p-chlorophenyl)-1-methyl- (8CI) (CA INDEX NAME)



RN 23441-93-2 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-1-methyl-4-o-tolyl- (8CI) (CA INDEX NAME)

L5 ANSWER 321 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



L5 ANSWER 322 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1970:35763 CAPLUS
DOCUMENT NUMBER: 72:35763
ORIGINAL REFERENCE NO.: 72:6589a,6592a
TITLE: Problems in application of the Hansch equation to a heterocyclic series
AUTHOR(S): Wulfert, Ernst; Bolla, Paul; Mathieu, Jean
CORPORATE SOURCE: Centre Rech., Roussel-UCLAF, Romainville, Fr.
SOURCE: Chimica Therapeutica (1969), 4(4), 257-9
CODEN: CHTPBA; ISSN: 0009-4374
DOCUMENT TYPE: Journal
LANGUAGE: French
GI For diagram(s), see printed CA Issue.
AB Application of the Hansch equation (CA 67:115392e) to 6-substituted quinazolinones, I[X = OH, OMe, O(CH2)2O(CH2)2OEt H, F, Cl, CF3, SO2Me, and NO2] with regard to antiinflammatory activity was attempted. The Hammett para σ values showed linear relations with carbonyl stretching frequencies and with half-neutralization potentials. When Hansch's solubility parameter, para π, was replaced by a modified function, π* (= 1.0943π - 1.0308σ + 0.0974), taking into account the influence of electronic effects on solubility, improved correlation with the biol. activity was observed.
IT 17629-04-8 20927-53-1 23441-63-6
23441-74-9 23441-83-0 23536-81-4
26953-39-9 26953-41-3 26953-42-4
26953-46-8
RL: PRP (Properties)
(substituent constant of)
RN 17629-04-8 CAPLUS
CN 2(1H)-Quinazolinone, 1-methyl-4-phenyl- (CA INDEX NAME)



RN 20927-53-1 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-1-methyl-4-phenyl- (CA INDEX NAME)



RN 23441-63-6 CAPLUS

L5 ANSWER 322 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
CN 2(1H)-Quinazolinone, 7-chloro-1-methyl-4-phenyl- (CA INDEX NAME)



RN 23441-74-9 CAPLUS
CN 2(1H)-Quinazolinone, 6-methoxy-1-methyl-4-phenyl- (CA INDEX NAME)



RN 23441-83-0 CAPLUS
CN 2(1H)-Quinazolinone, 1-methyl-6-(methylsulfonyl)-4-phenyl- (CA INDEX NAME)



RN 23536-81-4 CAPLUS
CN 2(1H)-Quinazolinone, 1-methyl-4-phenyl-6-(trifluoromethyl)- (CA INDEX NAME)



RN 26953-39-9 CAPLUS
CN 2(1H)-Quinazolinone, 6-hydroxy-1-methyl-4-phenyl- (CA INDEX NAME)

L5 ANSWER 322 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 26953-41-3 CAPLUS
CN 2(1H)-Quinazolinone, 6-[2-(2-ethoxyethoxy)ethoxy]-1-methyl-4-phenyl- (CA INDEX NAME)



RN 26953-42-4 CAPLUS
CN 2(1H)-Quinazolinone, 6-fluoro-1-methyl-4-phenyl- (CA INDEX NAME)



RN 26953-46-8 CAPLUS
CN 2(1H)-Quinazolinone, 1-methyl-6-nitro-4-phenyl- (CA INDEX NAME)



L5 ANSWER 323 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1969:479754 CAPLUS
DOCUMENT NUMBER: 71:79754
ORIGINAL REFERENCE NO.: 71:14751a,14754a
TITLE: Microbiological modification of benzodiazepines
INVENTOR(S): Greenspan, George; Ruelius, Hans W.; Alburn, Harvey E.
PATENT ASSIGNEE(S): American Home Products Corp.
SOURCE: U.S., 6 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 3453179	A	19690701	US 1967-614409	19670207
PRIORITY APPLN. INFO.:			US 1967-614409 A	19670207

AB A process for the microbiol. modification of benzodiazepine derivs., including diazepam, by fermentation of such derivs. in the presence of certain strains of the fungus, Pellicularia filamentosa, is described. The products obtained are benzodiazepine derivs. and quanazolinone derivs.
which are useful as intermediates for preparing other benzodiazepine and quinazolinone derivs. and (or) also for their pharmaceutical activity per se as tranquilizing agents. Thus, an agar slant of P. filamentosa f. microsclerotia CBS was washed with 5 ml. of distilled water, and one-half of
the resulting suspension was transferred to a 250-ml. flask containing 50 ml.
of the following medium (g./l.): corn-steep liquor 5, dextrose 20, peptone
20, distilled water 1000 ml. The flask was incubated on a rotary shaker, 250
rpm., at 28°. After 66 hrs. of agitation, a 10% mycelial transfer was made to a new flask of medium. Following 24 hrs. of incubation as above 12.5 mg. of diazepam in 0.5 ml. of EtOH was added, returning the flask to the shaker. Five-ml. samples were taken after 1, 2, 3, and 6 days. The pH of the samples was adjusted to 10-11 with 2N NaOH, and 1 ml.
of methylisobutyl ketone was added to each sample prior to equilibration. An aliquot of the extract was spotted on Whatman Number 4 paper, and the papergram was run in toluene-propylene glycol. The products were detected
by uv absorption and a fluorescent screen.

IT 20927-53-1P
RL: BMF (Bioindustrial manufacture); BIOL (Biological study); PREP (Preparation)
(manufacture of, by Rhizoctonia solani)

RN 20927-53-1 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-1-methyl-4-phenyl- (CA INDEX NAME)



L5 ANSWER 324 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1969:449975 CAPLUS
DOCUMENT NUMBER: 71:49975
ORIGINAL REFERENCE NO.: 71:9193a,9196a
TITLE: 2(1H)-Quinazolinones
INVENTOR(S): Allais, Andre; Meier, Jean
PATENT ASSIGNEE(S): Roussel-UCLAF
SOURCE: Fr., 11 pp.
CODEN: FRXXAK
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
FR 1520743		19680412	FR 1967-97203	19670302
DE 1695656			DE	
FR 6158			FR	
GB 1181570			GB	

GI For diagram(s), see printed CA Issue.
AB I are prepared from o-aminophenyl ketones and KOCN (and urea). A mixture of
11.6 g. 2-amino-5-chlorobenzophenone (II), 4.4 g. KOCN, and 58 ml. HOAc is
heated 15 hrs. at 55%, added to water, and worked up to give 7.2 g.
4-phenyl-6-chloro-2(1H)-quinazolinone (III), m. 318°. Similarly
prepared is I (R = Me, R1 = Ph, R2 = Cl, R3 = H) (IV). A mixture of 80 g. II
and 20 g. urea is heated 25 min. at 195° to give 44 g. III. III
(40 g.) is treated with 20 ml. MeI in HCONMe2 in the presence of 7.50 g.
50% NaH suspension to give 27 g. IV, m. 220°. Also prepared,
according to the above methods, are the following I (R, R1, R2, R3, and
m.p. given): PhCH2, Ph, Cl, H, 182°; Et2NCH2CH2, Ph, Cl, H,
100-1°; MeO2CCH2, Ph, Cl, H, 167°; H, m-ClC6H4, MeO, H,
228°; Me, M-ClC6H4, MeO, H, 199°; H, Ph, H, Cl,
286-7°; Me, Ph, H, Cl, 190°; Et, Ph, Cl, H, 168°; Bu,
Ph, Cl, H, 205°; allyl, Ph, Cl, H, 190°; HOCH2CH2, Ph, Cl,
H, 200°; HO(CH2)3, Ph, Cl, H, 136°; EtOCH2CH2OCH2CH2, Ph,
Cl, H, 70°; furfuryl, Ph, Cl, H, 200°; Cl(CH2)3, Ph, Cl, H,
152° (then 170°); HO2CCH2, Ph, Cl, H, 225-60°
(decomposition); H, Ph, MeO, H, 287°; Me, Ph, MeO, H, 166°; H,
Ph, H, H, 251-2°; Me, Ph, H, H, 136-7°; H, p-MeOC6H4, Cl, H,
306; Me, p-MeOC6H4, Cl, H, 216°; H, Ph, CF3, H, 229°; Me,
Ph, CF3, H, 198-200°; H, Ph, MeS, H, 250°; Me, Ph, MeS, H,
158°; H, Ph, MeSO2, H, 378°; Me, Ph, MeSO2, H, 238°;
H, o-ClC6H4, Cl, H, 330°; Me, o-ClC6H4, Cl, H, 198°; H,
p-ClC6H4, Cl, H, 276°; Me, p-ClC6H4, Cl, H, 222°; H,
o-tolyl, Cl, H, 267-8°; Me, o-tolyl, Cl, H, 212-13°; H,
cyclohexyl, Cl, H, 275-7°; Me, cyclohexyl, Cl, H, 171-2°;
and the following V (R, R1, R2, R3, R4, and m.p. given): H, Ph, H, Cl, Cl,
33-4°; Me, Ph, H, Cl, Cl, 360°; H, Ph, H, Cl, Me,
346°; Me, Ph, H, Cl, Me, 325-7°; H, Ph, Cl, H, H,
284°; Me, Ph, Cl, H, H, 259°. Also prepared, according to
known methods, are (m.p. given): 5,2-Me(AcNH)C6H3COC6H4Cl-3, -;

L5 ANSWER 324 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
5,2-MeO(H2N)C6H3COC6H4Cl-3, 86° (picrate m. 164°);
3,5,2-Me-(Cl)(H2N)C6H2Bz, 88°; 2,5-H2N(MeSO2)C6H3Bz, 152-3°.
IT 17629-04-8P 20927-53-1P 23441-63-6P
23441-64-7P 23441-65-8P 23441-66-9P
23441-67-0P 23441-68-1P 23441-69-2P
23441-70-5P 23441-71-6P 23441-72-7P
23441-74-9P 23441-78-3P 23441-81-8P
23441-83-0P 23441-85-2P 23441-88-5P
23441-90-9P 23441-92-1P 23441-93-2P
23465-52-3P 23465-53-4P 23465-54-5P,
1(2H)-Quinazolineacetic acid, 6-chloro-2-oxo-4-phenyl-, methyl ester
23465-55-6P 23536-81-4P 23536-82-5P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 17629-04-8 CAPLUS
CN 2(1H)-Quinazolinone, 1-methyl-4-phenyl- (CA INDEX NAME)



RN 20927-53-1 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-1-methyl-4-phenyl- (CA INDEX NAME)



RN 23441-63-6 CAPLUS
CN 2(1H)-Quinazolinone, 7-chloro-1-methyl-4-phenyl- (CA INDEX NAME)



L5 ANSWER 324 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

RN 23441-64-7 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-1-ethyl-4-phenyl- (CA INDEX NAME)



RN 23441-65-8 CAPLUS
CN 2(1H)-Quinazolinone, 1-butyl-6-chloro-4-phenyl- (CA INDEX NAME)



RN 23441-66-9 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-4-phenyl-1-(2-propenyl)- (9CI) (CA INDEX NAME)



RN 23441-67-0 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-1-(2-hydroxyethyl)-4-phenyl- (CA INDEX NAME)



L5 ANSWER 324 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
RN 23441-68-1 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-1-[2-(2-ethoxyethoxy)ethyl]-4-phenyl- (CA INDEX NAME)



RN 23441-69-2 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-1-(3-hydroxypropyl)-4-phenyl- (CA INDEX NAME)



RN 23441-70-5 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-1-furfuryl-4-phenyl- (8CI) (CA INDEX NAME)



RN 23441-71-6 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-1-(3-chloropropyl)-4-phenyl- (CA INDEX NAME)

L5 ANSWER 324 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 23441-72-7 CAPLUS
CN 1(2H)-Quinazolineacetic acid, 6-chloro-2-oxo-4-phenyl- (CA INDEX NAME)



RN 23441-74-9 CAPLUS
CN 2(1H)-Quinazolinone, 6-methoxy-1-methyl-4-phenyl- (CA INDEX NAME)



RN 23441-78-3 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-4-(4-methoxyphenyl)-1-methyl- (CA INDEX NAME)

L5 ANSWER 324 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 23441-81-8 CAPLUS
CN 2(1H)-Quinazolinone, 1-methyl-6-(methylthio)-4-phenyl- (CA INDEX NAME)



RN 23441-83-0 CAPLUS
CN 2(1H)-Quinazolinone, 1-methyl-6-(methylsulfonyl)-4-phenyl- (CA INDEX NAME)



RN 23441-85-2 CAPLUS
CN 2(1H)-Quinazolinone, 6,8-dichloro-1-methyl-4-phenyl- (CA INDEX NAME)

L5 ANSWER 324 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 23441-88-5 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-4-(2-chlorophenyl)-1-methyl- (CA INDEX NAME)



RN 23441-90-9 CAPLUS
CN 2(1H)-Quinazolinone, 5-chloro-1-methyl-4-phenyl- (CA INDEX NAME)



RN 23441-92-1 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-4-(p-chlorophenyl)-1-methyl- (8CI) (CA INDEX NAME)

L5 ANSWER 324 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 23441-93-2 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-1-methyl-4-o-tolyl- (8CI) (CA INDEX NAME)



RN 23465-52-3 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-4-phenyl-1-(phenylmethyl)- (CA INDEX NAME)



RN 23465-53-4 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-1-[2-(diethylamino)ethyl]-4-phenyl- (CA INDEX NAME)



L5 ANSWER 324 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

RN 23465-54-5 CAPLUS
CN 1(2H)-Quinazolineacetic acid, 6-chloro-2-oxo-4-phenyl-, methyl ester (CA INDEX NAME)



RN 23465-55-6 CAPLUS
CN 2(1H)-Quinazolinone, 4-(3-chlorophenyl)-6-methoxy-1-methyl- (CA INDEX NAME)



RN 23536-81-4 CAPLUS
CN 2(1H)-Quinazolinone, 1-methyl-4-phenyl-6-(trifluoromethyl)- (CA INDEX NAME)



RN 23536-82-5 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-1,8-dimethyl-4-phenyl- (CA INDEX NAME)

L5 ANSWER 324 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



L5 ANSWER 325 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1969:11668 CAPLUS
DOCUMENT NUMBER: 70:11668
ORIGINAL REFERENCE NO.: 70:2187a,2190a
TITLE: 1-Methyl-4-phenyl-2(1H)-quinazolinone
AUTHOR(S): Ott, Hans; Denzer, Max
CORPORATE SOURCE: Sandoz Pharm., Hanover, NJ, USA
SOURCE: Journal of Organic Chemistry (1968), 33(11), 4263-6
CODEN: JOCEAH; ISSN: 0022-3263
DOCUMENT TYPE: Journal
LANGUAGE: English
GI For diagram(s), see printed CA Issue.
AB 1-Methyl-4-phenyl-1,2,3,4-tetra-hydroquinazoline (I) is prepared by the NaBH4 reduction of 4-phenylquinazoline methiodide. I is treated with KMnO4 to give 1-methyl-4-phenyl-2(1H)-quinazolinone (II). II is also prepared from o-MeNHC6H4COPh and H2NCO2Et and from 4-phenyl-2(1H)-quinazolinone and MeI.
IT 17629-04-8P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 17629-04-8 CAPLUS
CN 2(1H)-Quinazolinone, 1-methyl-4-phenyl- (CA INDEX NAME)



L5 ANSWER 326 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1969:4080 CAPLUS
DOCUMENT NUMBER: 70:4080
ORIGINAL REFERENCE NO.: 70:765a,768a
TITLE: Quinazolines and 1,4-benzodiazepines. XLIII. Oxidations with ruthenium tetroxide
AUTHOR(S): Felix, Arthur M.; Earley, J. V.; Fryer, R. Ian; Sternbach, L. H.
CORPORATE SOURCE: Chem. Res. Dep., Hoffmann-La Roche Inc., Nutley, NJ, USA
SOURCE: Journal of Heterocyclic Chemistry (1968), 5(5), 731-4
CODEN: JHTCAD; ISSN: 0022-152X
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 70:4080
GI For diagram(s), see printed CA Issue.
AB 7-Chloro-1-methyl-5-phenyl-1,2,4,5-tetrahydro-3H-1,4-benzodiazepine (I) was oxidized with RuO4 to 7-chloro-2,3,-dihydro-1-methyl-5-phenyl-1H-1,4-benzodiazepine, which on further treatment with RuO4 at 0° gave 7-chloro-1,3-dihydro-1-methyl-5-phenyl-2H-1,4-benzodiazepin-2-one (II), further oxidized to 6-chloro-1,2-dihydro-1-methyl-4-phenylquinazolin-2-one, also prepared by HCl treatment of 7-chloro-1-methyl-5-phenyl-1H-1,4-benzodiazepine-2,3-dione and RuO4 oxidation of 7-chloro-4,5-dihydro-1-methyl-5-phenyl-1H-1,4-benzodiazepine-2,3-dione. RuO4 oxidation of 7-chloro-1,3-dihydro-3-hydroxy-5-phenyl-2H-1,4-benzodiazepin-2-one led to 7-chloro-5-phenyl-1H-1,4-benzodiazepine-2,3-dione.
IT 20927-53-1P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 20927-53-1 CAPLUS
CN 2(1H)-Quinazolinone, 6-chloro-1-methyl-4-phenyl- (CA INDEX NAME)



L5 ANSWER 327 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1915:9607 CAPLUS
DOCUMENT NUMBER: 9:9607
ORIGINAL REFERENCE NO.: 9:1485a-i,1486a-e
TITLE: Diacylamides
AUTHOR(S): Mumm, Otto; Hesse, Hugo; Volquartz, Hans
CORPORATE SOURCE: Univ. Kiel
SOURCE: Berichte der Deutschen Chemischen Gesellschaft (1915),
48, 379-91
CODEN: BDCGAS; ISSN: 0365-9496
DOCUMENT TYPE: Journal
LANGUAGE: Unavailable
GI For diagram(s), see printed CA Issue.
AB cf. C. A. 4, 1750. While many alkyl derivs. of acid amides are known in the 2 isomeric forms RCONHR' and RC(:NH)OR', thus far (with 1 possible exception; cf. Kuhara, C. A. 5, 1278) the corresponding acyl compds. have been obtained in only 1 form, to which has generally been assigned the amide structure, RCONHCOR'. In the preparation of diacylamides by shaking an imide chloride in Et2O or ligroin with the Na salt of an acid in H2O, the O-acyl compound is probably an intermediate product and rearranges into the N-acyl isomer: RCCl:NR' + NaO2CR''→RC(O2CR''):NR'→RCONR'COR' ', and attempts have now been made in various ways to isolate 2 such isomeric forms. To show whether intramol. rearrangement is possible under the conditions of the experiment PhCCl:NPh was treated with m-O2NC6H4.CO2Na on the 1 hand, and m-O2NC6H4Cl:NPh with BzONa on the other; if there were no rearrangement the products should be different, but as a matter of fact they were identical, O2NC6H4CONPhBz. A residue of high mol. weight was next chosen as the entering acyl; PhCCl:NPh and Ph3CCO2Na gave triphenylocetylbenzanilide, microscopic needles from C6H6, m. 185-6°, which again was identical with the product from BzONa and triphenylacetanilide imide chloride, prismatic columns from ligroin, m. 137°; this chloride was obtained by warming with PCl3 triphenylacetanilide, m. 167-8°, which, in turn, was prepared from Ph3CCOCl and PhNH2. Similarly, PhCCl:NPh with mono-Na malonate gave malonylmonobenzanilide, prisms from C6H6, m. 100-1° (gas evolution); with (CH2CO2Na)2, succinyldibenzanilide, prisms from MeOH, m. 146-7°; with Na fumarate, fumaryldibenzanilide, m. 194° (decomposition). It was thought that if the entering (aromatic) acyl or the imide chloride were substituted in the o-position, the rearrangement of the O- into the N-acyl compound might be prevented, but again no isomeric forms could be detected. PhCCl:NPh and o-MeC6H4CO2Na gave o-toluylbenzanilide, m. 134-5°; o-MeC6H4N:CPhCl and NaOBz yielded dibenzoyl-o-toluidide, prisms from alc., was obtained from O2NC6H4N:CPhCl and NaOBz. Dibenzoyl-m-toluidide, needles from alc., m. 140-1°; p-toluidide, prisms from alc., m. 142-4°; m-nitroanilide, prisms from alc., m. 150-1°; methylamide, MeNBz2, prismatic columns from alc., m. 94-5°; benzylamide, prisms from alc., m. 180°, were similarly obtained from BzONa. Thinking the strength of the acid whose radical enters might influence the stability of the O-acyl compd., salts of acids of the most varied strength and of various phenols were tried but again, except in the case of PhOH itself, no isomers were obtained. PhCCl:NCH2Ph and PhCH:CHCO2Na gave cinnamoylbenzoylbenzylamide, prisms from alc., m. 113°. PhCCl:NPh and PhONa give PhC(OPh):NPh (Hantzsch, Ber. 26, 956 (1893)), m. 105°, which, when heated 1 hr. at 240° and crystd. from alc., rearranges into BzNPh2, m. 180°, obtained from BzCl and NHPh2 (Hofmann, Ann. 132, 166 (1865)). Benzanilide-o-nitrophenyl ether, from PhCCl:NPh and O2NC6H4ONa, cubes from alc., m. 116°, could not be converted into an isomer. Benzpicrylanilide, long needles from alc., m. 195-6°; benzpicryl-o-toluidide, light yellow rhombs from alc., m.223-4°; [o-hydroxybenzoyl] benzanilide, prisms from C6H6, m. 189°; [o-hydroxybenzoyl] benz-o-toluidide, needles from alc. or C6H6, m. 122-3°. Treatment of PhCCl:NPh in the presence of C5H5N with acids in abs. Et2O (Claisen, Ann. 291, 106(1896)) gave products identical with those obtained as above from the salts. The above syntheses do not permit of deciding whether in the diacylamides both acyl groups are really attached to the N or whether the compds. are not perhaps at least partially O-acylated derivs. It was now attempted to clear this up by so choosing the acid residues that here would be a possibility of intramol. ring formation; from the structure of the resulting cyclic compd. it should then be possible to deduce that of the diacylamide. PhCCl:NPh and o-H2NC6H4CO2Na give diphenylquinazolone (C. A. 4, 3233), so that the H2NC6H4CO residue must be attached to the N; on the other hand, the 3 isomeric O2NC6H4N:CPhCl and H2NC6H4CO2Na yield benzoylanthranil, so that the H2NC6H4CO must be attached to the O. With MeNHC6H4CO2Na is obtained [o-methylaminobenzoyl]benzanilide, prisms from AcOEt, m. 188°, which when boiled several hrs. with dil. HCl changes into an (apparently cyclic) isomer, NMe.C6H4.CO.NPh.CPhOH, m. 142°. In some cases, the decompn. of the diacylamides at room or elevated temp. may also throw light on their structure. Thus, oxalyldibenzanilide, from PhCCl:NPh and (CO2K)2 prisms from alc., m. 212-3° (gas evolution), when heated 1 hr. at 220-30°, gives 1 mol. each of CO, CO2 and BzNPhCPh:NPh, showing that at least 1 side of it is acylated on the O. Oxalyldibenz-o-toluidide, m. 171-3°. When (CO2K)2 reacts on p-O2NC6H4N:CPhCl, not only does the O-acyl at once rearrange into the N-acyl compd. but the Bz is also replaced by a HO2CCO group and the product obtained is dioxalyl-p-nitro-bensanilide, O2NC6H4N(COCO2H)2, needles from AcOH, m. 270° (decompn.), converted by dil. HCl into O2NC6H4NHCOCO2H. HO2CCO2Na and PhCCl:NPh likewise yield an O-acyl compd. which, however, spontaneously loses 1 mol. each of CO and CO2 and forms BzNHPh. The great tendency of the O- to rearrange into the N-acyl derivs. is probably conditioned by partial valences on the migrating C and the N atom. That the compds. sometimes react like O-acyl derivs. is probably due to the fact that they exist in a tautomeric equil. of the 2 forms.
IT 860758-56-1P, 2(1)-Quinazolone, 3,4-dihydro-4-hydroxy-1-methyl-3,4-diphenyl-
RL: PREP (Preparation)
(preparation of)
RN 860758-56-1 CAPLUS

L5 ANSWER 327 OF 327 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
CN 2(1H)-Quinazolinone, 3,4-dihydro-4-hydroxy-1-methyl-3,4-diphenyl- (CA INDEX NAME)



10/ 540,359

```
=> d his

     (FILE 'HOME' ENTERED AT 16:56:23 ON 29 MAY 2008)

     FILE 'REGISTRY' ENTERED AT 16:56:51 ON 29 MAY 2008
L1             STRUCTURE UPLOADED
L2              36 S L1
L3            1304 S L1 FUL

     FILE 'CAPLUS' ENTERED AT 16:57:23 ON 29 MAY 2008
L4             370 S L3
L5             327 S L4 NOT (ISOPROPYL OR CYCLOPENTYL)

=> log y
COST IN U.S. DOLLARS                            SINCE FILE      TOTAL
                                                  ENTRY    SESSION
FULL ESTIMATED COST                              1788.79    1967.36

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)      SINCE FILE      TOTAL
                                                  ENTRY    SESSION
CA SUBSCRIBER PRICE                              -261.60    -261.60

STN INTERNATIONAL LOGOFF AT 17:00:39 ON 29 MAY 2008
```